0000950170-24-09614810-Q Perspective Therapeutics, Inc. 20240813202408131604531604541604540 0 0000950170-24-096148 10-Q 80 20240630 20240813 20240813 Perspective Therapeutics, Inc. 0000728387 3841 411458152 DE 1231 10-Q 34 001-33407 241201301 2401 ELLIOT AVENUE SUITE 320 SEATTLE WA 98121 206-676-0900 2401 ELLIOTT AVENUE SUITE 320 SEATTLE WA 98121 Isoray, Inc. 20181231 IsoRay, Inc. 20050805 CENTURY PARK PICTURES CORP 19920703 10-Q 1 catx-20240630.htm 10-Q 10-Q falseQ2--12-3100007283870.10.10.10.10.10000728387catx:NetSalesGreaterThan15MillionMembercatx:GTMedicalTechnologiesIncMember2024-04-120000728387us-gaap:EquipmentMember2024-06-300000728387us-gaap:RetainedEarningsMembercatx:ATMAgreementMember2024-04-012024-06-300000728387catx:PromissoryNoteMember2024-06-300000728387catx:OtherMember2023-12-310000728387catx:StockholderPlaintiffSettlementsMember2023-12-310000728387catx:PublicOfferingMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000728387catx:SeriesBConvertiblePreferredStockMember2024-06-300000728387catx:OtherMember2023-01-012023-12-310000728387catx:Cesium131BusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-01-012023-06-300000728387us-gaap:BuildingMember2024-06-300000728387catx:ChicagoIllinoisMemberus-gaap:SubsequentEventMember2024-08-022024-08-020000728387us-gaap:LandMember2023-12-310000728387catx:LantheusInvestmentAgreementMembercatx:LantheusAlphaTherapyLlcMember2024-03-060000728387us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300000728387catx:May2024PreFundedWarrantsMembercatx:TheUnderwritingAgreementMembercatx:BofASecuritiesIncMember2024-05-242024-05-240000728387catx:GTMedicalTechnologiesIncMember2024-04-120000728387us-gaap:LandMember2024-06-3000007283872024-01-012024-03-310000728387catx:AmendedTwoThousandTwentyIncentivePlanMember2024-05-310000728387catx:ViewpointMolecularTargetingIncMember2023-01-012023-06-300000728387us-gaap:CommonStockMembercatx:PublicOfferingMember2024-01-012024-03-3100007283872023-06-300000728387srt:ScenarioForecastMember2024-01-012024-12-310000728387catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember2024-01-172024-01-170000728387us-gaap:RetainedEarningsMembercatx:PublicOfferingMember2024-01-012024-03-310000728387us-gaap:EmployeeStockOptionMember2024-01-012024-06-3000007283872023-03-310000728387catx:SeriesBConvertiblePreferredStockMember2023-12-310000728387us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000728387catx:MarchTwoThousandTwentyFourInvestmentAgreementMember2024-01-012024-03-310000728387us-gaap:CommonStockMember2023-01-012023-03-310000728387catx:LantheusInvestmentAgreementMembercatx:OptionAgreementMember2024-01-082024-01-080000728387catx:ViewpointMolecularTargetingIncMember2024-04-012024-06-300000728387catx:MayTwoThousandTwentyFourPreFundedWarrantsMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000728387us-gaap:AdditionalPaidInCapitalMember2023-12-310000728387catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000728387us-gaap:CommonStockMember2022-12-310000728387catx:RegisteredOfferingMember2024-04-012024-06-300000728387us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300000728387catx:LantheusInvestmentAgreementMembercatx:LantheusAlphaTherapyLlcMember2024-01-080000728387catx:GTMedicalTechnologiesIncMembercatx:GTMedicalStockMember2024-04-120000728387us-gaap:CommonStockMember2024-03-310000728387catx:PromissoryNoteMember2023-12-310000728387catx:LantheusInvestmentAgreementMembercatx:LantheusAlphaTherapyLlcMember2024-03-042024-03-040000728387us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000728387catx:RegisteredOfferingMembercatx:TheUnderwritingAgreementMembercatx:BofASecuritiesIncMember2024-05-240000728387us-gaap:CommonStockMembercatx:ATMAgreementMember2024-04-012024-06-300000728387catx:ViewpointMolecularTargetingIncMember2024-01-012024-06-300000728387catx:PublicOfferingMember2024-01-012024-03-3100007283872024-06-300000728387us-gaap:USTreasuryBillSecuritiesMember2023-12-310000728387catx:PromissoryNoteMembercatx:ViewpointMolecularTargetingIncMember2019-07-192019-07-190000728387us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000728387us-gaap:AdditionalPaidInCapitalMember2022-12-310000728387us-gaap:CommonStockMember2024-01-012024-03-310000728387catx:March2024PrivatePlacementMember2024-03-040000728387us-gaap:RetainedEarningsMember2024-01-012024-03-310000728387catx:ProgenicsApaMember2024-01-082024-01-080000728387catx:Cesium131BusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-12-310000728387catx:RegisteredOfferingMemberus-gaap:RetainedEarningsMember2024-04-012024-06-300000728387catx:LantheusInvestmentAgreementMemberus-gaap:CommonStockMember2024-01-012024-03-310000728387catx:OppenheimerCoMember2024-04-112024-04-110000728387us-gaap:LeaseholdImprovementsMember2023-12-310000728387us-gaap:RetainedEarningsMember2023-03-310000728387catx:LantheusInvestmentAgreementMembercatx:OptionAgreementMember2024-03-310000728387us-gaap:RetainedEarningsMember2023-12-310000728387us-gaap:CommonStockMember2023-06-300000728387catx:ViewpointMolecularTargetingIncMember2023-02-032023-02-030000728387us-gaap:OverAllotmentOptionMember2024-01-172024-01-170000728387catx:OppenheimerCoMember2023-12-012023-12-310000728387us-gaap:CommonStockMember2024-04-012024-06-300000728387catx:HoustonTexasMemberus-gaap:SubsequentEventMember2024-07-152024-07-150000728387catx:LantheusInvestmentAgreementMember2024-01-082024-01-080000728387us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300000728387catx:LeaseWithBoardOfRegentsMember2024-04-0100007283872024-06-142024-06-140000728387catx:OtherMember2024-06-300000728387catx:ProgenicsMember2024-03-0100007283872024-03-310000728387catx:Cesium131BusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-04-012024-06-300000728387catx:GTMedicalTechnologiesIncMembercatx:NetSalesBetween10And15MillionMember2024-04-120000728387us-gaap:CommonStockMember2024-06-300000728387catx:LantheusInvestmentAgreementMember2024-01-080000728387catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember2024-01-170000728387catx:ViewpointMolecularTargetingIncMember2023-02-030000728387us-gaap:RetainedEarningsMember2024-04-012024-06-300000728387us-gaap:WarrantMember2024-01-012024-06-300000728387us-gaap:WarrantMember2023-01-012023-06-300000728387catx:PublicOfferingMember2024-01-170000728387catx:ViewpointMolecularTargetingIncMember2023-04-012023-06-300000728387catx:LantheusInvestmentAgreementMember2024-01-012024-03-3100007283872024-06-300000728387catx:OtherMember2024-01-012024-06-300000728387catx:PublicOfferingMember2024-01-172024-01-170000728387us-gaap:RetainedEarningsMember2023-01-012023-03-310000728387us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000728387catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember2024-01-012024-03-310000728387catx:PromissoryNoteForPurchasingLandAndBuildingMembercatx:ViewpointMolecularTargetingIncMember2022-12-290000728387catx:Cesium131BusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-04-012023-06-300000728387us-gaap:RetainedEarningsMembercatx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember2024-01-012024-03-3100007283872023-04-012023-06-300000728387catx:NetSalesOf10MillionOrLessMembercatx:GTMedicalTechnologiesIncMember2024-04-120000728387catx:ViewpointMolecularTargetingIncMembersrt:MaximumMember2023-02-032023-02-030000728387us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300000728387catx:MarchTwoThousandTwentyFourInvestmentAgreementMemberus-gaap:RetainedEarningsMember2024-01-012024-03-310000728387catx:LantheusInvestmentAgreementMemberus-gaap:RetainedEarningsMember2024-01-012024-03-310000728387us-gaap:RetainedEarningsMember2023-06-3000007283872024-04-012024-06-300000728387us-gaap:CommonStockMembercatx:RegisteredOfferingMember2024-04-012024-06-300000728387catx:ATMAgreementMember2024-04-012024-06-300000728387catx:ATMAgreementMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000728387us-gaap:AdditionalPaidInCapitalMember2024-03-310000728387catx:IsorayNoteMembercatx:ViewpointMolecularTargetingIncMember2022-11-220000728387us-gaap:RetainedEarningsMember2023-04-012023-06-300000728387catx:OppenheimerCoMember2024-04-110000728387catx:Cesium131BusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-01-012024-06-300000728387us-gaap:CommonStockMembercatx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember2024-01-012024-03-310000728387us-gaap:CommonStockMember2023-03-310000728387us-gaap:AdditionalPaidInCapitalMember2023-06-300000728387catx:March2024PrivatePlacementMember2024-03-042024-03-040000728387catx:OppenheimerCoMember2023-11-1700007283872023-01-012023-06-300000728387us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-3000007283872023-12-310000728387catx:May2024PreFundedWarrantsMembercatx:TheUnderwritingAgreementMembercatx:BofASecuritiesIncMember2024-05-240000728387catx:AmendedTwoThousandTwentyIncentivePlanMember2024-05-312024-05-310000728387us-gaap:LeaseholdImprovementsMember2024-06-3000007283872024-01-012024-06-300000728387catx:LantheusInvestmentAgreementMembercatx:LantheusAlphaTherapyLlcMember2024-01-082024-01-080000728387us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000728387catx:MarchTwoThousandTwentyFourInvestmentAgreementMemberus-gaap:CommonStockMember2024-01-012024-03-310000728387us-gaap:RetainedEarningsMember2024-06-300000728387us-gaap:CommonStockMember2023-04-012023-06-300000728387catx:OppenheimerCoMember2023-12-310000728387catx:LantheusInvestmentAgreementMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000728387us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300000728387us-gaap:USTreasuryBillSecuritiesMember2024-06-300000728387us-gaap:EmployeeStockOptionMember2023-01-012023-06-300000728387catx:Cesium131BusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-06-300000728387srt:MinimumMembercatx:ViewpointMolecularTargetingIncMember2023-02-032023-02-030000728387us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000728387us-gaap:AdditionalPaidInCapitalMember2024-06-300000728387catx:PromissoryNoteMembercatx:ViewpointMolecularTargetingIncMember2019-07-190000728387catx:OfficeSpaceWithUnicoPropertiesMember2023-07-010000728387catx:StockholderPlaintiffSettlementsMember2024-06-300000728387us-gaap:RetainedEarningsMember2024-03-310000728387us-gaap:CommonStockMember2023-12-310000728387us-gaap:BuildingMember2023-12-310000728387us-gaap:EquipmentMember2023-12-310000728387us-gaap:FairValueMeasurementsRecurringMember2023-12-3100007283872022-12-310000728387us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300000728387catx:RegisteredOfferingMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000728387catx:MarchTwoThousandTwentyFourInvestmentAgreementMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000728387us-gaap:AdditionalPaidInCapitalMember2023-03-310000728387catx:MayTwoThousandTwentyFourPreFundedWarrantsMember2024-04-012024-06-3000007283872023-12-140000728387catx:RegisteredOfferingMembercatx:TheUnderwritingAgreementMembercatx:BofASecuritiesIncMember2024-05-242024-05-240000728387us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-3000007283872024-08-070000728387us-gaap:CashAndCashEquivalentsMemberus-gaap:USTreasuryBillSecuritiesMember2023-12-310000728387catx:MayTwoThousandTwentyFourPreFundedWarrantsMemberus-gaap:CommonStockMember2024-04-012024-06-300000728387us-gaap:InProcessResearchAndDevelopmentMember2024-06-300000728387us-gaap:RetainedEarningsMember2022-12-3100007283872023-01-012023-03-310000728387catx:GTMedicalTechnologiesIncMember2024-04-122024-04-120000728387catx:MayTwoThousandTwentyFourPreFundedWarrantsMemberus-gaap:RetainedEarningsMember2024-04-012024-06-300000728387us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300000728387us-gaap:InProcessResearchAndDevelopmentMember2023-12-31iso4217:USDxbrli:sharesxbrli:purecatx:MonthlyPaymentsxbrli:sharescatx:Plaintiffiso4217:USD Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q â˜’ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 OR â˜ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _____ to _____ Â Commission File Number: 001-33407 Â PERSPECTIVE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Â Delaware 41-1458152 (State or other jurisdiction of incorporation ororganization) (I.R.S. EmployerIdentification No.) Â Â 2401 Elliott Avenue, Suite 320Seattle, Washington 98121 (Address of principal executive offices) (Zip Code) Registrantâ€™s telephone number, including area code: (206) 676-0900 Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value CATX NYSE American LLC Â Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜’ Smaller reporting company â˜’ Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ Â Number of shares outstanding of each of the issuerâ€™s classes of common stock as of the latest practicable date: Â Class Outstanding as of August 7, 2024 Common stock, $0.001 par value 67,427,667 Â Â Â Â Â Â Â CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Â In addition to historical information, this Quarterly Report on Form 10-Q (Form 10-Q), contains certain â€œforward-looking statementsâ€ within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). This statement is included for the express purpose of availing Perspective Therapeutics, Inc. of the protections of the safe harbor provisions of the PSLRA. Â This Form 10-Q, including Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations in Part I, Item 2, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements contained in this Form 10-Q other than statements of historical fact, including, without limitation, statements regarding our future financial condition, results of operations, business strategy and plans and objectives of management for future operations, industry trends and other future events are forward-looking statements. In some cases, you can identify forward-looking statements by terminology, such as â€œbelieve,â€ â€œexpect,â€ â€œanticipate,â€ â€œintend,â€ â€œestimate,â€ â€œforecast,â€ â€œproject,â€ â€œmay,â€ â€œcould,â€ â€œmight,â€ â€œplan,â€ â€œshould,â€ â€œwill,â€ â€œwouldâ€ or the negative of these terms and other similar expressions, although not all forward-looking statements contain these identifying terms. Forward-looking statements in this Form 10-Q include, among other things: Â â€¢the timing, progress and results of our preclinical studies and clinical trials of our current and future program candidates, including statements regarding the timing of our planned regulatory communications, submissions and approvals, initiation and completion of studies or trials and related preparatory work and the period during which the results of the trials will become available, and our research and development programs; â€¢our ability to obtain and maintain regulatory approvals for our future program candidates; â€¢our manufacturing capabilities and strategy, including the scalability and commercial viability of our manufacturing methods and processes; â€¢our ability to identify patients with the diseases treated by our program candidates and to enroll these patients in our clinical trials; â€¢our expectations regarding the potential functionality, capabilities and benefits of our program candidates, if approved, for commercial use; â€¢the potential size of the commercial market for our program candidates; â€¢our expectations regarding the scope of any approved indication for any program candidate; â€¢our ability to successfully commercialize our program candidates; â€¢our ability to leverage technology to identify and develop future program candidates; â€¢our estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for or ability to obtain additional funding before we can expect to generate any revenue from product sales; â€¢our belief regarding the sufficiency of our cash resources to fund our current planned operating expenses and capital expenditure requirements into mid-2026; â€¢our competitive position and expectations regarding developments and projections relating to our competitors or our industry; and â€¢expectations, beliefs, intentions and strategies regarding the future. Â These statements are based on certain assumptions and analyses made by us in light

of our experience and our assessment of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances. Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by management will be realized or, even if substantially realized, that they will have the expected consequences to or effects on our business operations. Readers are cautioned not to place undue reliance on such forward-looking statements as they speak only of our views as of the date the statement was made (or any earlier date indicated in such statement). While we may update certain forward-looking statements from time to time, we undertake no obligation to do so, whether as a result of new information, future events or otherwise, except as required by applicable law. Our U.S. Securities and Exchange Commission (SEC) filings are available publicly on the SECâ€™s website at www.sec.gov. Â Â i Table of ContentsÂ AVAILABLE INFORMATION As soon as reasonably practicable after they are filed electronically with the SEC, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, other SEC filings and amendments to those reports are available without charge on our website, www.perspectivetherapeutics.com, which we also use to announce material information to the public. We are providing the address to our website solely for the information of investors. We do not intend the address to be an active link or to otherwise incorporate the contents of the website into this Form 10-Q. ii Table of ContentsÂ PERSPECTIVE THERAPEUTICS, INC. Table of Contents Â PART I FINANCIAL INFORMATION Â Â Item 1 Financial Statements 1 Â Â Â Condensed Consolidated Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023 1 Â Â Â Â Â Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023 (unaudited) 2 Â Â Â Â Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 (unaudited) 3 Â Â Â Â Condensed Consolidated Statements of Changes in Stockholdersâ€™ Equity for the three and six months ended June 30, 2024 and 2023 (unaudited) 4 Â Â Â Notes to the Unaudited Condensed Consolidated Financial Statements 5 Â Â Item 2 Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 17 Â Â Item 3 Quantitative and Qualitative Disclosures About Market Risk 27 Â Â Item 4 Controls and Procedures 27 Â Â PART II OTHER INFORMATION Â Â Item 1 Legal Proceedings 28 Â Â Item 1A Risk Factors 28 Â Â Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 28 Â Â Item 3 Defaults Upon Senior Securities 28 Â Â Item 4 Mine Safety Disclosures 28 Â Â Item 5 Other Information 28 Â Â Item 6 Exhibits 29 Â Â Signatures Â 30 Â iii Table of ContentsÂ PART I - FINANCIAL INFORMATION ITEM 1 - FINANCIAL STATEMENTS Perspective Therapeutics, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (In thousands, except shares and par value data) Â Â June 30, Â Â December 31, Â Â 2024 Â Â 2023 Â Â Â (unaudited) Â Â Â Â ASSETS Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 252,004 Â Â $ 9,238 Â Short-term investments Â Â 40,865 Â Â Â - Â Accounts receivable, net of allowance for doubtful accounts: 2024 - $606; 2023 - $650 Â Â 142 Â Â Â 1,165 Â Prepaid expenses and other current assets Â Â 1,226 Â Â Â 1,133 Â Current assets held for sale, discontinued operations Â Â - Â Â Â 5,301 Â Total current assets Â Â 294,237 Â Â Â 16,837 Â Noncurrent assets: Â Â Â Â Â Â Property and equipment, net Â Â 14,747 Â Â Â 5,576 Â Right-of-use asset, net Â Â 2,019 Â Â Â 747 Â Restricted cash Â Â 182 Â Â Â 182 Â Intangible assets, in-process research and development Â Â 50,000 Â Â Â 50,000 Â Goodwill Â Â 24,062 Â Â Â 24,062 Â Other assets, net Â Â 672 Â Â Â 487 Â Total assets Â $ 385,919 Â Â $ 97,891 Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERS' EQUITY Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable and accrued expenses Â $ 6,127 Â Â $ 6,909 Â Lease liability Â Â 720 Â Â Â 46 Â Accrued personnel expenses Â Â 2,309 Â Â Â 3,588 Â Note payable Â Â 54 Â Â Â 49 Â Deferred Income (Note 3) Â Â 1,400 Â Â Â - Â Current liabilities of discontinued operations Â Â - Â Â Â 5,072 Â Total current liabilities Â Â 10,610 Â Â Â 15,664 Â Noncurrent liabilities: Â Â Â Â Â Â Lease liability Â Â 1,450 Â Â Â 780 Â Note payable Â Â 1,651 Â Â Â 1,676 Â Deferred Income (Note 3) Â Â 26,600 Â Â Â - Â Deferred tax liability Â Â 4,592 Â Â Â 4,592 Â Other noncurrent liabilities Â Â 19 Â Â Â - Â Total liabilities Â Â 44,922 Â Â Â 22,712 Â Â Â Â Â Â Â Commitments and contingenciesÂ (Note 10) Â Â Â Â Â Â Â Â Â Â Â Stockholders' equity: Â Â Â Â Â Â Preferred stock, $0.001Â par value; 7,000,000Â shares authorized; 5,000,000Â designated Series B convertible preferred stock; noÂ shares issued and outstanding as of June 30, 2024 and December 31, 2023 Â Â - Â Â Â - Â Common stock, $0.001Â par value; 750,000,000Â shares authorized; 67,425,167Â and 28,180,985Â shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively1 Â Â 67 Â Â Â 28 Â Additional paid-in capital1 Â Â 517,358 Â Â Â 227,591 Â Accumulated deficit Â Â (176,428) Â Â (152,440) Total stockholders' equity Â Â 340,997 Â Â Â 75,179 Â Â Â Â Â Â Â Total liabilities and stockholders' equity Â $ 385,919 Â Â $ 97,891 Â Â 1. Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Table of ContentsÂ Perspective Therapeutics, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (unaudited) (Dollars and shares in thousands, except for per-share amounts) Â Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Grant revenue Â $ 526 Â Â $ 588 Â Â $ 851 Â Â $ 821 Â Â Â Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 9,275 Â Â Â 5,370 Â Â Â 16,727 Â Â Â 8,679 Â General and administrative Â Â 5,514 Â Â Â 4,987 Â Â Â 11,392 Â Â Â 11,650 Â Change in estimate of asset retirement obligation (Note 4) Â Â - Â Â Â (15) Â Â - Â Â Â (15) Loss on disposal of property and equipment Â Â - Â Â Â - Â Â Â - Â Â Â 22 Â Total operating expenses Â Â 14,789 Â Â Â 10,342 Â Â Â 28,119 Â Â Â 20,336 Â Â Â Â Â Â Â Â Â Â Â Â Operating loss Â Â (14,263) Â Â (9,754) Â Â (27,268) Â Â (19,515) Â Â Â Â Â Â Â Â Â Â Â Â Non-operating income (expense): Â Â Â Â Â Â Â Â Â Â Â Â Interest income Â Â 3,076 Â Â Â 294 Â Â Â 4,287 Â Â Â 668 Â Interest and other expense Â Â (23) Â Â (26) Â Â (52) Â Â (44) Equity in loss of affiliate Â Â (4) Â Â - Â Â Â (6) Â Â - Â Total non-operating income (expense), net Â Â 3,049 Â Â Â 268 Â Â Â 4,229 Â Â Â 624 Â Â Â Â Â Â Â Â Â Â Â Â Net loss from continuing operations Â Â (11,214) Â Â (9,486) Â Â (23,039) Â Â (18,891) Net loss from discontinued operations Â Â (429) Â Â (1,620) Â Â (890) Â Â (3,086) Loss recognized on classification as held for sale Â Â (61) Â Â - Â Â Â (59) Â Â - Â Net loss before deferred income tax benefit Â Â (11,704) Â Â (11,106) Â Â (23,988) Â Â (21,977) Deferred income tax benefit Â Â - Â Â Â - Â Â Â - Â Â Â 10,500 Â Net loss Â $ (11,704) Â $ (11,106) Â $ (23,988) Â $ (11,477) Â Â Â Â Â Â Â Â Â Â Â Â Basic and diluted loss per share: Â Â Â Â Â Â Â Â Â Â Â Â Loss from continuing operations1 Â $ (0.17) Â $ (0.34) Â $ (0.40) Â $ (0.33) Loss from discontinued operations1 Â Â (0.01) Â Â (0.06) Â Â (0.01) Â Â (0.12) Basic and diluted loss per share1 Â $ (0.18) Â $ (0.40) Â $ (0.41) Â $ (0.45) Â Â Â Â Â Â Â Â Â Â Â Â Weighted average shares used in computing net loss per share: Â Â Â Â Â Â Â Â Â Â Â Â Basic and diluted1 Â Â 66,648 Â Â Â 27,999 Â Â Â 58,079 Â Â Â 25,443 Â Â 1. Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. Â The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Table of ContentsÂ Perspective Therapeutics, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows (unaudited) (In thousands) Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Â Â Â Â Net loss Â $ (23,988) Â $ (11,477) Adjustments to reconcile net loss to net cash provided by or used in operating activities: Â Â Â Â Â Â Lease expense Â Â 71 Â Â Â (14) Depreciation expense Â Â 916 Â Â Â 425 Â Write-off of inventory associated with discontinued product Â Â - Â Â Â 298 Â Loss on disposal of property and equipment Â Â - Â Â Â 22 Â Amortization of other assets Â Â 12 Â Â Â 20 Â Accretion of asset retirement obligation Â Â - Â Â Â 17 Â Equity in loss of affiliate Â Â 6 Â Â Â - Â Accrued interest on short-term investments Â Â (360) Â Â - Â Change in allowance for doubtful accounts Â Â (44) Â Â - Â Change in estimate of asset retirement obligation Â Â - Â Â Â (15) Loss on divestiture Â Â 59 Â Â Â - Â Share-based compensation Â Â 1,375 Â Â Â 2,567 Â Deferred income tax benefit Â Â - Â Â Â (10,500) Changes in operating assets and liabilities: Â Â Â Â Â Â Accounts receivable Â Â 1,023 Â Â Â 250 Â Inventory related to discontinued operations (Note 4) Â Â 11 Â Â Â 144 Â Prepaid expenses and other current assets Â Â (93) Â Â (445) Accounts payable and accrued expenses Â Â (763) Â Â 442 Â Deferred Income1 Â Â 28,000 Â Â Â - Â Accrued personnel expenses Â Â (1,279) Â Â 471 Â Net cash provided by (used in) operating activities Â Â 4,946 Â Â Â (17,795) Â Â Â Â Â Â Â CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Â Â Â Â Additions to property and equipment Â Â (10,087) Â Â (756) Additions to other assets Â Â - Â Â Â (18) Proceeds from maturity of short-term investments Â Â 38,225 Â Â Â 22,764 Â Purchases of short-term investments Â Â (78,730) Â Â - Â Net cash acquired in acquisition of Viewpoint Â Â - Â Â Â 2,699 Â Net cash (used in) provided by investing activities Â Â (50,592) Â Â 24,689 Â Â Â Â Â Â Â CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Â Â Â Â Repayment of notes payable Â Â (20) Â Â (35) Proceeds from sales of common stock, pursuant to exercise of warrants, net Â Â 123 Â Â Â - Â Proceeds from sales of common stock, pursuant to exercise of option Â Â 254 Â Â Â 532 Â Proceeds from the issuance of common stock and Pre-funded Warrants, net1 Â Â 288,055 Â Â Â - Â Issuance costs related to common stock issued in exchange for Viewpoint common stock Â Â - Â Â Â (65) Net cash provided by financing activities Â Â 288,412 Â Â Â 432 Â Â Â Â Â Â Â Net increase in cash, cash equivalents and restricted cash Â Â 242,766 Â Â Â 7,326 Â Cash, cash equivalents and restricted cash beginning of period Â Â 9,420 Â Â Â 21,175 Â CASH, CASH EQUIVALENTS AND RESTRICTED CASH END OF PERIOD Â $ 252,186 Â Â $ 28,501 Â Â Â Â Â Â Â Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets: Â Â Â Â Â Â Cash and cash equivalents Â $ 252,004 Â Â $ 28,319 Â Restricted cash Â Â 182 Â Â Â 182 Â Total cash, cash equivalents and restricted cash shown on the condensed consolidated statements of cash flows Â $ 252,186 Â Â $ 28,501 Â Â Â Â Â Â Â Supplemental schedule of noncash investing and financing activities: Â Â Â Â Â Â Recognition of operating lease liability and right-of-use asset Â $ 1,497 Â Â $ - Â Fair value of Viewpoint assets acquired including goodwill Â Â - Â Â Â 85,885 Â 13,654,5072Â shares of Perspective Therapeutics common stock issued in exchange for Viewpoint common stock Â Â - Â Â Â (54,618) Assumption of Viewpoint stock options and warrants at fair value Â Â - Â Â Â (7,836) Note receivable and accrued interest from Viewpoint forgiven Â Â - Â Â Â (6,171) 1. See Note 3, Investments and Agreements, for additional information. 2. Amount for prior period presented has been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 3 Table of ContentsÂ Perspective Therapeutics, Inc. and Subsidiaries Condensed Consolidated Statements of Changes in Stockholdersâ€™ Equity (unaudited) (In thousands, except shares) Â Â Common Stock Â Â Â Â Â Â Â Â Â Â Â Shares1 Â Â Amount1 Â Â Additional Paid-in Capital1 Â Â Accumulated Deficit Â Â Total Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balances at December 31, 2022 Â Â 14,211,276 Â Â $ 14 Â Â $ 160,560 Â Â $ (105,932) Â $ 54,642 Â Issuance of common stock in exchange forÂ Â Â Viewpoint common stock, Â Â Â net of issuance costs Â Â 13,654,507 Â Â 14 Â Â Â Â 54,539 Â Â Â - Â Â Â 54,553 Â Assumption of Viewpoint stock optionsÂ Â Â and warrants at fair value Â Â - Â Â Â - Â Â Â 7,836 Â Â Â - Â Â Â 7,836 Â Share-based compensation Â Â - Â Â Â - Â Â Â 1,368 Â Â Â - Â Â Â 1,368 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â (371) Â Â (371) Balances at March 31, 2023 Â Â 27,865,783 Â Â $ 28 Â Â $ 224,303 Â Â $ (106,303) Â $ 118,028 Â Issuance of common stock pursuant toÂ Â Â exercise of options Â Â 182,158 Â Â Â - Â Â Â 532 Â Â Â - Â Â Â 532 Â Share-based compensation Â Â - Â Â Â - Â Â Â 1,199 Â Â Â - Â Â Â 1,199 Â Net loss Â Â - Â Â Â - Â Â Â (11,106) Â Â (11,106) Balances at June 30, 2023 Â Â 28,047,941 Â Â $ 28 Â Â $ 226,034 Â Â $ (117,409) Â $ 108,653 Â Â Â Common Stock Â Â Â Â Â Â Â Â Â Â Â Shares1 Â Â Amount1 Â Â Additional Paid-in Capital1 Â Â Accumulated Deficit Â Â Total Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balances at December 31, 2023 Â Â 28,180,985 Â Â $ 28 Â Â $ 227,591 Â Â $ (152,440) Â $ 75,179 Â Issuance of common stock pursuant to theÂ Â Â Public Offering, net2 Â Â 15,639,954 Â Â Â 16 Â Â Â 53,125 Â Â Â - Â Â Â 53,141 Â Issuance of Jan. 2024 Pre-fundedÂ Â Â Warrants, net2 Â Â - Â Â Â - Â Â Â 10,208 Â Â Â - Â Â Â 10,208 Â Issuance of common stock pursuant to theÂ Â Â Lantheus Investment Agreement, net2 Â Â 5,634,235 Â Â Â 6 Â Â Â 20,840 Â Â Â - Â Â Â 20,846 Â Issuance of common stock pursuant to theÂ Â Â March 2024 Investment Agreement, net2 Â Â 9,200,998 Â Â Â 9 Â Â Â 82,010 Â Â Â - Â Â Â 82,019 Â Issuance of common stock pursuant toÂ Â Â exercise of options Â Â 35,424 Â Â Â - Â Â Â 126 Â Â Â - Â Â Â 126 Â Share-based compensation Â Â - Â Â Â - Â Â Â 656 Â Â Â - Â Â Â 656 Â Net loss Â Â - Â Â Â - Â Â Â (12,284) Â Â (12,284) Balances at March 31, 2024 Â Â 58,691,596 Â Â $ 59 Â Â $ 394,556 Â Â $ (164,724) Â $ 229,891 Â Issuance of common stock pursuantÂ Â Â Â Â to exercise of options Â Â 24,450 Â Â Â - Â Â Â 128 Â Â Â - Â Â Â 128 Â Issuance of stock pursuant to exerciseÂ Â Â of common stock warrants Â Â 22,401 Â Â Â - Â Â Â 123 Â Â Â - Â Â Â 123 Â Issuance of common stock pursuant to the ATM, net2 Â Â 3,535,246 Â Â Â 3 Â Â Â 47,930 Â Â Â - Â Â Â 47,933 Â Issuance of common stock pursuant to theÂ Â Â Registered Offering, net2 Â Â 5,151,588 Â Â Â 5 Â Â Â 71,863 Â Â Â - Â Â Â 71,868 Â Issuance of May 2024 Pre-fundedÂ Â Â Warrants, net2 Â Â - Â Â Â - Â Â Â 2,040 Â Â Â - Â Â Â 2,040 Â Share-based compensation Â Â - Â Â Â - Â Â Â 719 Â Â Â - Â Â Â 719 Â Cancellation of fractional sharesÂ Â due to the 1-for-10 reverse stock split Â Â (114) Â Â - Â Â Â (1) Â Â - Â Â Â (1) Net loss Â Â - Â Â Â - Â Â Â - Â Â Â (11,704) Â Â (11,704) Balances at June 30, 2024 Â Â 67,425,167 Â Â $ 67 Â Â $ 517,358 Â Â $ (176,428) Â $ 340,997 Â Â 1. Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. 2. See Note 3, Investments and Agreements, for additional information. Â The accompanying notes are an integral part of these condensed consolidated financial statements. 4 Table of ContentsÂ Perspective Therapeutics, Inc. Notes to the Unaudited Condensed Consolidated Financial Statements Â 1.Basis of Presentation and Summary of Significant Accounting PoliciesPerspective Therapeutics, Inc. is developing the next generation of precision-targeted alpha therapies (TAT) for oncology that have the potential to treat a large population of cancer patients across multiple tumor types, including those with metastatic disease. The accompanying unaudited condensed consolidated financial statements are those of Perspective Therapeutics, Inc., and its wholly owned subsidiaries, referred to herein as â€œPerspective Therapeuticsâ€ or the â€œCompany.â€ All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair statement of the condensed consolidated financial statements have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited consolidated financial statements and related notes as set forth in the Companyâ€™s Annual Report on Form 10-K for the period ended December 31, 2023 filed with the SEC on March 28, 2024 (2023 Form 10-K).The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures are adequate for the information not to be misleading. The unaudited condensed consolidated financial statements reflect, in managementâ€™s opinion, all adjustments of a normal, recurring nature that are necessary for the fair statement of the Companyâ€™s financial position, results of operations and cash flows for the interim periods, but are not necessarily indicative of the results expected for the full fiscal year or any other period.The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2024 will be 0%.MergerOn February 3, 2023, the Company completed the merger of Isoray Acquisition Corp., a Delaware corporation and wholly owned subsidiary of the Company, with Viewpoint Molecular Targeting, Inc. (Viewpoint) (such transaction being the Merger). Pursuant to the Merger, the Company issued 13,654,507 shares of its common stock, par value $0.001 per share (Common Stock), representing approximately 49% of its fully diluted outstanding capital stock as of the close of the Merger. Viewpoint is an alpha-particle radiopharmaceutical company in the alpha-emitter market developing oncology therapeutics and complementary imaging agents. For additional information, see Note 14, Merger, in this Form 10-Q.Discontinued OperationsOn April 12, 2024, the Company completed the sale of its Cesium-131 brachytherapy business and substantially all of the assets of Isoray Medical, Inc. (Isoray), a wholly owned subsidiary of Perspective Therapeutics, to GT Medical Technologies, Inc., a Delaware corporation (GT Medical) (such transaction being the GT Medical Closing). Pursuant to the GT Medical Closing, GT Medical issued to Isoray 279,516 shares of GT Medicalâ€™s common stock, par value $0.0001 per share, representing 0.5% of GT Medicalâ€™s issued and outstanding capital stock on a fully diluted basis as of the closing. Accordingly, the financial information and operating results of the Cesium-131 brachytherapy business have been presented as discontinued operations in the condensed consolidated financial statements for all periods presented. Unless otherwise noted, discussion within these notes to the condensed consolidated financial statements relates to continuing operations. For additional information, see Note 4, Discontinued Operations, in this Form 10-Q.Reverse Stock SplitOn June 14, 2024, the Company effected a 1-for-10 reverse stock split (Reverse Split) of the Companyâ€™s issued and outstanding shares of Common Stock, and the Common Stock began trading on a split-adjusted basis on June 17, 2024. The Reverse Split did not reduce the total number of authorized shares of Common Stock or the Companyâ€™s preferred stock (Preferred Stock), or change the par values of the Common Stock or Preferred Stock. The Reverse Split affected all stockholders uniformly and did not affect any stockholderâ€™s ownership percentage of the shares of Common Stock (except to the extent that the Reverse Split resulted in some of the stockholders receiving cash in lieu of fractional shares). All outstanding options and warrants entitling their holders to purchase shares of Common Stock were adjusted as a result of the Reverse Split, in accordance with the terms of each such security. In addition, the number of shares reserved for future issuance pursuant to the Companyâ€™s equity incentive plans was also adjusted accordingly. As a result, all historical per share data, number of shares issued and outstanding, and outstanding options and warrants for the periods presented in the accompanying condensed consolidated financial

statements and notes thereto have been adjusted retroactively in this Form 10-Q, where applicable, to reflect the Reverse Split.LiquidityThe Company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company has had a history of operating losses and an absence of significant recurring cash inflows from revenue. At June 30, 2024, the 5 Table of ContentsÂ Company had cash, cash equivalents and short-term investments of $292.9 million and total accumulated deficit of $176.4 million. The Company has historically financed its operations primarily through selling equity.The Company believes that its $292.9 million of cash, cash equivalents and short-term investments as of June 30, 2024 will enable it to fund its current planned operations into mid-2026, though it may raise additional capital through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements and/or government funding and grants.The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The operating plan may change as a result of many factors currently unknown to management, and there can be no assurance that the current operating plan will be achieved in the timeframe anticipated by management or at all, and the Company may need to seek additional funds sooner than anticipated. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from potential unknown factors.ReclassificationsIn addition to the discontinued operations discussed above, during the first quarter of 2024, the Company made certain reclassifications to prior period amounts in the condensed consolidated financial statements and accompanying notes to conform to the current period presentation. The reclassification of these items had no impact on net loss, financial position or cash flows in the current or prior periods. Specifically, accrued payroll and related taxes and accrued vacation were combined to create accrued personnel, and accrued protocol expense and accrued waste disposal were included in accounts payable and accrued expenses, all of which are presented on the condensed consolidated balance sheets and condensed consolidated statement of cash flows.Significant Accounting PoliciesThe Companyâ€™s significant accounting policies and recent accounting pronouncements are described in Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements in Item 8 of the 2023 Form 10-K. There have been no changes to the Companyâ€™s significant accounting policies, and the Company has not adopted any significant accounting policies during the six months ended June 30, 2024. 2.Loss per ShareBasic and diluted loss per share is calculated by dividing net loss by the weighted average number of shares of Common Stock outstanding and does not include the impact of any potentially dilutive common stock equivalents. In January 2024 and May 2024, the Company issued pre-funded warrants in connection with the Public Offering (as defined below) and the Registered Offering (as defined below), respectively (see Note 3, Investments and Agreements, in this Form 10-Q). As the pre-funded warrantsâ€™ exercise price is nominal and there are no conditions that must be satisfied prior to their exercise, the pre-funded warrants are included in the calculation of the basic and diluted earnings per share as of June 30, 2024. At each of June 30, 2024 and 2023, the calculation of diluted weighted average shares did not include common stock warrants or options that were potentially convertible into Common Stock as those would be antidilutive due to the Companyâ€™s net loss position.Securities not considered in the calculation of diluted loss per share, but that could be dilutive in the future, are as follows (in thousands):Â Â June 30, 2024Â Â June 30, 2023Â Common stock warrantsÂ Â 416Â Â Â 603Â Common stock optionsÂ Â 6,934Â Â Â 4,487Â Total potential dilutive securitiesÂ Â 7,350Â Â Â 5,090Â Â Effective upon the closing of the Merger with Viewpoint on February 3, 2023, the Company assumed 338,709 warrants to purchase shares of Common Stock with an exercise price of $2.70 per share and 2,426,342 options to purchase shares of Common Stock with exercise prices ranging from $1.30 to $3.00 per share. Â 3.Investments and AgreementsMay 2024 Registered OfferingOn May 24, 2024, the Company entered into an underwriting agreement with BofA Securities, Inc., as representative of the underwriters named therein, in connection with its previously announced underwritten offering (Registered Offering) of 5,151,588 shares (Registered Offering Shares) of Common Stock and, in lieu of Registered Offering Shares to certain investors, pre-funded warrants (May 2024 Pre-funded Warrants) to purchase 146,425 shares of Common Stock. The price to the investors for the Registered Offering Shares was 6 Table of ContentsÂ $15.10 per Registered Offering Share, and the price to the investors for the May 2024 Pre-funded Warrants was $15.09 per May 2024 Pre-funded Warrant, which represents the per share price for the Registered Offering Shares less the $0.01 per share exercise price for each such May 2024 Pre-funded Warrant. The Registered Offering closed on May 29, 2024. BofA Securities, Inc., Oppenheimer & Co. Inc. and RBC Capital Markets, LLC acted as joint book-running managers for the Registered Offering and B. Riley Securities, Inc. acted as a co-manager for the Registered Offering. JonesTrading Institutional Services LLC acted as a financial advisor for the Registered Offering.The gross proceeds to the Company from the Registered Offering were approximately $80 million, before underwriting discounts and commissions and estimated expenses of the Registered Offering.The Company intends to use the net proceeds from the Registered Offering for: (i) the continued clinical development of VMT-Î±-NET, VMT-01/02 and PSV359; (ii) the continued development of PSV40X and additional preclinical product candidates as well as a broader development platform; and (iii) the build out, operation and expansion of manufacturing facilities, as well as for working capital and other general corporate purposes. A portion of the net proceeds may also be used to acquire, license or invest in complementary products, technologies, intellectual property or businesses, although the Company has no present commitments or agreements to do so.The Registered Offering was made pursuant to the Companyâ€™s automatic shelf registration statement on Form S-3 (File No. 333-279692) (the May 2024 Registration Statement), which became effective upon filing with the SEC on May 24, 2024, a related base prospectus, free writing prospectus and prospectus supplement each dated May 24, 2024.The May 2024 Pre-funded Warrants became exercisable subsequent to the filing and effectiveness of an amendment to the Companyâ€™s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on June 14, 2024. The exercise price and the number of shares of Common Stock issuable upon exercise of each May 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to the Companyâ€™s stockholders. The May 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of May 2024 Pre-funded Warrants may not exercise such May 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would be more than 4.99% or 9.99%, as elected by such holder, of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the May 2024 Pre-funded Warrants. A holder of May 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 daysâ€™ prior notice to the Company.Â March 2024 Private Placement with Institutional InvestorsOn March 4, 2024, the Company entered into an investment agreement (the March 2024 Investment Agreement) with certain accredited institutional investors (Institutional Investors) pursuant to which the Company agreed to issue and sell, in a private placement (the March 2024 Private Placement), 9,200,998 shares of Common Stock, for a purchase price of $9.50 per share, representing the closing price of the Common Stock on March 1, 2024. The closing of the March 2024 Private Placement occurred on March 6, 2024.The gross proceeds to the Company from the March 2024 Private Placement were approximately $87.4 million, before deducting fees payable to the Placement Agents (as defined below) and other estimated transaction expenses. The Company intends to use the net proceeds from the March 2024 Private Placement for general corporate and working capital purposes, which may include research and development expenditures, preclinical study and clinical trial expenditures, manufacturing expenditures, commercialization expenditures, capital expenditures, acquisitions of new technologies, products or businesses and investments.The March 2024 Private Placement was conducted pursuant to a Placement Agency Agreement, dated March 4, 2024 (the Placement Agency Agreement), by and between the Company and Oppenheimer & Co. Inc., as representative of the placement agents named therein (the Placement Agents). Per the Placement Agency Agreement, the Company agreed to: (i) pay the Placement Agents a cash fee equal to 5.85% of the gross proceeds received by the Company from the sale of the shares; and (ii) reimburse the Placement Agents for certain fees and expenses. Lantheus Agreements Investment AgreementOn January 8, 2024, the Company entered into an investment agreement (the Lantheus Investment Agreement) with Lantheus Alpha Therapy, LLC, a Delaware limited liability company and wholly owned subsidiary of Lantheus Holdings, Inc. (Lantheus), pursuant to which the Company agreed to sell and issue to Lantheus in a private placement transaction certain shares (the Lantheus Shares) of Common Stock. The closing of the purchase and sale of the Lantheus Shares to Lantheus by the Company (the Lantheus Closing) 7 Table of ContentsÂ was subject to the Company raising at least $50.0 million of gross proceeds (excluding Lantheusâ€™ investment) in a qualifying third-party financing transaction, which occurred on January 22, 2024.The number of Lantheus Shares sold was 5,634,235, representing 19.99% of the outstanding shares of Common Stock as of January 8, 2024. Pursuant to the Lantheus Investment Agreement, the Company agreed to cooperate in good faith to negotiate and enter into a registration rights agreement with Lantheus, obligating the Company to file a registration statement on Form S-3 with the SEC to register for resale the Lantheus Shares issued at the Lantheus Closing. The Company filed such Form S-3 on March 29, 2024, and the SEC declared it effective on April 9, 2024 (File No. 333-278362).The Lantheus Investment Agreement also contains agreements of the Company and Lantheus whereby Lantheus is provided certain board observer and information rights of the Company, as well as standstill provisions prohibiting Lantheus from taking certain actions for a specified period of time, subject to certain exceptions.The Lantheus Investment Agreement also provides Lantheus with certain pro rata participation rights to maintain its ownership position in the Company in the event that the Company makes any public or non-public offering of any equity or voting interests in the Company or any securities that are convertible or exchangeable into (or exercisable for) equity or voting interests in the Company, subject to certain exceptions.Pursuant to the Lantheus Investment Agreement, the Company is required to notify Lantheus within 10 business days of the end of a fiscal quarter in which the Company issued shares of Common Stock pursuant to that certain At Market Issuance Sales Agreement among the Company, Oppenheimer & Co. Inc., B. Riley Securities, Inc., and JonesTrading Institutional Services LLC dated November 17, 2023 (the ATM Agreement), of (i) the number of shares of Common Stock issued during such fiscal quarter pursuant to the ATM Agreement and (ii) the average price per share received by the Company before commissions (the ATM Average Price). Upon receipt of such notice, Lantheus may elect, at its option, to purchase all or a portion of its Pro Rata Portion (as defined in the Lantheus Investment Agreement) of such shares at an aggregate price equal to the number of shares purchased multiplied by the ATM Average Price for such quarter (the ATM Participation Right). Pursuant to the Lantheus Investment Agreement, Lantheus may not exercise the ATM Participation Right more than two times per calendar year. Asset Purchase AgreementOn January 8, 2024, the Company entered into an Asset Purchase Agreement (the Progenics APA) with Progenics Pharmaceuticals, Inc., a Delaware corporation (Progenics) and affiliate of Lantheus, pursuant to which the Company acquired certain assets and the associated lease of Progenicsâ€™ radiopharmaceutical manufacturing facility in Somerset, New Jersey for a purchase price of $8.0 million in cash. The transactions contemplated by the Progenics APA closed on March 1, 2024. Option AgreementOn January 8, 2024, the Company entered into an option agreement (the Option Agreement) with Lantheus whereby Lantheus was granted an exclusive option to negotiate an exclusive, worldwide, royalty- and milestone-bearing right and license to [212Pb]VMT-Î±-NET, the Companyâ€™s clinical-stage alpha therapy developed for the treatment of neuroendocrine tumors. If good-faith negotiations fail, Lantheus has a one-year right to reenter negotiations if a third party offers to purchase or license the [212Pb]VMT-Î±-NET program. Additionally, Lantheus has a right to co-fund the Investigational New Drug (IND) application, enabling studies for early-stage therapeutic candidates targeting prostate-specific membrane antigen and gastrin-releasing peptide receptor and, prior to IND filing, a right to negotiate for an exclusive license to such candidates. In consideration of the rights granted by the Company to Lantheus pursuant to the Option Agreement, Lantheus paid to the Company a one-time payment of $28.0 million, subject to certain withholding provisions associated with the closing of the Progenics APA.Under the terms of the Option Agreement, Lantheus also has a right of first offer and last look protections for any third-party merger and acquisition transactions involving the Company for a 12-month period beginning on January 8, 2024.The Company determined that the Option Agreement should be accounted for as a research and development arrangement in accordance with ASC 730-20, Research and Development Arrangements, as Lantheus held approximately 19.9% of the Companyâ€™s outstanding Common Stock at March 31, 2024. The Option Agreement contains no repayment provisions, does not create any obligation to enter into any license, transfer or sale agreements with Lantheus, and does not restrict the use of the funds in any way.Accordingly, the balance sheet reports current and long-term liabilities related to these options under the caption, â€œDeferred Income.â€ The values for each distinct option within the Option Agreement were determined by estimating the fair value of each distinct option by a third-party valuation firm and the liabilities will be recognized as income in the condensed consolidated statement of operations as the various options expire. 8 Table of ContentsÂ January 2024 Public OfferingOn January 17, 2024, the Company entered into an underwriting agreement (Underwriting Agreement) with Oppenheimer & Co. Inc., as representative of the underwriters named therein (the Underwriters), in connection with its previously announced underwritten public offering (Public Offering) of 13,207,521 shares (Public Shares) of Common Stock and, in lieu of Public Shares to certain investors, pre-funded warrants (Jan. 2024 Pre-funded Warrants) to purchase 3,008,694 shares of Common Stock. The price to the public for the Public Shares was $3.70 per Public Share, and the price to the public for the Jan. 2024 Pre-funded Warrants was $3.69 per Jan. 2024 Pre-funded Warrant, which represents the per share price for the Public Shares less the $0.01 per share exercise price for each such Jan. 2024 Pre-funded Warrant. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 2,432,432 shares of Common Stock at the same price per share as the Public Shares, which was fully exercised by the Underwriters on January 18, 2024. The Public Offering closed on January 22, 2024.The gross proceeds to the Company from the Public Offering were approximately $69.0 million, before underwriting discounts and commissions and estimated expenses of the Public Offering.The Company intends to use the net proceeds from the Public Offering for general corporate purposes, which may include research and development expenditures, preclinical study and clinical trial expenditures, manufacturing expenditures, commercialization expenditures, working capital, capital expenditures, acquisitions of new technologies, products or businesses and investments.The Public Offering was made pursuant to the Companyâ€™s shelf registration statement on Form S-3 (File No. 333-275638), declared effective by the SEC on December 14, 2023, a base prospectus dated December 14, 2023, and the related prospectus supplement dated January 17, 2024.The Jan. 2024 Pre-funded Warrants are exercisable at any time after the date of issuance. The exercise price and the number of shares of Common Stock issuable upon exercise of each Jan. 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to the Companyâ€™s stockholders. The Jan. 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of Jan. 2024 Pre-funded Warrants may not exercise such Jan. 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would beneficially own more than 4.99% of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the Jan. 2024 Pre-funded Warrants. A holder of Jan. 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 daysâ€™ prior notice to the Company.Â ATM AgreementPursuant to the ATM Agreement, the Company has established an â€œat-the-marketâ€ equity program under which it may offer and sell shares of its Common Stock, from time to time.On November 17, 2023, the Company filed a shelf registration statement on Form S-3 with the SEC (File No. 333-275638) and accompanying base prospectus, declared effective by the SEC on December 14, 2023, for the offer and sale of up to $200 million of its securities (December 2023 Registration Statement). Also on November 17, 2023, the Company filed a prospectus supplement with the SEC in connection with the offering of up to $50 million of shares of its Common Stock pursuant to the ATM Agreement under the December 2023 Registration Statement. In December 2023, the Company sold 123,882 shares under the ATM Agreement at an average price of approximately $3.03 per common share for gross proceeds of approximately $0.4 million.On April 11, 2024, the Company sold 3,535,246 shares of its Common Stock under the ATM Agreement at an average price of approximately $14.00 per common share, resulting in gross proceeds of approximately $49.5 million.On May 25, 2024, the Company terminated the offering of securities pursuant to the December 2023 Registration Statement in connection with the filing and effectiveness of the May 2024 Registration Statement.For additional information related to the various agreements discussed above, see Note 20, Subsequent Events, in the Companyâ€™s 2023 Form 10-K. Â 4.Discontinued OperationsThe GT Medical Closing occurred on April 12, 2024 (GT Medical Closing Date). Previously, the Company announced that on December 7, 2023, Isoray entered into an Asset Purchase Agreement (GT Medical APA) by and among Isoray, the Company, and GT Medical pursuant to which Isoray would sell to GT Medical, and GT Medical would purchase from Isoray, all of Isorayâ€™s right, title and interest in and to substantially all of the assets of Isoray related to Isorayâ€™s commercial Cesium-131 business (the Business) including equipment, 9 Table of ContentsÂ certain contracts, inventory and intellectual property. Subject to limited exceptions set forth in the GT Medical APA, GT Medical did not assume the liabilities of Isoray.Pursuant to the terms of, and subject to the conditions specified in, the GT Medical APA, at the GT Medical Closing, (i) GT Medical issued to Isoray 279,516 shares of GT Medicalâ€™s common stock, par value $0.0001 per share, representing 0.5% of GT Medicalâ€™s issued and outstanding capital stock on a fully diluted basis as of the GT Medical Closing Date and (ii) Isoray has the right to receive, and GT Medical is obligated to pay, certain cash royalty

payments during each of the first four years beginning upon the GT Medical Closing Date (each such year, a Measurement Period), as summarized below:â€¢with respect to GT Medicalâ€™s net sales of Cesium-131 brachytherapy seeds for cases that do not utilize GT Medicalâ€™s GammaTile Therapy: (a) if such net sales for a Measurement Period are $10 million or less, 3.0% of such net sales; (b) if such net sales for a Measurement Period are greater than $10 million and less than $15 million, 4.0% of such net sales; and (c) if such net sales for a Measurement Period are $15 million or more, 5.0% of such net sales; andâ€¢with respect to GT Medicalâ€™s net sales of GT Medicalâ€™s GammaTile Therapy utilizing Cesium-131 brachytherapy seeds: 0.5% of such net sales for a Measurement Period.In accordance with ASC 205-20, Presentation of Financial Statements â€“ Discontinued Operations, the following table presents the major classes of assets and liabilities of discontinued operations of the Business reported in the condensed consolidated balance sheets and prior year amounts have been reclassified.Â Â Â June 30, 2024 Â Â December 31, 2023 Â (in thousands) Â Â Â Â Â Â Assets held for sale of discontinued operations, current Â Â Â Â Â Â Inventory Â $ - Â Â $ 3,148 Â Prepaid expenses and other current assets Â Â - Â Â Â 169 Â Property and equipment, net Â Â - Â Â Â 1,263 Â Right-of-use asset, net Â Â - Â Â Â 676 Â Other assets, net Â Â - Â Â Â 45 Â Total current assets held for sale of discontinued operations Â $ - Â Â $ 5,301 Â Â Â Â Â Â Â Â Liabilities held for sale of discontinued operations, current Â Â Â Â Â Â Lease liability Â $ - Â Â $ 677 Â Asset retirement obligation Â Â - Â Â Â 225 Â Loss recognized on classification as held for sale Â Â - Â Â Â 4,170 Â Total current liabilities of discontinued operations Â $ - Â Â $ 5,072 Â The following table presents the components of discontinued operations in relation to the Business reported in the unaudited condensed consolidated statements of operations (in thousands):Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Sales, net Â $ 205 Â Â $ 1,500 Â Â $ 2,178 Â Â $ 3,330 Â Cost of sales Â Â 162 Â Â Â 1,840 Â Â Â 1,564 Â Â Â 3,416 Â Gross profit Â Â 43 Â Â Â (340) Â Â 614 Â Â Â (86) Â Â Â Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 21 Â Â Â 283 Â Â Â 69 Â Â Â 831 Â Sales and marketing Â Â 138 Â Â Â 911 Â Â Â 941 Â Â Â 1,723 Â General and administrative Â Â 313 Â Â Â 86 Â Â Â 494 Â Â Â 446 Â Total operating expenses Â Â 472 Â Â Â 1,280 Â Â Â 1,504 Â Â Â 3,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total loss from discontinued operations Â $ (429) Â $ (1,620) Â $ (890) Â $ (3,086) The Company determined the loss recognized on classification as held for sale by identifying the assets and liabilities that are included in the GT Medical APA and are included in the table above. Additionally, the loss recognized on classification as held for sale was determined using the estimated fair value of the GT Medical stock of $0.2 million received less the carrying value of the net assets sold. The fair value of the stock received was determined based on information provided to the Company by GT Medical from a current valuation study that was prepared for them. Excluded from the calculation of the loss are contingent royalties that could be received from future sales.10 Table of ContentsÂ Certain amounts included in the unaudited condensed consolidated statements of cash flows related to the discontinued operations are as follows (in thousands):Â Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Depreciation Â $ - Â Â $ 111 Â Amortization Â Â - Â Â Â 18 Â Write-off of inventory associated with discontinued product Â Â - Â Â Â 298 Â Share-based compensation Â Â 166 Â Â Â 535 Â Additions to property and equipment Â Â - Â Â Â 186 Â For the three and six months ended June 30, 2024 and 2023, there was no provision (benefit) for income taxes recorded related to the discontinued operations. Additionally, the Company is in a loss position and has recorded a full valuation allowance for the deferred tax assets associated with the discontinued operations. Â 5.Property and EquipmentThe Companyâ€™s property and equipment consisted of the following as of:Â Â Â June 30, 2024 Â Â December 31, 2023 Â Â Â (in thousands) Â Building Â $ 1,770 Â Â $ 1,770 Â Land Â Â 1,283 Â Â Â 1,283 Â Equipment Â Â 9,470 Â Â Â 2,683 Â Leasehold improvements Â Â 3,490 Â Â Â 179 Â Other1 Â Â 319 Â Â Â 330 Â Property and equipment Â Â 16,332 Â Â Â 6,245 Â Less accumulated depreciation Â Â (1,585) Â Â (669) Property and equipment, net Â $ 14,747 Â Â $ 5,576 Â 1.Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized.Â On July 15, 2024 and August 2, 2024, the Company purchased a building located in Houston, Texas, for $4.7 million and a building in Chicago, Illinois, for $5.0 million, respectively, which it intends to use for the manufacture of its program candidates upon completion of modifications and installation of equipment. Â 6.Goodwill and Other Intangible AssetsGoodwillThe carrying amount of goodwill as of both June 30, 2024 and December 31, 2023 was $24.1 million and has been recorded in connection with the Companyâ€™s Merger of Viewpoint in February 2023. The Company tests goodwill and indefinite-lived intangible assets for impairment during the fourth quarter of each year, or more frequently should circumstances change or events occur that would more likely than not reduce the fair value of its assets. No testing was deemed necessary during the three and six months ended June 30, 2024.The following table summarizes the components of the Companyâ€™s other intangible assets (in thousands): Â June 30, 2024 Â Â Cost Â Â Accumulated Amortization Â Â Net Carrying Value Â Indefinite-lived intangible assets Â Â Â Â Â Â Â Â Â In-process research and development Â $ 50,000 Â Â $ - Â Â $ 50,000 Â Total Â $ 50,000 Â Â $ - Â Â $ 50,000 Â Â 11 Table of ContentsÂ Â December 31, 2023 Â Â Cost Â Â Accumulated Amortization Â Â Net Carrying Value Â Indefinite-lived intangible assets Â Â Â Â Â Â Â Â Â In-process research and development Â $ 50,000 Â Â $ - Â Â $ 50,000 Â Total Â $ 50,000 Â Â $ - Â Â $ 50,000 Â The Companyâ€™s IPR&D assets represent the estimated fair value of Viewpointâ€™s pipeline of radiotherapy product candidates acquired in February 2023. The estimated fair value of the IPR&D assets at the acquisition date was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flow estimates for Viewpointâ€™s pipeline of radiotherapy program candidates were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the Merger date and the time and resources needed to complete development. Â 7.Held-to-Maturity InvestmentsThe following table summarizes the carrying values and fair values of the Companyâ€™s financial instruments (in thousands): Â June 30, 2024 Â Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Estimated Fair Value Â U.S. Treasury Bills Â $ 40,865 Â Â $ - Â Â $ (11) Â $ 40,854 Â The Company has investments in U.S. Treasury Bills, some of which mature over a period greater than 90 days and are classified as short-term investments. The U.S. Treasury Bills are carried at amortized cost and classified as held-to-maturity as the Company has the intent and the ability to hold them until they mature. The carrying value of the U.S. Treasury Bills are adjusted for accretion of discounts over the remaining life of the investment. Income related to the U.S. Treasury Bills is recognized in interest income in the Companyâ€™s condensed consolidated statement of operations. Based on its analysis of the held-to-maturity securities, the Company determined the gross unrealized losses were primarily due to changes in interest rates and not due to credit risks. As such, the Company did not record a credit allowance as of June 30, 2024. As of December 31, 2023, the Company had no held-to-maturity investments, and no held-to-maturity investments were presented in cash and cash equivalents on its condensed consolidated balance sheet. Â 8.Fair Value MeasurementsFair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:Level 1 - Observable inputs such as quoted prices in active markets;Level 2 - Inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions (less active markets), or model-driven valuations in which all significant inputs are observable or can be derived principally from, or corroborated with, observable market data; andLevel 3 - Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.Included in the Companyâ€™s cash and cash equivalents in the condensed consolidated balance sheet is its money market fund, which is measured at fair value on a recurring basis and categorized using the fair value hierarchy (in thousands): Â June 30, 2024 Â Â Â Estimated Fair ValueLevel 1 Â Money market fund Â $ 249,663 Â There were no Level 2 or Level 3 financial instruments measured at fair value on a recurring basis at June 30, 2024, and the Company did not have any financial instruments measured at fair value on a recurring basis at December 31, 2023.For information related to our short-term investments, see Note 7, Held-to-Maturity Investments. Â 12 Table of ContentsÂ 9.Share-Based CompensationOn May 31, 2024, the Company held its 2024 Annual Meeting of Stockholders (Annual Meeting). At the Annual Meeting, the Companyâ€™s stockholders approved the Companyâ€™s Third Amended and Restated 2020 Equity Incentive Plan (the Amended and Restated Plan) which, among other things, (a) increased the aggregate number of shares of Common Stock authorized for issuance under the Amended and Restated Plan by 4,870,092 for a total of 12,500,000 shares of Common Stock, and (b) adjusted the â€œevergreenâ€ provision included therein, such that the number of shares of Common Stock available for the grant of awards under the Amended and Restated Plan will automatically increase on January 1 of each year in an amount equal to 5% of the number of shares of Common Stock issued and outstanding on December 31 of the immediately preceding year (subject to adjustment in the event of stock splits and other similar events); provided, however, that the Companyâ€™s Board of Directors may act prior to January 1 of a given year to provide that there will be no increase in the share limit for such year or provide that the increase for such year will be a lesser number of shares of Common Stock.The following table presents the share-based compensation expense recognized for all share-based compensation arrangements (in thousands):Â Three Months Ended June 30, Â Six Months Ended June 30, Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development $ 259 Â Â $ 429 Â Â $ 522 Â Â $ 584 Â General and administrative Â 328 Â Â Â 621 Â Â Â 687 Â Â Â 1,448 Â Total share-based compensation $ 587 Â Â $ 1,050 Â Â $ 1,209 Â Â $ 2,032 Â Â 10.Commitments and ContingenciesThe Company has been in settlement negotiations with a representative for six stockholder plaintiff firms alleging the Company violated Delaware law in its preliminary proxy statement that was disseminated to stockholders in November 2022 for the Companyâ€™s annual meeting held in December 2022. Based on these settlement negotiations to date, the Company estimates that it will settle for no more than an aggregate of $0.2 million and, therefore, recorded an estimated liability of $0.2 million as of December 31, 2023. There was no change in the estimate as of June 30, 2024. This balance is included in accrued expenses on the unaudited condensed consolidated balance sheets. Â 11.Related PartiesÂ In connection with the Lantheus Investment Agreement entered into with Lantheus on January 8, 2024, the Company agreed to sell and issue the Lantheus Shares. The number of Lantheus Shares sold was 5,634,235, representing 19.99% of the outstanding shares of Common Stock as of January 8, 2024.Â On January 8, 2024, the Company entered into the Progenics APA with Progenics, an affiliate of Lantheus, for a purchase price of $8.0 million. On March 1, 2024, the Company closed on the transactions contemplated by the Progenics APA.Â On March 4, 2024, the Company entered into the March 2024 Investment Agreement in which the Company agreed to issue and sell 9,200,998 shares of Common Stock. Lantheus, a significant stockholder of the Company, purchased part of the shares issued to increase their ownership percentage to approximately 19.9% in the Company following the closing of the March 2024 Investment Agreement on March 6, 2024.Â For additional information regarding the Lantheus Investment Agreement, the Progenics APA and the March 2024 Investment Agreement, see Note 3, Investments and Agreements. Â 12.LeasesThe Company accounts for its leases under ASC 842, Leases. Effective April 1, 2024, the Company entered into a lease with the Board of Regents, State of Iowa, for lab and office space at the BioVentures Center. The lease terminates in March 2026. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $1.1 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate.The Company acquired a lease from Progenics, an affiliate of Lantheus, for a production facility in Somerset, New Jersey effective on March 1, 2024 (see Note 3, Investments and Agreements, in this Form 10-Q). The lease terminates on November 29, 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $0.3 million on the balance sheet based 13 Table of ContentsÂ upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate.On July 1, 2023, the Company entered into a lease with Unico Properties LLC for office space in Seattle, Washington that terminates in October 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $0.8 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate.The weighted average remaining term and discount rate for the Companyâ€™s operating leases as of June 30, 2024 was 3.2 years and 8%, respectively.The Companyâ€™s operating lease expense was $0.2 million and $0.3 million for the three and six months ended June 30, 2024, respectively, and there was no operating lease expense for the three and six months ended June 30, 2023.The following table presents the future operating lease payments and lease liability included on the condensed consolidated balance sheet related to the Companyâ€™s operating leases as of June 30, 2024 (in thousands):Â Year Ending December 31, Â Â Â 2024 (remaining six months) Â $ 408 Â 2025 Â Â 949 Â 2026 Â Â 482 Â 2027 Â Â 320 Â 2028 Â Â 283 Â Total Â Â 2,442 Â Less: imputed interest Â Â (272) Total lease liability Â Â 2,170 Â Less current portion Â Â (720) Non-current lease liability Â $ 1,450 Â Â Asset Retirement ObligationThe Company had an asset retirement obligation (ARO) associated with the facility it leased in Richland, Washington. This lease is included in the GT Medical APA and was assigned to GT Medical upon the GT Medical Closing, which occurred on April 12, 2024. As such, this liability is no longer reported as an ARO in the Companyâ€™s condensed consolidated financial statements as of June 30, 2024 and December 31, 2023. However, the Company maintains the estimated liability in its condensed consolidated financial statements related to hazardous waste removal. The estimated liability at each of June 30, 2024 and December 31, 2023 was $0.5 million and is included within the accounts payable and accrued expenses in the condensed consolidated balance sheets. Â 13.Notes PayableThe Company assumed two notes payable effective upon the closing of the Merger with Viewpoint on February 3, 2023. On July 19, 2019, Viewpoint entered in a promissory note agreement with the Iowa Economic Development Authority (IEDA) for $0.1 million at 3% interest rate to be paid over 36 monthly payments beginning on the first day of the first month following Viewpoint closing on a $1.0 million equity fundraising round. Final payment was paid in September 2023. The loan was granted as a form of financial assistance to Viewpoint from IEDA.Â On December 29, 2022, Viewpoint obtained a promissory note in the amount of $1.7 million for the purpose of purchasing land and a building in Coralville, Iowa. The note bears interest at 6.15% per annum and is collateralized by the property. The note requires monthly principal and interest payments, and a balloon payment of approximately $1.5 million is due on December 29, 2027.The following table presents the current and long-term portions of the note payable (in thousands):Â Â June 30, Â Â December 31, Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Note payable Â $ 1,705 Â Â $ 1,725 Â Less: current portion Â Â (54) Â Â (49) Note payable, long-term portion Â $ 1,651 Â Â $ 1,676 Â Â 14 Table of ContentsÂ The following table presents the future principal payments included on the condensed consolidated balance sheet related to the Companyâ€™s note payable as of June 30, 2024 (in thousands):Â Years ending December 31: Â Â Â 2024 (remaining six months) Â $ 29 Â 2025 Â Â 52 Â 2026 Â Â 55 Â 2027 Â Â 1,569 Â Total Â $ 1,705 Â Â 14.MergerOn February 3, 2023, the Company acquired 100% of the issued and outstanding equity and voting shares of Viewpoint Molecular Targeting, Inc. in exchange for 13,654,507 shares of Common Stock with a fair value of $54.6 million based on the closing market price of $4.00 per share on the acquisition date. At the closing of the Merger, the Company forgave the note receivable entered into in November 2022 and the associated accrued interest with Viewpoint that was included in the note receivable. The total amount forgiven was $6.2 million, representing the $6.0 million loan and $0.2 million accrued interest. The Company also assumed all of Viewpointâ€™s outstanding stock options and warrants as of the Merger date.Â Viewpoint is developing the next generation of TAT for oncology that have the potential to treat a large population of cancer patients across multiple tumor types, including those with metastatic disease. By leveraging its proprietary TAT platform, Viewpoint aims to develop alpha-emitting radiopharmaceuticals that can be attached to targeting peptides to deliver the radioactive payload directly to difficult to treat tumors. The Merger was completed to provide the Company with a new isotope in a larger market. The Company accounted for the transaction as a business combination in accordance ASC 805, Business Combinations. The Company has performed an allocation of the purchase price paid for the assets acquired and the liabilities assumed with the assistance of an independent valuation firm. The Viewpoint purchase price consideration and allocation to net assets acquired is presented below (in thousands except for share price):Â Fair value of consideration transferred Â Â Â Perspective Therapeutics common stock issued (13,654,507Â x $4.00) Â $ 54,618 Â Assumption of Viewpoint stock options and warrants at fair value Â Â 7,836 Â Note receivable and interest from Viewpoint forgiven Â Â 6,171 Â Total fair value of consideration transferred Â $ 68,625 Â Â Recognized amounts of identifiable net assets acquired Â Â Â Assets acquired Â Â Â Cash and cash equivalents Â $ 2,699 Â Grants receivable Â Â 95 Â Prepaid expenses Â Â 396 Â Property and equipment Â Â 5,050 Â Right of use asset Â Â 10 Â Intangible assets, in-process research and development Â Â 50,000 Â Other assets Â Â 316 Â Total assets acquired Â Â 58,566 Â Â Â Liabilities assumed Â Â Accounts payable and accrued expenses Â Â 2,968 Â Lease liability Â Â 10 Â Accrued payroll and related taxes Â Â 1,642 Â Accrued vacation Â Â 333 Â Notes payable Â Â 1,807 Â Deferred tax liability Â Â 7,243 Â Total liabilities assumed Â Â 14,003 Â Â Â Â Net assets acquired, excluding goodwill Â Â 44,563 Â Total purchase price consideration Â Â 68,625 Â Â Â Â Goodwill Â $ 24,062

Â Â 15 Table of ContentsÂ Goodwill is calculated as the difference between the acquisition date fair value of the consideration and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized and is not currently assumed to be deductible for tax purposes. The goodwill is attributable to the workforce of the acquired business and the synergies expected to arise from the acquisition of Viewpoint.Upon completion of the Merger, Viewpoint became a wholly owned subsidiary of the Company and its results of operations have been included in the Companyâ€™s condensed consolidated financial statements.Since the closing date, Viewpointâ€™s results of operations have been reported in the Companyâ€™s condensed consolidated financial statements and include grant revenue of approximately $0.5 million and $0.6 million, respectively, and operating loss of $13.6 million and $7.3 million, respectively, for the three months ended June 30, 2024 and 2023, and grant revenue of approximately $0.9 million and $0.8 million, respectively, and operating loss of $23.7 million and $11.1 million, respectively, for the six months ended June 30, 2024 and 2023.The pro forma financial information below represents the combined results of operations as if the acquisition had occurred on January 1, 2022, the beginning of the comparable prior year reporting period. The unaudited pro forma financial information is presented for informational purposes only and is neither indicative of the results of operations that would have occurred if the acquisition had taken place at the beginning of the period presented nor indicative of future operating results.The information below reflects certain nonrecurring pro forma adjustments that were directly related to the business combination based on available information and certain assumptions that we believe are reasonable:Â Â Three Months Ended June 30, 2023Â Â Six Months Ended June 30, 2023Â (in thousands)Â Â Â Â Â Â Â Grant revenueÂ $ 588Â Â $ 905Â Net lossÂ Â (9,486)Â Â (16,160)Â 16 Table of ContentsÂ ITEM 2 â€“ MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together (i) with the unaudited condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (Form 10-Q), (ii) with our audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on March 28, 2024 (2023 Form 10-K) and (iii) with other filings we have made with the SEC. As discussed under the heading â€œCautionary Note Regarding Forward-Looking Statements,â€ this discussion contains forward-looking statements that reflect our plans, estimates and beliefs, and involves numerous risks and uncertainties, including but not limited to those described under the heading â€œRisk Factorsâ€ in our 2023 Form 10-K that may cause actual results to differ materially from those described in or implied by any forward-looking statements. Unless the context otherwise requires, references in these notes to â€œthe Company,â€ â€œPerspective,â€ â€œwe,â€ â€œus,â€ and â€œourâ€ except where the context requires otherwise, refer to Perspective Therapeutics, Inc. and its subsidiaries. References to â€œViewpointâ€ refer to Viewpoint Molecular Targeting, Inc., a wholly owned subsidiary, and references to â€œIsorayâ€ refer to Isoray Medical, Inc., a wholly owned subsidiary. Overview We are developing the next generation of precision-targeted alpha therapies (TAT) for oncology that have the potential to treat a large population of cancer patients across multiple tumor types, including those with metastatic disease. By leveraging our proprietary TAT platform, we aim to develop alpha-emitting radiopharmaceuticals that can be attached to targeting peptides to deliver the radioactive payload directly to difficult-to-treat tumors. The foundation of our TAT platform is our Pb-specific chelator (PSC) and peptide linker technology, which is designed to enable us to connect our alpha-emitting isotope of choice, Lead-212 (212Pb or Pb-212), to a desired targeting peptide to deliver radiation directly to cancer cells. Unlike commercially available chelators and linkers, our proprietary PSC and peptide linker have shown, in preclinical studies, the differentiated ability to promote enhanced clearance of the non-tumor localized 212Pb payload without sacrificing the uptake of the alpha particle into the tumor. Rapid clearance of the alpha-emitting isotope from normal tissues is important to enhance tolerability and widen the therapeutic window of our program candidates. We are also developing complementary diagnostics that utilize the same targeting peptide and imaging isotopes such as Lead-203 (203Pb or Pb-203), Gallium-68 (68Ga or Ga-68) or Copper-64 (64Cu or Cu-64) to provide the opportunity to understand which patients may respond to targeted therapy. Our platform generates TATs that are comprised of three components: (i) a targeting peptide that is designed to selectively target ligands that are unique to, or preferentially expressed on, cancer cells throughout the body; (ii) the alpha-emitting medical isotope 212Pb designed to kill cancer cells; and (iii) our proprietary linker that attaches the targeting molecule to the radioactive payload. We utilized our TAT platform to discover, design and develop our initial programs, VMT-Î±-NET and VMT01, which are currently in ongoing Phase 1 clinical trials, and we plan to continue to leverage our platform to assess the potential of and develop multiple additional pipeline programs. Using our proprietary platform technology, VMT-Î±-NET and VMT01 are engineered to target cancer-specific receptors on tumor cells. [212Pb]VMT-Î±-NET is a TAT in development for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing tumors who have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera. We have initiated dosing in Cohorts 1 and 2 of our Phase 1/2a study of [212Pb]VMT-Î±-NET in patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs). In April 2024, we announced that this program was selected by the U.S. Food and Drug Administration (FDA) to participate in the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program. FDAâ€™s CDRP Program was initiated in 2022 to facilitate alignment of CMC development of novel products under investigational new drug (IND) applications with expedited clinical development timeframes based upon the anticipated clinical benefits of earlier patient access. During the quarter ended June 30, 2024, the observation period was completed for dose limiting toxicity (DLT) in seven patients enrolled in Cohort 2. Subsequently, the safety monitoring committee (SMC) determined that the safety data observations during the DLT period supported proceeding with dose escalation to Cohort 3, as well as expanding the number of patients for inclusion in Cohort 2 by 40 for a total of up to 47. The protocol amendment to expand the number of patients dosed at 5 mCi has been allowed to proceed, and patient enrollment is open. Data informing the SMCâ€™s recommendation and FDA consultation is expected to be submitted to an upcoming scientific forum in the second half of 2024. Based on FDA interactions prior to the initiation of patient dosing in this study, the decision to open a Cohort 3 would follow after consultation and alignment with the agency, which is expected prior to year end. [212Pb]VMT01 is a TAT in development for second-line or later treatment of patients with progressive MC1R-positive metastatic melanoma. In January 2024, we announced that we began patient recruitment for the second dosing cohorts (Cohort 2) in clinical studies for [212Pb]VMT01, after the SMC unanimously recommended moving forward. As of August 9, 2024, we had initiated dosing of patients in Cohort 1 and in Cohort 2 of the Phase 1/2a clinical study of [212Pb]VMT01. A total of seven patients received activities of 5 mCi of [212Pb]VMT01 in Cohort 2. In March 2024, we entered into a clinical trial collaboration with Bristol Meyerâ€™s Squibb to evaluate the safety and tolerability of [212Pb]VMT01 in combination with Bristol Meyerâ€™s Squibbâ€™s nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. An amendment has been submitted to explore the combination of the 17 Table of ContentsÂ checkpoint inhibitor nivolumab with [212Pb]VMT01 in patients with histologically confirmed melanoma and positive MC1R imaging scans in our ongoing Phase 1/2a clinical study of [212Pb]VMT01. In January 2024, we announced that we have a license agreement with Mayo Clinic for the rights to Mayo's prostate-specific membrane antigen (PSMA) Alpha-PET DoubLET platform technology for the treatment of PSMA-expressing cancers, with an initial focus on prostate. This radiopharmaceutical platform provides detailed PET imaging-based diagnosis and dosimetry using long-lived CU-64 for imaging and alpha-particle targeted therapies using 212Pb. Preclinical studies are ongoing to assess whether this new molecular entity meets the hurdle for progressing into the clinic with potential to achieve best-in-class profile. In March 2024, we disclosed a novel pre-IND stage asset (PSV359) that targets fibroblast activation protein-Î±, which is associated with a variety of solid tumors. We are currently working on an IND which we expect to file in late 2024. If the study may proceed, we expect that the U.S. Phase 1 study would commence in 2025. Â Pre-targeting technology enabling the use of antibodies to direct radiolabeled ligands to tumor sites. Antibodies can bind with high specificity to a wider variety of cancer-specific proteins preferentially expressed on the surface of tumor cells. However, the amount of time required for an adequate amount of antibodies to bind to the cancer-specific proteins may not align with the properties of the desired isotope. By attaching an additional chemical entity to an antibody that would bind to a radioligand, the resultant modified antibodies may be administered separately from and in advance of the radioligand as appropriate. Preclinical optimization of this platform is underway, and initial targeting antibodies have been identified for further investigation. Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting On June 10, 2024, we announced six updates featuring our alpha-particle radiopharmaceuticals at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting. The data presentations highlighted favorable safety profiles and potential benefits of our lead clinical candidates. Specifically, we reported on a Phase 0 imaging trial that is evaluating the optimal imaging timepoint(s) for diagnostic/dosimetric performance of [203Pb]-VMT-Î±-NET in neuroendocrine tumors. Investigators analyzed 48 lesions across nine patients, and the results showed that tumor uptake of [203Pb]-VMT-Î±-NET peaked at approximately four hours post-injection, with 98% of maximum uptake observed at one hour. The results suggest that imaging with [203Pb] VMT-Î±-NET at four hours post-injection has the best overall diagnostic performance, followed closely by imaging at one hour. The lead investigator reported on an exploratory first-in-human use of [212Pb]VMT-Î±-NET in adult patients with histologically confirmed metastatic NETs and medullary thyroid carcinomas in an investigator-led research study in India. The investigator reported updated safety and anti-tumor activity of [212Pb]VMT-Î±-NET administered at 2.5 MBq/kg every eight weeks in 13 patients as of the data cut-off date of May 31, 2024. All patients received prior treatments, eight of whom received prior peptide receptor radionuclide therapy (PRRT) treatment. Six patients remained eligible for further treatments as of the data cut-off date. The investigator concluded that the toxicity profile suggests the potential for dose escalation to achieve optimal treatment responses. Confirmed tumor response per RECIST 1.1 was reported to be observed in eight of the thirteen patients, while unconfirmed responses were observed in two additional patients who eventually had progressive disease and died. Median progression free survival was reported to be 16.4 months (95% confidence interval: 3.5 to NA). The investigator also reported higher absorbed doses in the tumors compared to select other tissues. Additionally, another investigator reported on 212Pb-VMT-Î±-NET planning based on 203Pb-VMT-Î±-NET predictive dosimetry in an investigator-sponsored trial. The investigators applied patient-specific dosimetry in a Phase 0 imaging trial (NCT05111509) of [203Pb]VMT-a-NET and in the first cohort of a Phase I absorbed-dose escalation study (NCT06148636) of [212Pb]VMT-Î±-NET. Ten patients with Î²-PRRT-relapsed or refractory gastroenteropancreatic NETs received [203Pb]VMT-Î±-NET (5 mCi) followed by sequential blood sampling, planar imaging and qSPECT/CT imaging at 1 hour, 4 hours, 24 hours and 48 hours post-administration. Three of ten patients received amino acid infusions while seven patients did not receive amino acids. The dosimetry showed that the average renal doses for patients who received amino acids was 0.46Â±0.20 Gy/mCi, as compared to 0.56Â±0.16 Gy/mCi for patients who did not receive amino acids; the difference was not statistically significant. For the three patients who received [212Pb]VMT-Î±-NET treatment, based upon their individual dosimetry results, they were prescribed 5.3, 7.3, and 13.3 mCi cumulative activity (delivered over two cycles), respectively, to reach the cohort target renal dose of 3.5 Gy. Higher levels of targeted renal-absorbed doses are in the protocol for subsequent cohorts. Researchers also presented a novel cyclic peptide targeting human fibroblast activation protein (FAP), which was discovered by us via phage display methods. FAP is a protein abundantly expressed in certain cancer cells as well as cancer-associated fibroblasts in tumor lesions and involved in promoting disease progression. The peptide was conjugated to a Pb-specific chelator via a molecular linker to form a novel construct, PSV-359. The purpose of this study was to evaluate the in vitro and in vivo performance of [203/212Pb]PSV-359 in preclinical xenograft models. Overall, strong anti-tumor clinical activity of [212Pb]PSV-359 was found in both FAP on cancer cells and FAP in stromal tissues xenograft models. 18 Table of ContentsÂ Funding Requirements We have had recurring losses since inception. We expect our expenses to increase in connection with our ongoing activities, particularly as we advance and expand preclinical activities, clinical trials and potential commercialization of our program candidates. Our costs will also increase as we: â€¢continue the development of our clinical-stage metastatic melanoma tumor and neuroendocrine tumor assets, including VMT01 and VMT-Î±-NET; â€¢continue the development of our other program candidates; â€¢continue to initiate and progress other supporting studies required for regulatory approval of our program candidates; â€¢initiate preclinical studies and clinical trials for any additional indications for our current program candidates and any future program candidates that we may pursue; â€¢continue to build our portfolio of program candidates through the acquisition or in-license of additional program candidates or technologies; â€¢continue to develop, maintain, expand and protect our intellectual property portfolio; â€¢pursue regulatory approvals for our current and future program candidates that successfully complete clinical trials; â€¢continue to build our manufacturing capabilities through facility acquisitions; â€¢support our marketing and distribution infrastructure to commercialize any future program candidates for which we may obtain marketing approval; and â€¢hire additional clinical, medical, development and other personnel. As of June 30, 2024, we had cash, cash equivalents and short-term investments of $292.9 million. We believe our cash, cash equivalents and short-term investments will be sufficient to fund our current planned operations for at least the next 12 months from the date the consolidated financial statements in this report were issued and into mid-2026. Monthly operating expenses are budgeted to increase for research and development and general and administrative expenses in 2024 as management works to implement its strategy to advance our two clinical assets, VMT01 and VMT-Î±-NET, in their clinical trials and to progress our preclinical assets towards clinical trials. Management anticipates a significant increase in expenses, particularly in research and development, as it undertakes these activities in 2024. Facility Acquisitions On July 15, 2024 and August 2, 2024, we purchased a building located in Houston, Texas, for $4.7 million and a building in Chicago, Illinois, for $5.0 million, respectively, which we intend to use for the manufacture of our program candidates upon completion of modifications and installation of equipment. We continue to seek other facilities as we look to expand our research and development capabilities. Reverse Stock Split On June 14, 2024, we effected a 1-for-10 reverse stock split (Reverse Split) of our issued and outstanding shares of common stock, par value $0.001 per share (Common Stock), and our Common Stock began trading on a split-adjusted basis on June 17, 2024. The Reverse Split did not reduce the total number of authorized shares of our Common Stock or our preferred stock (Preferred Stock), or change the par values of our Common Stock or Preferred Stock. The Reverse Split affected all stockholders uniformly and did not affect any stockholderâ€™s ownership percentage of our shares of Common Stock (except to the extent that the Reverse Split resulted in some of the stockholders receiving cash in lieu of fractional shares). All outstanding options and warrants entitling their holders to purchase shares of Common Stock were adjusted as a result of the Reverse Split, in accordance with the terms of each such security. In addition, the number of shares reserved for future issuance pursuant to our equity incentive plans was also adjusted accordingly. As a result, all historical per share data, number of shares issued and outstanding, and outstanding options and warrants for the periods presented in this Form 10-Q have been adjusted retroactively, where applicable, to reflect the Reverse Split. Amended and Restated Equity Incentive Plan On May 31, 2024, we held our 2024 Annual Meeting of Stockholders (Annual Meeting). At the Annual Meeting, our stockholders approved our Third Amended and Restated 2020 Equity Incentive Plan (the Amended and Restated Plan) which, among other things, (a) increased the aggregate number of shares of Common Stock authorized for issuance under the Amended and Restated Plan by 4,870,092 for a total of 12,500,000 shares of Common Stock, and (b) adjusted the â€œevergreenâ€ provision included therein, such that the number of shares of Common Stock available for the grant of awards under the Amended and Restated Plan will automatically increase on January 1 of each year in an amount equal to 5% of the number of shares of Common Stock issued and outstanding on December 31 of the immediately preceding year (subject to adjustment in the event of stock splits and other similar events); provided, however, that 19 Table of ContentsÂ our Board of Directors may act prior to January 1 of a given year to provide that there will be no increase in the share limit for such year or provide that the increase for such year will be a lesser number of shares of Common Stock. May 2024 Registered Offering On May 24, 2024, we entered into an underwriting agreement with BofA Securities, Inc., as representative of the underwriters named therein, in connection with our previously announced underwritten offering (Registered Offering) of 5,151,588 shares (Registered Offering Shares) of our Common Stock and, in lieu of Registered Offering Shares to certain investors, pre-funded warrants (May 2024 Pre-funded Warrants) to purchase 146,425 shares of Common Stock. The price to the investors for the Registered Offering Shares was $15.10 per Registered Offering Share, and the price to the investors for the May 2024 Pre-funded Warrants was $15.09 per May 2024 Pre-funded Warrant, which represents the per share price for the Registered Offering Shares less the $0.01 per share exercise price for each such May 2024 Pre-funded Warrant. The Registered Offering closed on May 29, 2024. BofA Securities, Inc., Oppenheimer & Co. Inc. and RBC Capital Markets, LLC acted as joint book-running managers for the Registered Offering and B. Riley Securities, Inc. acted as a co-manager for the Registered Offering. JonesTrading Institutional Services LLC acted as a financial advisor for the Registered Offering. Our gross proceeds from the Registered Offering were approximately $80 million, before underwriting discounts and commissions and expenses associated with the Registered Offering. Brachytherapy Divestiture On April 12, 2024 (GT Medical Closing Date), we completed the sale of substantially all of the assets (GT Medical Closing) of Isoray to GT Medical Technologies, Inc. (GT Medical). As previously disclosed, on December 7, 2023, we entered into an Asset Purchase Agreement (the GT Medical APA) with Isoray and GT Medical. Pursuant to the GT Medical APA, Isoray sold to GT Medical, and GT Medical purchased from Isoray, all of Isorayâ€™s right, title and interest in and to substantially all of the assets of Isoray related to Isorayâ€™s commercial Cesium-131 business including equipment, certain contracts and leases, inventory and intellectual property. Subject to limited exceptions set forth in the GT Medical APA, GT Medical did not assume the liabilities of Isoray. Â Pursuant to the terms of, and subject to the conditions specified in, the GT Medical APA, at the GT Medical Closing, (i) GT

Medical issued to Isoray 279,516 shares of GT Medicalâ€™s common stock, par value $0.0001 per share, representing 0.5% of GT Medicalâ€™s issued and outstanding capital stock on a fully diluted basis (excluding Series C-1 warrants which, if exercised, will reduce Isorayâ€™s ownership to 0.44% of GT Medicalâ€™s issued and outstanding capital stock on a fully diluted basis) as of the GT Medical Closing Date and (ii) Isoray has the right to receive, and GT Medical is obligated to pay, certain cash royalty payments during each of the first four years beginning upon the GT Medical Closing Date (each such year, a Measurement Period), as summarized below: â€¢with respect to GT Medicalâ€™s net sales of Cesium-131 brachytherapy seeds for cases that do not utilize GT Medicalâ€™s GammaTile Therapy: (a) if such net sales for a Measurement Period are $10 million or less, 3.0% of such net sales; (b) if such net sales for a Measurement Period are greater than $10 million and less than $15 million, 4.0% of such net sales; and (c) if such net sales for a Measurement Period are $15 million or more, 5.0% of such net sales; and â€¢with respect to GT Medicalâ€™s net sales of GT Medicalâ€™s GammaTile Therapy utilizing Cesium-131 brachytherapy seeds: 0.5% of such net sales for a Measurement Period. Â As a result of the transaction, we have effectively exited the brachytherapy segment and are focused exclusively on our radiopharmaceutical development segment, our only operating segment and reporting segment. The sale of the brachytherapy segment represents a strategic shift that had a major effect on our operations. We accounted for the transaction as discontinued operations on the date the divestiture was announced. Accordingly, we are reporting the results of the brachytherapy segment operations and cash flows, and balance sheet classifications for the current and comparative periods as discontinued operations. Prior to the consummation of the sale, we were neither actively marketing the brachytherapy business for sale nor had intentions to abandon it. Â For additional information regarding our brachytherapy divestiture, see our Forms 8-K filed with the SEC on December 12, 2023, April 3, 2024 and April 16, 2024. Â Recent Licensing and Clinical Trial Collaboration Agreements; Manufacturing Facility Acquisition Â In January 2024, we entered into an exclusive in-licensing of Stony Brook Universityâ€™s Cuburbit[7]uril-admantane (CB7-Adma) pre-targeting platform which covers the global intellectual property rights. Pre-targeting using the CB7-Adma platform involves two steps. First, an antibody that binds with high specificity to a cancer-specific protein is administered via intravenous injection. This antibody is chemically modified to include the CB7 chemical entity and accumulates over time at the tumor site. Then, a radionuclide held tightly by our proprietary chelator attached to an Adma group is administered. The Adma group binds to the CB7 group that was previously attached to the cancerous cells with remarkable specificity, delivering radiation dose selectively to the tumor sites. Central to this innovation is CB7-Adma (host-guest) complex formation, driving the interaction between the antibody and radioligand. The chosen host-guest pair, CB7-Adma, demonstrates promising in vivo stability, modularity and low immunogenicity. The platformâ€™s potential was validated through in vivo profiling of ligands, employing a CB7-modified CEA targeting antibody. The agreement with Stony 20 Table of ContentsÂ Brook University will expire on the later of the expiration date of the last to expire licensed patents or 20 years from the date of the first sale of a product utilizing the intellectual property. Â In March 2024, we announced a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb]VMT01 in combination with Bristol Myers Squibbâ€™s nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. This combination study is an amendment to our ongoing Phase1/2a study of [212Pb]VMT01 in patients with metastatic melanoma. Â In March 2024, we acquired the assets and associated lease of Lantheusâ€™ radiopharmaceutical manufacturing facility in Somerset, New Jersey. We believe we will be able to convert the facility, which has three production suites, to manufacture finished radiopharmaceutical product. As a Current Good Manufacturing Practice (CGMP) compliant facility, we intend to utilize the facility to manufacture clinical supply of high quality 203Pb-labeled tumor-specific peptides to visualize and diagnose tumors, and 212Pb-labeled radiopharmaceuticals to treat target tumors with TAT. Moreover, with its three CGMP suites at the facility, we expect to have the capacity to meet future clinical trial and commercial demands at major cancer treatment centers throughout the Northeastern U.S. We intend to continue to expand our manufacturing and supply network during 2024 as we anticipate increasing our clinical trial activities. Â Viewpoint Merger On February 3, 2023, we completed the merger of Isoray Acquisition Corp., a Delaware corporation and wholly owned subsidiary of ours, with Viewpoint Molecular Targeting, Inc. (Viewpoint) (such transaction being the Merger). Pursuant to the Merger, we issued 13,654,507 shares of Common Stock, representing approximately 49% of our fully diluted outstanding capital stock as of the closing of the Merger. Viewpoint is developing the next generation of precision-targeted alpha therapies (TAT) for oncology that have the potential to treat a large population of cancer patients across multiple tumor types, including those with metastatic disease. Â For additional information regarding the Merger, see our Forms 8-K filed with the SEC on September 28, 2022 and on February 6, 2023, and our Form 8-K/A filed with the SEC on April 21, 2023. Critical Accounting Policies and Estimates The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these condensed consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities. Actual results may differ from these estimates under different assumptions or conditions and could, therefore, differ materially from those estimates if actual conditions differ from our assumptions. The accounting policies and related risks described in Part II, Item 7 and Note 2, Accounting Policies, to the consolidated financial statements included in Part II, Item 8 of our 2023 Form 10-K are those that depend most heavily on these judgments and estimates. As of June 30, 2024, there have been no material changes to any of the critical accounting policies and estimates contained therein. Results of Operations We previously presented our results in two segments: Drug Operations and Brachytherapy. Due to the divestiture of all of the brachytherapy segment to GT Medical and the classification of the assets and operations of the brachytherapy segment as discontinued operations in our condensed consolidated financial statements, we have now determined that we operate in only one segment. As a result, the following does not include a discussion of the results of our discontinued operations. For additional information regarding our discontinued operations, see Note 4, Discontinued Operations, to the condensed consolidated financial statements in this Form 10-Q. 21 Table of ContentsÂ The following table sets forth our results of operations for the periods presented (in thousands): Â Â Three Months Ended June 30, Â Â Â Â Six Months Ended June 30, Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â 2024 Â Â 2023 Â Â Change Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Grant revenue Â $ 526 Â Â $ 588 Â Â $ (62) Â $ 851 Â Â $ 821 Â Â $ 30 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

Pre-funded Warrants are exercisable at any time after the date of issuance. The exercise price and the number of shares of Common Stock issuable upon exercise of each Jan. 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to our stockholders. The Jan. 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of Jan. 2024 Pre-funded Warrants may not exercise such Jan. 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would beneficially own more than 4.99% of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the Jan. 2024 Pre-funded Warrants. A holder 24 Table of ContentsÂ of Jan. 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 daysâ€™ prior notice to us. Funding Requirements We expect our expenses to increase in connection with our ongoing activities, particularly as we advance and expand preclinical activities, clinical trials and potential commercialization of our program candidates. Our costs will also increase as we: â€¢continue the development of our clinical-stage metastatic melanoma tumor and neuroendocrine tumor assets, including VMT01 and VMT-Î±-NET; â€¢continue the development of our other program candidates; â€¢continue to initiate and progress other supporting studies required for regulatory approval of our program candidates; â€¢initiate preclinical studies and clinical trials for any additional indications for our current program candidates and any future program candidates that we may pursue; â€¢continue to build our portfolio of program candidates through the acquisition or in-license of additional program candidates or technologies; â€¢continue to develop, maintain, expand and protect our intellectual property portfolio; â€¢pursue regulatory approvals for our current and future program candidates that successfully complete clinical trials; â€¢continue to build our manufacturing capabilities through facility acquisitions; â€¢support our marketing and distribution infrastructure to commercialize any future product candidates for which we may obtain marketing approval; and â€¢hire additional clinical, medical, development and other personnel. At June 30, 2024, we had cash, cash equivalents and short-term investments of $292.9 million. We believe our cash, cash equivalents and short-term investments will be sufficient to fund our current planned operations and capital investments into mid-2026. Monthly operating expenses are budgeted to increase for research and development and general and administrative expenses in 2024 as management works to implement our strategy to advance our two clinical assets, VMT-Î±-NET and VMT01, in our clinical trials and to progress our preclinical assets towards clinical trials. Management anticipates a significant increase of expenses, particularly in research and development, as we undertake these activities in 2024 and beyond. We expect we will need to raise additional capital until we are profitable, which may never occur. If no additional capital is raised through either additional public or private equity financings, debt financings, strategic relationships, alliances and licensing agreements, or a combination thereof, we may delay, limit or reduce discretionary spending in areas related to research and development activities and other general and administrative expenses in order to fund our operating costs and working capital needs. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We expect that we will require additional capital to pursue in-licenses or acquisitions of other program candidates. If we receive regulatory approvals for our program candidates, we expect to incur commercialization expenses related to program manufacturing, sales, marketing and distribution, depending on where we choose to commercialize or whether we commercialize jointly or on our own. Because of the numerous risks and uncertainties associated with research, development and commercialization of our program candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including: â€¢the scope, progress, results and costs of researching and developing our program candidates, and conducting preclinical studies and clinical trials; â€¢the costs, timing and outcome of regulatory review of our program candidates; â€¢the costs and timing of hiring new employees to support our continued growth; â€¢the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; â€¢the extent to which we acquire or in-license other program candidates and technologies; and â€¢our ability to generate cash, and successfully obtain additional working capital, to fund our operating, investing and financing activities. 25 Table of ContentsÂ Until such time, if ever, that we can generate program revenue sufficient to achieve profitability, we expect to finance our cash needs through a combination of public and private equity offerings, debt financings, other third-party funding, strategic alliances, licensing arrangements or marketing and distribution arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other third-party funding, strategic alliances, licensing arrangements, outright sales of program candidates or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we will be required to delay, limit, reduce or terminate our program development or future commercialization efforts or grant rights to develop and market programs or program candidates that we would otherwise prefer to develop and market ourselves. Capital expenditures Management is reviewing all aspects of research and development and general and administrative functions to evaluate the most efficient deployment of capital to ensure that the appropriate materials, systems and personnel are available to support and drive clinical trials and preclinical activities. Financing activities When we do require capital in the future, we expect to finance our cash needs through sales of equity, possible strategic collaborations, debt financing or through other sources that may be dilutive to existing stockholders. Management anticipates that if it raises additional financing that it will be at a discount to the market price and it will be dilutive to stockholders. Other Commitments and Contingencies We presented our other commitments and contingencies in our 2023 Form 10-K for the period ended December 31, 2023. There have been no material changes outside of the ordinary course of business in those obligations during the six months ended June 30, 2024, other than those disclosed in Note 10, Commitments and Contingencies, to the condensed consolidated financial statements in this Form 10-Q. Off-Balance Sheet Arrangements We have no off-balance sheet arrangements. 26 Table of ContentsÂ ITEM 3 â€“ QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK We are a smaller reporting company, as defined by Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the Exchange Act), and are not required to provide the information required under this item. ITEM 4 â€“ CONTROLS AND PROCEDURES Evaluation of Disclosure Controls and Procedures Under the supervision and with the participation of our management, including our principal executive officer and co-principal financial officers, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of June 30, 2024. Based on that evaluation, our principal executive officer and our co-principal financial officers concluded that the design and operation of our disclosure controls and procedures were effective. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. However, management believes that our system of disclosure controls and procedures are designed to provide a reasonable level of assurance that the objectives of the system will be met. Changes in Internal Control over Financial Reporting There have not been any changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 27 Table of ContentsÂ PART II - OTHER INFORMATION ITEM 1 â€“ LEGAL PROCEEDINGS We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition. ITEM 1A â€“ RISK FACTORS A description of the risk factors associated with our business was included under the heading â€œRisk Factorsâ€ contained in Part I, Item 1A of our 2023 Form 10-K. There have been no material changes in our risk factors since such 2023 Form 10-K filing. ITEM 2 â€“ UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS None. ITEM 3 â€“ DEFAULTS UPON SENIOR SECURITIES None. ITEM 4 - MINE SAFETY DISCLOSURES Not applicable. ITEM 5 â€“ OTHER INFORMATIONÂ Rule 10b5-1 Trading Arrangements During the three months ended June 30, 2024, none of our directors or executive officers adopted, modified or terminated any â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408 of Regulation S-K. Â 28 Table of ContentsÂ ITEM 6 â€“ EXHIBITS (Except as otherwise indicated (a) all exhibits were previously filed, (b) all omitted exhibits are intentionally omitted, and (c) all documents referenced below were filed under SEC file number 001-33407.) Â Exhibits: 1.1+ Â Underwriting Agreement, by and between Perspective Therapeutics, Inc. and BofA Securities, Inc., as representative of the underwriters named therein, dated May 24, 2024, incorporated by reference to Exhibit 1.1 of the Form 8-K filed on May 29, 2024. Â Â Â 2.1 Agreement and Plan of Merger, dated September 27, 2022, by and between Isoray, Inc., Isoray Acquisition Corp., Viewpoint Molecular Targeting, Inc., and Cameron Gray, incorporated by reference to Exhibit 2.1 of the Form 8-K filed on September 28, 2022. 2.2 First Amendment to Agreement and Plan of Merger, dated October 21, 2022, between Isoray, Inc., Isoray Acquisition Corp., Viewpoint Molecular Targeting, Inc., and Cameron Gray, incorporated by reference to Exhibit 2.1 of the Form 8-K filed on October 24, 2022. Â Â Â 3.1 Amended and Restated Certificate of Incorporation of Perspective Therapeutics, Inc. as of February 14, 2023, incorporated by reference to Exhibit 3.1 of the Form 8-K filed on February 16, 2023. 3.2 Â Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Perspective Therapeutics, Inc., effective June 14, 2024, incorporated by reference to Exhibit 3.1 of the Form 8-K filed on June 14, 2024. Â Â Â 3.3 Amended and Restated Bylaws of Perspective Therapeutics, Inc. as of February 14, 2023, incorporated by reference to Exhibit 3.2 of the Form 8-K filed on February 16, 2023. Â Â Â 4.1 Â Form of Pre-funded Warrant to Purchase Common Stock, incorporated by reference to Exhibit 4.1 of the Form 8-K filed on May 29, 2024. Â Â Â 10.1*#! Â Perspective Therapeutics, Inc. Third Amended and Restated 2020 Equity Incentive Plan. Â Â Â 10.2*#! Â Isoray, Inc. 2017 Equity Incentive Plan. Â Â Â 31.1* Â Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â 31.2* Â Certification of Co-Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â 31.3* Â Certification of Co-Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â 32** Â Certification of Principal Executive Officer and Co-Principal Financial Officers Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â 101.INS* Â Inline XBRL Instance Document Â Â Â 101.SCH* Â Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents Â Â Â 104 Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) Â Â Â * Â Filed herewith ** Â Furnished herewith + Â Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish supplementally a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request. The Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules or exhibits so furnished. # Â Filed herewith solely to reflect the 1-for-10 reverse stock split of the Company effective June 14, 2024. ! Â Denotes Management Contract or Compensatory Plan or Arrangement Â 29 Table of ContentsÂ SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Dated: August 13, 2024 Â Â Â Â PERSPECTIVE THERAPEUTICS, INC., a Delaware corporation Â Â Â Â Â /s/ Johan (Thijs) Spoor Â Â Johan (Thijs) Spoor Â Â Chief Executive Officer(Principal Executive Officer) Â Â Â Â Â Â /s/ Jonathan Hunt Â Â Jonathan Hunt Â Â Chief Financial Officer(Co-Principal Financial Officer) Â Â Â Â Â Â /s/ Mark J. Austin Â Â Mark J. Austin Â Â Vice President of Finance and Corporate Controller(Co-Principal Financial Officer, Principal Accounting Officer, Corporate Secretary) Â 30 EX-10.1 2 catx-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 PERSPECTIVE THERAPEUTICS, INC.THIRD AMENDED AND RESTATED2020 EQUITY INCENTIVE PLAN (AMENDED AND RESTATED MAY 31, 2024) (Conformed Version Reflecting Reverse Stock Split Effective June 14, 2024) 1.Purpose; Eligibility. 1.1General Purpose. The name of this plan is the Perspective Therapeutics, Inc. Third Amended and Restated 2020 Equity Incentive Plan (the â€œPlanâ€). The purposes of the Plan are to (a) enable Perspective Therapeutics, Inc., a Delaware corporation (the â€œCompanyâ€), and any Affiliate to attract and retain the types of Employees, Consultants and Directors who will contribute to the Companyâ€™s long range success; (b) provide incentives that align the interests of Employees, Consultants and Directors with those of the stockholders of the Company; and (c) promote the success of the Companyâ€™s business. 1.2Eligible Award Recipients. The persons eligible to receive Awards are the Employees, Consultants and Directors of the Company and its Affiliates and such other individuals designated by the Committee who are reasonably expected to become Employees, Consultants and Directors after the receipt of Awards. 1.3Available Awards. Awards that may be granted under the Plan include: (a) Incentive Stock Options, (b) Non-qualified Stock Options, (c) Stock Appreciation Rights, and (d) Restricted Awards. 2.Definitions. â€œAffiliateâ€ means a corporation or other entity that, directly or through one or more intermediaries, controls, is controlled by or is under common control with, the Company by virtue of being part of a parent-subsidiary group in which each entity owns at least fifty percent (50%) of the equity interests in the other entity. â€œApplicable Lawsâ€ means the requirements related to or implicated by the administration of the Plan under applicable state corporate law, United States federal and state securities laws, the Code, any stock exchange or quotation system on which the shares of Common Stock are listed or quoted, and the applicable laws of any foreign country or jurisdiction where Awards are granted under the Plan. â€œAwardâ€ means any right granted under the Plan, including an Incentive Stock Option, a Non-qualified Stock Option, a Stock Appreciation Right or a Restricted Award. â€œAward Agreementâ€ means a written agreement, contract, certificate or other instrument or document evidencing the terms and conditions of an individual Award granted under the Plan which may, in the discretion of the Company, be transmitted electronically to any Participant. Each Award Agreement shall be subject to the terms and conditions of the Plan. â€œBoardâ€ means the Board of Directors of the Company, as constituted at any time. Â â€œCauseâ€ means: With respect to any Employee or Consultant: (a)If the Employee or Consultant is a party to an employment or service agreement with the Company or its Affiliates and such agreement provides for a definition of Cause, the definition contained therein; or (b)If no such agreement exists, or if such agreement does not define Cause: (i) the commission of, or plea of guilty or no contest to, a felony or a crime involving moral turpitude or the commission of any other act involving willful malfeasance or material fiduciary breach with respect to the Company or an Affiliate; (ii) conduct that results in or is reasonably likely to result in harm to the reputation or business of the Company or any of its Affiliates; (iii) gross negligence or willful misconduct with respect to the Company or an Affiliate; or (iv) material violation of state or federal securities laws. With respect to any Director, a determination by a majority of the disinterested Board members that the Director has engaged in any of the following: (a) malfeasance in office; (b) gross misconduct or neglect; (c) false or fraudulent misrepresentation inducing the directorâ€™s appointment; (d) willful conversion of corporate funds; or (e) repeated failure to participate in Board meetings on a regular basis despite having received proper notice of the meetings in advance. The Committee or disinterested Board members, as applicable, in its absolute discretion, shall determine the effect of all matters and questions relating to whether a Participant has been discharged for Cause. â€œChange in Controlâ€ means: (a) One Person (or more than one Person acting as a group) acquires ownership of stock of the Company that, together with the stock held by such person or group, constitutes more than 50% of the total fair market value or total voting power of the stock of the Company; provided, that, a Change in Control shall not occur if any Person (or more than one Person acting as a group) owns more than 50% of the total fair market value or total voting power of the Companyâ€™s stock and acquires additional stock; (b) One Person (or more than one Person acting as a group) acquires (or has acquired during the twelve-month period ending on the date of the most recent acquisition) 2 Â ownership of the Companyâ€™s stock possessing 30% or more of the total voting power of the stock of such corporation; (c) A majority of the members of the Board are replaced during any twelve-month period by directors whose appointment or election is not endorsed by majority of the Board before the date of appointment or election; or (d) One Person (or more than one Person acting as a group), acquires (or has acquired during the twelve-month period ending on the date of the most recent acquisition) assets from the Company that have a total gross fair market value equal to or more than 40% of the total gross fair market value of all of the assets of the Company immediately before such acquisition(s). â€œCodeâ€ means the Internal Revenue Code of 1986, as it may be amended from time to time. Any reference to a section of the Code shall be deemed to include a reference to any regulations promulgated thereunder. â€œCommitteeâ€ means a committee of one or more members of the Board appointed by the Board to administer the Plan in accordance with Section 3.3 and Section 3.4. â€œCommon Stockâ€ means the common stock, $0.001 par value per share, of the Company, or such other securities of the Company as may be designated by the Committee from time to time in substitution thereof. â€œCompanyâ€ means Perspective Therapeutics, Inc., a Delaware corporation, and any successor thereto. â€œConsultantâ€ means any individual who is engaged by the Company or any Affiliate to render consulting or advisory services. â€œContinuous Serviceâ€ means that the Participantâ€™s service with the Company or an Affiliate, whether as an Employee, Consultant or Director, is not interrupted or terminated.

The Participantâ€™s Continuous Service shall not be deemed to have terminated merely because of a change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participantâ€™s Continuous Service; provided further that if any Award is subject to Section 409A of the Code, this sentence shall only be given effect to the extent consistent with Section 409A of the Code. For example, a change in status from an Employee of the Company to a Director of an Affiliate will not constitute an interruption of Continuous Service. The Committee or its delegate, in its sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including sick leave, military leave or any other personal or family leave of absence. â€œDeferred Stock Units (DSUs)â€ has the meaning set forth in Section 7.2(b)(ii) hereof. â€œDirectorâ€ means a member of the Board or a member of the Board of Directors of any Affiliate of the Company. 3 Â â€œDisabilityâ€ means that the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment; provided, however, for purposes of determining the term of an Incentive Stock Option pursuant to Section 6.10 hereof, the term Disability shall have the meaning ascribed to it under Section 22(e)(3) of the Code. The determination of whether an individual has a Disability shall be determined under procedures established by the Committee. Except in situations where the Committee is determining Disability for purposes of the term of an Incentive Stock Option pursuant to Section 6.10 hereof within the meaning of Section 22(e)(3) of the Code, the Committee may rely on any determination that a Participant is disabled for purposes of benefits under any long-term disability plan maintained by the Company or any Affiliate in which a Participant participates. â€œDisqualifying Dispositionâ€ has the meaning set forth in Section 14.11. â€œEffective Dateâ€ shall mean October 6, 2023, which is the date as of which this Plan was approved by the Companyâ€™s stockholders at the Companyâ€™s 2023 annual meeting of stockholders. â€œEmployeeâ€ means any person (including those who serve as an Officer or Director but are also employed by the Company) employed by the Company or an Affiliate; provided, that, for purposes of determining eligibility to receive Incentive Stock Options, an Employee shall mean an employee of the Company or a parent or subsidiary corporation within the meaning of Section 424 of the Code. Mere service as a Director or payment of a directorâ€™s fee by the Company or an Affiliate shall not be sufficient to constitute â€œemploymentâ€ by the Company or an Affiliate. â€œExchange Actâ€ means the Securities Exchange Act of 1934, as amended. â€œFair Market Valueâ€ means, as of any date, the value of the Common Stock as determined below. If the Common Stock is listed on any established stock exchange or a national market system, the Fair Market Value shall be the closing price of a share of Common Stock (or if no sales were reported the closing price on the date immediately preceding such date) as quoted on such exchange or system on the day of determination, as reported in the Wall Street Journal or such other source as the Company deems reliable. In the absence of an established market for the Common Stock, the Fair Market Value shall be determined by the Committee in accordance with Section 409A of the Code, and such determination shall be conclusive and binding on all persons. â€œFree Standing Rightsâ€ has the meaning set forth in Section 7.1(a). â€œGrant Dateâ€ means the date on which the Committee adopts a resolution, or takes other appropriate action, expressly granting an Award to a Participant that specifies the key terms and conditions of the Award or, if a later date is set forth in such resolution, then such date as is set forth in such resolution. â€œIncentive Stock Optionâ€ means an Option intended to qualify as an incentive stock option within the meaning of Section 422 of the Code. â€œNon-Employee Directorâ€ means a Director who is a â€œnon-employee directorâ€ within the meaning of Rule 16b-3. 4 Â â€œNon-qualified Stock Optionâ€ means an Option that by its terms does not qualify or is not intended to qualify as an Incentive Stock Option. â€œOfficerâ€ means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder. â€œOptionâ€ means an Incentive Stock Option or a Non-qualified Stock Option granted pursuant to the Plan. â€œOptionholderâ€ means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option. â€œOption Exercise Priceâ€ means the price at which a share of Common Stock may be purchased upon the exercise of an Option. â€œParticipantâ€ means an eligible person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award. â€œPermitted Transfereeâ€ means: (a) a member of the Optionholderâ€™s immediate family (child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships), any person sharing the Optionholderâ€™s household (other than a tenant or employee), a trust in which these persons have more than 50% of the beneficial interest, a foundation in which these persons (or the Optionholder) control the management of assets, and any other entity in which these persons (or the Optionholder) own more than 50% of the voting interests; (b) third parties designated by the Committee in connection with a program established and approved by the Committee pursuant to which Participants may receive a cash payment or other consideration in consideration for the transfer of a Non-qualified Stock Option; and (c) such other transferees as may be permitted by the Committee in its sole discretion. â€œPlanâ€ means this Perspective Therapeutics, Inc. Amended and Restated 2020 Equity Incentive Plan, as further amended and/or amended and restated from time to time. â€œRelated Rightsâ€ has the meaning set forth in Section 7.1(a). â€œRestricted Awardâ€ means any Award granted pursuant to Section 7.2(a). â€œRestricted Periodâ€ has the meaning set forth in Section 7.2(a). â€œRule 16b-3â€ means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time. â€œSecurities Actâ€ means the Securities Act of 1933, as amended. â€œStock Appreciation Rightâ€ means the right pursuant to an Award granted under Section 7.1 to receive, upon exercise, an amount payable in cash or shares equal to the number of shares subject to the Stock Appreciation Right that is being exercised multiplied by the excess of (a) the 5 Â Fair Market Value of a share of Common Stock on the date the Award is exercised, over (b) the exercise price specified in the Stock Appreciation Right Award Agreement. â€œStock for Stock Exchangeâ€ has the meaning set forth in Section 6.4. â€œSubstitute Awardsâ€ means Awards granted solely in assumption of, or in substitution for, outstanding awards previously granted by a company acquired by the Company or with which the Company combines. â€œTen Percent Stockholderâ€ means a person who owns (or is deemed to own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or of any of its Affiliates. 3.Administration. 3.1Authority of Committee. The Plan shall be administered by the Committee or, in the Boardâ€™s sole discretion, by the Board. Subject to the terms of the Plan, the Committeeâ€™s charter and Applicable Laws, and in addition to other express powers and authorization conferred by the Plan, the Committee shall have the authority: (a)to construe and interpret the Plan and apply its provisions; (b)to promulgate, amend, and rescind rules and regulations relating to the administration of the Plan; (c)to authorize any person to execute, on behalf of the Company, any instrument required to carry out the purposes of the Plan; (d)to delegate its authority to one or more Officers of the Company with respect to Awards that do not involve â€œinsidersâ€ within the meaning of Section 16 of the Exchange Act; (e)to determine when Awards are to be granted under the Plan and the applicable Grant Date; (f)from time to time to select, subject to the limitations set forth in this Plan, those Participants to whom Awards shall be granted; (g)to determine the number of shares of Common Stock to be made subject to each Award; (h)to determine whether each Option is to be an Incentive Stock Option or a Non-qualified Stock Option; (i)to prescribe the terms and conditions of each Award, including, without limitation, the exercise price and medium of payment and vesting provisions, and to specify the provisions of the Award Agreement relating to such grant; 6 Â (j)to amend any outstanding Awards, including for the purpose of modifying the time or manner of vesting, or the term of any outstanding Award; provided, however, that if any such amendment impairs a Participantâ€™s rights or increases a Participantâ€™s obligations under his or her Award or creates or increases a Participantâ€™s federal income tax liability with respect to an Award, such amendment shall also be subject to the Participantâ€™s consent; (k)to determine the duration and purpose of leaves of absences which may be granted to a Participant without constituting termination of their employment for purposes of the Plan, which periods shall be no shorter than the periods generally applicable to Employees under the Companyâ€™s employment policies; (l)to make decisions with respect to outstanding Awards that may become necessary upon a change in corporate control or an event that triggers anti-dilution adjustments; (m)to interpret, administer, reconcile any inconsistency in, correct any defect in and/or supply any omission in the Plan and any instrument or agreement relating to, or Award granted under, the Plan; and (n)to exercise discretion to make any and all other determinations which it determines to be necessary or advisable for the administration of the Plan. The Committee also may modify the purchase price or the exercise price of any outstanding Award, but in no event shall the modification be less than the Fair Market Value on the date of the modification, provided that if the modification effects a repricing, stockholder approval shall be required before the repricing is effective. 3.2Committee Decisions Final. All decisions made by the Committee pursuant to the provisions of the Plan shall be final and binding on the Company and the Participants, unless such decisions are determined by a court having jurisdiction to be arbitrary and capricious. 3.3Delegation. The Committee or, if no Committee has been appointed, the Board may delegate administration of the Plan to a committee or committees of one or more members of the Board, and the term â€œCommitteeâ€ shall apply to any person or persons to whom such authority has been delegated. The Committee shall have the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board or the Committee shall thereafter be to the committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may abolish the Committee at any time and revest in the Board the administration of the Plan. The members of the Committee shall be appointed by and serve at the pleasure of the Board. From time to time, the Board may increase or decrease the size of the Committee, add additional members to, remove members (with or without cause) from, appoint new members in substitution therefor, and fill vacancies, however caused, in the Committee. The Committee shall act pursuant to a vote of the majority of its members or, in the case of a Committee comprised of only two members, the unanimous consent of its members, whether present or not, or by the written consent of the majority of its members and minutes shall be kept of all of its meetings and copies thereof shall be provided to the Board. Subject to the limitations prescribed by the Plan and the Board, the Committee may establish and follow such rules and regulations for 7 Â the conduct of its business as it may determine to be advisable. Notwithstanding the foregoing, the Board, and not the Committee, shall administer the Plan with respect to all Awards to any Director who is not also an Employee. 3.4Committee Composition. Except as otherwise determined by the Board, the Committee shall consist solely of two or more Non-Employee Directors. The Board shall have discretion to determine whether or not it intends to comply with the exemption requirements of Rule 16b-3. However, if the Board intends to satisfy such exemption requirements, with respect to any insider subject to Section 16 of the Exchange Act, the Committee shall be a compensation committee of the Board that at all times consists solely of two or more Non-Employee Directors. Within the scope of such authority, the Board or the Committee may delegate to a committee of one or more members of the Board who are not Non-Employee Directors the authority to grant Awards to eligible persons who are not then subject to Section 16 of the Exchange Act. Nothing herein shall create an inference that an Award is not validly granted under the Plan in the event Awards are granted under the Plan by a compensation committee of the Board that does not at all times consist solely of two or more Non-Employee Directors. 3.5Indemnification. In addition to such other rights of indemnification as they may have as Directors or members of the Committee, and to the extent allowed by Applicable Laws, the Committee shall be indemnified by the Company against the reasonable expenses, including attorneyâ€™s fees, actually incurred in connection with any action, suit or proceeding or in connection with any appeal therein, to which the Committee may be party by reason of any action taken or failure to act under or in connection with the Plan or any Award granted under the Plan, and against all amounts paid by the Committee in settlement thereof (provided, however, that the settlement has been approved by the Company, which approval shall not be unreasonably withheld) or paid by the Committee in satisfaction of a judgment in any such action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such action, suit or proceeding that such Committee did not act in good faith and in a manner which such person reasonably believed to be in the best interests of the Company, or in the case of a criminal proceeding, had no reason to believe that the conduct complained of was unlawful; provided, however, that within 60 days after institution of any such action, suit or proceeding, such Committee shall, in writing, offer the Company the opportunity at its own expense to handle and defend such action, suit or proceeding. 4.Shares Subject to the Plan. 4.1Subject to adjustment in accordance with Section 11, a total of 12,500,000â€¬ shares of Common Stock shall be available for the grant of Awards under the Plan. In addition, on the first day of each fiscal year beginning after the date of the Companyâ€™s 2024 annual meeting of stockholders, the number of shares of Common Stock available for the grant of Awards under the Plan shall be automatically increased in an amount equal to 5% of the number of shares of Common Stock issued and outstanding on the last day of the immediately preceding fiscal year (subject to adjustment in accordance with Section 11); provided, however, that the Board may act prior to the first day of a given fiscal year to provide that there will be no increase in the share limit for such year or provide that the increase for such year will be a lesser number of shares of Common Stock. Notwithstanding the foregoing, subject to adjustment in accordance with Section 11, no more than 12,500,000â€¬ shares shall be available for the grant of Incentive Stock Options 8 Â under the Plan. During the terms of the Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Awards. 4.2Shares of Common Stock available for distribution under the Plan may consist, in whole or in part, of authorized and unissued shares, treasury shares or shares reacquired by the Company in any manner. 4.3Any shares of Common Stock subject to an Award that is canceled, forfeited or expires prior to exercise or realization, either in full or in part, shall again become available for issuance under the Plan. Notwithstanding anything to the contrary contained herein: shares subject to an Award under the Plan shall not again be made available for issuance or delivery under the Plan if such shares are (a) shares tendered in payment of an Option, (b) shares delivered or withheld by the Company to satisfy any tax withholding obligation, or (c) shares covered by a stock-settled Stock Appreciation Right or other Awards that were not issued upon the settlement of the Award. 4.4Any shares of Common Stock issued by the Company as Substitute Awards in connection with the assumption or substitution of outstanding grants from any acquired company shall not reduce the shares of Common Stock available for Awards under the Plan to the extent that the rules and regulations of any stock exchange or other trading market on which the shares of Common Stock are listed or traded provide an exemption from stockholder approval for assumption, substitution, conversion, adjustment, or replacement of outstanding awards in connection with mergers, acquisitions, or other corporate combinations. 5.Eligibility. 5.1Eligibility for Specific Awards. Incentive Stock Options may be granted only to Employees. Awards other than Incentive Stock Options may be granted to Employees, Consultants and Directors and those individuals whom the Committee determines are reasonably expected to become Employees, Consultants and Directors following the Grant Date. 5.2Ten Percent Stockholders. A Ten Percent Stockholder shall not be granted an Incentive Stock Option unless the Option Exercise Price is at least 110% of the Fair Market Value of the Common Stock at the Grant Date and the Option is not exercisable after the expiration of five years from the Grant Date. 6.Option Provisions. Each Option granted under the Plan shall be evidenced by an Award Agreement. Each Option so granted shall be subject to the conditions set forth in this Section 6, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. All Options shall be separately designated Incentive Stock Options or Non-qualified Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. Notwithstanding the foregoing, the Company shall have no liability to any Participant or any other person if an Option designated as an Incentive Stock Option fails to qualify as such at any time or if an Option is determined to constitute â€œnonqualified deferred compensationâ€ within the meaning of Section 409A of the Code and the terms of such Option do not satisfy the requirements of Section 409A of the Code. The provisions of separate Options need not be 9 Â identical, but each Option shall include (through incorporation of provisions hereof by reference in the Option or otherwise) the substance of each of the following provisions: 6.1Term. Subject to the provisions of Section 5.2 regarding Ten Percent Stockholders, no Incentive Stock Option shall be exercisable after the expiration of 10 years from the Grant Date. The term of a Non-qualified Stock Option granted under the Plan shall be determined by the Committee; provided, however, no Non-qualified Stock Option shall be exercisable after the expiration of 10 years from the Grant Date. 6.2Exercise Price of an Incentive Stock Option. Subject to the provisions of Section 5.2 regarding Ten Percent Stockholders, the Option Exercise Price of each Incentive Stock Option shall be not less than 100% of the Fair Market Value of the Common Stock subject to the Option on the Grant Date. Notwithstanding the foregoing, an Incentive Stock Option may be granted with an Option Exercise Price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section 424(a) of the Code. 6.3Exercise Price of a Non-qualified Stock Option. The Option Exercise Price of each Non-qualified Stock Option shall be not less than 100% of the Fair Market Value of the Common Stock subject to the Option on the Grant Date. Notwithstanding the foregoing, a Non-qualified Stock Option may be granted with an Option Exercise Price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section 409A of the Code. 6.4Consideration. The Option Exercise Price of Common Stock acquired pursuant to an Option shall be paid, to the extent permitted by applicable statutes and regulations, either (a) in cash or by certified or bank check at the time the Option is exercised or (b) in the discretion of the Committee, upon such terms as the Committee shall approve, the Option Exercise Price may be paid: (i) by delivery to the Company of other Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the date of delivery equal to the Option Exercise Price (or portion thereof) due for the number of shares being acquired, or by means of attestation whereby the Participant identifies for delivery specific shares of Common Stock that have an aggregate Fair

Market Value on the date of attestation equal to the Option Exercise Price (or portion thereof) and receives a number of shares of Common Stock equal to the difference between the number of shares thereby purchased and the number of identified attestation shares of Common Stock (a â€œStock for Stock Exchangeâ€); (ii) a â€œcashlessâ€ exercise program established with a broker; (iii) by reduction in the number of shares of Common Stock otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the aggregate Option Exercise Price at the time of exercise; (iv) any combination of the foregoing methods; or (v) in any other form of legal consideration that may be acceptable to the Committee. Unless otherwise specifically provided in the Option, the exercise price of Common Stock acquired pursuant to an Option that is paid by delivery (or attestation) to the Company of other Common Stock acquired, directly or indirectly from the Company, shall be paid only by shares of the Common Stock of the Company that have been held for more than six months (or such longer or shorter period of time required to avoid a charge to earnings for financial accounting purposes). Notwithstanding the foregoing, during any period for which the Common Stock is publicly traded (i.e., the Common Stock is listed on any established stock exchange or a national market system) an exercise by a Director or Officer that 10 Â involves or may involve a direct or indirect extension of credit or arrangement of an extension of credit by the Company, directly or indirectly, in violation of Section 402(a) of the Sarbanes-Oxley Act of 2002 shall be prohibited with respect to any Award under this Plan. 6.5Transferability of an Incentive Stock Option. An Incentive Stock Option shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Optionholder only by the Optionholder. Notwithstanding the foregoing, the Optionholder may, by delivering written notice to the Company, in a form satisfactory to the Company, designate a third party who, in the event of the death of the Optionholder, shall thereafter be entitled to exercise the Option. 6.6Transferability of a Non-qualified Stock Option. A Non-qualified Stock Option may, in the sole discretion of the Committee, be transferable to a Permitted Transferee, upon written approval by the Committee to the extent provided in the Award Agreement. If the Non-qualified Stock Option does not provide for transferability, then the Non-qualified Stock Option shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Optionholder only by the Optionholder. Notwithstanding the foregoing, the Optionholder may, by delivering written notice to the Company, in a form satisfactory to the Company, designate a third party who, in the event of the death of the Optionholder, shall thereafter be entitled to exercise the Option. 6.7Vesting of Options. Each Option may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The Option may be subject to such other terms and conditions on the time or times when it may be exercised (which may be based on performance or other criteria) as the Committee may deem appropriate. The vesting provisions of individual Options may vary. No Option may be exercised for a fraction of a share of Common Stock. 6.8Termination of Continuous Service. Unless otherwise provided in an Award Agreement or in an employment agreement the terms of which have been approved by the Committee, in the event an Optionholderâ€™s Continuous Service terminates (other than upon the Optionholderâ€™s death or Disability), the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination) but only within such period of time ending on the earlier of (a) the date three months following the termination of the Optionholderâ€™s Continuous Service or (b) the expiration of the term of the Option as set forth in the Award Agreement; provided that, if the termination of Continuous Service is by the Company for Cause, all outstanding Options (whether or not vested) shall immediately terminate and cease to be exercisable. If, after termination, the Optionholder does not exercise his or her Option within the time specified in the Award Agreement, the Option shall terminate. 6.9Extension of Termination Date. An Optionholderâ€™s Award Agreement may also provide that if the exercise of the Option following the termination of the Optionholderâ€™s Continuous Service for any reason would be prohibited at any time because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act or any other state or federal securities law or the rules of any securities exchange or interdealer quotation system, then the Option shall terminate on the earlier of (a) the expiration of the term of the Option 11 Â in accordance with Section 6.1 or (b) the expiration of a period after termination of the Participantâ€™s Continuous Service that is three months after the end of the period during which the exercise of the Option would be in violation of such registration or other securities law requirements. 6.10Disability of Optionholder. Unless otherwise provided in an Award Agreement, in the event that an Optionholderâ€™s Continuous Service terminates as a result of the Optionholderâ€™s Disability, the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination), but only within such period of time ending on the earlier of (a) the date 12 months following such termination or (b) the expiration of the term of the Option as set forth in the Award Agreement. If, after termination, the Optionholder does not exercise his or her Option within the time specified herein or in the Award Agreement, the Option shall terminate. 6.11Death of Optionholder. Unless otherwise provided in an Award Agreement, in the event an Optionholderâ€™s Continuous Service terminates as a result of the Optionholderâ€™s death, then the Option may be exercised (to the extent the Optionholder was entitled to exercise such Option as of the date of death) by the Optionholderâ€™s estate, by a person who acquired the right to exercise the Option by bequest or inheritance or by a person designated to exercise the Option upon the Optionholderâ€™s death, but only within the period ending on the earlier of (a) the date 12 months following the date of death or (b) the expiration of the term of such Option as set forth in the Award Agreement. If, after the Optionholderâ€™s death, the Option is not exercised within the time specified herein or in the Award Agreement, the Option shall terminate. 6.12Incentive Stock Option $100,000 Limitation. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and its Affiliates) exceeds $100,000, the Options or portions thereof which exceed such limit (according to the order in which they were granted) shall be treated as Non-qualified Stock Options. 7.Provisions of Awards Other Than Options. 7.1Stock Appreciation Rights. (a)General Each Stock Appreciation Right granted under the Plan shall be evidenced by an Award Agreement. Each Stock Appreciation Right so granted shall be subject to the conditions set forth in this Section 7.1, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. Stock Appreciation Rights may be granted alone (â€œFree Standing Rightsâ€) or in tandem with an Option granted under the Plan (â€œRelated Rightsâ€). (b)Grant Requirements Any Related Right that relates to a Non-qualified Stock Option may be granted at the same time the Option is granted or at any time thereafter but before the exercise or 12 Â expiration of the Option. Any Related Right that relates to an Incentive Stock Option must be granted at the same time the Incentive Stock Option is granted. (c)Term of Stock Appreciation Rights The term of a Stock Appreciation Right granted under the Plan shall be determined by the Committee; provided, however, no Stock Appreciation Right shall be exercisable later than the tenth anniversary of the Grant Date. (d)Vesting of Stock Appreciation Rights Each Stock Appreciation Right may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The Stock Appreciation Right may be subject to such other terms and conditions on the time or times when it may be exercised as the Committee may deem appropriate. The vesting provisions of individual Stock Appreciation Rights may vary. No Stock Appreciation Right may be exercised for a fraction of a share of Common Stock. The Committee may, but shall not be required to, provide for an acceleration of vesting and exercisability in the terms of any Stock Appreciation Right upon the occurrence of a specified event. (e)Exercise and Payment Upon exercise of a Stock Appreciation Right, the holder shall be entitled to receive from the Company an amount equal to the number of shares of Common Stock subject to the Stock Appreciation Right that is being exercised multiplied by the excess of (i) the Fair Market Value of a share of Common Stock on the date the Award is exercised, over (ii) the exercise price specified in the Stock Appreciation Right or related Option. Payment with respect to the exercise of a Stock Appreciation Right shall be made on the date of exercise. Payment shall be made in the form of shares of Common Stock (with or without restrictions as to substantial risk of forfeiture and transferability, as determined by the Committee in its sole discretion), cash or a combination thereof, as determined by the Committee. (f)Exercise Price The exercise price of a Free Standing Stock Appreciation Right shall be determined by the Committee, but shall not be less than 100% of the Fair Market Value of one share of Common Stock on the Grant Date of such Stock Appreciation Right. A Related Right granted simultaneously with or subsequent to the grant of an Option and in conjunction therewith or in the alternative thereto shall have the same exercise price as the related Option, shall be transferable only upon the same terms and conditions as the related Option, and shall be exercisable only to the same extent as the related Option; provided, however, that a Stock Appreciation Right, by its terms, shall be exercisable only when the Fair Market Value per share of Common Stock subject to the Stock Appreciation Right and related Option exceeds the exercise price per share thereof and no Stock Appreciation Rights may be granted in tandem with an Option unless the Committee determines that the requirements of Section 7.1(b) are satisfied. 13 Â (g)Reduction in the Underlying Option Shares Upon any exercise of a Related Right, the number of shares of Common Stock for which any related Option shall be exercisable shall be reduced by the number of shares for which the Stock Appreciation Right has been exercised. The number of shares of Common Stock for which a Related Right shall be exercisable shall be reduced upon any exercise of any related Option by the number of shares of Common Stock for which such Option has been exercised. 7.2Restricted Awards. (a)General A Restricted Award is an Award of actual shares of Common Stock (â€œRestricted Stockâ€) or hypothetical Common Stock units (â€œRestricted Stock Unitsâ€) having a value equal to the Fair Market Value of an identical number of shares of Common Stock, which may, but need not, provide that such Restricted Award may not be sold, assigned, transferred or otherwise disposed of, pledged or hypothecated as collateral for a loan or as security for the performance of any obligation or for any other purpose for such period (the â€œRestricted Periodâ€) as the Committee shall determine. Each Restricted Award granted under the Plan shall be evidenced by an Award Agreement. Each Restricted Award so granted shall be subject to the conditions set forth in this Section 7.2, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. (b)Restricted Stock and Restricted Stock Units (i)Each Participant granted Restricted Stock shall execute and deliver to the Company an Award Agreement with respect to the Restricted Stock setting forth the restrictions and other terms and conditions applicable to such Restricted Stock. If the Committee determines that the Restricted Stock shall be held by the Company or in escrow rather than delivered to the Participant pending the release of the applicable restrictions, the Committee may require the Participant to additionally execute and deliver to the Company (A) an escrow agreement satisfactory to the Committee, if applicable and (B) the appropriate blank stock power with respect to the Restricted Stock covered by such agreement. If a Participant fails to execute an agreement evidencing an Award of Restricted Stock and, if applicable, an escrow agreement and stock power, the Award shall be null and void. Subject to the restrictions set forth in the Award, the Participant generally shall have the rights and privileges of a stockholder as to such Restricted Stock, including the right to vote such Restricted Stock and the right to receive dividends; provided that, any cash dividends and stock dividends with respect to the Restricted Stock shall be withheld by the Company for the Participantâ€™s account, and interest may be credited on the amount of the cash dividends withheld at a rate and subject to such terms as determined by the Committee. The cash dividends or stock dividends so withheld by the Committee and attributable to any particular share of Restricted Stock (and earnings thereon, if applicable) shall be distributed to the Participant in cash or, at the discretion of the Committee, in shares of Common Stock having a Fair Market Value equal to the amount of such dividends, if applicable, upon the release of restrictions on such share and, if such share is forfeited, the Participant shall have no right to such dividends. 14 Â (ii)The terms and conditions of a grant of Restricted Stock Units shall be reflected in an Award Agreement. No shares of Common Stock shall be issued at the time a Restricted Stock Unit is granted, and the Company will not be required to set aside funds for the payment of any such Award. A Participant shall have no voting rights with respect to any Restricted Stock Units granted hereunder. The Committee may also grant Restricted Stock Units with a deferral feature, whereby settlement is deferred beyond the vesting date until the occurrence of a future payment date or event set forth in an Award Agreement (â€œDeferred Stock Unitsâ€). At the discretion of the Committee, each Restricted Stock Unit or Deferred Stock Unit (representing one share of Common Stock) may be credited with an amount equal to the cash and stock dividends paid by the Company in respect of one share of Common Stock (â€œDividend Equivalentsâ€). Dividend Equivalents shall be paid currently (and in no case later than the end of the calendar year in which the dividend is paid to the holders of the Common Stock or, if later, the 15th day of the third month following the date the dividend is paid to holders of the Common Stock). (c)Restrictions (i)Restricted Stock awarded to a Participant shall be subject to the following restrictions until the expiration of the Restricted Period, and to such other terms and conditions as may be set forth in the applicable Award Agreement: (A) if an escrow arrangement is used, the Participant shall not be entitled to delivery of the stock certificate; (B) the shares shall be subject to the restrictions on transferability set forth in the Award Agreement; (C) the shares shall be subject to forfeiture to the extent provided in the applicable Award Agreement; and (D) to the extent such shares are forfeited, the stock certificates shall be returned to the Company, and all rights of the Participant to such shares and as a stockholder with respect to such shares shall terminate without further obligation on the part of the Company. (ii)Restricted Stock Units and Deferred Stock Units awarded to any Participant shall be subject to (A) forfeiture until the expiration of the Restricted Period, and satisfaction of any applicable performance goals during such period, to the extent provided in the applicable Award Agreement, and to the extent such Restricted Stock Units or Deferred Stock Units are forfeited, all rights of the Participant to such Restricted Stock Units or Deferred Stock Units (iii)shall terminate without further obligation on the part of the Company and (B) such other terms and conditions as may be set forth in the applicable Award Agreement. (iv)The Committee shall have the authority to remove any or all of the restrictions on the Restricted Stock, Restricted Stock Units and Deferred Stock Units whenever it may determine that, by reason of changes in Applicable Laws or other changes in circumstances arising after the date the Restricted Stock or Restricted Stock Units or Deferred Stock Units are granted, such action is appropriate. (d)Restricted Period With respect to Restricted Awards, the Restricted Period shall commence on the Grant Date and end at the time or times set forth on a schedule established by the Committee 15 Â in the applicable Award Agreement. No Restricted Award may be granted or settled for a fraction of a share of Common Stock. The Committee may, but shall not be required to, provide for an acceleration of vesting in the terms of any Award Agreement upon the occurrence of a specified event. (e)Delivery of Restricted Stock and Settlement of Restricted Stock Units Upon the expiration of the Restricted Period with respect to any shares of Restricted Stock, the restrictions set forth in Section 7.2(c) and the applicable Award Agreement shall be of no further force or effect with respect to such shares, except as set forth in the applicable Award Agreement. If an escrow arrangement is used, upon such expiration, the Company shall deliver to the Participant, or his or her beneficiary, without charge, the stock certificate evidencing the shares of Restricted Stock which have not then been forfeited and with respect to which the Restricted Period has expired (to the nearest full share) and any cash dividends or stock dividends credited to the Participantâ€™s account with respect to such Restricted Stock and the interest thereon, if any. Upon the expiration of the Restricted Period with respect to any outstanding Restricted Stock Units, or at the expiration of the deferral period with respect to any outstanding Deferred Stock Units, the Company shall deliver to the Participant, or his or her beneficiary, without charge, one share of Common Stock for each such outstanding vested Restricted Stock Unit or Deferred Stock Unit (â€œVested Unitâ€) and cash equal to any Dividend Equivalents credited with respect to each such Vested Unit in accordance with Section 7.2(b)(ii) hereof and the interest thereon or, at the discretion of the Committee, in shares of Common Stock having a Fair Market Value equal to such Dividend Equivalents and the interest thereon, if any; provided, however, that, if explicitly provided in the applicable Award Agreement, the Committee may, in its sole discretion, elect to pay cash or part cash and part Common Stock in lieu of delivering only shares of Common Stock for Vested Units. If a cash payment is made in lieu of delivering shares of Common Stock, the amount of such payment shall be equal to the Fair Market Value of the Common Stock as of the date on which the Restricted Period lapsed in the case of Restricted Stock Units, or the delivery date in the case of Deferred Stock Units, with respect to each Vested Unit. (f)Stock Restrictions Each certificate representing Restricted Stock awarded under the Plan shall bear a legend in such form as the Company deems appropriate. 8.Securities Law Compliance. Each Award Agreement shall provide that no shares of Common Stock shall be purchased or sold thereunder unless and until (a) any then applicable requirements of state or federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel and (b) if required to do so by the Company, the Participant has executed and delivered to the Company a letter of investment intent in such form and containing such provisions as the Committee may require. The Company shall use reasonable efforts to seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise of the Awards; provided, however, that this undertaking shall not require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority which counsel for the 16 Â Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company shall be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Awards unless and until such authority is obtained. 9.Use of Proceeds from Stock. Proceeds from the sale of Common Stock pursuant to Awards, or upon exercise thereof, shall constitute general funds of the Company. 10.Miscellaneous. 10.1Stockholder Rights. Except as provided in the Plan or an Award Agreement, no Participant shall be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until such Participant has satisfied all requirements for exercise of the Award pursuant to its terms and no adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property) or distributions of other rights for which the record date is prior to the date such Common Stock certificate is issued, except as provided in Section 11 hereof.

10.2No Employment or Other Service Rights. Nothing in the Plan or any instrument executed or Award granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or shall affect the right of the Company or an Affiliate to terminate (a) the employment of an Employee with or without notice and with or without Cause or (b) the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be. 10.3Transfer; Approved Leave of Absence. For purposes of the Plan, no termination of employment by an Employee shall be deemed to result from either (a) a transfer of employment to the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another, or (b) an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the Employeeâ€™s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Committee otherwise so provides in writing, in either case, except to the extent inconsistent with Section 409A of the Code if the applicable Award is subject thereto. 10.4Withholding Obligations. To the extent provided by the terms of an Award Agreement and subject to the discretion of the Committee, the Participant may satisfy any federal, state or local tax withholding obligation relating to the exercise or acquisition of Common Stock under an Award by any of the following means (in addition to the Companyâ€™s right to withhold from any compensation paid to the Participant by the Company) or by a combination of such means: (a) tendering a cash payment; (b) authorizing the Company to withhold shares of Common Stock from the shares of Common Stock otherwise issuable to the Participant as a result of the exercise or acquisition of Common Stock under the Award, provided, however, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law; (c) delivering to the Company previously owned and unencumbered shares of Common Stock of the Company; or (d) by such other method as may be set forth in the Award Agreement. 17 Â 11.Adjustments Upon Changes in Stock. In the event of changes in the outstanding Common Stock or in the capital structure of the Company by reason of any stock or extraordinary cash dividend, stock split, reverse stock split, an extraordinary corporate transaction such as any recapitalization, reorganization, merger, consolidation, combination, exchange, or other relevant change in capitalization occurring after the Grant Date of any Award, Awards granted under the Plan and any Award Agreements, the exercise price of Options and Stock Appreciation Rights, the maximum number of shares of Common Stock subject to all Awards stated in Section 4 and the maximum number of shares of Common Stock subject to Incentive Stock Options stated in Section 4 will be equitably adjusted or substituted, as to the number, price or kind of a share of Common Stock or other consideration subject to such Awards to the extent necessary to preserve the economic intent of such Award. In the case of adjustments made pursuant to this Section 11, unless the Committee specifically determines that such adjustment is in the best interests of the Company or its Affiliates, the Committee shall, in the case of Incentive Stock Options, ensure that any adjustments under this Section 11 will not constitute a modification, extension or renewal of the Incentive Stock Options within the meaning of Section 424(h)(3) of the Code and in the case of Non-qualified Stock Options, ensure that any adjustments under this Section 11 will not constitute a modification of such Non-qualified Stock Options within the meaning of Section 409A of the Code. Any adjustments made under this Section 11 shall be made in a manner which does not adversely affect the exemption provided pursuant to Rule 16b-3 under the Exchange Act. The Company shall give each Participant notice of an adjustment hereunder and, upon notice, such adjustment shall be conclusive and binding for all purposes. 12.Effect of Change in Control. 12.1Unless otherwise provided in an Award Agreement or in a Participantâ€™s employment or service agreement, notwithstanding any provision of the Plan to the contrary, in the event of a Change in Control, all outstanding Options and Stock Appreciation Rights shall become immediately exercisable with respect to 100% of the shares subject to such Options or Stock Appreciation Rights, and the Restricted Period shall expire immediately with respect to 100% of the shares of Restricted Stock or Restricted Stock Units. To the extent practicable, any actions taken by the Committee under the immediately preceding sentence shall occur in a manner and at a time which allows affected Participants the ability to participate in the Change in Control with respect to the shares of Common Stock subject to their Awards. 12.2In addition, in the event of a Change in Control, the Committee may in its discretion and upon at least 10 daysâ€™ advance notice to the affected persons, cancel any outstanding Awards and pay to the holders thereof, in cash or stock, or any combination thereof, the value of such Awards based upon the price per share of Common Stock received or to be received by other stockholders of the Company in the event. In the case of any Option or Stock Appreciation Right with an exercise price (or SAR Exercise Price in the case of a Stock Appreciation Right) that equals or exceeds the price paid for a share of Common Stock in connection with the Change in Control, the Committee may cancel the Option or Stock Appreciation Right without the payment of consideration therefor. 12.3The obligations of the Company under the Plan shall be binding upon any successor corporation or organization resulting from the merger, consolidation or other reorganization of the 18 Â Company, or upon any successor corporation or organization succeeding to all or substantially all of the assets and business of the Company and its Affiliates, taken as a whole. 13.Amendment of the Plan and Awards. 13.1Amendment of Plan. The Board at any time, and from time to time, may amend or terminate the Plan. However, except as provided in Section 11 relating to adjustments upon changes in Common Stock and Section 13.3, no amendment shall be effective unless approved by the stockholders of the Company to the extent stockholder approval is necessary to satisfy any Applicable Laws. At the time of such amendment, the Board shall determine, upon advice from counsel, whether such amendment will be contingent on stockholder approval. 13.2Stockholder Approval. The Board may, in its sole discretion, submit any other amendment to the Plan for stockholder approval. 13.3Contemplated Amendments. It is expressly contemplated that the Board may amend the Plan in any respect the Board deems necessary or advisable to provide eligible Employees, Consultants and Directors with the maximum benefits provided or to be provided under the provisions of the Code and the regulations promulgated thereunder relating to Incentive Stock Options or to the nonqualified deferred compensation provisions of Section 409A of the Code and/or to bring the Plan and/or Awards granted under it into compliance therewith. 13.4No Impairment of Rights. Rights under any Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan unless (a) the Company requests the consent of the Participant and (b) the Participant consents in writing. 13.5Amendment of Awards. The Committee at any time, and from time to time, may amend the terms of any one or more Awards; provided, however, that the Committee may not affect any amendment which would otherwise constitute an impairment of the rights under any Award unless (a) the Company requests the consent of the Participant and (b) the Participant consents in writing. 14.General Provisions. 14.1Forfeiture Events. The Committee may specify in an Award Agreement that the Participantâ€™s rights, payments and benefits with respect to an Award shall be subject to reduction, cancellation, forfeiture or recoupment upon the occurrence of certain events, in addition to applicable vesting conditions of an Award. Such events may include, without limitation, breach of non-competition, non-solicitation, confidentiality, or other restrictive covenants that are contained in the Award Agreement or otherwise applicable to the Participant, a termination of the Participantâ€™s Continuous Service for Cause, or other conduct by the Participant that is detrimental to the business or reputation of the Company and/or its Affiliates. 14.2Clawback. Notwithstanding any other provisions in this Plan, any Award which is subject to recovery under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement (or any policy adopted by the Company pursuant to any such law, government regulation or stock exchange listing requirement). 19 Â 14.3Other Compensation Arrangements. Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, subject to stockholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases. 14.4Sub-plans. The Committee may from time to time establish sub-plans under the Plan for purposes of satisfying blue sky, securities, tax or other laws of various jurisdictions in which the Company intends to grant Awards. Any sub-plans shall contain such limitations and other terms and conditions as the Committee determines are necessary or desirable. All sub-plans shall be deemed a part of the Plan, but each sub-plan shall apply only to the Participants in the jurisdiction for which the sub-plan was designed. 14.5Unfunded Plan. The Plan shall be unfunded. Neither the Company, the Board nor the Committee shall be required to establish any special or separate fund or to segregate any assets to assure the performance of its obligations under the Plan. 14.6Recapitalizations. Each Award Agreement shall contain provisions required to reflect the provisions of Section 11. 14.7Delivery. Upon exercise of a right granted under this Plan, the Company shall issue Common Stock or pay any amounts due within a reasonable period of time thereafter. Subject to any statutory or regulatory obligations the Company may otherwise have, for purposes of this Plan, 30 days shall be considered a reasonable period of time. 14.8No Fractional Shares. No fractional shares of Common Stock shall be issued or delivered pursuant to the Plan. The Committee shall determine whether cash, additional Awards or other securities or property shall be issued or paid in lieu of fractional shares of Common Stock or whether any fractional shares should be rounded, forfeited or otherwise eliminated. 14.9Other Provisions. The Award Agreements authorized under the Plan may contain such other provisions not inconsistent with this Plan, including, without limitation, restrictions upon the exercise of the Awards, as the Committee may deem advisable. 14.10Section 409A. The Plan is intended to comply with Section 409A of the Code to the extent subject thereto, and, accordingly, to the maximum extent permitted, the Plan shall be interpreted and administered to be in compliance therewith. Any payments described in the Plan that are due within the â€œshort-term deferral periodâ€ as defined in Section 409A of the Code shall not be treated as deferred compensation unless Applicable Laws require otherwise. Notwithstanding anything to the contrary in the Plan, to the extent required to avoid accelerated taxation and tax penalties under Section 409A of the Code, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the six (6) month period immediately following the Participantâ€™s termination of Continuous Service shall instead be paid on the first payroll date after the six-month anniversary of the Participantâ€™s separation from service (or the Participantâ€™s death, if earlier). Notwithstanding the foregoing, neither the Company nor the Committee shall have any obligation to take any action to prevent the assessment of any excise tax or penalty on any Participant under Section 409A of the Code and 20 Â neither the Company nor the Committee will have any liability to any Participant for such tax or penalty. 14.11Disqualifying Dispositions. Any Participant who shall make a â€œdispositionâ€ (as defined in Section 424 of the Code) of all or any portion of shares of Common Stock acquired upon exercise of an Incentive Stock Option within two years from the Grant Date of such Incentive Stock Option or within one year after the issuance of the shares of Common Stock acquired upon exercise of such Incentive Stock Option (a â€œDisqualifying Dispositionâ€) shall be required to immediately advise the Company in writing as to the occurrence of the sale and the price realized upon the sale of such shares of Common Stock. 14.12Section 16. It is the intent of the Company that the Plan satisfy, and be interpreted in a manner that satisfies, the applicable requirements of Rule 16b-3 as promulgated under Section 16 of the Exchange Act so that Participants will be entitled to the benefit of Rule 16b-3, or any other rule promulgated under Section 16 of the Exchange Act, and will not be subject to short-swing liability under Section 16 of the Exchange Act. Accordingly, if the operation of any provision of the Plan would conflict with the intent expressed in this Section 14.12, such provision to the extent possible shall be interpreted and/or deemed amended so as to avoid such conflict. 14.13Beneficiary Designation. Each Participant under the Plan may from time to time name any beneficiary or beneficiaries by whom any right under the Plan is to be exercised in case of such Participantâ€™s death. Each designation will revoke all prior designations by the same Participant, shall be in a form reasonably prescribed by the Committee and shall be effective only when filed by the Participant in writing with the Company during the Participantâ€™s lifetime. 14.14Expenses. The costs of administering the Plan shall be paid by the Company. 14.15Severability. If any of the provisions of the Plan or any Award Agreement is held to be invalid, illegal or unenforceable, whether in whole or in part, such provision shall be deemed modified to the extent, but only to the extent, of such invalidity, illegality or unenforceability and the remaining provisions shall not be affected thereby. 14.16Plan Headings. The headings in the Plan are for purposes of convenience only and are not intended to define or limit the construction of the provisions hereof. 14.17Non-Uniform Treatment. The Committeeâ€™s determinations under the Plan need not be uniform and may be made by it selectively among persons who are eligible to receive, or actually receive, Awards. Without limiting the generality of the foregoing, the Committee shall be entitled to make non-uniform and selective determinations, amendments and adjustments, and to enter into non-uniform and selective Award Agreements. 15.Effective Date of Plan. The Plan became effective in 2020 and was amended with the approval of the Companyâ€™s stockholders in December 2021, December 2022, October 2023 and May 2024. The Plan shall continue in effect from the Effective Date. 16.Termination or Suspension of the Plan. The Plan shall terminate automatically on the ten-year anniversary of the Effective Date. No Award shall be granted pursuant to the Plan after such date, but Awards theretofore granted may extend beyond that date. The Board may suspend or 21 Â terminate the Plan at any earlier date pursuant to Section 13.1 hereof. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. 17.Choice of Law. The law of the State of Delaware shall govern all questions concerning the construction, validity and interpretation of this Plan, without regard to such stateâ€™s conflict of law rules. 22 EX-10.2 3 catx-ex10_2.htm EX-10.2 EX-10.2 Exhibit 10.2 ISORAY, INC. 2017 EQUITY INCENTIVE PLAN (Conformed Version Reflecting Reverse Stock Split Effective June 14, 2024) Â 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the IsoRay, Inc. 2017 Equity Incentive Plan (the â€œPlanâ€). The purposes of the Plan are to (a) enable IsoRay, Inc., a Minnesota corporation (the â€œCompanyâ€), and any Affiliate to attract and retain the types of Employees, Consultants and Directors who will contribute to the Companyâ€™s long range success; (b) provide incentives that align the interests of Employees, Consultants and Directors with those of the shareholders of the Company; and (c) promote the success of the Companyâ€™s business. 1.2 Eligible Award Recipients. The persons eligible to receive Awards are the Employees, Consultants and Directors of the Company and its Affiliates and such other individuals designated by the Committee who are reasonably expected to become Employees, Consultants and Directors after the receipt of Awards. 1.3 Available Awards. Awards that may be granted under the Plan include: (a) Incentive Stock Options, (b) Non-qualified Stock Options, (c) Stock Appreciation Rights, and (d) Restricted Awards. Â 2. Definitions. â€œAffiliateâ€ means a corporation or other entity that, directly or through one or more intermediaries, controls, is controlled by or is under common control with, the Company by virtue of being part of a parent-subsidiary group in which each entity owns at least fifty percent (50%) of the equity interests in the other entity. â€œApplicable Lawsâ€ means the requirements related to or implicated by the administration of the Plan under applicable state corporate law, United States federal and state securities laws, the Code, any stock exchange or quotation system on which the shares of Common Stock are listed or quoted, and the applicable laws of any foreign country or jurisdiction where Awards are granted under the Plan. â€œAwardâ€ means any right granted under the Plan, including an Incentive Stock Option, a Non-qualified Stock Option, a Stock Appreciation Right or a Restricted Award. â€œAward Agreementâ€ means a written agreement, contract, certificate or other instrument or document evidencing the terms and conditions of an individual Award granted under the Plan which may, in the discretion of the Company, be transmitted electronically to any Participant. Each Award Agreement shall be subject to the terms and conditions of the Plan. â€œBoardâ€ means the Board of Directors of the Company, as constituted at any time. â€œCauseâ€ means: With respect to any Employee or Consultant: Â (a) If the Employee or Consultant is a party to an employment or service agreement with the Company or its Affiliates and such agreement provides for a definition of Cause, the definition contained therein; or Â Â (b) If no such agreement exists, or if such agreement does not define Cause: (i) the commission of, or plea of guilty or no contest to, a felony or a crime involving moral turpitude or the commission of any other act involving willful malfeasance or material fiduciary breach with respect to the Company or an Affiliate; (ii) conduct that results in or is reasonably likely to result in harm to the reputation or business of the Company or any of its Affiliates; (iii) gross negligence or willful misconduct with respect to the Company or an Affiliate; or (iv) material violation of state or federal securities laws. Â Â With respect to any Director, a determination by a majority of the disinterested Board members that the Director has engaged in any of the following: Â (a) malfeasance in office; Â Â (b) gross misconduct or neglect; Â Â (c) false or fraudulent misrepresentation inducing the directorâ€™s appointment; Â Â (d) willful conversion of corporate funds; or Â Â (e) repeated failure to participate in Board meetings on a regular basis despite having received proper notice of the meetings in advance. The Committee or disinterested Board members, as applicable, in its absolute discretion, shall determine the effect of all matters and questions relating to whether a Participant has been discharged for Cause. â€œChange in Controlâ€ means: Â (a) One Person (or more than one Person acting as a group) acquires ownership of stock of the Company that, together with the stock held by such person or group, constitutes more than 50% of the total fair market value or total voting power of the stock of the Company; provided, that, a Change in Control shall not occur if any Person (or more than one Person acting as a group) owns more than 50% of the total fair market value or total voting power of the Companyâ€™s stock and acquires additional stock; Â Â (b) One Person (or more than one Person acting as a group) acquires (or has acquired during the twelve-month period ending on the date of the most recent acquisition) ownership of the Companyâ€™s stock possessing 30% or more of the total voting power of the stock of such corporation; Â Â (c) A majority of the members of the Board are replaced during any twelve-month period by directors whose appointment or election is not endorsed by majority of the Board before the date of appointment or election; or Â Â (d) One Person (or more than one Person acting as a group), acquires (or has acquired during the twelve-month period ending on the date of the most recent acquisition) assets from the Company that have a total gross fair market value equal to or more than 40% of the total gross fair market value of all of the assets of the Company immediately before such acquisition(s). Â Â â€œCodeâ€ means the Internal Revenue Code of 1986, as it may be amended from time to time. Any reference to a section of the Code shall be deemed to include a reference to any regulations promulgated thereunder. â€œCommitteeâ€ means a committee of one or more members of the Board appointed by the Board to

administer the Plan in accordance with Section 3.3 and Section 3.4. â€œCommon Stockâ€ means the common stock, $0.001 par value per share, of the Company, or such other securities of the Company as may be designated by the Committee from time to time in substitution thereof. â€œCompanyâ€ means IsoRay, Inc., a Minnesota corporation, and any successor thereto. â€œConsultantâ€ means any individual who is engaged by the Company or any Affiliate to render consulting or advisory services. â€œContinuous Serviceâ€ means that the Participantâ€™s service with the Company or an Affiliate, whether as an Employee, Consultant or Director, is not interrupted or terminated. The Participantâ€™s Continuous Service shall not be deemed to have terminated merely because of a change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participantâ€™s Continuous Service; provided further that if any Award is subject to Section 409A of the Code, this sentence shall only be given effect to the extent consistent with Section 409A of the Code. For example, a change in status from an Employee of the Company to a Director of an Affiliate will not constitute an interruption of Continuous Service. The Committee or its delegate, in its sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including sick leave, military leave or any other personal or family leave of absence. â€œCovered Employeeâ€ has the same meaning as set forth in Section 162(m)(3) of the Code, as interpreted by IRS Notice 2007-49. â€œDeferred Stock Units (DSUs)â€ has the meaning set forth in Section 7.2 hereof. â€œDirectorâ€ means a member of the Board or a member of the Board of Directors of any Affiliate of the Company. â€œDisabilityâ€ means that the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment; provided, however, for purposes of determining the term of an Incentive Stock Option pursuant to Section 6.10 hereof, the term Disability shall have the meaning ascribed to it under Section 22(e)(3) of the Code. The determination of whether an individual has a Disability shall be determined under procedures established by the Committee. Except in situations where the Committee is determining Disability for purposes of the term of an Incentive Stock Option pursuant to Section 6.10 hereof within the meaning of Section 22(e)(3) of the Code, the Committee may rely on any determination that a Participant is disabled for purposes of benefits under any long-term disability plan maintained by the Company or any Affiliate in which a Participant participates. â€œDisqualifying Dispositionâ€ has the meaning set forth in Section 14.12. â€œEffective Dateâ€ shall mean the date as of which this Plan is adopted by the Board. â€œEmployeeâ€ means any person (including those who serve as an Officer or Director but are also employed by the Company) employed by the Company or an Affiliate; provided, that, for purposes of determining eligibility to receive Incentive Stock Options, an Employee shall mean an employee of the Company or a parent or subsidiary corporation within the meaning of Section 424 of the Code. Mere service as a Director or payment of a directorâ€™s fee by the Company or an Affiliate shall not be sufficient to constitute â€œemploymentâ€ by the Company or an Affiliate. â€œExchange Actâ€ means the Securities Exchange Act of 1934, as amended. â€œFair Market Valueâ€ means, as of any date, the value of the Common Stock as determined below. If the Common Stock is listed on any established stock exchange or a national market system, the Fair Market Value shall be the closing price of a share of Common Stock (or if no sales were reported the closing price on the date immediately preceding such date) as quoted on such exchange or system on the day of determination, as reported in the Wall Street Journal or such other source as the Company deems reliable. In the absence of an established market for the Common Stock, the Fair Market Value shall be determined by the Committee in accordance with Section 409A of the Code, and such determination shall be conclusive and binding on all persons. Â â€œFree Standing Rightsâ€ has the meaning set forth in Section 7.1(a). â€œGrant Dateâ€ means the date on which the Committee adopts a resolution, or takes other appropriate action, expressly granting an Award to a Participant that specifies the key terms and conditions of the Award or, if a later date is set forth in such resolution, then such date as is set forth in such resolution. â€œIncentive Stock Optionâ€ means an Option intended to qualify as an incentive stock option within the meaning of Section 422 of the Code. â€œNon-Employee Directorâ€ means a Director who is a â€œnon-employee directorâ€ within the meaning of Rule 16b-3. â€œNon-qualified Stock Optionâ€ means an Option that by its terms does not qualify or is not intended to qualify as an Incentive Stock Option. â€œOfficerâ€ means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder. â€œOptionâ€ means an Incentive Stock Option or a Non-qualified Stock Option granted pursuant to the Plan. â€œOptionholderâ€ means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option. â€œOption Exercise Priceâ€ means the price at which a share of Common Stock may be purchased upon the exercise of an Option. â€œOutside Directorâ€ means a Director who is an â€œoutside directorâ€ within the meaning of Section 162(m) of the Code and Treasury Regulations Section 1.162-27(e)(3) or any successor to such statute and regulation. â€œParticipantâ€ means an eligible person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award. â€œPermitted Transfereeâ€ means: (a) a member of the Optionholderâ€™s immediate family (child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships), any person sharing the Optionholderâ€™s household (other than a tenant or employee), a trust in which these persons have more than 50% of the beneficial interest, a foundation in which these persons (or the Optionholder) control the management of assets, and any other entity in which these persons (or the Optionholder) own more than 50% of the voting interests; (b) third parties designated by the Committee in connection with a program established and approved by the Committee pursuant to which Participants may receive a cash payment or other consideration in consideration for the transfer of a Non-qualified Stock Option; and (c) such other transferees as may be permitted by the Committee in its sole discretion. â€œPlanâ€ means this IsoRay, Inc. 2017 Equity Incentive Plan, as amended and/or amended and restated from time to time. â€œRelated Rightsâ€ has the meaning set forth in Section 7.1(a). â€œRestricted Awardâ€ means any Award granted pursuant to Section 7.2(a). â€œRestricted Periodâ€ has the meaning set forth in Section 7.2(a). â€œRule 16b-3â€ means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time. â€œSecurities Actâ€ means the Securities Act of 1933, as amended. â€œStock Appreciation Rightâ€ means the right pursuant to an Award granted under Section 7.1 to receive, upon exercise, an amount payable in cash or shares equal to the number of shares subject to the Stock Appreciation Right that is being exercised multiplied by the excess of (a) the Fair Market Value of a share of Common Stock on the date the Award is exercised, over (b) the exercise price specified in the Stock Appreciation Right Award Agreement. â€œStock for Stock Exchangeâ€ has the meaning set forth in Section 6.4. Â â€œSubstitute Awardsâ€ means Awards granted solely in assumption of, or in substitution for, outstanding awards previously granted by a company acquired by the Company or with which the Company combines. â€œTen Percent Shareholderâ€ means a person who owns (or is deemed to own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or of any of its Affiliates. Â 3. Administration. 3.1 Authority of Committee. The Plan shall be administered by the Committee or, in the Boardâ€™s sole discretion, by the Board. Subject to the terms of the Plan, the Committeeâ€™s charter and Applicable Laws, and in addition to other express powers and authorization conferred by the Plan, the Committee shall have the authority: (a) to construe and interpret the Plan and apply its provisions; (b) to promulgate, amend, and rescind rules and regulations relating to the administration of the Plan; (c) to authorize any person to execute, on behalf of the Company, any instrument required to carry out the purposes of the Plan; (d) to delegate its authority to one or more Officers of the Company with respect to Awards that do not involve Covered Employees or â€œinsidersâ€ within the meaning of Section 16 of the Exchange Act; (e) to determine when Awards are to be granted under the Plan and the applicable Grant Date; (f) from time to time to select, subject to the limitations set forth in this Plan, those Participants to whom Awards shall be granted; (g) to determine the number of shares of Common Stock to be made subject to each Award; (h) to determine whether each Option is to be an Incentive Stock Option or a Non-qualified Stock Option; (i) to prescribe the terms and conditions of each Award, including, without limitation, the exercise price and medium of payment and vesting provisions, and to specify the provisions of the Award Agreement relating to such grant; (j) to amend any outstanding Awards, including for the purpose of modifying the time or manner of vesting, or the term of any outstanding Award; provided, however, that if any such amendment impairs a Participantâ€™s rights or increases a Participantâ€™s obligations under his or her Award or creates or increases a Participantâ€™s federal income tax liability with respect to an Award, such amendment shall also be subject to the Participantâ€™s consent; (k) to determine the duration and purpose of leaves of absences which may be granted to a Participant without constituting termination of their employment for purposes of the Plan, which periods shall be no shorter than the periods generally applicable to Employees under the Companyâ€™s employment policies; (l) to make decisions with respect to outstanding Awards that may become necessary upon a change in corporate control or an event that triggers anti-dilution adjustments; (m) to interpret, administer, reconcile any inconsistency in, correct any defect in and/or supply any omission in the Plan and any instrument or agreement relating to, or Award granted under, the Plan; and (n) to exercise discretion to make any and all other determinations which it determines to be necessary or advisable for the administration of the Plan. The Committee also may modify the purchase price or the exercise price of any outstanding Award, but in no event shall the modification be less than the Fair Market Value on the date of the modification, provided that if the modification effects a repricing, shareholder approval shall be required before the repricing is effective. Â 3.2 Committee Decisions Final. All decisions made by the Committee pursuant to the provisions of the Plan shall be final and binding on the Company and the Participants, unless such decisions are determined by a court having jurisdiction to be arbitrary and capricious. 3.3 Delegation. The Committee or, if no Committee has been appointed, the Board may delegate administration of the Plan to a committee or committees of one or more members of the Board, and the term â€œCommitteeâ€ shall apply to any person or persons to whom such authority has been delegated. The Committee shall have the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board or the Committee shall thereafter be to the committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may abolish the Committee at any time and revest in the Board the administration of the Plan. The members of the Committee shall be appointed by and serve at the pleasure of the Board. From time to time, the Board may increase or decrease the size of the Committee, add additional members to, remove members (with or without cause) from, appoint new members in substitution therefor, and fill vacancies, however caused, in the Committee. The Committee shall act pursuant to a vote of the majority of its members or, in the case of a Committee comprised of only two members, the unanimous consent of its members, whether present or not, or by the written consent of the majority of its members and minutes shall be kept of all of its meetings and copies thereof shall be provided to the Board. Subject to the limitations prescribed by the Plan and the Board, the Committee may establish and follow such rules and regulations for the conduct of its business as it may determine to be advisable. Notwithstanding the foregoing, the Board, and not the Committee, shall administer the Plan with respect to all Awards to any Director who is not also an Employee. 3.4 Committee Composition. Except as otherwise determined by the Board, the Committee shall consist solely of two or more Non-Employee Directors who are also Outside Directors. The Board shall have discretion to determine whether or not it intends to comply with the exemption requirements of Rule 16b-3 and/or Section 162(m) of the Code. However, if the Board intends to satisfy such exemption requirements, with respect to Awards to any Covered Employee and with respect to any insider subject to Section 16 of the Exchange Act, the Committee shall be a compensation committee of the Board that at all times consists solely of two or more Non-Employee Directors who are also Outside Directors. Within the scope of such authority, the Board or the Committee may (a) delegate to a committee of one or more members of the Board who are not Outside Directors the authority to grant Awards to eligible persons who are either (i) not then Covered Employees and are not expected to be Covered Employees at the time of recognition of income resulting from such Award or (ii) not persons with respect to whom the Company wishes to comply with Section 162(m) of the Code or (b) delegate to a committee of one or more members of the Board who are not Non-Employee Directors the authority to grant Awards to eligible persons who are not then subject to Section 16 of the Exchange Act. Nothing herein shall create an inference that an Award is not validly granted under the Plan in the event Awards are granted under the Plan by a compensation committee of the Board that does not at all times consist solely of two or more Non-Employee Directors who are also Outside Directors. 3.5 Indemnification. In addition to such other rights of indemnification as they may have as Directors or members of the Committee, and to the extent allowed by Applicable Laws, the Committee shall be indemnified by the Company against the reasonable expenses, including attorneyâ€™s fees, actually incurred in connection with any action, suit or proceeding or in connection with any appeal therein, to which the Committee may be party by reason of any action taken or failure to act under or in connection with the Plan or any Award granted under the Plan, and against all amounts paid by the Committee in settlement thereof (provided, however, that the settlement has been approved by the Company, which approval shall not be unreasonably withheld) or paid by the Committee in satisfaction of a judgment in any such action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such action, suit or proceeding that such Committee did not act in good faith and in a manner which such person reasonably believed to be in the best interests of the Company, or in the case of a criminal proceeding, had no reason to believe that the conduct complained of was unlawful; provided, however, that within 60 days after institution of any such action, suit or proceeding, such Committee shall, in writing, offer the Company the opportunity at its own expense to handle and defend such action, suit or proceeding. Â 4. Shares Subject to the Plan. 4.1 Subject to adjustment in accordance with Section 11, a total of 400,000 shares of Common Stock shall be available for the grant of Awards under the Plan; provided that, no more than 200,000 shares of Common Stock may be granted as Incentive Stock Options. Additionally, a Director who is not also an Employee may not be granted Â Awards covering more than 10,000 shares of Common Stock in any fiscal year. During the terms of the Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Awards. 4.2 Shares of Common Stock available for distribution under the Plan may consist, in whole or in part, of authorized and unissued shares, treasury shares or shares reacquired by the Company in any manner. 4.3 Subject to adjustment in accordance with Section 11, no Participant shall be granted, during any one (1) year period, Options to purchase Common Stock and Stock Appreciation Rights with respect to more than 50,000 shares of Common Stock in the aggregate or any other Awards with respect to more than 50,000 shares of Common Stock in the aggregate. If an Award is to be settled in cash, the number of shares of Common Stock on which the Award is based shall not count toward the individual share limit set forth in this Section 4. 4.4 Any shares of Common Stock subject to an Award that is canceled, forfeited or expires prior to exercise or realization, either in full or in part, shall again become available for issuance under the Plan. Notwithstanding anything to the contrary contained herein: shares subject to an Award under the Plan shall not again be made available for issuance or delivery under the Plan if such shares are (a) shares tendered in payment of an Option, (b) shares delivered or withheld by the Company to satisfy any tax withholding obligation, or (c) shares covered by a stock-settled Stock Appreciation Right or other Awards that were not issued upon the settlement of the Award. 4.5 Any shares of Common Stock issued by the Company as Substitute Awards in connection with the assumption or substitution of outstanding grants from any acquired company shall not reduce the shares of Common Stock available for Awards under the Plan to the extent that the rules and regulations of any stock exchange or other trading market on which the shares of Common Stock are listed or traded provide an exemption from shareholder approval for assumption, substitution, conversion, adjustment, or replacement of outstanding awards in connection with mergers, acquisitions, or other corporate combinations. Â 5. Eligibility. 5.1 Eligibility for Specific Awards. Incentive Stock Options may be granted only to Employees. Awards other than Incentive Stock Options may be granted to Employees, Consultants and Directors and those individuals whom the Committee determines are reasonably expected to become Employees, Consultants and Directors following the Grant Date. 5.2 Ten Percent Shareholders. A Ten Percent Shareholder shall not be granted an Incentive Stock Option unless the Option Exercise Price is at least 110% of the Fair Market Value of the Common Stock at the Grant Date and the Option is not exercisable after the expiration of five years from the Grant Date. 6. Option Provisions. Each Option granted under the Plan shall be evidenced by an Award Agreement. Each Option so granted shall be subject to the conditions set forth in this Section 6, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. All Options shall be separately designated Incentive Stock Options or Non-qualified Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. Notwithstanding the foregoing, the Company shall have no liability to any Participant or any other person if an Option designated as an Incentive Stock Option fails to qualify as such at any time or if an Option is determined to constitute â€œnonqualified deferred compensationâ€ within the meaning of Section 409A of the Code and the terms of such Option do not satisfy the requirements of Section 409A of the Code. The provisions of separate Options need not be identical, but each Option shall include (through incorporation of provisions hereof by reference in the Option or otherwise) the substance of each of the following provisions: 6.1 Term. Subject to the provisions of Section 5.2 regarding Ten Percent Shareholders, no Incentive Stock Option shall be exercisable after the expiration of 10 years from the Grant Date. The term of a Non-qualified Stock Option granted under the Plan shall be determined by the Committee; provided, however, no Non-qualified Stock Option shall be exercisable after the expiration of 10 years from the Grant Date. 6.2 Exercise Price of an Incentive Stock Option. Subject to the provisions of Section 5.2 regarding Ten Percent Shareholders, the Option Exercise Price of each Incentive Stock Option shall be not less than 100% of the Fair Market Value of the Common Stock subject to the Option on the Grant Date. Notwithstanding the foregoing, an Incentive Stock Option may be granted with an Option Exercise Price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption

or substitution for another option in a manner satisfying the provisions of Section 424(a) of the Code. Â 6.3 Exercise Price of a Non-qualified Stock Option. The Option Exercise Price of each Non-qualified Stock Option shall be not less than 100% of the Fair Market Value of the Common Stock subject to the Option on the Grant Date. Notwithstanding the foregoing, a Non-qualified Stock Option may be granted with an Option Exercise Price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section 409A of the Code. 6.4 Consideration. The Option Exercise Price of Common Stock acquired pursuant to an Option shall be paid, to the extent permitted by applicable statutes and regulations, either (a) in cash or by certified or bank check at the time the Option is exercised or (b) in the discretion of the Committee, upon such terms as the Committee shall approve, the Option Exercise Price may be paid: (i) by delivery to the Company of other Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the date of delivery equal to the Option Exercise Price (or portion thereof) due for the number of shares being acquired, or by means of attestation whereby the Participant identifies for delivery specific shares of Common Stock that have an aggregate Fair Market Value on the date of attestation equal to the Option Exercise Price (or portion thereof) and receives a number of shares of Common Stock equal to the difference between the number of shares thereby purchased and the number of identified attestation shares of Common Stock (a â€œStock for Stock Exchangeâ€); (ii) a â€œcashlessâ€ exercise program established with a broker; (iii) by reduction in the number of shares of Common Stock otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the aggregate Option Exercise Price at the time of exercise; (iv) any combination of the foregoing methods; or (v) in any other form of legal consideration that may be acceptable to the Committee. Unless otherwise specifically provided in the Option, the exercise price of Common Stock acquired pursuant to an Option that is paid by delivery (or attestation) to the Company of other Common Stock acquired, directly or indirectly from the Company, shall be paid only by shares of the Common Stock of the Company that have been held for more than six months (or such longer or shorter period of time required to avoid a charge to earnings for financial accounting purposes). Notwithstanding the foregoing, during any period for which the Common Stock is publicly traded (i.e., the Common Stock is listed on any established stock exchange or a national market system) an exercise by a Director or Officer that involves or may involve a direct or indirect extension of credit or arrangement of an extension of credit by the Company, directly or indirectly, in violation of Section 402(a) of the Sarbanes-Oxley Act of 2002 shall be prohibited with respect to any Award under this Plan. 6.5 Transferability of an Incentive Stock Option. An Incentive Stock Option shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Optionholder only by the Optionholder. Notwithstanding the foregoing, the Optionholder may, by delivering written notice to the Company, in a form satisfactory to the Company, designate a third party who, in the event of the death of the Optionholder, shall thereafter be entitled to exercise the Option. 6.6 Transferability of a Non-qualified Stock Option. A Non-qualified Stock Option may, in the sole discretion of the Committee, be transferable to a Permitted Transferee, upon written approval by the Committee to the extent provided in the Award Agreement. If the Non-qualified Stock Option does not provide for transferability, then the Non-qualified Stock Option shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Optionholder only by the Optionholder. Notwithstanding the foregoing, the Optionholder may, by delivering written notice to the Company, in a form satisfactory to the Company, designate a third party who, in the event of the death of the Optionholder, shall thereafter be entitled to exercise the Option. 6.7 Vesting of Options. Each Option may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The Option may be subject to such other terms and conditions on the time or times when it may be exercised (which may be based on performance or other criteria) as the Committee may deem appropriate. The vesting provisions of individual Options may vary. No Option may be exercised for a fraction of a share of Common Stock. 6.8 Termination of Continuous Service. Unless otherwise provided in an Award Agreement or in an employment agreement the terms of which have been approved by the Committee, in the event an Optionholderâ€™s Continuous Service terminates (other than upon the Optionholderâ€™s death or Disability), the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination) but only within such period of time ending on the earlier of (a) the date three months following the termination of the Optionholderâ€™s Continuous Service or (b) the expiration of the term of the Option as set forth in the Award Agreement; provided that, if the termination of Continuous Service is by the Company for Cause, all outstanding Options (whether or not vested) shall immediately terminate and cease to be exercisable. If, after Â termination, the Optionholder does not exercise his or her Option within the time specified in the Award Agreement, the Option shall terminate. 6.9 Extension of Termination Date. An Optionholderâ€™s Award Agreement may also provide that if the exercise of the Option following the termination of the Optionholderâ€™s Continuous Service for any reason would be prohibited at any time because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act or any other state or federal securities law or the rules of any securities exchange or interdealer quotation system, then the Option shall terminate on the earlier of (a) the expiration of the term of the Option in accordance with Section 6.1 or (b) the expiration of a period after termination of the Participantâ€™s Continuous Service that is three months after the end of the period during which the exercise of the Option would be in violation of such registration or other securities law requirements. 6.10 Disability of Optionholder. Unless otherwise provided in an Award Agreement, in the event that an Optionholderâ€™s Continuous Service terminates as a result of the Optionholderâ€™s Disability, the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination), but only within such period of time ending on the earlier of (a) the date 12 months following such termination or (b) the expiration of the term of the Option as set forth in the Award Agreement. If, after termination, the Optionholder does not exercise his or her Option within the time specified herein or in the Award Agreement, the Option shall terminate. 6.11 Death of Optionholder. Unless otherwise provided in an Award Agreement, in the event an Optionholderâ€™s Continuous Service terminates as a result of the Optionholderâ€™s death, then the Option may be exercised (to the extent the Optionholder was entitled to exercise such Option as of the date of death) by the Optionholderâ€™s estate, by a person who acquired the right to exercise the Option by bequest or inheritance or by a person designated to exercise the Option upon the Optionholderâ€™s death, but only within the period ending on the earlier of (a) the date 12 months following the date of death or (b) the expiration of the term of such Option as set forth in the Award Agreement. If, after the Optionholderâ€™s death, the Option is not exercised within the time specified herein or in the Award Agreement, the Option shall terminate. 6.12 Incentive Stock Option $100,000 Limitation. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and its Affiliates) exceeds $100,000, the Options or portions thereof which exceed such limit (according to the order in which they were granted) shall be treated as Non-qualified Stock Options. Â Â 7. Provisions of Awards Other Than Options. Â Â 7.1 Stock Appreciation Rights. Â Â (a) General Each Stock Appreciation Right granted under the Plan shall be evidenced by an Award Agreement. Each Stock Appreciation Right so granted shall be subject to the conditions set forth in this Section 7.1, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. Stock Appreciation Rights may be granted alone (â€œFree Standing Rightsâ€) or in tandem with an Option granted under the Plan (â€œRelated Rightsâ€). Â (b) Grant Requirements Any Related Right that relates to a Non-qualified Stock Option may be granted at the same time the Option is granted or at any time thereafter but before the exercise or expiration of the Option. Any Â Related Right that relates to an Incentive Stock Option must be granted at the same time the Incentive Stock Option is granted. Â (c) Term of Stock Appreciation Rights The term of a Stock Appreciation Right granted under the Plan shall be determined by the Committee; provided, however, no Stock Appreciation Right shall be exercisable later than the tenth anniversary of the Grant Date. Â (d) Vesting of Stock Appreciation Rights Each Stock Appreciation Right may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The Stock Appreciation Right may be subject to such other terms and conditions on the time or times when it may be exercised as the Committee may deem appropriate. The vesting provisions of individual Stock Appreciation Rights may vary. No Stock Appreciation Right may be exercised for a fraction of a share of Common Stock. The Committee may, but shall not be required to, provide for an acceleration of vesting and exercisability in the terms of any Stock Appreciation Right upon the occurrence of a specified event. Â (e) Exercise and Payment Upon exercise of a Stock Appreciation Right, the holder shall be entitled to receive from the Company an amount equal to the number of shares of Common Stock subject to the Stock Appreciation Right that is being exercised multiplied by the excess of (i) the Fair Market Value of a share of Common Stock on the date the Award is exercised, over (ii) the exercise price specified in the Stock Appreciation Right or related Option. Payment with respect to the exercise of a Stock Appreciation Right shall be made on the date of exercise. Payment shall be made in the form of shares of Common Stock (with or without restrictions as to substantial risk of forfeiture and transferability, as determined by the Committee in its sole discretion), cash or a combination thereof, as determined by the Committee. Â Â (f) Exercise Price The exercise price of a Free Standing Stock Appreciation Right shall be determined by the Committee, but shall not be less than 100% of the Fair Market Value of one share of Common Stock on the Grant Date of such Stock Appreciation Right. A Related Right granted simultaneously with or subsequent to the grant of an Option and in conjunction therewith or in the alternative thereto shall have the same exercise price as the related Option, shall be transferable only upon the same terms and conditions as the related Option, and shall be exercisable only to the same extent as the related Option; provided, however, that a Stock Appreciation Right, by its terms, shall be exercisable only when the Fair Market Value per share of Common Stock subject to the Stock Appreciation Right and related Option exceeds the exercise price per share thereof and no Stock Appreciation Rights may be granted in tandem with an Option unless the Committee determines that the requirements of Section 7.1(b) are satisfied. Â (g) Reduction in the Underlying Option Shares Upon any exercise of a Related Right, the number of shares of Common Stock for which any related Option shall be exercisable shall be reduced by the number of shares for which the Stock Appreciation Right has been exercised. The number of shares of Common Stock for which a Related Right shall be exercisable shall be reduced upon any exercise of any related Option by the number of shares of Common Stock for which such Option has been exercised. Â 7.2 Restricted Awards. Â Â Â Â (a) General A Restricted Award is an Award of actual shares of Common Stock (â€œRestricted Stockâ€), which may, but need not, provide that such Restricted Award may not be sold, assigned, transferred or otherwise disposed of, pledged or hypothecated as collateral for a loan or as security for the performance of any obligation or for any other purpose for such period (the â€œRestricted Periodâ€) as the Committee shall determine. Each Restricted Award granted under the Plan shall be evidenced by an Award Agreement. Each Restricted Award so granted shall be subject to the conditions set forth in this Section 7.2, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. Â (b) Restricted Stock Each Participant granted Restricted Stock shall execute and deliver to the Company an Award Agreement with respect to the Restricted Stock setting forth the restrictions and other terms and conditions applicable to such Restricted Stock. If the Committee determines that the Restricted Stock shall be held by the Company or in escrow rather than delivered to the Participant pending the release of the applicable restrictions, the Committee may require the Participant to additionally execute and deliver to the Company (A) an escrow agreement satisfactory to the Committee, if applicable and (B) the appropriate blank stock power with respect to the Restricted Stock covered by such agreement. If a Participant fails to execute an agreement evidencing an Award of Restricted Stock and, if applicable, an escrow agreement and stock power, the Award shall be null and void. Subject to the restrictions set forth in the Award, the Participant generally shall have the rights and privileges of a shareholder as to such Restricted Stock, including the right to vote such Restricted Stock and the right to receive dividends; provided that, any cash dividends and stock dividends with respect to the Restricted Stock shall be withheld by the Company for the Participantâ€™s account, and interest may be credited on the amount of the cash dividends withheld at a rate and subject to such terms as determined by the Committee. The cash dividends or stock dividends so withheld by the Committee and attributable to any particular share of Restricted Stock (and earnings thereon, if applicable) shall be distributed to the Participant in cash or, at the discretion of the Committee, in shares of Common Stock having a Fair Market Value equal to the amount of such dividends, if applicable, upon the release of restrictions on such share and, if such share is forfeited, the Participant shall have no right to such dividends. Â (c) Restrictions Restricted Stock awarded to a Participant shall be subject to the following restrictions until the expiration of the Restricted Period, and to such other terms and conditions as may be set forth in the applicable Award Agreement: (A) if an escrow arrangement is used, the Participant shall not be entitled to delivery of the stock certificate; (B) the shares shall be subject to the restrictions on transferability set forth in the Award Agreement; (C) the shares shall be subject to forfeiture to the extent provided in the applicable Award Agreement; and (D) to the extent such shares are forfeited, the stock certificates shall be returned to the Company, and all rights of the Participant to such shares and as a shareholder with respect to such shares shall terminate without further obligation on the part of the Company. Â (d) Restricted Period With respect to Restricted Awards, the Restricted Period shall commence on the Grant Date and end at the time or times set forth on a schedule established by the Committee in the applicable Award Agreement. No Restricted Award may be granted or settled for a fraction of a share of Common Stock. The Committee may, but shall not be required to, provide for an acceleration of vesting in the terms of any Award Agreement upon the occurrence of a specified event. Â (e) Delivery of Restricted Stock Â Â Upon the expiration of the Restricted Period with respect to any shares of Restricted Stock, the restrictions set forth in Section 7.2(c) and the applicable Award Agreement shall be of no further force or effect with respect to such shares, except as set forth in the applicable Award Agreement. If an escrow arrangement is used, upon such expiration, the Company shall deliver to the Participant, or his or her beneficiary, without charge, the stock certificate evidencing the shares of Restricted Stock which have not then been forfeited and with respect to which the Restricted Period has expired (to the nearest full share) and any cash dividends or stock dividends credited to the Participantâ€™s account with respect to such Restricted Stock and the interest thereon, if any. Â (f) Stock Restrictions Each certificate representing Restricted Stock awarded under the Plan shall bear a legend in such form as the Company deems appropriate. 8. Securities Law Compliance. Each Award Agreement shall provide that no shares of Common Stock shall be purchased or sold thereunder unless and until (a) any then applicable requirements of state or federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel and (b) if required to do so by the Company, the Participant has executed and delivered to the Company a letter of investment intent in such form and containing such provisions as the Committee may require. The Company shall use reasonable efforts to seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise of the Awards; provided, however, that this undertaking shall not require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority which counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company shall be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Awards unless and until such authority is obtained. 9. Use of Proceeds from Stock. Proceeds from the sale of Common Stock pursuant to Awards, or upon exercise thereof, shall constitute general funds of the Company. 10. Miscellaneous. 10.1 [Intentionally Omitted.] 10.2 Shareholder Rights. Except as provided in the Plan or an Award Agreement, no Participant shall be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until such Participant has satisfied all requirements for exercise of the Award pursuant to its terms and no adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property) or distributions of other rights for which the record date is prior to the date such Common Stock certificate is issued, except as provided in Section 11 hereof. 10.3 No Employment or Other Service Rights. Nothing in the Plan or any instrument executed or Award granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or shall affect the right of the Company or an Affiliate to terminate (a) the employment of an Employee with or without notice and with or without Cause or (b) the service of a Director pursuant to the By-laws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be. 10.4 Transfer; Approved Leave of Absence. For purposes of the Plan, no termination of employment by an Employee shall be deemed to result from either (a) a transfer of employment to the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another, or (b) an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the Employeeâ€™s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Committee otherwise so provides in writing, in either case, except to the extent inconsistent with Section 409A of the Code if the applicable Award is subject thereto. 10.5 Withholding Obligations. To the extent provided by the terms of an Award Agreement and subject to the discretion of the Committee, the Participant may satisfy any federal, state or local tax withholding obligation relating to the exercise or acquisition of Common Stock under an Award by any of the following means (in addition Â to the Companyâ€™s right to withhold from any compensation paid to the Participant by the Company) or by a combination of such means: (a) tendering a cash payment; (b) authorizing the Company to withhold shares of Common Stock from the shares of Common Stock otherwise issuable to the Participant as a result of the exercise or acquisition of Common Stock under the Award, provided, however, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law; or (c) delivering to the Company previously owned and unencumbered

shares of Common Stock of the Company. 11. Adjustments Upon Changes in Stock. In the event of changes in the outstanding Common Stock or in the capital structure of the Company by reason of any stock or extraordinary cash dividend, stock split, reverse stock split, an extraordinary corporate transaction such as any recapitalization, reorganization, merger, consolidation, combination, exchange, or other relevant change in capitalization occurring after the Grant Date of any Award, Awards granted under the Plan and any Award Agreements, the exercise price of Options and Stock Appreciation Rights, the maximum number of shares of Common Stock subject to all Awards stated in Section 4 and the maximum number of shares of Common Stock with respect to which any one person may be granted Awards during any period stated in Section 4 will be equitably adjusted or substituted, as to the number, price or kind of a share of Common Stock or other consideration subject to such Awards to the extent necessary to preserve the economic intent of such Award. In the case of adjustments made pursuant to this Section 11, unless the Committee specifically determines that such adjustment is in the best interests of the Company or its Affiliates, the Committee shall, in the case of Incentive Stock Options, ensure that any adjustments under this Section 11 will not constitute a modification, extension or renewal of the Incentive Stock Options within the meaning of Section 424(h)(3) of the Code and in the case of Non-qualified Stock Options, ensure that any adjustments under this Section 11 will not constitute a modification of such Non-qualified Stock Options within the meaning of Section 409A of the Code. Any adjustments made under this Section 11 shall be made in a manner which does not adversely affect the exemption provided pursuant to Rule 16b-3 under the Exchange Act. Further, with respect to Awards intended to qualify as â€œperformance-based compensationâ€ under Section 162(m) of the Code, any adjustments or substitutions will not cause the Company to be denied a tax deduction on account of Section 162(m) of the Code. The Company shall give each Participant notice of an adjustment hereunder and, upon notice, such adjustment shall be conclusive and binding for all purposes. Â 12. Effect of Change in Control. 12.1 Unless otherwise provided in an Award Agreement or in a Participantâ€™s employment or service agreement, notwithstanding any provision of the Plan to the contrary, in the event of a Change in Control, all Options and Stock Appreciation Rights shall become immediately exercisable with respect to 100% of the shares subject to such Options or Stock Appreciation Rights, and/or the Restricted Period shall expire immediately with respect to 100% of the shares of Restricted Stock or Restricted Stock Units. To the extent practicable, any actions taken by the Committee under the immediately preceding sentence shall occur in a manner and at a time which allows affected Participants the ability to participate in the Change in Control with respect to the shares of Common Stock subject to their Awards. 12.2 In addition, in the event of a Change in Control, the Committee may in its discretion and upon at least 10 daysâ€™ advance notice to the affected persons, cancel any outstanding Awards and pay to the holders thereof, in cash or stock, or any combination thereof, the value of such Awards based upon the price per share of Common Stock received or to be received by other shareholders of the Company in the event. In the case of any Option or Stock Appreciation Right with an exercise price (or SAR Exercise Price in the case of a Stock Appreciation Right) that equals or exceeds the price paid for a share of Common Stock in connection with the Change in Control, the Committee may cancel the Option or Stock Appreciation Right without the payment of consideration therefor. 12.3 The obligations of the Company under the Plan shall be binding upon any successor corporation or organization resulting from the merger, consolidation or other reorganization of the Company, or upon any successor corporation or organization succeeding to all or substantially all of the assets and business of the Company and its Affiliates, taken as a whole. Â 13. Amendment of the Plan and Awards. 13.1 Amendment of Plan. The Board at any time, and from time to time, may amend or terminate the Plan. However, except as provided in Section 11 relating to adjustments upon changes in Common Stock and Section 13.3, no amendment shall be effective unless approved by the shareholders of the Company to the extent shareholder Â approval is necessary to satisfy any Applicable Laws. At the time of such amendment, the Board shall determine, upon advice from counsel, whether such amendment will be contingent on shareholder approval. 13.2 Shareholder Approval. The Board may, in its sole discretion, submit any other amendment to the Plan for shareholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of Section 162(m) of the Code and the regulations thereunder regarding the exclusion of performance-based compensation from the limit on corporate deductibility of compensation paid to certain executive officers. 13.3 Contemplated Amendments. It is expressly contemplated that the Board may amend the Plan in any respect the Board deems necessary or advisable to provide eligible Employees, Consultants and Directors with the maximum benefits provided or to be provided under the provisions of the Code and the regulations promulgated thereunder relating to Incentive Stock Options or to the nonqualified deferred compensation provisions of Section 409A of the Code and/or to bring the Plan and/or Awards granted under it into compliance therewith. 13.4 No Impairment of Rights. Rights under any Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan unless (a) the Company requests the consent of the Participant and (b) the Participant consents in writing. 13.5 Amendment of Awards. The Committee at any time, and from time to time, may amend the terms of any one or more Awards; provided, however, that the Committee may not affect any amendment which would otherwise constitute an impairment of the rights under any Award unless (a) the Company requests the consent of the Participant and (b) the Participant consents in writing. Â 14. General Provisions. 14.1 Forfeiture Events. The Committee may specify in an Award Agreement that the Participantâ€™s rights, payments and benefits with respect to an Award shall be subject to reduction, cancellation, forfeiture or recoupment upon the occurrence of certain events, in addition to applicable vesting conditions of an Award. Such events may include, without limitation, breach of non-competition, non-solicitation, confidentiality, or other restrictive covenants that are contained in the Award Agreement or otherwise applicable to the Participant, a termination of the Participantâ€™s Continuous Service for Cause, or other conduct by the Participant that is detrimental to the business or reputation of the Company and/or its Affiliates. 14.2 Clawback. Notwithstanding any other provisions in this Plan, any Award which is subject to recovery under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement (or any policy adopted by the Company pursuant to any such law, government regulation or stock exchange listing requirement). 14.3 Other Compensation Arrangements. Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, subject to shareholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases. 14.4 Sub-plans. The Committee may from time to time establish sub-plans under the Plan for purposes of satisfying blue sky, securities, tax or other laws of various jurisdictions in which the Company intends to grant Awards. Any sub-plans shall contain such limitations and other terms and conditions as the Committee determines are necessary or desirable. All sub-plans shall be deemed a part of the Plan, but each sub-plan shall apply only to the Participants in the jurisdiction for which the sub-plan was designed. Â 14.5 [Intentionally Omitted.] 14.6 Unfunded Plan. The Plan shall be unfunded. Neither the Company, the Board nor the Committee shall be required to establish any special or separate fund or to segregate any assets to assure the performance of its obligations under the Plan. 14.7 Recapitalizations. Each Award Agreement shall contain provisions required to reflect the provisions of Section 11. Â 14.8 Delivery. Upon exercise of a right granted under this Plan, the Company shall issue Common Stock or pay any amounts due within a reasonable period of time thereafter. Subject to any statutory or regulatory obligations the Company may otherwise have, for purposes of this Plan, 30 days shall be considered a reasonable period of time. 14.9 No Fractional Shares. No fractional shares of Common Stock shall be issued or delivered pursuant to the Plan. The Committee shall determine whether cash, additional Awards or other securities or property shall be issued or paid in lieu of fractional shares of Common Stock or whether any fractional shares should be rounded, forfeited or otherwise eliminated. 14.10 Other Provisions. The Award Agreements authorized under the Plan may contain such other provisions not inconsistent with this Plan, including, without limitation, restrictions upon the exercise of the Awards, as the Committee may deem advisable. 14.11 Section 409A. The Plan is intended to comply with Section 409A of the Code to the extent subject thereto, and, accordingly, to the maximum extent permitted, the Plan shall be interpreted and administered to be in compliance therewith. Any payments described in the Plan that are due within the â€œshort-term deferral periodâ€ as defined in Section 409A of the Code shall not be treated as deferred compensation unless Applicable Laws require otherwise. Notwithstanding anything to the contrary in the Plan, to the extent required to avoid accelerated taxation and tax penalties under Section 409A of the Code, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the six (6) month period immediately following the Participantâ€™s termination of Continuous Service shall instead be paid on the first payroll date after the six-month anniversary of the Participantâ€™s separation from service (or the Participantâ€™s death, if earlier). Notwithstanding the foregoing, neither the Company nor the Committee shall have any obligation to take any action to prevent the assessment of any excise tax or penalty on any Participant under Section 409A of the Code and neither the Company nor the Committee will have any liability to any Participant for such tax or penalty. 14.12 Disqualifying Dispositions. Any Participant who shall make a â€œdispositionâ€ (as defined in Section 424 of the Code) of all or any portion of shares of Common Stock acquired upon exercise of an Incentive Stock Option within two years from the Grant Date of such Incentive Stock Option or within one year after the issuance of the shares of Common Stock acquired upon exercise of such Incentive Stock Option (a â€œDisqualifying Dispositionâ€) shall be required to immediately advise the Company in writing as to the occurrence of the sale and the price realized upon the sale of such shares of Common Stock. 14.13 Section 16. It is the intent of the Company that the Plan satisfy, and be interpreted in a manner that satisfies, the applicable requirements of Rule 16b-3 as promulgated under Section 16 of the Exchange Act so that Participants will be entitled to the benefit of Rule 16b-3, or any other rule promulgated under Section 16 of the Exchange Act, and will not be subject to short-swing liability under Section 16 of the Exchange Act. Accordingly, if the operation of any provision of the Plan would conflict with the intent expressed in this Section 14.13, such provision to the extent possible shall be interpreted and/or deemed amended so as to avoid such conflict. 14.14 Section 162(m). To the extent the Committee issues any Award that is intended to be exempt from the deduction limitation of Section 162(m) of the Code, the Committee may, without shareholder or grantee approval, amend the Plan or the relevant Award Agreement retroactively or prospectively to the extent it determines necessary in order to comply with any subsequent clarification of Section 162(m) of the Code required to preserve the Companyâ€™s federal income tax deduction for compensation paid pursuant to any such Award. 14.15 Beneficiary Designation. Each Participant under the Plan may from time to time name any beneficiary or beneficiaries by whom any right under the Plan is to be exercised in case of such Participantâ€™s death. Each designation will revoke all prior designations by the same Participant, shall be in a form reasonably prescribed by the Committee and shall be effective only when filed by the Participant in writing with the Company during the Participantâ€™s lifetime. 14.16 Expenses. The costs of administering the Plan shall be paid by the Company. 14.17 Severability. If any of the provisions of the Plan or any Award Agreement is held to be invalid, illegal or unenforceable, whether in whole or in part, such provision shall be deemed modified to the extent, but only to the extent, of such invalidity, illegality or unenforceability and the remaining provisions shall not be affected thereby. 14.18 Plan Headings. The headings in the Plan are for purposes of convenience only and are not intended to define or limit the construction of the provisions hereof. Â 14.19 Non-Uniform Treatment. The Committeeâ€™s determinations under the Plan need not be uniform and may be made by it selectively among persons who are eligible to receive, or actually receive, Awards. Without limiting the generality of the foregoing, the Committee shall be entitled to make non-uniform and selective determinations, amendments and adjustments, and to enter into non-uniform and selective Award Agreements. 15. Effective Date of Plan. The Plan shall become effective as of the Effective Date, but no Award shall be exercised (or, in the case of a stock Award, shall be granted) unless and until the Plan has been approved by the shareholders of the Company, which approval shall be within twelve (12) months before or after the date the Plan is adopted by the Board. 16. Termination or Suspension of the Plan. The Plan shall terminate automatically on the ten-year anniversary of the Effective Date. No Award shall be granted pursuant to the Plan after such date, but Awards theretofore granted may extend beyond that date. The Board may suspend or terminate the Plan at any earlier date pursuant to Section 13.1 hereof. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. 17. Choice of Law. The law of the State of Minnesota shall govern all questions concerning the construction, validity and interpretation of this Plan, without regard to such stateâ€™s conflict of law rules. Â As adopted by the Board of Directors of IsoRay, Inc. on May 4, 2017. Â EX-31.1 4 catx-ex31_1.htm EX-31.1 EX-31.1 Exhibit 31.1 Â CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Johan (Thijs) Spoor, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Perspective Therapeutics, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: August 13, 2024 Â Â /s/ Johan (Thijs) Spoor Â Johan (Thijs) Spoor Â Chief Executive Officer Â (Principal Executive Officer) Â EX-31.2 5 catx-ex31_2.htm EX-31.2 EX-31.2 Exhibit 31.2 Â CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jonathan Hunt, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Perspective Therapeutics, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: August 13, 2024 Â Â /s/ Jonathan Hunt Â Jonathan Hunt Â Chief Financial Officer Â (Co-Principal Financial Officer) Â EX-31.3 6 catx-ex31_3.htm EX-

31.3 EX-31.3 Exhibit 31.3 Â CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Mark J. Austin, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Perspective Therapeutics, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: August 13, 2024 Â Â /s/ Mark J. Austin Â Mark J. Austin Â Vice President of Finance and Corporate Controller Â (Co-Principal Financial Officer, Principal Accounting Officer, Corporate Secretary) Â EX-32 7 catx-ex32.htm EX-32 EX-32 Exhibit 32 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report on Form 10-Q of Perspective Therapeutics, Inc. (the â€œCompanyâ€) for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), we, Johan (Thijs) Spoor, Chief Executive Officer of the Company, Jonathan Hunt, Chief Financial Officer, and Mark J. Austin, Vice President of Finance and Corporate Controller, of the Company, certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge: Â 1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 13, 2024 Â /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer(Principal Executive Officer) /s/ Jonathan Hunt Jonathan Hunt Chief Financial Officer(Co-Principal Financial Officer) /s/ Mark J. Austin Mark J. Austin Vice President of Finance and Corporate Controller(Co-Principal Financial Officer, Principal Accounting Officer, Corporate Secretary) Â EX-101.SCH 8 catx-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Note 12 - Leases - Summary of Future Operating Lease Payments and Lease Liability (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Disclosure - Note 4 - Discontinued Operations - Schedule of Discontinued Operations (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) 2 link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Operations (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100090 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 100100 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100110 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 995457 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995467 - Disclosure - Note 2 - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995477 - Disclosure - Note 3 - Investments and Agreements link:presentationLink link:calculationLink link:definitionLink 995487 - Disclosure - Note 4 - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 995497 - Disclosure - Note 5 - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 995507 - Disclosure - Note 6 - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 995517 - Disclosure - Note 7 - Held-to-Maturity Investments link:presentationLink link:calculationLink link:definitionLink 995527 - Disclosure - Note 8 - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995537 - Disclosure - Note 9 - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995547 - Disclosure - Note 10 - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995557 - Disclosure - Note 11 - Related Parties link:presentationLink link:calculationLink link:definitionLink 995567 - Disclosure - Note 12 - Leases link:presentationLink link:calculationLink link:definitionLink 995577 - Disclosure - Note 13 - Notes Payable link:presentationLink link:calculationLink link:definitionLink 995587 - Disclosure - Note 14 - Merger link:presentationLink link:calculationLink link:definitionLink 995597 - Disclosure - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995607 - Disclosure - Note 2 - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995617 - Disclosure - Note 4 - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 995627 - Disclosure - Note 5 - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 995637 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995647 - Disclosure - Note 7 - Held-to-Maturity Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 995657 - Disclosure - Note 8 - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995667 - Disclosure - Note 9 - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995677 - Disclosure - Note 12 - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995687 - Disclosure - Note 13 - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 995697 - Disclosure - Note 14 - Merger (Tables) link:presentationLink link:calculationLink link:definitionLink 995707 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995717 - Disclosure - Note 2 - Loss Per Share - Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares (Details) link:presentationLink link:calculationLink link:definitionLink 995727 - Disclosure - Note 2 - Loss Per Share (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995737 - Disclosure - Note 3 - Investments and Agreements (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995747 - Disclosure - Note 4 - Discontinued Operations (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995757 - Disclosure - Note 4 - Discontinued Operations - Schedule of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 995767 - Disclosure - Note 5 - Property and Equipment (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995777 - Disclosure - Note 5 - Property and Equipment - Summary of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995787 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995797 - Disclosure - Note 6 - Goodwill and Other Intangible Assets - Summary of Components of Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995807 - Disclosure - Note 7 - Held-to-Maturity Investments - Summary of Carrying Values and Fair Values of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 995817 - Disclosure - Note 7 - Held-to-Maturity Investments (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995827 - Disclosure - Note 8 - Fair Value Measurements - Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995837 - Disclosure - Note 8 - Fair Value Measurements (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995847 - Disclosure - Note 9 - Share-Based Compensation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995857 - Disclosure - Note 9 - Share-Based Compensation - Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 995867 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995877 - Disclosure - Note 11 - Related Parties (Detailed Textual) link:presentationLink link:calculationLink link:definitionLink 995887 - Disclosure - Note 12 - Leases (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995897 - Disclosure - Note 12 - Leases - Summary of Future Operating Lease Payments and Lease Liability (Details) link:presentationLink link:calculationLink link:definitionLink 995907 - Disclosure - Note 13 - Notes Payable (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995917 - Disclosure - Note 13 - Notes Payable - Summary of Note Payable (Details) link:presentationLink link:calculationLink link:definitionLink 995927 - Disclosure - Note 13 - Notes Payable - Summary of Maturity of Note Payable (Details) link:presentationLink link:calculationLink link:definitionLink 995937 - Disclosure - Note 14 - Merger (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995947 - Disclosure - Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 995957 - Disclosure - Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 995967 - Disclosure - Note 14 - Merger - Summary of Preliminary Purchase Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 995977 - Disclosure - Note 14 - Merger - Summary of Pro Forma Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2025 Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Document Transition Report Disposal Group, Including Discontinued Operation, Assets, Current Total current assets held for sale of discontinued operations Current assets held for sale, discontinued operations Right of use asset catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets amount of right of use assets acquired at acquisition date. Money Market Funds [Member] Money Market Fund [Member] Represents the difference between shares and warrants prices. Shares And Warrants Price Difference Shares and warrants, price difference per share Issuance costs related to common stock issued in exchange for Viewpoint common stock us-gaap_PaymentsOfStockIssuanceCosts Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Loss from discontinued operations, Basic Geographical [Axis] Represents the percentage of net sales receivable as part of a royalty agreement. Royalty Agreement Percentage Of Net Sales Receivable Royalty agreement percentage of net sales receivable Other noncurrent liabilities Other Liabilities, Noncurrent Prepaid expenses and other current assets us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Viewpoint Molecular Targeting, Inc. [Member] Represents Viewpoint Molecular Targeting, Inc. Viewpoint Molecular Targeting, Inc. [Member] Fair Value, Inputs, Level 1 [Member] Level 1 [Member] 2028 us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Unrecognized compensation expense Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Summary of Preliminary Purchase Price Allocation Represents the option agreement. Option Agreement [Member] Option Agreement [Member] Lantheus Alpha Therapy, LLC. Lantheus Alpha Therapy, LLC [Member] Non-current lease liability Lease liability, non-current Lease liability Operating lease liability and right of use asset for new lease Amount of operating lease liability and right of use assets for new lease. Fair Value Measurement [Domain] Maturities of Long-Term Debt [Abstract] Disposal Groups, Including Discontinued Operations [Table] Related Party Transactions [Abstract] Balance Sheet Location [Axis] Total current assets us-gaap_AssetsCurrent Total liabilities and stockholders' equity us-gaap_LiabilitiesAndStockholdersEquity catx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue Fair value of the options grants in period. Stock option awards grant in period fair value Entity Address, State or Province Litigation Case [Domain] Issuance of common stock, net Stock Issued During Period, Value, New Issues Amount raised through selling of equity Reverse stock split, ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Accrued payroll and related taxes catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPayrollAndRelatedTax Amount of accrued payroll and related taxes, assumed at the acquisition date. Trading Symbol Other [Member] Other [Member] Related to other property plant and equipment not specifically disclosed. Common stock, issued (in shares) Common stock, shares issued us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2026 Isoray Note [Member] Relating to the Isoray note. Prepaid expenses and other current assets Prepaid expenses and other current assets Consolidated Entities [Domain] Relating to net sales between $10 and 15 million. Net Sales Between 10 And 15 Million [Member] Net Sales Between $10 and 15 Million [Member] Cash and Cash Equivalents [Member] Cash and Cash Equivalents [Member] Grants receivable us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables Schedule of Long-Term Debt Instruments [Table] Balances (in shares) Balances (in shares) us-gaap_SharesOutstanding 2027 Fair value of Viewpoint assets acquired including goodwill The value of an asset or business acquired in a noncash (or part noncash) acquisition, including goodwill. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Business Combination Disclosure [Text Block] Merger Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract] Liabilities held for sale of discontinued operations, current Entity Address, City or Town Related Party Transaction [Line Items] 2024 (remaining six months) us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Non-current liabilities: Noncurrent liabilities: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Operating lease, weighted average discount rate Debt Disclosure [Text Block] Notes Payable Property, Plant and Equipment [Table Text Block] Summary of Property and Equipment us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Number of Options Outstanding, Expired Stock option awards expired Disposal Group Name [Axis] Subsequent Event [Member] Subsequent Event [Member] Subsequent Event Type [Axis] Equity Interest Issued or Issuable, Type [Domain] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Grant revenue Business Acquisition, Pro Forma Revenue Progenics APA. Progenics APA [Member] Amortization of other assets Amortization, Total Amortization Series B Preferred Stock [Member] Series B Preferred Stock [Member] Current liabilities: Current liabilities: Net cash acquired in acquisition of Viewpoint Current assets: Current assets: Counterparty Name [Axis] Preferred stock, par value (in dollars per share) Preferred stock, par value Statement of Stockholders' Equity [Abstract] Relating to GT Medical stock. G T Medical Stock [Member] GT Medical Stock [Member] GT Medical Technologies, Inc. [Member] Refers to information regarding the entity GT Medical Technologies, Inc. GT Medical Technologies, Inc. [Member] Less current portion Lease liability Lease liability Repayment provisions. Repayment Provisions Repayment provisions Total us-gaap_LongTermDebt Note 8 - Share-based Compensation Property and equipment, net Property and equipment, net Property and equipment, net Class of Stock [Domain] Interest income Accounts Receivable, Credit Loss Expense (Reversal) Change in allowance for doubtful accounts Deferred Income, Current Deferred Income (Note 3) Scenario [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Entity Central Index Key us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss Held-to-maturity investments Series B convertible preferred stock. Series B Convertible Preferred Stock [Member] us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Warrants to purchase shares of common stock Total purchase price consideration Plan Name [Domain] Assets, Noncurrent [Abstract] Noncurrent assets: Aggregate maximum estimate settlement amount. Aggregate maximum estimate settlement amount Loss on disposal of property and

equipment us-gaap_GainLossOnDispositionOfAssets Perspective Therapeutics common stock issued (13,654,507 x $4.00) Business combination, fair value of common stock Preferred stock, shares outstanding (in shares) Preferred stock, shares outstanding Noncash lease expense Represents the noncash expense incurred for leases. Lease expense Discontinued Operations [Member] Discontinued Operations [Member] HTM, amortized cost, Total HTM, amortized cost HTM, Amortized Cost Total current liabilities us-gaap_LiabilitiesCurrent Entity Tax Identification Number us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Net loss from continuing operations Net loss from continuing operations Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Changes in operating assets and liabilities: Financial Instruments [Domain] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value, Beginning Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value, Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Financial instruments measured at fair value Lessee, Operating Leases [Text Block] Leases Plan Name [Axis] Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax Net loss before deferred income tax benefit Promissory Note [Member] Represents promissory note. ROFO Option. ROFO Option [Member] Geographical [Domain] Total assets us-gaap_Assets Right of use asset, net Right of use asset Right-of-use asset, net Cancellation of fractional shares due to the 1-for-10 reverse stock split Stock Redeemed or Called During Period, Value Entity Registrant Name Proceeds from Issuance or Sale of Equity, Total Proceeds from Issuance or Sale of Equity Gross proceeds from public offering Lessee, Lease, Description [Line Items] Related Party, Type [Domain] Equity Interest Type [Axis] Accumulated deficit Total accumulated deficit Accumulated deficit Accumulated deficit Progenics. Progenics [Member] Limited Liability Company or Limited Partnership, Business, Formation Date Limited liability company, Formation date Retained Earnings [Member] Accumulated Deficit [Member] Assumption of Viewpoint stock options and warrants at fair value Assumption fair value of stock options and warrants in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition. Class of Stock [Axis] Deferred Income Tax Liabilities, Net Deferred tax liability Disposal Group, Including Discontinued Operation, Liabilities, Current Total current liabilities of discontinued operations Current liabilities of discontinued operations Minimum [Member] Minimum [Member] Proceeds from sales of common stock, pursuant to exercise of option Note 3 - Loss Per Share - Antidilutive Securities (Details) Total lease liability Lease liability Total lease liability, Total Public offering. Public Offering [Member] Public Offering [Member] Forecast [Member] Forecast [Member] Equity Component [Domain] Note payable Note payable, long-term portion Note payable, long-term portion Common Stock Options [Member] Land [Member] Land Note 10 - Leases Percentage of issued and outstanding capital stock. Percentage Of Issued And Outstanding Capital Stock Percentage of issued and outstanding capital stock Adjustments to reconcile net loss to net cash provided by or used in operating activities: Measurement Frequency [Axis] Debt Disclosure [Abstract] Loss on divestiture Gain (Loss) on Disposition of Business Loss recognized on classification as held for sale Entity Current Reporting Status Common stock, authorized (in shares) Common stock, shares authorized Research and development Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Loss from discontinued operations, Diluted Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Basis of Presentation and Summary of Significant Accounting Policies Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations Percentage of increase in common stock capital shares for future issuance Percentage Of Increase In Common Stock Capital Shares For Future Issuance Percentage of increase in common stock capital shares for future issuance. Assets [Abstract] ASSETS Proceeds from the ATM Agreement, net Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis Fair Value Measurements, Nonrecurring [Table Text Block] Note receivable and accrued interest from Viewpoint forgiven Forgiven of notes receivable and accrued interest assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition. Common stock, $0.001 par value; 750,000,000 shares authorized; 67,425,167 and 28,180,985 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively Common stock, $.001 par value; 750,000,000 shares authorized; 280,571,026 and 142,112,766 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively Underwriting Agreement [Member] The Underwriting Agreement [Member] Represents the Underwriting Agreement. Inventory related to discontinued operations Increase (Decrease) In Inventory Related to Discontinued Operations Increase (DeIncrease (decrease) in inventory related to discontinued operations.crease) In Inventory Related to Discontinued Operations Amount classified as loss of classification attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. Disposal Group Including Discontinued Operation Loss On Classification Current Loss recognized on classification as held for sale Income (Loss) from Continuing Operations, Per Diluted Share Loss from continuing operations, Diluted Discontinued Operation, Tax Effect of Discontinued Operation Discontinued operations, Provision (benefit) for income taxes Amount classified as lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. Disposal Group Including Discontinued Operation Lease Liabilities Current Lease liability Cash and cash equivalents us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Current Fiscal Year End Date Share-based compensation us-gaap_ShareBasedCompensation Share-Based Payment Arrangement, Noncash Expense, Total Operating loss Operating loss Operating loss us-gaap_RepaymentsOfDebt Principal payments Business acquisition, shares (in shares) Common stock issued pursuant to merger, Shares Business acquisition, number of common shares exchanged Operating Activities [Domain] Operating Activities [Axis] Total fair value of consideration transferred us-gaap_BusinessCombinationConsiderationTransferred1 Deferred Income Tax Expense (Benefit) Deferred tax benefit Deferred income tax benefit Deferred Income Tax Expense (Benefit), Total Deferred income tax benefit Research and Development [Member] Research and Development Expense [Member] Research and Development Expenses [Member] Stock Issued During Period, Shares, Acquisitions Issuance of common stock in exchange for Viewpoint common stock, net of issuance costs (in shares) Share-based compensation us-gaap_AllocatedShareBasedCompensationExpense Indefinite-Lived Intangible Assets [Axis] Disposal Groups, Including Discontinued Operations [Table Text Block] Schedule of Discontinued Operations Equipment [Member] Equipment [Member] Share based compensation arrangements by share based payment award options exercise price. Share Based Compensation Arrangements By Share Based Payment Award Options Exercise Price Options exercise price per share Disposal Group Name [Domain] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] us-gaap_DebtInstrumentFaceAmount Debt instrument, face amount Measurement Basis [Axis] Sale of Stock, Price Per Share Sale of stock, price per share Change in estimate of asset retirement obligation (Note 4) Change in estimate of asset retirement obligation Change in estimate of asset retirement obligation (Note 4) Asset Retirement Obligation, Revision of Estimate Operating expenses: Property, Plant and Equipment [Abstract] Options assumed, Options (in shares) Gross number of share options (or share units) assumed during the period. Options to purchase shares of common stock Number of Options Outstanding, Options assumed A T M Agreement [Member] A T M Agreement [Member] A T M agreement. Promissory Note for Purchasing Land and Building [Member] Represents promissory note for purchasing land and building. Commitments and Contingencies Disclosure [Abstract] Other assets, net Other assets, net Disposal Group, Including Discontinued Operation, Revenue Sales, net Granted, Options (in shares) Number of Options Outstanding, Granted Stock option awards granted Depreciation, Total Depreciation expense Depreciation, Total Depreciation us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss HTM, Gross Unrealized Losses HTM, Gross Unrealized Losses Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] US Treasury Bill Securities [Member] U.S. Treasury Bills [Member] Assumption of Viewpoint stock options and warrants at fair value catx_AdjustmentsToAdditionalPaidInCapitalAssumptionOfStockOptionsAndWarrantsAtFairValue Amount of increase in additional paid in capital (APIC) resulting from the assumption of stock options and warrants at fair value. Accounts payable and accrued expenses catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables and accrued expenses, assumed at the acquisition date. Stockholders' equity: Stockholders' equity: Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Entity [Domain] Loss on disposal of property and equipment us-gaap_GainLossOnSaleOfPropertyPlantEquipment Investments and agreements disclosure. Investments And Agreements Disclosure [Text Block] Investments and Agreements Lease Contractual Term [Domain] Earnings Per Share [Abstract] Basic and diluted loss per share: Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Summary of Future Operating Lease Payments and Lease Liability Indefinite-Lived Intangible Assets, Major Class Name [Domain] us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs Note receivable, forgiven amount Loss Contingencies [Table] Litigation Case [Axis] Disposal Group, Including Discontinued Operation, Other Assets, Current Other assets, net Payments to purchase buildings Lessee, Lease, Description [Table] In Process Research and Development [Member] In-process Research and Development Scenario [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Prepaid expenses us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets Business Acquisition, Pro Forma Information [Table Text Block] Summary of Pro Forma Computation of Earnings Per Share Net assets acquired, excluding goodwill us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet March two thousand twenty four investment agreement. March Two Thousand Twenty Four Investment Agreement [Member] March 2024 Investment Agreement [Member] Basic loss per share Basic and diluted loss per share (in dollars per share) Basic loss per share Cash Equivalents, at Carrying Value, Total Cash Equivalents, at Carrying Value Cash equivalents Write-off of inventory associated with discontinued product Write-off of inventory associated with discontinued product Write-off of inventory associated with discontinued product Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Total Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Beginning Balance Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Ending Balance Debt Securities, Held-to-Maturity, Allowance for Credit Loss Held-to-maturity, allowance for credit loss Commitments and contingencies (Note 9) Commitments and contingencies (Note 10) Issuance of stock pursuant to exercise of common stock warrants Stock Issued During Period Value Warrant Exercises Stock issued during period value warrant exercises. Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block] Summary of Stock Options Business Combinations [Abstract] Income Statement [Abstract] Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Related Party, Type [Axis] Accounts payable and accrued expenses Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets (Excluding Goodwill), Total Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning Balance Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance Intangible assets, in-process research and development Statistical Measurement [Domain] Loss Contingencies [Line Items] us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by (used in) operating activities BofA Securities, Inc [Member] Bof A Securities, Inc [Member] BofA Securities, Inc. Proceeds from investment agreement net. Proceeds from Investment Agreement Net Proceeds from Investment Agreement, net Document Period End Date Statistical Measurement [Axis] Disposal Group, Including Discontinued Operation, Operating Expense Total operating expenses Total operating expenses Accounts Receivable, Allowance for Credit Loss, Beginning Balance Accounts Receivable, Allowance for Credit Loss, Ending Balance Accounts Receivable, Allowance for Credit Loss Allowance for doubtful accounts Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Diluted loss per share Earnings Per Share, Diluted Diluted loss per share Accumulated Amortization Accumulated amount of amortization of indefinite-lived assets. catx_SharesIssuedPercentOfFullydilutedOutstandingCapitalStock Represents number of shares issued as a percentage of fully diluted outstanding capital stock. Percentage of fully-diluted outstanding capital stock Cancellation of fractional shares due to the 1-for-10 reverse stock split (in shares) Cancellation of fractional shares due to the 1-for-10 reverse stock split (in shares) Stock Redeemed or Called During Period, Shares Debt Instrument, Name [Domain] Fair Value Hierarchy and NAV [Domain] Disposal Group, Including Discontinued Operation, Consideration Estimated fair value Program license option. Program License Option [Member] Fair Value, Recurring [Member] us-gaap_NumberOfReportableSegments Number of reportable segments Additional paid-in capital Additional paid-in capital Schedule of Maturities of Long-Term Debt [Table Text Block] Summary of Maturity of Note Payable Cash, Cash Equivalents, and Short-Term Investments Cash, cash equivalents and short-term investments Total cash equivalents and short-term investments Issuance of common stock pursuant to exercise options (in shares) Number of Options Outstanding, Exercised Number of Options Outstanding, Exercised Options exercised Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Note receivable and interest from Viewpoint forgiven Amount of liabilities forgiven by the acquirer as part of consideration transferred in a business combination. Stock Issued During Period, Value, Acquisitions Issuance of common stock in exchange for Viewpoint common stock, net of issuance costs Entity Address, Postal Zip Code Entity Interactive Data Current VMT option or program license option. VMT Option or Program License Option [Member] 13,654,507 shares of Perspective Therapeutics common stock issued in exchange for Viewpoint common stock us-gaap_StockIssued1 Disposal Group, Including Discontinued Operation, Assets, Current [Abstract] Assets held for sale of discontinued operations, current Over-Allotment Option [Member] Over-Allotment Option [Member] Accrued personnel expenses Increase (Decrease) in Employee Related Liabilities Increase (Decrease) in Employee Related Liabilities, Total Less: imputed interest us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Schedule of Indefinite-Lived Intangible Assets [Table] Net loss us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss Relating to Prefunded Warrants. Prefunded Warrants [Member] Prefunded Warrants [Member] Pre-funded Warrants [Member] Entity Incorporation, State or Country Code Equity Components [Axis] Lease With Energy Northwest [Member] Represents lease with Energy Northwest. Accounts receivable us-gaap_IncreaseDecreaseInAccountsReceivable Investments, Debt and Equity Securities [Abstract] Maximum amount of securities offer and sale. Maximum Amount Of Securities Offer And Sale Maximum amount of securities offer and sale Local Phone Number Property, Plant and Equipment [Line Items] Sale of Stock [Axis] Increase (Decrease) in Deferred Revenue Deferred Income Disposal Group, Including Discontinued Operation, Inventory, Current Inventory Goodwill Balance Balance Goodwill Represents Lantheus Investment Agreement. Lantheus Investment Agreement [Member] Lantheus Investment Agreement Lantheus Investment Agreement [Member] Repayment of notes payable us-gaap_RepaymentsOfNotesPayable Less: current portion us-gaap_NotesPayableCurrent Notes payable, current Notes Payable, Current, Total Note payable Statement of Cash Flows [Abstract] Debt Securities, Held-to-Maturity [Table] Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Fair Value Measurements Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Held-to-Maturity Securities [Line Items] Represents the March 2024 private placement. March 2024 Private Placement [Member] March 2024 Private Placement [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) Common stock, par value us-gaap_DebtInstrumentInterestRateStatedPercentage Debt instrument, interest rate us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Unrecognized compensation expense, weighted-average expected recognition period Long-Lived Tangible Asset [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Net loss from discontinued operations Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Relating to net sales greater than $15 million. Net Sales Greater Than 15 Million [Member] Net Sales Greater Than $15 Million [Member] Maximum [Member] Maximum [Member] Proceeds from Pre-funded Warrants, net Proceeds from prefunded warrants net. Proceeds From Prefunded Warrants Net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current Property and equipment, net Issuance of common stock pursuant to exercise of warrants (in shares) Stock Issued During Period Shares Common Stock Warrant Exercised Stock issued during period shares common stock warrant exercised. Office Space With Unico Properties [Member] Represents Office Space With Unico Properties. Fair Value, Inputs, Level 3 [Member] Level 3 [Member] Share-based compensation Share-based compensation us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid Debt instrument balloon payment Fair Value, Recurring and Nonrecurring [Table] May 2024 Pre-funded Warrants [Member] May 2024 pre-funded warrants. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net increase in cash, cash equivalents and restricted cash General and Administrative [Member] General and Administrative Expense [Member] General and Administrative Expenses [Member] Number of Businesses Acquired Number of affiliated predecessor companies acquired us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Number of Options Outstanding, Forfeited Stock option awards forfeited catx_DebtInstrumentNumberOfPaymentInstallment Represents number of installment to pay debt. Debt instrument, number of monthly payments Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares City Area Code CASH FLOWS FROM OPERATING ACTIVITIES: Interest and other expense. Interest and Other Expense Interest and other expense Interest

and other expense Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Held-to-Maturity Investments Assumption of Viewpoint stock options and warrants at fair value catx_BusinessCombinationOptionsAndWarrantsAssumption The amount of fair value of options and warrants assumed in business acquisition. Options assumed, Price (in dollars per share) Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. Options exercise price per share Weighted Average Exercise Price, Options assumed Restricted cash Restricted cash Business Acquisition [Line Items] Discontinued Operations, Disposed of by Sale [Member] Discontinued Operations, Disposed of by Sale [Member] Non-Rule 10b5-1 Arrangement Modified Flag. Non-Rule 10b5-1 Arrangement Modified [Flag] Non-Rule 10b5-1 Arrangement Modified Less accumulated depreciation us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment General and administrative Issuance of common stock pursuant to exercise of warrants (in shares) Stock Issued During Shares Common Stock Warrant Exercised Stock issued during shares common stock warrant exercised. Basic and diluted (in shares) Basic Total loss from discontinued operations Disposal Group, Including Discontinued Operation, Operating Income (Loss) Net loss from discontinued operations CASH FLOWS FROM FINANCING ACTIVITIES: Represents the amount of gross proceeds raised as part of an investment agreement. Investment Agreement Contingent Amount Of Gross Proceeds Raised Investment agreement, contingent amount of gross proceeds raised Offering [Member] Underwritten Offering [Member] Underwritten Offering. HTM, gross unrealized gains HTM, Gross Unrealized Gains Statement [Table] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of Weighted Average Fair Value of Stock Option Awards Granted and Key Assumptions Lease liability us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation Asset Acquisition, Consideration Transferred, Total Asset Acquisition, Consideration Transferred Asset purchase price in cash Purchase price Document Fiscal Period Focus Total us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Equity in loss of affiliate Income (Loss) from Equity Method Investments Equity in loss of affiliate Loss on equity method investment Grant revenue Grant revenue Related Party Transactions Disclosure [Text Block] 2026 Statement [Line Items] Antidilutive securities (in shares) Total potential dilutive securities Amount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation. Disposal Group Including Discontinued Operation Research and Development Expense Research and development Disposal Group, Including Discontinued Operation, Gross Profit (Loss) Gross profit Gross profit Warrant [Member] Common Stock Warrants [Member] Viewpoint liabilities assumed including deferred tax liabilities established through accounting for business combinations (see Note 14) Viewpoint liabilities assumed including deferred tax liabilities established through accounting for business combinations {(see Note 13)} Viewpoint liabilities assumed including deferred tax liabilities established through accounting for business combinations (Note 14), Total Accounts receivable, net of allowance for doubtful accounts: 2024 - $606; 2023 - $650 Accounts receivable, net Common Stock [Member] Common Stock [Member] Debt Instrument [Line Items] Amount classified as right of use asset attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. Disposal Group Including Discontinued Operation Property Right Of Use Asset Current Right-of-use asset, net Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements Building [Member] Building Adjustments to additional paid in capital, issuance of pre-funded warrants. Adjustments To Additional Paid In Capital, Issuance of Pre-funded Warrants Issuance of Pre-funded Warrants, net Entity Common Stock, Shares Outstanding Proceeds from maturity of short-term investments Proceeds from maturity of short-term investments Loss Contingency Accrual us-gaap_LossContingencyAccrualAtCarryingValue Estimated liability us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment Property and equipment Antidilutive Securities, Name [Domain] Notes Tables us-gaap_TableTextBlock Rule 10b 51 Arr Modified Flag. Rule 10b 51 Arr Modified [Flag] Rule 10b5-1 Arrangement Modified Schedule of Debt [Table Text Block] Summary of Note Payable Discontinued Operations and Disposal Groups [Abstract] Cover [Abstract] Document Fiscal Year Focus Notes payable Represents the percent of outstanding shares. Percent Of Outstanding Shares Percent of outstanding shares Accretion of asset retirement obligation Accretion of discount Sale of Stock [Domain] Percentage of ownership considered for warrant exercise Percentage Of Ownership Considered for Warrant Exercise Two Percentage of ownership considered for warrant exercise two. One-time payment received for rights granted. One-Time Payment Received For Rights Granted One-time payment received for rights granted Security Exchange Name Schedule of Change in Asset Retirement Obligation [Table Text Block] Preferred stock, shares issued (in shares) Preferred stock, shares issued Preferred stock, shares authorized (in shares) Preferred stock, shares authorized Property and equipment, gross Note payable Note payable Modification of operating lease liability and right of use asset Relating to net sales of $ 10 million or less. Net Sales Of 10 Million Or Less [Member] Net Sales of $10 Million or Less [Member] Business Acquisition, Acquiree [Domain] Legal Entity [Axis] Estimated hazardous waste removal liability. Estimated Hazardous Waste Removal Liability Estimated hazardous waste removal liability Financial Instrument [Axis] Weighted average shares used in computing net loss per share: Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock pursuant to exercise of options Entity Emerging Growth Company us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Intrinsic value associated with exercises us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Business acquisition, percentage of voting interests acquired Amendment Flag HTM, fair value HTM, Estimated Fair Value Debt Securities, Held-to-Maturity, Fair Value, Total Stockholder Plaintiff Settlements [Member] Related to stockholder plaintiff settlements. Stockholder Plaintiff Settlements January 2024 Pre-funded Warrants [Member] January Two Thousand Twenty Four Pre-funded Warrants [Member] January two thousand twenty four pre-funded warrants. Maximum increase or decrease in ownership percentage. Maximum Increase Or Decrease In Ownership Percentage Maximum increase or decrease in ownership percentage May 2024 Pre-funded Warrants [Member] May Two Thousand Twenty Four Pre-funded Warrants [Member] May two thousand twenty four pre-funded warrants. Leases [Abstract] Represents the Oppenheimer & Co. Oppenheimer Co [Member] Oppenheimer & Co [Member] January 2024 Public Offering [Member] January 2024 public offering. Entity File Number Investment agreements. Investment Agreements [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Amended 2020 Incentive Plan [Member] Amended Two Thousand Twenty Incentive Plan [Member] Amended two thousand twenty incentive plan. 2024 (remaining six months) Goodwill and Intangible Assets Disclosure [Abstract] Registered Offering [Member] Registered offering. January two thousand twenty four public offering. January Two Thousand Twenty Four Public Offering [Member] January 2024 Public Offering [Member] Share-Based Payment Arrangement [Abstract] Deferred Income, Noncurrent Deferred Income (Note 3) Total liabilities assumed us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Disposal Group Classification [Domain] Note receivable Note receivable Note receivable, forgiven amount, loan Debt Instrument [Axis] Estimate of Fair Value Measurement [Member] Represents the cash fee percentage. Placement Agents Cash Fee Percentage Placement agents cash fee, percentage us-gaap_DebtInstrumentPeriodicPayment Debt instrument, periodic payment Total operating expenses us-gaap_OperatingExpenses us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths 2025 Reverse stock split Stockholders' Equity, Reverse Stock Split Preferred stock, $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible preferred stock; no shares issued and outstanding as of June 30, 2024 and December 31, 2023 Preferred stock, $.001 par value; 7,000,000 shares authorized: Series B: 5,000,000 shares allocated; no shares issued and outstanding Entity Small Business Entity Shell Company Notes To Financial Statements [Abstract] Accrued interest on short-term investments catx_AccruedInterestOnShortTermInvestments Amount of accrued interest on short-term investments. us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Warrant exercise price per share Class of Warrant or Right [Domain] Isoray. Isoray [Member] Isoray [Member] Earnings Per Share [Text Block] Loss Per Share Entity Address, Address Line One Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Antidilutive Securities [Axis] us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill Intangible assets, in-process research and development Summary of Components of Other Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets: Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets: Subsequent Event Type [Domain] Amount of sales and marketing expense attributable to disposal group, including, but not limited to, discontinued operation. Disposal Group Including Discontinued Operation Sales and Marketing Expense Sales and marketing Income Statement Location [Axis] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree 2027 Debt Securities, Held-to-Maturity [Table Text Block] Summary of Carrying Values and Fair Values of Financial Instruments May 2024 Public Offering [Member] May Two Thousand Twenty Four Public Offering [Member] May two thousand twenty four public offering. Fair Value, Inputs, Level 2 [Member] Level 2 [Member] Class of Financing Receivable [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Class of Financing Receivable [Domain] Title of 12(b) Security Additions to other assets Payments to Acquire Other Productive Assets Lease Contractual Term [Axis] Other assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from the issuance of common stock and Pre-funded Warrants, net Proceeds from Issuance of Common Stock and Prefunded Warrants Net Proceeds from issuance of common stock and prefunded warrants net. Accounts payable and accrued expenses us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Accounts payable and accrued expenses Loss recognized on classification as held for sale Gain (Loss) on Sale of Assets and Asset Impairment Charges Accrued vacation catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedVacation Amount of accrued vacation, assumed at the acquisition date. Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] [Default] Long-Lived Tangible Asset [Domain] Business acquisition, price per share (in dollars per share) Business acquisition, closing market price us-gaap_InterestExpenseDebt Interest expense Houston Texas [Member] Houston Texas [Member] Houston Texas. Common stock, outstanding (in shares) Common stock, shares outstanding Share-Based Payment Arrangement [Text Block] Share-Based Compensation Chicago Illinois [Member] Chicago Illinois. Proceeds from sales of common stock, pursuant to exercise of warrants, net Proceeds from Warrant Exercises Indefinite-Lived Intangible Assets [Line Items] us-gaap_LesseeOperatingLeaseDiscountRate Lessee, operating lease, discount rate Income Statement Location [Domain] Relating to Cesium-131 Business. Cesium-131 Business [Member] Cesium-131 Business [Member] Percentage of ownership considered for warrant exercise. Percentage Of Ownership Considered for Warrant Exercise Percentage of ownership considered for warrant exercise Document Type Loss Contingency, Number of Plaintiffs Number of plaintiff us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash (used in) provided by investing activities Document Quarterly Report Counterparty Name [Domain] Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Other Intangible Assets Disposal Group, Including Discontinued Operation, Costs of Goods Sold Cost of sales Disposal Group Classification [Axis] Net cash provided by financing activities us-gaap_NetCashProvidedByUsedInFinancingActivities Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Entity Filer Category Supplemental schedule of noncash investing and financing activities: Lease with Board of Regents [Member] Lease with Board of Regents. Balance Sheet Location [Domain] Short-term investments Short-term investments Short-Term Investments, Total us-gaap_NonoperatingIncomeExpense Total non-operating income (expense), net Total liabilities us-gaap_Liabilities Property, Plant and Equipment [Table] us-gaap_InterestReceivable Accrued interest Total stockholders' equity Balances Balances us-gaap_StockholdersEquity Shares issued in exchange for common stock (in shares) Disposal Group, Including Discontinued Operation, General and Administrative Expense General and administrative Consolidated Entities [Axis] Net loss Net loss Non-operating income (expense): Proceeds from Public Offering, net Proceeds from Issuance Initial Public Offering Deferred tax liability Purchases of short-term investments us-gaap_PaymentsToAcquireHeldToMaturitySecurities Statement of Financial Position [Abstract] Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Diluted Shares Issued, Price Per Share Stock purchase price per share us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective income tax rate Income (Loss) from Continuing Operations, Per Basic Share Loss from continuing operations, Basic Program preclinical co-funding option. Program Preclinical Co-Funding Option [Member] us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Operating lease, weighted average remaining term Total assets acquired us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current Prepaid expenses and other current assets Leasehold Improvements [Member] Leasehold improvements Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Fair Value Disclosures [Abstract] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Summary of Estimated Purchase Consideration Fair Value Hierarchy and NAV [Axis] Measurement Frequency [Domain] Additions to property and equipment us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment, Total Additions to property and equipment Reclassification, Comparability Adjustment [Policy Text Block] Reclassifications Issuance of common stock, net (in shares) Stock issued during period, shares Shares issued and sell Accrued personnel expenses Employee-related Liabilities, Current Employee-related Liabilities, Current, Total us-gaap_OperatingLeaseExpense Operating lease, expense Business Acquisition [Axis] Cash, cash equivalents and restricted cash beginning of period CASH, CASH EQUIVALENTS AND RESTRICTED CASH END OF PERIOD Total cash, cash equivalents and restricted cash shown on the condensed consolidated statements of cash flows Class of Warrant or Right [Axis] Recognition of operating lease liability and right of use asset. Recognition of Operating Lease liability and Right of Use Asset Recognition of operating lease liability and right-of-use asset VMT Option [Member] VMT option. Amount classified as asset retirement obligation attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. Disposal Group Including Discontinued Operation Asset Retirement Obligation Current Asset retirement obligation XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document And Entity Information - shares 6 Months Ended Jun. 30, 2024 Aug. 07, 2024 Cover [Abstract] Â Â Entity Central Index Key 0000728387 Â Entity Registrant Name PERSPECTIVE THERAPEUTICS, INC. Â Amendment Flag false Â Current Fiscal Year End Date --12-31 Â Document Fiscal Period Focus Q2 Â Document Fiscal Year Focus 2024 Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Jun. 30, 2024 Â Document Transition Report false Â Entity File Number 001-33407 Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 41-1458152 Â Entity Address, Address Line One 2401 Elliott Avenue, Suite 320 Â Entity Address, City or Town Seattle Â Entity Address, State or Province WA Â Entity Address, Postal Zip Code 98121 Â City Area Code 206 Â Local Phone Number 676-0900 Â Title of 12(b) Security Common Stock, $0.001 par value Â Trading Symbol CATX Â Security Exchange Name NYSEAMER Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 67,427,667 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1:

http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The file number consists of up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 11 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 252,004 $ 9,238 Short-term investments 40,865 0 Accounts receivable, net of allowance for doubtful accounts: 2024 - $606; 2023 - $650 142 1,165 Prepaid expenses and other current assets 1,226 1,133 Current assets held for sale, discontinued operations 0 5,301 Total current assets 294,237 16,837 Noncurrent assets: Â Â Property and equipment, net 14,747 5,576 Right-of-use asset, net 2,019 747 Restricted cash 182 182 Intangible assets, in-process research and development 50,000 50,000 Goodwill 24,062 24,062 Other assets, net 672 487 Total assets 385,919 97,891 Current liabilities: Â Â Accounts payable and accrued expenses 6,127 6,909 Lease liability 720 46 Accrued personnel expenses 2,309 3,588 Note payable 54 49 Deferred Income (Note 3) 1,400 0 Current liabilities of discontinued operations 0 5,072 Total current liabilities 10,610 15,664 Noncurrent liabilities: Â Â Lease liability 1,450 780 Note payable 1,651 1,676 Deferred Income (Note 3) 26,600 0 Deferred tax liability 4,592 4,592 Other noncurrent liabilities 19 0 Total liabilities 44,922 22,712 Commitments and contingencies (Note 10) Stockholders' equity: Â Â Preferred stock, $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible preferred stock; no shares issued and outstanding as of June 30, 2024 and December 31, 2023 0 0 Common stock, $0.001 par value; 750,000,000 shares authorized; 67,425,167 and 28,180,985 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively [1] 67 28 Additional paid-in capital [1] 517,358 227,591 Accumulated deficit (176,428) (152,440) Total stockholders' equity 340,997 75,179 Total liabilities and stockholders' equity $ 385,919 $ 97,891 [1] Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45

-Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2 + Details Name: us-gaap_DeferredIncomeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2 + Details Name: us-gaap_DeferredIncomeNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5 + Details Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance

Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 12 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets (Parentheticals) $ in Thousands Jun. 30, 2024 USD ($) $ / shares shares Dec. 31, 2023 USD ($) $ / shares shares Allowance for doubtful accounts | $ $ 606 $ 650 Preferred stock, par value | $ / shares $ 0.001 $ 0.001 Preferred stock, shares authorized 7,000,000 7,000,000 Common stock, par value | $ / shares $ 0.001 $ 0.001 Common stock, shares authorized 750,000,000 750,000,000 Common stock, shares issued 67,425,167 28,180,985 Common stock, shares outstanding 67,425,167 28,180,985 Series B Convertible Preferred Stock [Member] Â Â Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=catx_SeriesBConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 13 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Statement [Abstract] Â Â Â Â Grant revenue $ 526 $ 588 $ 851 $ 821 Operating expenses: Â Â Â Â Research and development 9,275 5,370 16,727 8,679 General and administrative 5,514 4,987 11,392 11,650 Change in estimate of asset retirement obligation (Note 4) 0 (15) 0 (15) Loss on disposal of property and equipment 0 0 0 22 Total operating expenses 14,789 10,342 28,119 20,336 Operating loss (14,263) (9,754) (27,268) (19,515) Non-operating income (expense): Â Â Â Â Interest income 3,076 294 4,287 668 Interest and other expense (23) (26) (52) (44) Equity in loss of affiliate (4) 0 (6) 0 Total non-operating income (expense), net 3,049 268 4,229 624 Net loss from continuing operations (11,214) (9,486) (23,039) (18,891) Net loss from discontinued operations (429) (1,620) (890) (3,086) Loss recognized on classification as held for sale (61) 0 (59) 0 Net loss before deferred income tax benefit (11,704) (11,106) (23,988) (21,977) Deferred income tax benefit 0 0 0 10,500 Net loss $ (11,704) $ (11,106) $ (23,988) $ (11,477) Basic and diluted loss per share: Â Â Â Â Loss from continuing operations, Basic [1] $ (0.17) $ (0.34) $ (0.4) $ (0.33) Loss from continuing operations, Diluted [1] (0.17) (0.34) (0.4) (0.33) Loss from discontinued operations, Basic [1] (0.01) (0.06) (0.01) (0.12) Loss from discontinued operations, Diluted [1] (0.01) (0.06) (0.01) (0.12) Basic loss per share [1] (0.18) (0.4) (0.41) (0.45) Diluted loss per share [1] $ (0.18) $ (0.4) $ (0.41) $ (0.45) Weighted average shares used in computing net loss per share: Â Â Â Â Basic [1] 66,648 27,999 58,079 25,443 Diluted [1] 66,648 27,999 58,079 25,443 [1] Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. X - DefinitionInterest and other expense. + ReferencesNo definition available. + Details Name: catx_InterestAndOtherExpense Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the asset retirement obligation from changes in the amount or timing of the estimated cash flows associated with the settlement of the obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 410 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481850/410-20-50-1 + Details Name: us-gaap_AssetRetirementObligationRevisionOfEstimate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI

https://asc.fasb.org//1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPer basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPer diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3 + Details Name: us-gaap_GainLossOnDispositionOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 1 -SubTopic 20 -Topic 940 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue that is not accounted for under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -

Subparagraph (SX 210.5-03(1)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RevenueNotFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 14 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Operations (Parenthetical) Jun. 14, 2024 Income Statement [Abstract] Â Reverse stock split 1-for-10 reverse stock split Reverse stock split, ratio 0.1 X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended 12 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Â Â Â Â Â Net Income (Loss) $ (11,704) $ (12,284) $ (11,106) $ (371) $ (23,988) $ (11,477) Â Adjustments to reconcile net loss to net cash provided by or used in operating activities: Â Â Â Â Â Â Â Lease expense Â Â Â Â 71 (14) Â Depreciation expense Â Â Â Â 916 425 Â Write-off of inventory associated with discontinued product Â Â Â Â 0 298 Â Loss on disposal of property and equipment Â Â Â Â 0 22 Â Amortization of other assets Â Â Â Â 12 20 Â Accretion of asset retirement obligation Â Â Â Â 0 17 Â Equity in loss of affiliate 4 Â 0 Â 6 0 Â Accrued interest on short-term investments Â Â Â Â (360) 0 Â Change in allowance for doubtful accounts Â Â Â Â (44) 0 Â Change in estimate of asset retirement obligation 0 Â (15) Â 0 (15) Â Loss on divestiture Â Â Â Â 59 0 Â Share-based compensation Â Â Â Â 1,375 2,567 Â Deferred income tax benefit 0 Â 0 Â 0 (10,500) Â Changes in operating assets and liabilities: Â Â Â Â Â Â Â Accounts receivable Â Â Â Â 1,023 250 Â Inventory related to discontinued operations Â Â Â Â 11 144 Â Prepaid expenses and other current assets Â Â Â Â (93) (445) Â Accounts payable and accrued expenses Â Â Â Â (763) 442 Â Deferred Income [1] Â Â Â Â 28,000 0 Â Accrued personnel expenses Â Â Â Â (1,279) 471 Â Net cash provided by (used in) operating activities Â Â Â Â 4,946 (17,795) Â CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Â Â Â Â Â Additions to property and equipment Â Â Â Â (10,087) (756) Â Additions to other assets Â Â Â Â 0 (18) Â Proceeds from maturity of short-term investments Â Â Â Â 38,225 22,764 Â Purchases of short-term investments Â Â Â Â (78,730) 0 Â Net cash acquired in acquisition of Viewpoint Â Â Â Â 0 2,699 Â Net cash (used in) provided by investing activities Â Â Â Â (50,592) 24,689 Â CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Â Â Â Â Â Repayment of notes payable Â Â Â Â (20) (35) Â Proceeds from sales of common stock, pursuant to exercise of warrants, net Â Â Â Â 123 0 Â Proceeds from sales of common stock, pursuant to exercise of option Â Â Â Â 254 532 Â Proceeds from Issuance of Common Stock and Prefunded Warrants Net [1] Â Â Â Â 288,055 0 Â Issuance costs related to common stock issued in exchange for Viewpoint common stock Â Â Â Â 0 (65) Â Net cash provided by financing activities Â Â Â Â 288,412 432 Â Net increase in cash, cash equivalents and restricted cash Â Â Â Â 242,766 7,326 Â Cash, cash equivalents and restricted cash beginning of period Â $ 9,420 Â $ 21,175 9,420 21,175 $ 21,175 CASH, CASH EQUIVALENTS AND RESTRICTED CASH END OF PERIOD 252,186 Â 28,501 Â 252,186 28,501 9,420 Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets: Â Â Â Â Â Â Â Cash and cash equivalents 252,004 Â 28,319 Â 252,004 28,319 9,238 Restricted cash 182 Â 182 Â 182 182 182 Total cash, cash equivalents and restricted cash shown on the condensed consolidated statements of cash flows $ 252,186 Â $ 28,501 Â 252,186 28,501 $ 9,420 Supplemental schedule of noncash investing and financing activities: Â Â Â Â Â Â Â Recognition of operating lease liability and right-of-use asset Â Â Â Â 1,497 0 Â Fair value of Viewpoint assets acquired including goodwill Â Â Â Â 0 85,885 Â 13,654,507 shares of Perspective Therapeutics common stock issued in exchange for Viewpoint common stock Â Â Â Â 0 (54,618) Â Assumption of Viewpoint stock options and warrants at fair value Â Â Â Â 0 (7,836) Â Note receivable and accrued interest from Viewpoint forgiven Â Â Â Â $ 0 $ (6,171) Â [1] See Note 3, Investments and Agreements, for additional information. X - DefinitionAmount of accrued interest on short-term investments. + ReferencesNo definition available. + Details Name: catx_AccruedInterestOnShortTermInvestments Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (DeIncrease (decrease) in inventory related to discontinued operations.crease) In Inventory Related to Discontinued Operations + ReferencesNo definition available. + Details Name: catx_IncreaseDecreaseInInventoryRelatedToDiscontinuedOperations Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the noncash expense incurred for leases. + ReferencesNo definition available. + Details Name: catx_NoncashExpenseLease Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAssumption fair value of stock options and warrants in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition. + ReferencesNo definition available. + Details Name: catx_NoncashOrPartNoncashAcquisitionAssumptionOfStockOptionsAndWarrants Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionForgiven of notes receivable and accrued interest assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition. + ReferencesNo definition available. + Details Name: catx_NoncashOrPartNoncashAcquisitionNotesReceivableAndAccruedInterestForgiven Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe value of an asset or business acquired in a noncash (or part noncash) acquisition, including goodwill. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesNo definition available. + Details Name: catx_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredIncludingGoodwill Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of common stock and prefunded warrants net. + ReferencesNo definition available. + Details Name: catx_ProceedsFromIssuanceOfCommonStockAndPrefundedWarrantsNet Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRecognition of operating lease liability and right of use asset. + ReferencesNo definition available. + Details Name: catx_RecognitionOfOperatingLeaseLiabilityAndRightOfUseAsset Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: catx_ReconciliatoinOfCashCashEquivalentsAndRestrictedCashToTheConsolidatedBalanceSheetsAbstract Namespace Prefix: catx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details Name: us-gaap_AdjustmentForAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 410 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481879/410-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 410 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481850/410-20-50-1 + Details Name: us-gaap_AssetRetirementObligationAccretionExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the asset retirement obligation from changes in the amount or timing of the estimated cash flows associated with the settlement of the obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 410 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481850/410-20-50-1 + Details Name: us-gaap_AssetRetirementObligationRevisionOfEstimate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details Name: us-gaap_CashAcquiredFromAcquisition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted

and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B + Details Name: us-gaap_GainLossOnSaleOfBusiness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow through purchase of long-term held-to-maturity securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireHeldToMaturitySecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name

Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireOtherProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5 + Details Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fair value of stock issued in noncash financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5 + Details Name: us-gaap_StockIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 16 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) 6 Months Ended Jun. 30, 2023 shares Statement of Cash Flows [Abstract] Â Shares issued in exchange for common stock (in shares) 136,545,072 [1] [1] Amount for prior period presented has been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. X - DefinitionThe number of shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfCashFlowsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands Total Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] January 2024 Pre-funded Warrants [Member] January 2024 Pre-funded Warrants [Member] Common Stock [Member] [1] January 2024 Pre-funded Warrants [Member] Additional Paid-in Capital [Member] [1] January 2024 Pre-funded Warrants [Member] Accumulated Deficit [Member] May 2024 Pre-funded Warrants [Member] May 2024 Pre-funded Warrants [Member] Common Stock [Member] [1] May 2024 Pre-funded Warrants [Member] Additional Paid-in Capital [Member] [1] May 2024 Pre-funded Warrants [Member] Accumulated Deficit [Member] Public Offering [Member] Public Offering [Member] Common Stock [Member] Public Offering [Member] Additional Paid-in Capital [Member] [1] Public Offering [Member] Accumulated Deficit [Member] Lantheus Investment Agreement [Member] Lantheus Investment Agreement [Member] Common Stock [Member] Lantheus Investment Agreement [Member] Additional Paid-in Capital [Member] [1] Lantheus Investment Agreement [Member] Accumulated Deficit [Member] March 2024 Investment Agreement [Member] March 2024 Investment Agreement [Member] Common Stock [Member] March 2024 Investment Agreement [Member] Additional Paid-in Capital [Member] [1] March 2024 Investment Agreement [Member] Accumulated Deficit [Member] A T M Agreement [Member] A T M Agreement [Member] Common Stock [Member] A T M Agreement [Member] Additional Paid-in Capital [Member] [1] A T M Agreement [Member] Accumulated Deficit [Member] Registered Offering [Member] Registered Offering [Member] Common Stock [Member] Registered Offering [Member] Additional Paid-in Capital [Member] [1] Registered Offering [Member] Accumulated Deficit [Member] Balances (in shares) at Dec. 31, 2022 [1] Â 14,211,276 Â Â Â

http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued pursuant to acquisitions during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 10:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 18 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) Jun. 14, 2024 Statement of Stockholders' Equity [Abstract] Â Reverse stock split 1-for-10 reverse stock split Reverse stock split, ratio 0.1 X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Net Income (Loss) $ (11,704) $ (12,284) $ (11,106) $ (371) $ (23,988) $ (11,477) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 20 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Trading Arrangements, by Individual Â Â Material Terms of Trading Arrangement Â ITEM 5 â€" OTHER INFORMATIONÂ Rule 10b5-1 Trading Arrangements During the three months ended June 30, 2024, none of our directors or executive officers adopted, modified or terminated any â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408 of Regulation S-K. Rule 10b5-1 Arrangement Adopted false Â Non-Rule 10b5-1 Arrangement Adopted false Â Rule 10b5-1 Arrangement Terminated false Â Non-Rule 10b5-1 Arrangement Terminated false Â Rule 10b5-1 Arrangement Modified false Â Non-Rule 10b5-1 Arrangement Modified false Â X - DefinitionNon-Rule 10b5-1 Arrangement Modified Flag. + ReferencesNo definition available. + Details Name: catx_NonRule10B51ArrangementModifiedFlag Namespace Prefix: catx_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionRule 10b 51 Arr Modified Flag. + ReferencesNo definition available. + Details Name: catx_Rule10B51ArrModifiedFlag Namespace Prefix: catx_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 1 - Basis of Presentation and Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Basis of Presentation and Summary of Significant Accounting Policies 1.Basis of Presentation and Summary of Significant Accounting PoliciesPerspective Therapeutics, Inc. is developing the next generation of precision-targeted alpha therapies (TAT) for oncology that have the potential to treat a large population of cancer patients across multiple tumor types, including those with metastatic disease. The accompanying unaudited condensed consolidated financial statements are those of Perspective Therapeutics, Inc., and its wholly owned subsidiaries, referred to herein as â€œPerspective Therapeuticsâ€ or the â€œCompany.â€ All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair statement of the condensed consolidated financial statements have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited consolidated financial statements and related notes as set forth in the Companyâ€™s Annual Report on Form 10-K for the period ended December 31, 2023 filed with the SEC on March 28, 2024 (2023 Form 10-K).The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures are adequate for the information not to be misleading. The unaudited condensed consolidated financial statements reflect, in managementâ€™s opinion, all adjustments of a normal, recurring nature that are necessary for the fair statement of the Companyâ€™s financial position, results of operations and cash flows for the interim periods, but are not necessarily indicative of the results expected for the full fiscal year or any other period.The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2024 will be 0%.MergerOn February 3, 2023, the Company completed the merger of Isoray Acquisition Corp., a Delaware corporation and wholly owned subsidiary of the Company, with Viewpoint Molecular Targeting, Inc. (Viewpoint) (such transaction being the Merger). Pursuant to the Merger, the Company issued 13,654,507 shares of its common stock, par value $0.001 per share (Common Stock), representing approximately 49% of its fully diluted outstanding capital stock as of the close of the Merger. Viewpoint is an alpha-particle radiopharmaceutical company in the alpha-emitter market developing oncology therapeutics and complementary imaging agents. For additional information, see Note 14, Merger, in this Form 10-Q.Discontinued OperationsOn April 12, 2024, the Company completed the sale of its Cesium-131 brachytherapy business and substantially all of the assets of Isoray Medical, Inc. (Isoray), a wholly owned subsidiary of Perspective Therapeutics, to GT Medical Technologies, Inc., a Delaware corporation (GT Medical) (such transaction being the GT Medical Closing). Pursuant to the GT Medical Closing, GT Medical issued to Isoray 279,516 shares of GT Medicalâ€™s common stock, par value $0.0001 per share, representing 0.5% of GT Medicalâ€™s issued and outstanding capital stock on a fully diluted basis as of the closing. Accordingly, the financial information and operating results of the Cesium-131 brachytherapy business have been presented as discontinued operations in the condensed consolidated financial statements for all periods presented. Unless otherwise noted, discussion within these notes to the condensed consolidated financial statements relates to continuing operations. For additional information, see Note 4, Discontinued Operations, in this Form 10-Q.Reverse Stock SplitOn June 14, 2024, the Company effected a 1-for-10 reverse stock split (Reverse Split) of the Companyâ€™s issued and outstanding shares of Common Stock, and the Common Stock began trading on a split-adjusted basis on June 17, 2024. The Reverse Split did not reduce the total number of authorized shares of Common Stock or the Companyâ€™s preferred stock (Preferred Stock), or change the par values of the Common Stock or Preferred Stock. The Reverse Split affected all stockholders uniformly and did not affect any stockholderâ€™s ownership percentage of the shares of Common Stock (except to the extent that the Reverse Split resulted in some of the stockholders receiving cash in

lieu of fractional shares). All outstanding options and warrants entitling their holders to purchase shares of Common Stock were adjusted as a result of the Reverse Split, in accordance with the terms of each such security. In addition, the number of shares reserved for future issuance pursuant to the Companyâ€™s equity incentive plans was also adjusted accordingly. As a result, all historical per share data, number of shares issued and outstanding, and outstanding options and warrants for the periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively in this Form 10-Q, where applicable, to reflect the Reverse Split.LiquidityThe Company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company has had a history of operating losses and an absence of significant recurring cash inflows from revenue. At June 30, 2024, the Company had cash, cash equivalents and short-term investments of $292.9 million and total accumulated deficit of $176.4 million. The Company has historically financed its operations primarily through selling equity.The Company believes that its $292.9 million of cash, cash equivalents and short-term investments as of June 30, 2024 will enable it to fund its current planned operations into mid-2026, though it may raise additional capital through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements and/or government funding and grants.The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The operating plan may change as a result of many factors currently unknown to management, and there can be no assurance that the current operating plan will be achieved in the timeframe anticipated by management or at all, and the Company may need to seek additional funds sooner than anticipated. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from potential unknown factors.ReclassificationsIn addition to the discontinued operations discussed above, during the first quarter of 2024, the Company made certain reclassifications to prior period amounts in the condensed consolidated financial statements and accompanying notes to conform to the current period presentation. The reclassification of these items had no impact on net loss, financial position or cash flows in the current or prior periods. Specifically, accrued payroll and related taxes and accrued vacation were combined to create accrued personnel, and accrued protocol expense and accrued waste disposal were included in accounts payable and accrued expenses, all of which are presented on the condensed consolidated balance sheets and condensed consolidated statement of cash flows.Significant Accounting PoliciesThe Companyâ€™s significant accounting policies and recent accounting pronouncements are described in Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements in Item 8 of the 2023 Form 10-K. There have been no changes to the Companyâ€™s significant accounting policies, and the Company has not adopted any significant accounting policies during the six months ended June 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 2 - Loss Per Share 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Loss Per Share 2.Loss per ShareBasic and diluted loss per share is calculated by dividing net loss by the weighted average number of shares of Common Stock outstanding and does not include the impact of any potentially dilutive common stock equivalents. In January 2024 and May 2024, the Company issued pre-funded warrants in connection with the Public Offering (as defined below) and the Registered Offering (as defined below), respectively (see Note 3, Investments and Agreements, in this Form 10-Q). As the pre-funded warrantsâ€™ exercise price is nominal and there are no conditions that must be satisfied prior to their exercise, the pre-funded warrants are included in the calculation of the basic and diluted earnings per share as of June 30, 2024. At each of June 30, 2024 and 2023, the calculation of diluted weighted average shares did not include common stock warrants or options that were potentially convertible into Common Stock as those would be antidilutive due to the Companyâ€™s net loss position.Securities not considered in the calculation of diluted loss per share, but that could be dilutive in the future, are as follows (in thousands):Â Â June 30, 2024Â Â June 30, 2023Â Common stock warrants Â Â 416Â Â Â Â 603Â Common stock options Â Â 6,934Â Â Â Â 4,487Â Total potential dilutive securities Â Â 7,350Â Â Â Â 5,090Â Â Effective upon the closing of the Merger with Viewpoint on February 3, 2023, the Company assumed 338,709 warrants to purchase shares of Common Stock with an exercise price of $2.70 per share and 2,426,342 options to purchase shares of Common Stock with exercise prices ranging from $1.30 to $3.00 per share. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 3 - Investments and Agreements 6 Months Ended Jun. 30, 2024 Investment Agreements [Abstract] Â Investments and Agreements 3.Investments and AgreementsMay 2024 Registered OfferingOn May 24, 2024, the Company entered into an underwriting agreement with BofA Securities, Inc., as representative of the underwriters named therein, in connection with its previously announced underwritten offering (Registered Offering) of 5,151,588 shares (Registered Offering Shares) of Common Stock and, in lieu of Registered Offering Shares to certain investors, pre-funded warrants (May 2024 Pre-funded Warrants) to purchase 146,425 shares of Common Stock. The price to the investors for the Registered Offering Shares was $15.10 per Registered Offering Share, and the price to the investors for the May 2024 Pre-funded Warrants was $15.09 per May 2024 Pre-funded Warrant, which represents the per share price for the Registered Offering Shares less the $0.01 per share exercise price for each such May 2024 Pre-funded Warrant. The Registered Offering closed on May 29, 2024. BofA Securities, Inc., Oppenheimer & Co. Inc. and RBC Capital Markets, LLC acted as joint book-running managers for the Registered Offering and B. Riley Securities, Inc. acted as a co-manager for the Registered Offering. JonesTrading Institutional Services LLC acted as a financial advisor for the Registered Offering.The gross proceeds to the Company from the Registered Offering were approximately $80 million, before underwriting discounts and commissions and estimated expenses of the Registered Offering.The Company intends to use the net proceeds from the Registered Offering for: (i) the continued clinical development of VMT-Î±-NET, VMT-01/02 and PSV359; (ii) the continued development of PSV40X and additional preclinical product candidates as well as a broader development platform; and (iii) the build out, operation and expansion of manufacturing facilities, as well as for working capital and other general corporate purposes. A portion of the net proceeds may also be used to acquire, license or invest in complementary products, technologies, intellectual property or businesses, although the Company has no present commitments or agreements to do so.The Registered Offering was made pursuant to the Companyâ€™s automatic shelf registration statement on Form S-3 (File No. 333-279692) (the May 2024 Registration Statement), which became effective upon filing with the SEC on May 24, 2024, a related base prospectus, free writing prospectus and prospectus supplement each dated May 24, 2024.The May 2024 Pre-funded Warrants became exercisable subsequent to the filing and effectiveness of an amendment to the Companyâ€™s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on June 14, 2024. The exercise price and the number of shares of Common Stock issuable upon exercise of each May 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to the Companyâ€™s stockholders. The May 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of May 2024 Pre-funded Warrants may not exercise such May 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would be more than 4.99% or 9.99%, as elected by such holder, of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the May 2024 Pre-funded Warrants. A holder of May 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 daysâ€™ prior notice to the Company.Â March 2024 Private Placement with Institutional InvestorsOn March 4, 2024, the Company entered into an investment agreement (the March 2024 Investment Agreement) with certain accredited institutional investors (Institutional Investors) pursuant to which the Company agreed to issue and sell, in a private placement (the March 2024 Private Placement), 9,200,998 shares of Common Stock, for a purchase price of $9.50 per share, representing the closing price of the Common Stock on March 1, 2024. The closing of the March 2024 Private Placement occurred on March 6, 2024.The gross proceeds to the Company from the March 2024 Private Placement were approximately $87.4 million, before deducting fees payable to the Placement Agents (as defined below) and other estimated transaction expenses. The Company intends to use the net proceeds from the March 2024 Private Placement for general corporate and working capital purposes, which may include research and development expenditures, preclinical study and clinical trial expenditures, manufacturing expenditures, commercialization expenditures, capital expenditures, acquisitions of new technologies, products or businesses and investments.The March 2024 Private Placement was conducted pursuant to a Placement Agency Agreement, dated March 4, 2024 (the Placement Agency Agreement), by and between the Company and Oppenheimer & Co. Inc., as representative of the placement agents named therein (the Placement Agents). Per the Placement Agency Agreement, the Company agreed to: (i) pay the Placement Agents a cash fee equal to 5.85% of the gross proceeds received by the Company from the sale of the shares; and (ii) reimburse the Placement Agents for certain fees and expenses. Lantheus Agreements Investment AgreementOn January 8, 2024, the Company entered into an investment agreement (the Lantheus Investment Agreement) with Lantheus Alpha Therapy, LLC, a Delaware limited liability company and wholly owned subsidiary of Lantheus Holdings, Inc. (Lantheus), pursuant to which the Company agreed to sell and issue to Lantheus in a private placement transaction certain shares (the Lantheus Shares) of Common Stock. The closing of the purchase and sale of the Lantheus Shares to Lantheus by the Company (the Lantheus Closing) was subject to the Company raising at least $50.0 million of gross proceeds (excluding Lantheusâ€™ investment) in a qualifying third-party financing transaction, which occurred on January 22, 2024.The number of Lantheus Shares sold was 5,634,235, representing 19.99% of the outstanding shares of Common Stock as of January 8, 2024. Pursuant to the Lantheus Investment Agreement, the Company agreed to cooperate in good faith to negotiate and enter into a registration rights agreement with Lantheus, obligating the Company to file a registration statement on Form S-3 with the SEC to register for resale the Lantheus Shares issued at the Lantheus Closing. The Company filed such Form S-3 on March 29, 2024, and the SEC declared it effective on April 9, 2024 (File No. 333-278362).The Lantheus Investment Agreement also contains agreements of the Company and Lantheus whereby Lantheus is provided certain board observer and information rights of the Company, as well as standstill provisions prohibiting Lantheus from taking certain actions for a specified period of time, subject to certain exceptions.The Lantheus Investment Agreement also provides Lantheus with certain pro rata participation rights to maintain its ownership position in the Company in the event that the Company makes any public or non-public offering of any equity or voting interests in the Company or any securities that are convertible or exchangeable into (or exercisable for) equity or voting interests in the Company, subject to certain exceptions.Pursuant to the Lantheus Investment Agreement, the Company is required to notify Lantheus within 10 business days of the end of a fiscal quarter in which the Company issued shares of Common Stock pursuant to that certain At Market Issuance Sales Agreement among the Company, Oppenheimer & Co. Inc., B. Riley Securities, Inc., and JonesTrading Institutional Services LLC dated November 17, 2023 (the ATM Agreement), of (i) the number of shares of Common Stock issued during such fiscal quarter pursuant to the ATM Agreement and (ii) the average price per share received by the Company before commissions (the ATM Average Price). Upon receipt of such notice, Lantheus may elect, at its option, to purchase all or a portion of its Pro Rata Portion (as defined in the Lantheus Investment Agreement) of such shares at an aggregate price equal to the number of shares purchased multiplied by the ATM Average Price for such quarter (the ATM Participation Right). Pursuant to the Lantheus Investment Agreement, Lantheus may not exercise the ATM Participation Right more than two times per calendar year. Asset Purchase AgreementOn January 8, 2024, the Company entered into an Asset Purchase Agreement (the Progenics APA) with Progenics Pharmaceuticals, Inc., a Delaware corporation (Progenics) and affiliate of Lantheus, pursuant to which the Company acquired certain assets and the associated lease of Progenicsâ€™ radiopharmaceutical manufacturing facility in Somerset, New Jersey for a purchase price of $8.0 million in cash. The transactions contemplated by the Progenics APA closed on March 1, 2024. Option AgreementOn January 8, 2024, the Company entered into an option agreement (the Option Agreement) with Lantheus whereby Lantheus was granted an exclusive option to negotiate an exclusive, worldwide, royalty- and milestone-bearing right and license to [212Pb]VMT-Î±-NET, the Companyâ€™s clinical-stage alpha therapy developed for the treatment of neuroendocrine tumors. If good-faith negotiations fail, Lantheus has a one-year right to reenter negotiations if a third party offers to purchase or license the [212Pb]VMT-Î±-NET program. Additionally, Lantheus has a right to co-fund the Investigational New Drug (IND) application, enabling studies for early-stage therapeutic candidates targeting prostate-specific membrane antigen and gastrin-releasing peptide receptor and, prior to IND filing, a right to negotiate for an exclusive license to such candidates. In consideration of the rights granted by the Company to Lantheus pursuant to the Option Agreement, Lantheus paid to the Company a one-time payment of $28.0 million, subject to certain withholding provisions associated with the closing of the Progenics APA.Under the terms of the Option Agreement, Lantheus also has a right of first offer and last look protections for any third-party merger and acquisition transactions involving the Company for a 12-month period beginning on January 8, 2024.The Company determined that the Option Agreement should be accounted for as a research and development arrangement in accordance with ASC 730-20, Research and Development Arrangements, as Lantheus held approximately 19.9% of the Companyâ€™s outstanding Common Stock at March 31, 2024. The Option Agreement contains no repayment provisions, does not create any obligation to enter into any license, transfer or sale agreements with Lantheus, and does not restrict the use of the funds in any way.Accordingly, the balance sheet reports current and long-term liabilities related to these options under the caption, â€œDeferred Income.â€ The values for each distinct option within the Option Agreement were determined by estimating the fair value of each distinct option by a third-party valuation firm and the liabilities will be recognized as income in the condensed consolidated statement of operations as the various options expire. January 2024 Public OfferingOn January 17, 2024, the Company entered into an underwriting agreement (Underwriting Agreement) with Oppenheimer & Co. Inc., as representative of the underwriters named therein (the Underwriters), in connection with its previously announced underwritten public offering (Public Offering) of 13,207,521 shares (Public Shares) of Common Stock and, in lieu of Public Shares to certain investors, pre-funded warrants (Jan. 2024 Pre-funded Warrants) to purchase 3,008,694 shares of Common Stock. The price to the public for the Public Shares was $3.70 per Public Share, and the price to the public for the Jan. 2024 Pre-funded Warrants was $3.69 per Jan. 2024 Pre-funded Warrant, which represents the per share price for the Public Shares less the $0.01 per share exercise price for each such Jan. 2024 Pre-funded Warrant. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 2,432,432 shares of Common Stock at the same price per share as the Public Shares, which was fully exercised by the Underwriters on January 18, 2024. The Public Offering closed on January 22, 2024.The gross proceeds to the Company from the Public Offering were approximately $69.0 million, before underwriting discounts and commissions and estimated expenses of the Public Offering.The Company intends to use the net proceeds from the Public Offering for general corporate purposes, which may include research and development expenditures, preclinical study and clinical trial expenditures, manufacturing

expenditures, commercialization expenditures, working capital, capital expenditures, acquisitions of new technologies, products or businesses and investments.The Public Offering was made pursuant to the Companyâ€™s shelf registration statement on Form S-3 (File No. 333-275638), declared effective by the SEC on December 14, 2023, a base prospectus dated December 14, 2023, and the related prospectus supplement dated January 17, 2024.The Jan. 2024 Pre-funded Warrants are exercisable at any time after the date of issuance. The exercise price and the number of shares of Common Stock issuable upon exercise of each Jan. 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to the Companyâ€™s stockholders. The Jan. 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of Jan. 2024 Pre-funded Warrants may not exercise such Jan. 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would beneficially own more than 4.99% of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the Jan. 2024 Pre-funded Warrants. A holder of Jan. 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 daysâ€™ prior notice to the Company.Â ATM AgreementPursuant to the ATM Agreement, the Company has established an â€œat-the-marketâ€ equity program under which it may offer and sell shares of its Common Stock, from time to time.On November 17, 2023, the Company filed a shelf registration statement on Form S-3 with the SEC (File No. 333-275638) and accompanying base prospectus, declared effective by the SEC on December 14, 2023, for the offer and sale of up to $200 million of its securities (December 2023 Registration Statement). Also on November 17, 2023, the Company filed a prospectus supplement with the SEC in connection with the offering of up to $50 million of shares of its Common Stock pursuant to the ATM Agreement under the December 2023 Registration Statement. In December 2023, the Company sold 123,882 shares under the ATM Agreement at an average price of approximately $3.03 per common share for gross proceeds of approximately $0.4 million.On April 11, 2024, the Company sold 3,535,246 shares of its Common Stock under the ATM Agreement at an average price of approximately $14.00 per common share, resulting in gross proceeds of approximately $49.5 million.On May 25, 2024, the Company terminated the offering of securities pursuant to the December 2023 Registration Statement in connection with the filing and effectiveness of the May 2024 Registration Statement.For additional information related to the various agreements discussed above, see Note 20, Subsequent Events, in the Companyâ€™s 2023 Form 10-K. X - DefinitionInvestment agreements. + ReferencesNo definition available. + Details Name: catx_InvestmentAgreementsAbstract Namespace Prefix: catx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionInvestments and agreements disclosure. + ReferencesNo definition available. + Details Name: catx_InvestmentsAndAgreementsDisclosureTextBlock Namespace Prefix: catx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 4 - Discontinued Operations 6 Months Ended Jun. 30, 2024 Discontinued Operations and Disposal Groups [Abstract] Â Discontinued Operations 4.Discontinued OperationsThe GT Medical Closing occurred on April 12, 2024 (GT Medical Closing Date). Previously, the Company announced that on December 7, 2023, Isoray entered into an Asset Purchase Agreement (GT Medical APA) by and among Isoray, the Company, and GT Medical pursuant to which Isoray would sell to GT Medical, and GT Medical would purchase from Isoray, all of Isorayâ€™s right, title and interest in and to substantially all of the assets of Isoray related to Isorayâ€™s commercial Cesium-131 business (the Business) including equipment, certain contracts, inventory and intellectual property. Subject to limited exceptions set forth in the GT Medical APA, GT Medical did not assume the liabilities of Isoray.Pursuant to the terms of, and subject to the conditions specified in, the GT Medical APA, at the GT Medical Closing, (i) GT Medical issued to Isoray 279,516 shares of GT Medicalâ€™s common stock, par value $0.0001 per share, representing 0.5% of GT Medicalâ€™s issued and outstanding capital stock on a fully diluted basis as of the GT Medical Closing Date and (ii) Isoray has the right to receive, and GT Medical is obligated to pay, certain cash royalty payments during each of the first four years beginning upon the GT Medical Closing Date (each such year, a Measurement Period), as summarized below:â€¢with respect to GT Medicalâ€™s net sales of Cesium-131 brachytherapy seeds for cases that do not utilize GT Medicalâ€™s GammaTile Therapy: (a) if such net sales for a Measurement Period are $10 million or less, 3.0% of such net sales; (b) if such net sales for a Measurement Period are greater than $10 million and less than $15 million, 4.0% of such net sales; and (c) if such net sales for a Measurement Period are $15 million or more, 5.0% of such net sales; andâ€¢with respect to GT Medicalâ€™s net sales of GT Medicalâ€™s GammaTile Therapy utilizing Cesium-131 brachytherapy seeds: 0.5% of such net sales for a Measurement Period.In accordance with ASC 205-20, Presentation of Financial Statements â€“ Discontinued Operations, the following table presents the major classes of assets and liabilities of discontinued operations of the Business reported in the condensed consolidated balance sheets and prior year amounts have been reclassified.Â Â Â June 30, 2024 Â Â December 31, 2023 Â (in thousands) Â Â Â Â Â Â Assets held for sale of discontinued operations, current Â Â Â Â Â Â Inventory Â $ - Â Â $ 3,148 Â Prepaid expenses and other current assets Â Â - Â Â Â 169 Â Property and equipment, net Â Â - Â Â Â 1,263 Â Right-of-use asset, net Â Â - Â Â Â 676 Â Other assets, net Â Â - Â Â Â 45 Â Total current assets held for sale of discontinued operations Â $ - Â Â $ 5,301 Â Â Â Â Â Â Â Â Liabilities held for sale of discontinued operations, current Â Â Â Â Â Â Lease liability Â $ - Â Â $ 677 Â Asset retirement obligation Â Â - Â Â Â 225 Â Loss recognized on classification as held for sale Â Â - Â Â Â 4,170 Â Total current liabilities of discontinued operations Â $ - Â Â $ 5,072 Â The following table presents the components of discontinued operations in relation to the Business reported in the unaudited condensed consolidated statements of operations (in thousands):Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Sales, net Â $ 205 Â Â $ 1,500 Â Â $ 2,178 Â Â $ 3,330 Â Cost of sales Â Â 162 Â Â Â 1,840 Â Â Â 1,564 Â Â Â 3,416 Â Gross profit Â Â 43 Â Â Â (340) Â Â 614 Â Â Â (86) Â Â Â Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 21 Â Â Â 283 Â Â Â 69 Â Â Â 831 Â Sales and marketing Â Â 138 Â Â Â 911 Â Â Â 941 Â Â Â 1,723 Â General and administrative Â Â 313 Â Â Â 86 Â Â Â 494 Â Â Â 446 Â Total operating expenses Â Â 472 Â Â Â 1,280 Â Â Â 1,504 Â Â Â 3,000 Â Â Â Â Â Â Â Â Â Â Â Â Total loss from discontinued operations Â $ (429) Â $ (1,620) Â $ (890) Â $ (3,086) The Company determined the loss recognized on classification as held for sale by identifying the assets and liabilities that are included in the GT Medical APA and are included in the table above. Additionally, the loss recognized on classification as held for sale was determined using the estimated fair value of the GT Medical stock of $0.2 million received less the carrying value of the net assets sold. The fair value of the stock received was determined based on information provided to the Company by GT Medical from a current valuation study that was prepared for them. Excluded from the calculation of the loss are contingent royalties that could be received from future sales.Certain amounts included in the unaudited condensed consolidated statements of cash flows related to the discontinued operations are as follows (in thousands):Â Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Depreciation Â $ - Â Â $ 111 Â Amortization Â Â - Â Â Â 18 Â Write-off of inventory associated with discontinued product Â Â - Â Â Â 298 Â Share-based compensation Â Â 166 Â Â Â 535 Â Additions to property and equipment Â Â - Â Â Â 186 Â For the three and six months ended June 30, 2024 and 2023, there was no provision (benefit) for income taxes recorded related to the discontinued operations. Additionally, the Company is in a loss position and has recorded a full valuation allowance for the deferred tax assets associated with the discontinued operations. X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205-20/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//360/tableOfContent + Details Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 5 - Property and Equipment 6 Months Ended Jun. 30, 2024 Notes To Financial Statements [Abstract] Â Property and Equipment 5.Property and EquipmentThe Companyâ€™s property and equipment consisted of the following as of:Â Â June 30, 2024 Â Â December 31, 2023 Â Â Â (in thousands) Â Building Â $ 1,770 Â Â $ 1,770 Â Land Â Â 1,283 Â Â Â 1,283 Â Equipment Â Â 9,470 Â Â Â 2,683 Â Leasehold improvements Â Â 3,490 Â Â Â 179 Â Other1 Â Â 319 Â Â Â 330 Â Property and equipment Â Â 16,332 Â Â Â 6,245 Â Less accumulated depreciation Â Â (1,585) Â Â (669) Property and equipment, net Â $ 14,747 Â Â $ 5,576 Â 1.Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized.Â On July 15, 2024 and August 2, 2024, the Company purchased a building located in Houston, Texas, for $4.7 million and a building in Chicago, Illinois, for $5.0 million, respectively, which it intends to use for the manufacture of its program candidates upon completion of modifications and installation of equipment. X - ReferencesNo definition available. + Details Name: catx_NotesToFinancialStatementsAbstract Namespace Prefix: catx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 6 - Goodwill and Other Intangible Assets 6 Months Ended Jun. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Goodwill and Other Intangible Assets 6.Goodwill and Other Intangible AssetsGoodwillThe carrying amount of goodwill as of both June 30, 2024 and December 31, 2023 was $24.1 million and has been recorded in connection with the Companyâ€™s Merger of Viewpoint in February 2023. The Company tests goodwill and indefinite-lived intangible assets for impairment during the fourth quarter of each year, or more frequently should circumstances change or events occur that would more likely than not reduce the fair value of its assets. No testing was deemed necessary during the three and six months ended June 30, 2024.The following table summarizes the components of the Companyâ€™s other intangible assets (in thousands): Â June 30, 2024 Â Â Cost Â Â Accumulated Amortization Â Â Net Carrying Value Â Indefinite-lived intangible assets Â Â Â Â Â Â Â Â In-process research and development Â $ 50,000 Â Â $ - Â Â $ 50,000 Â Total Â $ 50,000 Â Â $ - Â Â $ 50,000 Â Â Â December 31, 2023 Â Â Cost Â Â Accumulated Amortization Â Â Net Carrying Value Â Indefinite-lived intangible assets Â Â Â Â Â Â Â Â In-process research and development Â $ 50,000 Â Â $ - Â Â $ 50,000 Â Total Â $ 50,000 Â Â $ - Â Â $ 50,000 Â The Companyâ€™s IPR&D assets represent the estimated fair value of Viewpointâ€™s pipeline of radiotherapy product candidates acquired in February 2023. The estimated fair value of the IPR&D assets at the acquisition date was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flow estimates for Viewpointâ€™s pipeline of radiotherapy program candidates were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the Merger date and the time and resources needed to complete development. X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 7 - Held-to-Maturity Investments 6 Months Ended Jun. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Held-to-Maturity Investments 7.Held-to-Maturity InvestmentsThe following table summarizes the carrying values and fair values of the Companyâ€™s financial instruments (in thousands): Â June 30, 2024 Â Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Estimated Fair Value Â U.S. Treasury Bills Â $ 40,865 Â Â $ - Â Â $ (11) Â $ 40,854 Â The Company has investments in U.S. Treasury Bills, some of which mature over a period greater than 90 days and are classified as short-term investments. The U.S. Treasury Bills are carried at amortized cost and classified as held-to-maturity as the Company has the intent and the ability to hold them until they mature. The carrying value of the U.S. Treasury Bills are adjusted for accretion of discounts over the remaining life of the investment. Income related to the U.S. Treasury Bills is recognized in interest income in the Companyâ€™s condensed consolidated statement of operations. Based on its analysis of the held-to-maturity securities, the Company determined the gross unrealized losses were primarily due to changes in interest rates and not due to credit risks. As such, the Company did not record a credit allowance as of June 30, 2024. As of December 31, 2023, the Company had no held-to-maturity investments, and no held-to-maturity investments were presented in cash and cash equivalents on its condensed consolidated balance sheet. X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//320/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6BReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph (b) -Publisher SECReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//946-320/tableOfContentReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//940-320/tableOfContentReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//942-320/tableOfContent + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 8 - Fair Value Measurements 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements 8.Fair Value MeasurementsFair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:Level 1 - Observable inputs such as quoted prices in active markets;Level 2 - Inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions (less active markets), or model-driven valuations in which all significant inputs are observable or can be derived principally from, or corroborated with, observable market data; andLevel 3 - Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.Included in the Companyâ€™s cash and cash equivalents in the condensed consolidated balance sheet is its money market fund, which is measured at fair value on a recurring basis and categorized using the fair value hierarchy (in thousands): Â Â June 30, 2024 Â Â Â Estimated Fair ValueLevel 1 Â Money market fund Â $ 249,663 Â There were no Level 2 or Level 3 financial instruments measured at fair value on a recurring basis at June 30, 2024, and the Company did not have any financial instruments measured at fair value on a recurring basis at December 31, 2023.For information related to our short-term investments, see Note 7, Held-to-Maturity Investments. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or

nonrecurring basis. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//820/tableOfContent + Details Name: us-gaap_FairValueMeasurementInputsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 9 - Share-Based Compensation 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Share-Based Compensation 9.Share-Based CompensationOn May 31, 2024, the Company held its 2024 Annual Meeting of Stockholders (Annual Meeting). At the Annual Meeting, the Companyâ€™s stockholders approved the Companyâ€™s Third Amended and Restated 2020 Equity Incentive Plan (the Amended and Restated Plan) which, among other things, (a) increased the aggregate number of shares of Common Stock authorized for issuance under the Amended and Restated Plan by 4,870,092 for a total of 12,500,000 shares of Common Stock, and (b) adjusted the â€œevergreenâ€ provision included therein, such that the number of shares of Common Stock available for the grant of awards under the Amended and Restated Plan will automatically increase on January 1 of each year in an amount equal to 5% of the number of shares of Common Stock issued and outstanding on December 31 of the immediately preceding year (subject to adjustment in the event of stock splits and other similar events); provided, however, that the Companyâ€™s Board of Directors may act prior to January 1 of a given year to provide that there will be no increase in the share limit for such year or provide that the increase for such year will be a lesser number of shares of Common Stock.The following table presents the share-based compensation expense recognized for all share-based compensation arrangements (in thousands):Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development $ 259 Â Â $ 429 Â Â $ 522 Â Â $ 584 Â General and administrative Â 328 Â Â Â 621 Â Â Â 687 Â Â Â 1,448 Â Total share-based compensation $ 587 Â Â $ 1,050 Â Â $ 1,209 Â Â $ 2,032 Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 10 - Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies 10.Commitments and ContingenciesThe Company has been in settlement negotiations with a representative for six stockholder plaintiff firms alleging the Company violated Delaware law in its preliminary proxy statement that was disseminated to stockholders in November 2022 for the Companyâ€™s annual meeting held in December 2022. Based on these settlement negotiations to date, the Company estimates that it will settle for no more than an aggregate of $0.2 million and, therefore, recorded an estimated liability of $0.2 million as of December 31, 2023. There was no change in the estimate as of June 30, 2024. This balance is included in accrued expenses on the unaudited condensed consolidated balance sheets. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//450/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 11 - Related Parties 6 Months Ended Jun. 30, 2024 Related Party Transactions [Abstract] Â Related Party Transactions Disclosure [Text Block] 11.Related PartiesÂ In connection with the Lantheus Investment Agreement entered into with Lantheus on January 8, 2024, the Company agreed to sell and issue the Lantheus Shares. The number of Lantheus Shares sold was 5,634,235, representing 19.99% of the outstanding shares of Common Stock as of January 8, 2024.Â On January 8, 2024, the Company entered into the Progenics APA with Progenics, an affiliate of Lantheus, for a purchase price of $8.0 million. On March 1, 2024, the Company closed on the transactions contemplated by the Progenics APA.Â On March 4, 2024, the Company entered into the March 2024 Investment Agreement in which the Company agreed to issue and sell 9,200,998 shares of Common Stock. Lantheus, a significant stockholder of the Company, purchased part of the shares issued to increase their ownership percentage to approximately 19.9% in the Company following the closing of the March 2024 Investment Agreement on March 6, 2024.Â For additional information regarding the Lantheus Investment Agreement, the Progenics APA and the March 2024 Investment Agreement, see Note 3, Investments and Agreements. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 12 - Leases 6 Months Ended Jun. 30, 2024 Leases [Abstract] Â Leases 12.LeasesThe Company accounts for its leases under ASC 842, Leases. Effective April 1, 2024, the Company entered into a lease with the Board of Regents, State of Iowa, for lab and office space at the BioVentures Center. The lease terminates in March 2026. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $1.1 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate.The Company acquired a lease from Progenics, an affiliate of Lantheus, for a production facility in Somerset, New Jersey effective on March 1, 2024 (see Note 3, Investments and Agreements, in this Form 10-Q). The lease terminates on November 29, 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $0.3 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate.On July 1, 2023, the Company entered into a lease with Unico Properties LLC for office space in Seattle, Washington that terminates in October 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $0.8 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate.The weighted average remaining term and discount rate for the Companyâ€™s operating leases as of June 30, 2024 was 3.2 years and 8%, respectively.The Companyâ€™s operating lease expense was $0.2 million and $0.3 million for the three and six months ended June 30, 2024, respectively, and there was no operating lease expense for the three and six months ended June 30, 2023.The following table presents the future operating lease payments and lease liability included on the condensed consolidated balance sheet related to the Companyâ€™s operating leases as of June 30, 2024 (in thousands):Â Year Ending December 31, Â Â 2024 (remaining six months) Â $ 408 Â 2025 Â Â 949 Â 2026 Â Â 482 Â 2027 Â Â 320 Â 2028 Â Â 283 Â Total Â Â 2,442 Â Less: imputed interest Â Â (272) Total lease liability Â Â 2,170 Â Less current portion Â Â (720) Non-current lease liability Â $ 1,450 Â Â Asset Retirement ObligationThe Company had an asset retirement obligation (ARO) associated with the facility it leased in Richland, Washington. This lease is included in the GT Medical APA and was assigned to GT Medical upon the GT Medical Closing, which occurred on April 12, 2024. As such, this liability is no longer reported as an ARO in the Companyâ€™s condensed consolidated financial statements as of June 30, 2024 and December 31, 2023. However, the Company maintains the estimated liability in its condensed consolidated financial statements related to hazardous waste removal. The estimated liability at each of June 30, 2024 and December 31, 2023 was $0.5 million and is included within the accounts payable and accrued expenses in the condensed consolidated balance sheets. X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 13 - Notes Payable 6 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] Â Notes Payable 13.Notes PayableThe Company assumed two notes payable effective upon the closing of the Merger with Viewpoint on February 3, 2023. On July 19, 2019, Viewpoint entered in a promissory note agreement with the Iowa Economic Development Authority (IEDA) for $0.1 million at 3% interest rate to be paid over 36 monthly payments beginning on the first day of the first month following Viewpoint closing on a $1.0 million equity fundraising round. Final payment was paid in September 2023. The loan was granted as a form of financial assistance to Viewpoint from IEDA.Â On December 29, 2022, Viewpoint obtained a promissory note in the amount of $1.7 million for the purpose of purchasing land and a building in Coralville, Iowa. The note bears interest at 6.15% per annum and is collateralized by the property. The note requires monthly principal and interest payments, and a balloon payment of approximately $1.5 million is due on December 29, 2027.The following table presents the current and long-term portions of the note payable (in thousands):Â Â June 30, Â Â December 31, Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Note payable Â $ 1,705 Â Â $ 1,725 Â Less: current portion Â Â (54) Â Â (49) Note payable, long-term portion Â $ 1,651 Â Â $ 1,676 Â Â The following table presents the future principal payments included on the condensed consolidated balance sheet related to the Companyâ€™s note payable as of June 30, 2024 (in thousands):Â Years ending December 31: Â Â 2024 (remaining six months) Â $ 29 Â 2025 Â Â 52 Â 2026 Â Â 55 Â 2027 Â Â 1,569 Â Total Â $ 1,705 Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1CReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1CReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1CReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1IReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1IReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50

-Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 14 - Merger 6 Months Ended Jun. 30, 2024 Business Combinations [Abstract] Â Merger 14.MergerOn February 3, 2023, the Company acquired 100% of the issued and outstanding equity and voting shares of Viewpoint Molecular Targeting, Inc. in exchange for 13,654,507 shares of Common Stock with a fair value of $54.6 million based on the closing market price of $4.00 per share on the acquisition date. At the closing of the Merger, the Company forgave the note receivable entered into in November 2022 and the associated accrued interest with Viewpoint that was included in the note receivable. The total amount forgiven was $6.2 million, representing the $6.0 million loan and $0.2 million accrued interest. The Company also assumed all of Viewpointâ€™s outstanding stock options and warrants as of the Merger date.Â Viewpoint is developing the next generation of TAT for oncology that have the potential to treat a large population of cancer patients across multiple tumor types, including those with metastatic disease. By leveraging its proprietary TAT platform, Viewpoint aims to develop alpha-emitting radiopharmaceuticals that can be attached to targeting peptides to deliver the radioactive payload directly to difficult to treat tumors. The Merger was completed to provide the Company with a new isotope in a larger market. The Company accounted for the transaction as a business combination in accordance ASC 805, Business Combinations. The Company has performed an allocation of the purchase price paid for the assets acquired and the liabilities assumed with the assistance of an independent valuation firm. The Viewpoint purchase price consideration and allocation to net assets acquired is presented below (in thousands except for share price):Â Fair value of consideration transferred Â Â Â Perspective Therapeutics common stock issued (13,654,507Â x $4.00) Â $ 54,618 Â Assumption of Viewpoint stock options and warrants at fair value Â Â 7,836 Â Note receivable and interest from Viewpoint forgiven Â Â 6,171 Â Total fair value of consideration transferred Â $ 68,625 Â Â Recognized amounts of identifiable net assets acquired Â Â Â Assets acquired Â Â Â Cash and cash equivalents Â $ 2,699 Â Grants receivable Â Â 95 Â Prepaid expenses Â Â 396 Â Property and equipment Â Â 5,050 Â Right of use asset Â Â 10 Â Intangible assets, in-process research and development Â Â 50,000 Â Other assets Â Â 316 Â Total assets acquired Â Â 58,566 Â Â Â Â Liabilities assumed Â Â Â Accounts payable and accrued expenses Â Â 2,968 Â Lease liability Â Â 10 Â Accrued payroll and related taxes Â Â 1,642 Â Accrued vacation Â Â 333 Â Notes payable Â Â 1,807 Â Deferred tax liability Â Â 7,243 Â Total liabilities assumed Â Â 14,003 Â Â Â Â Net assets acquired, excluding goodwill Â Â 44,563 Â Total purchase price consideration Â Â 68,625 Â Â Â Â Â Goodwill Â $ 24,062 Â Â Goodwill is calculated as the difference between the acquisition date fair value of the consideration and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized and is not currently assumed to be deductible for tax purposes. The goodwill is attributable to the workforce of the acquired business and the synergies expected to arise from the acquisition of Viewpoint.Upon completion of the Merger, Viewpoint became a wholly owned subsidiary of the Company and its results of operations have been included in the Companyâ€™s condensed consolidated financial statements.Since the closing date, Viewpointâ€™s results of operations have been reported in the Companyâ€™s condensed consolidated financial statements and include grant revenue of approximately $0.5 million and $0.6 million, respectively, and operating loss of $13.6 million and $7.3 million, respectively, for the three months ended June 30, 2024 and 2023, and grant revenue of approximately $0.9 million and $0.8 million, respectively, and operating loss of $23.7 million and $11.1 million, respectively, for the six months ended June 30, 2024 and 2023.The pro forma financial information below represents the combined results of operations as if the acquisition had occurred on January 1, 2022, the beginning of the comparable prior year reporting period. The unaudited pro forma financial information is presented for informational purposes only and is neither indicative of the results of operations that would have occurred if the acquisition had taken place at the beginning of the period presented nor indicative of future operating results.The information below reflects certain nonrecurring pro forma adjustments that were directly related to the business combination based on available information and certain assumptions that we believe are reasonable:Â Â Three Months Ended June 30, 2023 Â Â Six Months Ended June 30, 2023 Â (in thousands) Â Â Â Â Â Â Grant revenue Â $ 588 Â Â $ 905 Â Net loss Â Â (9,486) Â Â (16,160) X - DefinitionThe entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//805/tableOfContent + Details Name: us-gaap_BusinessCombinationDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Reclassifications ReclassificationsIn addition to the discontinued operations discussed above, during the first quarter of 2024, the Company made certain reclassifications to prior period amounts in the condensed consolidated financial statements and accompanying notes to conform to the current period presentation. The reclassification of these items had no impact on net loss, financial position or cash flows in the current or prior periods. Specifically, accrued payroll and related taxes and accrued vacation were combined to create accrued personnel, and accrued protocol expense and accrued waste disposal were included in accounts payable and accrued expenses, all of which are presented on the condensed consolidated balance sheets and condensed consolidated statement of cash flows. X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 2 - Loss Per Share (Tables) 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares Securities not considered in the calculation of diluted loss per share, but that could be dilutive in the future, are as follows (in thousands):Â Â June 30, 2024 Â Â June 30, 2023 Â Common stock warrants Â Â 416 Â Â Â 603 Â Common stock options Â Â 6,934 Â Â Â 4,487 Â Total potential dilutive securities Â Â 7,350 Â Â Â 5,090 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 4 - Discontinued Operations (Tables) 6 Months Ended Jun. 30, 2024 Discontinued Operations and Disposal Groups [Abstract] Â Schedule of Discontinued Operations In accordance with ASC 205-20, Presentation of Financial Statements â€“ Discontinued Operations, the following table presents the major classes of assets and liabilities of discontinued operations of the Business reported in the condensed consolidated balance sheets and prior year amounts have been reclassified.Â Â Â June 30, 2024 Â Â December 31, 2023 Â (in thousands) Â Â Â Â Â Â Assets held for sale of discontinued operations, current Â Â Â Â Â Â Inventory Â $ - Â Â $ 3,148 Â Prepaid expenses and other current assets Â Â - Â Â Â Â 169 Â Property and equipment, net Â Â - Â Â Â 1,263 Â Right-of-use asset, net Â Â - Â Â Â 676 Â Other assets, net Â Â - Â Â Â 45 Â Total current assets held for sale of discontinued operations Â $ - Â Â $ 5,301 Â Â Â Â Â Â Â Â Liabilities held for sale of discontinued operations, current Â Â Â Â Â Â Lease liability Â $ - Â Â $ 677 Â Asset retirement obligation Â Â - Â Â Â 225 Â Loss recognized on classification as held for sale Â Â - Â Â Â 4,170 Â Total current liabilities of discontinued operations Â $ - Â Â $ 5,072 Â The following table presents the components of discontinued operations in relation to the Business reported in the unaudited condensed consolidated statements of operations (in thousands):Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Sales, net Â $ 205 Â Â $ 1,500 Â Â $ 2,178 Â Â $ 3,330 Â Cost of sales Â Â 162 Â Â Â 1,840 Â Â Â 1,564 Â Â Â 3,416 Â Gross profit Â Â 43 Â Â Â (340) Â Â 614 Â Â Â (86) Â Â Â Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 21 Â Â Â 283 Â Â Â 69 Â Â Â 831 Â Sales and marketing Â Â 138 Â Â Â 911 Â Â Â 941 Â Â Â 1,723 Â General and administrative Â Â 313 Â Â Â 86 Â Â Â 494 Â Â Â 446 Â Total operating expenses Â Â 472 Â Â Â 1,280 Â Â Â 1,504 Â Â Â 3,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total loss from discontinued operations Â $ (429) Â $ (1,620) Â $ (890) Â $ (3,086) Certain amounts included in the unaudited condensed consolidated statements of cash flows related to the discontinued operations are as follows (in thousands):Â Â Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Depreciation Â $ - Â Â $ 111 Â Amortization Â Â - Â Â Â 18 Â Write-off of inventory associated with discontinued product Â Â - Â Â Â 298 Â Share-based compensation Â Â 166 Â Â Â 535 Â Additions to property and equipment Â Â - Â Â Â 186 Â X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5CReference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5D -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5DReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3AReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3 + Details Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 5 - Property and Equipment (Tables) 6 Months Ended Jun. 30, 2024 Property, Plant and Equipment [Abstract] Â Summary of Property and Equipment The Companyâ€™s property and equipment consisted of the following as of:Â Â June 30, 2024 Â Â December 31, 2023 Â Â Â (in thousands) Â Building Â $ 1,770 Â Â $ 1,770 Â Land Â Â 1,283 Â Â Â 1,283 Â Equipment Â Â 9,470 Â Â Â 2,683 Â Leasehold improvements Â Â 3,490 Â Â Â 179 Â Other1 Â Â 319 Â Â Â 330 Â Property and equipment Â Â 16,332 Â Â Â 6,245 Â Less accumulated depreciation Â Â (1,585) Â Â (669) Property and equipment, net Â $ 14,747 Â Â $ 5,576 Â 1.Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized. X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 6 - Goodwill and Other Intangible Assets (Tables) 6 Months Ended Jun. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Summary of Components of Other Intangible Assets The following table summarizes the components of the Companyâ€™s other intangible assets (in thousands): Â Â June 30, 2024 Â Â Â Cost Â Â Accumulated Amortization Â Â Net Carrying Value Â Indefinite-lived intangible assets Â Â Â Â Â Â Â Â Â In-process research and development Â $ 50,000 Â Â $ - Â Â $ 50,000 Â Total Â $ 50,000 Â Â $ - Â Â $ 50,000 Â Â Â December 31, 2023 Â Â Cost Â Â Accumulated Amortization Â Â Net Carrying Value Â Indefinite-lived intangible assets Â Â Â Â Â Â Â Â Â In-process research and development Â $ 50,000 Â Â $ - Â Â $ 50,000 Â Total Â $ 50,000 Â Â $ - Â Â $ 50,000 Â X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b),(d) -SubTopic 30 -Topic 350 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3 + Details Name: us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 7 - Held-to-Maturity Investments (Tables) 6 Months Ended Jun. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Summary of Carrying Values and Fair Values of Financial Instruments The following table summarizes the carrying values and fair values of the Companyâ€™s financial instruments (in thousands): Â June 30, 2024 Â Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Estimated Fair Value Â U.S. Treasury Bills Â $ 40,865 Â Â $ - Â Â $ (11) Â $ 40,854 Â X - DefinitionTabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic

320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 15: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5B + Details Name: us-gaap_HeldToMaturitySecuritiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 8 - Fair Value Measurements (Tables) 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis Companyâ€™s cash and cash equivalents in the condensed consolidated balance sheet is its money market fund, which is measured at fair value on a recurring basis and categorized using the fair value hierarchy (in thousands): Â Â June 30, 2024 Â Â Â Estimated Fair ValueLevel 1 Â Money market fund Â $ 249,663 Â X - DefinitionTabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 9 - Share-Based Compensation (Tables) 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements The following table presents the share-based compensation expense recognized for all share-based compensation arrangements (in thousands):Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Research and development $ 259 Â Â $ 429 Â Â $ 522 Â Â $ 584 Â General and administrative Â 328 Â Â Â 621 Â Â Â 687 Â Â Â 1,448 Â Total share-based compensation $ 587 Â Â $ 1,050 Â Â $ 1,209 Â Â $ 2,032 Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 12 - Leases (Tables) 6 Months Ended Jun. 30, 2024 Notes Tables Â Summary of Future Operating Lease Payments and Lease Liability The following table presents the future operating lease payments and lease liability included on the condensed consolidated balance sheet related to the Companyâ€™s operating leases as of June 30, 2024 (in thousands):Â Year Ending December 31, Â Â Â 2024 (remaining six months) Â $ 408 Â 2025 Â Â 949 Â 2026 Â Â 482 Â 2027 Â Â 320 Â 2028 Â Â 283 Â Total Â Â 2,442 Â Less: imputed interest Â Â (272) Total lease liability Â Â 2,170 Â Less current portion Â Â (720) Non-current lease liability Â $ 1,450 Â X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 44 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 13 - Notes Payable (Tables) 6 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] Â Summary of Note Payable The following table presents the current and long-term portions of the note payable (in thousands):Â Â June 30, Â Â December 31, Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Note payable Â $ 1,705 Â Â $ 1,725 Â Less: current portion Â Â (54) Â Â (49) Note payable, long-term portion Â $ 1,651 Â Â $ 1,676 Â Summary of Maturity of Note Payable The following table presents the future principal payments included on the condensed consolidated balance sheet related to the Companyâ€™s note payable as of June 30, 2024 (in thousands):Â Years ending December 31: Â Â Â 2024 (remaining six months) Â $ 29 Â 2025 Â Â 52 Â 2026 Â Â 55 Â 2027 Â Â 1,569 Â Total Â $ 1,705 Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 45 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 14 - Merger (Tables) 6 Months Ended Jun. 30, 2024 Business Combinations [Abstract] Â Summary of Estimated Purchase Consideration The Viewpoint purchase price consideration and allocation to net assets acquired is presented below (in thousands except for share price):Â Fair value of consideration transferred Â Â Â Perspective Therapeutics common stock issued (13,654,507Â x $4.00) Â $ 54,618 Â Assumption of Viewpoint stock options and warrants at fair value Â Â 7,836 Â Note receivable and interest from Viewpoint forgiven Â Â 6,171 Â Total fair value of consideration transferred Â $ 68,625 Â Summary of Preliminary Purchase Price Allocation Recognized amounts of identifiable net assets acquired Â Â Â Assets acquired Â Â Â Cash and cash equivalents Â $ 2,699 Â Grants receivable Â Â 95 Â Prepaid expenses Â Â 396 Â Property and equipment Â Â 5,050 Â Right of use asset Â Â 10 Â Intangible assets, in-process research and development Â Â 50,000 Â Other assets Â Â 316 Â Total assets acquired Â Â 58,566 Â Â Â Â Â Liabilities assumed Â Â Â Accounts payable and accrued expenses Â Â 2,968 Â Lease liability Â Â 10 Â Accrued payroll and related taxes Â Â 1,642 Â Accrued vacation Â Â 333 Â Notes payable Â Â 1,807 Â Deferred tax liability Â Â 7,243 Â Total liabilities assumed Â Â 14,003 Â Â Â Â Net assets acquired, excluding goodwill Â Â 44,563 Â Total purchase price consideration Â Â 68,625 Â Â Â Â Â Goodwill Â $ 24,062 Â Summary of Pro Forma Computation of Earnings Per Share The information below reflects certain nonrecurring pro forma adjustments that were directly related to the business combination based on available information and certain assumptions that we believe are reasonable:Â Â Three Months Ended June 30, 2023 Â Â Six Months Ended June 30, 2023 Â (in thousands) Â Â Â Â Â Â Grant revenue Â $ 588 Â Â $ 905 Â Net loss Â Â (9,486) Â Â (16,160) X - DefinitionTabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionProFormaInformationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2 + Details Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Paragraph 1 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details Name: us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended Jun. 14, 2024 Apr. 12, 2024 $ / shares shares Apr. 11, 2024 USD ($) $ / shares shares Feb. 03, 2023 $ / shares shares Dec. 31, 2023 USD ($) $ / shares shares Jun. 30, 2024 USD ($) $ / shares Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) $ / shares Jun. 30, 2023 USD ($) Dec. 31, 2024 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Common stock, par value | $ / shares Â Â Â Â $ 0.001 $ 0.001 Â $ 0.001 Â Â Reverse stock split, ratio 0.1 Â Â Â Â Â Â Â Â Â Â Cash, cash equivalents and short-term investments | $ Â Â Â Â Â $ 292,900 Â $ 292,900 Â $ 292,900 Â Accumulated deficit | $ Â Â Â Â Â $ (152,440) (176,428) Â (176,428) Â Â Loss on equity method investment | $ Â Â Â Â Â Â $ 4 $ 0 $ 6 $ 0 Â Forecast [Member] Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Effective income tax rate Â Â Â Â Â Â Â Â Â 0.00% GT Medical Technologies, Inc. [Member] Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares | shares Â 279,516 Â Â Â Â Â Â Â Â Â Common stock, par value | $ / shares Â $ 0.0001 Â Â Â Â Â Â Â Â Â Percentage of issued and outstanding capital stock Â 0.50% Â Â Â Â Â Â Â Â Â Oppenheimer & Co [Member] Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares | shares Â Â 3,535,246 Â 123,882 Â Â Â Â Â Stock purchase price per share | $ / shares Â Â $ 14 Â $ 3.03 Â Â Â Â Â Proceeds from issuance of common stock | $ Â Â $ 49,500 Â $ 400 Â Â Â Â Â Viewpoint Molecular Targeting, Inc. [Member] Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Common stock issued pursuant to merger, Shares | shares Â Â Â 13,654,507 Â Â Â Â Â Â Â Percentage of fully-diluted outstanding capital stock Â Â Â 49.00% Â Â Â Â Â Â Common stock, par value | $ / shares Â Â Â $ 0.001 Â Â Â Â Â Â X - DefinitionPercentage of issued and outstanding capital stock. + ReferencesNo definition available. + Details Name: catx_PercentageOfIssuedAndOutstandingCapitalStock Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresents number of shares issued as a percentage of fully diluted outstanding capital stock. + ReferencesNo definition available. + Details Name: catx_SharesIssuedPercentOfFullydilutedOutstandingCapitalStock Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of equity interests issued or issuable to acquire entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 + Details Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionCash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashCashEquivalentsAndShortTermInvestments Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=catx_GTMedicalTechnologiesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=catx_OppenheimerCoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=catx_ViewpointMolecularTargetingIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 2 - Loss Per Share - Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares (Details) - shares shares in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total potential dilutive securities 7,350 5,090 Common Stock Warrants [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total potential dilutive securities 416 603 Common Stock Options [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total potential dilutive securities 6,934 4,487 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 2 - Loss Per Share (Details Textual) - Viewpoint Molecular Targeting, Inc. [Member] Feb. 03, 2023 $ / shares shares Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Â Warrants to purchase shares of common stock | shares 338,709 Warrant exercise price per share $ 2.7 Options to purchase shares of common stock | shares 2,426,342 Minimum [Member] Â Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Â Options exercise price per share $ 1.3 Maximum [Member] Â Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Â Options exercise price per share $ 3 X - DefinitionShare based compensation arrangements by share based payment award options exercise price. + ReferencesNo definition available. + Details Name: catx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePrice Namespace Prefix: catx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) assumed during the period. + ReferencesNo definition available. + Details Name: catx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodGross Namespace Prefix: catx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B + Details Name: us-gaap_EarningsPerShareBasicLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=catx_ViewpointMolecularTargetingIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 3 - Investments and Agreements (Details Textual) - USD ($) 1 Months Ended May 24, 2024 Apr. 11, 2024 Mar. 04, 2024 Jan. 17, 2024 Jan. 08, 2024 Dec. 31, 2023 Jun. 30, 2024 Mar. 31, 2024 Dec. 14, 2023 Nov. 17, 2023 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Common stock, par value Â Â Â Â Â $ 0.001 $ 0.001 Â Â Â Maximum amount of securities offer and sale Â Â Â Â Â Â Â Â $ 200,000,000 Â January 2024 Pre-funded Warrants [Member] Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Warrants to purchase shares of common stock Â Â Â 3,008,694 Â Â Â Â Â Â Â Warrant exercise price per share Â Â Â $ 3.69 Â Â Â Â Â Â Percentage of ownership considered for warrant exercise Â Â Â 4.99% Â Â Â Â Â Â Maximum increase or decrease in ownership percentage Â Â Â 19.99% Â Â Â Â Â Â March 2024 Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares Â Â 9,200,998 Â Â Â Â Â Â Â Stock purchase price per share Â Â $ 9.5 Â Â Â Â Â Â Â Proceeds from issuance of common stock Â Â $ 87,400,000 Â Â Â Â Â Â Â Placement agents cash fee, percentage Â Â 5.85% Â Â Â Â Â Â Â Lantheus Investment Agreement Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Stock issued during period, shares Â Â Â Â 5,634,235 Â Â Â Â Â Investment agreement, contingent amount of gross proceeds raised Â Â Â Â $ 50,000,000 Â Â Â Â Â Percent of outstanding shares Â Â Â Â 19.99% Â Â Â Â Â Asset purchase price in cash Â Â Â Â Â $ 8,000,000 Â Â Â Â Â Lantheus Investment Agreement | Option Agreement [Member] Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Percent of outstanding shares Â Â Â Â Â Â Â Â 19.90% Â Â One-time payment received for rights granted Â Â Â Â 28,000,000 Â Â Â Â Â Repayment provisions Â Â Â Â Â $ 0 Â Â Â Â Â Â Public Offering [Member] Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares Â Â Â 13,207,521 Â Â Â Â Â Â Sale of stock, price per share Â Â Â $ 3.7 Â Â Â Â Â Â Shares and warrants, price difference per share Â Â Â $ 0.01 Â Â Â Â Â Â Gross proceeds from public offering Â Â Â $ 69,000,000 Â Â Â Â Â Â Over-Allotment Option [Member] Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Stock issued during period, shares Â Â Â 2,432,432 Â Â Â Â Â Â Oppenheimer & Co [Member] Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares Â 3,535,246 Â Â Â 123,882 Â Â Â Â Stock purchase price per share Â $ 14 Â Â Â Â $ 3.03 Â Â Â Â Proceeds from issuance of common stock Â $ 49,500,000 Â Â Â $ 400,000 Â Â Â Â Maximum amount of securities offer and sale Â Â Â Â Â Â Â Â Â $ 50,000,000 BofA Securities, Inc [Member] | Underwriting Agreement [Member] | May 2024 Pre-funded Warrants [Member] Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Warrants to purchase shares of common stock 146,425 Â Â Â Â Â Â Â Â Â Warrant exercise price per share $ 15.09 Â Â Â Â Â Â Â Â Â Percentage of ownership considered for warrant exercise 4.99% Â Â Â Â Â Â Â Â Â Percentage of ownership considered for warrant exercise 9.99% Â Â Â Â Â Â Â Â Â Maximum increase or decrease in ownership percentage 19.99% Â Â Â Â Â Â Â Â Â BofA Securities, Inc [Member] | Registered Offering [Member] | Underwriting Agreement [Member] Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares 5,151,588 Â Â Â Â Â Â Â Â Â Sale of stock, price per share $ 15.1 Â Â Â Â Â Â Â Â Â Shares and warrants, price difference per share $ 0.01 Â Â Â Â Â Â Â Â Â Gross proceeds from public offering $ 80,000,000 Â Â Â Â Â Â Â Â Â X - DefinitionRepresents the amount of gross proceeds raised as part of an investment agreement. + ReferencesNo definition available. + Details Name: catx_InvestmentAgreementContingentAmountOfGrossProceedsRaised Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum amount of securities offer and sale. + ReferencesNo definition available. + Details Name: catx_MaximumAmountOfSecuritiesOfferAndSale Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum increase or decrease in ownership percentage. + ReferencesNo definition available. + Details Name: catx_MaximumIncreaseOrDecreaseInOwnershipPercentage Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionOne-time payment received for rights granted. + ReferencesNo definition available. + Details Name: catx_OneTimePaymentReceivedForRightsGranted Namespace Prefix: catx_ Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the percent of outstanding shares. + ReferencesNo definition available. + Details Name: catx_PercentOfOutstandingShares Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage of ownership considered for warrant exercise. + ReferencesNo definition available. + Details Name: catx_PercentageOfOwnershipConsideredForWarrantExercise Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage of ownership considered for warrant exercise two. + ReferencesNo definition available. + Details Name: catx_PercentageOfOwnershipConsideredForWarrantExerciseTwo Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresents the cash fee percentage. + ReferencesNo definition available. + Details Name: catx_PlacementAgentsCashFeePercentage Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepayment provisions. + ReferencesNo definition available. + Details Name: catx_RepaymentProvisions Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the difference between shares and warrants prices. + ReferencesNo definition available. + Details Name: catx_SharesAndWarrantsPriceDifference Namespace Prefix: catx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=catx_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=catx_March2024PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=catx_LantheusInvestmentAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=catx_OptionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=catx_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=catx_OppenheimerCoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=catx_BofASecuritiesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=catx_TheUnderwritingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=catx_May2024PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=catx_RegisteredOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 4 - Discontinued Operations (Details Textual) - USD ($) 3 Months Ended 6 Months Ended Apr. 12, 2024 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Common stock, par value Â $ 0.001 Â $ 0.001 Â $ 0.001 Discontinued operations, Provision (benefit) for income taxes Â $ 0 $ 0 $ 0 Â GT Medical Technologies, Inc. [Member] Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Stock issued during period, shares 279,516 Â Â Â Â Â Â Common stock, par value $ 0.0001 Â Â Â Â Â Â Percentage of issued and outstanding capital stock 0.50% Â Â Â Â Â Â Royalty agreement percentage of net sales receivable 0.50% Â Â Â Â Â Â GT Medical Technologies, Inc. [Member] | Net Sales of $10 Million or Less [Member] Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Royalty agreement percentage of net sales receivable 3.00% Â Â Â Â Â Â GT Medical Technologies, Inc. [Member] | Net Sales Between $10 and 15 Million [Member] Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Royalty agreement percentage of net sales receivable 4.00% Â Â Â Â Â Â GT Medical Technologies, Inc. [Member] | Net Sales Greater Than $15 Million [Member] Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Royalty agreement percentage of net sales receivable 5.00% Â Â Â Â Â Â GT Medical Technologies, Inc. [Member] | GT Medical Stock [Member] Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Estimated fair value $ 200,000 Â Â Â Â Â Â X - DefinitionPercentage of issued and outstanding capital stock. + ReferencesNo definition available. + Details Name: catx_PercentageOfIssuedAndOutstandingCapitalStock Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresents the percentage of net sales receivable as part of a royalty agreement. + ReferencesNo definition available. + Details Name: catx_RoyaltyAgreementPercentageOfNetSalesReceivable Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5CReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1 + Details Name: us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=catx_GTMedicalTechnologiesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=catx_NetSalesOf10MillionOrLessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=catx_NetSalesBetween10And15MillionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=catx_NetSalesGreaterThan15MillionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=catx_GTMedicalStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 4 - Discontinued Operations - Schedule of Discontinued Operations (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Assets held for sale of discontinued operations, current Â Â Â Â Â Â Total current assets held for sale of discontinued operations $ 0 Â $ 0 Â $ 5,301 Liabilities held for sale of discontinued operations, current Â Â Â Â Â Â Total current liabilities of discontinued operations 0 Â 0 Â 5,072 Depreciation Â Â 916 $ 425 Â Amortization Â Â 12 20 Â Write-off of inventory associated with discontinued product Â Â 0 298 Â Share-based compensation Â Â 1,375 2,567 Â Additions to property and equipment Â Â 10,087 756 Â Discontinued Operations, Disposed of by Sale [Member] | Cesium-131 Business [Member] Â Â Â Â Â Â Assets held for sale of discontinued operations, current Â Â Â Â Â Â Inventory 0 Â 0 Â 3,148 Prepaid expenses and other current assets 0 Â 0 Â 169 Property and equipment, net 0 Â 0 Â 1,263 Right-of-use asset, net 0 Â 0 Â 676 Other assets, net 0 Â 0 Â 45 Total current assets

held for sale of discontinued operations 0 Â 0 Â 5,301 Liabilities held for sale of discontinued operations, current Â Â Â Â Â Lease liability 0 Â 0 Â 677 Asset retirement obligation 0 Â 0 Â 225 Loss recognized on classification as held for sale 0 Â 0 Â 4,170 Total current liabilities of discontinued operations 0 Â 0 Â $ 5,072 Sales, net 205 $ 1,500 2,178 3,330 Â Cost of sales 162 1,840 1,564 3,416 Â Gross profit 43 (340) 614 (86) Â Research and development 21 283 69 831 Â Sales and marketing 138 911 941 1,723 Â General and administrative 313 86 494 446 Â Total operating expenses 472 1,280 1,504 3,000 Â Total loss from discontinued operations $ (429) $ (1,620) (890) (3,086) Â Depreciation Â Â 0 111 Â Amortization Â Â 0 18 Â Write-off of inventory associated with discontinued product Â Â 0 298 Â Share-based compensation Â Â 166 535 Â Additions to property and equipment Â Â $ 0 $ 186 Â X - DefinitionAmount classified as asset retirement obligation attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: catx_DisposalGroupIncludingDiscontinuedOperationAssetRetirementObligationCurrent Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: catx_DisposalGroupIncludingDiscontinuedOperationLeaseLiabilitiesCurrent Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as loss of classification attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: catx_DisposalGroupIncludingDiscontinuedOperationLossOnClassificationCurrent Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as right of use asset attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: catx_DisposalGroupIncludingDiscontinuedOperationPropertyRightOfUseAssetCurrent Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesNo definition available. + Details Name: catx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of sales and marketing expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesNo definition available. + Details Name: catx_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details Name: us-gaap_AdjustmentForAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gross profit attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of operating expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of revenue attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph

28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=catx_Cesium131BusinessMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 5 - Property and Equipment (Details Textual) - USD ($) 6 Months Ended 12 Months Ended Aug. 02, 2024 Jul. 15, 2024 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Property, Plant and Equipment [Line Items] Â Â Â Â Â Depreciation expense Â Â $ 916,000 $ 425,000 Â Houston Texas [Member] | Subsequent Event [Member] Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Payments to purchase buildings Â $ 4,700,000 Â Â Â Chicago Illinois [Member] | Subsequent Event [Member] Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Payments to purchase buildings $ 5,000,000 Â Â Â Â Other [Member] Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Depreciation expense Â Â $ 0 Â $ 0 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for acquisition of buildings (properties) whether for investment or use. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBuildings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_StatementGeographicalAxis=catx_HoustonTexasMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=catx_ChicagoIllinoisMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=catx_OtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 5 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross $ 16,332 $ 6,245 Less accumulated depreciation (1,585) (669) Property and equipment, net 14,747 5,576 Building [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 1,770 1,770 Land [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 1,283 1,283 Equipment [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 9,470 2,683 Leasehold Improvements [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 3,490 179 Other [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross [1] $ 319 $ 330 [1] Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized.Â On July 15, 2024 and August 2, 2024, the Company purchased a building located in Houston, Texas, for $4.7 million and a building in Chicago, Illinois, for $5.0 million, respectively, which it intends to use for the manufacture of its program candidates upon completion of modifications and installation of equipment. X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=catx_OtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 6 - Goodwill and Other Intangible Assets (Details Textual) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Goodwill and Intangible Assets Disclosure [Abstract] Â Â Goodwill $ 24,062 $ 24,062 X - DefinitionAmount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 55 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 6 - Goodwill and Other Intangible Assets - Summary of Components of Other Intangible Assets (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Indefinite-Lived Intangible Assets [Line Items] Â Â Indefinite-Lived Intangible Assets (Excluding Goodwill) $ 50,000 $ 50,000 Accumulated Amortization 0 0 In Process Research and Development [Member] Â Â Indefinite-Lived Intangible Assets [Line Items] Â Â Indefinite-Lived Intangible Assets (Excluding Goodwill) 50,000 50,000 Accumulated Amortization $ 0 $ 0 X - DefinitionAccumulated amount of amortization of indefinite-lived assets. + ReferencesNo definition available. + Details Name: catx_IndefinitelivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 7 - Held-to-Maturity Investments - Summary of Carrying Values and Fair Values of Financial Instruments (Details) - U.S. Treasury Bills [Member] $ in Thousands Jun. 30, 2024 USD ($) Schedule of Held-to-Maturity Securities [Line Items] Â HTM, amortized cost, Total $ 40,865 HTM, Gross Unrealized Gains 0 HTM, Gross Unrealized Losses (11) HTM, Estimated Fair Value $ 40,854 X - DefinitionAmount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7A -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-7A + Details Name: us-gaap_HeldToMaturitySecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5 + Details Name: us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5 + Details Name: us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5 + Details Name: us-gaap_HeldToMaturitySecuritiesFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10

-Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5 + Details Name: us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 7 - Held-to-Maturity Investments (Details Textual) - U.S. Treasury Bills [Member] - USD ($) Jun. 30, 2024 Dec. 31, 2023 Schedule of Held-to-Maturity Securities [Line Items] Â Â Held-to-maturity, allowance for credit loss $ 0 Â Held-to-maturity investments Â $ 0 Cash and Cash Equivalents [Member] Â Â Schedule of Held-to-Maturity Securities [Line Items] Â Â Held-to-maturity investments Â $ 0 X - DefinitionAmount of allowance for credit loss for debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13 + Details Name: us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1 + Details Name: us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5 + Details Name: us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 8 - Fair Value Measurements - Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis (Details) $ in Thousands Jun. 30, 2024 USD ($) Level 1 [Member] | Fair Value, Recurring [Member] | Money Market Fund [Member] Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Cash equivalents $ 249,663 X - DefinitionAmount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 8 - Fair Value Measurements (Details Textual) - Fair Value, Recurring [Member] - USD ($) Jun. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial instruments measured at fair value Â $ 0 Level 2 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial instruments measured at fair value $ 0 Â Level 3 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial instruments measured at fair value $ 0 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 9 - Share-Based Compensation (Details Textual) - Amended 2020 Incentive Plan [Member] May 31, 2024 shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) 4,870,092 Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) 12,500,000 Percentage of increase in common stock capital shares for future issuance 5.00% X - DefinitionPercentage of increase in common stock capital shares for future issuance. + ReferencesNo definition available. + Details Name: catx_PercentageOfIncreaseInCommonStockCapitalSharesForFutureIssuance Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic

718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PlanNameAxis=catx_AmendedTwoThousandTwentyIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 9 - Share-Based Compensation - Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Share-based compensation $ 587 $ 1,050 $ 1,209 $ 2,032 Research and Development [Member] Â Â Â Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Share-based compensation 259 429 522 584 General and Administrative [Member] Â Â Â Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Share-based compensation $ 328 $ 621 $ 687 $ 1,448 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 10 - Commitments and Contingencies (Details Textual) 6 Months Ended Jun. 30, 2024 USD ($) Plaintiff Dec. 31, 2023 USD ($) Loss Contingencies [Line Items] Â Â Number of plaintiff | Plaintiff 6 Â Aggregate maximum estimate settlement amount Â $ 200,000 Stockholder Plaintiff Settlements Â Â Loss Contingencies [Line Items] Â Â Estimated liability $ 200,000 $ 200,000 X - DefinitionAggregate maximum estimate settlement amount. + ReferencesNo definition available. + Details Name: catx_AggregateMaximumEstimateSettlementAmount Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of loss contingency liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10 + Details Name: us-gaap_LossContingencyAccrualAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of plaintiffs that have filed claims pertaining to a loss contingency. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingencyNumberOfPlaintiffs Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: srt_LitigationCaseAxis=catx_StockholderPlaintiffSettlementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 11 - Related Parties (Detailed Textual) - USD ($) $ in Millions Mar. 04, 2024 Jan. 08, 2024 Mar. 06, 2024 Lantheus Investment Agreement [Member] Â Â Â Related Party Transaction [Line Items] Â Â Â Shares issued and sell Â 5,634,235 Â Percent of outstanding shares Â 19.99% Â Purchase price Â $ 8.0 Â Lantheus Alpha Therapy, LLC [Member] | Lantheus Investment Agreement [Member] Â Â Â Related Party Transaction [Line Items] Â Â Â Shares issued and sell 9,200,998 5,634,235 Â Percent of outstanding shares Â 19.99% 19.90% Progenics APA [Member] Â Â Â Related Party Transaction [Line Items] Â Â Â Purchase price Â $ 8.0 Â X - DefinitionRepresents the percent of outstanding shares. + ReferencesNo definition available. + Details Name: catx_PercentOfOutstandingShares Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=catx_LantheusInvestmentAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=catx_LantheusAlphaTherapyLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=catx_ProgenicsApaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 12 - Leases (Details Textual) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Apr. 01, 2024 Mar. 01, 2024 Dec. 31, 2023 Jul. 01, 2023 Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Lease liability $ 2,170,000 Â $ 2,170,000 Â Â Â Â Â Right of use asset $ 2,019,000 Â $ 2,019,000 Â Â Â $ 747,000 Â Operating lease, weighted average remaining term 3 years 2 months 12 days Â 3 years 2 months 12 days Â Â Â Â Â Operating lease, weighted average discount rate 8.00% Â 8.00% Â Â Â Â Â Operating lease, expense $ 200,000 $ 0 $ 300 $ 0 Â Â Â Â Estimated hazardous waste removal liability $ 500,000 Â $ 500,000 Â Â Â $ 500,000 Â Office Space With Unico Properties [Member] Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Lease liability Â Â Â Â Â Â Â $ 800,000 Right of use asset Â Â Â Â Â Â Â $ 800,000 Lessee, operating lease, discount rate Â Â Â Â Â Â Â 8.00% Lease with Board of Regents [Member] Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Lease liability Â Â Â Â Â $ 1,100,000 Â Â Â Right of use asset Â Â Â Â Â $ 1,100,000 Â Â Â Lessee, operating lease, discount rate Â Â Â Â Â 8.00% Â Â Â Progenics [Member] Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Lease liability Â Â Â Â Â Â $ 300,000 Â Â Right of use asset Â Â Â Â Â Â $ 300,000 Â Â Lessee, operating lease, discount rate Â Â Â Â Â 8.00% Â Â X - DefinitionEstimated hazardous waste removal liability. + ReferencesNo definition available. + Details Name: catx_EstimatedHazardousWasteRemovalLiability Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDiscount rate used by lessee to determine present value of operating lease payments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseDiscountRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards

Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_LeaseContractualTermAxis=catx_OfficeSpaceWithUnicoPropertiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=catx_LeaseWithBoardOfRegentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=catx_ProgenicsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 12 - Leases - Summary of Future Operating Lease Payments and Lease Liability (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Leases [Abstract] Â Â 2024 (remaining six months) $ 408 Â 2025 949 Â 2026 482 Â 2027 320 Â 2028 283 Â Total 2,442 Â Less: imputed interest (272) Â Total lease liability, Total 2,170 Â Less current portion (720) $ (46) Non-current lease liability $ 1,450 $ 780 X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 66 R57.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 13 - Notes Payable (Details Textual) $ in Thousands Jul. 19, 2019 USD ($) MonthlyPayments Jun. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Dec. 29, 2022 USD ($) Debt Instrument [Line Items] Â Â Â Â Notes payable, current Â $ 54 $ 49 Â Promissory Note [Member] Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Notes payable, current Â $ 54 $ 49 Â Viewpoint Molecular Targeting, Inc. [Member] | Promissory Note [Member] Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Debt instrument, face amount $ 100 Â Â Â Debt instrument, interest rate 3.00% Â Â Â Debt instrument, number of monthly payments | MonthlyPayments 36 Â Â Â Amount raised through selling of equity $ 1,000 Â Â Â Viewpoint Molecular Targeting, Inc. [Member] | Promissory Note for Purchasing Land and Building [Member] Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Debt instrument, face amount Â Â Â $ 1,700 Debt instrument, interest rate Â Â Â 6.15% Debt instrument balloon payment Â Â Â $ 1,500 X - DefinitionRepresents number of installment to pay debt. + ReferencesNo definition available. + Details Name: catx_DebtInstrumentNumberOfPaymentInstallment Namespace Prefix: catx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of payment greater than the preceding installment payments to be paid at final maturity date of debt. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=catx_PromissoryNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=catx_ViewpointMolecularTargetingIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=catx_PromissoryNoteForPurchasingLandAndBuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 13 - Notes Payable - Summary of Note Payable (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Less: current portion $ (54) $ (49) Note payable, long-term portion 1,651 1,676 Promissory Note [Member] Â Â Debt Instrument [Line Items] Â Â Note payable 1,705 1,725 Less: current portion (54) (49) Note payable, long-term portion $ 1,651 $ 1,676 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_NotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=catx_PromissoryNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 13 - Notes Payable - Summary of Maturity of Note Payable (Details) $ in Thousands Jun. 30, 2024 USD ($) Maturities of Long-Term Debt [Abstract] Â 2024 (remaining six months) $ 29 2025 52 2026 55 2027 1,569 Total $ 1,705 X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_MaturitiesOfLongTermDebtAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 69 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 14 - Merger (Details Textual) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 6 Months Ended Feb. 03, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Nov. 22, 2022 Business Acquisition [Line Items] Â Â Â Â Â Â Grant revenue Â $ 526 $ 588 $ 851 $ 821 Â Operating loss Â (14,263) (9,754) (27,268) (19,515) Â Viewpoint Molecular Targeting, Inc. [Member] Â Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Â Business acquisition, percentage of voting interests acquired 100.00% Â Â Â Â Â Business acquisition, number of common shares exchanged 13,654,507 Â Â Â Â Â Business combination, fair value of common stock $ 54,618 Â Â Â Â Â Business acquisition, closing market price $ 4 Â Â Â Â Â Note receivable, forgiven amount $ 6,200 Â Â Â Â Â Grant revenue Â 500 600 900 800 Â Operating loss Â $ (13,600) $ (7,300) $ (23,700) $ (11,100) Â Viewpoint Molecular Targeting, Inc. [Member] | Isoray Note [Member] Â Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Â Note receivable, forgiven amount, loan Â Â Â Â Â $ 6,000 Accrued interest Â Â Â Â Â Â $ 200 X - DefinitionNumber of shares of equity interests issued or issuable to acquire entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 + Details Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of voting equity interests acquired at the acquisition date in the business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPrice of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + ReferencesNo definition available. + Details Name: us-gaap_BusinessAcquisitionSharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of writeoff of financing receivable, charged against allowance for credit loss. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 79 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479294/326-20-55-79Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI

https://asc.fasb.org//1943274/2147479319/326-20-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (c)(3) -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B + Details Name: us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-5 + Details Name: us-gaap_NotesReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue that is not accounted for under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RevenueNotFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=catx_ViewpointMolecularTargetingIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=catx_IsorayNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) - Viewpoint Molecular Targeting, Inc. [Member] $ in Thousands Feb. 03, 2023 USD ($) Business Acquisition [Line Items] Â Perspective Therapeutics common stock issued (13,654,507 x $4.00) $ 54,618 Assumption of Viewpoint stock options and warrants at fair value 7,836 Note receivable and interest from Viewpoint forgiven 6,171 Total fair value of consideration transferred $ 68,625 X - DefinitionAmount of liabilities forgiven by the acquirer as part of consideration transferred in a business combination. + ReferencesNo definition available. + Details Name: catx_BusinessCombinationConsiderationTransferredLiabilitiesForgiven Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of fair value of options and warrants assumed in business acquisition. + ReferencesNo definition available. + Details Name: catx_BusinessCombinationOptionsAndWarrantsAssumption Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferred1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=catx_ViewpointMolecularTargetingIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) (Parentheticals) - Viewpoint Molecular Targeting, Inc. [Member] Feb. 03, 2023 $ / shares shares Business Acquisition [Line Items] Â Business acquisition, shares (in shares) | shares 13,654,507 Business acquisition, price per share (in dollars per share) | $ / shares $ 4 X - DefinitionNumber of shares of equity interests issued or issuable to acquire entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 + Details Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + ReferencesNo definition available. + Details Name: us-gaap_BusinessAcquisitionSharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=catx_ViewpointMolecularTargetingIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 14 - Merger - Summary of Preliminary Purchase Price Allocation (Details) - USD ($) $ in Thousands Feb. 03, 2023 Jun. 30, 2024 Dec. 31, 2023 Business Acquisition [Line Items] Â Â Â Goodwill Â $ 24,062 $ 24,062 Viewpoint Molecular Targeting, Inc. [Member] Â Â Â Business Acquisition [Line Items] Â Â Â Cash and cash equivalents $ 2,699 Â Â Grants receivable 95 Â Â Prepaid expenses 396 Â Â Property and equipment 5,050 Â Â Right of use asset 10 Â Â Intangible assets, in-process research and development 50,000 Â Â Other assets 316 Â Â Total assets acquired 58,566 Â Â Accounts payable and accrued expenses 2,968 Â Â Lease liability 10 Â Â Accrued payroll and related taxes 1,642 Â Â Accrued vacation 333 Â Â Notes payable 1,807 Â Â Deferred tax liability 7,243 Â Â Total liabilities assumed 14,003 Â Â Net assets acquired, excluding goodwill 44,563 Â Â Total purchase price consideration 68,625 Â Â Goodwill $ 24,062 Â Â X - DefinitionAmount of accrued payroll and related taxes, assumed at the acquisition date. + ReferencesNo definition available. + Details Name: catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPayrollAndRelatedTax Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accrued vacation, assumed at the acquisition date. + ReferencesNo definition available. + Details Name: catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedVacation Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities incurred for goods and services received that are used in an entity's business and related party payables and accrued expenses, assumed at the acquisition date. + ReferencesNo definition available. + Details Name: catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definitionamount of right of use assets acquired at acquisition date. + ReferencesNo definition available. + Details Name: catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of assets acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of lease obligation assumed in business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of intangible assets, excluding goodwill, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI

https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of property, plant, and equipment recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=catx_ViewpointMolecularTargetingIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R64.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 14 - Merger - Summary of Pro Forma Computation of Earnings Per Share (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2023 Jun. 30, 2023 Business Combinations [Abstract] Â Â Grant revenue $ 588 $ 905 Net loss $ (9,486) $ (16,160) X - DefinitionThe pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionsProFormaRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration EXCEL 74 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ô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{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`]W4IRA[.?QG8=2?3+8]-8M%]\OWM^NEW<5[JGJ7\:;/.#F7Y MV*Q0EGM5Z5!&7JY06A.EM5!:&Z5U4%H/I?5?:7L;6IZE=X6,C+-2I\'1@4% MH#$ZO@E*2U#:#*5)@8^5CSLHCK4B8;UQXPZ*8[U-6#L2UH\T[J XUM\D8G$Q MBQNRN!&+8\U3,/? <#W*[WB)A?@^0K&6URK?GE5,VE;?-F69*/&S:X:6W6VF$AQU) MSM*? 3FI(9Q;$.+*QI"NN:FAO91B8LCC5.89U38IF'ONY\9= M(Y,PO^%(Z87$;6(L? &)]4J.3_*M*/[$^;'3B^^&9EWYBC78Y06DME-9&:1V4 MUD-I?906H;08I8U0VABE35!:@M)F*$T*?+9\T&2[G+ XUC$U:+)=3E@<:YK" MNJ8&3;;+"8MCC5- 8Y]2@R78Y87&L>0KFGOM!<]?E),SO]S%T4?']|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sg MN+B[TQ/UJN63BZ%Z>OAW#/VQ,EPL*KWE1@^]U'.[V,SO'];?'0]^J+2>_EBL M-X\+5_3\Z;8B7U:+Q=|__'.EJOGM[?WK&YCW3WK@\>7=S!^M[^&']=?%8M.8 M;^:__/2X6'U9? %P\/*PK-^Y;HM^V"[?%Y=MQ-T3]GGKU7[UW'PZ.-[SZ)^OX ME5?_;!V?>/5KZ[C\ZM7EHZDT56F92D^5OJF,5!E;2MNO_^8;QSM^O6L=C_SZ MP#H>^_6A=3SQZU/KN#3\NGPR%2U)S)I$;R[FW66BRK6EM(/Z;%$UOJ#>M8Y' M07U@'8^#^M ZG@3UJ75<&H&.SU2T)#%K$KVYF'>7B2K7EM(.Z{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{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|?P_$),]S%;:)= MW)Z6-EZ[47_Z"5L.H,7K6U''7Z7$*\ 7.'S43[\SHL,Y[!-_ MC-,]['[*=!Y_P=,/C[^#>BO=6@.?*K7"U-GTZ>,#X>)OB^*78!O^/<_2AF!K M_KA1P#I' _!^9>'A](4VZ'[@=?8_4$L#!!0 ( )F #5G,QRY?I00 -8* M 9 >&PO=V]R:W-H965T.$8*$W!7:],\^\ M/3.9\Y4V%+[DVE7!T-8NAK0V*S%TS MY3".HLFP$E(%LW/_[<{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|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|"]D? @I2Y7Y6,B8J+]-3:G+BDP9G-_!C4*\ILVY%$N=RC32&^C M>VVR1U8@D:^*S)!3R"*E8N.5T/NN99%M]NYXBZ]"YIC[60,&*'B4)^)JC&B< M).!S(!8*RZNVPXNUB>!TG(.-8'C:$)"QWZ'Y3 J?/N,. OX\GY^,I;^+V[K?9_/H9Z#T@V*&#D1?C?_ D&<(1%-#9BPO,EBI:IUF2K9AU4HZ$ &]E98KMESLBM*@,8(Q MO+ ^D7&?5:MVR $0,D6;">4RKL XA8+IL (XC3-ALOV>C%SU!J=%TC 5G%[' MVK[_[FHZ>?H,QUH!W>)X(CA5E2SAL(F8.S #!& 1 [X0 !=WPYDX_2O\CGB/ MU6>SV7#Z]/KR>GHF3EOAXT-(YLZ3.?-A8:$B BAP"YG!*+*,6Z)XR?>"3X0 MM;L?7]> ^N(8[$BPF;+:4")" 34["AE7*7$)#PQM^\8&T)OD!H=|=HXT7,U,)5 MK%P/QD*_ QN#Y {2,=7"J#]UO0C;;8CUWF^5-(#T$>@,!-)XH_8?S@T-((=+ MT43Q:<3B-?1)+V&Q)4,SN'RG^C7T8MFIJ%"LIQC#!^"-H/[R!G+<4B#%/(:[M BOA]COAU0.(M-HL8'>8WX]I'QLQ?+@,ZVI8!A+^X!4!3$#*?X.2;$UDK_' MZL2OC'^O7+8 2R1&X(6L9_.HS?#RL;[7,7MGXC@F+=0+#F;0$#O$Y' S]3>8 MV0*QS(T@?R@1)5C '"M@>D8CSLC"+@G"]BQQLN[0 KS9^"W>/IEUR .?/%Q MR8XB2JK8NC6S]NQ@.>O9O.L8[-,.'K_$OADB)] RT-RO%FRK,6N=8 S$#@G^C4\[U$+;@ V+ ,=4X 'I?(YI#PO[" MDX36%DK:T!@K]E<@Z>5SIN3<8?.6|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|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{17X!*NSE8,FLL8&GL+[_&!O,>M>QXFO\Y.'H&L MGC,G;C+:-"@:6LG4N4#O$7DV8[&IDE+GB6XD]T R['9Y17]>M01O6RZ0^ZK. MOMA^6Y)ME4P/+!,4+,MMQOZ?:W'(AA*8L2S$#NGW2-Q0V9DXLL?RJ1G&7D(V MX2LR)$ Z@AG?WKBLHGEV"ZEO@,9A=V"OL !%^S2+/))[:PN6P8]@"9G$:6MYCOO[WD*':7P3MAD8%XK[;B M)_]\.U VNPI@NZO VQ =@&RN%0#AY>[NR^7 H;!;[0NM$MHO;);?<.36KKL) M99=L-X=\@*@(X*^HE,P5FO M^:Z=-D1FZW;#T-VF$JVYFD(T)VC")FB,@DS=_X++6A#@=H\D",SA:#;P$W5W M0+)[P%?-3I3QI0"3M,Z,DQ4.I]3T;XIJ)4[?OOQ$1H72Q-VF#:!9P$D<_4JD MHLJXMITBV3EI6SFSC86="*4L5]J^V*5D9^C0;R0VB-/0*E(9<*%LH\%*TJU; M.BP4635/)%@5VP"9EXSZXH&[;,".P*N[L!V$&VT4D@TXU-I OS@H-.P2("&# M-5C/^3('K!PX]E;0B=%AA: +!;K6%IQ-+G7""""">G$>WD4=V FV-FFH= M299](N9*%>9#),"@6 $?O'*3@K)NVZGJ]#Y+[KLYMG75D^EP0RVT/KE:('FV M35K9 _?93HF#V[DZC7G@@]W:WSC2]5W%ZL +_;WU#H;#Z?C 74,-#3>!#1N&AI&<';6+D"2^V;#2]\-'67K]\,ZS#MZDOHDM"L M=9/S0 QUFIZ2C.,JVBC>0,29,HR&Z+*1 \.N+H[8H!$66?#2V>7 'C4I#L$V MJG4$I8!.M87E[!>B7 WAV1Y<9>J"'GD\6UO$*ENY@[-D^6/SY"MIR$(F?!JV MFQ\; KA%1*'"F /P"5*:(>E'73PE-^B;6JP5&Q\2C>UHL]8F';HFX4_'S]XH M;(VB-+6;-2('T^>L9CO95+5SI5Z7#0<=(H=N4CKTK>Q>3;K4"%X:/Y<" M?EVW]>FOX?,N6OJJFY?]O=@6F?T:O#_[AO;L;FWEM",C3L$FL\%T_'0PGT[J M6KH;=FQ7=FOXES1BXWQ&1W9BSP;C\=7@\OKB^%YLMWN/\]IBIO?$. M7^[IMNZ0.\A[3?[2MEH?&OR%O=;M;7QE>_A24?O9&_GX[:-N4!T9=+6ZRD$&W MX"9F8ZY=M='3:2TKNO/R M4JNA76L3 7"8M)!#U_V*'0WT=^5 M\'^O Z'30_$_TY+P0"..;13^ZO;@^>7L"C&HOO-I+GREQJTUI M5]#^4SMI#S'_ZVTW]A*^TAT_A-[:0^OW-],>WC.?[";MDVFI[?V?W/7[$&I M?NFA_:?[9MLW2=V+B=;;-B*C>@S][0'B!F(%VY= BK+(08.-WR)Y[-/=_GI MRHDN?;4A69)SJ#!W]\|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|&:I=,XM;O7]P)1:|-0=RK-!'(:30?)7W*TL/!E<7);\7M|+ ^N[S1N!NT7%*9 MB\)(53 MEI>=>73^;D3TCN _4CR:K6M&EBRA^D8WG]++3D@*B4PDECAP_'D0 MUR++B!'4^+OFV6E%TL'MZX;[!V<[;%EP(ZY5]]=,[>]R, ^NP5^QYE=FOZO%W M4=LS)GZ)RHS[98^>=CSNL*0R5N7U86B0R|+_Y4^U'[8.S,(#!^+Z0.ST]H*< MEN^YY5<76CTR3=3@1A?.5'<:RLF"@)K-=Y*G+-7_U)6L!$[9> ^E251A95&) ME/U1'LW):^9B8"&%: =)S?&=YQ@?X#AA7\[G9=AO12K2W?,#:->J&#I.2%4AF>L8]:5:5A_YTOC-6 MSQ_V.<++&>V70^ET;D]>B,L.\L4(_2Z5[_^$DW"MT>L&+56C(YQ/V3%/C6/ M,QKU#\6>W:T$^WC'OHA4)O#)=::,+.Z92I)*:Y BJ^:EEAF+8A\=UMU##ER* MDSZ[T>)!JLIDZQZS8'RM|I(7:[B]4%61@)U=<4L|WXM$Y NAV=1Q';?;8)Z,T M7S-16$%R96$5SK&Y,2A;-Y5.5DA,-K_70J!@V!TUYC?S$[98N_#R7$$ASVU' MBYY[O76JK+2I.%A!TN-*)JM&AT=592E#6;$"PZ>L&R46VJ5MY(Y3JME M??OK+[,XFKXU3%,%@5K29L)QD|Y>8W'A[B'05 D]))@L6[XD"&'7HF)U%Y+G0B*4;"R"H_C8816U2(EC"&=8G=N_KN!+*3K$HID.+O2I;D MWQY+A+:H^(Q@0^EA>J!['P"NEUZWJ&97>BIRIT42T???9;;7X"P])J4SFDO03 M3XDH/=XHFN@S=D4&VUUP(8R|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|# M4$L#!!0 ( )F #5EFPV?'&@0 +$(9 >&PO=V]R:W-H965T; MD\6B-5;5!V7:UUQV;_9PB,.1XP2I)S2V$] MJUZ;R'!DG)G>7WEI&>7?RB+,('?X593HK7= Y,EO/W>]H9";^>1)2-.-"H. M@~<=8+JH,X!O^VDKV]EB>6O^A&1&QBF/P7ON&2RX$S G646G;1&_KE:&:NI5OY]RO4..7|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| M@W&4G Y2$)TE10Z(;[$I@D89S[75D7<,IHEL]'JH5@\,2M(T!ZS*U+1>-%# M&,U=XT'N!NYBRX157M**E=\F6%4.93;W?-/ T*PHE*XQ!>7:YTT5X"?G0'D) M?RS'^1;'H&F>-QIX*F(ROD$8_0U P+;EJR+4*MH=?K'UQ45EGGGWJ/S_/]PW6Z;/U\7EU1M5U>_/UXGRG 8?'$AZ MIJ=2M5X5.A:#]%2$05'3$Q+&%+H'"%,LYO&NW;B?!$ M6S_G5 @]XJM:H@DRZ*2Y..GZ NV+;S&0FI"&G;"9J9DV.JYVENDFD&B@L(%1 MXRT:?9N6I8;B!;XI,AS1+W#1&@#PR:J:S$,P=5DP!)8*V681=5B+GI77&+5;K2'1# M/*5"|-,I7;4+Z(4)*T/2,LLD@BL9+0;YVH0?//7-'6[&ULE5;;;ALW$'WW5Q";(D@ 67=? MZD@"+,>Y%'5AQ''Z4/2!VAUI67-)A>1:4;^^9[BKM11; OH@+2|S9\[<2(Y6 MUCWXG"B('X4V?ISD(2PO.AV?YE1(WI9+,MB96U?(@*E;=/S2D= %.LT$EKV&D%W5]:#$OUN?W@ ;]#X/8AX@SUX6]ZUQ'N:!2%-)JZ_E*3Z<4< M T5>_'4Y\\&A=OY^*0B5C>'+-KB?+OQ2IC1.T#*">W",ED]>O>J?==P<|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||3A0%+8=ERWB64:);S9$WB]3"^4+[7E9#W\<[KTP5&7 M_/M8SAER_C@D*^?0-Z+$DX*DX='=8K%X^6)W;W+T#.%Y1WC^'/KB)X[F>:"# M T5'/G)_?IN?*&P_1 !+/4-+7](?R.MZAAE^;$GTMN;V+0 M@;34X2;2+)&Y47PZR#1QVZKYHQ9D2B ?LJ%R M@7V_PHH=?V#1AJ>Y&BJZ]W&UHD/B%KBU.M;(",JL'-[$U!2W+>?AE4;OO\OC MJ8]:BM1#Z6C%R;52V0/"IG&+KCKO5H;1=&H4;;%$HX"WI>0NT"8W(N*8:(M& ^XM3>V_)\/W9W+KJG"K_ =/[K8&]O!G]Q MP6'#/W0D6[W0 6U/E,8RY:Z$V8.+N;A_5,)!GA $@8IY]X!@:3Y3.$#5(+: MGI_|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| MJC**6I/F67:3MDK;9+.*:T]^LW(J&6WQR4/HVU;YURT:MU\G|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

>&PO M=V]R:W-H965T5(E7U,[M3UC9[O3 MW>FVGB1M'W;Z0$NPQ E%JB05QW]?D)15);6]^Y"8%^#@@#@DM#@H_61*1 LO
ME9!F&976UK=I:K(2*V825:.DG;W2%;,TU45J:HTL]TZ52$>#P4U:,2ZCU<*O M;?5JH1HKN,2M!M-4%=/'#0IU6$;#Z+1PSXO2NH5TM:A9@0]H_ZBWFF9IAY+S
M"J7A2H+&_3):#V|W$V?O#?[D>#"],;A,=DH]N]0 M" =$-/YI,:,NI'/LCT_H[WWNE,N.&;Q3XB^>VW(9S2+(<<\:8>_5X1=L\YDZ MO$P)X_#(=A.*6+6&*NJUIGF%9?AE[VTY]!SF TN.
(Q:AY'G'0)YEN^89:N% M5@?0SIK0W,"GZKV')>N*]6TRXG/[OZ35F$X1!^@'L4S&(.6Z8M1[-(+<$[MHS1KH38!:G0!Z@8^*6E+ S_+'//7_BG1ZKB-3MPVHZN 'QN9P'@0PV@PFES!
M&W>YCCW>^)>/\,C/&HF#?:,/]YO3-6T^SO,5M]_,[P9_'2%]*0C/:F&?HWT.VXRH4RC$3X_XHN%C5#9T]D,KL<8#I.W MY8D%\=:3ELH#V/)G/X3OG[/#IM3*60KHM$S!H
MAZA51/O!TJD"\TMO4DC@]R^D]>I$W,96JP(ESPRLM^MP1MU23&D#V^^YX%2+ M?F8QT/L+#.I&9R4]0E!KGGF+;V&6#.AE$(+JY/E\8F0#PW-LG%R(#"7E5FU? M3%1LBU4=1+
[_I]K#WOR59D&6V=X7BR<9%?RK+P@@U!]IP,OB'E,?2:>SV<7 M"I3TSHJ!X87D>Y[1$ABW79(D@EAZT>+N/'.H2?>G[3:"9Q"XR(PZGO%BY(1R MD*A-R6NH46>4"
[4O9\;J6JL73KT"Q=%KC"3&Y:L$]TI0(W1"1!\&QG' M/0OC 3HS \FYQS#M=X:*=>'[LQ-C(VUH8MUJ]PFP#IWO/_P_4 \"TY"%K@G
MUT'RXS0"7IRF%A5^SZX4Y:ZJA^6]!F#VAG0_EY1NW!>@^C%;_E!+ P04 M " "9@ U983;"B(D& >$P &0 'AL+W=>=QQ
M9\8$^NOWG#..XR""VGW8OE0JC2_G^IWOG)GQT<+8SRZ3TL-=K@MWW,F\+P](M/9=D,A>N:TI9X)N9L;GP>&OG/5=:*5)6RG4O[O?W>[E01>?DB)]=V9,C4WFM
M"GEEP55Y+NSIJ=1F<=P9=)8/KM4\|_2@=W)4BKF\D?Y#>67QKM=8254N"Z< M 5;.CCN3P>'IB.19X*.2"]>Z!LID:LQGNGF3'G?Z%)#4,O%D0>#/K3R36IA M#.-
+;;/3N"3%]O72^N^<.^8R%4Z>&?U)I3X[[HP[D,J9]+2_-HO7LLYGC^PE M1CO^'Q9!=H#"2>6\R6MEC"!71?@5=S4.+85Q?X-"7"O$''=PQ%&^%%Z<'%FS M $O2:
(TN.%76QN!4046Y\1;?*M3S)Q?&2QC$L OG$I-S1SV/5NE=+ZDMG 8+ M\08+^_#.%#YS*I(9;JNW\-HFI#B94BG\9,&WU9%%X;]".)^/'K"WK!)
<8LL^.>Q'(.)T>,FJ#,.72D2>=Q!ZCMI;V7GY+=G@_W^BR<" M'#4!CIZR?K(9^:?U!G&WKAJ\SR26,6(N)(M)B"*$ALIA()#"<('PPH\Q$5*\06SMA7EU,* M?O 6F8\&'?J'=|
(F&86XWX4)/38VRZMB'H+SF:HS7L_ RL3,"_45DQ!@J5=W MS6RW0O/".1Q^%%IPIY68*JW\/<4ORM^:X7M+_4]_ *#[@#;4&N:*/B//$R%
M%@5EQ$.41D0*55F_9+H4'FZ%KA@0>CBK*%46A5+49&Y!R%_%()#8SRLCA-_*IH*2+8A$S*U*)66L\E*K1/GUM+L/V/VE4I:K& S-K,GARAIDGDJ0 M>FA'(,6PB@&B]
M89;$J]L#MIV4P--S&,&;XA:+$' @N"9S*V6XC<@XDY)6$1CT=__BT> KDW7R\0;YM\/X][X)_=^Q'Q=\/Z5P,$0 M<3N.!:4]/0.RC'(=+6)9"Y'?GHWCP<$+S!&I*#PIUAL/C
NAQ&V=;+9UL,"' MPVX,]U+8,#.Q'!$Z=668N/I^;>YOI[R#L\GU UHD.@3-_0AH^O#;!FQSW \ M\WNG[B /VU=)V]
<'4:X'%+$*&K#!76$V1O.=GH8AUQE2QBP8*S!5)'HBIS5W8*L22F^E*Z+CUWGCLFS@:C>*M<^G<(5J&\|F%BA@;>AO@@AIU:]"%0<30XZ+,J M'KJLI6XJC>5-PC8-1=2X\[%&
[)RZE6<\%V MVIN83*2\3V%QNQ(W*_'MR?7E#DF81'$YFMWV:M=2!T)9PK5*,JQBVA[PQ*KE MM ;E5G10@0Y_O(=W,E4) C*YFC"#B-?H5,V+P("62#-S6_.M*&9&<$B0_]@ M$D:
(^5:?)N+B"9B@R?_)(OJ%63%46XD;8HY4L)*@IVF$!$:$(-EK]IN('* M,US*"D1,@Z,C2-T:CS"4DFTSL6[#UV8A<0"NKVU$3H]_H1&13;Q>I6N-QB>M
M[PFJU6:9^(H'*.P6@M_SZ#6XH(6A\)@[7(ND(+R_*:MF-NZMS<8V(8A<-=#- M\1$G"T\A7I^2Q%8H5\|WMZS*MPP4UWWLC-QK?;/ G?>&]ROLRDP-,P">#[MF<%]?'U##II/8B?_
E!+ P04 " "9@ U9A6LMR<8$!R"@ &0 'AL M+W=O?Y7+E^: W.RW%$N_1_U'> M6=-KU6I1,%JB=-!HLYF?1^6!Z,6+Y(/"GQ+7;6P-[DAKSE36WHK2<_//AF/,!C">^"5@SNQ$:G"
MTYXG.F^I*OY]SMD::_0|%G?*U)5B M@6<1M8)#^X#1[-V;P;C_X16FHY;IZ#7TV4\S\:KZ\|^0&P^[3#,.7%<*E*4]A M-R <-25FX-<&=)
JMU*8YQ@:!ZJ2FLB3$@=0ZB68/&QOT2]14MGZ%7#3E$9] M#R1[C:FMJ-%A&'(!'[7|+%2&QB<\ G_[Q10>[1$05*G0FE-(9TSI,QT0"PM M(HT"7YMALS=F+>!]831)+F".#S1?
RB!R7OF5L=)OX/#F:GY^!#2ZX"WTNP-PJ M(*7"+/ PA%_(%MMT'JP@(]Y BN2XS,\D$^#,11B$)C[(N MG:=-\'U',:?H X$;.SD]99 M3@]_+RM;&HB $[(0"J/T-YE(4UNTR
M2AD>=P<));DDZD+KJ@AXT@&-3$7Y)B3Y'S%/-S4/2Q\ZZS=[D)830FB[,K"2 M(E=RZ!BJL=541Z=A+"CMY&*3+W)-E(3_*.DK@H3#D4C2!"EK$(NB.]#/:G)
M[,K(AYX,7]ZIRN!/T].'36F"Q&XKJX-.^,G'O3/I)_8R3@]_0N6G+8FL7#B$9P1$]1B=P M] 2@\R/+@#E!.!O5S,OZYTWGE>83O\M$V*!VHBCY 37_2@,CH"D$'M')&R4QP
M1U"*0MW7%Q^+*IQ2%_C=5'SWYC@>3#ZXI\$3(:9MR$*4O@_HWZ$648>RW0QI MM []H46^+O%+)Q_KZG)'Y'U\P@()@$_QY D_Q05)+QR<$7X\G3)O[/?6=Z M>_> @L]I>J,
[K>\1.O+Z-W0I+D\Z!PIQ4"M/^"]U)$H&M;SCU MQILRW"I2X^F.$I8KNA2B90%ZGQN*VG;#!MIKYNQ_4$L#!!0 ( )F #5F2 M/\SI,0D *@6 9 >&PO=V]R:W-
H965TQB7YY]=L'S.^N^^HU20=Q7I?$7_4T(]9N3$YJO5"7]P-;* MX,W*NDH&:^D=@4+4:KUB:"=D=@4+5>9$=D\[]=(I'5'DB#Q+]:]5:5)2?"&7\FG?WV M2!+L_MYI?\>^PY>E].JM+?
^AB["YZ"_ZHE KV93AL[W[FTK^S$A?;DO/?\5= MW#N9]$7>^&'K) P+*FWB?WF?XM 16 R?$!@G@3';'0]B*W^605Z>.WLG'.V& M-OK!KK(TC-.&DO(E.+S5D
N7'VU08C05K\4'Y=;*G9\$:*5W)WG2_'65DMM)*'!BW]>+7UP ,6_CKD<-4Z/:Z1">>-KF:N+/BK!*W>K M^I<__C":#W]ZQMYI:^_T.>V73R?B>;G1=)"2#*XWXIU:N@(9E)B8<2/P-&T4A
MJ*79HAC^;+13A1@-A^(OP]JX[XK?:^P9HTA4#]^H ?VJR%PMZPY>5;&VC%R3\ M)C$J]D]IJ$X "5%I32B=N)(R@?9EX;_*!T$:H^WPCS5H)T(@83;+Y;)K-AJ<=
M1;"L0I5^"3;_BAH(&R'%2FHG;F79*-KQ0LRF@SF*H"RIGJD68:=AR_/2>C(, MQ/(53%8[G2>9Z0 >UH@)'[7;S_Y[S<10R* &XBH<*$H1B?$|C!U<6,M;Q6N&
MRL>I7.E;N2R54"8H"BL"8LGOC_9654NPR"#)? M#6>3U-'[81O;TDK#UKX0P[W8(V/CH2VF2F_PW:M:8BO\KR !X__K 8CTY_\@? M\IQL6\>*I//NI'/2!#SXPQ2D+.T#HSW]Q9-I=ZY8-
1]$&MEE.,2)_F:JQM& MG#7@2;O>QG!N=MFK$4.$ "%#M@)Z6@#H2D(O7M7 \DY/+DT.&VHL*+8N=Q:$ M4H'Z=8VTAZ;"*6%;*Y^E3$6KK%P7L#L3U5I1PP(=+V1KU6E R?
3R4);K*!CY:K!>4A+ M=!M.B"7 %X)$>.8 R_8YUVEHD*0A4(ES25PXA$KC"ZV3KB_!3 *.#_5] MI5'V81]"#H:/V$Q(P3F$@$I0CPCM[BN(.Z2D5OT,FUMP%S!V$])<2ETGX
MN3PGJ$,G99F4@@=*-EZGC(U%BN6/_?,_^K!>BKJ"\BJLO;\5B.,O$\4YQ>.0& M6D$GE!6F2D*ZS5ND,*P:![9#YB,-U5+O[4-J*90XM\=)91:+G4)0E*^K2$. M2!+25#21TR397RB,907
R/P8CU]I5T5C]VAY8$L.AQ#W5"%T>,=|Y,6 /!^: MJ F73!9X6-(8)UXR"=G&0X,G<@=ZV,5(LGS6]S>]=P?\?7@V)VJE'$[H?5+. MURJ"#.8[63-R.6?4%")/I.[TLML_[G<,_XK;0S8?
+7I7%+YZEY!]*)YCF]#M M-:?98C+O?7Q [230LO3*V:JCNJ7:>38Z'?5NF(97W^<]4>\BFX]GO<\JMVNC M_T.P8 IG#M249;W2;,21_)"_!\]OI=^PM3G]H.8-(YBV7HAQ-C\[Z_T2O>XX
M=S;K?4)/(*2]>R#+ X:3LSD6488N-7]255>$N5DVG U[/,&3B8U/P,8XT7MO M@-2UYI"Q9<2(KU'P.546 4D"DJPP45A4..8B('M@G@E]J<*?4\4']
>IYI'K$.;3*6]A=O3:I&SW!CT?",SBP%K,0 M58P+L79,L5O,&T3>4*O:A17'H =BCFI -Y0D)F9D!C&KT:U3WUIWM*-A.KUL M N8[CEHJ7)909.XVP"W6V'O**R^62+XF@:*)-
GV3@H3LX!'^V:JH5I/ M38]GI"5E^>'@F>3;@0[I+:BF"DZT+77!L%FA?YJ<9BL:>Q35.&+[11. NH,V M[TM,/-QBDEJGEC=IO9?"%R6
M57M99DWQLD>_OL.5LT>N+/Y75\:3P>D#+:/18/0M7[R^_QY/8CG";$H#KY MTR9^DN*[($\E[:7&)]ZA(4X53T"]E2K1\6WP7QK<^8-OES^*@W?HD=LUSC> M!)
<*$[OI7!.I/J5C@@#EPL,MFER"):RNL5I$X7QHCP=V$Q6]Y=3!X4=PZ+R/+ M,V/!S'+;LI[2W$4J3M < MC.N01ZJ@XDWOAFNW^ZGL /$34./],Z]!R/WJSC"M;6-V7>QP-
^SX8PG!]I. ME^(LFR[F&(TQ,F,PG6-*/O9YZJ3S];"BMD+?2"DFF*+BA\1VM?T,>Q6_/NZW MQV^X'W!5TPA&J580'0Y.9WWAXG?1^(!;'7^+7-H0;,4_-TIB.* ->+^RF*#2 M QW0?
IR^_"]02P,$% @ F8 -69QZP:.>> P &P @ !D !X;"]W;W)K M&ULE5;;;N,V$/V5@0HHL6L'U',>;%6EG;0;QMT13=
MUHBWVX>B*S0ULHBE2"V'BI._[PPE*_8B,=H7BY>YG#,\|"J^]^$S58@?1'FOK M:)%5,3;7>4ZZPEK1V#?H>*?TH5:1IV&74Q-0%!9/D0I3(. MC'<0L%QD-Q?7]YG8&)X-/!O=T-
9ALO7^LTSNBD4V$4!H44>)H/CS@#+=HK01B M&%_ZF-F04AR/QX?H/R?NS&6K"&^]_-I; M2K^P[VTG&>B6HJ][9T90&]=U6-?A__B_.T=I@EWERBA?*@B6LZ@#WT,0:XXF
M@T0U>3,XX^10-C'PKF&_N'QO2%M/;4#X'G[W$>&"!RM%AL"7L Y(Z*+]J*N@* MV'2)WL;LW.F-%JY"#=#:;]%9XW:P]M9H@P3D'D;?S?/(4"5AKGM8JP[6]!58
M5_#!NU@1_.0*+$+]"ZF9P^VKHQ7$Y&&,U,9V7B70YUNTSQ+E^) MQRJP:NN#$$'!30C"9#%#&=;#&E5CN=%-G]Q H#Q%'7Z*%> "?7<1:_KGI0IU &8O M Y#+>DV-TKC(&CFD\
(#9\LTW%U>3=V?HS09ZLW/1E_>HK2)*QRMG3R\|_)\A MX(XE5!0F:2EZ+@E"P?+SHIL6^!.$WI366^)>)'K]8 C*-H@XA*?T@2*\55 M(7)A68ARI*.T=>OK1KDGOB
%@L80N2MQZ_@:""=O@O$!.*'QG*,6\1*PL41A M1 6W'4[.(V(1%RKRI#1..6V4!>(+D0Z7TFDK%G_**P@=WZ&4@7VE9QZ8ZC8$ MD4.?LCFZ6&/XR 9?
PQ1F[$@@(1B0"E2HX.!C.I"/PON.6S5>71D?.DD@]?9F< M5E1!:R8VD5B/09@?!\;".\H0##@+?@H>U6KBB5B/9@?!\;".3OR;S]V"]C93]9'.O*":9,#/F MEU(8IVW+%?HH]:[QD&:56WOJW ?
D"C$OJ>>^,HOJSA[Z5EDN+4+J ML!WO5RP'44BBYJ]/7[J-^5'*LTK-B^$D*ATO7M8'5Z^FZ[A/YMWS^8'%?7:& M-6VQ9-
?)^(>W&83N*>HFT3>I_6]]Y,^7GA7;3R3!\']@^2]0 M2P,$% @ F8 -61[NSCC% @ $P8 !D !X;"]W;W)K&ULC551;]HP$'[OKSAETETM1]K DAT)9!)*"!"=MFF=4.G6AVD)/KD0
MJXZ=V4I[I_OW0_WV;YCLE7ZP-2%%]!(2%X(JLH)+7&HP55$P
M_6>.0FVG7M_;+=SR36[=@A]/2K;!%=KOY5*3YWVGSJ77B08L8J86_5]A.V>H8.+U'"U+^P;7,##Y+*6%6T MQ<2@X++YLJ]?'V'/ZG/ZG(&P+PIIWLU'-
|HI9%D^TVH)VV83FC%IJ74WDN'27LK*: MHISJ/Q-6800WL-790PL4<,J9QKA]Q(ZM!9IW$]_2+B[73UK$>8,8OH(X@ALE M;6[@6]:8OJSWB5U',=Q1GC(='ul4]\P@00_"((R.X TZR8,:_
WC73DLO- MOMJ?L[6QFE[(KT-Z&[CH,)SKFK$I68)3CJK"H'Y$+WW[IC/APA&W5DHV/H M\8JZ,*T$@LI@A4FEN>5H@*X-%HI:(T6-*7)"R:22K#ZJ5/N%1>5I6TIE#
MJ$0*:VPRJ5]W0%EE*Y?I;HL9R)2@<6+@M ZKRC"9FG?C$$WHKV+T5V/<&)PM5 M=%*6*BY@^W3FDEK.(J/8!3\$U6E8VQ@U+L<1!#UHHOSDSMEF8"2"D5:3E;' MT#P?PGEO,
Q@V LN SAT^?Y>HQ:H-_4X,DZUM$W/=JO=Q)LUC?ZJ";$=0X5I5UVZ^E(&?5ZE-;=0N@>*9(BFMXS;H_@?BOU!+ M P04 " "9@ U9DVE^#D% !J#@
'AL+W=OF8O29I.TNS$V^:ATP=: M@BTVDJB0U%[R]05)2_$FMIOVQ:)(X '!"#X[%[(SZI U!0E;4Z'Q1:-Z?C ML"-!M57%Y.,EEN+^?!! ,NHV/?
%UHLS&>GS5LC0O4OS2X8FVI/XK[7W##9V+P,E$J M^POW3G8R&4#6*BVX2J3Y4/'=G#)]Y;"JF_1R'<*(36;V?>GG--)N?27$/ MTD@3FEE8JE:G;.UN92%EG3*24_/?Q.
(8817'.5B5KSNL4_#V469U;L+1",5*>"-%VRCX\V*IM*0<^FM7()R= M>+<=4U>GJF$9G@^H/$O#('BY-J\V&H N$E2BI6_!Z#=ID'S0.6MG#BOTM)&0E4PJ5,606VEU;
MR=F2EUQS=Y)O6Q'?K-"10;IL%?%6BKI+(Z0F&5[; U+*J?'0!JV4*G.S.F2 ME9:Z+3=GL)&I2_VZ0O7F&&U1 E1 M8'!#8Y@Y[P61E9UB%\|<1!,F,Y VV?K1R^*7EC;G (=3TH2")
M89A$GFWA([$:M0J==G>>3!/O@P5WH-U^//%NA::4^,[FS[+<4)H,(S_PWFU= M]G\TSND9MXG3!>L9#IUD:?++TUS:K 6Q+/G?Y24(PG#BO1,V:3*QKOE7@U]# M=].9DV/?
NT3I;.62T.ET-; MLS;GVI7#KL)0WPJ<3&Y9>9K3IJYM(1&??!>@+XL%?]AXMF",34"_*.I-986LDQSL:<6R50^A MF$:0S""- N>JE:&YYS-:D"!*818$,(L#\F1*A-
Y@319**|=R^M1S\|$Q,PNU MB,@X$<]BB.-DDT+B!X<@GAIR86K)^8:<[W<95QJ&*RFJ TEV!'$X(]IF%0R3 MT-^LTUFW(D03#;BBUD 37]_S>)V5;?Z_,R9CJH
5I;1R24D"FYSHB!_1V9ZS&UY4D S ML_5:7Q+8-3&,M^:_"N7:3KF*+-'=N%&PW^T'Z0LW/WX3=U/X>R;7G-PH<46J M_LF4YE;I)EOWHD5CI\FET#2;VF5!?P90&@$Z7PF:*#:&EL$:%
(MA:3LW?=&?Z;T5L7R1RR'GS9LAYG.V5;F9*1 M=EF[I76UG=[8/2*V=%;MJD9)*QNE*V9IJK>!J36RHG6]1!"'8194C$MO,6MM*[V8]<8*+G&EP315Q?3$
M$H?:S[W(.QJ^\&UIG2%8S&JVQ4>T?]Z BAP-PZ!$:_'3Z@$ Z(:'P_8'I]2.=X.CZB M_];F3KFLF<$')?[EA2WGWL2@ C>L$?+VO^.AWQ&#B]7PK1?V'=[4X]8-\:J MZN!,\XK+
[L^>#G4X<9B$%QSB@T/<\NX"M2S?,\L6,ZWVH-UN0G.#-M76F\AQ MZ0]ET6I:Y>1G%Y^511C\K[#2=-#-@:/@.3!7SWO":2F_AYBM;"S2WL\!2-.<3 MY ?
D98<<7T#.)X.2MC3P2198O/8/B5/3Y27-67F.?+:U&DD![<7Q$J]LY!*L',4GV-[(@#\J:B7\/-SX)*V5_/W`UV,2LY:H
M Z7!BTYzb...

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{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{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|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{'6,'9S@_S&VUV.VCXJSKQ^-6B7\?5LMCL/ M0ZQHDK,-8FWY6U&=!H3M]1JHS5%^8-50S:TR3-? 7ZE8L$0BQ1Q5UKF/ZR&* MLK+H*) {FE=F$*ZSS\N822W$0>@#>GW.LSLJ.+O:JXC[\"U!+ P04 " "9 M@ U9Q%)L?G\$ "Q' &0 'AL+W=O:#QFUCB2$+B1MKEQ7+A*:$7G. M-S37=U9<9$3!4[%VY490LBR#,N;ZGC=T,Y+FSG1<7IN)Z9@7BJ4YG0DDBBRPC M8G=-&=]`.P\7_B2KA-E+KC3\8:LZ3U57S??S'LKW2IDHESZ: E79&"J2]\^QNM'VA@> O.9/D? M,>NVGH,6A50\JX/U"+(TKW()4RW$04!P>2+ KP/\HP#?/Q$0U-'!6P/".B!\ M:\"@#B@?W.V>O10N(HI,QX)OD3"M-H31'#PDO),F7Y6SS[5A;UY#9N?H\ S M6#]\QG9@(CLFH@N-P24FL&#B-V#\\B%]OQOC:H<:F_S&)K_D!B>Y%%\0'R%LJHR-+U8OGZ[FPX$@P//;#.J;>?D#28BA:VX]]F8NM)=OT8YE9{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}& ;O(S"$3S,I]"[N/R7QC>EM?6%;7VAXQV>X&VL4U.: M,?]+\.W5 F4!4UQ]^\6]5%J:/\;O+L,U\:B,V#,+6)5DA1//=("N4,O>_MF M$ MK:Y}@S=PL]B;.M*-^"HD]0"YS==EEM2:+'9EMPUT6?DC]78>! M46M@}}]'J$NI1D4'2E'8K12U2M%K2G&74G2L%'4KQ:U2_)I2TJ44'RD-HOC$ M_26M5G)6:R\$T85UBR=%3#9+@_\+\@X:VL_&.R"WE"AAN#"SH)\:LK.=-G6A1 MNAY?"FFA@MS,Z)1V@-F?R-,VS:)'1OMT,_^ E!+ P04 " "9@ U9_DJ M%)<% K)@ &0 'AL+W=O6)>(-S8@X9UN;JRIJ<(TO(SPN M'2]+OQ+Z(ZN4?DJ"\;NRYO;Y=7 +GM$4QK+$D'4OQV=T30M2:H?7QKHH(U9 M.AY>? Z.'UHWN*%}3CE[.J21)*M!'^B@+DKY2CSY]F*.7+UZA%\A" M8D,X%2C)T.<\D>),-:KKCQM6")OQ<22JEH>Q^S^^]%?HZ&=N7N M:MSGSW? 710]^<GX<]$CL_M;MCMT'CE.Y.X94#%MU#BO>\ G>32%4BQ#H.OY2 M)"%I9J_/?Z@V="MI)OI1=/&F1KIZ9#FU%'3HMB>G50,W=@O(=']4Q__07[]F^Z M7$/"'YI"P ! (60L(B(%A',6ZK&-=$GT:JH87X%*Q?] MW=1S_(FU.TRZQF8\[MH$QS9C#M"=M0HV-T[.)@%ZN,_)>._*><>3_W%).9)*O M4 M%H#>LY,%O\V";\Q"N5?;LD3]!NZ8VNX5*>`H(U$K>YF9,W2;Q^?H\QW-%I1K M)T\C_=0<0<+FD+ $A9"PB(@6$<\HU8\(_CE=@2I&$C8'!(60,)"2%@$!.LH M9MPJ9FR<,EK%D+UBS!:."6?4N]@#*5BU*]@YB:H.R,:6_?Z-W4X[!S_ML;U%,F;LT.D:@0%D+ 0$A8!P3H:N6@UG5<'"W >.A[KF>/>.2NQJNA4C4#" DA8" F+(@& =C6! {7X>PGZ<2)8=% MDI-.)2N2<+0C:4$/E2)9?*^31Q.BL]=V?=S;QLW,/3E5'.'"T)06@M(B*%I7 M(0>5*OP#\TBLOC;*Y24C_)Y*M.5)K/WN:^'"VG#[NC#&/UD7D+0 E!:"TB(H M6E<7SEX7CE$750F3TY@F.[)(J9HT&%\G.YHCDK$BEUHU.$=]\!W;[@O^&/AD M04#2 E!:"$]+H&A=0>R+AMA88?1^#RUVAD>9T%C-QH>YT%CY@Q^MQZG0A<7X.IO_1UT. [PMSV%R9.Z4FA/%^MCQ\A55TZJ5&2.>G(^(6ES4%H M2@M!:1$4K:NM?,D1^_ E MPCB*)F"%N RRU-L6.DM58P67N-<,A=I.@V'P;+CEZ{Z0YBE-5OC M'=IO]4*3%O91"EZA-%Q)T+B:!A?#!UGBSOL#WSENS9X,KI*E4@].N2FF0>2 M4&!N701&RP8O40@7B# >NYA!G]{Y[LO/T:.]]53+DAF\5.('+VPY#=X'4."*-M- <-+>JNTG[.H9NWBY$L9_8=N=C0+(&V-5U3D30<5EN[*GK@]['#]/X!8>X4<^:\GC%\BO M<3F .'0"<12/X"V8I"-. WR=\!"0VM+W)NY[$_LHQ\N^!!TFWJR!YW\0QONS8A[;N;T(W)10.'"*?+! M&56LVQ9%N:MJ)59+96D(05C2JX?:'.#]E.+1Z10WB?T[FOT!4$L#!!0 (M)F #5GN>C\G0 4 .8< 9 >&PO=V]R:W-H965TQ).N\)!\?'KZBICLAOZL-I1H])#Q5%X.-UMGY<*CB#4V(.M.A493>&;E9)T7 JUT.524J615#"A]CSHF%"6#J838MKWM(V%;GF+*6W$JD\ M28A_$"YV%T,_,'3A2]LO='FPG VS!C2Z\HYT8)^O&C M$AW4;9K P^,G]8_%X&$P"Z+HE>#_L*7>7 S& [2D*Y)S_47L_J#5@$9&+Q9< M%?_1KKK7&Z X5UHD53#T(&%I^4D>*A_' 7]X3 "N O!K X(('AM0%@%A 69 MDN1O4S$$!LXB&X,/4 .YW6L*W#.+T[+/0%/DA>H]NJ%Q3 M"0=W90H@L4*WDG(&K9K3VUS&&R ,%UE,T27G(B,%,_=V3C5A7+V#X*]W<_3V MS3OT!K$4W6]$KDBZ5-.AAKZ:%H=QU:\/9;_P,_WZ2!>GR M.$/9PT!-^90__M,T]/4> 5X6%/^-P>/JS77_S(^ZT/ETNQN2.Q M!LJ@1AG8U&>_"[!<, <[!B%DCCR56BD6%F*F>VQD.O0A/A]M#%"_=U1AC6(Q MM{{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{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{Z]GO>P<,/7F;$+?A*7;(US-+?E3-';UE27J#07 I0N!I[Y[VSZ<#6NX*O M'+=Z9PS6R4+*.SOYE(Z]P K"!)? &,CJZ;""">6Z)2,/AM-KC[3 W?$#^WOG MG;PLF,:LS3

6^2:5I16M[/0LNW/5H^'Z^T$;1"_*CJ^,U8[^;T8;&F2[9 M$L<>I8)&M4$O>?VJ-PS>==G|3V2/S/=;_U]I,D'Q82A)-F@]+#+:0T?.KA- MLTTR&(UB?[-KX'G-
:3!H:Q[I&K2Z!GMU75/VYE)W_MT'SXX[/NV/AD]$=53U MAM2U){K\G=>^L&^O34,-2UD)4R= N]H&{KG+&?]/>9W65TRM.?UU&POW#"@NBL>_) M.??8ODE<^I5:S#V5GKX?)Z-
WYA@$L_<(IV#A"}:K5P80 Q\?@P\7W: MF'3W(.D]RIAP;UMX+?0W8N(@GC>\H^$#_P1X6PL&, RDC.^M.$V!"@%+Z2G]%V@TX40J9XL M'-H>W""U3LY${4UNF\'^='=>7[P"K'AADG#
<&V[X-#/LE48I*<:,[YF(J? 9Y M=?M^66J'4TF68;OCKPGFD),,"YE2V:0) 55HV.M& MRLBT$,1X6#'JAI:=4,[OX.GQ,JO27F0;ZV:*0C1-;.AN6AG; ?U--:N]*=MY ME:Y7LL="?
9GKX0C3AUJCMY)F;&'ZBZPQ@*F'N#HI2[[\S-E4Y-0._N"$PSY9 M\,Q9(=F3S@:E,M$!*GWOD4K%)IN1WY*4]W2A5N6TR'#/[1/T_&_G>4H%E81O MFM:U?\RS_&K'4?
>M+)NGRJYAI\=Z2W#L)CNG8#(^!9,G4)-1ZTW>L9L\ MA9GLOMF3_24FPZ,T&=3;M8T]X=;.L(EZL/,>^#}@'_72;WQG'"%1-V;L32E MXMG&4,LK,M;_K&
{IZ^M3FI$Y5_<-./#7[>\T9?,\::ZZA8FIHKU]WO\'PPKC9 M]NM<3*1T0=-1W973L6EZNJ&SU@<0=I$;<[@1C&,Q-P(8E@=S@'$L"\OS/XVG
MAX{'8IBWGA/IH9P>RK$L%S(R'RR/FY/HPSW2)(FB.,9F=#1R.AAA|Q,'\'6K M8=Z @>6!3"^;.WRU\0K97P?8FNZK$&RD>"5B(\7G&A#WO $C2=RKC>4!!K8* M6.U ?
G<>J"DW)XI@53%OV!V,(TF"(5"+[A]-8V1V8OBXUP>[2Z(H2=P(8&X' M480A<##?B"-8 /&!(%)GWX,[[*%B]IX+U+[C#/U!+ P04 " "9@ U9EXJ[M', 3 @ "P
%]R96QS+RYR96QSG9*Y;L,P#$!_Q="> , ?0(8@S9?$6 M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!Y10.TXI+::+J1C]$%)I6M6X 4BV M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D
N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(= MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/[*X 4$L#!!0 (M)F #5EL+QQ)]00 K /
>&PO=V]R:V)O;VLN>&ULQ9I;;^,H%(#__M"LK3{D,W\;47-96ZOF/\W:7O'+- MGWG+S?MTY+9;-B(=%[SC/UDS'4U&1*_DVV>I^$\I#&T?%DJV[724]2>>F#)\ ML7/XP4(^TF?
MCACZ_(T"R'143Z#")5?:N!*N?@J,KPP*]WL;(V]Y.YBZIH9] M4G*SYN+%5@-W,?9NP\5A^]L'\4S]GS#*Y9(OV+5<,#HF3!]'Q5H+*/2*K_6(M"-JQZ6A;A%R*AMP(T$B,]%7!67MG<)?
SYK^K@W@>C%49QQ.J%GCP(>#O)*B M84*SAL"6EBUO@*,A?].6B@4C'F2.0.8'A/PG]R -!+(X".2#Q8%+/<@2@2P/ M"!E$LD(@JT-'%AYDC4#6AX0L/?T MG;QJ,F?
?6[\QFNN%ZW4&\7\H7R"C>6382%G0O.&?*H: /6(Y=*4?%B1Q^C M?4;4-P,+YRMD%20C1S!Z:ZZ)7)*Y8AJN<45]X628<;*!E>,P<\#\(K5K=O*P MHF%+8ZI)!I:-PRL
;R9>F3:NA0F%/./R13'6^9B8;;*!=>,P2\"TSPKD?UQL MX,F^7S.UDP)AOLD&%H[#K 3LP[\T*>N,W#%]Q_/_-CKFG6Q@\3C,4\!TX\\1C)I.E!U4J:&TGZ!C MZLD'5D_K$^
$]@Z]HU(5_:Y]S$Q^^1){&/U\\V>AE#.*'F?"L,+/G 9OG(M$7'\+DQ]?$S,+'D*L^QF.^2/1]O(02?$S)*G,$LLG0AFKSEFECR%66+I1(B)
MF25/8998.A&NJF!F*5*8)99.A)B868H49HFERFYI'-+IAK\. M76+F*5.8)XKIKT27F'G*%.:)9D5!-#'SE"G,$\4,HHF^QTGAGVCR%D03\T^9 MPC]1S"":F(7*%!.*YIA!-#$+E8=
<60NCB5FH/.3*6AA-S$)E"@M%,?UH5IB% MJA06BF;L?C0KS$)5"@M%,8-H8A:]DJRO1=8!PQ?@F(6])/.?/>N4?2KG8V(6 MJI+,@OQI6I]H:O+(?IB-CXE^3Y!D%N1A0B_==!U5[W;"
<>MC8A:JDLR%]LPI M=[+W"K-0E<)">S!_!]7'Q"Q4I;!0##-\TC$+52DL%,S08X]0C5FH3O)^Q\,, M'J$;'Q.S4)WD_4X$,VCT&K-0G<1"L6C.?4S,0G42"\6B&7R(A5FH=A8:N\+Z
MXKQA2RY8\Q7^0L/Q!6T7P,%[\4729OL!Y_;CTXM? M4$L#!!0 ( )F #5G22;QM$0(!&PO7W)E;',O=V]R:V)O M,VLN>&UL+G)E,'/-V3MNVT 4A>&M"%R 1_0"^D0*=
(8/!4Q)'CY%\0'8OCTJQS:<=^=ZF[?U\7\"?"JV8WCOV/E.IZ M5XYMO>OZ00I#.'V009/,'.03Y_$$!03%_4(.@/'_0/03=SQ_T $$/\P<]0M#C M_$&R1!F7!$D3K
FT%N1;*P6!%L(Q!8D6PC,%D1;"-069%L(W!:$6PCD%J1;M".P6Q%L(J%;46PGT5M1;"36R<BN!WHIZ*X'>BGHK@=Z*>BN!WH9Z&X'>AGH;@=Z&>AN!WC;9+'"'0VU!O(]#;4&\CT-M0 M;R/0VU!O(]#;4&\CT-M0;R/0VU%O)]#;)46\GT-M1;R?0VU%O)]#;)YO=!'H[
MZNT$>COJ[01Z.^KM!'H[ZNT$>COJ!01Z!^H=!'H'ZAT$>@?J'01Z!^H=!'H'-MZAT$>L?D9R6!WH%Z!X'>@7H'@=Z!>@>!WH%ZIX'>&?7.!'IGU#L3Z)U1[TR@ M=T:],X'>&?
7.WZEW'3\/I5Y[OM;X_.^D>CS?6ZZ/ORR_3D{>W@O.Z,;B/O\% M4$L#!!0 ( )F #5G B&UTZ0$ 'XE 3 6T-O;G1E;G1?5'EP97-= M+GAM;,W:74_",!0&X+]"=FM8Z=?
\B"CWJH7_H&Z'61A6YNV(/Q[NP$F&B4: M3'QO6*#M>><]ZDN>*ZZ>MHS#:M$T?IMDB1G?%6"@7U}J06T==6IE;WY]8OOH7 MYDRY-"_$Q&12L-)VD;HXCGV-,'9]2W.S:N+H;I-
^#K7MHFG)F2CF]W&/FN: M&>>:NC0QK,-U5WU*&>\]3\G1RV!,6M0MG:4/&ODSH5[X/V)]{6)/W=46C1^/C MO6G3+K9I6(C;AD)^O,07/=KYO"ZILN6J34?
RX#R9*BR(8MODNZ)GQY-CNF': M??*3\X00V/$Z_XX\S?J__RSX$2!\2I \%TH<&Z:_ Z>,&UL4$L! A0#% @ F8 -68DLQ^/O *P(!$ M (!KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ MF8
-69E&PO=V]R:W-H965T&UL4$L! A0#% @ MF8 -6>\]H./K!P UB$!@ ("!+PX 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ F8 -6UP\>>@"_M "O!@ & @(%$,P >&PO=V]R:W-
H965T&UL4$L! A0#% @ F8 -66'OJ/PQ*P LF0" !@ ("! M8C8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ F8 -67U[=U>##0 {"4 !D M ("!Q&H 'AL+W=O >&PO M=V]R:W-
H965T&UL4$L! A0#% @ F8 -66DN;=Q'"0 &A@ !D ("! MN9$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ F8 -6:8&PO=V]R:W-H965T&UL4$L! A0#% @ F8 -64BK#:MJ M P
E < !D ("!:+, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ F8 -685K+&PO=V]R M:W-H965TL'CG@, !L(M 9 " @2C0 !X;"]W;W)K&UL M4$L! A0#% @ F8 -61[NSCC% @ $P8 !D
("!_=, M 'AL+W=O&PO=V]R:W-H965T@, &P' 9 M " @6G< !X;"]W;W)K&UL4$L! A0#% @ MF8 -63O*20S8 @ W@8 !D ("!&N 'AL+W=O&UL4$L! A0#% @ F8 -60N)K2S3 @ MAP8
!D ("!7.D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ F8 -69%X]TX=!0 PPL !D M ("!_, 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ F8 -68C"]7WX @ Y@D !D
("!L@0! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ F8 - M6<1>XF%% Z3H !D ("!C!P! 'AL+W=OOX# "[&0 &0 M @($()0$ >&PO=V]R:W-H965T&UL4$L! A0#% @ F8
-6:1)]",X @ +04 M !D ("!S2X! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ F8 -65 0O=ZU @)PD !D M ("!.C&PO=V]R:W-H965T M&UL4$L! A0# M% @ F8 -6:K*ES^C @ 8P8
!D ("!#T ! 'AL+W=O M&PO=V]R:W-H965TKZ0(%H) 9 " @&UL4$L! A0#% @ F8 -6=@4 MEE2- P -A(!D ("!Z4D! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ F8 -6<12;'Y_!
L1P !D M ("!R5&PO M=V]R:W-H965T&UL4$L! A0#% @ F8 -63?Y*A27!0 *R8 !D ("! M(F(! 'AL+W=O&PO=V]R:W-H965T0(%,% 9 M " @11K 0!X;"]W;W)K&UL4$L! A0#% M @ F8
-6>YZ/R= !0 YAP !D ("!Q&T! 'AL+W=O&UL4$L! A0#% @ F8 -69>*NQS $P(L M (!@WD! %]R96QS+RYR96QS4$L! A0#% @ F8 -66PO*$GU M! "L \ (!;'H! 'AL+W=O!
0!,0V]N=&5N=%]4>7!E&UL4$L% 3!@ !($@ KQ, /&# 0 $! end XML 75 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and
Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C.
105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function()
{Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var
d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 76 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /*
v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a
{ display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px;
text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; }
.report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white;
border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report
th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica,
Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report
td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header
rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re,
.report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td
{ border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space:
nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding:
0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more
{ display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-
size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html1692981true600false6 falsefalseR1.htm100000 - Document - Document And Entity
InformationSheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-documentandentityinformationDocument And Entity InformationCover1
falsefalseR2.htm100010 - Statement - Condensed Consolidated Balance
SheetsSheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsCondensed Consolidated Balance
SheetsStatements2 falsefalseR3.htm100040 - Statement - Condensed Consolidated Balance Sheets
(Parentheticals)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalsCondensed
Consolidated Balance Sheets (Parentheticals)Statements3 falsefalseR4.htm100060 - Statement - Condensed Consolidated Statements of Operations
(Unaudited)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-Condensed
Consolidated Statements of Operations (Unaudited)Statements4 falsefalseR5.htm100070 - Statement - Condensed Consolidated Statements of Operations
(Parenthetical)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsParentheticalCondensed
Consolidated Statements of Operations (Parenthetical)Statements5 falsefalseR6.htm100080 - Statement - Condensed Consolidated Statements of Cash Flows
(Unaudited)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-Condensed
Consolidated Statements of Cash Flows (Unaudited)Statements6 falsefalseR7.htm100090 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)
(Parentheticals)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-
parentheticalsCondensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)Statements7 falsefalseR8.htm100100 - Statement - Condensed Consolidated
Statements of Changes in Stockholders' Equity (Unaudited)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-
statements-of-changes-in-stockholders-equity-unaudited-Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)Statements8
falsefalseR9.htm100110 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)
(Parentheticals)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited
Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals)Statements9 falsefalseR10.htm995410 - Disclosure - Pay vs Performance
DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes10 falsefalseR11.htm995445 - Disclosure - Insider Trading
ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes11 falsefalseR12.htm995457 - Disclosure - Note 1 - Basis of
Presentation and Summary of Significant Accounting PoliciesSheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-
and-summary-of-significant-accounting-policiesNote 1 - Basis of Presentation and Summary of Significant Accounting PoliciesNotes12 falsefalseR13.htm995467 - Disclosure -
Note 2 - Loss Per ShareSheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareNote 2 - Loss Per ShareNotes13
falsefalseR14.htm995477 - Disclosure - Note 3 - Investments and
AgreementsSheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsNote 3 - Investments and AgreementsNotes14
falsefalseR15.htm995487 - Disclosure - Note 4 - Discontinued
OperationsSheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsNote 4 - Discontinued OperationsNotes15
falsefalseR16.htm995497 - Disclosure - Note 5 - Property and
EquipmentSheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentNote 5 - Property and EquipmentNotes16
falsefalseR17.htm995507 - Disclosure - Note 6 - Goodwill and Other Intangible
AssetsSheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsNote 6 - Goodwill and Other Intangible
AssetsNotes17 falsefalseR18.htm995517 - Disclosure - Note 7 - Held-to-Maturity
InvestmentsSheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsNote 7 - Held-to-Maturity InvestmentsNotes18
falsefalseR19.htm995527 - Disclosure - Note 8 - Fair Value
MeasurementsSheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsNote 8 - Fair Value MeasurementsNotes19
falsefalseR20.htm995537 - Disclosure - Note 9 - Share-Based
CompensationSheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationNote 9 - Share-Based CompensationNotes20
falsefalseR21.htm995547 - Disclosure - Note 10 - Commitments and
ContingenciesSheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesNote 10 - Commitments and
ContingenciesNotes21 falsefalseR22.htm995557 - Disclosure - Note 11 - Related
PartiesSheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedPartiesNote 11 - Related PartiesNotes22 falsefalseR23.htm995567 -
Disclosure - Note 12 - LeasesSheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesNote 12 - LeasesNotes23
falsefalseR24.htm995577 - Disclosure - Note 13 - Notes PayableNotesPayable:http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableNote 13
- Notes PayableNotes24 falsefalseR25.htm995587 - Disclosure - Note 14 - MergerSheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-
mergerNote 14 - MergerNotes25 falsefalseR26.htm995597 - Disclosure - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies
(Policies)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPo
- Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Policies)Policieshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-
note-1-basis-of-presentation-and-summary-of-significant-accounting-policies26 falsefalseR27.htm995607 - Disclosure - Note 2 - Loss Per Share
(Tables)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareTablesNote 2 - Loss Per Share
(Tables)Tableshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShare27 falsefalseR28.htm995617 - Disclosure - Note 4 -

Discontinued Operations (Tables)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsTablesNote 4 - Discontinued Operations (Tables)Tableshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperations28 falsefalseR29.htm995627 - Disclosure - Note 5 - Property and Equipment (Tables)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentTablesNote 5 - Property and Equipment (Tables)Tableshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipment29 falsefalseR30.htm995637 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Tables)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsTablesNote 6 - Goodwill and Other Intangible Assets (Tables)Tableshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssets30 falsefalseR31.htm995647 - Disclosure - Note 7 - Held-to-Maturity Investments (Tables)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsTablesNote 7 - Held-to-Maturity Investments (Tables)Tableshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestments31 falsefalseR32.htm995657 - Disclosure - Note 8 - Fair Value Measurements (Tables)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsTablesNote 8 - Fair Value Measurements (Tables)Tableshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurements32 falsefalseR33.htm995667 - Disclosure - Note 9 - Share-Based Compensation (Tables)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationTablesNote 9 - Share-Based Compensation (Tables)Tableshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensation33 falsefalseR34.htm995677 - Disclosure - Note 12 - Leases (Tables)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesTablesNote 12 - Leases (Tables)Tableshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12Leases34 falsefalseR35.htm995687 - Disclosure - Note 13 - Notes Payable (Tables)Noteshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableTablesNote 13 - Notes Payable (Tables)Tableshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayable35 falsefalseR36.htm995697 - Disclosure - Note 14 - Merger (Tables)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-tablesNote 14 - Merger (Tables)Tableshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger36 falsefalseR37.htm995707 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textualNote 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)Details37 falsefalseR38.htm995717 - Disclosure - Note 2 - Loss Per Share - Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares (Details)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeigh 2 - Loss Per Share - Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares (Details)Details38 falsefalseR39.htm995727 - Disclosure - Note 2 - Loss Per Share (Details Textual)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextualNote 2 - Loss Per Share (Details Textual)Detailshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareTables39 falsefalseR40.htm995737 - Disclosure - Note 3 - Investments and Agreements (Details Textual)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextualNote 3 - Investments and Agreements (Details Textual)Detailshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreements40 falsefalseR41.htm995747 - Disclosure - Note 4 - Discontinued Operations (Details Textual)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextualNote 4 - Discontinued Operations (Details Textual)Detailshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsTables41 falsefalseR42.htm995757 - Disclosure - Note 4 - Discontinued Operations - Schedule of Discontinued Operations (Details)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetailsNote 4 - Discontinued Operations - Schedule of Discontinued Operations (Details)Details42 falsefalseR43.htm995767 - Disclosure - Note 5 - Property and Equipment (Details Textual)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextualNote 5 - Property and Equipment (Details Textual)Detailshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentTables43 falsefalseR44.htm995777 - Disclosure - Note 5 - Property and Equipment - Summary of Property and Equipment (Details)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetailsNote 5 - Property and Equipment - Summary of Property and Equipment (Details)Details44 falsefalseR45.htm995787 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Details Textual)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsDetailsTextualNote 6 - Goodwill and Other Intangible Assets (Details Textual)Detailshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsTables45 falsefalseR46.htm995797 - Disclosure - Note 6 - Goodwill and Other Intangible Assets - Summary of Components of Other Intangible Assets (Details)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAs 6 - Goodwill and Other Intangible Assets - Summary of Components of Other Intangible Assets (Details)Details46 falsefalseR47.htm995807 - Disclosure - Note 7 - Held-to-Maturity Investments - Summary of Carrying Values and Fair Values of Financial Instruments (Details)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinanci 7 - Held-to-Maturity Investments - Summary of Carrying Values and Fair Values of Financial Instruments (Details)Details47 falsefalseR48.htm995817 - Disclosure - Note 7 - Held-to-Maturity Investments (Details Textual)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextualNote 7 - Held-to-Maturity Investments (Details Textual)Detailshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsTables48 falsefalseR49.htm995827 - Disclosure - Note 8 - Fair Value Measurements - Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis (Details)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCas 8 - Fair Value Measurements - Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis (Details)Details49 falsefalseR50.htm995837 - Disclosure - Note 8 - Fair Value Measurements (Details Textual)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextualNote 8 - Fair Value Measurements (Details Textual)Detailshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsTables50 falsefalseR51.htm995847 - Disclosure - Note 9 - Share-Based Compensation (Details Textual)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextualNote 9 - Share-Based Compensation (Details Textual)Detailshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationTables51 falsefalseR52.htm995857 - Disclosure - Note 9 - Share-Based Compensation - Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements (Details)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecogn 9 - Share-Based Compensation - Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements (Details)Details52 falsefalseR53.htm995867 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextualNote 10 - Commitments and Contingencies (Details Textual)Detailshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote10CommitmentsAndContingencies53 falsefalseR54.htm995877 - Disclosure - Note 11 - Related Parties (Detailed Textual)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextualNote 11 - Related Parties (Detailed Textual)Detailshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedParties54 falsefalseR55.htm995887 - Disclosure - Note 12 - Leases (Details Textual)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextualNote 12 - Leases (Details Textual)Detailshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesTables55 falsefalseR56.htm995897 - Disclosure - Note 12 - Leases - Summary of Future Operating Lease Payments and Lease Liability (Details)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetailsNo 12 - Leases - Summary of Future Operating Lease Payments and Lease Liability (Details)Details56 falsefalseR57.htm995907 - Disclosure - Note 13 - Notes Payable (Details Textual)Noteshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextualNote 13 - Notes Payable (Details Textual)Detailshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableTables57 falsefalseR58.htm995917 - Disclosure - Note 13 - Notes Payable - Summary of Note Payable (Details)Noteshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetailsNote 13 - Notes Payable - Summary of Note Payable (Details)Details58 falsefalseR59.htm995927 - Disclosure - Note 13 - Notes Payable - Summary of Maturity of Note Payable (Details)Noteshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfMaturityOfNotePayableDetailsNote 13 - Notes Payable - Summary of Maturity of Note Payable (Details)Details59 falsefalseR60.htm995937 - Disclosure - Note 14 - Merger (Details Textual)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textualNote 14 - Merger (Details Textual)Detailshttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-tables60 falsefalseR61.htm995947 - Disclosure - Note 14 - Merger - Summary of Estimated Purchase Consideration (Details)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsNote 14 - Merger - Summary of Estimated Purchase Consideration (Details)Details61 falsefalseR62.htm995957 - Disclosure - Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) (Parentheticals)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParenthetic 14 - Merger - Summary of Estimated Purchase Consideration (Details) (Parentheticals)Details62 falsefalseR63.htm995967 - Disclosure - Note 14 - Merger - Summary of Preliminary Purchase Price Allocation (Details)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetailsNote 14 - Merger - Summary of Preliminary Purchase Price Allocation (Details)Details63 falsefalseR64.htm995977 - Disclosure - Note 14 - Merger - Summary of Pro Forma Computation of Earnings Per Share (Details)Sheethttp://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfProFormaComputationOfEarningsPerShareDetailsNote 14 - Merger - Summary of Pro Forma Computation of Earnings Per Share (Details)Details64 falsefalseAll ReportsBookAll Reports catx-20240630.htmcatx-20240630.xsd http://fasb.org/us-gaap/2023http://xbrl.sec.gov/dei/2023http://xbrl.sec.gov/ecd/2023falsefalse JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "catx-20240630.htm": { "nsprefix": "catx", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "dts": { "inline": { "local": ["catx-20240630.htm"] }, "schema": { "local": ["catx-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"] } }, "keyStandard": 250, "keyCustom": 48, "axisStandard": 29, "axisCustom": 0, "memberStandard": 25, "memberCustom": 34, "hidden": { "total": 11, "http://fasb.org/us-gaap/2023": 7, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 169, "entityCount": 1, "segmentCount": 60, "elementCount": 622, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 633, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 5 }, "report": { "R1": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "dei:EntityRegistrantName",

```
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-gaap:ShortTermInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } }, "R3": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "longName": "100040 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-", "longName": "100060 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_1708ebd5-b6be-499e-b9b9-0a884f98c6ea", "name": "us-gaap:RevenueNotFromContractWithCustomer", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1708ebd5-b6be-499e-b9b9-0a884f98c6ea", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } }, "R5": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical", "longName": "100070 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)", "shortName": "Condensed Consolidated Statements of Operations (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_eca5b390-8393-49f9-9a1a-ed9e155f8510", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "link:footnote", "p", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": null }, "R6": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-", "longName": "100080 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_1708ebd5-b6be-499e-b9b9-0a884f98c6ea", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "catx:NoncashExpenseLease", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } }, "R7": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals", "longName": "100090 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_2edc0d5f-8ad1-4f5a-b0b5-ca01d921af28", "name": "us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2cdc0d5f-8ad1-4f5a-b0b5-ca01d921af28", "name": "us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-", "longName": "100100 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "C_b7bcc91b-af3f-4df6-9cad-275f4ebb0a18", "name": "us-gaap:SharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a9ea8421-e0be-4b95-ae47-3e4d4d96a19f", "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } }, "R9": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParentheticals", "longName": "100110 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "C_eca5b390-8393-49f9-9a1a-ed9e155f8510", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "link:footnote", "p", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": null }, "R10": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_1708ebd5-b6be-499e-b9b9-0a884f98c6ea", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": null }, "R11": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "longName": "995457 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Note 1 - Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShare", "longName": "995467 - Disclosure - Note 2 - Loss Per Share", "shortName": "Note 2 - Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreements", "longName": "995477 - Disclosure - Note 3 - Investments and Agreements", "shortName": "Note 3 - Investments and Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "catx:InvestmentsAndAgreementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "catx:InvestmentsAndAgreementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperations", "longName": "995487 - Disclosure - Note 4 - Discontinued Operations", "shortName": "Note 4 - Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipment", "longName": "995497 - Disclosure - Note 5 - Property and Equipment", "shortName": "Note 5 - Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssets", "longName": "995507 - Disclosure - Note 6 - Goodwill and Other Intangible Assets", "shortName": "Note 6 - Goodwill and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestments", "longName": "995517 - Disclosure - Note 7 - Held-to-Maturity Investments", "shortName": "Note 7 - Held-to-Maturity Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurements", "longName": "995527 - Disclosure - Note 8 - Fair Value Measurements", "shortName": "Note 8 - Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19",
```

```
"firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensation", "longName": "995537 - Disclosure - Note 9 - Share-Based Compensation", "shortName": "Note 9 - Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote10CommitmentsAndContingencies", "longName": "995547 - Disclosure - Note 10 - Commitments and Contingencies", "shortName": "Note 10 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedParties", "longName": "995557 - Disclosure - Note 11 - Related Parties", "shortName": "Note 11 - Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12Leases", "longName": "995567 - Disclosure - Note 12 - Leases", "shortName": "Note 12 - Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayable", "longName": "995577 - Disclosure - Note 13 - Notes Payable", "shortName": "Note 13 - Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger", "longName": "995587 - Disclosure - Note 14 - Merger", "shortName": "Note 14 - Merger", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995597 - Disclosure - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareTables", "longName": "995607 - Disclosure - Note 2 - Loss Per Share (Tables)", "shortName": "Note 2 - Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsTables", "longName": "995617 - Disclosure - Note 4 - Discontinued Operations (Tables)", "shortName": "Note 4 - Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentTables", "longName": "995627 - Disclosure - Note 5 - Property and Equipment (Tables)", "shortName": "Note 5 - Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsTables", "longName": "995637 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Tables)", "shortName": "Note 6 - Goodwill and Other Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsTables", "longName": "995647 - Disclosure - Note 7 - Held-to-Maturity Investments (Tables)", "shortName": "Note 7 - Held-to-Maturity Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:HeldToMaturitySecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:HeldToMaturitySecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsTables", "longName": "995657 - Disclosure - Note 8 - Fair Value Measurements (Tables)", "shortName": "Note 8 - Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationTables", "longName": "995667 - Disclosure - Note 9 - Share-Based Compensation (Tables)", "shortName": "Note 9 - Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesTables", "longName": "995677 - Disclosure - Note 12 - Leases (Tables)", "shortName": "Note 12 - Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first":
```

```
true, "unique": true } }, "R35": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableTables", "longName": "995687 - Disclosure - Note 13 - Notes Payable (Tables)", "shortName": "Note 13 - Notes Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-tables", "longName": "995697 - Disclosure - Note 14 - Merger (Tables)", "shortName": "Note 14 - Merger (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "longName": "995707 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_3589cb3c-785a-4eea-a3eb-35da56d48bbb", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "C_9e16f619-101e-455c-85d6-0becdf3eedd4", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } }, "R38": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSl "longName": "995717 - Disclosure - Note 2 - Loss Per Share - Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares (Details)", "shortName": "Note 2 - Loss Per Share - Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual", "longName": "995727 - Disclosure - Note 2 - Loss Per Share (Details Textual)", "shortName": "Note 2 - Loss Per Share (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_00e32e8f-0d0b-41a8-9365-848f7cfe4a30", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_00e32e8f-0d0b-41a8-9365-848f7cfe4a30", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "longName": "995737 - Disclosure - Note 3 - Investments and Agreements (Details Textual)", "shortName": "Note 3 - Investments and Agreements (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_3589cb3c-785a-4eea-a3eb-35da56d48bbb", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_67686253-d31c-4b33-87f1-4efe2fb38aac", "name": "catx:MaximumAmountOfSecuritiesOfferAndSale", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "catx:InvestmentsAndAgreementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } }, "R41": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual", "longName": "995747 - Disclosure - Note 4 - Discontinued Operations (Details Textual)", "shortName": "Note 4 - Discontinued Operations (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1708ebd5-b6be-499e-b9b9-0a884f98c6ea", "name": "us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } }, "R42": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails", "longName": "995757 - Disclosure - Note 4 - Discontinued Operations - Schedule of Discontinued Operations (Details)", "shortName": "Note 4 - Discontinued Operations - Schedule of Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_cd974e09-db9f-4006-b212-e0c1944377b4", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } }, "R43": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual", "longName": "995767 - Disclosure - Note 5 - Property and Equipment (Details Textual)", "shortName": "Note 5 - Property and Equipment (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_dd202802-e62e-4ada-8a99-643da023b1e6", "name": "us-gaap:PaymentsToAcquireBuildings", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } }, "R44": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails", "longName": "995777 - Disclosure - Note 5 - Property and Equipment - Summary of Property and Equipment (Details)", "shortName": "Note 5 - Property and Equipment - Summary of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsDetailsTextual", "longName": "995787 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Details Textual)", "shortName": "Note 6 - Goodwill and Other Intangible Assets (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-gaap:Goodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": null }, "R46": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails", "longName": "995797 - Disclosure - Note 6 - Goodwill and Other Intangible Assets - Summary of Components of Other Intangible Assets (Details)", "shortName": "Note 6 - Goodwill and Other Intangible Assets - Summary of Components of Other Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "catx:IndefinitelivedIntangibleAssetsAccumulatedAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } }, "R47": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments "longName": "995807 - Disclosure - Note 7 - Held-to-Maturity Investments - Summary of Carrying Values and Fair Values of Financial Instruments (Details)", "shortName": "Note 7 - Held-to-Maturity Investments - Summary of Carrying Values and Fair Values of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_4a612984-0438-4e0d-a138-ec5b77eeaa5c", "name": "us-gaap:HeldToMaturitySecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:HeldToMaturitySecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4a612984-0438-4e0d-a138-ec5b77eeaa5c", "name": "us-gaap:HeldToMaturitySecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:HeldToMaturitySecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual", "longName": "995817 - Disclosure - Note 7 - Held-to-Maturity Investments (Details Textual)", "shortName": "Note 7 - Held-to-Maturity Investments (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_4a612984-0438-4e0d-a138-ec5b77eeaa5c", "name": "us-gaap:DebtSecuritiesHeldToMaturityAllowanceForCreditLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4a612984-0438-4e0d-a138-ec5b77eeaa5c", "name": "us-gaap:DebtSecuritiesHeldToMaturityAllowanceForCreditLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R49": { "role":
```

```
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
"longName": "995827 - Disclosure - Note 8 - Fair Value Measurements - Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed
Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Note 8 - Fair Value Measurements - Summary of Money Market Fund
Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_500d0f24-1116-4260-90bb-91b61b912063",
"name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table",
"ix:continuation", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "C_500d0f24-1116-4260-90bb-91b61b912063", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "U_USD",
"xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-
gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R50": {
"role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual", "longName": "995837 - Disclosure - Note 8
- Fair Value Measurements (Details Textual)", "shortName": "Note 8 - Fair Value Measurements (Details Textual)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_5bf05927-94e4-4a95-9984-6b298f0f8ffd", "name": "us-
gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF",
"ancestors": [ "span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "C_5bf05927-94e4-4a95-9984-6b298f0f8ffd", "name": "us-
gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF",
"ancestors": [ "span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true,
"unique": true } }, "R51": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual", "longName":
"995847 - Disclosure - Note 9 - Share-Based Compensation (Details Textual)", "shortName": "Note 9 - Share-Based Compensation (Details Textual)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_38d0f025-b28e-421d-83b7-c7dd95cfbc94", "name":
"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null,
"decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1,
"baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_38d0f025-b28e-421d-83b7-c7dd95cfbc94", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null,
"decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1,
"baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R52": { "role":
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForShareI
"longName": "995857 - Disclosure - Note 9 - Share-Based Compensation - Summary of Share-based Compensation Expense Recognized for Share-based Compensation
Arrangements (Details)", "shortName": "Note 9 - Share-Based Compensation - Summary of Share-based Compensation Expense Recognized for Share-based Compensation
Arrangements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef":
"C_1708ebd5-b6be-499e-b9b9-0a884f98c6ea", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals":
"-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "C_1708ebd5-b6be-499e-b9b9-0a884f98c6ea", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef":
"U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true,
"unique": true } }, "R53": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual",
"longName": "995867 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual)", "shortName": "Note 10 - Commitments and Contingencies (Details
Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_39e83072-f64a-
4330-a9f8-6c6753757143", "name": "us-gaap:LossContingencyNumberOfPlaintiffs", "unitRef": "U_Plaintiff", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [
"span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "C_39e83072-f64a-4330-a9f8-6c6753757143", "name": "us-gaap:LossContingencyNumberOfPlaintiffs", "unitRef": "U_Plaintiff",
"xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ],
"reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R54": { "role":
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual", "longName": "995877 - Disclosure - Note 11 - Related
Parties (Detailed Textual)", "shortName": "Note 11 - Related Parties (Detailed Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "54", "firstAnchor": { "contextRef": "C_df83baa6-486b-4fda-92bc-9eb801eed56f", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef":
"U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "catx:InvestmentsAndAgreementsDisclosureTextBlock", "div", "body", "html" ],
"reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_bfd13d90-c529-4b89-a799-077676c27f83", "name": "us-
gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-
gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } }, "R55": { "role":
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual", "longName": "995887 - Disclosure - Note 12 - Leases (Details
Textual)", "shortName": "Note 12 - Leases (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55",
"firstAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-
gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef":
"C_1708ebd5-b6be-499e-b9b9-0a884f98c6ea", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [
"span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } }, "R56": { "role":
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails", "longName":
"995897 - Disclosure - Note 12 - Leases - Summary of Future Operating Lease Payments and Lease Liability (Details)", "shortName": "Note 12 - Leases - Summary of Future
Operating Lease Payments and Lease Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56",
"firstAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef":
"U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div",
"us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil":
"false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-
gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R57": { "role":
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual", "longName": "995907 - Disclosure - Note 13 - Notes Payable
(Details Textual)", "shortName": "Note 13 - Notes Payable (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "57", "firstAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-gaap:NotesPayableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang":
null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": {
"contextRef": "C_513fc3d4-d3e9-47e0-9d3f-2782358efea1", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5",
"ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } }, "R58": { "role":
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails", "longName": "995917 - Disclosure - Note
13 - Notes Payable - Summary of Note Payable (Details)", "shortName": "Note 13 - Notes Payable - Summary of Note Payable (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-
gaap:NotesPayableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1,
"baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_862255d9-6407-4514-976d-8e55cdfe1e0b", "name": "us-gaap:NotesPayable", "unitRef":
"U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-
gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } }, "R59": { "role":
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfMaturityOfNotePayableDetails", "longName": "995927 -
Disclosure - Note 13 - Notes Payable - Summary of Maturity of Note Payable (Details)", "shortName": "Note 13 - Notes Payable - Summary of Maturity of Note Payable
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-
9aaa-35ac8d1b31f4", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock",
"div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-
35ac8d1b31f4", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"
], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } }, "R60": { "role":
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual", "longName": "995937 - Disclosure - Note 14 - Merger (Details
Textual)", "shortName": "Note 14 - Merger (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60",
"firstAnchor": { "contextRef": "C_1708ebd5-b6be-499e-b9b9-0a884f98c6ea", "name": "us-gaap:RevenueNotFromContractWithCustomer", "unitRef": "U_USD", "xsiNil": "false",
"lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": {
"contextRef": "C_00e32e8f-0d0b-41a8-9365-848f7cfe4a30", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "unitRef": "U_pure", "xsiNil": "false",
"lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-
20240630.htm", "unique": true } }, "R61": { "role":
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails", "longName": "995947 -
Disclosure - Note 14 - Merger - Summary of Estimated Purchase Consideration (Details)", "shortName": "Note 14 - Merger - Summary of Estimated Purchase Consideration
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_d93a6545-8db6-
4844-aa12-536bf511e889", "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "unitRef": "U_USD", "xsiNil": "false", "lang":
null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ],
"reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d93a6545-8db6-4844-aa12-536bf511e889", "name":
"catx:BusinessCombinationOptionsAndWarrantsAssumption", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table",
"ix:continuation", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } },
"R62": { "role":
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals", "longName":
"995957 - Disclosure - Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) (Parentheticals)", "shortName": "Note 14 - Merger - Summary of Estimated
Purchase Consideration (Details) (Parentheticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "62",
"firstAnchor": { "contextRef": "C_d93a6545-8db6-4844-aa12-536bf511e889", "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
"unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-
gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1,
"baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": null }, "R63": { "role":
```

```
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails", "longName": "995967 - Disclosure - Note 14 - Merger - Summary of Preliminary Purchase Price Allocation (Details)", "shortName": "Note 14 - Merger - Summary of Preliminary Purchase Price Allocation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_c62f5efb-aa0b-41a4-9aaa-35ac8d1b31f4", "name": "us-gaap:Goodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_00e32e8f-0d0b-41a8-9365-848f7cfe4a30", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "unique": true } }, "R64": { "role": "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfProFormaComputationOfEarningsPerShareDetails", "longName": "995977 - Disclosure - Note 14 - Merger - Summary of Pro Forma Computation of Earnings Per Share (Details)", "shortName": "Note 14 - Merger - Summary of Pro Forma Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_10d554ad-d639-48e5-882c-cb7dd276bcb2", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_10d554ad-d639-48e5-882c-cb7dd276bcb2", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240630.htm", "first": true, "unique": true } } }, "tag": { "catx_ATMAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "ATMAgreementMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "A T M Agreement [Member]", "label": "A T M Agreement [Member]", "documentation": "A T M agreement." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued expenses", "label": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "terseLabel": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r26" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net of allowance for doubtful accounts: 2024 - $606; 2023 - $650", "label": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r247", "r248" ] }, "catx_AccruedInterestOnShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "AccruedInterestOnShortTermInvestments", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "negatedLabel": "Accrued interest on short-term investments", "label": "catx_AccruedInterestOnShortTermInvestments", "documentation": "Amount of accrued interest on short-term investments." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less accumulated depreciation", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r52", "r184", "r548" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r757" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "terseLabel": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r103" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r418", "r419", "r420", "r570", "r830", "r831", "r832", "r908", "r930" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r763" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r763" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r763" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r763" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentForAmortization", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "Amortization of other assets", "totalLabel": "Amortization, Total", "verboseLabel": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r9", "r50" ] }, "catx_AdjustmentsToAdditionalPaidInCapitalAssumptionOfStockOptionsAndWarrantsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalAssumptionOfStockOptionsAndWarrantsAtFairValue", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Assumption of Viewpoint stock options and warrants at fair value", "label": "catx_AdjustmentsToAdditionalPaidInCapitalAssumptionOfStockOptionsAndWarrantsAtFairValue", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the assumption of stock options and warrants at fair value." } } }, "auth_ref": [] }, "catx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceOfPreFundedWarrants", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital, issuance of pre-funded warrants.", "label": "Adjustments To Additional Paid In Capital, Issuance of Pre-funded Warrants", "terseLabel": "Issuance of Pre-funded Warrants, net" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "label": "Share-based compensation", "terseLabel": "Share-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r57", "r58", "r384" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash provided by or used in operating activities:" } } }, "auth_ref": [] }, "catx_AggregateMaximumEstimateSettlementAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "AggregateMaximumEstimateSettlementAmount", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Aggregate maximum estimate settlement amount.", "label": "Aggregate maximum estimate settlement amount" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r728", "r739", "r749", "r774" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r731", "r742", "r752", "r777" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r763" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r770" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r735", "r743", "r753", "r770", "r778", "r782", "r790" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r788" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForSharel ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r413", "r421" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": {
```

```
"periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance", "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r191", "r250", "r293", "r296", "r299", "r925" ] }, "catx_AmendedTwoThousandTwentyIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "AmendedTwoThousandTwentyIncentivePlanMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Amended 2020 Incentive Plan [Member]", "label": "Amended Two Thousand Twenty Incentive Plan [Member]", "documentation": "Amended two thousand twenty incentive plan." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSl
], "lang": { "en-us": { "role": { "label": "Antidilutive securities (in shares)", "terseLabel": "Total potential dilutive securities", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r230" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSl
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r45" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSl
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSl
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r45" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r437" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "totalLabel": "Asset Acquisition, Consideration Transferred, Total", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Asset purchase price in cash", "verboseLabel": "Purchase price", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r704", "r905", "r906", "r907" ] }, "us-gaap_AssetRetirementObligationAccretionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationAccretionExpense", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion of asset retirement obligation", "label": "Accretion of discount", "documentation": "Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability." } } }, "auth_ref": [ "r313", "r314" ] }, "us-gaap_AssetRetirementObligationRevisionOfEstimate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationRevisionOfEstimate", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in estimate of asset retirement obligation (Note 4)", "negatedLabel": "Change in estimate of asset retirement obligation", "terseLabel": "Change in estimate of asset retirement obligation (Note 4)", "label": "Asset Retirement Obligation, Revision of Estimate", "documentation": "Amount of increase (decrease) in the asset retirement obligation from changes in the amount or timing of the estimated cash flows associated with the settlement of the obligation." } } }, "auth_ref": [ "r315" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "us-gaap_Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r149", "r187", "r203", "r237", "r241", "r243", "r290", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r438", "r441", "r464", "r541", "r608", "r707", "r719", "r870", "r871", "r913" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "us-gaap_AssetsCurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r180", "r192", "r203", "r290", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r438", "r441", "r464", "r707", "r870", "r871", "r913" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Noncurrent assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "totalLabel": "Total current assets held for sale of discontinued operations", "terseLabel": "Current assets held for sale, discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r78", "r94", "r129", "r131", "r178", "r179" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]", "terseLabel": "Assets held for sale of discontinued operations, current" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r785" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r786" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r781" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r781" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r781" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r781" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r781" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r781" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r784" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r783" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r782" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r782" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Balance
```

Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual"], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": ["r64", "r65"] }, "catx_BofASecuritiesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "BofASecuritiesIncMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "BofA Securities, Inc [Member]", "label": "Bof A Securities, Inc [Member]", "documentation": "BofA Securities, Inc." } } }, "auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Building [Member]", "terseLabel": "Building", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": ["r130"] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r435", "r699", "r700"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r59", "r61", "r435", "r699", "r700"] }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Business acquisition, shares (in shares)", "verboseLabel": "Common stock issued pursuant to merger, Shares", "terseLabel": "Business acquisition, number of common shares exchanged", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": ["r144"] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r435"] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired", "terseLabel": "Business acquisition, percentage of voting interests acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": ["r60"] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-tables"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Summary of Pro Forma Computation of Earnings Per Share", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": ["r800", "r801"] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionSharePrice", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Business acquisition, price per share (in dollars per share)", "terseLabel": "Business acquisition, closing market price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfProFormaComputationOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": ["r433", "r434"] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfProFormaComputationOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Grant revenue", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": ["r433", "r434"] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total fair value of consideration transferred", "label": "us-gaap_BusinessCombinationConsiderationTransferred1", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": ["r1", "r2", "r13"] }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Perspective Therapeutics common stock issued (13,654,507 x $4.00)", "terseLabel": "Business combination, fair value of common stock", "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": ["r1", "r2"] }, "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "Total purchase price consideration", "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": ["r13", "r18"] }, "catx_BusinessCombinationConsiderationTransferredLiabilitiesForgiven": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "BusinessCombinationConsiderationTransferredLiabilitiesForgiven", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails"], "lang": { "en-us": { "role": { "label": "Note receivable and interest from Viewpoint forgiven", "documentation": "Amount of liabilities forgiven by the acquirer as part of consideration transferred in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger"], "lang": { "en-us": { "role": { "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Merger", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": ["r142", "r436"] }, "catx_BusinessCombinationOptionsAndWarrantsAssumption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "BusinessCombinationOptionsAndWarrantsAssumption", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Assumption of Viewpoint stock options and warrants at fair value", "label": "catx_BusinessCombinationOptionsAndWarrantsAssumption", "documentation": "The amount of fair value of options and warrants assumed in business acquisition." } } }, "auth_ref": [] }, "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPayrollAndRelatedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPayrollAndRelatedTax", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll and related taxes", "label": "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPayrollAndRelatedTax", "documentation": "Amount of accrued payroll and related taxes, assumed at the acquisition date." } } }, "auth_ref": [] }, "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedVacation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedVacation", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued vacation", "label": "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedVacation", "documentation": "Amount of accrued vacation, assumed at the acquisition date." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total assets acquired", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": ["r63"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "crdr": "credit",

"presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "documentation": "Amount of lease obligation assumed in business combination." } } }, "auth_ref": ["r63"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r63"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r63"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Grants receivable", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r63"] }, "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables and accrued expenses, assumed at the acquisition date." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "Deferred tax liability", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": ["r63"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "terseLabel": "Intangible assets, in-process research and development", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": ["r63"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities assumed", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": ["r63"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Net assets acquired, excluding goodwill", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": ["r62", "r63"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "Notes payable", "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": ["r63"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r63"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "terseLabel": "Property and equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": ["r62", "r63"] }, "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Right of use asset", "label": "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets", "documentation": "amount of right of use assets acquired at acquisition date." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAcquiredFromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAcquiredFromAcquisition", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Net cash acquired in acquisition of Viewpoint", "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)." } } }, "auth_ref": ["r36"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "terseLabel": "Cash and Cash Equivalents, at Carrying Value", "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r40", "r182", "r675"] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, and Short-Term Investments", "terseLabel": "Cash, cash equivalents and short-term investments", "totalLabel": "Total cash equivalents and short-term investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": ["r820"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash beginning of period", "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH END OF PERIOD", "label": "Total cash, cash equivalents and restricted cash shown on the condensed consolidated statements of cash flows", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash

includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r40", "r120", "r201"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r3", "r120"] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq], "lang": { "en-us": { "role": { "totalLabel": "Cash Equivalents, at Carrying Value, Total", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r815", "r924"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Supplemental schedule of noncash investing and financing activities:" } } }, "auth_ref": [] }, "catx_Cesium131BusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "Cesium131BusinessMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Relating to Cesium-131 Business.", "label": "Cesium-131 Business [Member]", "terseLabel": "Cesium-131 Business [Member]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r761"] }, "catx_ChicagoIllinoisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "ChicagoIllinoisMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual"], "lang": { "en-us": { "role": { "label": "Chicago Illinois [Member]", "documentation": "Chicago Illinois." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r171", "r188", "r189", "r190", "r203", "r224", "r225", "r227", "r229", "r235", "r236", "r290", "r325", "r327", "r328", "r329", "r332", "r333", "r363", "r364", "r366", "r367", "r369", "r464", "r562", "r563", "r564", "r565", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r595", "r617", "r639", "r654", "r655", "r656", "r657", "r658", "r796", "r825", "r834"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r55"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Warrant exercise price per share", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r370"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Warrants to purchase shares of common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r370"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r762"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r762"] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r437"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 9)", "terseLabel": "Commitments and contingencies (Note 10)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r33", "r72", "r543", "r594"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote10CommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r133", "r317", "r318", "r660", "r866"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r709", "r710", "r711", "r713", "r714", "r715", "r716", "r830", "r831", "r908", "r929", "r930"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "verboseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r102"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, authorized (in shares)", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r102", "r595"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, issued (in shares)", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r102"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, outstanding (in shares)", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r15", "r102", "r595", "r614", "r930", "r931"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value; 750,000,000 shares authorized; 67,425,167 and 28,180,985 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively",

```
"label": "Common stock, $.001 par value; 750,000,000 shares authorized; 280,571,026 and 142,112,766 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } }, "auth_ref": [ "r102", "r545", "r707" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r767" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r766" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r768" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r765" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r206", "r438", "r439", "r441", "r442", "r489", "r670", "r869", "r872", "r873" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r206", "r438", "r439", "r441", "r442", "r489", "r670", "r869", "r872", "r873" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r204", "r205", "r338", "r365", "r487", "r676", "r678" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayable" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Notes Payable", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r134", "r202", "r334", "r340", "r341", "r342", "r343", "r344", "r345", "r350", "r357", "r358", "r360" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r23", "r99", "r100", "r150", "r151", "r206", "r335", "r336", "r337", "r338", "r339", "r341", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r472", "r689", "r690", "r691", "r692", "r693", "r826" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt instrument, face amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r68", "r69", "r335", "r472", "r690", "r691" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt instrument, interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r30", "r336" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r206", "r335", "r336", "r337", "r338", "r339", "r341", "r346", "r347", "r348", "r349", "r351", "r352", "r353", "r354", "r355", "r356", "r359", "r472", "r689", "r690", "r691", "r692", "r693", "r826" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r31", "r206", "r335", "r336", "r337", "r338", "r339", "r341", "r346", "r347", "r348", "r349", "r351", "r352", "r353", "r354", "r355", "r356", "r472", "r689", "r690", "r691", "r692", "r693", "r826" ] }, "catx_DebtInstrumentNumberOfPaymentInstallment": { "xbrltype": "integerItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "DebtInstrumentNumberOfPaymentInstallment", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual" ], "lang": { "en-us": { "role": { "label": "catx_DebtInstrumentNumberOfPaymentInstallment", "documentation": "Represents number of installment to pay debt." }, "terseLabel": "Debt instrument, number of monthly payments" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentPeriodicPayment", "terseLabel": "Debt instrument, periodic payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r31", "r74" ] }, "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "terseLabel": "Debt instrument balloon payment", "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r31", "r53", "r54", "r67", "r68", "r69", "r73", "r135", "r136", "r206", "r335", "r336", "r337", "r338", "r339", "r341", "r346", "r347", "r348", "r349", "r351", "r352", "r353", "r354", "r355", "r356", "r359", "r472", "r689", "r690", "r691", "r692", "r693", "r826" ] }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLoss", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual" ], "lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Total", "periodStartLabel": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Beginning Balance", "periodEndLabel": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Ending Balance", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss", "terseLabel": "Held-to-maturity, allowance for credit loss", "documentation": "Amount of allowance for credit loss for debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r273", "r293", "r296", "r299" ] }, "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss", "terseLabel": "Held-to-maturity investments", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r256", "r274", "r276", "r536" ] }, "us-gaap_DeferredIncomeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeCurrent", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Income, Current", "terseLabel": "Deferred Income (Note 3)", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r799" ] }, "us-gaap_DeferredIncomeNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeNoncurrent", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Income, Noncurrent", "terseLabel": "Deferred Income (Note 3)", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r799" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Income Tax Expense (Benefit)", "label": "Deferred tax benefit", "verboseLabel": "Deferred income tax benefit", "totalLabel": "Deferred Income Tax Expense (Benefit), Total", "negatedLabel": "Deferred income tax benefit", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r9", "r141", "r170", "r430", "r431", "r828" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r423", "r424", "r542" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
```

```
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation, Total", "label": "Depreciation expense", "totalLabel": "Depreciation, Total", "verboseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r9", "r51" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r382", "r386", "r414", "r415", "r417", "r702" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "terseLabel": "Net loss from discontinued operations", "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r82", "r83", "r84", "r85", "r86", "r92", "r111", "r926" ] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "terseLabel": "Loss from discontinued operations, Basic", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "terseLabel": "Loss from discontinued operations, Diluted", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "terseLabel": "Discontinued operations, Provision (benefit) for income taxes", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r83", "r84", "r85", "r86", "r92", "r96", "r425", "r429", "r432" ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Disposed of by Sale [Member]", "terseLabel": "Discontinued Operations, Disposed of by Sale [Member]", "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results." } } }, "auth_ref": [ "r6" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r178" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "catx_DisposalGroupIncludingDiscontinuedOperationAssetRetirementObligationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetRetirementObligationCurrent", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as asset retirement obligation attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group Including Discontinued Operation Asset Retirement Obligation Current", "terseLabel": "Asset retirement obligation" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Estimated fair value", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of sales", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r93", "r179" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r93" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "terseLabel": "Gross profit", "totalLabel": "Gross profit", "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r93", "r179" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "terseLabel": "Inventory", "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r78", "r94", "r129", "r131" ] }, "catx_DisposalGroupIncludingDiscontinuedOperationLeaseLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationLeaseLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group Including Discontinued Operation Lease Liabilities Current", "terseLabel": "Lease liability" } } }, "auth_ref": [] }, "catx_DisposalGroupIncludingDiscontinuedOperationLossOnClassificationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationLossOnClassificationCurrent", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as loss of classification attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group Including Discontinued Operation Loss On Classification Current", "terseLabel": "Loss recognized on classification as held for sale" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "terseLabel": "Total operating expenses", "totalLabel": "Total operating expenses", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r93" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total loss from discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "terseLabel": "Net loss from discontinued operations", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r93" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current", "terseLabel": "Other assets, net", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r78", "r94", "r129", "r131" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r78", "r94", "r129", "r131" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "terseLabel": "Property and equipment, net", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal
```

operating cycle, if longer." } } }, "auth_ref": ["r4", "r78", "r94", "r129", "r131"] }, "catx_DisposalGroupIncludingDiscontinuedOperationPropertyRightOfUseAssetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyRightOfUseAssetCurrent", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount classified as right of use asset attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group Including Discontinued Operation Property Right Of Use Asset Current", "terseLabel": "Right-of-use asset, net" } } }, "auth_ref": [] }, "catx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group Including Discontinued Operation Research and Development Expense", "terseLabel": "Research and development" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Sales, net", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r93", "r179"] }, "catx_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of sales and marketing expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group Including Discontinued Operation Sales and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperations"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Discontinued Operations", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r77", "r128"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r699", "r700"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r723"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r756"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Basic and diluted loss per share." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "totalLabel": "Basic loss per share", "label": "Basic and diluted loss per share (in dollars per share)", "terseLabel": "Basic loss per share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r198", "r212", "r213", "r214", "r215", "r216", "r222", "r224", "r227", "r228", "r229", "r233", "r451", "r452", "r537", "r554", "r679"] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicLineItems", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r224", "r225", "r227"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "totalLabel": "Diluted loss per share", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted loss per share", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r198", "r212", "r213", "r214", "r215", "r216", "r224", "r227", "r228", "r229", "r233", "r451", "r452", "r537", "r554", "r679"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Loss Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r221", "r230", "r231", "r232"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "terseLabel": "Effective income tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r426"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accrued personnel expenses", "label": "Employee-related Liabilities, Current", "totalLabel": "Employee-related Liabilities, Current, Total", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r28"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForShareI], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual"], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Unrecognized compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r416"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual"], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Unrecognized compensation expense, weighted-average expected recognition period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r416"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSh "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Common Stock Options [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname":

```
"EntityAddressStateOrProvince", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [
"r721" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname":
"EntityCommonStockSharesOutstanding", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ],
"lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-
information" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname":
"EntityDomain", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesTables" ], "lang": { "en-us": { "role": { "label":
"Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r721" ] }, "dei_EntityFileNumber": { "xbrltype":
"fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri":
"http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-
and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r721" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype":
"edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] },
"dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r795" ] },
"dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r721" ]
}, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r721" ] },
"dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r721" ] }, "dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r721" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"EquipmentMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Equipment [Member]", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } },
"auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain",
"presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-
unaudited-" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r15", "r177", "r195", "r196", "r197", "r207", "r208", "r209", "r211",
"r217", "r219", "r234", "r291", "r292", "r371", "r418", "r419", "r420", "r427", "r428", "r443", "r444", "r445", "r446", "r447", "r448", "r450", "r465", "r466", "r467", "r468",
"r469", "r470", "r481", "r556", "r557", "r558", "r570", "r639" ] }, "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "EquityInterestIssuedOrIssuableByTypeAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Equity Interest Type [Axis]", "documentation": "Information by type of equity interests that are issued or issuable in a business combination." } } }, "auth_ref": [] }, "us-
gaap_EquityInterestIssuedOrIssuableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"EquityInterestIssuedOrIssuableTypeDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Equity Interest Issued or Issuable, Type [Domain]", "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination." } } }, "auth_ref": [
"r144" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r764" ] },
"ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r728", "r739", "r749", "r774" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label":
"Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r725", "r736", "r746", "r771" ] }, "us-
gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"EstimateOfFairValueFairValueDisclosureMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r348",
"r463", "r690", "r691" ] }, "catx_EstimatedHazardousWasteRemovalLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630",
"localname": "EstimatedHazardousWasteRemovalLiability", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Estimated hazardous waste removal liability.", "label": "Estimated Hazardous Waste Removal Liability", "terseLabel": "Estimated hazardous waste removal liability" } } }, "auth_ref": [] },
"ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category." } } }, "auth_ref": [ "r770" ]
}, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r454", "r455", "r458" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r454", "r455", "r458" ] }, "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnNonrecurringBasisTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis", "label": "Fair Value Measurements, Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3)." } } }, "auth_ref": [ "r16", "r66", "r147" ] }, "us-
gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r348", "r373", "r374", "r375", "r376", "r377", "r378", "r455", "r494", "r495", "r496", "r690", "r691",
"r696", "r697", "r698" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"FairValueByMeasurementBasisAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
```

```
], "lang": { "en-us": { "role": { "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r22", "r66", "r348", "r690", "r691" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r454", "r455", "r456", "r457", "r459" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r348", "r690", "r691" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r348", "r373", "r378", "r455", "r494", "r696", "r697", "r698" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r348", "r373", "r378", "r455", "r495", "r690", "r691", "r696", "r697", "r698" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r348", "r373", "r374", "r375", "r376", "r377", "r378", "r455", "r496", "r690", "r691", "r696", "r697", "r698" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementInputsDisclosureTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis." } } }, "auth_ref": [ "r146" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value, Beginning Balance", "periodEndLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value, Ending Balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "terseLabel": "Financial instruments measured at fair value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r17" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r348", "r373", "r374", "r375", "r376", "r377", "r378", "r494", "r495", "r496", "r690", "r691", "r696", "r697", "r698" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r453", "r459" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r294", "r295", "r300", "r301", "r302", "r305", "r306", "r307", "r359", "r368", "r449", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r553", "r687", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r854", "r855", "r856", "r857" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLossesWriteOffs", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs", "terseLabel": "Note receivable, forgiven amount", "documentation": "Amount of writeoff of financing receivable, charged against allowance for credit loss." } } }, "auth_ref": [ "r14", "r298", "r304", "r685" ] }, "us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Financing Receivable [Axis]", "documentation": "Information by class of financing receivable determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk." } } }, "auth_ref": [ "r47", "r48", "r173", "r174", "r175", "r176", "r249", "r251", "r252", "r253", "r254", "r300", "r301", "r302", "r682", "r683", "r684", "r685", "r686", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813" ] }, "us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Financing Receivable [Domain]", "documentation": "Financing receivables determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk." } } }, "auth_ref": [ "r173", "r174", "r175", "r176", "r251", "r252", "r253", "r254", "r682", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r732", "r743", "r753", "r778" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r732", "r743", "r753", "r778" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r732", "r743", "r753", "r778" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r732", "r743", "r753", "r778" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r732", "r743", "r753", "r778" ] }, "catx_GTMedicalStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "GTMedicalStockMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Relating to GT Medical stock.", "label": "G T Medical Stock [Member]", "terseLabel": "GT Medical Stock [Member]" } } }, "auth_ref": [] }, "catx_GTMedicalTechnologiesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "GTMedicalTechnologiesIncMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "label": "GT Medical Technologies, Inc. [Member]", "documentation": "Refers to information regarding the entity GT Medical Technologies, Inc.", "terseLabel": "GT Medical Technologies, Inc. [Member]" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal of property and equipment", "label": "us-gaap_GainLossOnDispositionOfAssets", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": [ "r824", "r862", "r863" ] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on divestiture", "label": "Gain (Loss) on Disposition of Business", "terseLabel": "Loss recognized on classification as held for sale", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r440", "r824" ] }, "us-
```

gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal of property and equipment", "label": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": ["r9"] }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "Loss recognized on classification as held for sale", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value." } } }, "auth_ref": ["r824"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r115", "r619"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForShare
], "lang": { "en-us": { "role": { "verboseLabel": "General and Administrative [Member]", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r113"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": ["r185", "r309", "r535", "r688", "r707", "r860", "r861"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssets"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Other Intangible Assets", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": ["r126"] }, "us-gaap_HeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecurities", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
], "lang": { "en-us": { "role": { "totalLabel": "HTM, amortized cost, Total", "label": "HTM, amortized cost", "terseLabel": "HTM, Amortized Cost", "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r169", "r272", "r300", "r859"] }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
], "lang": { "en-us": { "role": { "label": "HTM, gross unrealized gains", "terseLabel": "HTM, Gross Unrealized Gains", "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r163", "r282"] }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
], "lang": { "en-us": { "role": { "label": "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss", "negatedLabel": "HTM, Gross Unrealized Losses", "terseLabel": "HTM, Gross Unrealized Losses", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r164", "r283"] }, "us-gaap_HeldToMaturitySecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecuritiesFairValue", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
], "lang": { "en-us": { "role": { "label": "HTM, fair value", "terseLabel": "HTM, Estimated Fair Value", "totalLabel": "Debt Securities, Held-to-Maturity, Fair Value, Total", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r162", "r281", "r536", "r540"] }, "us-gaap_HeldToMaturitySecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecuritiesTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsTables"], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity [Table Text Block]", "terseLabel": "Summary of Carrying Values and Fair Values of Financial Instruments", "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853"] }, "catx_HoustonTexasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "HoustonTexasMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Houston Texas [Member]", "label": "Houston Texas [Member]", "documentation": "Houston Texas." } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails"
], "lang": { "en-us": { "role": { "label": "In Process Research and Development [Member]", "terseLabel": "In-process Research and Development", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "terseLabel": "Net loss from continuing operations", "totalLabel": "Net loss from continuing operations", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r0", "r109", "r157", "r237", "r240", "r242", "r244", "r538", "r551", "r681"] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Loss from continuing operations, Basic", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r108", "r155", "r158", "r198", "r210", "r212", "r213", "r214", "r215", "r224", "r227", "r228", "r452", "r537", "r927"] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Loss from continuing operations, Diluted", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r108", "r198", "r210", "r212", "r213", "r214", "r215", "r224", "r227", "r228", "r229", "r452", "r537", "r927"] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "negatedLabel": "Equity in loss of affiliate", "terseLabel": "Income (Loss) from Equity Method Investments", "label": "Equity in loss of affiliate", "negatedTerseLabel": "Loss on equity method investment", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": ["r9", "r110", "r156", "r239", "r289", "r550"] }, "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "label": "Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax", "totalLabel": "Net loss before deferred income tax benefit", "documentation": "Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments." } } }, "auth_ref": ["r114", "r821"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": ["r699", "r700"] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r12", "r20", "r25", "r78", "r87", "r88", "r89", "r90", "r91", "r95", "r97", "r98", "r132"] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType",

```
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForShare
], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r312",
"r316", "r624" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"IncomeStatementLocationDomain", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForShare
], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r316", "r624" ] },
"us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-
condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "documentation": "The
increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but
not paid." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-
condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "us-
gaap_IncreaseDecreaseInAccountsReceivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle)
from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": {
"label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred Income", "documentation": "Amount of increase (decrease) in deferred income and obligation to
transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r673" ] }, "us-
gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued personnel expenses", "label": "Increase (Decrease) in Employee
Related Liabilities", "totalLabel": "Increase (Decrease) in Employee Related Liabilities, Total", "documentation": "The increase (decrease) during the reporting period in the
aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r8"
] }, "catx_IncreaseDecreaseInInventoryRelatedToDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630",
"localname": "IncreaseDecreaseInInventoryRelatedToDiscontinuedOperations", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": {
"negatedLabel": "Inventory related to discontinued operations", "label": "Increase (Decrease) In Inventory Related to Discontinued Operations", "documentation": "Increase
(DeIncrease (decrease) in inventory related to discontinued operations.crease) In Inventory Related to Discontinued Operations" } } }, "auth_ref": [] }, "us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-
statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-
gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-
condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "us-
gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } }
}, "auth_ref": [ "r8" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails"
], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and
goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r310", "r311" ] }, "us-
gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails"
], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These
concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived
Intangible Assets (Excluding Goodwill)", "totalLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Total", "periodStartLabel": "Indefinite-Lived Intangible Assets
(Excluding Goodwill), Beginning Balance", "periodEndLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance", "terseLabel": "Intangible assets, in-
process research and development", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite
period of benefit." } } }, "auth_ref": [ "r127" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails"
], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset
(for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are
similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r49", "r127" ] },
"catx_IndefinitelivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname":
"IndefinitelivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails"
], "lang": { "en-us": { "role": { "label": "Accumulated Amortization", "documentation": "Accumulated amount of amortization of indefinite-lived assets." } } }, "auth_ref": [] },
"ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual." } } }, "auth_ref": [ "r735", "r743", "r753",
"r770", "r778", "r782", "r790" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } },
"auth_ref": [ "r788" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies
and Procedures:" } } }, "auth_ref": [ "r724", "r794" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023",
"localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider
Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r724", "r794" ] },
"ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider
Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r724", "r794" ] },
"catx_InterestAndOtherExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "InterestAndOtherExpense",
"crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-" ],
"lang": { "en-us": { "role": { "documentation": "Interest and other expense.", "label": "Interest and Other Expense", "terseLabel": "Interest and other expense", "negatedLabel":
"Interest and other expense" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual" ],
"lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseDebt", "terseLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for
as interest expense for debt." } } }, "auth_ref": [ "r118", "r354", "r362", "r692", "r693" ] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "InterestReceivable", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_InterestReceivable", "terseLabel": "Accrued interest", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called
accrued interest or accrued interest receivable." } } }, "auth_ref": [ "r818", "r932" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": {
"terseLabel": "Write-off of inventory associated with discontinued product", "verboseLabel": "Write-off of inventory associated with discontinued product", "label": "Write-off
of inventory associated with discontinued product", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including,
but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r308" ] },
"catx_InvestmentAgreementContingentAmountOfGrossProceedsRaised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630",
"localname": "InvestmentAgreementContingentAmountOfGrossProceedsRaised", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "Represents the amount of gross proceeds raised as part of an investment agreement.", "label": "Investment Agreement Contingent Amount Of Gross
Proceeds Raised", "terseLabel": "Investment agreement, contingent amount of gross proceeds raised" } } }, "auth_ref": [] }, "catx_InvestmentAgreementsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "InvestmentAgreementsAbstract", "lang": { "en-us": { "role": {
"documentation": "Investment agreements.", "label": "Investment Agreements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": {
"label": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } },
"auth_ref": [ "r116", "r238" ] }, "catx_InvestmentsAndAgreementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240630", "localname": "InvestmentsAndAgreementsDisclosureTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreements" ], "lang": { "en-us": { "role": { "documentation": "Investments
and agreements disclosure.", "label": "Investments And Agreements Disclosure [Text Block]", "terseLabel": "Investments and Agreements" } } }, "auth_ref": [] }, "us-
gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestments" ], "lang": { "en-us": { "role": { "label": "Investments in Debt
```

```
and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Held-to-Maturity Investments", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": { "r148", "r160", "r161", "r172", "r255", "r258", "r460", "r461" } }, "catx_IsorayMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "IsorayMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "documentation": "Isoray.", "label": "Isoray [Member]", "terseLabel": "Isoray [Member]" } } }, "auth_ref": [] }, "catx_IsorayNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "IsorayNoteMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual" ], "lang": { "en-us": { "role": { "label": "Isoray Note [Member]", "documentation": "Relating to the Isoray note." } } }, "auth_ref": [] }, "catx_January2024PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "January2024PublicOfferingMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "January 2024 Public Offering [Member]", "documentation": "January 2024 public offering." } } }, "auth_ref": [] }, "catx_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "JanuaryTwoThousandTwentyFourPreFundedWarrantsMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "January 2024 Pre-funded Warrants [Member]", "label": "January Two Thousand Twenty Four Pre-funded Warrants [Member]", "documentation": "January two thousand twenty four pre-funded warrants." } } }, "auth_ref": [] }, "catx_JanuaryTwoThousandTwentyFourPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "JanuaryTwoThousandTwentyFourPublicOfferingMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "documentation": "January two thousand twenty four public offering.", "label": "January Two Thousand Twenty Four Public Offering [Member]", "terseLabel": "January 2024 Public Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Land [Member]", "terseLabel": "Land", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r877" ] }, "catx_LantheusAlphaTherapyLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "LantheusAlphaTherapyLlcMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual" ], "lang": { "en-us": { "role": { "documentation": "Lantheus Alpha Therapy, LLC.", "label": "Lantheus Alpha Therapy, LLC [Member]" } } }, "auth_ref": [] }, "catx_LantheusInvestmentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "LantheusInvestmentAgreementMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "documentation": "Represents Lantheus Investment Agreement.", "label": "Lantheus Investment Agreement [Member]", "terseLabel": "Lantheus Investment Agreement", "verboseLabel": "Lantheus Investment Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermAxis", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r802" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermDomain", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r802" ] }, "catx_LeaseWithBoardOfRegentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "LeaseWithBoardOfRegentsMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Lease with Board of Regents [Member]", "documentation": "Lease with Board of Regents." } } }, "auth_ref": [] }, "catx_LeaseWithEnergyNorthwestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "LeaseWithEnergyNorthwestMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Lease With Energy Northwest [Member]", "documentation": "Represents lease with Energy Northwest." } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r130" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesTables" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r476" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r476" ] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseDiscountRate", "terseLabel": "Lessee, operating lease, discount rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": [ "r705" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Summary of Future Operating Lease Payments and Lease Liability", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r911" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "totalLabel", "Total", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r480" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r480" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r480" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r480" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r480" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "2024 (remaining six months)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r911" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r480" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12Leases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r473" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "us-gaap_Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r27", "r203", "r290", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r439", "r441", "r442", "r464", "r593", "r680", "r719", "r870", "r913", "r914" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [
```

```
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r107", "r152", "r547", "r707", "r827", "r858", "r909" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "us-gaap_LiabilitiesCurrent", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r29", "r181", "r203", "r290", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r439", "r441", "r442", "r464", "r707", "r870", "r913", "r914" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "totalLabel": "Total current liabilities of discontinued operations", "terseLabel": "Current liabilities of discontinued operations", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r78", "r94", "r129", "r131", "r178", "r179" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]", "terseLabel": "Liabilities held for sale of discontinued operations, current" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOtherThanLongTermDebtNoncurrentAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities:", "terseLabel": "Noncurrent liabilities:" } } }, "auth_ref": [] }, "us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessFormationDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LimitedLiabilityCompanyOrLimitedPartnershipBusinessFormationDate", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Limited Liability Company or Limited Partnership, Business, Formation Date", "terseLabel": "Limited liability company, Formation date", "documentation": "Date the limited liability company (LLC) or limited partnership (LP) was formed, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfMaturityOfNotePayableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "us-gaap_LongTermDebt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r23", "r151", "r347", "r361", "r690", "r691", "r923" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfMaturityOfNotePayableDetails" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "verboseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r206", "r352" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfMaturityOfNotePayableDetails" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "verboseLabel": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r206", "r352" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfMaturityOfNotePayableDetails" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "verboseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r206", "r352" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfMaturityOfNotePayableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2024 (remaining six months)", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r829" ] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermNotesPayable", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Note payable", "totalLabel": "Note payable, long-term portion", "label": "Note payable, long-term portion", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r31" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r319", "r320", "r321", "r324", "r867", "r868" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r319", "r320", "r321", "r324", "r867", "r868" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Accrual", "label": "us-gaap_LossContingencyAccrualAtCarryingValue", "verboseLabel": "Estimated liability", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r319", "r797" ] }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNumberOfPlaintiffs", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Number of Plaintiffs", "terseLabel": "Number of plaintiff", "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency." } } }, "auth_ref": [ "r867", "r868" ] }, "catx_March2024PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "March2024PrivatePlacementMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Represents the March 2024 private placement.", "label": "March 2024 Private Placement [Member]", "terseLabel": "March 2024 Private Placement [Member]" } } }, "auth_ref": [] }, "catx_MarchTwoThousandTwentyFourInvestmentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "MarchTwoThousandTwentyFourInvestmentAgreementMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "documentation": "March two thousand twenty four investment agreement.", "label": "March Two Thousand Twenty Four Investment Agreement [Member]", "terseLabel": "March 2024 Investment Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_MaturitiesOfLongTermDebtAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MaturitiesOfLongTermDebtAbstract", "lang": { "en-us": { "role": { "label": "Maturities of Long-Term Debt [Abstract]" } } }, "auth_ref": [] }, "catx_MaximumAmountOfSecuritiesOfferAndSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "MaximumAmountOfSecuritiesOfferAndSale", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Maximum amount of securities offer and sale.", "label": "Maximum Amount Of Securities Offer And Sale", "terseLabel": "Maximum amount of securities offer and sale" } } }, "auth_ref": [] }, "catx_MaximumIncreaseOrDecreaseInOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "MaximumIncreaseOrDecreaseInOwnershipPercentage", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Maximum increase or decrease in ownership percentage.", "label": "Maximum Increase Or Decrease In Ownership Percentage", "terseLabel": "Maximum increase or decrease in ownership percentage" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r380", "r521", "r555", "r585", "r586", "r645", "r647", "r649", "r650", "r652", "r671", "r672", "r682", "r694", "r701", "r708", "r874", "r915", "r916", "r917", "r918", "r919", "r920" ] }, "catx_May2024PreFundedWarrantsMember": { "xbrltype": "domainItemType",
```

```
"nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "May2024PreFundedWarrantsMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "May
2024 Pre-funded Warrants [Member]", "documentation": "May 2024 pre-funded warrants." } } }, "auth_ref": [] },
"catx_MayTwoThousandTwentyFourPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname":
"MayTwoThousandTwentyFourPreFundedWarrantsMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited-", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-
changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "May 2024 Pre-funded Warrants [Member]", "label": "May Two Thousand Twenty Four
Pre-funded Warrants [Member]", "documentation": "May two thousand twenty four pre-funded warrants." } } }, "auth_ref": [] },
"catx_MayTwoThousandTwentyFourPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname":
"MayTwoThousandTwentyFourPublicOfferingMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "May 2024 Public Offering [Member]", "label": "May Two Thousand Twenty
Four Public Offering [Member]", "documentation": "May two thousand twenty four public offering." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r762" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure
Name", "terseLabel": "Name" } } }, "auth_ref": [ "r762" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname":
"MinimumMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual" ], "lang": { "en-us": {
"role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r380", "r521", "r555", "r585", "r586", "r645",
"r647", "r649", "r650", "r652", "r671", "r672", "r682", "r694", "r701", "r708", "r874", "r915", "r916", "r917", "r918", "r919", "r920" ] }, "ecd_MnpiDiscTimedForCompValFlag":
{ "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI
Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r781" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money Market Fund [Member]", "documentation": "Fund that invests in short-term
money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit,
and other highly liquid securities." } } }, "auth_ref": [ "r878" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": {
"role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r789" ] },
"ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named
Executive Officers, Footnote" } } }, "auth_ref": [ "r763" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": {
"totalLabel": "Net cash provided by financing activities", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "documentation": "Amount of cash inflow (outflow)
from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a
return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors
on long-term credit." } } }, "auth_ref": [ "r200" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": {
"label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": {
"label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash (used in) provided by investing activities", "documentation": "Amount of cash inflow
(outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or
equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r200" ] }, "us-
gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-
gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"NetCashProvidedByUsedInOperatingActivities", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-
statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by
(used in) operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows
include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r120", "r121", "r122" ] }, "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-
gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net loss",
"verboseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r112",
"r122", "r159", "r179", "r193", "r194", "r197", "r203", "r210", "r212", "r213", "r214", "r215", "r218", "r219", "r226", "r237", "r240", "r242", "r244", "r290", "r325", "r326",
"r327", "r328", "r329", "r330", "r331", "r332", "r333", "r452", "r464", "r552", "r616", "r637", "r638", "r681", "r717", "r870" ] },
"catx_NetSalesBetween10And15MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname":
"NetSalesBetween10And15MillionMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual" ], "lang": { "en-us": { "role": { "documentation":
"Relating to net sales between $10 and 15 million.", "label": "Net Sales Between 10 And 15 Million [Member]", "terseLabel": "Net Sales Between $10 and 15 Million [Member]"
} } }, "auth_ref": [] }, "catx_NetSalesGreaterThan15MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630",
"localname": "NetSalesGreaterThan15MillionMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual" ], "lang": { "en-us": { "role": { "documentation":
"Relating to net sales greater than $15 million.", "label": "Net Sales Greater Than 15 Million [Member]", "terseLabel": "Net Sales Greater Than $15 Million [Member]" } } },
"auth_ref": [] }, "catx_NetSalesOf10MillionOrLessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname":
"NetSalesOf10MillionOrLessMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual" ], "lang": { "en-us": { "role": { "documentation":
"Relating to net sales of $ 10 million or less.", "label": "Net Sales Of 10 Million Or Less [Member]", "terseLabel": "Net Sales of $10 Million or Less [Member]" } } }, "auth_ref":
[] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description
[Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r762" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-
NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r732", "r743", "r753", "r770", "r778" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO
Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r760" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r759" ] },
"ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r770" ] },
"catx_NonRule10B51ArrangementModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname":
"NonRule10B51ArrangementModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Non-
Rule 10b5-1 Arrangement Modified Flag.", "label": "Non-Rule 10b5-1 Arrangement Modified [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Modified" } } }, "auth_ref":
[] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
"terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r789" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": {
"role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r789" ] },
"catx_NoncashExpenseLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "NoncashExpenseLease", "crdr":
"debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang":
{ "en-us": { "role": { "label": "Noncash lease expense", "documentation": "Represents the noncash expense incurred for leases.", "terseLabel": "Lease expense" } } },
"auth_ref": [] }, "catx_NoncashOrPartNoncashAcquisitionAssumptionOfStockOptionsAndWarrants": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240630", "localname": "NoncashOrPartNoncashAcquisitionAssumptionOfStockOptionsAndWarrants", "crdr": "credit",
"presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-
us": { "role": { "label": "Assumption of Viewpoint stock options and warrants at fair value", "documentation": "Assumption fair value of stock options and warrants in acquiring
a business or in consideration for an asset received in a noncash or part noncash acquisition." } } }, "auth_ref": [] }, "us-
gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals" ], "lang": { "en-us":
{ "role": { "label": "Shares issued in exchange for common stock (in shares)", "documentation": "The number of shares issued as [noncash or part noncash] consideration for a
business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash
payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r41",
"r42", "r43" ] }, "catx_NoncashOrPartNoncashAcquisitionNotesReceivableAndAccruedInterestForgiven": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240630", "localname": "NoncashOrPartNoncashAcquisitionNotesReceivableAndAccruedInterestForgiven", "crdr": "credit",
"presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-
```

*us": { "role": { "label": "Note receivable and accrued interest from Viewpoint forgiven", "documentation": "Forgiven of notes receivable and accrued interest assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition." } } }, "auth_ref": [] },
"catx_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredIncludingGoodwill", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Fair value of Viewpoint assets acquired including goodwill", "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition, including goodwill. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Viewpoint liabilities assumed including deferred tax liabilities established through accounting for business combinations (see Note 14)", "terseLabel": "Viewpoint liabilities assumed including deferred tax liabilities established through accounting for business combinations {(see Note 13)}", "totalLabel": "Viewpoint liabilities assumed including deferred tax liabilities established through accounting for business combinations (Note 14), Total", "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r41", "r42", "r43"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total non-operating income (expense), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r117"] },
"us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "label": "Non-operating income (expense):" } } }, "auth_ref": [] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails"], "lang": { "en-us": { "role": { "label": "Note payable", "totalLabel": "Note payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r23", "r151", "r923"] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "negatedLabel": "Less: current portion", "label": "us-gaap_NotesPayableCurrent", "terseLabel": "Notes payable, current", "totalLabel": "Notes Payable, Current, Total", "verboseLabel": "Note payable", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": ["r26"] }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableNet", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Note receivable", "verboseLabel": "Note receivable", "terseLabel": "Note receivable, forgiven amount, loan", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": ["r247", "r303", "r603"] },
"catx_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfBusinessesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfBusinessesAcquired", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Number of Businesses Acquired", "terseLabel": "Number of affiliated predecessor companies acquired", "documentation": "The number of businesses acquired by the entity during the period." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of reportable segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r835"] },
"catx_OfficeSpaceWithUnicoPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "OfficeSpaceWithUnicoPropertiesMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Office Space With Unico Properties [Member]", "documentation": "Represents Office Space With Unico Properties." } } }, "auth_ref": [] },
"catx_OneTimePaymentReceivedForRightsGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "OneTimePaymentReceivedForRightsGranted", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": {
"documentation": "One-time payment received for rights granted.", "label": "One-Time Payment Received For Rights Granted", "terseLabel": "One-time payment received for rights granted" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "us-gaap_OperatingExpenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating loss", "terseLabel": "Operating loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r237", "r240", "r242", "r244", "r681"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseExpense", "terseLabel": "Operating lease, expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r910"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails"], "lang": {
"en-us": { "role": { "label": "Total lease liability", "terseLabel": "Lease liability", "totalLabel": "Total lease liability, Total", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r475"] }, "catx_OperatingLeaseLiabilityAndRightOfUseAssetForNewLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "OperatingLeaseLiabilityAndRightOfUseAssetForNewLease", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Operating lease liability and right of use asset for new lease", "documentation": "Amount of operating lease liability and right of use assets for new lease." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "negatedLabel": "Less current portion", "label": "Lease liability", "terseLabel": "Lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r475"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Non-current lease liability", "label": "Lease liability, non-current", "terseLabel": "Lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r475"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Right of use asset, net", "terseLabel": "Right of use asset", "verboseLabel": "Right-of-use asset, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r474"] },
"us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent", "terseLabel": "Operating lease, weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r479", "r706"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "terseLabel": "Operating lease, weighted average remaining term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r478", "r706"] }, "catx_OppenheimerCoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "OppenheimerCoMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "documentation": "Represents the Oppenheimer & Co.", "label": "Oppenheimer Co [Member]", "terseLabel": "Oppenheimer & Co [Member]" } } }, "auth_ref": [] }, "catx_OptionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "OptionAgreementMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Represents the option agreement.", "label": "Option Agreement [Member]", "terseLabel": "Option Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri":*

```
"http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
"presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies" ],
"lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
"terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies", "documentation": "The entire disclosure for the organization, consolidation and basis of
presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements,
as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE
and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of
financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4)
how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided
in more than one note to the financial statements." } } }, "auth_ref": [ "r76", "r123", "r124", "r145" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other assets, net",
"terseLabel": "Other assets, net", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r186" ] }, "us-gaap_OtherLiabilitiesNoncurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other
noncurrent liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if
longer." } } }, "auth_ref": [ "r32" ] }, "catx_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname":
"OtherMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Other [Member]", "label": "Other [Member]", "documentation": "Related to other property plant and equipment not specifically disclosed." } } },
"auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure,
Amount" } } }, "auth_ref": [ "r762" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous
Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r730", "r741", "r751", "r776" ] },
"ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel":
"Compensation Amount" } } }, "auth_ref": [ "r733", "r744", "r754", "r779" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r733", "r744", "r754", "r779" ] }, "us-gaap_OverAllotmentOptionMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OverAllotmentOptionMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Over-
Allotment Option [Member]", "terseLabel": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial
allotment." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } },
"auth_ref": [ "r758" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-
statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "negatedLabel": "Issuance costs related to common stock issued in exchange for Viewpoint common
stock", "label": "us-gaap_PaymentsOfStockIssuanceCosts", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } },
"auth_ref": [ "r38" ] }, "us-gaap_PaymentsToAcquireBuildings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"PaymentsToAcquireBuildings", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Payments to
purchase buildings", "documentation": "The cash outflow for acquisition of buildings (properties) whether for investment or use." } } }, "auth_ref": [ "r119" ] }, "us-
gaap_PaymentsToAcquireHeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"PaymentsToAcquireHeldToMaturitySecurities", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of short-term investments", "label": "us-
gaap_PaymentsToAcquireHeldToMaturitySecurities", "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities." } } }, "auth_ref":
[ "r37", "r257" ] }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"PaymentsToAcquireOtherProductiveAssets", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "negatedLabel": "Additions to other assets", "label": "Payments to Acquire Other Productive
Assets", "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified
as other." } } }, "auth_ref": [ "r119" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": {
"negatedLabel": "Additions to property and equipment", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "totalLabel": "Payments to Acquire Property,
Plant, and Equipment, Total", "terseLabel": "Additions to property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical
assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-
constructed assets." } } }, "auth_ref": [ "r119" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text
Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r761" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r761" ] },
"ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation
Amount" } } }, "auth_ref": [ "r760" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation":
[ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r770" ] }, "ecd_PeoName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r763" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO
Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r759" ] }, "catx_PercentOfOutstandingShares": { "xbrltype":
"percentItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "PercentOfOutstandingShares", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "Represents the percent of outstanding shares.", "label": "Percent Of Outstanding Shares", "terseLabel": "Percent of outstanding shares" } } }, "auth_ref": [] },
"catx_PercentageOfIncreaseInCommonStockCapitalSharesForFutureIssuance": { "xbrltype": "percentItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240630", "localname": "PercentageOfIncreaseInCommonStockCapitalSharesForFutureIssuance", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel":
"Percentage of increase in common stock capital shares for future issuance", "label": "Percentage Of Increase In Common Stock Capital Shares For Future Issuance",
"documentation": "Percentage of increase in common stock capital shares for future issuance." } } }, "auth_ref": [] }, "catx_PercentageOfIssuedAndOutstandingCapitalStock":
{ "xbrltype": "percentItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "PercentageOfIssuedAndOutstandingCapitalStock",
"presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "documentation": "Percentage of issued and outstanding capital stock.", "label": "Percentage Of Issued And Outstanding Capital Stock",
"terseLabel": "Percentage of issued and outstanding capital stock" } } }, "auth_ref": [] }, "catx_PercentageOfOwnershipConsideredForWarrantExercise": { "xbrltype":
"percentItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "PercentageOfOwnershipConsideredForWarrantExercise", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "Percentage of ownership considered for warrant exercise.", "label": "Percentage Of Ownership Considered for Warrant Exercise", "terseLabel": "Percentage
of ownership considered for warrant exercise" } } }, "auth_ref": [] }, "catx_PercentageOfOwnershipConsideredForWarrantExerciseTwo": { "xbrltype": "percentItemType",
"nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "PercentageOfOwnershipConsideredForWarrantExerciseTwo", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel":
"Percentage of ownership considered for warrant exercise", "label": "Percentage Of Ownership Considered for Warrant Exercise Two", "documentation": "Percentage of
ownership considered for warrant exercise two." } } }, "auth_ref": [] }, "catx_PlacementAgentsCashFeePercentage": { "xbrltype": "percentItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240630", "localname": "PlacementAgentsCashFeePercentage", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "Represents the cash fee percentage.", "label": "Placement Agents Cash Fee Percentage", "terseLabel": "Placement agents cash fee, percentage" } } },
"auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Plan
Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r879", "r880", "r881", "r882", "r883", "r884", "r885",
"r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904" ] }, "us-
gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Plan
Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886",
"r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904" ] }, "us-
gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"PortionAtFairValueFairValueDisclosureMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Portion at Fair Value Measurement [Member]", "axisDefault": "Portion at Fair Value Measurement [Member] [Default]",
"documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r462" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label":
"Preferred stock, par value (in dollars per share)", "terseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock
nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r101", "r363" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [
```

```
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized (in shares)", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r101", "r595" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued (in shares)", "terseLabel": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r101", "r363" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding (in shares)", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r101", "r595", "r614", "r930", "r931" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible preferred stock; no shares issued and outstanding as of June 30, 2024 and December 31, 2023", "label": "Preferred stock, $.001 par value; 7,000,000 shares authorized: Series B: 5,000,000 shares allocated, no shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r101", "r544", "r707" ] }, "catx_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "PrefundedWarrantsMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Relating to Prefunded Warrants.", "label": "Prefunded Warrants [Member]", "terseLabel": "Prefunded Warrants [Member]", "verboseLabel": "Pre-funded Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r820" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r814" ] }, "catx_ProceedsFromInvestmentAgreementNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "ProceedsFromInvestmentAgreementNet", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from investment agreement net.", "label": "Proceeds from Investment Agreement Net", "terseLabel": "Proceeds from Investment Agreement, net" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Public Offering, net", "label": "Proceeds from Issuance Initial Public Offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from the ATM Agreement, net", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r5" ] }, "catx_ProceedsFromIssuanceOfCommonStockAndPrefundedWarrantsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "ProceedsFromIssuanceOfCommonStockAndPrefundedWarrantsNet", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the issuance of common stock and Pre-funded Warrants, net", "label": "Proceeds from Issuance of Common Stock and Prefunded Warrants Net", "documentation": "Proceeds from issuance of common stock and prefunded warrants net." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Issuance or Sale of Equity, Total", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Gross proceeds from public offering", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r5", "r562" ] }, "catx_ProceedsFromPrefundedWarrantsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "ProceedsFromPrefundedWarrantsNet", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Pre-funded Warrants, net", "documentation": "Proceeds from prefunded warrants net.", "label": "Proceeds From Prefunded Warrants Net" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturity of short-term investments", "label": "Proceeds from maturity of short-term investments", "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "Proceeds from sales of common stock, pursuant to exercise of option", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r5", "r19" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of common stock, pursuant to exercise of warrants, net", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r822" ] }, "catx_ProgenicsApaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "ProgenicsApaMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual" ], "lang": { "en-us": { "role": { "documentation": "Progenics APA.", "label": "Progenics APA [Member]" } } }, "auth_ref": [] }, "catx_ProgenicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "ProgenicsMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Progenics.", "label": "Progenics [Member]" } } }, "auth_ref": [] }, "catx_ProgramLicenseOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "ProgramLicenseOptionMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Program license option.", "label": "Program License Option [Member]" } } }, "auth_ref": [] }, "catx_ProgramPreclinicalCoFundingOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "ProgramPreclinicalCoFundingOptionMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Program preclinical co-funding option.", "label": "Program Preclinical Co-Funding Option [Member]" } } }, "auth_ref": [] },
"catx_PromissoryNoteForPurchasingLandAndBuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "PromissoryNoteForPurchasingLandAndBuildingMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Promissory Note for Purchasing Land and Building [Member]", "documentation": "Represents promissory note for purchasing land and building." } } }, "auth_ref": [] },
"catx_PromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "PromissoryNoteMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails" ], "lang": { "en-us": { "role": { "label": "Promissory Note [Member]", "documentation": "Represents promissory note." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r128", "r166", "r167", "r168" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r130", "r183", "r549" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
```

```
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Property and equipment, net", "label": "Property and equipment, net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r10", "r539", "r549", "r707" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r130" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Change in allowance for doubtful accounts", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r199", "r297" ] }, "catx_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "PublicOfferingMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "documentation": "Public offering.", "label": "Public Offering [Member]", "terseLabel": "Public Offering [Member]" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r758" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r758" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r372", "r380", "r409", "r410", "r411", "r497", "r521", "r555", "r585", "r586", "r645", "r647", "r649", "r650", "r652", "r671", "r672", "r682", "r694", "r701", "r708", "r711", "r865", "r874", "r916", "r917", "r918", "r919", "r920" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r372", "r380", "r409", "r410", "r411", "r497", "r521", "r555", "r585", "r586", "r645", "r647", "r649", "r650", "r652", "r671", "r672", "r682", "r694", "r701", "r708", "r711", "r865", "r874", "r916", "r917", "r918", "r919", "r920" ] }, "catx_RecognitionOfOperatingLeaseLiabilityAndRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "RecognitionOfOperatingLeaseLiabilityAndRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "documentation": "Recognition of operating lease liability and right of use asset.", "label": "Recognition of Operating Lease liability and Right of Use Asset", "terseLabel": "Recognition of operating lease liability and right-of-use asset" } } }, "auth_ref": [] }, "catx_ReconciliatoinOfCashCashEquivalentsAndRestrictedCashToTheConsolidatedBalanceSheetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "ReconciliatoinOfCashCashEquivalentsAndRestrictedCashToTheConsolidatedBalanceSheetsAbstract", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets:", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r725", "r736", "r746", "r771" ] }, "catx_RegisteredOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "RegisteredOfferingMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "label": "Registered Offering [Member]", "documentation": "Registered offering." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r379", "r485", "r486", "r588", "r589", "r590", "r591", "r592", "r613", "r615", "r644" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r620", "r621", "r624" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r379", "r485", "r486", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r588", "r589", "r590", "r591", "r592", "r613", "r615", "r644", "r912" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedParties" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary, (b) subsidiaries of a common parent, (c) and entity and its principal owners, and (d) affiliates." } } }, "auth_ref": [ "r482", "r483", "r484", "r486", "r488", "r567", "r568", "r569", "r622", "r623", "r624", "r642", "r643" ] }, "catx_RepaymentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "RepaymentProvisions", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Repayment provisions.", "label": "Repayment Provisions", "terseLabel": "Repayment provisions" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfDebt", "terseLabel": "Principal payments", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r823" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of notes payable", "label": "us-gaap_RepaymentsOfNotesPayable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r39" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r204", "r205", "r338", "r365", "r487", "r677", "r678" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r75", "r422", "r921" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForSharei
], "lang": { "en-us": { "role": { "verboseLabel": "Research and Development [Member]", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expenses [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement
```

Determination Date:" } } }, "auth_ref": ["r726", "r737", "r747", "r772"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r727", "r738", "r748", "r773"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r734", "r745", "r755", "r780"] }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted cash", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r40", "r165", "r201"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "verboseLabel": "Total accumulated deficit", "terseLabel": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r104", "r137", "r546", "r559", "r560", "r566", "r596", "r707"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r177", "r207", "r208", "r209", "r211", "r217", "r219", "r291", "r292", "r418", "r419", "r420", "r427", "r428", "r443", "r445", "r446", "r448", "r450", "r556", "r558", "r570", "r930"] }, "us-gaap_RevenueNotFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueNotFromContractWithCustomer", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Grant revenue", "terseLabel": "Grant revenue", "documentation": "Amount of revenue that is not accounted for under Topic 606." } } }, "auth_ref": ["r803"] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Modification of operating lease liability and right of use asset", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r477", "r706"] }, "catx_RofoOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "RofoOptionMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "ROFO Option.", "label": "ROFO Option [Member]" } } }, "auth_ref": [] }, "catx_RoyaltyAgreementPercentageOfNetSalesReceivable": { "xbrltype": "percentItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "RoyaltyAgreementPercentageOfNetSalesReceivable", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of net sales receivable as part of a royalty agreement.", "label": "Royalty Agreement Percentage Of Net Sales Receivable", "terseLabel": "Royalty agreement percentage of net sales receivable" } } }, "auth_ref": [] }, "catx_Rule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "Rule10B51ArrModifiedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "documentation": "Rule 10b 51 Arr Modified Flag.", "label": "Rule 10b 51 Arr Modified [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r789"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r789"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock, price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "auth_ref": ["r381", "r833"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r220", "r381", "r797", "r833"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSh], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": ["r45"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r45"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": ["r59", "r61", "r435"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Summary of Estimated Purchase Consideration", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": ["r59", "r61"] }, "us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Change in Asset Retirement Obligation [Table Text Block]", "documentation": "Tabular disclosure of the changes in carrying amount of a liability for asset retirement obligations, for changes such as new obligations, changes in estimates of existing obligations, spending on existing obligations, property dispositions, and foreign currency translation." } } }, "auth_ref": ["r864"] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r437"] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableTables"], "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Summary of Note Payable", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsTables"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of Discontinued Operations", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r12", "r20", "r25", "r78", "r87", "r88", "r89", "r90", "r91", "r95", "r97", "r98", "r132"] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": ["http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share."

```
} } }, "auth_ref": [ "r44", "r46", "r224", "r225", "r227" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForShareI
], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about
amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income,
amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r56" ] }, "us-
gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based
Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Share-based Compensation Expense Recognized for Share-based
Compensation Arrangements", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to
statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } },
"auth_ref": [ "r56" ] }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ScheduleOfHeldToMaturitySecuritiesLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
], "lang": { "en-us": { "role": { "label": "Schedule of Held-to-Maturity Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table.
These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r271", "r272",
"r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288" ] }, "us-
gaap_ScheduleOfHeldToMaturitySecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ScheduleOfHeldToMaturitySecuritiesTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity [Table]", "documentation": "Disclosure of information about investment in debt security measured at
amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285",
"r286", "r287", "r288" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails"
], "lang": { "en-us": { "role": { "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill,
lacking physical substance and exist in perpetuity." } } }, "auth_ref": [ "r21", "r127" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsTables" ], "lang": { "en-us": { "terseLabel":
"Summary of Components of Other Intangible Assets", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of
assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": [ "r21", "r127"
] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of
Long-Term Debt [Table Text Block]", "terseLabel": "Summary of Maturity of Note Payable", "documentation": "Tabular disclosure of maturity and sinking fund requirement
for long-term debt." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": {
"role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not
intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and
accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
"presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of
Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Summary of Preliminary Purchase Price Allocation", "documentation":
"Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the
following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [
"r143" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual" ], "lang": { "en-us": { "role": { "label": "Schedule of
Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions.
Examples of related party transactions include transactions between (a) a parent company and its subsidiary, (b) subsidiaries of a common parent, (c) and entity and its
principal owners, and (d) affiliates." } } }, "auth_ref": [ "r70", "r71", "r620", "r621", "r624" ] }, "us-
gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based
Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]", "terseLabel": "Summary of Stock
Options", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining
contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not
been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r139" ] }, "us-
gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Schedule
of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement."
} } }, "auth_ref": [ "r383", "r385", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404",
"r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of
Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Weighted Average Fair Value of Stock Option Awards
Granted and Key Assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options,
including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free
rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r140" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri":
"http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-
entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r720" ] },
"dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange
Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r722" ] }, "us-gaap_SegmentDiscontinuedOperationsMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDiscontinuedOperationsMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ],
"lang": { "en-us": { "role": { "label": "Discontinued Operations [Member]", "terseLabel": "Discontinued Operations [Member]", "documentation": "Component or group of
components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a
business or nonprofit activity on acquisition classified as held-for-sale." } } }, "auth_ref": [ "r7", "r79", "r80", "r81" ] }, "srt_SegmentGeographicalDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual" ], "lang": { "en-us": { "role": { "label":
"Geographical [Domain]" } } }, "auth_ref": [ "r245", "r246", "r582", "r583", "r584", "r646", "r648", "r651", "r653", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668",
"r669", "r674", "r695", "r711", "r876", "r928" ] }, "us-gaap_SegmentOperatingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "SegmentOperatingActivitiesDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ],
"lang": { "en-us": { "role": { "label": "Operating Activities [Domain]", "documentation": "Operations of an entity including continuing and discontinued operations." } } },
"auth_ref": [] }, "catx_SeriesBConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname":
"SeriesBConvertiblePreferredStockMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": {
"documentation": "Series B convertible preferred stock.", "label": "Series B Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-
gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesBPreferredStockMember", "presentation":
[ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label":
"Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r816", "r817",
"r875" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr":
"debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": {
"terseLabel": "Share-based compensation", "label": "us-gaap_ShareBasedCompensation", "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
"documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Share-
Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These
concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r383", "r385", "r387",
"r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409",
```

```
"r410", "r411", "r412" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)", "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-
based payment arrangement." } } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
"presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": {
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)", "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment
arrangement." } } }, "auth_ref": [ "r703" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "terseLabel": "Intrinsic value associated with
exercises", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share
units converted) into shares." } } }, "auth_ref": [ "r405" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "negatedLabel": "Number of Options Outstanding, Expired",
"terseLabel": "Stock option awards expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the
plan agreements." } } }, "auth_ref": [ "r397" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
"presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": {
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Number of Options Outstanding,
Forfeited", "terseLabel": "Stock option awards forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of
occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r396" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Granted,
Options (in shares)", "terseLabel": "Number of Options Outstanding, Granted", "verboseLabel": "Stock option awards granted", "documentation": "Gross number of share
options (or share units) granted during the period." } } }, "auth_ref": [ "r394" ] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award
under share-based payment arrangement." } } }, "auth_ref": [ "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400",
"r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412" ] },
"catx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240630", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePrice",
"presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "Share based compensation arrangements by share based payment award options exercise price.", "label": "Share Based Compensation Arrangements By
Share Based Payment Award Options Exercise Price", "terseLabel": "Options exercise price per share" } } }, "auth_ref": [] },
"catx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodGross": { "xbrltype": "sharesItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodGross",
"presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual" ], "lang": { "en-us": { "role": { "label":
"Options assumed, Options (in shares)", "documentation": "Gross number of share options (or share units) assumed during the period.", "terseLabel": "Options to purchase
shares of common stock", "verboseLabel": "Number of Options Outstanding, Options assumed" } } }, "auth_ref": [] },
"catx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue",
"crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-
us": { "role": { "label": "catx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue", "documentation": "Fair value of the options
grants in period.", "terseLabel": "Stock option awards grant in period fair value" } } }, "auth_ref": [] },
"catx_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType",
"nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname":
"SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Options assumed,
Price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
"terseLabel": "Options exercise price per share", "verboseLabel": "Weighted Average Exercise Price, Options assumed" } } }, "auth_ref": [] },
"catx_SharesAndWarrantsPriceDifference": { "xbrltype": "perShareItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname":
"SharesAndWarrantsPriceDifference", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "Represents the difference between shares and warrants prices.", "label": "Shares And Warrants Price Difference", "terseLabel": "Shares and warrants, price
difference per share" } } }, "auth_ref": [] }, "catx_SharesIssuedPercentOfFullydilutedOutstandingCapitalStock": { "xbrltype": "percentItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240630", "localname": "SharesIssuedPercentOfFullydilutedOutstandingCapitalStock", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "label": "catx_SharesIssuedPercentOfFullydilutedOutstandingCapitalStock", "documentation": "Represents number of shares issued as a
percentage of fully diluted outstanding capital stock.", "terseLabel": "Percentage of fully-diluted outstanding capital stock" } } }, "auth_ref": [] }, "us-
gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Stock purchase price per share", "documentation": "Per share or per unit amount of
equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"SharesOutstanding", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-
stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balances (in shares)", "periodEndLabel": "Balances (in shares)", "label": "us-
gaap_SharesOutstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-
gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit",
"presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label":
"Short-term investments", "terseLabel": "Short-term investments", "totalLabel": "Short-Term Investments, Total", "documentation": "Amount of investments including trading
securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r153", "r154", "r819" ] },
"us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label":
"Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r171", "r188", "r189", "r190", "r203", "r224", "r225",
"r227", "r229", "r235", "r236", "r290", "r325", "r327", "r328", "r329", "r332", "r333", "r363", "r364", "r366", "r367", "r369", "r464", "r562", "r563", "r564", "r565", "r570",
"r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r595", "r617", "r639", "r654", "r655", "r656", "r657", "r658", "r796", "r825", "r834" ] },
"us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis",
"presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-
unaudited-" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r34",
"r177", "r195", "r196", "r197", "r207", "r208", "r209", "r211", "r217", "r219", "r234", "r291", "r292", "r371", "r418", "r419", "r420", "r427", "r428", "r443", "r444", "r445",
"r446", "r447", "r448", "r450", "r465", "r466", "r467", "r468", "r469", "r470", "r481", "r556", "r557", "r558", "r570", "r639" ] }, "srt_StatementGeographicalAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual" ], "lang": { "en-us": { "role": { "label":
"Geographical [Axis]" } } }, "auth_ref": [ "r245", "r246", "r582", "r583", "r584", "r646", "r648", "r651", "r653", "r659", "r661", "r662", "r663", "r664", "r665", "r666", "r667",
"r668", "r669", "r674", "r695", "r711", "r876", "r928" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"StatementLineItems", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesTables",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r207", "r208", "r209", "r234", "r522", "r561", "r581",
"r587", "r588", "r589", "r590", "r591", "r592", "r595", "r598", "r599", "r600", "r601", "r602", "r604", "r605", "r606", "r607", "r609", "r610", "r611", "r612", "r613", "r615",
"r618", "r619", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r639", "r712" ] }, "us-gaap_StatementOfCashFlowsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash
Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_StatementOperatingActivitiesSegmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"StatementOperatingActivitiesSegmentAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ],
"lang": { "en-us": { "role": { "label": "Operating Activities [Axis]", "documentation": "Information by continuing and discontinuing operations." } } }, "auth_ref": [] },
"srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [
```

```
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r220", "r381", "r797", "r798", "r833" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesTables",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r207", "r208", "r209", "r234", "r522", "r561", "r581",
"r587", "r588", "r589", "r590", "r591", "r592", "r595", "r598", "r599", "r600", "r601", "r602", "r604", "r605", "r606", "r607", "r609", "r610", "r611", "r612", "r613", "r615",
"r618", "r619", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r639", "r712" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock":
{ "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or
TSR Estimation Method" } } }, "auth_ref": [ "r729", "r740", "r750", "r775" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-
us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares
equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssued1", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": {
"negatedLabel": "13,654,507 shares of Perspective Therapeutics common stock issued in exchange for Viewpoint common stock", "label": "us-gaap_StockIssued1",
"documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r41", "r42", "r43" ] }, "us-
gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-
statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of
common stock in exchange for Viewpoint common stock, net of issuance costs (in shares)", "documentation": "Number of shares of stock issued during the period pursuant to
acquisitions." } } }, "auth_ref": [ "r101", "r102", "r137" ] }, "catx_StockIssuedDuringPeriodSharesCommonStockWarrantExercised": { "xbrltype": "sharesItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240630", "localname": "StockIssuedDuringPeriodSharesCommonStockWarrantExercised", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "terseLabel": "Issuance of common stock pursuant to exercise of warrants (in shares)", "label": "Stock Issued During Period Shares Common Stock Warrant
Exercised", "documentation": "Stock issued during period shares common stock warrant exercised." } } }, "auth_ref": [] }, "us-
gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock, net (in shares)", "terseLabel": "Stock issued during period, shares", "label": "Shares issued and sell",
"documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r15", "r101", "r102", "r137", "r562", "r639", "r655" ] }, "us-
gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "label": "Issuance of common stock pursuant to exercise options (in shares)", "terseLabel": "Number of Options Outstanding, Exercised", "negatedLabel":
"Number of Options Outstanding, Exercised", "verboseLabel": "Options exercised", "documentation": "Number of share options (or share units) exercised during the current
period." } } }, "auth_ref": [ "r15", "r101", "r102", "r137", "r395" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of common stock in exchange for Viewpoint common stock, net of
issuance costs", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r15", "r34", "r137" ] }, "us-
gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "verboseLabel": "Issuance of common stock, net", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Amount raised through selling of
equity", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public
offering." } } }, "auth_ref": [ "r15", "r101", "r102", "r137", "r570", "r639", "r655", "r718" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock pursuant to exercise of options",
"documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r15", "r34", "r137" ] },
"catx_StockIssuedDuringPeriodValueWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname":
"StockIssuedDuringPeriodValueWarrantExercises", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-
consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of stock pursuant to exercise of common stock
warrants", "label": "Stock Issued During Period Value Warrant Exercises", "documentation": "Stock issued during period value warrant exercises." } } }, "auth_ref": [] },
"catx_StockIssuedDuringSharesCommonStockWarrantExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname":
"StockIssuedDuringSharesCommonStockWarrantExercised", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-
consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock pursuant to exercise of
warrants (in shares)", "label": "Stock Issued During Shares Common Stock Warrant Exercised", "documentation": "Stock issued during shares common stock warrant
exercised." } } }, "auth_ref": [] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"StockRedeemedOrCalledDuringPeriodShares", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-
statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "negatedLabel": "Cancellation of fractional shares due to the 1-for-10 reverse stock
split (in shares)", "terseLabel": "Cancellation of fractional shares due to the 1-for-10 reverse stock split (in shares)", "label": "Stock Redeemed or Called During Period,
Shares", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r15" ] }, "us-
gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-
consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Cancellation of fractional shares due to the 1-for-10
reverse stock split", "label": "Stock Redeemed or Called During Period, Value", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise
price or redemption price." } } }, "auth_ref": [ "r15" ] }, "catx_StockholderPlaintiffSettlementsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240630", "localname": "StockholderPlaintiffSettlementsMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "label":
"Stockholder Plaintiff Settlements [Member]", "documentation": "Related to stockholder plaintiff settlements.", "terseLabel": "Stockholder Plaintiff Settlements" } } },
"auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit",
"presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Balances", "periodEndLabel": "Balances", "label": "us-gaap_StockholdersEquity",
"documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r102",
"r105", "r106", "r125", "r597", "r614", "r640", "r641", "r707", "r719", "r827", "r858", "r909", "r930" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders'
equity:", "terseLabel": "Stockholders' equity." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParentheticals",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "terseLabel": "Reverse stock split, ratio", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to
the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r24" ] }, "us-
gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityReverseStockSplit",
"presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParentheticals",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals" ], "lang": { "en-us":
{ "role": { "terseLabel": "Reverse stock split", "label": "Stockholders' Equity, Reverse Stock Split", "documentation": "Description of the reverse stock split arrangement. Also
provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r138" ] },
"us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the
balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r471", "r490" ] }, "us-gaap_SubsequentEventTypeAxis": {
```

```
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial
statements are issued or available to be issued." } } }, "auth_ref": [ "r471", "r490" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements
are issued or available to be issued." } } }, "auth_ref": [ "r471", "r490" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TableTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote12LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Tables", "label": "us-
gaap_TableTextBlock" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]",
"terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r769" ] }, "catx_TheUnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240630", "localname": "TheUnderwritingAgreementMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "verboseLabel":
"Underwriting Agreement [Member]", "label": "The Underwriting Agreement [Member]", "documentation": "Represents the Underwriting Agreement." } } }, "auth_ref": [] },
"ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } },
"auth_ref": [ "r761" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return
Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r768" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role":
{ "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r788" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": {
"role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r790" ] }, "dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-
gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or
another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial
instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267",
"r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r359",
"r368", "r449", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510",
"r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r553", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r854", "r855", "r856", "r857" ] },
"ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } },
"auth_ref": [ "r791" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } }
}, "auth_ref": [ "r792" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } },
"auth_ref": [ "r790" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } },
"auth_ref": [ "r790" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement,
Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r793" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us":
{ "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r791" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "label":
"Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than
collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r437" ] }, "us-gaap_USTreasuryBillSecuritiesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryBillSecuritiesMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "US Treasury Bill Securities [Member]", "terseLabel": "U.S. Treasury Bills [Member]", "documentation": "This category includes
information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing,
and are backed by the full faith and credit of the United States government." } } }, "auth_ref": [ "r922" ] }, "catx_UnderwrittenOfferingMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "UnderwrittenOfferingMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel":
"Offering [Member]", "label": "Underwritten Offering [Member]", "documentation": "Underwritten Offering." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": {
"xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying
Security Market Price Change" } } }, "auth_ref": [ "r787" ] }, "catx_ViewpointMolecularTargetingIncMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240630", "localname": "ViewpointMolecularTargetingIncMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-note-14-merger-details-textual" ], "lang": { "en-us": { "role": { "label": "Viewpoint Molecular
Targeting, Inc. [Member]", "documentation": "Represents Viewpoint Molecular Targeting, Inc.", "terseLabel": "Viewpoint Molecular Targeting, Inc. [Member]" } } },
"auth_ref": [] }, "catx_VmtOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "VmtOptionMember",
"presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": {
"label": "VMT Option [Member]", "documentation": "VMT option." } } }, "auth_ref": [] }, "catx_VmtOptionOrProgramLicenseOptionMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "VmtOptionOrProgramLicenseOptionMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "VMT option or program license option.", "label": "VMT Option or Program License Option [Member]" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240630/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSh
], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Common Stock Warrants [Member]", "documentation": "Security that gives the holder the right to
purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r709", "r710", "r713", "r714",
"r715", "r716" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-
consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "label":
"Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "documentation": "The average number of shares or units issued and outstanding that
are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r223", "r229"
] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-
consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "label": "Weighted average shares used in computing net loss per share:" } } }, "auth_ref": []
}, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.perspectivetherapeutics.com/20240630/taxonomy/role/statement-condensed-
consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "label": "Basic and diluted (in shares)", "terseLabel": "Basic", "documentation": "Number of
[basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of
time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r222", "r229" ] }, "catx_statement-
statement-note-10-leases-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "statement-statement-note-10-
```

leases-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Leases" } } }, "auth_ref": [] }, "catx_statement-statement-note-8-sharebased-compensation-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240630", "localname": "statement-statement-note-8-sharebased-compensation-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Share-based Compensation" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB TOPIC 4.C)", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50",

"Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1A" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1C" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.18)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification",

```
"Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" },
"r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "
(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
}, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification",
"Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r141": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic
6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805",
"Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r143": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" },
"r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org//810/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification",
"Publisher": "FASB", "URI": "https://asc.fasb.org//820/tableOfContent" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r149": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-
03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic":
"942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r161": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-
320/tableOfContent" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "5", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r163": { "role":
"http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r164": { "role": "http://fasb.org/us-
gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-
45-5" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)",
"SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r167": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" },
"r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "SubTopic": "10", "Topic":
"310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229",
"Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229",
"Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229",
"Section": "1404", "Paragraph": "(a)", "Publisher": "SEC" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229",
"Section": "1404", "Paragraph": "(b)", "Publisher": "SEC" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229",
"Section": "1405", "Paragraph": "(a)", "Subparagraph": "(4)", "Publisher": "SEC" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K
(SK)", "Number": "229", "Section": "1405", "Paragraph": "(c)", "Publisher": "SEC" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r180": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-
10-45-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r183": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r184": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r185": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r188": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r193": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r196": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-
10-50-6" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r199": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r200": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" },
```

"r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-42" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-42" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-42" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "44", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-44" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

"https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-6" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481879/410-20-45-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",

```
"Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r333": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r334": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-
20-50-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r338": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-
20-50-1B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r342": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-
20-50-1C" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r346": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-
20-50-1D" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r350": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-
20-50-1E" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r354": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-
20-50-1I" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r359": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-
20-50-4" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r363": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-
10-50-13" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r367": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r370": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-
20-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r374": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r375": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r376": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r377": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r378": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r379": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-
80-50-5" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org//718/tableOfContent" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r384": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" },
"r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r387": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r388": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r389": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r391": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r392": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r393": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r394": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r395": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role":
```

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r457": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r458": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" },
"r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r461": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r464": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-
30-45-20" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r468": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r471": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-
30-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher":
"FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-
45-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r476": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-
20-50-4" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r480": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-
50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r486": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r489": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-
10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r492": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r493": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r494": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r495": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r496": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r497": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r498": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r499": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r500": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r501": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r502": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r503": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-
50-7" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r507": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r508": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r509": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r510": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r511": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r512": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r513": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r514": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r515": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r516": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r517": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-
50-50-4" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50",
```

```
"Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r521": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-
235-50-15" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r525": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r526": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r527": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r528": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r529": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r530": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r531": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r532": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r533": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r534": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r535": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r536": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r537": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r538": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r539": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-
40-50-7A" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r557": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r558": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r559": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r560": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r561": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r562": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r563": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r564": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r565": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r566": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" },
"r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-
20-50-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r571": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" },
"r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r574": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-
205-50-7" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r578": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-
```

205-50-7" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-11" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-79" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "80", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-80" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-
10-50-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r707": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-
210-50-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r711": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r718": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "d1-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q",
"Number": "240", "Section": "308", "Subsection": "a" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section":
"16", "Subsection": "J", "Paragraph": "a" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection":
"F", "Paragraph": "1", "Subparagraph": "i" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r730": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence":
"D" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "E" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 40-F", "Section": "19", "Paragraph": "a" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "1" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section":
"19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F",
"Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-
F", "Section": "19", "Paragraph": "b" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "i" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r760": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r765": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5",
"Subparagraph": "i" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r769": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" },
"r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",
"Paragraph": "6", "Subparagraph": "i" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r774": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "B" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r777": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "E" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r780": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" },
"r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x",
"Paragraph": "1" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "x", "Paragraph": "2" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r785": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2",
"Subparagraph": "ii", "Sentence": "D" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r788": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r789": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" },
"r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a",
"Paragraph": "2", "Subparagraph": "A" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r793": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2",
```

```
"Subparagraph": "D" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r796": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r797": { "role":
"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r798": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "2", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481174/470-10-25-2" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r801": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r802": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r807": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name":
"Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r811": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r816": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r817": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r818": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r819": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r820": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r821": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r825": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r826": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r827": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r828": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r829": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r830": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r831": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r835": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r838": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r839": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r840": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r841": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r842": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r843": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r844": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r845": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r846": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r847": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r848": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r849": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r853": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r854": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r855": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r856": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r857": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r858": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r859": { "role":
```

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r919": { "role":

*"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" } } } ZIP 82 0000950170-24-096148-xbrl.zip IDEA: XBRL DOCUMENT length 644 0000950170-24-096148-xbrl.zip M4$L#!!0 ( )F #5E"R42A"-L! $4V&0 1 8V%T>'TR,#(T,#8S,'YH M=&WLOGM7'$F2)OQ}?
T6L9GNGZKQRY/>+5%5[D$KJ84:W%M3,]/M%QZ\074DF MG9$IB?WU:^9Y(4%(0B*! +)F6D"&9[B[71]S-S?_Y?]\.APT'_*X:T?#7_^5 M;=%_;?
(PCE(W/_U7[=WG^WL_O^>U__/(_"6E^?['SNGF=/S;;<=)^R+^W M71R,NNDX-S_MOOJYV1D.VF%N_OOINY?-[Z,X/#(Z,%^O4W0#V/K!\WNHM.',,JX
MU6P/LT[_%;7O,M='G_(:6OVSH,)D -(,NQ^?; R\H]B:S3>?\2<=$> M"/_G5YKCX^"[9?-/G[4_-3]\NFC:?OK2>QD. SF.#%\T'XZ&KX'QXS:>_[4T M&3^;!_E1]"0#&) //3D[)93/4+_,+
<6M_].$1 M/(#OD%B=,+U[2C2>?LQH^/"T3D_$?6>P>P=,' MO_V/YI>#[!/\'Z9M)-!_HU1\k=?'LU^QT\/\17*T?R/Z?MAU\?//L-)V#[MR![P\4$39W_]^F"2/TT>5=OQ"-_Z,/[:7\(H'3?
=Y'B0?WUPZ,?[(?!GXXYZL>3 MT?]L#X]&Q&8Q#VR9,CG] @/V[LT:5+#B0GIXCTDI%@-",E49FSH=H+F,'0'V(O MN7V\+8#38]HU5U_,?#[\ZE]FKS+!2;]7KAL!36<%"T]D4)0XEVQ1$=ME##*,
F$ MG_'LUP? Y,>E_903*7X INFW^N.71Z>&>?ZH?1")"0W^H21)I)&*>&L9,4+X M,)&_R:V.>N&,7H##\H.W*91>@&?=3\T@]_^QB\T2N95B(IF0IV+1&JEB7,\
M$5DT]RQ'R@I?'>6SZ7B\'.3?LQ_'R,TA3\V2$(8!QV\T$B=T\XG8PA+JA!) MX9^0C2!*.*MH4$%JL3K2YT,0_N-G,-BQ'^P,4_[T'_GXQX9)X3_#K,#F"R-]
M,?:QPH+94'6,UBLNB#5)$^E,(%8P3VPI.08>N)%F,=2Y77_\;'1XV$Y0 +KM M84+E!%4"C-/FSP0@:EY4+H%X3P.1S$OBO/=$*!]M8D&P(\ATTV$[^\(?[__8 M_1UL2=<^'K8#T/#Q-(-
RGS]TRP+7D1>BK05=DYP25R(G*1GA0HH\.G&)H0ME M70PB$F,5T#MG3T!Y PPJ>:63M"&$'QZZX 9D1!"7,B,RA4B#=@*3F:/.=VC"V=GYY CZ(QP% M_D+'TA4'K
!.@Z7*3*EB%:.GYG,$0/1!DW)L#\&2_/(@Y_6+T]8&X 9)HPF9 M-P'AVUKJQV+"7R! 9HQ9+QQ1,L)@C+#*$4S"6CB;+F8]<*76G"1!HYE&"]8HF M@/"JE$%%P&6 V?7*.>J33W>:
%30PJ)(,&,!*N!S(9{'2*)@8,Z=,=]&WA$ MWIHC.!(9$UT8(!E)@ @"}>!GM(\.=@"VP!R"<=*(++(++ [1XA'IV'4.)<,KCKF M[K=?,%9ZW-70!/IN:NST&.\KP\ZP&\#C%/J9P=C''IB>++ YEN?
NH0V]]&9 M=]8_N]%T?//^JL>#C.4$]$YZ]M})[#5@\"'" TF9).!!*%&N:,-5 H*H!XNO MYNJN%W^U"?\N;1XW==CY7'S_;.<_3COGLU>O*[+^^B>9G\FZ.P3,#2VDU?Y M,$
7J86G=6GA 6!O$ 0 --A^~^:A!QRV ;GM'OR&5'G\.D]V@47=7W$A((_W M#OR0J5?M8 #?GKWMET?G=G+!OI^-ID#"\9$?@_B!>*YT_=>]5SFU("![.1X,
M1X/1/CC8G6\1K>/SI#@T7GT/JIP<4$$GHAT%MZ&\(=;90 Q5BD: ,%F& MOG)FJ:PSDPU8] @"3(2BIWCR#L)?B,K3 CKM+JNKR^ZGH6M3Z\?':!;>
ME.HN5I1V>^_5]OXXYZL!V#Y>(+AUU)5*5N^9_ELR;BTTG15=A9/?DAV- =< MF1S1DAJ0'3#RSH HV:Q43"4S\+5]E9W?5%1@9(T$K0#L,@&*%,$ZU*E-ES0T7O6((PY&4[.??
KHN4SWZU2?P4D ZM: M[*3LYLED4"W%(#JX.G6YN@NYF>W4VI1,/S@K6_3#HC/43OQ@ZMW?>SBKD^L"-&E7)\7 M4007B> 6%P]!N9W!93ZI+%/.E!AZZ_J6[!PV\%WWN1#M
AUR]W06\T[.;,AO M:_ WSJDVO34^,7!!${/$.'",DA9+G+3P]N1\2IIR;7K+HQOWB:=T3%Q=@^\K_R V'QWFI.8]]0/<$MX]R!FY M>6(I3U(4NJ?\,?1J/.#OXY'TR,,[P=3W%3#-G5A?
9K3&R!@Q(P$!(03P<;,8B)]55*OVMIX^FT'.1OHXK>F' ,3,S9*9)X243F MP(G/5A)&-3..PL/H^L.84TN0?\VC ;$_.L!UOU5MQP_V1SN#03LAB861)+,@TB;<$@^1;,E2;I$ MYGC?
9.:'E/FE'Z;,$K Y#N\#8(W9";BU9RCQ$LR$L1QB.:^,};U3Y(L&;, '.MP&]3PWHDJV_IJ' MP)-!Q9&'[;#M)HBW/N3GGX[@?5>-LFYFJ=DI4:Q7 /X!7!%I=`%!Y&)2*$;' MD*+/O459\S#
{O_P8M&_R9ESS>E?T[94_1F)!D/UB.DPYS1NNS,.C]7]3MO&E M^_G,.C>H]Q_0Y_CCN,7,G;49GV_L9SX=E>W='*?8ZQ5M9)X56D6XO*#0KC.] MG- ::9D1Q#"P;A*)P'3E @+3D?JC-
2Y]$UH[_A&M-/ "B,XB0Z,B8R"$:\5 M)R$'?QG+ "=HWUC23X'WSDC-]V4*H1"O$PDMYB\!QQ*G# :111*7#GJOAW+ MSL[96$3T)\CNB P!0+$ @*,D3[(*%&
Z:WX@MB>L28U6SNGO8^CO8/1M .1 MW?L(+ST&@X+]?P*5U[@CDKF_ZSS1^/1BV@@M$@XT&,\9X?[V<$#%?ONF]H50_0I>*LYCJ1(/L;1!QP>TZ3-T>#2^RH[.V:/>
{MB=OY\:@2SPE MW%WF16]PT+X0*SR8 I&4="EY97,/?-FIE9KU.?+,=-',$499)E(!Q+(J:4)# MCJF(G%.2?=..KV1]UD?S3UZ,QCGZ[A]6/2\NM&O;.7,E,%.$(EJ*0"2@#.*S M@
ZT+$48:KSH+:SX5G3[WXX!8/T&<9X,9J.OS?D7@MWF;F@25IM>AGN>L\ M3S*33 .$H100CW7@VE)(/ L7@=^]"T-O28KG/7!H@()4*BD2;3$X(H#F2
M[$WA)JHBG>VK]&S#&U*+) ^L_Y)/EIN>?<&,]HQ?CT2$*U'12%UG?E(7TO,WC MW0,_SD^/SW_!F93OPZ!/Z#C/3HN\.9I\^S3]0K"NB'Q%]PF'AC1'#R%U'A> MTC/T%,8)YQ+$[E?
NW+\;V8@U!7=>%2N%*40S"A&&YBWRH%$Z,40Q2BA>I?, M>2ORO=:X3^B-*U0X280 ^R298B3$Z(C2TBDKDJ'ZRJ'WC_+HA6_'_^D'4[Y MRU__#=[HQ_'@^&7^D
>GC;V5P;S*!.3ZN'T<=W]C\=? M&,E*T^X=VLJK<8E7LP3IK#29]!ZU=L#2M\"*:]0 MB,[%O]^_ZWQ+,8S+P&#.$ &#]0Y.@=>2AH@LDTQ.>W;K$?#*%5W.N=T%N?2PL
MAN4@B8W%0(@:.G&9 PR56%XCA,)L;V%H#Y) OK8',.LUVL!(5CX).FEQ&? M0$WDJ/PIXWED3S.QS%LB@HQ!&^.9[ZU][_'B_,TD@P3N9/+@G;V(6%X'T%XP MTA(=#%AT
(&NOZ>)+Y ,LI:EJG7[EQL[W',C\I6M8<%##SQKDRU)++ 5LJ&6. M-!J?)3T5;[ZQLZK"?6" 'X(D0C8<(#KR@D2BA:D"'"^L,Y0FW=MP_#H7K&^M MV/@@:
@&5P]8(+Z(0F0JFCK$^%&%9E#ID]U%W'V(&A8T7R^1LWW,DOMU?Q0 M'W.9>,<,_D:58B9ZV;O",A>_!]E_;,;Y&>F+]N'86;<*_>&@!PE&@CB.M
M8L0%L.!X5HH:P'6,]Y:%MR!!^V829H)CC. X\J&!$R5E%@+BI^8,AK8G8LW M?65]#^+SVW)(8S4>OY09CX#2;!8D9S3CG%("F*(PQRZF'G+_1.7]TF-OK"(
MS%SY#G8/4KC3=7C6=HP_?1CDS\Z%+X=S+6?VUY6?'5)R1H-3U\F#4PAR,+T-M_I0 MZ&F=D6|)3"1'250U]PZXHUSA!IPLSIR4^RMK5Y$K_WL66 .V.RBYY56FUX&
MPT5]7628P&XU(9225F\M:;BNT/E"_=\/T]+GCT268&\^*-,8E&<)M-R@W<(KBSM<5C4("V%2<, M 1T(H2'QT(#O9%N-C\"ST M-AV]WYNU-Y V&I6C)DA/
J5XRPB+)#"0JJ"!*$Q%2E5O5_LVZ=\?NW#DBMGW MW?YK75F!41NID@88K$!].6&\)U902=&N4>PF!,V\3#99WRYT-?A<-_MC=&]>4 MS>.G[6!#@B]N2R018D+XDJ\ MT;!-&-
P^1RHL#S#8"!-N!=@0Z4 M+&2\RRU),*&&NOXJV47.1\PJ<+4?@$!O!SY>47#]6<6[]2RS!)\+]X!+3= 0 M+]N(!Y\P6*ED2PG@#AI$ZK(/$"K&L(.PQT6HF@(^] MK3[ZW1LK@\'3W\["-
W?:1OY-'#F)R!C30D12PA P%P!, 8I),(W-2"F-"[XIA M;,J77VOY\BL*C(O126,1-4RDD,8 W$JQ@&2#1(+8:>,[FI[Y^8_L^O75$-[MGX3/TG+P/)F"
(P)$09PS$#"K%)B,5BIQ:W<.KR']8!,SS*1(A2*22P!ZT M! ;,!4Q:$4E"1]+0TKMQLI],,17DVEF*2C#H%YXAG%FX\!?=D(&BIP MZSI)T*+^UDQ[@>^\T8/J5Y,]FZS@PEI!LHQU>
<81"ZZ1))&R\BH;?N;SM!/ M95V?'?4/NNB!(3H94%:!RYK@[9)U21>\8(1M5J8O;$+7M>V>G/!:245LPO5, M*R56&N-$"1V*8BQ;Y]L+7WJ<_P,;P\&H^H-KZ_ZW[47$4T^:0N+
<^+,4EO/P,K'6'*^73)Y8+'VCI4@0EXO (V[2H/,%!,;Q$(G+P5*6,PF9!>*,4EQ[^-?V=H6U+IH^@^F,?9Q,\:C[^'!5/_'Q?[63@Z1"NP2S &(PQ@5(&AR<&QU%>6?,.L+%.%KB$A;SV&!*(K
M;,0D(23(@0&&,>.L+T:E(3@7/OO3LJ U+G<7;G*I1 59,(#7Y,@S6C$%2$] MT\SEW%O_MLE[NI:\IQ[$U47HI$$] 85A$;)8!/$R&@+>2|>2* VZ=U)Z0P6(
MOG)#5NWW=9Z@F'1/\^1CSD-&0568>M4.!E>R&'HUA8>**#E$")9YX6"R%0=1 M<4#P1!8&6"T5FW]^;-?NP5'8UH*:XH&T!#^)BKC&L9K MN3IO;CCOY
(O57B0*V/*\'?"!+R04#@CQF7+G!).]"_O^0XR_V;[(%.#/C9@ M[2*\A,XF34(H&JQ0*=JZ,&CI75S9EW(W5X1Y#$L\& ?JF""&$,42[QW$C99* M8:V6B?5N!['V?E*
<'Q1ZH<2PE%HBP&M,AI,.S;1" @&F5)8:H96]W1'L5$/;@ M?! U2:00& %@"&(Q=TA*PA4\0R6 B_OI"8LRJRUU-+PWN7RWVS-P_V-.9CC8'<2M)$6GK6 JY>6?
M,"TK54&^3!1(:,$8SB>HG$;0FM'1%)M[=*A-SA<8%R[GL:TH$R1)E6(]8D1690G@09%HL>K!3GSY>\/#/U Y'@# MN1B"<9<3CR3E$O *1HA8E!!X3#5F]|;I-
Z>K7KAV_%_^L$1'/SU>_OIO\$8T M.<Y$"$2E[I)&T(5WY$Y+M-S+HNY!&&@;'/ MA?",A_53PETQ7<#8P'"+D8G&WL*J;X4RK_SQS&5_7]1RX?Z_=G76WD'^_H< M?\1Z';/]M>WR?,/-
/1V5]9_](-?>01@MX?"U?J@N;,*$ [P.W&?.=ZBD\0Z)) MR:E80G2]@QS+L^D#/SS#AVUH!!+W610-','^/B" O(9[.]2*E?@&=F\EIKBIX% MV-)4BB0A\42DXV!-\2XVO.9+!XLL>Y"(^2X/\-
SH M6_15>^ H.Q_K"O73X]4GYXQ!>W!TX,&+COW1\.kV^K6GU8.%8LIR4$8:(H,'U!:&!G9(3L!"%&BFD M#OUEYRT^$'#7[W67DLE@?
2*B!'#65'/B4Y+$)B>X=#0D<>6W&URQF;C6!.XU MXBBI"K-!@\EV>+<0*YZ${BP@*A:9@N!9Q/ZN>?=-NVXFZ41J;<#_!C#3,A)I ME,,'DH&D -#.F$B=[!W Z]-B]|I6HJ316%
(0M"AE@ZJ4B;."$5U<.$XGB"I[MQX<> >T-'CM'HB+(E**@REEA.IF$(!>0F7:41\X]FW2Q&J/W-[,]&X])I! M8(2Y;NAE,];Y9O!,CBH8D[/WJK?UVN>90WYPMJ;3HL$?
NWOCNI%R_+0=#$Z6 M<6\-&(I)%A8R\1A43EIFB34J$NLR8Y1)Q7AO3VI<2QWNYX='@]%QSM4]7,O= MY3>S&RN3 ^}-++1'*X3WTN+HH'$#CI$KRM,3 >BL(F_S1:\D?
O2(+E&61U%,\ M$ .O^F)3,NT<^'UJOG_QBV<33/G+CJ8%4@@J9S9;126:62#.', M8<%?+"BBE")*,<-B#M[PWMVHCMKS$O1EOZ+T9\"E%;,4H!+S4?+X[<"WV$G9
MS9/X'9EIBB=NA$+'@*9 MQV0LHV"(=\H1)HPH.?!@7>J4ID^;75>S;Z(Q&V)?-?)KFB]#3X1Q>]JG@0="LX3 M!;Y(Q6!43GU(5CUf,<6:)L|9G"8=Z(K$@:!D^#69#5PGS2,@;:VZ#R-
FQB MWD Y*BUL807|=+ -<<)0&QV!EIL1KST4I,A3;WW)4ZZXHN&X$=Y_JFFE)O8T\ M@#'0&J"?2L25B(91"JY9/&6G[CN:<+!?4JBT3)'B&MHW=EY-
90RM9.9%%B(*&\I8R*AY@A3 $D CURRO8TS+G"$LR^5 M:&!"OAMM-5>"),$B'B@0Q)K" 46X'@0UOLKSW;Z =3/UG(B5(/3)"M-;*]S|..UF3@;HE$RBMA K(N[A ?X)!BR02R+,XEPN
MMF?K#D DI)=KJ3VC2Q'"%$=2PJH8/FOB+6>$TZA"*,$<*%2&8B 0E!X8#@(+ *D!W/(6H0V_;:EP7 MY%QWE"%MQQO .P:C635A+FO_#]&XRIYIYFZ,WP['L7<=>=
[U]NR:6^AYC M>.*#MH#5BR&6"TJ$,EQ)RH*G_5V(ZN&F_1KW#XQF0L1LB2H6JUOA6E<*@@0'-MI@S"2 @JKWRQ^0?@WG><6EC72I?16GGC);$Q J6,HW@[HR7:1.:C\ M5=?
\1IB<1#MT9+V MA[.\F_:;B0Y,Q"8_[X8P>+1XN|SOX\?_IZ'(]"+\UX()QB.JOO:>T^]XM'1 MT:\T.X<:1].5"9_N%A]]K=-
SWO8*J'XP.'[KCVNFT&/P(VSUH0#/'7V\|;_&H^#@A932:#$>3_*"9C-[E MTOWZX,7KO?">R(R.C!P4G+B2E&<^XBW&SQHRGAT./_.>Z=YH'@8 MKM14(\,,|<8Q$H5,)7'AM$[-"[" <7G@=$HFRWM)C&I-,*0L"FJMR2%[:&:- MT8'F0I<,# RL1@/+&?%@F?; ,0=3L'EJD,1+K'AH)F,$+V<- MR1Y7!#%A+, (SIKKI+GP0ND"S8IP3CJO2;(!B^T8!E#*,B*T]#HFE8S
MU$0 MV:)P,(#:B80A 05!'&F2/EMG:?$4FR6?N;6.6"\ID11D,G@M20G #J^BCPQ%-MC)5H4A:6.$EQ:X9' E(JB>*)1EQC2B'5MS&8A L@>DX#>3-(HH[#Q=HL(#U
MK$2"!&_AKTRQ7#*1TR@S034I+E+">U/%WU'EJ,$-('A;C@Z428*66.:X MBMG!8V16C*72/F7031FQ1@E>M>3@;;IXD ^%=';\NNPAF%$&3T5XX*YE'@,<
M(8K@CO{4RC16B:I)$85>)NOM8Q"(99*1Z.AR3A\FW(NQ2PE4"L5&)O5Q!GI M"%?:*N44;BQ7NJ4$\W8$Y)/-;B=V<@ 8Z'^-1-FE=#/+!>A=N8[61AH-\I8,
M_.,UEU0'E6RL,V6*,QV(,'B/I]5XK4J.Q"0O(@?.@O6 9@*441D*+,J@:6 V M./%8EYN:4("(L@B;<0J412"(M1R++?E!?8'K##5F1H0! -& M#C3.@^530@{!'?R!L1"!$U1
=\&=IHZ4Z!3K(Q<'$=V>B(R3!J&+2A'XY"\ M#)P%3Q3S.#8--D3+.B& ?(4E*7,UWF!K0.^)!D<&\L: ,H4Y/#P@E K4&HXV M)+DHE 01$Q8E1(.]<7CQLB\N
M5!2[SJB55V&FR53I%PAGD"8"K!>%!*8F.< M"9; *N?35EE;FIW2F1CP52 [>$Z3@_Q2B9H4A!(*^>-*H)$'VP8>B8'2FK! M$F"A7- Y4"7CD? T@ U(8!&9 -L(E@#3;P#JAFB*#B
4FJ,1"LRRF!PX5RE! M_+/#X^;Q@-NC5C*\YJXW%(7!@;+| \Y=\PK1"AO=P9C#M6;N0I W= 8Y@-)Q MJW4D>#,()BDC14%_HG>92W RSJ>>3"YQ4&9;'&%:@>$ K &3 Y #/L48EU("
M?')&7*@KX.#!X.,)43#1"D*&K!C1C-+P7UQC?8-7BPLQQK!8,1EP0KF7'$" M3 8=+((&;M&)@X0&!)994>[1#$HPJD!FZF! VOID*"J@X&#>(N6 JE#X*(PU M% ,*& $P*1 L'=#V)A
UD'VTEH# .NF+P(RL&@#>'TR7J,T$O-Z F0<; LV< M 1AHX#>>"X &#UZ0H[7T$IH)A0!R8PX %LX V(7A#F*(!2V8I5_VIX\FQ!%Z, M*30. !3!9P6CE)Y#0UX*B5IA0M$L(E:4$\"L @
X9=>PD>R.-,E?7!H M=@JA.']}B!&<3B1:.R] U:!;5LE;RRF"*'*PSA*L' &OAU:1@:>ER@B+MA?+ MQ7,!V@#F&CR@!D/PKP04D.ED!D<;8S"L1P-
0H,")D@J#AB0UREDL+V6*9QS$$+E M+'UE%KR* K0&E)@-@CN0$!\0 44 !@7@O:AC0V-6%(A$X()AK0N !!J\2=1 M:@W>S%0G7L"# _R))(982:41QE ,40JX.?
N,$@*N5!5PPK*FX59,H57@CE\F\&T M>D"(N&!'@1,B _JF8@F.&(P33!VF(*$%V&@&.$198"-0CPTQ"6P"/'BN'H)'@!%\X!_C&0+2 0B8+VX#6*3DZCCEJ,F:-,"^!6X(1
M*0(1$((?0%&@H +OVO!><)#*7&$>PV'#B#"5'"D*X@XZ3$ Z@(@*/+5'* 6J MX'GA&%J5NB)/ 6)#*5](D0.(CBFCD%,P)9A$!P,&X+77$'VX@+J0N 4\#E"'" M(=U 7&0N8-
^RQ%+44>'F'1"!OA!%00I-D,H!X@+F@%M /RF MA![!P>TX<%)&+L#4 M, VZP 6$6("<.ECA/(B""$#V\A)V"O<(4'/S3PH0!WW")N)?[!* AS%04-%P(M02-8'H;.2WH
O]6&,*4P8E$5P4)809$@6!\0Q!3"8<%4A9ERL- !PPW141=$ M+6$6P$1;#V(']\DIT(I7:!%(1E ,Q[_@/$"!+++991 72H'6R 4;4T%] LY* MS"(JH 80<3&(A2!J R,MQ%
(1',!@)LI2+K%R(BG$(TS0!:B/:!8YA7 K,TLI["(%- M1+&$.#EKU "@GD)0#&$SV#3".&XV2PEA!%JD O8>'$4 J%9KW5W0+(G7/^%J M:H@N!% U2.%X%A.B:Q@&$$ 0=L'6 .6(!8..C%*
V. 6()A+RVJ&=EMI@1(FU MV:T6!4(A-"6HSG@H"S J*4*B^T]-=[A=!D(FXVBQH#2>@M&S*(-P240: M6 M$GJ&&(MF()"MT0 W0#: M#2P+8+T#L50%A!R-JJ&@H!%,&T2C(,(.
(EA0M0*!>8;04 "W1(UE+,_ 5@#K8L6IC93'((VH!O$ MH1AX@NJCH0>_"6(.,@<:8:LN)##P(-K.RH"LZ Z4;;BR@J@")#],D52]Z'7!TE MX"JP]+A*I<#52 -
.;\$W$B$$0(M,H1F^312+5TP+0O&R3XDQDN4 ":@M':($ M#=/&MP%(UO)@ RFH(D&=Q62\'@$!Q P1RP29_A-0[ ]"7,(S/14#KP>APH! MED'E-!4-
(MZ(#@0)HWF(/@U":!'MH"L^@C&D%K5>4P96%J(Y;=%P<3#XWJ$A ML= ,**;F=:T&F V8!HR#FK$>UQ$RA'D@(4QZ 3BQ+L*D5#R0!(AJT)F W;3 MH%64$KP;F*IT1;E#F) O-

9#X#4U"1$]@+<4L@ L@F;#.6A8 M-%, 8>#%8&N 5. @P88!RK711,HN;N,OB(BCM 81)DD*/!^$]2-4X/ (CP]B MS]
%H!K$.Q;,#6H/8V!S)3S"H^6,)%!)#X$G!,;^XE;Y@L#9AQ1U!!72&5V! M13NC$P7H:4 3(U MC#H S(WF$&(8 '9@1F D$_KY.H2R'I=P05M_ 41<1 0SFC$/B.OC M,.)(#8C(Q6U\
7R&J\S0"\7KDBW8MPP!@.94>PV!%V"'GAAO71SH"#A3ZL$> M8T ('A64G<-$588@QC)^VGA'D0#](OPRN&20&*BFACC>:3#38($0(%=)=%E& MB,,!U^-^"0 *AZMX@'4@CO4L
B&0!H\J$;K1=!QS-_OS "QRW?).[8??_D?3 M_ (_FVYRC',];(?D(&."SF.Z)=OADP>__7*@%D]QUYKX0;L_?#S(98(/?7,P MSN77!_\R&<7W1WX?-VR[(S]9=%A>Z_'1.).!
M8W_TI+XUY3B:%6A]C#D_8^!!?I+:[FC@CQ^W0_R3A,$H_OFDC(83TK7_-S]F M]&@R^[/XPW9P_'BO/S3[J?GF$8P:2>/C?@5]AS=%B(F>Z/?3C?7C[9'3TF'Y]#+.&8329C ZA M[0H-
\,]\/'[R98I1>C[%UD"'"/U[O[#W_O=G=V]Y[OMOL/G_VQ[N=O1WX=?OU M[WS_W[V:]NO__]\>?;FU:N=W=V=-Z^7%#]Z(;+!4!A.\9:N/,QH>/IT=^>1Q] MEY]<#[W^RX,)&>Y/1L,%):Z?
9P^;W[>>;34E]RBPF_7 M*$$+7WC]\V_.S')2'=O"E\]&C*,#9TZE_LN3,!J#;ZT# 6.&L\ O$/"QH^D$ MWOTHR>S?IS;HLOV$3/0CKK\N,M"KQTAJZA.^AOO.CL0]NUH1VTD^/"B];S
M1M J+8U&?;?8LG]Y N#D1YXZOB67CW]Y-!F?'<@N035F2;B<86X#U 0XO/%C2M'W[X]#1#^;2 .V7[1;2#4] ?L]I<]MS-2/?FV/;Y9L5EA<7UPU7+TCVDW:_O%N]X_MUWO-WIMF-]?
K:ALFFM&X8>]G MRR#;BXPFG=?!M=#A9PSV)@>Y.3F.W#S_% ^PD$2S'2?XF#DASQ/2C9/9.)D- MW>XVW5Z 43S_^%SVQF1S::C.?/3D5HYSOVH)0/-";3,"5<@=.&O=!C'&Y M)(;
[U7%=COUM'=KSV?F@TVX=[QT@AWB& ;]&DC\FQ]F/21ZNCU;_/AWF1M"' M%Z!*$<7*FON+^"8"4ALEHK0))C14HOD];JH\J+M0%S_#K-] 9]TZYLOGK?[M%],Y-
M19>!'XB2'7Z9BT"G8[Q--3C^66$^(O9X/#VQVFOGFWB5,W$&+C"F]- MG&I+EKF-)[,B.#X-># MT22,/JTQC/I](LW@6R/ MD3(5E$LD3?3<3?UPTDS&6TBV4TDNW%#&[HMZ'82
MR4Y.#.8\E,4DD^;]\C^TF^]7_OONH&6STWR;=IJQPE[;8:F-YD4+L1>@F9#' MCZ]H\]EHG877F(:)UB5%YB7ETEB)62C"Q"+XL?G]?2'#B9V5QNA*R4,B*$ MQ+*D-[T+?
2^5Y_*B*EB6DE-'N\9&SCNZ8[RA%K(*6F'3;MI&L G..B\L\W3IQK MM06W8XE/T:^LX:T\7&/H]#GVNZ00]K04GF]^D^!>*]RYPG4]?HZ9X9H3)5VB
MC,;0V:73U&;F%ZO%C8_FMK*6V*K%)!_^BQL%6_%YYZ(#8L,YI8*(3BV169'9Y4BX)H&G+6>*7(NKSVGO^T M,R]K-RLO^*-H_OE0>*Y4669XC^PT;2Q5-3W-.I? YRG/1F$N!S
OC!KOH9BOB6 ;FW]%,(/B65_,TJUWTTK- M&0G>&9*-T=+(1*U;$SK=3FF@'8<=,CD D!O]_>U1#_FL0!V=99YO@[;9%$'-QP4#M: RVI3WR@R9_RG&* M-P"Q? QQ!
(Y&X3HOTP@4$%&]3!"P=A&R6X;A[=FP2,ZZ'<]0@uC!J_O4!?[!A MTS?8=+(=^[_Q7)FGG3-) _RT<%HF)MA7>1]B.MT@RE.MO' %:!ORN?G3%P) M?/CIVZ@[1EHHX&YB1-
T_$18KS%((@B2E6%ZG%'=9#(4ASS9,_[I0$Z?ZI@.> MGR\0\-0*=@;K)[EZ%X&F6*/,$2,=BP!@E5&7/LR+=QH-W]}(7M^V@S98L9E> M)/J_J42Q\Y+F[GBFR_5D-JQD%8^7]]B?GVO-?
PK+9.3M.'G\)0JM[OVS+;'. MPTWSOV=-:/[N/DG)[^UD5N?!VE@#\5*X47P>E64VOF,..8\5!MU/K&:G:3 M?%.ODG_8_.D^*VO 2S8?_&:ZW9E5MU0"DO?)"[POP>$_$DOV9I E8TT6A:K
M5+]L!,QMZ]R]]WGS?S^U.'S<"<=-/,CQSP9&^B< D5QS]S# /4GQ?]S\Q'YN#GS7E'8 L,$?#. I M'DG&D/F?TQ8#9HB30YXW@)=^=CXY7?08;Y/@*4!.; I3CKD"4,:;6N2E:WZ" M]X$^-
=T4,%-W.,*#!HL#?Y,#/SDS^.:C/SU*'.+LR_Y_/RP\QWP[CY.L.QU8C3$]"_MGV;[QL^FXS%,;W;D'-W5Q$]^1+;,&H3T[[E;[Z+H
M&L;THROA7^GZJ]4WIOEJP03^Y04*\'O6*%O(';/>W)W\7S'>U:F#0#MO)!$Q@ M'H!A&X*&B.<&QTT&;'?<["'IZ\K'N]?_N)WYV8O:,<3]YQ^KJZ+LIM)14H?U^
ME_>GL]L'FEVRU_R$3M4\X8)OS1M,#MIZ.NP(3X==M.6?C7=IP'/W\U69YV!+ M\LP;H@)>:T%C(=Z"T4TF"1V5*D:N*:UGA5'(I[FUWICGC7G>F.=;:I[!(OIF M
%/)C8\1S#/N;Z1JL<8(3<_]M %U(^<^Z [!KD,OXP6" [MS"'0X?HA('%X' M\!7)MM_LCT+QUL S',=6\JE'=9"&C4?#',%.'WRI1'6Q^S)HMDW&WQY M?(N&B,;GC;\PUD7+=CAS/XP'PA?
QQ6I0L77!+3IKKBZHM:Y?0>WMV*+CZFO' ME+_RC'WMH?C:X>>5+C=UHZZ_CL_+\PW,?4G*NTRMTO6ZYPV9-SFC5TVW[8V: M]T;--\
[N-_GVA0I@6;O$2R&9&KR?,'GBJ7:$!NML%DJ7R^\AGE0 &S\#W=D? MC8_/V5VJC:I6Q7FCM6XTG1=YW/.S7S>JU7KCO#?:^SKIMONE$/X^T_/"NOR% M-62:)&5">)*UM.
*J*WW&.,=U$Q(96EB:SI,7-GW=-JUP]QUWU=[_+(EQO7W ME!C?X)*-2=S0;4.W#=U^T^I]OS\Q?&[S,U+^N N;-*:N:)B)02:6T@$+@Y<*;2 MI6PCUWQ-#GC!O+]6WCV;L>YZ'?%WW?
7Q/>F!]VDGY>ZF!Y:O;!3B$>%S]S?; M3!8R&7S$TA;W;N>%:+^^L[PSUO-WV%8_>1V?_)%?G2B7_"Q+$;#74G$ M.16)C,:24((CBB?!A68V7/ZDS3S(1=$XS[7.+X(N?
M#]:$7ZJTL4NKGB\G?: MF=[EN:HAU=S3<&)LR-> M'1[QPH+[\R\,P%IV$W!UF! 8:UH'7H?ZQ7/I=U%L;DEWZS8R9G%YV[N SQMS,/F MU/W$M^V,=%^YO.[SR-TWSB/?
$^59&UGG>/I%=?9 W_G!,"VUCU(1(YPD4B9. M+"N".)&R2#P$Y<190*U3,HG:0JR(>%!O->#\#.@\@%(OM(:#L7Q_LO'YQ&H(/IXX]/:\]SJTRT]FCY?
U5B\L+8B>9AN8I'ZVLCZRR.@VOQ? M)/'!^,3" H5G_L\7X/QC/_CHC[LY!%TE]F>4O/L$VUB2S>2NHD;=ZB6&:YC] ML^T_]G;>O-Y^]_?F]9N]Y\V[YW_=?O?[SNN_-
B_>O/LO^)6\?//F/_#OW;WM MO>>OGK_>V[UQ6MT94,CA9?(&\6S%@)-1<] "T,::'X.F%0.LQ^.%[;PS[?C[@,NZ*]4?'@)/_;]_%9['.Y) MZ0>GFI_>
[KY\M_WS5K.'HU]VA8O]L[*T.2W++N1/1[5B^=%T?#3J.F$M_\'/ MZC2!S6.\D[(>9]X[R$#Y/(5@H7O8[SCUF)X1^/19(8CEBMJG2^Y ?P:H).Z
M@]2M/JVC^^*1LNL3M(TBK6.V5<:6*K!:^/B5'P)&0LE;+L;^WG9Q.KM,&H\G M;@_]X+AKJV2)\6&Y$/AL-YX]);=[E;CJ8U"9OCO)LX0/EN'D+2MGL@"R"=#=\ M1?6^K&M?4++%?
B8WV^=45SDIJB(>XAH*!'1UQ_6GS]O-:Z LW\>>7[!:R^ MMI.Y[5OY]CCO T4KN:;CIDPGTW%>V3J."XX]A)9+=HV6['K8A'F>9(/[CI.\ M?UP)!=$&\ M_&]5",6!HZC@P-
]%W&5Y[/)HV6/>IG=WZ=OPU60K0>1Z#6H:[1_MG!5(-#;.+7[(@Q8&)Y6W'8CGP(\77FLF"WZ LKM_4',CL*K25Y@V5YSY MZQ=LKN4SL*LMU*,O??
=S59M[4QC"X0AU8ZYY\+WN.G>/^N#?5M8>H-=#,@!C M0_*@DJ[V#,][O%I@=8-),BEN_W)F[>&$'!H&>>[* S!F/'E2"4"PQ^YQ !V> M+8:?38!:3@0Z$^8O-^@[Y991X JMEHX+
(PT>EEY,O1WBZ$FEP%>FC P M3G9 M[5Y9:IB?W:;T[%MO!AN@4H.AJAX&3-!^19JHS:M>8CJN96M@E-4U=1-P27G6 M;/GA9 QN9MD\SLJUU"9S*
<6=V^[521RKB<[&=QR&T*>.9_5W M1N!><,MX.IS?_MD]G!7#F1F>VCW(->!;&!MV!R@>S;%*BVM;%[-"2S>; MRXP,@WKV"#?9?MT>QQX^C\9_U8<76LU2N>86?
68';60;/DGYU&K-7HIUM0H[H MT"]QU7=&23!Z<&7LA^CDX(/$OBFP>BH^M@Y\,H3G3Z]Z+71[8UN?Z;;*%%^ MMG&/ ?0H5+^*HG4(O]0_5O1HJ2<5T*V
R,\5=R.%&RG\+BF$YU,;.&9&,OJC MF5@NG,@BXEAU"'61 AS+0H#G!OLPCVL\\Z%=/)A[AM-='&8 G/.@ ^0W9DPP MVHCM1FQ_U'@NPTV(-
OE0L6LBE0+3AOSUR#0K5@!PLX99#IK-V>@8=3DX7@$ M.& 6X2Q?"..X0]?3B&HCM!NA_2ZAG2U?S!?A3F/IHQ&V0_-9IL.Z .91OA]^
M;I%#'F9X]0K\/P>\ESEFR.GAXBC#PCQ/N[P1W(W@?E<8>B*=^*Y%X+0B5'A* M(D^6\'2#2SV_!X:><6!\)PR:#4(I/'GXOA1@HW4OBC,+.; M1HQ5RA0K5I^8OFH/-
R9O(VQK%;8!ED3W^[B'$P]F>V2G0IV51YABGMQ].WTZR6#L?YGG. MS.C<5<]Y)M$L]JE>/F!:3FX^YKJ?(,"^(U]B'UP/:IZ]WG?31F/#E'ZTQ0: M=7ZP$?R-X'^GX-
=T@W(69DY+:6.;AW&YDAE]AU?V=/![Q%6E49784]MJBVVP M>;X%O&NA1+-UTKF>U]![F=*M*(S[1#>>M@FPND*^3:"O!'DBP@R[HOF25OS M0(Y&W4DBV!?"]96-
S.6*_#\6^8AU@[5JPZA9??EH7+=B\-%)E$MF+\1UHVP M7E185^7QX=S^UC2 NM"T2!"8[S[-[T5?L7>K2';,OCPO46FM M,-#5'([3^9VSK,B'2Y>^3-#L5DQI7F,/G+.A':#6P:
>%YYE5/I8#29@V7E2 M8YU47;8Z&K<(9NM!Y-F*.CN.TT,\T0CP8@MS>3O !O#BP?'#FIPW7WG]2HY> MI<'GR?;8YS^GP.+2SK;!9CM,J\N#XV63A\MN MCF=?/_?
%D6;YN2/"^K,H1BXI%P*/.M06"]L6^3-GB2_;C7O,E!H/!.M^?1/ M*D.!78R5(5,<[:"M$\:#Q/7^KB]3'=A=A]H=9?\G?&&PA(P?VORQ6ZF7@9'Y M#%XN3Q;@G6&5;3_-
URVS'X.DC&=M%X6N:K;R[!JRQ3=_WFK^ZP O20/A.O0@ M]T?U&PL]^//A_B.*H@3_V=E^"@,%]R]1(N]PYP,M1NKV& M [X':O'T"'RS<$83_G_RV04WV,_7R9#*=];"N0,X@Z#4?QS+?
=J&P_*WJ,RBML=H 5< M>4 ?[SL F&%P?*I&6#4*,\Q43QG5.[O/7 N[3.;"G_UP!MF'PQGBG%W\O7*2 M]#\>(KR='S0]Y_G?3N#\V:<6OSP#Z]#1"8S R (/E%CAQ=')@=#)RGG0K3@Z?
#C/3@<,Y@?=O$#I"*<[FB(" MQ45Y3#E,!5FS$2T #B#!66 QJSFZB)-]2O78P'P%9P%XNM$@#XZ7QUA7WPHF MJAU^R!@,=?6E@/P0',^.4IU]:^\>;?[[QYU^GP=OG[W,?/G^VM_.?
SYN] M?WO^;OOM\S_V=I[M/@3__NP'XL5U&(M:?.O;*G.=9%HHQ65*"*]Y2)_KYSV(M>V]'/5+VM7MP[=<>KGSS6^46@X]_[H\!124RE\!8"BUQ&V[Z'K#B7,=^E%W -!
[8%7N"KGNI^9O8,^I8 M5K#:7?.[1WK%.QS97H#.NZA%]V0ZWYI_@9T;&2\'^1.PHS@!Y@-][X[R'ER M'?@=*YGBP8E4\R!'@WJH+35/9^-H=G$]' MY?U)CO\-
@I/=4S7#5TJN+U*M)C#VV1&4KOW4',+[#KIF5KG\-(;!)@A55L', M!K:L$[;P#6S9&*L-N6Z3MF]@RT:T,RNYEK %BTB\+X/1Q][@E&=8UN(%C.@$
MIVS0R0VC$[%!)QN;M"'7;=+V#3K9B/9M)=<2G>"1_,EQ?Z!)/>Q?ZWG4:[\/ M1@.LWC_PM\\KZ/=K*[T#[_(3>[*QH)MR'4/-7^3N[*1\7Z0:PEJAJ-)[M[' M!>#-WQ!P7 ?*>8U=+\[J_[$
&\T7P_FI.;JK9/:X)*-$=J0ZQYJ_@:7W(J#/ M/.=NR]]EXBU1RDG%S>I[>*T%C>\#HSR:MGQLC3BM[\L!U+62[5IBM:U+,B-6#8 MY=FB,&M^[D6MV3Q)<-
>%EKIJW9H)>-.]Z0ZQZJ_@:]W #B_BN4&8RZZ1BFMAVP2..KV6V5 M[]KNSPT^66M*[0:?,!SNAESW4?4W^.16X)-SM^7O,O%.TF[A/>/1H'M_-![% MG!
.7%.62^VVPI*WRZXWN&.#.WJE)W?%D6[(=;]4?X,[^HX[9E5A[V]9V",_ MGKQOV_?U3H3K+@W[!LN5;\K"]LKZ;(S,'72D&W)M-'^#._J$.^YY6=A!WO># MV6)'QN%&/C0#?
DNH>JO\$;MP-O;/=&Y*\; M<^"I#M\S_W[<=G^G^GU]?QV8],XFA>S_C9P8P,W>]4==\5_;LAUOU1_S=N M!=RXOX=EIL-QWF[\4*VZY(^5SIM=[!Q/OSF.!VWDS;/ MC MX?
LN#]O1&'XLP,%UX)3?YT-H_H A-##!(:S@DPT6V6"17NG.77&N&W+=+]7? M8)%;@47N[^T$7($M^W_F2)\>UMLC\/.RU%!:>!A\UN[7KU*.X&>VRP1Z]TY:XX MTPVY[I?J,[#'K<
>Y]:=O,O$6V*/FSGW@ITV.R>=;O#&!F_T2C_NB@/=D.M^ MJ?X&;]P*O*%[(_'7C3?RIX,VM).O+&[DO"Z8\7S>UP9=K!5=N VZV+C+#;GN
MH>IOT,75.\BN_=IAT/4YQUWHW4]ZM]B_,2GWRZ0(^C6; C]]&.3Z:R_$XDS? M7^WNHA*$DTOMAR8.?->A[.QG,AREO/@.C L?+V8_R)]{:L9@N*"S?GNJ7*7LBE=\I,&N@ M=-
NVIX0+J#C_%TE^,#[15]#XS 7Y J-]! M?LVL3T,Q/?:SSN75!=/;(?Y)PF 4_UP'W?90Y^K]GK.?3GN( ]43$WT5NG@B M'E<_Q:9-\/;%?1T76X/_JK9\G$EF&
W2.H@S*PW6D.,%SNOEP=D>C.OULYWM ME^=6S3JZ*.V(T) MUO6"$F_SN#M"'_XA-WL'&;K)4T"'"W<-F9QBWZMFDW6GHVM3Z4HR<]&WGP_MS]9A*(,?@*[E]]U!SI-^\/#S:R)
[Q*9Z8^73&=&:721:=^V,ZP4A?MH9-I.# MT;0#G0+URI]B/IHTW8$?S\|'OEQ\\$/IKE)?N)_OF$J76O84:.K);B=#;3& MIWXZ&3T)HS% S3H6B#QQZ-B< .0<32&
(:#_E]&36%:,0D/YE\05@], ?=?EQ MEX&V((@+&LQBU_KN!V>7C#ZT71O:03LY?KSX_CG+/K/NM-YR3OQE#M#/:<"V M-/_:XZ\]XUO6?O?=-]O5U,+X7+H"(N*37Q_P!WV/ M)/GW'/-
AR.-&L/LHS1M/N/&$-V@_YGAWN5.C,+# .+!9<.#V2P&G_)LGL[Z; M.C,UI.(.",M&%^Z5+GRS8L(]U86-)][8F U>_Z8%^6DZ]-,$;T@_WU=NW_'I M]5R8-
YR\$F^VCI3&\^EXSG;!+;>!V[N[ST_M_/9(]]XZ/_#"U]$?,+\V:W'/ MIKL1X[O)USLUW6L(Z;[I!#$A^B:4Y1(9S<^FXS'\UOBNRY/N\<9-7%1COIK MOKZIGYO!?
A,6XE[,=R/(=Y2O=VN^ZPWX/G=K=1HMI@M.'B,]SAWV-WS?:GX6 MOF/UG?3);?",OCNH&7<1?\$+ 3[XP:GS!5^0P(M0ZX[8FW>.1SU;+ZG1>!+
M$_U?:^1]/XZYG:7O)53AE_83\'7X8NSK,:Z:X?SBO51,2THEL=9+(E6Q)$1I MB?U_[+WK!'.M@1G65-/N,E B:<@HDW@K,?@D\TL"Z^-"-_"&9?&!L\#:",= MB)0<.)Y\@;/HI(K">.\?$\
[LB'$S=##K-C*$:OGF @TGL_D2"CB<-N/IQ[18 MG]4'H!O(:7<12F:,D&YM4"]2#*CV!#H8>8HC4Z,F5CZD(AM\[WOOC>]R^N MUQ&#"#
(R2@Z=0A"S<#$'@EDN<4=)RA")4"!$R& D*,MZ[0VAQDKA613+:)LW._S.>3QEW\R;.FWEAHH+G:L._4V1.)G)I<_)PP X(7 ML>&H2I S\/-L_N)B#BYG[>W5I'4D6111MZ+
EBS@3W49 M^;,M(U,D6B8C]. "B&@DF(K$*>NQN2RUWDPH4V67H&,6@.PMH",2QF\-E% MKKUVG,DN5/&%/[Y/1-+:-X8Y:%^R:8Q8[/8:!1H\(-I#%' B">56$<"8. M6 H*!%,)'(T6(K?
*:RJS=FO[^DWD\2X1C'(^= 3KTUG,WJKDKR^P-2=I$MNC MEH6KIS"U07UYZGAZGHIV/DNKK@2HF#=WO<>OG/2HC/3]X0^$L[AQ+(ED08]: M_<^] <,-
A4"M=2HYIY3J)!;=^O5Q?C%>G,V*4_]2$//LU31,SFN#H1?7_/OX MTKT?1&4[RB;8AQ);J-,1-Q$W=XR;A!?45%%",#P7W&3UUA01$*760@D6@S6= MA,)WC)MK6P
YXH0B@.Y7,'W5W?.!^X3V10YNH_!^MG03C)P/:PN.<:<[T_^R M5-07N9M4*IH^,P*6<@,1*$6L";P*PG;B# Q*T:,ZZ"F!"M<#$'@E8Q.L^) M5:"
(M""L#V"8)J"",5I*;+PW2GGCN/A:F00K/:H4.GC7]W_(8]X/9L&X>2& M!:YPO&C_5[8?HT7$R5WDBA93W:7G]L$R5JH[:S>)FVOX.6]J>>2$K=,=VV9 ME TL">] L[K]T5F"2U&5S5-
*G J>LN[DD/;2]],W'1Y-(TO+YWP=>KNPM!(MB\'OH!"[<#$'@EV!:<]HBL!8D""8EF 4*0"F"PX%3V7V:^4E-TN*W#IVR9'4 M@_GQFS('4CAMW4^89;A?)%6D2*4P4-
P+]22NZB$2A*\B@%"D*&6.:'@0I1@ MC4I,$EL4+>E"!E]DTDP_)K<(K6^>)S_ODCMB4)7YYXC0NW0N02Q"Q=S(-CE M&"6$VUK,IZA9(3@!;U@&[XDWEN>L!.U"!N\"NW
#CP'AG:C@M%C.QV&95LT[MD$%Z[E3((<67Y&V"-WHP3+"07AJP=.:0>.\I(HIQL5:QODFZO>+U]U-RTQ%B%DQ$)(Z,(DRB(PIHI5DFG82#T88.P!5
MC+'A'W>K5].EFWX8^\E%9'@Q:LHSS^:SD!:U=O$BN7E8M,R+Z6.:S-I3$&2= MGOL>LLY=K",TY4$R"D31MAQ^!,N=!V:BY3(8S5SN0CR_*D"2QX5.T]_CCRE^ M\=55-OK+3Q<7-
W^9S>+OX\FDJY-),BH3-73Z03S#Q1P(GAF;':E9%2Q)72&KQFHBI=!S;:6N,[$!^LDRQT<@'O6B'OSL\GE=XB__2GC!\B(R(C M(N.]D5%:$G)1T!"[(""D*,A(F0++J R4)!)-
)SU+MXF,PFPQG[D_R+C3 J== MR'=2D/I]5> 4"YMVZG?L*:N.5QMW3]"C4M37EG',9/QA:UQU\TP,A*T2L54CNB)V[DR&[SLN"=!G)@)(7HB.B(Z+AA M4DGP5CI(;!4.S :"9Y(B07J.-
>"THZB:UWBHY6CXS=68."PP9'+-RZJ<,T M6-[RSH'V]]SCT,I,HB$/=F'[-=YN0U2;$5R-2-U@V5N=TR]+]X-\U[!?[ZL9 M\K-)O'7.?WUU]-=7O[YZ_^KEN^,H]8OFW?OCY__??
QW_^N+EVW?_LWGY?_[^ MZOW_16@9D*L-#5K0D->[L/T:[SYL K\]M3F '>!E@^K)V[GQ9+P<)VS>@3@Q MZ/&B(?=T8?LU7KQ&MP-Z/ JA3.%RT9RYSZZM33&-C0MA?
IYBDSZ=I>DB83K# M827X]_XP,B ';<09%STC$ +C()2+8+Q@$'@*41)&F%\K!KI1&L+%4]Y9^>31 M-!ZM//?+&*R*VVP.):D39X(N#(J3M[6(BI&T)TK1/LDT,L)E8$%%P<,&5?P@U
MD46C$E^[/[Q1[L C0)HE@Z_4CC?W=J"AVY+=5P&FST@M/780!Y)P'D-E9<3'HQFT[3!*/& M0_$O)),[=3!/C%*FP7FA01!;OK-:@?'.94\DBVR-3#;1P2]/SR:SSRF]31.W MW&
(\A8TXQE,0OW Q!X)?F01%+'<@B:X5/.)/'KV3)=YE,@B?37NSQ;[)8VI!@Z9R!F93S'S ^O18G_Z!2EKE:*C(X(47(()AX(T* MY?-':EEB161WHJ2O'3<>YQ?
CQ=ELX2:_%+P*SRUZI'ZXIJ3'U_Z^"'P5W]* MV"-X(G@B>-Z_(#")7@NE:AYS <+:^\BI'$ R)WT6C$C12>K&HX#G^@G=B&"+ MI'V+C+<>].!&(.00]PJK1B!A?<> S-
;SK3@&FNZ6]%I$&C1X:S,(Z0WXP#QD MI0/E/-)"3!U+^HXCXV2D*(;&$;$&OY@#02R>N-#:!: V"A!*R()#)@(K EL% M+2-
SH6,=W3%BR9%2@T]@P\JI&Z8Q3V\0L5@\J>Z!]J[L&X]'J3J(A#W9A^S5> MS(+$PD^X6\+=TBY,BB<7K! $"4$A(D!G.(.DK3,:)]SM':+A9\Z;R].1T)B MM ?Q:_"+.1#\-
C!$J8DEIF&O1:+OU&1YRSZ8?W:7YZ M_1YI9ZI7R2VVY>ZUE2-D]6@Q!P)9,AJFG280(A<@"'D*5HNR=2H\I3E,$PX2#'7"6L-F"LBL!I],0ZKKE;BYP\ M_
I[YP$3ID8*K[XC;N%B#@6WB!74VPB2]])CG79@0A3@/(N1ZP)0=*V?W\.O MOC\4M_#V.T9X'TGV+MTG3'<8C&\A>=Q%'E0Q;HN^!=F6-K65/"*D((401,L*
MG4@GS6"_)H_W[M.U;/"7J;.Z@2-IMWB)LM<&C^C5H\4<"'H7Z2K-@Q4-@%$ MO2SNG/:0?($G2A3W? M5GQ"]]DD*8P3XQ[WI>'F2YLWTQ]LQ2"E8N00KESR(
MED)B1H>:@R=H$=7<>S#,![B216H<$1WTC2K=>/K5-1Y\O 6ZW#WIR()HB.B M(Z+C_>/5K)ZS&071N()T3"%PF@10S,9,K"FPISK)4.X8';'>W1Y'M6D76IX> MI)A?
56I"!8\W!8%GRA@,WEA8%;S,8$Q00)U+,+C&:<\!=5GKH*(HF1 M95A($&4[0B)"8K<=%KP5-@M0]5XG%)9#T>3E1Q)2HI](&#]Y6-@])#(VTA0A M=<>?!]WO6F%HKN-K[VJH-
%NVY_*RYV)B=O\I9O ME^J,AV&1 HP_PV7^-]E"WS_G@,[H(1 M%Q 7T)!Q8?LZWOW>!>\MN[U;SL)_G\PF,;_+VZ_Q;OL*TGW3%&\:[C8#P?_O?+$5'D?-'VX*
MJ6X_NTL0K2*+$)5A(&2M]JZ3ADP9)=D&1G/J(KOK:KBM&'CCYL?S=TNW3/$? M,G*>WJ3YNQ,W_Z9^7/FV/K\|:W&Q^B@YD9)2R$&456?<@@V60]+:66%
(T"EV;_7MHBV.SIR72]8E#XZ,,))D*"O#P2KC(7L=.4],N[1V9\OX'KBW 3@S97DY M+2:AZYFDD(9*JW/8*(#'+>0D>9#"2$Y[MW9=T,EB MTEQG4-0D$$H7RY?%=H-PBO.L)9=JQX.3>V:
[,2V*]JETT[PK-%+,^*]U$ENA MY2>I.?M:C#R297MFM=/, 7.L=KDOP.52^8=;DI@)SB2UEE;9E66_6BS.?WCA MZ[%[7?PJ;A=I>NL=6*V)YHY I0@044E"^=YH3UH
MKVE9+VK!R(@&VEBRJR0[%I_H*[6Z_A\N5BZ:1Q//VQG<%GI6@\H@R&R&*,I MZM 8HPHPI3)D6Y.%;FW1.AS<='8?"-H+D+H@V"%KL6T:RNS+/#1NT5D4K -T%XF*K*D692\?
M9<5@W11 M_R'6^KW.2YE(>F?"6 HV4@P@J@*&9 W>, M%'R1T:BUK=TFR//(@]]NP/]! ?[.[5F1&*P3&B@CH2P/S>!EM*!S**M*N?"B
MDSYMUY9T1Q%1JGFBAE&02680+"EPOE@?HSKG+$Q.279LK-V\B79>D"TD^!] MJU59"YB&0GV@-#,@C&#@A E RN(5A1.%6&\[T(E=;A3WNZ]-$A^SS,1"%C4V
M1FFU2:9!^>)X)AAOXMH11"CVCPPMCXTI4>"R1%5^I%LLD:O=F*$7DF:DB; MB2@04H_WK2S+)86CKG @$:1KOMN!$7I-F4ZN5FJO)_MAS4R'EK<7* MOHAW]92K^K2SV6)
<9^+9/$U)+2*-%)NMJ6L(J9H6,5MJG8P1VJHQA;[>LFS9D;Q_+9F^#.QDLW0;&- M!(8$]H@$9A7SA"D"F416T^ T.&TI!"YBCHQ,I3I)O\" 6* KR:/E_Y_S5>
MZXC2)-6CPK!#YS6$,%S,@4"8T5IYDC)0G6B!(Z?!,T;!,9'J*86.H9.^R3N# M_,;T2-J,3C\'9?783'D7TCR$+]/S27N[(J8\#N,ET@G66.]WC?4.L_]_>I3+ M1H0+PD2(D(RJ8:
<@P1&G@!&:.0G"A+AVV6@3U?XV+=UXFN)+-Y^.IQ\6U]#B MQ0HL[D]Y1)7^>Y[G>JT&HEMAJ7VM>2<9$BN4I43VT722"R]UN++ MUGD]BJB5[=+(VBTFYNPK<>'!
4(C0N,6H9$K3SB/!I*EM=>)*- 8K0*JO&,V M:\M#)XG<6X-&+4=46T3&PRB@C!T"#HA3L,PLCA<-N<\+VZ_Q[C]4Q4@'H2IV MD%UC5Z&JR9?VR.VM-
Q=;7%_QIZRJCOC[+P6C'S,'=K](LE_V-I6[>:9&,AF M311GC.0&**UQ+"-JIIAF90E4M#&1R&@[*;1PK?7YT31N+ZIEY,C2G>W=OC&= M]N](6XB;B)N;GC++4R738=*7UZ%8$K M-
]]GL^6TJJ9NG?OU^J^4YSHI+L&J($$$6V21$ QLSI(Q%P(/^DGSZ73R;*F M'_[\)$W6A[^\>8QQ'IV7WN5Q4[V[.YN/Z;RI?X]+6@%]4 ([-B?N8&I_2M)FG MY7SF+JIZ-"[6XG?
E"21/4E@VRY/TG6+QW_ND5XCY^KRM>'99T4MQ3XB. MD&VH-5YLV1\S02)PVT213OJM12@%)STW!(H3^'E,[(M0I,Z2-$F*F4VDI+O
MGPJ\3063%FE5\>6L8.FCV!N4%0)*'CZYU_]PO<\\9\]]],EDVUHL?T0>PG 10 MP7B5O5,BD4?QM_E]$59[^HY;SV_ZF9I%M8:K3_&5U3[BITHY%T\L;EG$1EN]
MAXI5J9ZGS;N4FM<5IVCK\+0FNTT63Z\/X1+*?@2^U?<^ZNT_D7C;3Q1[:?9 M9*>%ZPJ4#P[+>_\N98WJN->-&Y>?EUT6GG:AWE[OWJ^K&6/"K05 RQ_7EQE
MD6H(=]]>NK47/?)XZJ9AW"9,E5^X-J^KF8SCCTV8N$415&?0X+I+*;+ MCU,FH#Y\.=63] GB>)Y:&?6L3,?YZ?1-/<5P,SGU^5A]M!W41221/Q7CZIXM" MD)4S]_?
Q;WYO#BWSKA)U8FO[O/ MBS\]^<^KE;FFY[Z:US*J$_E5O/5KZ>&:DWFEF_]1D.FW^CZW3T,-[-XT#>VK M%]BT]F[MVO<^+BEV)H">>5MTGG98BU&S:MI M>-

*I&RM^=^\4XCEUM!?00XNKXDS<[WTFT8O,+@O\VR[_-BB!NW7*Q'\OY_(J MGE\2T!XM6=M2ZFK^*L(<7\U?\]/YU)W'6M3XCWOTD7=O97LQ[)\N*DFOCLHN MRCY.B\J9G2_*KPH\I$\AG2U76\,TA_8YC5MM&'$!'X&Z<'"'/+@VVG?3F;L[M7\XN(YSULY2M2/WH]>E0Q-_I_*+7Q)]6;T4)>4K^X_(/0O7BLT5ZMDAEHU* MJW(.VKCVZK6??)N"\'&\&+=AX<_/+O_^AN2"U=L)_=2:_[A0RC<\3C=]C&SC M1>]\PZ=:,;?JW3QG;\$_M4_DH[\KN]ZYW9*BTYO^#*2I;R,'<._+M."?SAD^X MS5FX>;_^E9^PV]9W2?S%-J_E9^/EDT+XN2CU?8M#>SGOLD M@^_%+#Y&I$_1HO^=+L_01M_0F_:2GXJLC^R_U8SVP>{24U$#H$):1X=Y\<= MY[N-O-%QT"0<9!QT"0<9!Q'G-H^S=:M.K>C_;'3[5^L,_)\E56]N=(Z{8)_67NILNFWK2:G]>M7_@_M W: MUNM8[M L=G_9?W_K679?VC?$I*DF0*++(C78&A*H#VA+!ABF)/?WE0M3S?) M1PE>U0+WUB;PUEL@SAB1K0FJ-NC^MEA]ZZBO9\N?Y[/3>I&G?HY_CIQIWE7_/Z,VL9CE5OWED:NA(#@B./83'%6DE%$#*44.(G(#5HD SD=CA6"$ M) [T&CB1**5R$J+@N0=#9(8UB_X'$3"L?/L\<#1[V5]}'<'QP_Q]M^J"%)G\}YJH;K% M,R2_P3C-P#_"K7B@RSJPX.(5]W)9<,@'\EPT[$,M^,CD+N[B-9>20]M(E!? MX_IK7N\ANJ_,EK=ID=P\G+3ED&/ZF":SLUK#&@_L-SV"/(CCQ0V7KN(%7;6D&S$M MMW? WF?K1]#JS5+V%*AR<$R(6-1-KD"5M0 7E8:4O#+2247D6J;D9FGDVP*:(% A4 UZ*7L*5#Q8ZY@3X&?!&T$2!4,/E!1 M-=),(U(=KGDC>/5Y=;O?#BH:360/GB9 MD=)VX-BU];H8&$A\!I=?TC35MK$UCNAB>=9XL:P)1^Q1;_O0NYXSIWT. R M5=X#882 \(:=[DH66E$H"9&[GP7H<0+=RO4V#!&! B6O A";!&.48TYXZ3+H*)NX$J,;(&-^D(5<->RIY"E7_^ M9AX4$$,$"'"8}>,$C<">U]9)88F(7X<3=0!6E(VX98M7A&CC"5Y]7MWNE%1,G MG"@PW'(0Q!61)2.Y'RMF!A=L*+(.+.X$(O)N=_8G<3+B*"ST=C <]$-JQM,F M+9,%>):IF>7&+1:IUNM=CN>I!LR;F2]O[EI_^^GUK#@}.'5<;:^]#-GE.KTD M)H!V.D$HFA9$4<9@%0=[^V5WQU?N=W;]\&\'*%^/-M\|L+/JV;.O+X4XKP[S2?/?D+#)Q@$*V&O10'CU8_74[&5M'/Q&QEL 9DXD5< MAJ4C92ZL(Y^&X0QMXY^ZT*[7WG<]RL:B-+MD-84P?!AX$5D3BHJ M'H3QNLM7#DP@!GQDA M-.'F?+@*;*-W0Q#&TB:N[]VK.>^.Y+E*,R61 J&3! MY.B!%W67B*#,^C5 W"14BFKN\=0/CZ8O6B1%9-Y%7Q,%#=0W$0<3 E=Q3D0Q0Z531@S&"H4Z# M<<2XE(5)P722G8HX>*"NL1^&C]"(T+CK\RWN&.6#%A=@$L^@Z!4!(.5.$V3;5WQHE+=]D4,+\[Z?+6ML M=ZWY (IX9"IDJA)(U.2$FXM)"\MB!!{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j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}}Z +/.LCN[S(^ MO_+CXRLW_FO*LAV:S;83>3V0)30S 0AH&PQ[SC'IT(RFH)-'() MPAD-3C,#W&>G*-619-EIJLFK:9B=IHH?V74[)!4CIOC@8FQ8R@B1%I%V_Y$V M"1]3EA&TJ4GC*1:D-99 SK4P'(O.Y;6;.0]*9]D>TMJ1EEMLQ8- BT"+0(M MNR'0RMJ8P]!4-*R-(*@78 +/D(@FA.1,8E@[*WY0QLSV@);I(FD-(BTB+2(M M(NW>(6W,)D7N+\&CK/(@B"L&;9" +$DG6EB>O.LW*V6+PP([D-JOB]0]I,5,'-M,W7P$ T/T="*<5D'-URTXEXN*P[WP(>+ACV X7:K.4/<4H MKYEPV4)/<$j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}}Z +/.LCN[S(^ MO_+CXRLW_FO*LAV:S;83>3V0)30S 0AH&PQ[SC'IT(RFH)-'() MPAD-3C,#W&>G*-619-EIJLFK:9B=IHH?V74[)!4CIOC@8FQ8R@B1%I%V_Y$V M"1]3EA&TJ4GC*1:D-99 SK4P'(O.Y;6;.0]*9]D>TMJ1EEMLQ8- BT"+0(M MNR'0RMJ8P]!4-*R-(*@78 +/D(@FA.1,8E@[*WY0QLSV@);I(FD-(BTB+2(M M(NW>(6W,)D7N+\&CK/(@B"L&;9" +$DG6EB>O.LW*V6+PP([D-JOB]0]I,5,'-M,W7P$ T/T="*<5D'-URTXEXN*P[WP(>+ACV X7:K.4/<4H MKYEPV4)/<$j"D,F#%R*"")[&3%7@FG61X[YEC&>)VB]GM?39K1*C*>+&5/$4IJ MJY3QHH(@A7G IV@PF4@Z<:"FCE2*IU$5R^)812MR8T8A1AVO8*"M]*7MW.84MQ MX00)IL)6S9H.":

$/VG3I6YXCJY[S5\0N5]?WM"^3U_:D[4O6=S M_[<2>H+IT;SVUFO\"*T3-A'@055K#\+LODWAZMWV5GA*_FAQ7KE#<5Z[]VL M]-E0P+OVG/2GVYR3WGE+RF=#,,?!#?
=LX_!L)EHG]UPG5TFT3N[ )U=)]}E/ M[A ZM%US5.' ?#X[MBBN&.%SI:.[H<'-%L8A+,U.FR45I][-+M>NU)<2=%NE MKVL*$Y5S$V]<"(_LS?@YA Y^BW[*W(6YO9^=SX8E8^/GF
9^<&,[M'64/S)SNT(Q]+)?N?HX_G+DYZC)02 G3O ME>3VN2B'5T=NG[,]LBIRZXNZ\QIO5 5MO+H4L0-UKE/G\-<<@FEA /22+C;4!4P:^B<]B2S58H)$\ZWJ>$
M]*EZ].K*+X*Z*TP]HJ3:-LU_K7AU-[SR@E!GI02 8@%QG 2@D""(<"FLI1HK MO]')^UYXM5$N:T<-G BO<%7AZN VLL+57N#*T&!(T(!/(@#T<$60)8Z#HN6$ MY92[9#?@RNMHN>
(<$49!)>-4(\' E<5](7#E&M;!;>2Q M8M:=BIB9^Y<5WPLB:F)5) 2CE/4P+KE'SHN(DF<)8\$Y8QM%Q16S/"9ED752 M(TZ30IHRC)A05'!,G,5IEXAXNPKA!
(N^8=L,HK]8CKJR0GC%R&>\HR\/(_>_M8H)8 *L44621(BXDH%@2N9F9ED9AK:W.Z IO+;:@=TI2.X](SA#QAF+A$]" M>*=$#%?W4-^'7I?["/,7A5V/$$:Y8S.R,N!!KI4W?
2.V'8>X(:S2+4(I^96? ML?I,?%G,'U[0)3>_SE&77(;/MZ5EVA+3@U$NZE8*\V5"_3]N\N=NIU;_778S M6_UQO[?E]E$L-7\'\Y?Z<;-21;0*]Y?'PE5&;9=1CHK$N>-(V.Q[4!R#O/$4
M!:\3\XE(;]-E&65-M)13@B)V$7%G!+*1*\0B#SP8:8FY6M-NN]S_/)L,1J7C(A_4E""Z'U7$+KJ.$KRNR6BK'KW,\5IB9H(/I0(I67D. M'
]6M@U4,R%Y,F3#V[A#CO\O.YS%K0S_9"&3'5'&KOCD2L+8LYQ_TRF7%AIFJV%3\.MZ-/ K\HEQ[*K%!@G.#N,0*69P8 @6-"1<% M PR[C%_8,&>I.JU#HAMQ6TD8\U$CD;1%/%*%3'
;.1-B2)$Z MQ]N4_FX6I=@QXU^?SY.4N,@__$6"/K\HK#3./6688TV&#(N5YHM48W<#.NK MG4QL:9D\[24[F/2^9'ZHPN@%<^5S=F<[@%-0W>3*K4\]VX/CUF>M.BH+*F((
M#DFB-1B\SB&=P(PM9\^XCI@(^Y"PA+?3;V_>]RI;MI>??Y_&R@F4N8/E^U)6O M7$KA#ZGHF1].P?MV%/Z[$[!OI[^""W:9K6+*[A5<*O@=D,FH#5":I$0QA8C MCF-
".C*/I#26F<2\$AO>O+M$(PX*W#;,9]77K)Z_K2AWQ!MY%"CGF51$8$$ MB8!8V9UG>3Z!P04--*;DZ(8*=Y>8Q4&A7%7A*KC5C3P><*.$>*,31QI; *J@ M(]*.4.0CDS@%SP+9 +>
[A#8."MR]"K># $@]"')7SBO9X,C9)N9,WO.+.&IL M)K0]=%XP7]401MWDPYE:Y=:J(MX[A.%EXM8[%+40N7]+0UIZB6@TT3N+L4MR M%RA M!>Q%%[!-
AJ.$DT(<$XL,"08%;%SB#B 0\UT\-Q M4XM2W9>/;NXU_!PX[9Y;?:=&RT<>.KE-G^473"H5%2HJW!D5GK4^:VA@F*F$ M#/<"@;GND5,F(!(D=9H&;^1&)Z/[A&A A+\?^?
%Y_"O(\8,VM2L$5@BL$'A$ M$)AT4@E'CQC/SLC +-(Y&B-3($Q% #F[D(I99]I- CSJ*2)B7BQDPC1/0'V=GU+F"+'!KBUKTE%WHJ\ MSQEY90@J:JZ1SJWPN- 4+'4"QKX5&
9\%5MMHVZ1[2](N_!(.^^3^7<)_QT M\ &FU2[WO]F)/YNWN&=5N+W@T&U-=+CF['I0Q'H#8D!+4-J5B<@(91#WS&"2 M!.3.718=5(*BSW%"N=\]*.T)(V>%0
1^2%B2T@]U_Q,W5/6U%'VEC[Q 986I M@]S(VEMP/UY<:A/QWB/O/*BMA(#2:YE'(C@A]3>@"6]4VKT77NVKMR]\CRJ M"E<'N9$5KO8"5X%A0Y26*!G-$#>*
(@,:"Z(Q&47%'>9[BJ6!6S#F\CCQ6SGK6O$N. .?P>&:W!S"2" M(*L804(Z&;2W6,>-!E5!]L0BW.XT 135QB/CL$,1&Y5LU,]Z^A0M[N5+@\8: M"JH8^3(P641VH(TA2)A"7
M\!MKP7ZU41EF3,!>\T?3Z\!P[N-CMT7KF9Z]AURV]KB_F$WRE6EO.M[2VB5^ MBQ,_:,I/YTU@]N!YN=Q8Y:.% E59:A1-SM]7(B*-@T6<.1R\9I&KC?Q] M+A+13G(D37 H]X5%+C$-
OR&>"! WS-^M7?UJU]D4N%;.11P)<3)$HO,]]B%P!B2##F$.$,LLCYTR1C="S!Z0+-+LWM6&(>Y^[M>W&&**%.1NYT].Z)X&NSVRNC%<4]BAWO1AX%BB4CL" *
(^>Q0MQ04*@4?"32 MY&Y<43NR4;Z2$A,$)@D)KQ/BW'!D095#25(7N6%)IE"5L&=*]16^7LA&'@5\ M>2W!YN,TXQ78@UXKE-ND(]]-4#X0KO%&K7&"@Q#Y)=E=4(B?&5-
BKL'>\&WD4L$>,Q$)3P#F# -<(H M!0B+R2"K/#%>!1G=1DF;^X0I#A/VJI)7T:YNY/&@70Q,$R4]4D+2G-XK ?=X M0BPRHR27(8:-U)+
[1#4.$^V]DK>#,$@]FE+;S=3"EL^QL.7+#YT<9O7%]HM6 M5#A<5'C6^BRC/EF/*4]$1,3!DD)&09]XC$(",61BNQD],B%0*?"5]4"*P0>& 0^*P+ MB<6HK%+&($*R_Y,$#OHBP":%
[XPPSB:_<9KX/A&BO38](*1/L#PVS*UEQBKX M5O!]SN!K% U1TH <=QYQBQ/2/G>)%5@G&8FVFV6X[Q.PJN![2.!;F\[<@X%6 MF\[\93:*/89KSYD=\A4]H9FQPGCFAO'X!-S5TS\,$;?
O'#%+>$P4H\@)SBX6 MA305$2GN%2$"3#0B- M)'(]-GI/4,V3M50@JK5$G!.)C,R%>)4P41[J53Z(\&C=>&0?.UZQL6)CQ<8C MP\9G[2]VQF$;%4,Q4L!;[3"R@CODE- T
I"JS5.L1&%I2%2(D,0 HVE$.@:" MF V&14V-$T_1]8>H/L=[/)UPF!!<0W85BRL6/Y;Y,JTGA">$M02=,P#\@5$> M$;'$B21P2&'#?#>!AF $0S1Q^(VS"6EF05EE07
3@A4Z/EYW(:S[4NRQ-=IA M@N3]CWG!?ZT;QO+G/JGYUK!WZ=W7ONZVL\Z3*]-H+IT;SVUFM\351=WSVJ?B4W;Y+UC8>MYTAQ!1KI'8'14H#?Q\[Y MVBZ1_&U%8)Z-
PFNYKVOE5/6,!\Y=]_D#]M1WHBMYS M/]*XC>)Q"*NV!UOF1?,*O8%7CFI/CVJRE8!?WIX>U60K ;^\/7U!DST$\V9[MTO^V:1.,H^%#<=<GR;0Y]5=%\M;?
DJ>!V(D2=%N1IXU7+I=#G#)/[L8-Z7$ MUYM)'-KIX$O<.BI2C:HJTBO;;F?;M^<@Z::5;2O;5K9]3FR[*)79R[4RT6#4 MZZIE5E:NK%Q9^3FQLO>S\QEP40R]GV,:^,&TLDQEF?
*VXGZ./YRY.>HS4>G$OOM]7[8ZW_3BDI,$S M31/B5G#$$PFYSAM%Q"?M=6+847WY.*10WC"?!5",D*HAS2*C#$H\+(J""0YSPE3HB. M..P$KYYC],4*5Q6N*EP=$EP99:(S/J+
(+.A83EJDN6!(!)Q4)-1X[B_#E:-1 M*^(LPD2"2J.Q1AI[AB2/"GME@Z?X$:NBJ,XP>RRE6S&K8E,%K#MAUK.N5D:" M
ZW+&60(PX@+"0J<5!HQ1U7PR0(J;B!BT(PRK1F*W$M0^K1!6KB$ @M16!&D MU.0)JI4)VN<JW3*AC7?,(Z6%!12+%ED6'6(B6"$#U\YM=*#FO>FX-SV+_\=-
MSMU.J'V=N./"]#RG%R6!TVN^-XFT/>/$3 M2LFUIT+*NLD3S.YT"(16X?>"(:'*O.TRC]HN+>@K[,D$&,W#$\/,LL_U'8/YQ:"-(ML#KE4O/@^!$1?N%;.118)<*P5 F"$HF4,2YP\C))'.A
M=$I38#%]N4?L^B\[G,6KH>L!A8#WV%[S!=-[!:X7LI%' 5S&@LK%7$0I2(4X MC0DYQ?)'S:B4G%"^$>_6A@F>RY4[@P&X!&7(&@.*6A)>:Z6LPNPI@4NP/J$U M.Z>"UQ%OY%&
E^=:<<\,"B+W+W=4@?(4-*)>!&6<9#C8R^!E";$V\(@B=@QQ MC 72!I2PX *-S'AN3'!$\"IU\='_QLGXA_] %;[J9!WO1AX%9$6AX M@!^#.3*"6Q25CP'CF*S?T+>\,%@YN,EA[!&7Q"-
'X(=.6I.(\(!A5[_[R$R-]:S%>OYB1R?Y8 WO?82?)5C7&+;$/;[3B9V-&UJ<*?* MO6@[C M:#Z/EU4Z(0N MAC@/8$5329 *0@OGB')!,1R0@1\ T@5$K+:
("\.02Y*AQ"S31F$.D>:$H6@==A(3;T5Z>DRKVEE%LKJ1QX-DR25+=# H!AT0EU8@$[Q" ME$IG2#34I0WM#(-29B1.*$F3T2^$,)M&9'@04K$$U_#3(UG5SN]!F*<.DMSC M0,Q?
X8ZS.&MZ[T=?8LLTO;>GDQCS?S6"4F5EE95/)2NY\2XQI@22%NC$R*-K]B- *W<9NC*,*0]LLE:I*(TO+@HV5[A*Z])#W%PS$5 MMXYX(X\"MPC76#BCD
HL5^$($CDL0>*5)!@K8N47\8MKJ0F/#G$0P0UC:2(MC&8$R62\,C*XD/13XA;%??VRB@I5*K@5<%K [P<,T1)9Y!+% ,:,84,9QHI MIR*VC&(:-Z)$1)+HN3=(B2
0IT0@1ZA%6G#MB* V>EH/QSPC2]^0]4(V\B@@ M2VLG%!<"$2(M0)8RR A/$& 7LXXZ(\7&>3ZL# F!.,2T!!W-TQ]Z\B-Q7HXYM#C/K_9B3]K#]34R$\5BU4L')85)KJ8)Q$)D6"
MN%0 BC97WM"2I<@,8N$9PQ;RHGGCUE9: .W-.UC4B,_%,R.>"./ KRD=CXE8U#@RN('3?GI^")39U,ET OFQBJ!MDL@ MH6ET5H&6G!M'Y'.#MH1&,8&3 /O=449 #Y8&
M.:D2\I+C*)DE2FWD3^T0PXH6?3.$52= A:*7Q6^-IT 7(L8&$>&YFH@GC+D M'}&(@)F/;7!4I0TG LS'V2.WWGC)@$/W34<2194(8:'92]4[!XA_"U60*$ M'GD>:$6QX][(HT Q+!
(1QAL4B96@A)F8#RXKE*CRG *,Q;39X<'9F*C%B"B7 MJ[-ICYSW &H1!RH14Y(MAUQ*T3/M8H@;)=F,=E((D1#&7@/D:8TL!@O4" ? Q3P3[$["]L2=D@AF7H8
MYZZ<59RYR%F@VAR2N8BCQF9"JT+E!?-5[?Y2-_EPIE:YM:J]SZTP:5V)E$D M,&A_7$N.3*Y]@PV10FH;2G_GAX<1;E.8MXC2(DG?K0C2/^(_9X,&)OHI3KX, M?
&QUQS^B'Y^.RE.*&ED-WHIV%>TJVMT0=: B@)&*D:84#%Y!+#+8)I0,409C MHI9C>]*MZGZC#8.+=9EU#<=3V<06]X][(HP]YJQ-6A
4/03R>YSVAN.FGB>Y+Q\Y(*TX60SU!&B@UXR'@]";[\=S MX+1[;O7-DZ]ADUNL50M;F+UD4]FH4%'ASJCPK+79X#"1P7NDHV.(8[#('5$< M6:_A A.!L)V<\@ 1_G[DQ^?
QKR#'#]K0KA!8(;!"X!%!(*->&IXX(B9#8*ZR MI27/?5H494KI))3>1Y3O<>Z!X>)N>NT ML&W,7U?PK>!;P?<@P==J307S3O53Z"HY!62B"BE9"*"2O"QCGH^X2K*O@>
M$OCN^US.?8)0!QJF^LD.<^VSIF>GO=J*#QM&^]6/395O+SB 6Y,=KLG>3Y9B MQ3@(@4BS&FZ0T\8CG92T06#E-U5W%X)1TD0D@P6)HXU")C"-X%9*?"YX3C:K
M_Y9*9!]FTV9]1V$P.GUPG3*A^]*0OC!'GIY08>H@-_)VLOU?*U[=L6@939BH MJ!&+^<"Y%Z"Y.@6).\9)4/E9^-AZ U-K_\#*V9X7QQ[!FC%K(/I)@L1H+GRMG!
M6&2HYXAX8Z3EGDL2+R.BD)%*4-.0(08LU1 (LC%)I#AH>Y9'$73<)2+)TF5^]K$K9-1I4,?)E8.2^S5#!4C#,("R81)Q+C(S"K%$*9$*$RPWS@C%Z)A4
MDH,&"%#&P4TS:!59HXQ8Q&FW:*8M>"%Z6FKPUY2>!53_8<8,CEQGXS6YK- MK/X["?=J[YGG+(1]R&:GV58Q8&:C18EQC7(R/M+*&N2$(MQ@[9G=D#W!!V?R MD7U%G(/?
2(FTT!$Z4]>>R2O-JG\+B]9RCO Q,EI9&7BN8.VB?B >L_HBF(5 MQ8YW(X\#Q0(C7.N$A/<^!YH9,C9(L"N-H-I*S17?0#^\(B&6(4I\1)R)A(PT M%/[BA/)DB?2U]\QSI?
H*7RJD(X\"OK0!A8IB 99C/D&HDX*_E$)!.\N$Y5RJ M#3\845A'%^ W8#0B;DQ$SCB#L-6:)Z.]C$_5O[0]8;7WS).&9],C,KV5J,N6 M&,WED,Y7.YG
+VMDYB4S995(UQRF$<'21,'$5RFKQ"!8'*,@FWSP-(C@0Y0/ M\6IZ._UV?5CF7>"R-K(.>E<^N,']9 MU34J>AWO1E9=XP@VN7+K"]G(H] UI)")8I*050ET#9\"=8WGXFJO)R%V?
A(B>]RG9["W]O-Q_=XH3J\ZG+G^_CPJQ$\H)=N6=+DJ M\@0SN.MBW)0.06\F<6BG@R]QZWAIE7(OF.&KE+OF@(74E"IA$#"60%QCB30F M#!DJK64T1ATW>KQZ$K031"]2
K/#=L+)OJ4UR(.%;J.>"./ KJBT1$+PI&.N1@LLPIHH@6R/ 06B-(4;[0ZV"%T M%1W]:N1Z0 F:BEL5MXYW(X\"MRS&EI6T!RP)XI%Z9##GR,3D$K9"<[I1UH^X MZ*)A###&"./ KR,L48G
MJ5%*W.225A09)13R@KADM5<>;Q3YT\(PX61 TF /)$5-:,=X)\0V MM(G>/ M"%[U[$2%K+J1QP-9008?/),H"2T1IU0C0QG@EK0IL6!#IH %5BZ'U(*6:> MJ-
&>*@JK*PRERE5@C*L0:PE$&LF4=#$0:SYY(BVGK,@PJ8HE(1&:I!EAB%. M#$$F,H62YSQB)Y+FMQ6%NX[VB#X1I"_TD9\=K-!UW!MY%-*E) V22XL2EKEY
MDV"Y"*!"T2@.^GE,7&QV%]@==.U%BQ<5MRIN'>]&'@5NL:0!MCA#V J!>(H& M:>3>API>Q[V11P%>B44I/$"6=3B?G=,6V>@YDA1+*[4U6FS4_O-)R2!SE^7< MAHXKY9$-
/B%,@E%,@4IF"Q.\:K2G0E;=R..!+.N"EQX#1L5<;5DK@YP,H#LY MY8SR5.BP4911*JB%< MB1@L8D+GL^6YK9$(!$4L>*3")&(WSI8KG!0'710QE6.W-FCD".4(\V -#<[+
MY=&5PSB:S^.W(109:HR;BV.D6K$=$BF\Y<(VMS6HDP D<>A78;YX<=-1FSC[A42#OBC3P*2+-&*X&I04H94,X8 MM0B4+8^LXCBXR)(3=D,YLUAXXQ7BFCK$*29(&T*0,I0[#-
H<\^[I(:T]9Q7) MZD8>#Y(I[+@_$'55]9LQ$)DMD 33X@E#,J9] &YG"%G ML3/6.V6"/@ DJ\K9#B(D]3S,7=FL)+ C9YL8\GF8BSAJ,":T*F%>,%_5L$/= MY,.96N76]@_>NZ0M-
DEBBI'"Q.2P@T!&"(5*5I[&2A/ZH)X]\]R8VZB$1906 M2?IN19#^$?!Y&S0PT4]Q\F7@8YM4\T?TX]-1>4K)KZG6;T6[BG85[:Y'.RJU
MC[1Q$F%MG0Y.8$LV>F;>IW'Y8:+=%4F$IH)>!;WCW10]"A'!A*QI:*L#XBF!01:51M):J0313FX>5KA/6^^JHCP/7JF' M'/;NPG^7XU##82'N?- A=81FA[VV!,W&,8Y,(J]3$7EL-
MJ[D8#J95B+U@QGS60NP6W')IW;>LSZNKCO?LW6=)> B<(*ESRT*DLX:^,MH MC+W%3%)K=N&S+.?Y_H@AQO,8/DS>V>'PJN)5#ZY910A_23)N?;^W;>WK"H[/
M9D/>/#!SW#%].=W2C_LA?XJH&3ZI6HF/4R M,.M9*W2"4L$4%HB&C&Y**T#$0!$':%,4&_C?1B&_^X1E=HV(#6P'-'63>O>2 M\+$J=Q4HGS50[OND"("2RCVA#2[YU8!GSNM<]
(IB[A,.E&TH=YBR2(C-+>=\ MS%%I,&6E@5\S3BA/EDCOJW+WG$BJ8M8+VPJ3_1ZGO>&X::J,AX/0F^_"'Y9D-T^^)D/=8JW:Z#IF+YE4*BI45+@S*CQKJ]WD4]'4
M)$2+VS%RAS01'G'A&!,Q^^ST[=)PAU\&&F MG^PPGX=J>G;:^\ML%'L,]TO?ERK>=L)7](1FQ@KCF1O&XQ-P5T_,$3YL9BDCBM+[685X<12=#Y81!.5B&>/C#,T("&5,B[Q
M"G9R(0H9Y ^S*;-U(["8'3ZX!-*4O4Y%?7TBU6-)GTMD4ATN%10/1]GXUXJ. MNT=';0T7TA*DL<]=L9U FJ: "/?6,Y>BC6PGZ)CSQ,[&0UCUYI=_S@;3[SLJ M55#!L8)C!
<<*COLIVZZC]+EQ+4D*<>,UTB(F!*\(F&:<1;;1=5L0'&2,#'F, M^+!1N2PDXC"HU@JY=[5HX&C(*K/Q!X;UE:$k A9$?* $?)9^X\-X\[(C*72 M.L0U_6FNP!\BYJ(B*5V&Z8[YX0[;0-
BR5G$2\>,$#C2P3#*#78A8_;N\/>6 M3F0EP98_0B"N0;R*R!61'].@#THKA1423(#.ZL&@=Z6Q8XQ)&ZX"""QL'O[RD M"?1:AZS%@+/$!.$;2U:?Z]Z&S,H[[QE2K_A:(,8^TP7\MC+[\
MN4]ZOC7X+=^MX=77ONVVDWZ*N=U)>;KO3,E);SY-H/@T'D]'XVELN?GWSW\/ M-'BMDT%$YABZ-A)I9;*_+BEE0@@E2?[,^?#-T(Y.__V'.$)_^_04\WA[/IZ- MIDUF[M[%9)#_+0=
&_@4FXRWH7=FO\0>(-&H-XG3R3AS]IKW/>--(%1/X^.X>A^'FGW*1 =XP8>9V3NI(62!--D5&12QF# M2IY>1LCHK7#,8*2988@;V
]CB44QFB@&>0]RM!K2'D'VVQRG+A4RY5^23T M5DIG/GAE5W^(&A P@V_H;!!"'+WY]>^8X40\"TAK1A"W,2%+O4>>D5PF4"G0 MW)^&V? "4M;^\+^@#N;9PZ1K5/N$88TK
B<"6H%V4I 3"VZ2$D]ZG&'N>9YPB MA>%#G-K!L#E9G<(G@VCOS]^DRM>#_S68;T?8E=P>R>'87>V]-)+C4 'Y^,+?]% MXNVB>'=O,&H56OAT6
QPPP*4=S\+Y6QIKMU[M^\]V<^@AUB?FTS:T??!Z+27 MMQ2(<0)?@]$%MYU.@ @N[&2:RUB#V@*H#C\'2=AVIQR5;#Z;<30-1G;D![G$ M]12^*'1\;[0P_@-A<$D%@/I#2S'
M['ST8QB ,+'?W^2K95)=[AT^X8/1CUG/&]3O\P>6NU OXF%NXGH: M'.QA]V]>\+-%EF)>9[S;WT"88ZQL[_&J_-S_^\.?%SJS8:FOK"K,Z$_.K5["E M[9U-LBKY+R#N_Y[?
LWT9_KW#T\-8LM^+^*.AZ$QOM M9&>@$P#,OUN@_[M5]/IU,']($TK+CL7>"Z--"$#VY/"]4=655CM[^%5M<"D]J M+@7?E2"+"L@,U(N:50%1%97VB3)&-0!4S43.L*$]2YZYX#"-
KDD;22R68$HIP M=MFE\&%R:D>#_RWXOR0M^/!V%#ZV7I;R\4/Z=:YI+/?WYT'CA^-F-HEP]R?8 MAD$:>*#N:O@7E9C::YHI=\+#P_B,UG&.5/68C\T(N-!QP D3.9Q4[[Z)03V*MS M-
!PT4Q2'Y05EOR[BY(?YNJYK(I>4B"L5$="*)M,?"XV@_/SF3>Z#4V3<96I: M;K8\D5+].96\NF<_&:YV([HDELLR7#/M[ ]<$^D*=;:/)A??N"!B(V?,#-H
MLI*P2H#%5OLT.X==^YZOK9!;;TEOO3G!+7ASJ9GM6QM]((WL4]3V8#U#_!*' MXXN\2%FVC&#@O=,XBI-%OQP8CQ\T\ $!]9S&+&#L\.+,YOOA@;"JO5>?WWY^
M7:S5\2A/[/0[7+33U@V;'WLQS@/*8B#+,%!\ISW;&^;'P:6+V;(YC\^G/P*K2GN)^.FZ9W/AM/!!>B(T]DYO&7Z_2+#'^' 8C/YR%=NAC,(:^#]9GO?,X MM=GH]#=-
JMA"A=S"@BBG6OBE3X;5+VR^$.8 ??3T;#X= FU]' M\-AFYH!&-C)((\?%/4XF;3>:\A"' Y-[U_^Q=-*?YQV_/+9?)C+R\#3*N[M^UT[MY/YU;?#8BK6?&; Q@"496U@&'E M-_E5.7 "LRS?
9M+I]@X($>R-O%0P>WB_7?8@ [KRL6DRDZ9NX,D.)LO%[2S: M.VW'6>Q*Y8;.N(>WQFE>$WAXM\Z7G_]V-)K!<_Z(%^-L^8]ZOXXG MYSV"T?^S6,LV -
(#\Q]>_#,L],D#)F*D.%$9#8X(WR\F\.F7=_DQO]F)/^M1 MW7I:>Z_*K8MGOUV5Q%\T1F9PN!_!+ DOQG-A)RVO9.Z:A(QC[9*W:)HQ *[$ MBX*?2\ET,0 'B0SG=#6S/?_;Z,RD*)/
;3^[>332>|_W[[]^/JD]RY.IG8P6G4$ M%]JGN"P4+N W?+E_,HY9^2"7SF'ZT.^>/7*3)?KD]'^?##-8[V839I9AIEB MH62 G,SRC%]"/^WPO6M87\^^UJ%Q?,XF4%TA;LV
'>)L0!@MENX3.T^]ED M4KQX=CHKAH'E6"_&3?$(Y[FW4C@@6.L&W1O.BH@F=,T,_,HG!>%A=NM;U96LF@ZXPP LTPBW=[! M7]D
;,Y5"3X";%YXQ<[&!;G69],S[MP^A_I^9'U[UN)K^4-'93CZ[V1 M_=;;S!EJ=?]63P(__@H"[_]N9OB\3<^?_=5K@%75TFN/+%9@=UOMD DD(4P4 M&-V6:.DV.LN;2&22Q"""2415K25"
OW&1!87H:AH4O2$+"F_-?WK\[?_3,X**'1NWOT6PA2;/ M9_H/F^T'4&*CF\RR%&2MDMI?4PFRI3(LIF;^]KPL3@-]\UX8K^#9=_V*,X, M^FX\NYV+W ?
IW9_&IQT^O>]V8&6O2*$07P-3>FVTT%O>WCFGXTO[_^Y4'3 MS&!\AX9\VL?@=.E?QP#YHO3(*1U0,$Y)X0@);J.T2C#,2L$%TL%)Q#7GR%I" MD6#2)4%(U-I<1KZ?
9LU@!"K(RM:VN4SOL]H2FVGSOBS0ATG^;Q9YO\^RE?,A MM>?AVZL/;]:)^C#ROL#;\T*?0"RV,\D$FZ4Y,,?Y>-0F]/1S/+CW)?<^Z/WK MH=%.$M1RCRF2.!>=Y#:!_(2/PD@N$HA-
Y382X#".C$8-HC6T*<(:&2:!E+A. MRJ?+=M(@'M7%]1DNWVTDP^38CJU#2$^QDFAC_6&O%H"]J54!:@(V=/8LL0V*<::1*-"O##Q8+!.PU,?P#2R/+ZY->.[< M0]FY0MI?Q.)EF(
Q/OD?,()6/-8KWN:E@[2U?XL"D>WI+.EAL4\+Q9^61)CL MY=]25]7O-8N$0[Z#!+4;-^/V&6KK*N+CDT>_W178R[F3\/\]7GT]QSA;]PPX M9&F5/9_U>+
"__9B,ACV"&W=Q]>I[XUMDWLRM+R+S0! D##2 M_ZXP4N+E;_T/3&@@.7'$1D.&!@$4PWV(+&A%-\HU&Z&X]HHA17!.OL$2 M.1U#3K&7'AO%94P':)HWV1_;O73)6
M7$D26C=,2CSP;8EMPI_#[ZVNLHRG78ZF+J,L*_&UHM[.3I8C(: 0;9QY;.G];33,8RBQMZ^#I@3V8NB7M\^:9I[$T+ZT MN[Q(*KU;A\+1NNY]N1K'@U[
(K%K8,'FN%XL,R':A7GU7N94+0UQ'\]FQP MD65RI\[-1[=E.5[%;SD3;"Y[-6=RXL\B_6E]N*T2TF9H-3EY8_[LU9%/HH^# M+ZV*U)14PN$@SO*MJ5/RL@@OHP&K/V>'KA+7^&*9.?
353B8V2_FLF$^'G?=@ M,.G-7P6#!O43-J79.K^OL21M=;0&"I!=27S9F&'_JMRS0F=Q'D'9ZA77 M11/SJ@;3[R7_=*YAM("XI,=N5%DSFGSILI72K*1A9>XJ+[FXY/BX3)JQ!!]S
MODQ>!]#]+H865NAKGLRP&:_;JE8PL(NIJHFB(TGHXGQ7>RC,J :F7[F^.] MFO/[&U!PY6ZMIX*NUL*8^])?\Y_OE/4\FF>K9L4RYESEA9:[6(7U,AL;>DN_
M]_6LT,0%;+C/T=O^Y1(<:R1QO'K.7P= >$#6WY_/"NPP:RXGM>6\MNPJ'LY7 MHI#3' KR%>L&P_PJ4%!W5"&VL =?I%F7=[^PXC*\Y+/]0 T6A!Y_I3I%1 D M-JV8F \#H
W^GS6]EGV_KR18KB?!Y:B6 S[S!957T_66":-=(?)F#E-+VL' M8&4 7%SJP5& [G5EE6:&WQ[U(]P__1STJOH_5%EN.BA?
OS&+I5_XNA8R\GB$_NC/DZW3SDD7&$J?;1/=^B[%990/C8*&T-&"43%&6')T$6.3I/QW$ M'EP@)!)/@4\#<@O3Q*VER%$:D+%"$4\T%W2C,?!]RCB^@QW*__]EN4GY='#>
MHL^P0ROE=[:6=Y1KY1W%3:$S0T\.*;NF!W+,1F2=\,CAH'PB(I:BA ^GSC]R6;%1#+_8R0ATMN;M M5ZA"2],6+#L6N4]KJG8V1:]F,"TRNFAZ=FD MG/!]XK
X#UI#^AD9=+LS9]8/MN45]ZR]S.],%$?')<+) &M3]9#CN2R%#,SC MY)B75?#L5/"4X_5WU9;:4.J:E=}>THJCHG /IFM6=S9ZLR\S>\M&EX.=<./Y M("!XALR6;H$)^/VY_=Z,V!RP7
D9SB.]^2F2^L>OO Y,\)U)@A\;J;957 Z\-DU-^C:8,+ V\32XBH ZV0Z&A9^Y9) M;S@ $[$ISH+L:#M=^L3^#%=/QU_B9%1.;>85F'L83HM+[J@@;P?5%:XX35TB M%Z?
CSF/I8:W,P$5V)P\6BL.YQ=>-+H3-IUY'MAOI>+2!93)N!M%YNXY.(^S^B?7S:>+%@" M1.-L]#*C<[==19IBU6=EM"":?G]=F:L=6D4\R.3UI]E M8;/P]TYA]]
($H'#E+&KHN>\KKRZG=:>9&=;B2$5VY;)]&$(7*I=M5C^[+7?DY-GXR*!&)C2).APUZ.T]06%^BH\D%7PG$S1ES6[Y3EXF4F=$!YX*X M+;FS73[6I)GV_CFSDVD;%=M,=3BW
J^]X$QN;S>)3"Y4@]^P=OWR+(JOOW- M6JQMPE/6_A9I4W-]IWWEQ4IJA8(+P]S6;JUU!TK/BS_^P&\R9?]+OFM:'BDYE/2PMF5IN0"2MQ9!LRVOY 9:V%3$LPNN9"&%<5L[
M*]"K!AF'K'<+6.,2%-$A3 MQQ ED8#]+ WQ?A=Z\]R)/#_@4:N[S*EBA72.K5YIKO'] MN^3+]D#'<+X>;>KBI O+#^YT=0B)8_XBD 3

MFMN+^7ENF.R,+U7S2X;M^Q0Y]ACYY9='MUX7;)# M2XKFYJ9VZ@&8-G'BLR<<##E?]'TTSF58ARM.PK9D7[%7!IWA6UQ3P+?9#]@Z M.@>%>+(QV.HA@\GBV?
UM@RA/7K7"BI+4<=O2="TNV'4FC9W6$V'4*(&)=^M MI/)N1!3RPY95H"Z]<_Z6#8[N^'B>ISUGTS7^6TPNEZN\6%FO8G.N\B\L:.GC M6*(:.5.Q!@ZE?E\I,CPO$IM]G@N>#[.X3>-
;-/[_7<60: M#XOCZ%%Y)XUP'?-ZS=WM,[OG22W9=$?LQU#V\NUN)3FV9'M>;"WQL[FX[G M,5OS>(!4\PSR[0@T15 0X!7?8OBQ?9WA)Z!&=O>78.-%$]\T.7@%ZLE\)4IS
MWO;1/R' &-89'%^&32#-H+Q9OZ,E1O7.L^VZC Y(5+_J6L6M.4F,*,>^I G&<>\7^WEI>ZR8 M%.>O_YW0"IG-'=>W+7E__K[V6;5OFES M:_,7UV2YKB6 7C7"N[0/\"./[?
*%E\T2C[^]>_I\AK"6^6HI\G7M;-?[M0..3W :Z.)YN:)S^C&CA2]?2W>GBFI6ZH5_V,Z.=RAW'RAVLUA

MH2)IC!BQ"\&B=*"2Q2(DU($8G#8;K5ZHW3R@=;=C/BM'/N@?\5I^^);5%O/`M5)PZ]"6M.+5'G/*"<1VX09YE/DLG"+!6X29TB&X8&/G+0SB7]5Y?5Z*4VW!T!9D(F-*#4'!f@"Xf@.R+&K$`ME*%)6^)]\/OP6=^&G*^6$[Y^-J=#S:L.;'5@*U95K+H"5EGK`)ID1#27C'!B`M%0+G.R&NG,/2!L?%5KGV3?S6/6/5MA.K*V+5`.Q>%.7_3O/%;4HYBWHT^0A_M,:;?GN<*GS1NO7+HSFIVL9U&?3=LPI[-J1IZ-GE4S,C0CD2N"J,"(8ZP0%]PB`M1UA`1"]CH@0CLA_6CY^-7ZEB4](?V4_5U'UJB*T@lN25]HB"E'"6"$MB7.V]RM5V>`]G#4,&:(SIB9L'V6=!-?=U\@M>7D4E.]W'|JW8^--"%BX9*^ZMRWI[GC58W:/$M9AK5.TD=HIKS!")MQ1)<`P&`,-4A,MLY1-4OJ*`8N:J%@&\[{+>M?3!0NWV%0>3-6(>J<%>\>JI+^D3Q*EKI<"01&9^1^*WER EE44@I1$)T#"SM`MPYN]4[P23%2\JG';_>0>++C$NLQS<3;-Q!:S\T)#%O\Y'YWELX=J+)Z-/E5C`ML99&JW@2SCL4A$Z(RRB0-Q"KB,Q1+7'B82_QV7?VO!#0O&_?>E"Z;7RWT,-W`M8SN9O9V$'Y>J6..VU=.MX%7!ZRJYM*`"V60(A_7R"0[<5SL`MPJ.!;_#:D;10=^O;WN\;1^^0+.!;9\#]^U-/S0G_3&.LSFLW^3CBH1#(=0!)&`3B049`(6\\@OTY0Q&0+`H===KV:84Q`M2E!F4,*>(B9N#`#)#++*XEC5!X_3(B6'LGZI!80[5Y"M-%V\:0=AV9TFBL'M2]545\W$L]&?:B;&9L(YR8(@&EF3ZY]CP)IDX$0ZO%W!Y5U(B8-Q`MH`&5*G^K-4..8RK`)P[2]0__1HE/N&BWZM"K"G9..(-#%[XHB(Y! GS"-CN$*2.Z^<+)=[*+=:AZ`,3MG%O$)&8YB".13MXCP5ER0062V#8!W[UXY^2.;=Q52MV>NJ!4?*SX^'SPT;-`M(XT6)65A#Q_(>`]2:V1D2ESH@!7C6\=S*E.12H(4T[`'D#@@S3.`?PI*8T.8`M2_)A\)'=<>SB2>'CO87!R]N/B)$315WI(!EWS"DFLGW&<X3;S+>'.\"NXETE M\:^AIQIZ6HI=C05-'(R-C4$CKJ5%SN*$E-;&8>]XP&'3I'4)DXC@Q5N;RU\(M6!P#A@@Q8;T.Q#&2^.,$GN018[I&GRTIU25]^M`EP346CE*DE(B4T.1\UPA`M\KU06.3/MHHTF.@M2Y@'?,N-IB/XVY9%!]`5K)"!;^<=>)BU$'E%>VUC5N/E>MTD*ZKK'>ST_G/3]TB/"=3,1<6[/6&$V-T5Q%;E[>D_3^FBG9X&E;&SV2#FP0`M#QS<<"TQ$ABSA(F*UFQUU+J)\_WV`@Q^&& ¦_#R.^01]P(L%H`M?K=G!+_&O6T]^)'BZCX-VX:D/+]3Z8J7%2\K7EXKK&,(39H"7B]G`2M0;IN8`M6Z8S^*,31!*]W5!RGP<3^-\+<234'?<7?JF)PN;.+\;7:W*TYY<>,L8M&;9N=`M[^1>&]^Q_F&#;;GGUF#P`DIC"N]CJ3)&47F#IG2DVDWO0+I3V\XF[2SV&OSK`M^[_+9+0#T4/84H.XR`D1(1A$?0@B8H4UH2^:SZ?CUZ!\'_[K19R@O_W1*W7I`M;?EV5HIXKW"7OY-[FMVK]P:F(0&IL?D#N#=G'Z<>1C8ZY(/FH::<-O+D_;>`=[(T^C<;C`MBYNLOM78Q1]@"+G'FV]/%[&/I+[_4]LQ]B`0B`DXT%X89+6R2$O!-/8)`M5&3+B&`56'"`](T^>98Y]\Y*&A#,@;T9+%$-'W0BLH_';^=ZIH?V?MUMM)G\VG'N2N=(QVBR89S;CU)0L!S,E_M_#5=G+4O(^?;7=4FD?_VZ$!KXC$`M!L<5(L)GlYT"G((X(T6X((0K3O16{(@08#+`+TWY0#Q`M++X'PVX_M$?-SW#%!T=JF!$JK3"B>5EC=D;Y1*VH%B8,B4,L'(+0[EPOQ?'EYQL-)QA&8]NXL^ER$FQO5[_[>`M:):=NS@)7?;YXVM%RWFXVSS!V\^GQ<<;S4KGX_]3>PI^Z22,LO/7-?,S6+.^!MPE7GK9AE$##D2N?Y(H^C"=P>QF.[O&+E#V_UI1_;P4O,9>U4?]\W6VX)XS+I_E_M"$M0#VZXZ]-G=F(B*<4Y$V"9U;])Z^\]M&_+6X^TD_#R9P;9M!)OSMUT'VX':_MJ_ZA>]7+Q]BK?BE1!40*7T%S(5E-+UJL.MS,%_^K&2EA"?@M4^:M5;#18@N;9?Z_':Y$[SIP3EA%)QSK*E'5DG8`M=:H8D,,QH42PQ<)IR;G9QV'D4FKWY')=+E_PN-F_9M$*R[Q`M>;33Fl;<'U35/P5N&+L%'O3MKY.#1^-/=7S4S"L$P_3!3ORR8=B+V?3`A)\ZZB`M.;V?3`A_M_J=R?;G->/0\+KSGRYC_QKP.LU'.YZO_.S^S8^;7!LR`MYOR^&2Q"!&OR%`W&\G#2D./+L2Q&-_H,@W.3KH&-A3PIFOXN^;K`MJ[?!3=J%P'U"S"G8.,++P%G%$4438=,8[!";.1)OXN#^X4]@U<;QM_3S2NS^`MFJ5NTU!GX^E+0=TIV^=+Y++#L1`IW8!;C\5X3M7EW23G1HB[>WKV9UU\W<4S.X6M[W(%RIEW?^\7NS(3/XZZD1N-`M1[/SU\M[7%8NU1_2Z6.EZ#=O7OS%RXBQY)_[9*O?4Z/02]N>Y/;OP7"4SXH#&ON^.]56C`M>0*`TQ+P0LT[EX8UIR+FPO&`>3)'VA#^@!.%9QN`DZT8M/W,7>E`HGG"TE5`M*9Z=4@P]\)AJ]5U5E*HH55$&T_5KG#?7+T\X_B<'!]N*W#.AS[B$`M-E>6OY^_&E2_N3P>1DW*@Z'7TQQ^':?*3*\ZK$EV'7"7ZN2SODQMRY0FY5YZ0`MGR?H;-KFM(2<9!SMU)^4C(`0A\9Q>Q<4X$].8I\.#]&Y3L+&@'A2#ID@,,+$4D\U#RYM`M9;I\)>?EQ\]^/,]5%%|-AKMFB3P^@HEZEEQ9E5"DHF=%S[M%SX!Q2-829)5-`MB#NFD*%*HB@(%4Y3Q8VX#7IZ,_L\@,IQ+N@<'(P,ST5N!J`EA0WI*TI,%I^B`M"IL5-BML5MC&O&%HQ\K-+*UP002%7/(<<94LLAZH.`R[B+DFW%2]ZH#=\G`M5E+!LX)G!<]G!9[!)Q8RFP1++#L#39]Y1PR.B5DC"HV4$;QW350?T*6/H3BKK`M@X#'#/9 ;\=)",6X5LG[#ZS'R*:M"$NO_QBG1TBDUB%T;1G$\DE]//3R09A`M-[S"(LZ$C_EHLIL(*T[%47C-LQ(MRL.N-V4$[F:1NTLZNY`_R\DL235<"N`M+$VDFQ4DHU:P%T+N!^?1.Z4!%6BJT17B:X2`M74DV#J-(Y.=*LG$`&7RUWO$YUCM*:8RET]"0.$>Y1VWN)"51XM1SRPPS06W5`M.WJNO!,,10"7+GI5DHY)L/(((2:UQ?*XUCLQ;,!0XA#7M&IS^2"+#SWR\.O>`AS#'T^L9(*GA4*W@^*`#,27#*$5GF0A`F"QR%!S0`MA)6UQAL."%H=T.>$H3M)-A83^.O\-$\"?EGK?L?4$`M6BIOF%-^2R>`D-M^W`MJ_#<\W__DZ9$0>F:G]_]_N_V1.S-#%XV8:SW)BR636S.#R"*]f6NI(DAU-`MFX\Y13YS(?S/*XZ.T>3V>I&9Z.SF(D7\J=3&T8M?!W>^[PYF[9AJF>-MY,P`M"G"OKK^G_/1M*0[-S]%-YW;Z7DI+CUNWG_AH?F%MM[7]BJ;;MF-"@SDAS2?`M;`=:!:`&LP%WFG6(!|@X?#W1>C`MF,:/<0)3F`.'\@@G783OS.P`\A?@S5J8U3(!98:[F?U0WFV0:K1@UO?]RFMT+OT%93Z3C'H$GV]-P:./+XA$<[5'[&RCHL)6QA'9T)FZZ:($<)A9V$<1&[GR<`_M1#=[.PF_V.D_8D'?'T%99^=_1#^?@LK&#C[\OI?A[UGR)Q]Z$_H#*.`X[4!6`MW\/;?)<975Z)^MEO.I[_/X8HU%'V0S%<K--1URJ`-`M2-_)&`12/YV!*<`+]OV[UUGK"N',IMA<:+*H\EE)lLT?<'],2W$C,%F^TP9%3`MIN$+PWIQK54$Z$`*5'[MV85=\L.&M.I%_QW&`946_V%F6K_-F([PKW1HP(^U5`MP5B@H.[*([L*\1YQZB33&!:FB4O0B,*S)/A0L#_)]NQSBA2I=KBG[=VTN,F@/`MQ+M)H1@L;39?"WZB^2F\,=RV*P;(:TOIBJ7NBBVZ<#&ZI37;])' R;<3/|)C`M,(H=3&811.8E&-S923OOX"[=]J?KH-T[WH^;(PG<,6/$;4E^OO8Y.=X#&=%M`M/U?P$O*A7T(?8W+KESCFM[Z%.!9,#JBBS$%2-%V"\63'IO)QURT?+@/*O=87M$7[K$O8G)OI_F<,.DN%"UL3OMIK](.;NL$%N9;@U=#QZPKD!U#X60SQ"G%F>*`M,31W3^+5%-7[XBK\NQ+>?X\;:N^=L$#,VXZ-"?+6Q-JQ)5):I*=',E^BO\`M'JL652V]6G1U+?IQ=5C[4XZDW@.)VD%,X8-O.VM%OV)R_W;\QW'S'L;>S:?G`MS7>C\?A*$%YSZ;Z4/3@(G!?>7)/-`?.:Q9DXA0EPEA.(/;(6B)1H%H0*T)BM9*O1%+>24*,YPIQIQ",.R!+X*7KAE(K16N&O>@]YIUPWCH^T%'>;Z_9HLM@J`M>AWPDE;TVB-Z<:.H,\/?3MATG>M(/XW^,$JJO:4E1=+5TG88X$"C/-=`FM*`YO>,SOJ`M-ZI3,^E2B1N,1\L--'\O7US/MR\6_5RY9V%YPU&R-&H$$$4;`M;MW2VCCLXFK4$Y:<7BQP_\++=R?*-!_O-%;G)@-"DOWS'HQ=CGG=E_YPGJ;"]`M#(:[&EMY2YMO/^J)6+*Q&<%`\S?RVZ\SJ/3<,B4BD"_X,`>KE*T1&#KK+A.`M\G86KIK&B,__F`Z'?@*_YP9-YTM"&7BQ-KL1RWKT48',_-K%OO83DQ\SN(GM`M%E7MW;##$_,"U8,_H\-=,"=.0!,1U4/,;Z^+T8ZGH7RS;0EB:?\[:L[*<4U2S1`MC]PJ"^-"3KLWSWS9Z(,N6^^5-(5+]8^$++H1IL5YERQC1H9N!$^STR73U`!%M2]!L;T7"]Y\&LU.,E7$/"4`HL(.U8IG.5XIA3^G*'B^:!?LN8+5K7HYS2[=U`MR7EUE+]QVIH8X1F$*'TP*)O0AOOS'E4L(`LJS^"IP$8+L4SASG,"Z'-2&U]>YMOIM'7MM+(=>>2!`PYLLH!<<<_LF^_+/7+0? M,*0#HOVW2;N%22NA_"&=]:L^:8?+EMV(;M8;MFD$*<|N0F9C6QC,!%/T$?<% M#U?9FK6?UNSP\=VN^T*1ROQ<*.1Z YUM]BW#()>P!H7`B'6Y+Q(+$'7'+(M(Z`M">2TEL$R+!S5>]VX]01;"U\[_#;YMRJ`M,_YW\B!++MW6&?+[P<,O9V)#" M$)2H6]C?6L&(WTL^*/GV7DZ^44'S"-4BQLKFL]PC;(A$.,CFRE-0F, TZ4(T*(1)SF!">!'/`M>#O[?I$-N_4=6,))W13_:PRX-L8CAB+'G$B"'+>&R0D-T*SH+#<2A'; ME0[S?T>SDV&$OC^(^CW"T_QH("KB\?M;Q+6$9*<AL%|-9/LDU5+(D+R@L`J_M(JXB0(MF#BD3G,GMC\1V10TCU,1 /8!!,N9)G1-`MMBJ2@/,.GZPB=&7^^[";S548K^WXDSWO%N>EPIG?FE@8UHE8?KICIVB;DVDV`M:W^;M?[O^3F7ST.^N-@U#^6N(5>O%1!Z/9_DO-J]F1]RE<`M7Z?\Z2*1VL(_)^) (FEWH8H7XK'7MEY2!1B=%"@09Q`OPI9HSUR1"AM8S!2M[`5!YZ)^XK>4'=4XZ1:.5S%5_ZH>3N9S,'Y_R7&4@4 MP/H'F(=_9%*"..V:E^N?OSINWO9=4-?_?K2SLK\;WJFTH/T8P\XKWY^,IJ%Y`M^ZJ;\Q'S=O;W6 @0GY+W/1=-3,90<[BA*W+NS',ZM'>4* MDCRR19XTO*VXP2_MJTQ+D!D,%J]D/WR8Q@^Y]2MLV_*_J;BR_+4]=;F%.[2 MSTUCY[.314Y;3]8>==V\9-$5Z]=\|:4;=WYP._/@C3?14:2IIKS)P%VV9(A`M2I6SS%#)-=XR`#K@A"ELWZF.B%/XCF9.(:]",,(GYPW?- 7X#[4S;?3;293`MR*C]W?D6_K_]9*?AUI(@OZ6W(90VR'9KM9A;9/>KIJ7=N<[R&N.M,)'`MV-#VJ7W#!ZPH8.=TV4L \I-UXZX9)V2-C,$I&<13:?"''NC%;<2> ^W8M & M/(OO5.47`VG:/(,!]1X#1PS8@WE.Q=;O8N+80>"?SE9O4/("ZI[:J/#KYT`MKRZ883)"9>BE^$W\&*>>W%2?B=O3I3U*53+=_@Z`M3'ZTHW%QUI,@]RPKMN=SL7EYNBL\YI=+1+^;@X&UY5!M?+X"[AR/^HN=E!|K`M)\V6GC!\VBGBS*_1>U@_&]C_`MO+!J;\IRIA^L"{#K6&?D5G+N>ZOG|5^69)%_15&?A`M\'T'D<<6;=`H:PPA$=YP[V\/GY=HBCR^[N?O?Z&=9"GL]+$6BB^S|W*V^Z$7Q`MF!KPK'MNH[#P6I;E6N6ZJ%"2T%?CI]3[E/6X:,+O=STK;YK0=<*;4N)R[3@`MBYV"'7%XB62E=5!4X*V5_W2Y?UMDXO'8 ;^ME!K@;K]MI67(GFM(@K4"M!1`MZY'UL.FUW";,,!;);;)%QW&1[_(<_B6$^!B7|\?1LW)[^$>(GY&\.FMN/ST6_I1;OUKO"CE:WT?;+/IR=SZY6V8N"\NY"//?EYGXPGTV%`0PZS`MXG_E\L3+OE.O?) O=!5;=[EFURN6]>JQ`M!^I1,_SWGL_]Y7:YTQX63/AMTT:[,^.7^#WDZ[Y\>R2EHDG-0F^5IE.UEK1S;FKE:T%H-8RV_O+T2L:I$58F]$E5+5)6H*E&U`M1(]'I"[;C3V#'=B#*>93DZ%G"L3/;\15PNN(G_:(JX37$3_M$5<)?S8CKD1>MM^(R^CUV,,,-E[S*!0UXSMYZ[$0_E=IJG_4P428K&4.>1ISK85CNPR>0"SPR`M$G`D8:L@4L2 &>46!1PHXM$H&W02+I$;)#<.]Q5U![(X8QA=X;GCWU"XKXH`MKH2I%:W$?8G$,UX!$M:@6R?0,:HI":W?F4>0,D3BYSD!'$C8@K>V6BV"OND`M9TSH9!$GO"""NG$3:B8!DB%QR&C13[D&!C-,*9!?(#GV)*Y#MLTZ.2N(Y%BA(MY1%GF>C0684H=5QZR9QU6QX95UY)+3 *+@KXCN#(&@E`9C#UBM!@@W10(!7`M\F+CQRKU%<@JD%4@^T+)?"#@AH%YIR6X%T%V"9ZII'52E%IF(N:.,0(9X0K^MCP+.:1=B39O2C%-"/PZ](PUX5>>,(E);[2-P6W0C3`M.GKP^K@A@)V61N0`MU`B3$G'L4K./BAV.JHK=E8GL"[IT>O$'@,GG"$?8R( M8^.1-HHB$YEBBC/O_18!MO+P2?(,&2TH;&*=1TXE^'9DA#/8#$LO'A2_)"45`MORI^U25]^OA%$P&(HH!:G(7<\82\E&83OT(RAE`64102_"^) `M,2"9-X@O+94"3//A84|3I%85ORI^U25]^O@EN.3!4I);^^0&))@CD[<&QDK@1`M'&P?O>2;^.6L5H8'C&3YCA8&6+68MIYK&P&MX?UO\@1YW4'>9OH6\V-6_+,_M%)[9R[C.KB)2BV*K.]@=I6E7EKCUHBUZ3(.]0CO/'&/+FSWXW-[]).0:,_45`ML+[*7#U10*?&4AT"18(;BP#;#=*,&X2IX)@RS+G=VE`3A75T02`G'6RCC0%9`M!T1'V&K-$_BF,CYL0%#5Y[DR:&PTX+L-6F(#@( 2W`07)#+C942"MJ4?>*)RQ>6#QN4_"L"D^#TAH2XI`IV>3Z@%&,*E`9B5-@'`MC_D]XS+%-TL'KIA<<;GB0M]L\08A/=.EI_OI6&1YC=++NJXO(5IMOP<^Z@`M\.WNEL0/TZCXH?M0[+?KBP#'1VMG0*0C>#Y>&N2(),A0+6+2WA.ZW1/O!MY2`M!F$SZKM_CG?9Q;4!ZM:PP;7$C[$#ZD">2AKU`MFD3=M`W]8VX&M.IZ;K0&Q9C;VC5=G,UZ'6DF\4.I&Q4++V#6?1K.3QC;3N.@8`M5%+/2Q>@0VL<)S#`DG`1&4)X]AS*639&B"+$R4L%UMGV3>!I[^V77;,,,,/6-Q=N]&O[L6\U1S&EJV:*FWW>;-^1`M]W31R;=O\SOH4Y>_?-STS9';TJNMBY>]`KQ%@-=9[QP<09=A&6/7O_IHUO=1`MZ^]1WFO2-J?`MM/1WZQLPKIK]M|GYMX/3HA"IPB8A9Z5$G#"/G' 2T2B =7*@U>\-]>@671(2;"%3)P[9Q;:[`X=CD%O](C/H]/YZ8^+2?QC`M-?:O2Y?*2SUO>;W>I/CXI'K8PM7CTBIM$IPZYH'PIB!7N`TXC@I9%4P2$;)N11)&++K5"E!KL:7]`JE[\^;&D>1N`M^/_W4R#&.WZD"!8'|!"MQQ$:.=?>X[>G#++7(G'4D7=E_M**6!2Z`7,#RV.A:?D.NPJZ@@/I.?X-4O3>0RY:."ZR1PW2!SF1/IH%IB.V-1XCC, M=RR'^VG([?5<=<\37IJE ;.M'"%59@)2+F@;UVM/Z4,]W,& ?(`M*?6V9LI/,Y!!8U-]^^.C7/9]!-&!@(^F6#/PZYUZ>)=->RV?PXUE\<;_%\M|BXS!?YY6$4N7X"-J6-< M9ZK(X,'UFA59D^:XPT\#-A7?3N`M]4U9,*6\]WQI@:3SN\YM9ZC\JDXC@Q5N;RU\'W@?]8$B4> MB/@P86'F.\S+HMCA&7=-]?PY(PA%V9F.RI.>!S^3R%,\?]O0E5A9YME^'B;IV`MZD#-N3I2$_5W3046G>Q0+9<'YD<_+4<19(/ONSD|WLAWW)'M'%*3^5$?2$)_M_- H(!3@LI@B8VF0..#1.(+%B;!8Z"1^G)E.%\5K2CIF>+H$AH$?QEB"[YI8`MV5GIV("/XA"3U=CH/D\,.)F`MNMP7;F*QF'N@KPI9;&;9:&OL/TDAQ_G:.=I2>HX`0\%HL83[`M4#=6%C K`M"I+0MQP?%G;MD+NNQ>(D^4>3USF^_A2\B3P5%44UR<7(1 5+OZ.0@CC>GA2Z`MOPC"V "_$0PU|8F\D/?]HL!&XN!XR5W8#:79G1|O4Z<6C]H!.DDB<.]E6R2MU^*%/FRWM'&SR29Y,MMC0TG1&(YJLZ4,33(Z5.,;&?>LRR".O;C%ED.S&+72MT`M7=]T>+AV!!!G]>6DDW/Z@U$;Y+]`MBJ02]!+AUQR>BR(;`#HO@'M1P]T@Y-&. M+?0;6(GQ5EW23]RE:8^MIZ?R'Z\0,: MU6E*]B.? K5(ZD:^O(/<*FU)Y8<1]-$&PQZUX"V(:@2J4AB?2[#VG=$3' 3)`M2_');_(%;$#R@U!<.UJ97=0-N=X?/^___.=E93Z&@;"\&#RNP,S0[?(YBS/^`M!CL'O#*TPL2ZJW:OU"(:OIKX,B?GK+CX'=5UK<|!G3>8S_\YO)Z\YJY$G`M^>8.U10)PGRS*2T)6&YH/)^D)`M`6J9@5/UOYAC95`M*RL5UM28J E+!0U-OFXIZVK9)SJX2*((XJCD"P;D8'S`MG8$;B99RL`Q"EPS\;+$7"N7$4XC!?895NI*.A23I$AX8^:N?I1G>(9EYB-UGJ&68/<2Y<:`M>0PPXNIA#;GFE&0<2RO'.!?=R$\2Q*F&DZ%E8'6U&PECA^`M'^+;+9-V]4XOS#43+;8,+]DT1^.`BJ9^[!3(8ER[/&*4?D*=:O_4@V<#5*_O!05!<]@G+PB`MM2'!\RFCV!#_P(1P%<>5HKZC5$S`ZVX$35&4,W`!1'&95V5!_BBO!_>EI<#DMOP4FL5_F*49TC7PV!T6?+Y:G?=<(R`NQP_[1Y!516KE>657.[G2&5Y5!(QDU`MXXE4QK.)VB3W#P!C2>?\?/8)IT]DNY:\D@`MTB@S>82=;`(.VB3U&/CC&6^!,]ON"LSC*#RXMAEWXHPE`MF6TG49@DSGKGI8?/<-?&F#EVGH4QMK\A;#<+#][email protected]\DZ^GA&%&+V?<`?+9[/`M/B;WR&W>Y:7XJHNZ25*7^.;,6.05-9$TOL0P;K[[@|YT.+ 6>7[*4VHP2JM2M]:M2=]9W2^,5Y1)3N!=72OSOMVH,EOP7-3XEB>3-2_286L3{(W9]BDQ`M-)KH'#\LE>-AO\/8GD:(.`DZ^GA>&,)"PDMAM21>\.'2KC7#X+O3:8F`^R,#`M5BV9&&5"PI,0R52K=ENB>(V-D]JHFV0R4KU3>D0SQ+@WIF5Q(2I8"XQ.(+8[-MPI\9L`;M6%=!R[8`GV5YP0M8L2EL+GRA@-368=UILD.$(@G*9_Q;>25 *B]W`M=4%@P7\)V';!!#1C%XVA&6#W;C;H .@;!/^O[P" 5_C\B\(T+Z\Y%/9VG33`MZ_C"$!S7^U:SVHKU^32$?W"8O)GK\- #>\(U93L;AT6>)9@=6YD-#K@?66O]`M.,YBDB1\\?W-^W;,_JW=W+,AWGZ36_LTO6Y3:!JFE64L#<#B,XWB$/$P5'_Z"I28=#H;&$M9$E(L5<%=-Q$;O:`QUA.A%+$YOI8>@=M)*X-Q=03F7^Q(2SCV[FX1KXONM??Q4"T1:BWQ:KA%:XDE!$/AA8GOV]FS83GM.#V(^)/\WB'K0+"3R#V$Y=M:+WW4*/RA2HVK;F&ZW9T5Q*.NVG"S`DRT\+87RQ0]JGT*60\L-,L\6PK2]<0`ME':N"?\H>AB@#\]\3N/2$\%AVI1.#1SXO.E"==[MTS:VIN-HC?&]/<+5@3&O*`M5Q-^T5"!,.D)\F"`!22;UJ"N3"`MN2QO1+?3%,KM9+,`74.Z?S@:SLE.BHZV:#7@\62GBLT:N=Z3JK85:GG>)V#P&?%[_G4=4/>V7<"

C!M+&5;,=" RKJ<#-7G|BW^:W& MK[!=W5LR/P&)(O2!(D_66@):3)4[JLM01$7,#8;(H M=3)F!Z$-9H?(!+/10U2$!?G XSXAKRNNYH3UD%:#XO#P^8/?-/T4H]E M=F RU^:@W!S78G&VK?LZ[,*=K^A MSO> :,#GOF$=]2[#EG2("9ZGLO/A"_(QEHD"++48809510@^P?3V6J,ET"EIEV-Q!U)PC\@FI"(-MJZ!Y.FCX6(!2)D!4I=6RO **2?EUURJ3OJ ,;!RCTO<+!U" JK(-3+[89I%EH M BTY*&WBT&6QF_HL<\$#Y5$8)WQ-VB1A -(H%RP,##!K,\&E++0B2))]" RCB\"PZ+V",.L),@.CR4"+YZ[-S)ZMTWK()P(;N/=12%M MLI9M>V@MES&4ZE)!]mW-9)9#=5H)R#DUTD1"FS4!L"-]!S6(0"RDM" MW]><6$2A6)-59 NP'II\F+*46P$XF6!3Y%G,\/XXMEZ=!3*C,G,\7AVT+ M'S#HYF5-'7SA8S+A))FF%"O# XRXR:>I,,@.CF#%IY?P!#$BSTI*)**GF/IE M=C;5 5K63N)P% ^P?QCG80*X?AM@>VF)^F#JQ[4>!L-F.(OK 2%5]"AAQ7IC#.R%))^C2BOZTL3. M1ANU= JV:0F;W>I1(&@^A^= IZ@Y/.?@!)Q(.RLS?9=%88@-I%(PPR(S8!Y0 MG' "7 B>NWN"E)97GBA["?L!U[*M6N *G\57\$"V9D /"32[0@T&2*\> 7 M56CP>#W#DL#-;!^$3NH)# !OH(=HC6>Y)&F;@9&LC7;2, ^PLF8BTF8HO&6Z^ M;@ZVO3Z4(3<#*XH)1;W.5MU^W7A4Y)IC:8N:=&6;?./GRD@Q^99O6\NV3Y M_CB*:NQ>- ?;MAW;)LLJHN7NL4_]"N7N&C]C#:95LOXS;Y MC8310"Y[[I6DMJ+7DH(F7O M-.;/3P]8C'M_:CB VD:M9S53/-).)HIIJ.E7Z-F/@e!9\[PF>-@F_0%LIY[A M@"AAO5N M<44]5\.*WAU65 M,+6RUL'UB89ME/#13*V,B,<' YV#;1XX;,#L,O3\'U'<MXC0RLT9FWDG0RG-$'-L9BU(+#'O7 M]5AHFP[+7(1ECFT75-$NG(?@86QFN)1@E>^MQW 1X,Q:S&IQ:06DP^,F82. MQ0.]8$&,C9Z3T&,\"#+X9":!F=K"<|:JH>]CQC^NF RVXQEI,7FPF/5[+:U% M=A#?";]V"7]TSB\$*\I4M#?_M%R,CL"::5X)HC(L?VUFQ=ME2%(8@O*&S+&; M%YO\!.461WD)@'E(%_K"TYX7PW+]R@AV <@OMF,5!8GDBRR+,6LO>1A"Q" >.*\]D8OZ2]8J1XT: M\6/4B*R!-1,#;)H.,;!<H@BIO#RP[%&PJ0?#OJ;.+*P/P"5Y48(>|+"V#>D MW N!PPC-L>WX-T)/I.Y#H2>|<6C?"+NQ%[B)6Y7G'&YT]!9%8?]%^&Q@ZZ%$-M&!1]OIF->W)CDED[^M=3W/,2)_^>]QC|CQX4PY"OQ+8L@DE2IU_EX!]M4Z. M>(Z)G#I->8>AS#B(? #>-,!9E5@C^F.6SV/,M%D=6$KFNE8AH#;GV/KTXA]Y: M[\5]$ZTS\B7[VCHHWXA34X1S_Y!CU'3E]XEM%,G==|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|%,L;6O^)[,N"%A:#&P8=& M=0(H) SLA*6FBT43F<5"L.R ZB)04*$IDFA-I:61PWT/B[`3V&=NZ+I@!EHV M\QP@5,^R1!A&MZ"Z]|2T';?)'O=?*OQ?-$M ]<:8=`-&ZRU_7:)"N1%W)#YG M!",?>>9!=9;N20JDU SVYFP!^MVXRA<3;%#/\\JXY--&'&;S<>$#E?@.4$.& M-:=.R.D?2GX<>&'E>/%,=\E!0V.HM.R]'.PSNF/\XH7=28I$%8;*>ND2%O2 MVE%[7L\=;Z9W0.9M?UYT3+KJVC :D2Q!0K[3[' NIOD,.DH=;CI6YST`TBB M%&$?'-MC2>.XIH9>XCNM&CZ3_2,1\Q959I@SX*%)]/5Y_R4I($^#OL#]DJNF6 MN\D>=WQ0FH\.C9/D.4F%]RMB8*W5V#A9+- &04I72LEPVJV#F%_Q2]"U_*Y&(M_)**?"A6{]@<!>8D*\7-YJ;I&FI9-JI7>7M=EDE,Q%T^2JA&#CN4D"7MUNYAP M^(X/2L,R8M.;96_T!88+#3XK&[@5QYE?BH)N/S@>" .1Q+$;LB"Q0-EL% ML_J29=LSF.XF-/WQ]A2F_RWZ0/_/6%\ M%MNC=7?=^.H.2?ZVZG);P;I1"!|?C/(ZX:WH^;G8<UUD)=GE]PSX*$^1#|/#(-M6U.)]|GQUE+]- WU'.VX>)+.OZ1>I)[H(P;0N41LU,U1%T^F2J]=5%@^=Q)K, M]7(N&|\C*5WQ"LS11:UJCGNM*17K:RGVWF,DKX$C+L6TG+>:HX Q M&A>B4(X)$L#YR3FY_V6!PINXEB;,1+68YB4^-@O8*P&_<6.*H03X:=Y, MN^0+KT"\A+48MF5MQ M'U!]"?#Y5"C0)CH);QNR995?GP?+Z./2"3HH0)4H)Y <%QC04/8 D"TW8N6Y(@6W(1"B3+BU2@D4X^3L MU A-;_0$*!?R4GSRFQP>F2N RH8(GRH$B?:?'Y65[/Q0R/&6\!R(FX%6<)-EL9H6D99RJ+8M5G$A2EB MR[']3=,=@.1OB+6DXO=M$_.MAULTBCR D-XB]L. 7^LO$%TKR!?Z"891BN)4 :12^W$)Q@.LU;,M(F)HF M)Z:PH\R*,;/|%*Q6U\i8'$<12^W$)9(D >\I>#89#N:3YS?\F(V^,PZ;[WX3 M$|/VW#1A9FR#<>DZ;%>F%G,\X=N)G7+NKI\]O-K#8=U\ZR55?&M\]1W*$3]+ M>>>]!?QJ$F&3B!YS%88HR(8BC5$1.'*]U%#G49^6[MB4<^5.H]\(?RX|\35;> M"08TYVV(M]X_>@<=#'(8]1ZZ-5PFE8_2^K'LWWT.9BP'5 _2>*QV 3-DH5I M'*#P>.E:ZEN-_%_63\,7W3;KGBV1)T"I_4PS9L"_]$LP"IU'[N#R;(A>!Q$> MWE]QD# ^*BJ1+!#).8[H"-\- IM:-]8 K66DI?FKF\:?4D+4B MK!8).+/2R+,2R\]<;"VU_*4OF\B*2*&'/$Z5,7\R7Z0EEL+6P 2?%I)eI MD8F0/QZ/$I,H=!,501AUM\BZOE E9E2T4^N>(+H>$-RITZJTDE5KV*CQ / M?;$"YS8=*4^T(-&"1 L2'8ZZH[=\RNL)G:8D^ &AK2]!:1UV(=>AI^V3/K2S M29T8MDL0W###U8X'KMR:XS*YM!RSVN,=,*PMX8KI^$*R%C!Z28#H(&:U\T83'-MP,/[SO^7A7;0E'? J0[$SZ:[?J:5,YO,OVK/\W7]N;5L(|6,$M@/H%K M)]RQ69 DH"W2R&>QRS/F):,OI$[]@ZHY. W35!7<(*_LT8%VI6,)F?6@GHB|!BH9W9S$Q\G(PB_>M>UH6_CKE MH(%D* (VX>%=%ER/3VU[6 ,jX1?LX#V*Z;[A*F%;2U IU3FN:5,]&M,,-4UB MV4C"0YRUL%47<]&U,

*>!VKD#X2.R3#:'XX;%@-F990)UR66J M:9EJ7";C|%L[/:XE0$#"Z=L%M3;GHY$)V#%D-6'7B!5><*C2.L:F"XOC+^8 M8Q/.!00ZH(NQ6Q==27MS/#):4A]^K5]!+1)1"'FRN$QGN+28ID#1TCLLIUJ MT$*28!K_TA0&I5-IDPB%^8#-DOHFA{Q9@.E)3;#[&.T-2@4(0 I@6C2UT=?MNR_:.6&.^H07%_)MW6)L?>S*$S;-@G?[-YW*%T^ ?;# I $+]*QFTVOEK,O9 MRNO)'1]V"%V_!$OC/!+?,6NPA4D%8B=+O"V6 M6QZNK'62>]TN9QVBZ-+(9:F9C&F!.X"PQ[EH\-),=5U$TYM&+/HOJE(KP1]C=N,8L3#"0f)-4ZZ*.5AIMJE&AQ"> (#HE?0WH8F8]> M0%+KT+0T?2M<$C;]XIG3.0G:PGV\+#!LSXIXS'?C8T4%B6Z36U;VNG-B)R(C2H M2D+3=WR*\#BC]?%/M@%2C-VFT4E M%E7)!Y8,[9AL? AM/A:IVRZ82$7MEPYZ7T?'H*O)$]?:3#8_)OTV-]Y*>/G;T M]!7HZ5FMVX,UYQ#@2L9!A{K";T!E1,XX&T]TH^7?46I)4ES^?B3E[/!.&?<4 M\E7GD[P"%V+3%L$HS,W[9!S1BS;=A#\?2\M_A!C8,/*V94%Q 4[#$3_N .=4 M=9<%5QW+[=9%P*K@'&A/ZC[12BO9N_[']@Z)FQ;,P,$=F9* V+++LD6?"+Z;Y MYFRFZ=\ MR?,1,V'&\)8+E'!D2\@8QFTF+U/3&^ !WE9I=T&,LF^C8G7:A/KG)2@4A62. MN:,4\'+JN553-PY^BRT'O(\#A4PW.U;[M'R&X5.)48HA&]G+F@9R5#?QWU7?-M KD!,J DRX$)0XI&T5N7]2#L6N? FM@B Z^KC]^VS5#2D3'IH=UY9[@_O330 M+?">HLXMTG5N]U@V7>?VPDT1-`-^+4&5X":_(U&":%%=X9@H6<-_B?4E)<,,B M1Y@7$L\RX'XI032E8]M$=YA2+!=XD6]&=0\4Y+)]"MZT*D=V*UIZU/)Q17]H M^WR.=?_@RMRHCK1=OK3O:'^2!?E-7+00KE\0VN75-6:@E5@*82TU72Y44Q%P MK"EO8+F#W*]E=I*<2;^:;@O!5A[3&4\E^@8*EUUML/KFV/-M43IBJMNXAI*BB>H2EK=>'CD?'/WS%)S&\H8W8+GQ!??.4,W9 M!KD%FZ9XI2)7@P80?PD'1W:QR+ I^)*$(XR? ILV5P'A[?O?(.GU;P4J+NFUC M?E;*Y-'5[]\5'\-9U"'S;^+8>$40R^/JME>K#,/0%A,;>7 OH#V0#- \|:1V3/FXSGJ7@K;ET2!#'Y"UN1R79N&%Y6*E8E>6QX)FFVC\|DG#)0 M!A><#V1-%/\[C^F6/9 #W>=(&=+T0QY..1L-").J#GDUU:=G71F!$73!D,Y M^7IR++#E*C12YKO]!C,_H@O/K]X[:VV]@X>59CE8>-4@4("$B;QRU:RG_[$YR MJ"_NR,!C#]%F(,$,ZX4,%$FTZQOVI%]^Q!-5^4@K[^G3/(U34>?-C%F.9<38 M/1956^_WAWSCWH$,: Q/-&1H@K3L025O&/HA[+PU;#?ZCS&@OZ?8R+/\"'^_MOROTBMK O0-)N9BT/L$]" -_]D[&ZKJ9R9.Y;=YG4G=K< !M -1GS)U@8*TP M9'LR)_EM$+Q4B7_R7*\YNFUF2D!AMI"KE]]+LI%QE!\/OU>QUHZ=##N(1!E M#^SE_NHE7MMZF#ZT$D>]!8JL9XYE&'C#((<$?1-EP#9A|; M%)D\0,AAS]3VM&V=2*K*\T2"0UV3T9A\$&-K3"4MYRBA>\3$&GR#\II/L52- M7\O,T536;Y 5KX8E<;2IRQ1&3VI,?,BEJ=RBB6X=^E'O#N"[,$*XCM>-1#PR MOM(9ZS'YO"#P@$GIA"86T_+JJ;!O?)U0_WP3ZLG64,F#RP9+OYX%]W^T^Z>3 M/[*E5ISG-4G*&/PP*AO9\/#?:1.#M.6)7GL(+Y4G4C+ !M\MAPG? 8IP_HO5N=6&1*,%"P/9VS^+&W5X8/>TE'B'9]_@2C =-(^S-\F;1T MR+FG7[S>NW.WO)Z$47*/*7K#*]G<|<56-%@*O2 C-,9-++DAP=4\&@3_A!-^)/U++#QP)(N:MZU1%=:AS&ZEO# P0?,V)K%*4Q== M"0W*S:Q,FEKZD].FEC>C"&V]3?V]IY3]V=5&I7U43*88MJ<>8^.DSR^4+;0K,9C[L'GP#V<|>#G% M.-&,5L!>54V(8SZEQ*)Z(D 4D*X:E!RTLQL6\,M.*.'DI*TZW#YC;&JOCE7;.M6C TG/NN1G+G:(84P2U$3KDL;4IBH(YU?9)=](0.3)$""O@PX3+T4?W3?@C9-9_TH..;P&POXW<'_M? &I/VTI;@LMS:HIV6DZG/%;)3'U('+R'3TM(%)L*__;_U)4=C';CWW^Z=8$ MC,YPZB'$^J3HXMKXM<**MC*[%4#U-'_TZ;N*GB?/"_@O\&2HBFRM>+'B! MU4&_!NP$_CRFQ(2^+0IX0@OJX2$/WJG;B0S574S+F(3J)IPHBN.18A|^K*E;M%=V^KG^^:E%24_%SO1!S;)F"8;H1I=V"GH[+]%K:8'%>I%U'[8M)&SFF=K+4 MI$2U2.D;E:0M5[#_RK!), 8MR?&,Y%*.386G*:K//-J+>'[<SD&B>3'1,90O+ MFLNN!28306;/.04_+'31;XA'#/@DR4@L,*'ZU8J9_M^ 4NJ.Q@KVI#096(!=))UX6%+Q:@QE2C%A @N+X75=G,5^'![W)!E?V% MLY!?2\1$OG36-WP)66NTU+AXLJ&%\ES1{J-(!($-5!'"$L I2D%K9!D M8UAIS;7G!MW"8"M?@=LTE;_EN%- %J;K5P%\=.1U-L'W;10/Z^U@=E'XW.]T/-M ZADX9;,4H"%4.9X+!976/-"AW/MH,G@3N!\>9"K5H";X +^_<8W!VW)Q+W@(GM*A$76,<;JVL9(.(ZQ3O1TL1?Y[VV:IM)8!,Q?HJES;) M8A#D;77<>G;`_HUI[2SLR%GX1# 5G:O09T3S%3@?L(:&WN5JWG:%MR;EKH_U-&S M#2P2'E.CQJ7VTU0MCBEYT@>!MX$(P(3YKN6)[~N#\0!P#3^=6M^Z]L-AJB%N/6+S97E^OM,I%^_9AL8T6OB^7.&; MJ.8:@Q1(/L+ 8T3C_M^3]?+R^>?<9HP$ PGC0?UK++;>0HP4]]:4.0<&C0]28'TAR$Z589A M! P ;!]RNEV!79RJ{Z':? L&/|<@SS*WG>"4;>?OOT5?G[.68-#L:V!):E,E:& MP\|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}>YZIOE= M}7E7EJ;22;LDRF&]) +)4|DHU0R1^0FWR3C^C8#VO>O=XBW"9.=?V_2BYE"9^ =)]L\!7D5!5]3-;4X]F% %-4$*OTZ-F;BQB6$2Q:7*+E M-H45_ 6R+0>%%$]Z_*-O+[*'_%5Y]2(:2^05;\D>Q? +I!!$GRUP*T9>R M+ %)4QP0_/'RBL!J2M@^+/!LTQ+YT.91$QR;,TVUO2KCUNGS6YX@'0+2-NYA M:9MWPPQ&O,_!^-23"%%VBT-L9TJU?OXX[>I\H!E30]WUAOG>0?[8#@W6$^| MY?_^Y/_TXWD]@=Z,<>S-%P9Y#$;[_!M&_9@K\S"K_#84<4Z9,-3$_QN M&P,[ZW\8 TE6YK.8:SB+BGL57"/20/W//-YOMJYO3ANU/)^N[P_R[]K:;\E MA9;V+W-NVE? 2OM+3\KAU)V8$Z#5I#8Z=/#>*?7$SU[-]N;/55*UG^_)FIZGZQ<_V[A&<),O.+-D2P=E0 M^W8+B%-8G@,-WVQ:T.-^PSWR+07,3%+HJ45_6R+0>%%$]Z_*-O+[*'_%5Y]2(:2^05;]D>Q? MJ_V^4W"]EP*/N2I4Z[I#/O%L_]'II8NLI%B=L$YXA:1NCO8%]9{.]ANEJ*GZ1V_K*IJNI^$5NZXN:]HY3 M<^\7@'E^J;FJ:U5QT77'?'-8GH!F34W"X@7,$D]L>F(:.#%-EB]O M8MK0? [Z6[RLS]#45O])M?673U53\(K?U14UWQUDOZ_$5FD>.O:P7;SQXX'U* M?=3;4,]3?,;PF>9]V]4##-%\$[7@53*A/O.IN!33T^)5*(8T>P!S1R Z\5[K)^7'K'V_ZDW/Z4^GC%TH%KX,5O9$3[*#S M^%ENLF9US>]OB-6=462^5]VN*XP.:+I/MI7/GF4M?Q38@=YKS;8',%W-MKNBET(<-.BSQZL,2WLBS;NRO^4(W64<@- :N_(E9W1U&X@VC&L]QDS>J:.MU5\]JWN["%^-V"W6T0^7MI7/GF$M;.^1$.\ ]+.2H@5[K=GVQ6SE2V!;W]L==.!+ MVO-MB#[*X]\]VO]#9WK,^:2A#DZ<)0=PV_>W/!)\O[- M.W,U.BEK^F!A6|-V*>^KK*9Q!F+UX-XGS+#X'3,[JGUE!W[D?XJ_5 M?A"Y/]9Q;!>$PT 7C^2?T,"+IX"%7/P4(1L-AF/9VFD'>FX(]'Z MN_%\O0JW$66 7OZM\-[+"7O[M? HO^GVX|H"/$W&0"!;H@<+:[@Z"X 3GTF^E\-MSFL_\25S.M#?STG4E+-U.K5>K_F+ MTY+SBU3F/9XV7/&K7]_68]_V?HRQNU MAC6GR2[&TQ((;T2R^N/H;U$L?7-UO W:IY.DZ7<>G::_]3!P#B+HJ11!CTLB MZ-/E\6\S_%AZ9.G1T]&CQY<-V?H80,77DAZ+"!81ZHT[PX=?)R*LN5;V'(WL M 55?7B3<+EX'^D6DTIXWCJ-K'T6]_H3M90D9%]\6^K'FAE";[/'0>/T?!XWG M2.38^B2-5]776E^KDA>X<]N&Q*+OZT7?/:=;Z?;6EYNYL;?^,@WK=UP,RD6? MHD!4\ Y:,6@:,>K96.+VH)\VO=+NK:\-](O3 9NT;A'X^2^=@*.%IS45#479V;DXA7B.%M3"FN= M6*+B*QZ.("4/U1,#075)4GZ+:U\!?]=.}Z?'IRZ/5RPQ)/-^7@BH4/I]&GA+9YR1.- M\(1=K\$WL<'3F9L_U5" BH3(@[:M"!IL,::)B'CH0GPC60#IQD^[$]?W(PC_T&E2E\3!M_A M8- _\$WLA2-X#MVGD;N# ^8GB=24 M0-:2PB%Q)D.W47S%MQ-Z6Q:F1AP!NV M[PC9*9\P-"W,KU,&"Z)B1S<@BQ"8:SHM90"0G0L71172($Y"MU9A5'11 ME163=1N5Z&'& @V"A7PD"%QCX8<5]HVB5'BDQS>3ZDZV3G8R+#%MA"4$JS; M9L:!?: Z)*@<QVMJ]++>WY>*7S+W379.5]IJ:G0E M-*3N);#*P!<9OK#X>\|4@;=([JU H%;]C!!S<\QM8DL HZ>V22W_*G_U9/-MWY+$JH5&H6IM!MO7XJ#)4O3U:_7:%5K<-%;07;)DE$Y_]EHUYPZZG.+ MWZP8 G/"7,LV9F:K[VBV)>]6%-$Y&$ C0EU1K5<-YE4FW? *:%WOV#G[0LX6%&FY9Z?*",/ MJ8Q 3WPJ4"M_1XUX1'"*)L:LJ(I[?^+\%F7!ERXL?0837]K+1]6=,#V_+>]/M/+SLB0 K"?P0/6_3S1#^/+VH_NVG7JO]OOKE^*)"O}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|F";W<|NK=EHWMM=.^3 M1? =NIWRT$IO:DNC,74[= Y1)3GHF*%-M5$+$;3BAQX!0P69,$#D12'/F((P M>]M8;7R.RR *KZ)RR0O157,S-0%K%/'LJPL*!:Q(@3*ZB5]+=%+\N6V142,.(-M% ^]3 ^6C:1, <#($5S$?%= (L:PP37V5%#))#R1MI-D0+.U@L&9JW=>>K[+6>_T6HUV_7>+[/\D0Y@R8Z1'>PW&AW# M#PJ_7\[AU.O3H[X_7 5@15)]@1E:!'&H@%HBTB!Q%';A*HH*".?KD!>2*-X(BUN MU\#J%S)V"Z 60%<%4 .4TZY"7_G;IL5-BN["".AB0HYG++'XF)@^:E&&Z1SH ME#9.&&&0H3|PWAN4#W4C2/DCKX^P(&U!^B$T5Q>$B:DFRR *_ CIYER8BZDR M"AFX*

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|03 ML_]M/0'!?? P(068(V(/_3'5^ U,Q +=<@P-5Z7<2DS0CJG4N FJE8FOT:"B M10\QIQ49 $$1C@-THJ@9!G9B@CVC1-*ZH"A,0@2@,C86&,O\AUD M@1K"ELA<3Q0L@,,0BEXW5I6/-HB*? JSK+GGB0'.I.)LNR ;&6CL>K5A;HZ-M6=!!M2Z%;!)'(57,H?A!]M8G NR+<DQ>*Q\VON!Q29IP\9FNUITHB**2P M==CVC<8]8G@*#;5YW!4N;GF(8_,74231&Z!E;6HQ* (%GE]"3'S+D;++1NS MGU?RY2LF1_$RB[F34EM(B!RHLK_B"1"L)1DR5OY<(,.2,@O A(|"X*M*GJN-/T&(B)\I- MR,VN1(+=W0W>*ID/PC,*$G>!'U>,N%Q18*5S:Q.I"FF\,@108A?1O 4X)+\/ M=6VV%9W5NV;BLI#A+\+X%G!Q#L-EU&6 J7F2-Y(MLF# 5Q-I8X'NJ8%. M6ADDW %8#7WR9&!6O!B-@-V@B9*AYT0B=]!NYBJ,.=&B!S(+=/8L2U8#$FO- M1':JJ>CP@D2XF>2T/"6A=SP.=(Q7'I1@>MM@=3%7\^_Y$0FZ9ASQ^X$Q',QY MM;KU*.!3FAW'6,0EFW9M M[TT*#Z62 MTM(06W3+&3]B$P[3V*V&Z,"X))BJ^6F,7$2O*- ^KT%CHPB|'LNFJWWAAI MC]?85|*QCS:7%%J]4&?JO-H)E6M-C&E:W/}2E/**]V86 3/#S*0W//B5\4Z M*&AX-O.4]MD%U-V>ZWA[+9N!FA ++F32?KD'BTZPK)\L[B.K:YEBQ@M75V,? M2Q>H:AM'I^I24\Y6 E+CWZ|HA5Y'P;4H-47%)>D-N!$ + -4K((1:4(4" '7 M*2V64Y(|^>E5B1675ZN2$SAB70UR<;1^=WB3>%R2JZ/8F4J51\A()4N+()D MOP() F^/&>H"Z@E8SNA35_6=^ML7]H&]U&:GR5>Z!#!5<&]RN1N3F8,O>W_NN(8<2Z?(#CKZ0!)GB&#:?=H7>.(@Y0WD?ON*]MI3 M3@K6*Z(B8@6C92GIU3B5YG@X!Z#? IX6CR.I;#4%W*&]T^CP7)7?)RDX$=-3>R MAAEBY((Q8=6 ^==B)!WXJY?A.)]#]3MX((L;09IH*@RL(4,\$1"]YH8R0,F _M=-!-$!$5<(>G,1$7)23=A0EU ! "2,>0+.LSA4QA"L ? 3!)5WR83ATB"61B3RNHF#PI6W$N.*YM3_FU@EYW7CR:8Y"O(`LC#^ M!SD%D%@O,N$U>;RG;$O.I/^'XPK/AYY)%5=@X2A*2(7/Y /8'X*LTR'G1F3A1 M2=S0.4.&DVHATI?,?H% MR"L4LID ^S605PV*;'9O-L+O98:!HJRI:D#K>O1 M&V:F*VL6/BBNL+2PK8*Q!O:-6MCP@2X4"RSZ*IX83^V('%5 =-U7AH(DT&## M >$5]HFX4\? C%H]'!R%30TJ]7NS4JW^8W@2]CX]@ FFFX'#348TJ8V5#OS# MWC%A9'@.S+(B MM=*_!;X8IL-$+6DJ6%[K$UR/@Q@FZ_;V(%36*(#+S]HUK . 5PU)% MTR2,@$$5A. FB0)? 5H]6E(UB853]:W5]("5I./K7ZR9.@'T'U-P]D-]VA_;)~M6- QM^IDUA,;'&(=A$&UK\XDH3,IF9QL3=AG\!MTK-_^@TVN"8L\[U?W_R% M71=!V4SKDGHJRI\W@[2??!R? LB:C4JI.>.:OIX=?'L.J\UIRZBY.+PXN3/X_%9 MX9>/N+;/^O>)^'=`G[^>?S\|F>"!Y^OV"GAV=_%/PLY/S/UX70R+-#!TM& M/-@>$6LUU)335;)42W#PQ\%7U^+,,D-JH*L-F?,F6W;DGH7C6RGMLD,WE86 MFRT:@X^DH+[''Q3?>ELQA??1DELTJ*KFBK*Z?*GQO'T'+P%$+8S(>"DIBQ 5-M3S6.@N226@YY:!W<{!QM&1P]^OKE8H-P].SKYW/"SV]G7X^./R)*;A4"/GGU MYV-I"U4^TX]2CT-#YY$".$*?;P.HMNKT'NOAUA0HR4!!ETU39=Z<[@4A$YWD1 M1%5(%,H3FXME;:5S!GZ'M]'*3U&8U,%RX+NJE:L;5? -7$.4U>==I[MXBU]J;0]I5M.LHL4N*(\'1=M"#7V@:LV?V2RRS=26>FD9*#TM/"/9(+U\N- M]H\|'=F&SK24DDU@U)!8/2Z<*/,_N0[T&"(,ED3U';$%]F9QOGZ6+;1K\GZ4 MR74&_@\1^,-(M95SCO9_L8XX&,98=$GA0^'B4G=D_YT'LC%T:&30I-TRU-_M,-2"(G331%H5/'85H1=+T&Z A2O7V*QT!V M.,IGY%\+TI-%S:\MOB.1O@KI[R3UL9%ON8X CM]M3#8!.!B'@-G8%%VA\&PBR1(%NLRKY> M_'Z\2:HM,_GRZ>O9Z>'%R=#*"Y5*V0,9]N,BR/#A&,,$Y^/?]N@ MRSO\+"T2QQ]/OORV72:)M=@$47!297I1"R*,,"\=?HDE4BY5$9!- PM1#@ZIG&X2H)~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

*>!VKD#X2.R3#:'XX;%@-F990)UR66J M:9EJ7";C|%L[/:XE0$#"Z=L%M3;GHY$)V#%D-6'7B!5><*C2.L:F"XOC+^8 M8Q/.!00ZH(NQ6Q==27MS/#):4A]^K5]!+1)1"'FRN$QGN+28ID#1TCLLIUJ MT$*28!K_TA0&I5-IDPB%^8#-DOHFA{Q9@.E)3;#[&.T-2@4(0 I@6C2UT=?MNR_:.6&.^H07%_)MW6)L?>S*$S;-@G?[-YW*%T^ ?;# I $+]*QFTVOEK,O9 MRNO)'1]V"%V_!$OC/!+?,6NPA4D%8B=+O"V6 M6QZNK'62>]TN9QVBZ-+(9:F9C&F!.X"PQ[EH\-),=5U$TYM&+/HOJE(KP1]C=N,8L3#"0f)-4ZZ*.5AIMJE&AQ"> (#HE?0WH8F8]> M0%+KT+0T?2M<$C;]XIG3.0G:PGV\+#!LSXIXS'?C8T4%B6Z36U;VNG-B)R(C2H M2D+3=WR*\#BC]?%/M@%2C-VFT4E M%E7)!Y8,[9AL? AM/A:IVRZ82$7MEPYZ7T?'H*O)$]?:3#8_)OTV-]Y*>/G;T M]!7HZ5FMVX,UYQ#@2L9!A{K";T!E1,XX&T]TH^7?46I)4ES^?B3E[/!.&?<4 M\E7GD[P"%V+3%L$HS,W[9!S1BS;=A#\?2\M_A!C8,/*V94%Q 4[#$3_N .=4 M=9<%5QW+[=9%P*K@'&A/ZC[12BO9N_[']@Z)FQ;,P,$=F9* V+++LD6?"+Z;Y MYFRFZ=\ MR?,1,V'&\)8+E'!D2\@8QFTF+U/3&^ !WE9I=T&,LF^C8G7:A/KG)2@4A62. MN:,4\'+JN553-PY^BRT'O(\#A4PW.U;[M'R&X5.)48HA&]G+F@9R5#?QWU7?-M KD!,J DRX$)0XI&T5N7]2#L6N? FM@B Z^KC]^VS5#2D3'IH=UY9[@_O330 M+?">HLXMTG5N]U@V7>?VPDT1-`-^+4&5X":_(U&":%%=X9@H6<-_B?4E)<,,B M1Y@7$L\RX'XI032E8]M$=YA2+!=XD6]&=0\4Y+)]"MZT*D=V*UIZU/)Q17]H M^WR.=?_@RMRHCK1=OK3O:'^2!?E-7+00KE\0VN75-6:@E5@*82TU72Y44Q%P MK"EO8+F#W*]E=I*<2;^:;@O!5A[3&4\E^@8*EUUML/KFV/-M43IBJMNXAI*BB>H2EK=>'CD?'/WS%)S&\H8W8+GQ!??.4,W9 M!KD%FZ9XI2)7@P80?PD'1W:QR+ I^)*$(XR? ILV5P'A[?O?(.GU;P4J+NFUC M?E;*Y-'5[]\5'\-9U"'S;^+8>$40R^/JME>K#,/0%A,;>7 OH#V0#- \|:1V3/FXSGJ7@K;ET2!#'Y"UN1R79N&%Y6*E8E>6QX)FFVC\|DG#)0 M!A><#V1-%/\[C^F6/9 #W>=(&=+T0QY..1L-").J#GDUU:=G71F!$73!D,Y M^7IR++#E*C12YKO]!C,_H@O/K]X[:VV]@X>59CE8>-4@4("$B;QRU:RG_[$YR MJ"_NR,!C#]%F(,$,ZX4,%$FTZQOVI%]^Q!-5^4@K[^G3/(U34>?-C%F.9<38 M/1956^_WAWSCWH$,: Q/-&1H@K3L025O&/HA[+PU;#?ZCS&@OZ?8R+/\"'^_MOROTBMK O0-)N9BT/L$]" -_]D[&ZKJ9R9.Y;=YG4G=K< !M -1GS)U@8*TP M9'LR)_EM$+Q4B7_R7*\YNFUF2D!AMI"KE]]+LI%QE!\/OU>QUHZ=##N(1!E M#^SE_NHE7MMZF#ZT$D>]!8JL9XYE&'C#((<$?1-EP#9A|; M%)D\0,AAS]3VM&V=2*K*\T2"0UV3T9A\$&-K3"4MYRBA>\3$&GR#\II/L52- M7\O,T536;Y 5KX8E<;2IRQ1&3VI,?,BEJ=RBB6X=^E'O#N"[,$*XCM>-1#PR MOM(9ZS'YO"#P@$GIA"86T_+JJ;!O?)U0_WP3ZLG64,F#RP9+OYX%]W^T^Z>3 M/[*E5ISG-4G*&/PP*AO9\/#?:1.#M.6)7GL(+Y4G4C+ !M\MAPG? 8IP_HO5N=6&1*,%"P/9VS^+&W5X8/>TE'B'9]_@2C =-(^S-\F;1T MR+FG7[S>NW.WO)Z$47*/*7K#*]G<|<56-%@*O2 C-,9-++DAP=4\&@3_A!-^)/U++#QP)(N:MZU1%=:AS&ZEO# P0?,V)K%*4Q== M"0W*S:Q,FEKZD].FEC>C"&V]3?V]IY3]V=5&I7U43*88MJ<>8^.DSR^4+;0K,9C[L'GP#V<|>#G% M.-&,5L!>54V(8SZEQ*)Z(D 4D*X:E!RTLQL6\,M.*.'DI*TZW#YC;&JOCE7;.M6C TG/NN1G+G:(84P2U$3KDL;4IBH(YU?9)=](0.3)$""O@PX3+T4?W3?@C9-9_TH..;P&POXW<'_M? &I/VTI;@LMS:HIV6DZG/%;)3'U('+R'3TM(%)L*__;_U)4=C';CWW^Z=8$ MC,YPZB'$^J3HXMKXM<**MC*[%4#U-'_TZ;N*GB?/"_@O\&2HBFRM>+'B! MU4&_!NP$_CRFQ(2^+0IX0@OJX2$/WJG;B0S574S+F(3J)IPHBN.18A|^K*E;M%=V^KG^^:E%24_%SO1!S;)F"8;H1I=V"GH[+]%K:8'%>I%U'[8M)&SFF=K+4 MI$2U2.D;E:0M5[#_RK!), 8MR?&,Y%*.386G*:K//-J+>'[<SD&B>3'1,90O+ MFLNN!28306;/.04_+'31;XA'#/@DR4@L,*'ZU8J9_M^ 4NJ.Q@KVI#096(!=))UX6%+Q:@QE2C%A @N+X75=G,5^'![W)!E?V% MLY!?2\1$OG36-WP)66NTU+AXLJ&%\ES1{J-(!($-5!'"$L I2D%K9!D M8UAIS;7G!MW"8"M?@=LTE;_EN%- %J;K5P%\=.1U-L'W;10/Z^U@=E'XW.]T/-M ZADX9;,4H"%4.9X+!976/-"AW/MH,G@3N!\>9"K5H";X +^_<8W!VW)Q+W@(GM*A$76,<;JVL9(.(ZQ3O1TL1?Y[VV:IM)8!,Q?HJES;) M8A#D;77<>G;`_HUI[2SLR%GX1# 5G:O09T3S%3@?L(:&WN5JWG:%MR;EKH_U-&S M#2P2'E.CQJ7VTU0MCBEYT@>!MX$(P(3YKN6)[~N#\0!P#3^=6M^Z]L-AJB%N/6+S97E^OM,I%^_9AL8T6OB^7.&; MJ.8:@Q1(/L+ 8T3C_M^3]?+R^>?<9HP$ PGC0?UK++;>0HP4]]:4.0<&C0]28'TAR$Z589A M! P ;!]RNEV!79RJ{Z':? L&/|<@SS*WG>"4;>?OOT5?G[.68-#L:V!):E,E:& MP\|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}>YZIOE= M}7E7EJ;22;LDRF&]) +)4|DHU0R1^0FWR3C^C8#VO>O=XBW"9.=?V_2BYE"9^ =)]L\!7D5!5]3-;4X]F% %-4$*OTZ-F;BQB6$2Q:7*+E M-H45_ 6R+0>%%$]Z_*-O+[*'_%5Y]2(:2^05;]D>Q? MJ_V^4W"]EP*/N2I4Z[I

L/6.WS@PZ7"S.X7#JO.;^_'(@_#=BVFRVG5_>Z57??ZU=;}0Z M;,\#-]SM#?H#I]&I.^(QL.#R]%;![0>"A-/(\P?^PP"WUW)%K\&{5=Z&Z5H-.MIU'MM0%Z&]U6PQMT>;?
7&#QZL09RY7HUEUMUW<\/&B.ULHV'8.3'3P/%GM,!.M\@N:BQATFD!\.QVX;N$@8'A\'YXV^OUU$M^+>:!2F#P+AKN-T^_"(K>LU06GJ.M.$ZU!U2W.G"\?GW@IGKM_4?
AVQS;N]HBGQ\<3$62+8!<!]MJ?T1!&DZ5-%Q(MF],N"H!U]0'LH'K'1Q7]%0?)BL\/2+W1JN^CV+.F2Q&C5Z7\^H?19/C'&VDY1E@18ER_M...]OGPO&ODJ?F?>Q] >GR:C.B]855>^(L.
!ESYG1>YZ8+?!B&^(+]1-M.|(T*@A-/B(?]>.05ABHUYWU]LUF]IZMO:W.3:[:\/.LC)ZWAGZ72A@S;.T M>M^G=FRT%FP0!*O'UZM 5:-.,"9CO3@'F6OT7_0$5"1HGXB#!\O.
!OH8J*R< M'/L-S@\+.,'P&.ZMD_<0#_;UZ"=[RS.G0=/NUSB^* (&)N !P]TORPZ.]?F_+_- XV5)<-[B'NK;6P.{7LN M)- :Q#!-
Q\G!NWU1+BUJ^CZW2%V(+L6R3OA7?'XG<=3_J[.V& N=[_A MG??:=:=,;[3]G7:O47^'QL&]N'4NG=HP':U3$5F:67P3RVK"A[KP< 4K(,@^ MOND-!C)^$%5OD0G!P8Y\K'{X
;2"CL)W1J]^B$;'!8*),@GE% 6"U6DC"LG M"!EZ,CTS^DO0L*1227UL3TE2VRF?,*SQ)2M]^2%L.XP[DP4;C(2%LA=J*)3# M"CT^Q5#NRO!*F=Y+X_54UF[)8;]#ZP.17D>)-
S9C,T;@=7F"S5K.NNS<&C5G M.T#_F:7*K>2P3JO9[,9Z#0RK=[K==-+VLM7H-IW6<@8KQ+H8K.&ILG])P"F) MX53$5UB=0#*Z; MG6:+V&JWT^X\GS*K:MLB SL3JF+?
$9[N@#SMR)Y.#"M3"?MWV8ZI&MXGT8\S M[!'A2/(57)$G-I?QQ'S0CFI?8552]I#9'5]P7Y%W;HE*NO, ^D'5X6+O ,AWM M86T^GX=UBCV6=%)D6T_ 4RMY96"9/N?
1%@N\4HW9MG?LG-K;8N1U2]* M]PW%;3V?HDC\!OD;##'(B /^F_)W257\EL'R>2*H]S'&VV!'Z!696LM&Q5JR M;S=F^=F*Y^;4;\Y__?
1_7Q5$;#Y/T\DA]=>C27>H6A=#/_;F&S"!F]39,96) MOOZ0V.6SSV SS4LG!N,*YWE<\'F,,WP MN:..HFK.ZO$FZ976O$BGLQC9N3$M 18D2=_=,:UJ\!OP;FV5A34?1 M-7IB^)4
!2$5,9>I0A]YRMDG[&VW)YL!HIV)ZS(6]"RA0-QW7O6M'"'LV^M M$_L?@K$TE:7LF(-M3_0#U'(&OH=IJSQ@*>!S2N5?QU/Q:ZS1ZE?S\!+(5{M6X++Q08:!DT;IR(ZW-MD[
DTF%WY\L.=HEH+2BU;3+OWU=C"#SN%;1]%&*4P_2D/^97LO'4$ M#]%(B/P)\4>$"4^C>*+;<<7L$.O=R9>7X0_\G_<#03]NBF-@:OJE,ZX*++@_MS[\F;L"3Y-
JH)8L2*XW;W5Q8>+E3Q$__" 6\)-)-WHE\()#5/_% M$Q\:VDP'+BDQ'\B#WAPPR?)^S?OS-6H-V<.%&8U..NG2S(M(?=+.9: T>D,_02>CZ.8INF#6
GJEE5845'KBR$/!EC%%0RWI,\]#VR^("_DN>M7KFH5486=?#G"WM#LHPCX#8\%*_3\TL>RID64>MEL&51LV7(M'=M^=-'^>C2EY M5"^JUAZG:)[V5[7%;_]%DP?
P+GG"DBUY!,O]0,_A26Z"Z?Z9P1.&-N[&/K_M2=ZR\W$4Q1;W+.YMQ<8>@6$6['<>.G9V8X^))!GZ8C!;).'O_?C=/,;65%&P MX>0[
#=V8U;.\'!@]8LW_W<Z>F2+D*4I9OV>KUS]P^&;Q.5N%*POP.PF7.1NQ M1VL3_,747M+4_(C=!"VO$I=5H!T =KLQ]P)9$+ JT#.I0*<_L'^66.'&)<7 M6H2S"+<5&WL$6EF(WV7 Y-
F-/0+B_P3E@'V+14()AC)+%4'H2I/RP D-(1-W MHB#0WI;EVD:E4-/ZT'6C+ 1TNLJ?YN:>"S<6*8\G2Q44F^X3V72?QYOTL_[X M=)^_O^M'WN0?_^?O[X;I*/C'_P)02P,$% @ F8
-6:+J)V,&3P$ 4X04 M !$!C87!X+3(P,C0P-C,P+GA59.R]>W/C.)8G^O]^"MRZ'=%9<:5,.[.R M'CV/#?F5Y1TI[Y;655=O(<:..#%B&)TQ2I(2G;ZHW[W>\Y>) @Q9=(J1
MCXWK]=_K^Y#M"O;EO:]RW[[!HC"/>/0?2 M7W_WW__]O_WK_S4>DZNKZZ_D*WTFDWGD/-$+-)YR[?K@-*'GWWOA>*'O;B,8+GP'.$M&U'D=%S2YPEJN(O)M_3[
7C.UYU'5WY,KQ+&_N6"YYD(..R+4W?T\FKDONL5=([FE(M@R=JO^ \;B-ZY0?K"[JPMFIT;]]MO?_:6JZS<*@-R^U27*=4 ^7/ ML#]>^!<["L;1;D/#U!Q>'@/WO1\LA"?/^"?<>2/XY-
/XT^GLB>=V^-P^QCW M8WU".G^_])\^B#]BMT]*A\+&]8:P4*G9/'IB<_EX/ M_+E#^T\?\, ^/5DAC?JF3/PGX0WH2\$<[2K<55#]_X'I4FSHE

*OCR0?ZEO=!Y=.L9F0(F=S/"!W'W,$AX6ECA(^L, MOTSQO@W'2\O:[#<4?T@UGEONG+<,,O/Z]`_MG79+,.G[^.C\[*W:6*+3W_Y MY9 M";OL-
9)SWM>.C@(AQR"}]=O[^+D:P_ JK?N\7V,#&MYGA^QL?!7\I>;C>,M M?/X,^!W>"7)\?)?.8,T(_O#M_OK@E^1#9+WXGK_>?4 *'^"NBYB@,+.;%9#6V M/!L>D,B)=F,7TY83MRG(:
YC\?0$_P\D.$68BW^<>=#;Y M9.1 HHK)_>N'+!)$,^6U(!:GWQ^SG30"BE\)?T\P9^(3!)+B4=E>_RH'!)M JI_MB5_*[=.!J0!RE\YISP:9@-KP
\C'C@V_M\!L%]^WAQ6E4SMX49;;2*@3]9O77I=)\'_]{SUI9DQ>'ZE'^X?A"_E81)0AD/FQ<3UM1 MJ[<3I?]QNK,":++>B0-)R#W^],MTK3LH/C1XN\BX]RO=OAZ&[PQ#_-9PNSJUP
M=>7ZS^$WS]K:#OSU8YT#446BXE!\KGDHDF'PSL"!"!N)O(O'>KLH&JLF<[GH M^%,\Z..X03CV%V,_OIO'6[GFXZS6TH)2Q4GYL=%)41^4Y*2\G1,]=TBRVJE+ M^]:H(A,Q0GY]?
4)20WW=DTTWB9SN.+'"[S"\!XF^90]SLK/":X[.^?$#]#G9 My.BM&NA6G*%#?NI1=WL1OD!.SUI=L#X\,3QX_)(\'FEVS\MVO=+[%M^:#:4S> +W^\+(?KWBU'#4L
M=>W*C0 ,VQ77T17G^1$=GXX?K=!A]XVZ-,Q,%');+OXM=):>LX#U1D?2?.YO MT=*V'&]@.^<.W7LZNR1=7S#Y]_RK=*PP!G.#R>KCME>&9V5JS4#\GP M9!(/3^[$\&^'J[D5^N.-
'X9W-'A8P0>;9U-.-ZC8Z! S-Y!Y'X , 3]$$7K;.MLN9;]NG;>Z)A)!U%DV5 ^26=MWW%C2NV\]?\K?P$/R@DV9>;$'W;UL]!00?X M>;]V\.?\+2WQW[SM9_/[_'P7H/$SVL%GAQ+2!K^0O-
W,;UBQE[_D[^5G^$&2 N8]]F3/!M*YMOY8]??-]^=EP7=FB*)*YA;;PEAH=.P1#FW!S5G<_-N&-]_PGWZEKAWY:RO:!]#:*_]>WDZ7M*[8XM/\++<;?
M(LUQY(]O!57UU7W:VN9;^ .5Y02_6>2K6W<?UFXK04M*!;T8_Z6_@P_(#W"_M"!*5XMMN-M_-7Y@V@=`!=@W" M"!*5XMMN-M_-7Y@V@=`!=@W" M"!*5XMMN-M_-7Y@V@=`!=@W"

[KMO_4"K|V|&$],*"4V02:9D5*+=]?^G,<(FRJ&7^>L E M@,Y2|L#9PN(FY?X*>#J 0,\>6'SA>?KO_MQ@(\ZL1)F7[=ZA5+/]/>UT&UOHN MH'-H[,PM|]Q''&(V QR^V-Y3MVO_($?<,I7^_CGJIOPCVDN=).#R;P*R<%8 M3'O?0>R9H C5^L>T)6DA3RRNX=DN7;*T7/6J$4EC;@;'H S#C;*Q'#PM+-.^! M'Y¥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

&13&+&4>@FU8+)85Q^K)/57975F/DG&)3@PR'SR]AL1%8@BIU+;:UJ<(OR-_M'+:U2G<8TWD)LFNT4U3F/;"!IA%8C'..6,DX304ZKHO,YD@BBYX!N\E$K]0 M"/)=E\[Y&_;P\H,*

{IF7=49Q=G"W+0NS6$GH8-CG$D<8XE!"KI?TE,K@,IC!7_M_+U<<<1+Q?#>9SX.MY78HYK-X/&4$(H8X2L;$)AXTQE$RFE9"+\/(6:,0MZ/_M)-*% V9DCG_(AHD7S>?*

F%8Q06@6F[!!;,5.)1DL\,C[(DGFA7'(D]*>3$ M_'!H5ZRDK-$]{X4F1BOT<76>YLX<9WV;XMIS56!-8V$"=]8,.?<#NXRQEJ!# MI2W*50'H,@\]37F:0O(W.9:VK62UTGR0+=MB=R$-0_--9W=BPD27N9U(STQF M9Y=R7(@?K_SMQO>6.]!>]<NSMIC:-TL1&[P?(KO7[*G]-N'S%YL*M,-VB]VWX M.*PX*5Z&_0^7AWQCT(T70A>]e0O54J6YOX+'K*04B[*I,9(&?T\C^,;P|"3X M$:B_,Q3I#@+M8UHL0(R%! 3QD,0WBUFA@UDWAT^6@;+5KR&BO7"Z8!9<5-ZF M"R7QKY6.R H@Q$ WNG5"]0.SEL#&]-F#(]1R-DFUU2L_R*.I-T@:S/GT$-P'

MOSXY(N(*R@*OZ*W,8BD?_1]X>^SC91]S?YYF/XNH36#$HU^"\'S'O9\'20Z-G7 M^WQ,/3ISUE0$*O#@5;8$+-8H%(A3+;,F'0<81C"(K9XN 5L$TB\4+14$P?3CB

M&MD5YQOWKH1.IQV(>D#QP/78@RO(^0R!1YPZ(5fu%N$;7%W^3)?H0$"GZBF MI%$<4120M9]PTI^Z?LT&OO4(IHG,+!Q\1HQ1X'&4R*$E&[<$$"(U C%)'>L17'T9?SUP=-D&ZW\'7NCK?,B@GWO6W- M6:RS=0F?!H(#\KU9++.SN?_QYLE4'_UIWU%-!3VS18F&MT6FBZFJR:>F9QS M)K9]^HAUO+&"@7P\0=@HP&5IN"/G)K>.Z&$X3(#I-)

[#@#'\@'.8U\E@:'&2@,U>I/Y/2$K/EXF%<"O]9L M;>N84?FU 5,,+.)PP)*@3*8!8878S)1))):U,.F1AWC3% 9]0PR6%#05%0!V M_OZ]J8C(DEK-^Z@)G!#EY;+PPXG+T[3=XM1(2)Z\6l

(2.^ABT..?K7^:06V MOPU_M*(WM.U_P07>],[,W.!)(%-*SD,><9Q00&UC R6WI]{K0Q.[8O,2-O[_M]MZURW'<2!#]*SJ^>^Z=.:?27=7MMMT[NQ_R69VSF:6<3%7WF9T//DP1DFA3

MH(:/S)+1_44_!)\ "M*=B+>D2Z_(.LOD@\L'H:.ZU8^2OH2RCQ'M:7"B0_4I&>1Y69)!ATN8+I.(6=tU(O8M/:1Z]N6O?=2NJ^)Q)_'"*:,4!* MA<%%5[!%,56DS1\$Z-

65UZ$K]\FE2#PFNS%)')'Z+:(OT4{!] 2KT$AF^W:!H& M.O7?I(>MI]_E!-SN4;"%UB>|_Q!M((?*\EKS9?](G7$? =9C;'&..."[6/DY66KR1%AM8*?2A MHS'D8#F8&MDM&RU")2.PJS

)6>8KB;?70;J"CF)":*BI57 M5 X%[!P;^2Q^BI/OTK$##H@.X[B6^#S8)P&H?8)]N06)C=;72@C8V79@B:9:U M@5XX;V/PK=[!j#3^RF3UK,//Z4&5,S22R-A\5#*]

|2+R+|CW/N4@'+@6=8E M>^>[-^XHBER9Z<3=-Y)-9>]{LOG9'6L ES4!]2 MJ,/L@\/:"0:!MA -77>]@X+W]Y8?6(%)>ZO=EASOVKEZAU_I'B'9U3RB|L#

MFWR.ED;CI!F/0\$C .T6X<6?6K!O+>C"%O"U2>.@=*<9+B*,BXCA{*XV N-M1]J%\&A],/MX?^^M)2++A!|$_W7AJ,E4F!'<%//@9E%\DW2.&NY'M@;,DB

ML3(9\)3!9\ZR!&SV%?"DL.] W84\%B_[U E#G6=V;4Y\8-!'8_3X4YJ9_,# MNAF:)SDX8"\'7+V*+CV>Q*A"WDQ MN0\I_E]K?,BWQ?70\;S=04J.(K_W:W^<*]3#[@M1JASTCRKH 3-^BE]=9]U+ MS_NB($_63=O$GR1< F&5P'>@\(G)!P;]-IG[X\YQ$Z]?-T<'K+..@"PUZ%%F9 MGLMM@*'C>VI,.EDXB6WIAI6L/R[GZA,9E-O\4BFS-$1Z7K!:UB__%ASBU-Y0O

M/7CID>12P<_YUFH/'4MBI-&JQA-[-?(K@A1 M6&N O-TW!*&JW5^%Y#/ 93XOTK7!#.2-PT0'A-,M@L@3DB<&<:7:-X6<)QH[M*>0'_+D1!&*%[H3/""+C; @TR5+OVS]^+=L,'R'_U

M?!O=<5W,V.[Q67A;)TVQSW1#=N3F!!N$35L5:.^$@2[*C *]O6-:HE@P$O]!.,#&V^ MK YE=LM-/MXF<>&1(MPDW.8U%V[359RNJ6P^HF!]DR1-T6[;69V6UCU2DAPL

MNMZG1:,BJ4"2]I 2.$E?J)\&%P+ZK+V3^YF@G5<6RDUH2FN/%J92I+_5Y<;UB5I,>L59OZ^B^5W3VI[Y0JWAM S&SP6JYK>PB)-/3XM7-\:O

)1L758AS2,2M>P43(P6*0C9$WC@2C16F6]MX?L39'5!DSAH!^2+A A"Z!SC>&OG $DMW!'M'I'[AMZ);/9S@T:.GQ[4H-I M2I0_?

O[QYU'R!6DD<0BE4Z+C,WH#]D!+Q1RPAM2IR#9=+$D+#&&Y$X2(&9!R M*_[_"[KVIP4#D29\OHP!8K&>3^*V/^9 MPSL;1AL;PIG4(7;X<)27/=X.L]ATBT@A2RW86B-L?

8=D8;+2T*G"M/X+ MV -6?2E[X 7K4KU$H23-0.Q%5ML@6WLL7R7IEP1F9IK4N/1(4C%5VS-D7211I%$/D%>WV@6H:ZW6=A^= M!BH]T15_T57'L*MT6EO"4$/;]YU4%2DC5A

<@<\2'SSE0EDH+-%0>%78AW5I M"8OG]}R1E95(TI&G-B24;@:@6/ MG0F9A\8R8!-*]A<8_T2,2KW6\&(&-")R-W?X'FN* (C M.[ZM;PY^]JZ.WT-XL.B3!>VLX K3779S85Q?

OORZN'M8_OZRN'M>/B[NO_UV M^[*Z__9U<7F[NO_M?G5_^S*L\'$)G(S(#L$MSUHKD?H8>]\C4>?X5"!XO%"-

MM6/B+_OF8H,_2AP%{JBI$P@TG,JTGZ#1UR3PX0)0DN!Q13^99'HDZ"C7ZOTV M$6245-,B4J0TKM?@#F&MB#$;DCCC'",L;E>=I&@X9!]B MS8H)T"S*>*R$PP&A+;T@#;YTPD

7*BR:<,!?L48$L8)++VGKFSS0&&;XP_W^ M8#D!4=EV5K!MD35;CDD,4K$ (N37Q6(B5KC8(=>&LA#$Y7CJT"/CC(OO>(OG@H#R^3Z$MN2&_670D.lX+<@7>DK7F@H.$

M6(;>UES069NIP^CK$ZMVM; B(IKFNMXM('QE<)GBR0^(DSD:K*!+\@6 4%,] MESYAW5CA*X$S630'Z@_6AQ/>H(T5NU$3L!?_E4P:'@$!A+=$1RCF&V'"AY@O M$MS9.4H)W-

MJZ."]$#@X6I$N3]M*$N!- !"EX&V;XXE& MB,'ZU8^QTNNMT(?50 ,C9+4%666X17MV31^OF3,0K$(H-EW6A=C=A= M!BHJT15_T57'L*MT6EO"4$/;]YU4%2DC5A

+3^[@*B1H/_;B9\Q&NP9W MURQ_:N 5(^Q@[4^YVHXN+\)DJ(%*1@!0D$60B?K@"0/88P\IFL4.O'^RT]? MF&K.7S-V.":7,.ND7+O GTAI>P^8/\002>[VKVQ_I >\'C((&%CMW?

E!ZV[KZ]/OP8.===4U>[Y\DOJSW4EV@@D.[.G;Z0 .@W"'7V",,EMUD^R!$ER'3XE'YQ%D$RX1=[Z M2/N!+C=/+GZ0(F>S.1VV"+[FW,*?DE:C<%#9XB<'7;&90@K0@:UG3I1<1Q%3

M_4.G"W*^H@"DVC_Y#TFU0-)H=K! <]SD?^(K0'3G'M\ M1@<_:-TXBC&4=+D%76\H$$*\5?P%_,L.R^Y14]MKD-]1<,:'ZS!AUS#7*+_M+6'UT9QL2ETDN]H$&[21'-

$Z."SH>>9:@%]3*9H&V??$+KKZE+ M*FV,,&G!?DPO$'DTPOO]H3O4O0-A%D1#(V]O+KT*Y)W\AHEI4/PGJ896SV__MI_E7=)-

FA0W_B@X/KIK$Q/G0X$F3_(}\F4/IZECQX%QB'";BZ7H\+KC<,MI=7(;(MTO'A(MODF(Y0@W#-<28.BN;A:YK>.2X* MK]T(;?

V@8X%^LM2'K36X>QP:;KG^.R11X3IFNHIG<_A!;ZW'7^+#P24'C\K MS%6V\^=^\FH,FJHX[C8S"]B*2C=B797/B8TJ-9K6HAU;MO2_,AWO.B"K KP M)NN.8_+L%;B2>5,"W.

NV7QYNUX<(,F""[+B>-Z/C%7WUF#A9=1^$7T"4'R0 M3Q:*G*1)H2 YT;D5/RU(B[CAN[-ZJ;.2^O>ZU:6K7?=D *IVZ\,/T$7FU762

MIM@)!;>_CA)C,52[;H/W72*L$=MA9[5;O!'W"2]RL$4_+W]UK-/;N>EZUM=<(0'&U2]9?"$#$IY2RX;)OF7M%+B,]#;R@HE,M^\ME2;/A/>DE6#;_B$OA7Z$CK=_'^L=6!Z(+

[Y01F!$0TT#H_57Y.$_@8_CTMX[MG@,Z.=0/ZK/DL(H/]D'S4\N[&3HVL/ZD59P!>7P8!46'])_F;_T3HQ(W?]A MY)=;L/7&,_E361["(;1:]5U_N-:]@NGR($QK#26?*(-

\2L7;,1(FQROKHN)6RA9; M1-9'JE^/7W515.*Z6^%#R0564E'-@S0]JJ.5TP4\+ MLN3P#3IJAZ;@P""%*- NS'+O7\2Y65DA=72KN8@*;?H6)^R -C9?

U!CH7!1A;!0M3[945.NLN%S')@TO*L1&!./M49O\(M/Y';23XWSAT=&/Q*)3X"^CH#W<^\3CXS=('1,6#MGP*TQK\Y.N\]N]NB\CHL M#[\+7@(8D]J L5#V&0PRJ2U+01Z^R]A

@&.:'0$PMSPFYXOD POZA=&*>Q5S M*2GU+6NS M55QI5E)@,_G6]%%0NA_];VCDQ/=\#!@Q];-PT"QF,;PZ%MP$H=Q/T$.IAV(:

M;/R5^;@RZBU)PU9S&X6HU(7){QWPXQ;.**]PP4_.?+ 5+HAV3&4/+J5@F]N MHDHVD42O4R:.8]4*EH3PHK6:XH#5C&:((V5DDZ*(S4HX*\:^!\OM]#U@5M

MC]0]MA967.27'$V:Z1&@8HD1!636W?PHN:8'FTPG6#%+C. WGX R2*;:AS[M0TP%Y^7FU@I= B9G: K\VQ /M=2,;;+"],4[L4OZ6YQ 79VSZM 1+_VB=X$7/_H*&;Z!CH$##08O0TC

M9T_<\#-'TFBP0[A!CL[3-[P+2Q7U!]D)1(D*\?G:XX6AY!Q;DE#&_ML5',(?D&.4/$/G""H"HZ#(4? M.EV0\^HQKUU=*.#Y4S&B>20?VH#@YZ.$#2#MP/&#)Q)WBE7R8I*W_?>8.N1O

M4+(@.G$.'9A+EM3!1$?D#XP3W4H_;M30QA-110ZHG[AMI)3QVCR^X%#.)(T-*H=)Y>*MC-;7]';SDD-BZ M%P%=>)%>3234_IGEA,_E"

<218H>E/Z26SDKGD2@$A#]/P/WH9"T,^F@(_)L M B/IAE @-?X'TN2;Y8+$^8S"*#64&,>4E@\N_@/N9%Y,VIF_,4S^ Z'[HE4 M%U/M)P-RK9!'HD@W23]_15M'8_X_*_L(%GIC,LLL0N.

[V(V!BUX;__C^_UO MEP^WWU8OB\MO-XOGVY?5_WUZO8F^1W_V_)N\73[?+ ^\F3,.W;Q'=:U.BN'._M?_>@W2&T5,/L(%#V:0V:I}($C(O&]V*#],VKO\^N(! *E\M-TDIV&7P#*[S

M+MDUL!Z P&K=^K#DP/R,\)HE+E]KMBV\->[V/0#^PG^7F>TB]O9T+;Z+935D?URZ6Z9W-PO6]+0HF>U#)A2I5I:R+ ^DA:6F;[6&0;&5H'UXVQ@GE% M3,(*X%\&ZP+

5K!F&\K-E+,N(`#/ :;(:+>I#)=!'#DRWNUI$\/L_;?Q.@; M^HA6[\A]0X\8BfIP/0Z_^UH$RS]H1D2N_"'T%__F>U:V+RO\IQ"JX&'AF+)Y W^DP-E] *=]$?7 6S-

H=&'4/8[#YMLG!GG1F*G(0)5)O>HPO=S<(VR]FE9DJ-[; MNR1QO,J[IX!\S@JXP;T+'1]+(%X+U)=>>/U(_/20%8ST[47[#DEAVXT 6.?*R MMS,]T[HD)1IP++>T>6F[3? QXV4DF<=SJR\48

QK&4JQ5PCH!O"-^9E?512+KB M8:#7#VA%&=1=20.IOR+[KM<E]TH2"94'73!0_\U\]H^6BS5[UO@BWQ0)8_7% M*MAG]=8]I[39=":(G(14YS@_U)T2O\+BT48 @^]:0'H:(OK?

>O8[SNI3L-(N MA5!R']#M5M)/P+\YZ/W@.U[TB$>O8]<*5E:P14EQF^I3J3S)B/--(Q/OO4,< MA236\HOX_9<,-P(<5;7L/Y$5W&&MNHMJQ]8P G#F+']!P9L#64]\6OR8MT!]

M%2R:0G'ID+A1\K^#H/#-C_X3[1,ON5A:.+"/&8"*)G'8Y3>K[1]& 5Y5;UC2 MG52Y(;"DL>ERO/3R"2VO S6'I^*)X#&G@CM*_^0>L^,Q0'%ZZAYVUPF^N=3@^ MN*(W33K,"(6\,P:

;ONDOYS4O:6W?G!-_1.1G%HL/DB1HPJ)_4)I?13]T<(P#CM5TIFS_JQAH!2"'!6FR++\&\SNF.@"[,M9@W M5W.JF:/_)26JRFMJCI+7UN--I"#+-/MS"]#PEV7

6GS5[*QUXW5;EI!P%2:N+^ A @[^3E60D(TSXHX*LD-(J:1)(%PU M3&6B.2 6F,@W/T+D7U\.F-5<@Y4A",$E!Z?T10AM@S7TLZE>B^70U!?,9/"G M71*\]2Y[^E?4QJ*=3\EWM;

O+/"#8O1SWK[Y;YEN%'_73 C&&B^P*V6]&W-9K MDO=';U:NRB?O4@]&&@%&7[']%*UG=$C]JT^8::Z=@^?>>V &7KW]7'FHQ3KZ M">X^] .+L$@!U94'&%FB3.)ZT22"-

X*T[3++KSV&WQI13Q2/UDQ;^T5BMX1 M\KY\QLC^\O.CX[H/'&%TA3FE&$%)25I,*1E&[$:3C3<"H#X%@>0:T9&9KYZO MQ8_P72,0#$]"UGA*:,,B##-B^Y4JZERYFUMJ7??6F[AW5[L

<<^E\2(&%)Y M=S2B^RTWQ7N5FD"_^K[#CMENE4/WL:H1=,%A/9EQ6.K45)M!) Y+MDF\%=F M4>YI:>VZ8<%L=8W_N Q6_GM!U)(,,^*4!<;!!U8WL8%#X*%0:U$W8 T4*EKB

MVH:,'W>8[\"P76'%)8VIIAF(R5T^4&!6.\O+ Y9YLU6OL-HJ1@ O+75,>$[L M1="=(@D>K8\'J%_#",#A3!3?*,%0(\ 0]\26050_RPC@^,%Q54_0E< 3=/MQ MLP\N#);#55H<8<2I9\4Z,

MT8[%BX PWPF,7P#!f F/'-VE=$ =$8(W!? MO+!/5K ,B!1*PW-8$PR!,U-AIA% YKH15|-S9 2G-%'_@_EU]8ALR,(5,&GA M((.VOD+KG>>[_A;S7'&JHWRX$<0F\--(P@+D,_2?46J>)

&5$+16+5O!&6/$ M.>0MBG4&6Y83LM"7F1_\OP(?7SU(DPC>"_6.,/+151Q;W=;R8A3$YK;OB%! M8(UX0!>)74W">L5*]75449L_I[DU@(2[9F*:?U\0Q9_K!& I+P)*UPW?OP:

M;6+W&.Y [9+SRQIY5N#XWIWP@-8D*YPK>,K?8TOA!-']J1Z1$ZOKNOHEBL0N0[,. M(@>_|'46G0:3C#A_:DGK;S'L#$^EZ0%>6ZZ+I*LC*\&5#.0>?

<UG:N$9HK'Z6=KE=AN0AGV/UH>SC_>LG^0+BB*7/JLDZ[!"U%0G&G%67S'1 MP!.R]*B;-ZEE+BYY)9U@!$@->$.1)23I.EBQ8P[&CJRG;GDCT%5\<96"H&NF

MZ+^]2=!ND@'W]RS*?\:XQW!RR'4-?(-;YR9=\7?X01F&]@]RFINT3.%A?KJK2@$2A);$Z@_5&] M@YF7^1T,A*:_-(9?8UE\O<3#C0#GWB.YL6'(#S 4&S:4)FIG(VD,%^NBQN_D

MW$%&GS$YKTZY4]>N^]A'(&<+#F04<^!>A@.1B(0W8O7NKW9^%]>O7K',!SO M_#C(%/XZ;WR+-8R@%ZYG0]D%@8@0(D/B8RW]C*ZM(#CBO8KK$$AG&_%4FFQ/ME+

<;_UV@!)=':&;%YB&/_,$E%;R%?2>4[49NN8@3PDF',AK$?^CFC(.N%7)/$ M^<5BMSF160TF&W%R61!RU[B%W$#*)R\>R$=K4BL#_BE79+3>OJ=O-T8NU-9EO!,#Y?

D\D$Q6?!.F&?,S_(@!_M5Y]M!++#5JC]"!WM.F!?0<(N5'#$%U+5 VSACKOG5]^UWQW7YX#;=0[LYZAD> M$%WZ9_]O/1IQ/O2\@-2F)10L.%+4M]X\3GZU?F+SR-

Y>9/(_Y@T"5%HS3 M#T"A5&-5JR^92OQ2G:(]/N?'7)-V.2N>'"'CW<06;P+)[9//W!B^O>Q$U62E3J MZG4K+6<$.O*Z^XT?OT:,V&6R0>;,YD&N-M.(()52.J2"GEYBYVW:--3TBU

MRTK;A8P@Y-H.V10ZKME&;.H18!;SS6O^& C&&@%(&C&<2S,/TW_\U<&O8+#> M29HZ-UK_")";=*#,%|/[*%$4UM+/KJ EB'F,U0XTX3RX%IB'N MXF 7E7E& ,C*#]}6-

R"IH)77<{M<+01P ARA6IJ_=?\,@*X5/.0N-M(RUO6 M9A >@&=;>]"4UC <3"EEW]'''VQ,@:#K7/B_R*NL-ML(8*45|90[(C9?O0C@~M\Y$H^(P:I6>ISC4'T%QA)5X

O]61,A\2*:]2G4EM$?V' <<=**HIFCM/8:N. M;LN900D2=WS+ZI>5N=]-F32A#K^SF/N$3SY6,-W_ZQRN?;MBT12/- 0(4L<9

MO(5OZ,:*+$[M_JQ^F_A;_N(LO]ET$!25YIEVIWB5C;._V!$AJGUJ52SLT;C M2\)^:WMQ=5G5'.0LWU>N.(UMWF4VCM8"-]7K?65W%),R@L?=>/-\(@*79 MD-\|&V@POES2OOV

S!!Q#<96"QF!@Q*]PD^4)#S5%8P FA.C'(@O0+G:MY M"]/UO^2/@5H$^-#26N."*UT>A*/-/MR(SQ+' MHLGJS2KS# $PM2V!:2T)JRR4YI*&FZK.UD^4^[3 O0-

,O,D,L_VX$Z0GC>1]D07GUIXP]B5^#1W; ML8)CKO2SD*V+!AL!2I67L98TDNJ6M9., *V!VIDF3'',*3TL9P0Z9&')1H0;

M4[$!7_P=BD/U%,O;&49@/]^&CG1P3L+=>:;KXPI_6*23*DPS KS6*>[%IL:7<;3S M SA)[BO0]T>,0)U_.66N"\@\XPZY0AL_0&D_6H$FW,?21["I03D%8;M"!0&[MX^+Z]8]O* +S5?

@U0/CM"58[R_OR\Z/CNN)XC?HIVC,%$P,P/[^Y*/^$\CG MC%;<>75)IKP)1MR_!E8UX:/5C]&N;GG]%" -JLW)Q*4J.G:%,MHNI!\%R\T& M)+L#5F7 M_C=<]9~=2 V05!!>6:[K8YZ6_)-

_A0 # MJ5]F^EI&(**/EB!"Z:VWQ?6SS4?K2"U!Z$XE6D@^O%H3Y35/&.U/G"@D!G\ M@$^C^ ^YD93*]U[,1#RX_5CO0'X'4\OM9H,$W1E'W8$12/^*/*PLN5"BR=XI MG&:@

@N3\I(B%]J8E&@.AT>A8#B-)"M5POEW"T$H7+&EV+69U]?TIZ4=0U90IAI\R)4\|\9<?8T56\N!Y$.0):CT MJN@E'^I,^BF!DZK)Z=B9-O6L4$C#^?H!YFNY')/SJ^!93FKQLR?

Y=^1L=^ W M>\/W?8N84>@)R[?5^S3FQXVXI!71OR3PR!NAJ|\\V EA.@LR#+,Y"-MX(@+^@& MX9 :C_&_;*Y{[*Y8OVDR7S}GP-3TC*6Q+Y^O?OZ2NY^/ONUL'"R%N=:VZLRI

MGV/$2>8JJ.6K>_.NR@)<\/\%7 .!H]N$;_M=H]PHRF[<\7(A%Q)/6$?ET8+&_%RFWJG\K$;/BL:@12!CI9V!>VDZ4E6T7_W M.>'_;7'4B&5XX9,-0^87?[:X'*M@OL1\-VS4?":$,

(>22#C5LAKF:H$60L M"L?-O<#?P=,.2Q.?]ZI-VFU\%51S;KV8$,M+8:W&<46&$&9M.37Y]K2X48]@:.M+&08"QC6IWP9-/ S4A4YM2"$[7H'!M?^"%4CCF%G:=Z:D[GZ2B;Y\=9/>RS(%

M=;BO&H%XM+'FTD0C0$RRHK_Y$;?5P>41FAEBTZSB, M,!!B9+& %V'F)*#;W5449L MOJ/765P5K)>%!2N.#0P?SRC$5+D&\4-Q)OZQ*(IV$C: MV+9>S0AD)%90L4ND,,"

(+8,3S0IWRP#>]N0A.8&6A'HN-U6!GIMKV'HQ(U!1 MK5<%)C^Q?U(VW@B $>><6>P~'P'P/J4[- M(;Y^5S;BK/G>?<76|+43C0 Q5Q1>)1T:,N&N 0_$HF=XI MG&'W!5.JD.0A9IJ;L

J=BAH@&LYX\9@4J]\'6EB4; MV*>)O%'4S2@?-@+%?&N"O/]>W1PC *OW9!GDB2(/3S[631H7)QIH!-XS\;AI M=BV#W!QXRS!9)17$Z2Q+0V7'T"Y"7/O048(#4,5'[5LM.M3

>]W@=TN'&4%@ M?3XV6=!V[K=\ff]NA7[O;#>CGLVD+X)R 6VVB6S/4",HAY_&,(H>6ELP|_R#3 MD?!@262M\F0C0,W5L09!8{G)^>W$DDK]+&/(T=KB[2W?/12$.VC^12,=$%2

M*T7_ECQ\K1?1#_K20RMGCQ+W(S7TDLT2\D!GR(%)%VCX6?,#7-H00 *.TBM_7+Z7S96AW"Y^?(Y^3^X#" &IZ9NHE"\$>?+R:A,5 &)K:AVDO9G^@%M+9>;

MP,NE:SD_ZR>MVS!R\A"^]JOU3RNP_C3W\0HC|(SV_IOE[:SUV\B'960MG$[1X%6TCF"?SW: >^ M8,L[EMF*9*@9)BQOA(fE+2Z$BEZ?N]%^"!#9RUT3HWQ72,0S'D8\TK\;SI-

M]*0E8]0%P=]MI/VR7.*CLXE-MN3CJ(QHQ'F)$OK2BHV\HZF=I%^<()QTY[LV-M"K RY("M=_."HLBE)5,$\JK2+/W"_;OEQ59P7+W]QT6>/!+N7K'^SO>^7&@ M6IBRQ1KZ 4_JB+-

BC\L@*_>8F@?YG4!:3#SJ&/T;3U@ J4\;O[K.NB;3O6:\]J>T"[IWCBOH[EK^ M7?!)< HD<$F_K 15Q?BRZQ7GU:RR1\9@>',!C-_%L_?P#:KF8$,EB'6$RU M6'W!5.JD.0A9IJ;L

6RT@'Y"?T9;)P0US:YY7T0#]8,@%98;/)W*"QA!J!DQ M+3?%]@XDSYB$>5A(K-R_M&(<&0JSCM6N%(8:%9L:(W4>UDXP C;AB"WF*0H=M8901FR\F^(G<+-511FR>

M,:6PL),:ND?,AXJ3F9LE__Z]VT[V$NG A:0Z.D,2.4S?!B#.4=@.J[\72 M!"- 2D7N)(22>Z4]@XS8>CY6-5%<.\"V#HE. 2EOCK=V#N!5^88^(BR?N6_H MT?>B'1?,3@L:@9* 5

fR$O@S.,$,_M62]IRW69Z,2W916&F++M'7)=]7LX/T+_ZT/DEY6?!ERDA7?$EKCZ*?K!(OF/-MH'I0!^G2(QF?*W$"]?

HL(ZXWD9]7F\2#L:1!TH5F!NF/8?)KR"T_TFHA>2G5<6CK6'!MZLA?0*1]# _@Y(}#9IY&K,-8GC;2@ZSLS_0]M M9:O=@!$HSQ)P[CT;,1S/B= #)$V5M]\DEZ?14OH?3CAB+

(2ZCA7Y#KXWG%Z] ME>ZI*W^U0Y!&Y[N.#8;W*\N%NB]8,$<2L7>X3YE!3?%KB/X[AE*);^ VQA^3 MI&"*!NNGB 9UODAR1MJ7+K/95(Z^AS6-.&/JBC-D@PW IQ&1BA2 M

W<7(${'UG#8K&8$$432JE-_73M)_CX71>RH.YR:3C3C%U#]Q[V$A,'R PK4_ MBCT.7@^ QOE2JI?'1,=G#.Z)C&HV\)&H"B7/MTI[&NAZ4E?:M7S$">4ID("8"L6#3R\+:+1NI

,&7'U]73N0*"Q2PWXTX4Q;OLO(3W8QH74^\ M;\|=K01$>$Z,91FE@>$B^3K1&.-*1/=9L<5O8?)#IHP3]/ M\&H0,37,H_G:,>D^R5PG9+U^\,D/0A9IJ;L

[{(U28$ZGA8PX?U8C/2D# M 5U2J5\]1\0*)=85IAL!+K3'@^JE2R\IE!<7KQO^,/|_H"%7?+LIJQ@RX^Z M:+J&?E+ODY4EY_N;M:[T)1OZ6T90T!:T2O:]RZA=N%B#Z6: *RIS({?9*4PS

M CQ.YC-Q@1!GMPJXXP B064)#8 D4E&SG#]#.]7WWH$>:MT{27&P R?/%=;LFQ#LN9AXYB6]DP 5(^Q0BP!+PR]3ZVXK2](.-Q,+ M/)M#N&IE0[JNJ5_<)UKA[TZTN_*A-.;F&6TEQ?RDHXTXY7PL,+TR*1YM!#!U M^66R<48 @.^%S^P/5'&7M)D1#C8"E)IZ'*;5T,ABM,0NFOKX+OE<(P!E_HTL M7DKF!1? THS>94#WGM5C8#8A*_6N)?U/VO2T M[_(Y(!#90%/ZBCS\)]`]+^V]XSD@3$!,FH2Y]K>Z=NM#/O6%")N<###G9."-. M&ZM0{U[$/2=*0PP8\NBJUD;,58WR0C0>*%=]QZF&,LM1O? 7>< DDXT M<^X M'5;]6C]HC%BNC/5(Y\;"1H6Y<1PZ4AULA6@IAZX-&8=D[N?]:V1, 25>48 M*&BG<@/ITLA6"OYHN(018.<%(Q+LQ++%A:8NWP\&=%9 2*ZM.'!_,+<'M3 M-UB,\9TU6.;!IC[;"& S88'F_5>WB<_FR@J=M? T&RZAWWB%7]YM8.V? K3& M/SEKR[WVH0H_V3-L6&#&4IQGQ+D6XS=*'(569&8_@@6{JSHU7<,(P'L-,!XE M^\.@= (]2E$S>SDGT.N9@R$S2X=6QV&->KB36Q5F-]GDCT-U N\9,YV Y0$ D M68C2C"3SHJ>EC4 3X3!@R+K?'P'+_3=0W2&&X$>!T++\CO4%]K6T$HCBI#}(T M,]EX(P#+.2Z69 M9@'YB!E13-M/9E2!W2*$GWKI#F!\@5>X/0VZ-DK1#-.@/8P/$##6C<.RW?%M!S[fS%U#FMZ@]55HI!)"LEF"28:*6 MTUH[R0C0BKJ;Q./#'6@$")RW3?0Z"(8: 0:G- ENQ,%NE4EMN9%YRS^1Y/(.O MWHB"C<;ZOAD(YU77%$&.<+!^,U5B4*"2NJ#'%P=['BY^1Y26T/%;M5N&?W@ M_[-/I-.XTN_Z-]Q Y28H? D:10\6\Y:OK;&DP<_7=Z7OM.]+ ^UP\9GK#^IX_< M+ ^2' WZV(2\'EH#?DZU5D(;_'QZHZ1O,"-8!82UT'?YQ[>]_@$:5G_\T^"T9!9>B[L)&?APO+L"T1"02\<;^,'^V(9 :@0]+__4-]2'PJ' MBS4>TI/O#QQB\(MT0*H$^REM[0*TH3"%&"A"!2%;_W'KO_U@(P>@^ G^< %_M^,-':/_$+AZ[;^AH*R6$FS2P-;B[SP*6!3-)KV&D'!:A?2%S_^#SIR-L-?*PP\-V34K8%3*3CX2? QF1)SQ M.7(OCM>^+7YNY+-&!6!E?3"(K4:U2!,-'LH4M:650VS!NK8\[/?^(_+8.6_M>W5;S8W4L5%"C\N)-)Y:S$1"X;KV/*3CX5]|_]*1K_DUG$'CR55P?<#9 DV M6/AYI"U;]!'[M/.],6^M#!EI:Z*RKKFM58:.M#7\$H)R_'+@<)G0)=ASML7)V1:@Q4B T8>;!E8&EPT=^X;$<:1'+ O;2K)(-A?.T M/+BI54F&Y(E.V:M0-5C98'#7]!F_W*- AB@OL:^._1KM3EL+)1_NAQ M,H4)=|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{1HNS_?]+(IUB4- 649_0&%@2ZT8,KK(&D M,M,@L"")\(ML9?2-#+)@\Q+X11G&FF7,.'1<]+'1T.FL TB2V*DMQ@,N28BIZ*8%8Q1BIK0O.BI84)(F0ZG3EIR_4C55P?<#9 DV M6/AYI"U;]!'[M/.],6^M#!EI:Z*RKKFM58:.M#7\$H)R_'+@<)G0)=ASML7)V1:@Q4B T8>;!E8&EPT=^X;$<:1'+ O;2K)(-A?.T M/+BI54F&Y(E.V:M0-5C98'#7]!F_W*- AB@OL:^._1KM3EL+)1_NAQ M,H4)=|?;++)G&VGS?<]6*3/5AP=R_6.R>K(Y&EG7--<\6$ M\)X]#.JK!__[#W_ZY8^?_[X@.L6C_K?_CQ#XLXQ#OR#S0$#7Y+$@H>*%:$ M>R4;&(CDT!)V2"78.3GSS/$2,Q#Q98:H$%L=&59^C'0]9.AI:?9H^6 MG"F5(>5)L#+RR3[+B]8TQ4K,4,*7^>,5)/%T8+6DK_,&-55.SC#RE]GB)6] MR9UA8[V":XV5/T'0G^239)B9K^@JBUY6!E"YBNYECRZ#"'S%5@%'F2&F#E* MK#Q/-S:DB=KY6IGY:BU9]MWH M"3L;*WPEJ$PR_&C0 W*CD/U+%OW J<),2]"LL/3UX'M;J&H$G0]SK9GY>3X= M%NHER*,-TO4P&R+ ACKYVD#]9J+K7Y>Y0G:@&C1)M_%)*$_72%SJ)8,K9*8P M5=_,))9+A-S]" [+$6G1)OJ&FBHUPJJ9FDC[PDW7+*Y,0;.I@"[_J 2^A/$>? M1)5IV%+AJ3Q.VX99,7E:L;169Q;.(U P:\@O<<=57-VD:/F.BP MH-Z'L>RRD;V9E;$FD+,RA6K'M]36/OXC1@.P[OES<(AQ(7%N?$%2>A,KW$S M$7XCT(;!P45BBI1AK9'W?Q;XDP8*R N=*[CEAT#:&PI>?1/1IG95Y4[S&5&9 M]&;RZ7 6V*GW*A?)B>-(GP6>FOKB"VW+). $+)+#7MC5P^>K. EG]R&C\"(0$ M@5_F@D %V:(NXF$6*%.6Q/@A%3/"41L-J1+ ,02^C!54ZQD\#2>S(*EF8D0U ME&862.I)\E)^2V>!U+82F?IAS *_-!2X? 7D!G$.@2=I2=5))5\1F>%([7IUSQ(=187LMECH!+X.@NT M=7E1%13WV2"O2R")%Z9=1N9"QH5G@E!9/0L,*7\'EBK%8.\(96HWL?)D3ALU-M7;GJ0&@R35?OR74@"&^2 &PJ1"/D0^M92X.YX$V\Z7>,Z1\$IZ9Q/763=X>< M@!EALH&06\THF 6>6M_B,CG]>=+,KN"%U("S907'J:Z_KOP&ON_,#&CU^C3>Q60P0$@"A. MUG\BAA64P__T<<$>!K)C^!? &1?!#\(;"""#P!"BRHR4Q##B[B!VT9$ 3,)'+Q M"06DW+;@*!0G&P(<+1Q^&4<[+,.\$)E*0%4F&07,?1C&C0!))A@%A+C+N>HL M$XKF-;PZ*C-- $OQTLAFF .&]+]{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{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{1HNS_?]+(IUB4- 649_0&%@2ZT8,KK(&D M,M,@L"")\(ML9?2-#+)@\Q+X11G&FF7,.'1<]+'1T.FL TB2V*DMQ@,N28BIZ*8%8Q1BIK0O.BI84)(F0ZG3EIR_4C55P?<#9 DV M6/AYI"U;]!'[M/.],6^M#!EI:Z*RKKFM58:.M#7\$H)R_'+@<)G0)=ASML7)V1:@Q4B T8>;!E8&EPT=^X;$<:1'+ O;2K)(-A?.T M/+BI54F&Y(E.V:M0-5C98'#7]!F_W*- AB@OL:^._1KM3EL+)1_NAQ M,H4)=|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{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{1HNS_?]+(IUB4- 649_0&%@2ZT8,KK(&D M,M,@L"")\(ML9?2-#+)@\Q+X11G&FF7,.'1<]+'1T.FL TB2V*DMQ@,N28BIZ*8%8Q1BIK0O.BI84)(F0ZG3EIR_4C55P?<#9 DV M6/AYI"U;]!'[M/.],6^M#!EI:Z*RKKFM58:.M#7\$H)R_'+@<)G0)=ASML7)V1:@Q4B T8>;!E8&EPT=^X;$<:1'+ O;2K)(-A?.T M/+BI54F&Y(E.V:M0-5C98'#7]!F_W*- AB@OL:^._1KM3EL+)1_NAQ M,H4)=|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{1HNS_?]+(IUB4- 649_0&%@2ZT8,KK(&D M,M,@L"")\(ML9?2-#+)@\Q+X11G&FF7,.'1<]+'1T.FL TB2V*DMQ@,N28BIZ*8%8Q1BIK0O.BI84)(F0ZG3EIR_4C55P?<#9 DV M6/AYI"U;]!'[M/.],6^M#!EI:Z*RKKFM58:.M#7\$H)R_'+@<)G0)=ASML7)V1:@Q4B T8>;!E8&EPT=^X;$<:1'+ O;2K)(-A?.T M/+BI54F&Y(E.V:M0-5C98'#7]!F_W*- AB@OL:^._1KM3EL+)1_NAQ M,H4)=|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{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{1HNS_?]+(IUB4- 649_0&%@2ZT8,KK(&D M,M,@L"")\(ML9?2-#+)@\Q+X11G&FF7,.'1<]+'1T.FL TB2V*DMQ@,N28BIZ*8%8Q1BIK0O.BI84)(F0ZG3EIR_4C55P?<#9 DV M6/AYI"U;]!'[M/.],6^M#!EI:Z*RKKFM58:.M#7\$H)R_'+@<)G0)=ASML7)V1:@Q4B T8>;!E8&EPT=^X;$<:1'+ O;2K)(-A?.T M/+BI54F&Y(E.V:M0-5C98'#7]!F_W*- AB@OL:^._1KM3EL+)1_NAQ M,H4)=|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{1HNS_?]+(IUB4- 649_0&%@2ZT8,KK(&D M,M,@L"")\(ML9?2-#+)@\Q+X11G&FF7,.'1<]+'1T.FL TB2V*DMQ@,N28BIZ*8%8Q1BIK0O.BI84)(F0ZG3EIR_4C55P?<#9 DV M6/AYI"U;]!'[M/.],6^M#!EI:Z*RKKFM58:.M#7\$H)R_'+@<)G0)=ASML7)V1:@Q4B T8>;!E8&EPT=^X;$<:1'+ O;2K)(-A?.T M/+BI54F&Y(E.V:M0-5C98'#7]!F_W*- AB@OL:^._1KM3EL+)1_NAQ M,H4)=|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{1HNS_?]+(IUB4- 649_0&%@2ZT8,KK(&D M,M,@L"")\(ML9?2-#+)@\Q+X11G&FF7,.'1<]+'1T.FL TB2V*DMQ@,N28BIZ*8%8Q1BIK0O.BI84)(F0ZG3EIR_4C55P?<#9 DV M2]'LL/3UX'M;J&H$G0]SK9GY>3X= M%NHER*,-TO4P&R+ ACKYVD#]9J+K7Y>Y0G:@&C1)M_%)*$_72%SJ)8,K9*8P M5=_,))9+A-S]" [+$6G1)OJ&FBHUPJJ9FDC[PDW7+*Y,0;.I@"[_J 2^A/$>? M1)5IV%+AJ3Q.VX99,7E:L;169Q;.(U P:\@O<<=57-VD:/F.BP MH-Z'L>RRD;V9E;$FD+,RA6K'M]36/OXC1@.P[OES<(AQ(7%N?$%2>A,KW$S M$7XCT(;!P45BBI1AK9'W?Q;XDP8*R N=*[CEAT

*V7"IED3[E1>Z$(XWEQN+.."3=?O@5#X0*B_1DQ@;B8OQ@*?*EG-M7LQ7\ZM;?%7:8]ZO5!5'#_6IDR6DVX^#$Y Y*50#$1+O2R>+-LP+-\B!YWMH-MM/&^I*

*]MP$%!8$'V30QV2KHA*M'DV"L^;"P,..%8L&Z^T.G2"@;A/3_RYMY[M%88[=-:RL.Q1/FV&-9ZO68!)O;G5D@%OZC3>CQ&07QR_!^E,'?F&,A@A6YEV?,2@;*7XMDX]$(+K*

*M!6E$HZULQRRFX8|GCJ'$,?]Q6P\123(OYM#'J4X]P7Z8MW) 1\40.?GF78O3 M.A6!IV.(E/W3.ZH.[EKNX55]*0S/_;/IX?I<<5ZF8.G.9&?^SR/-Q2\^E,^ MD6%=3,F1_/E\14;_(ES757(>?SF?O^CGP?6))>QU_-Y-#^/%LZV!-V_G%(\ M+0O)Q=-"]K#E3>D#C29%4@1-AKE_XSV/#01S?0"S&A]WW-5G>]TTD.RNX624Q+4= M@6ZZ^6FK#817X!:^':?W]+FI;_W.!EB-*

*<:*R/FSEM^2P&[9C'.8MPEAWOT0 M9H7GMPF;;/ 5?=D,=(_(YH.0\%%1FH/:9-/NMS0073Y&RC/^_V" .=+S[Z! MQ&;__+M+,"R-9%69]0VLK\C#0H&+]W9I[QW/*

*>X!LH(*8&IS#1$^AWRD_*H M]$F;NK=]R%"'7L]MZ@\\9.HA.8W)6E'X&@)O(L(VS?KTY3.$R3@1%10\3%->Y'A;Y*T= M9%[Q\S"(P3N7]XF)!W:=QH7F*1WOHLH[.G% MZT?.9O."*

(HQ!@G%Q21&UB=KT&AG5I 168X%IMH8V4;`\,"QL3F9 %_SN=_,- MK@"'V"<89-Z&ZZQ3D@F&_%DDO[UI'VVV\-&C1^O#V\<=[UD$P MXRZTT2V+RG/+-28+M?K

*+]+E=ZR*D13M\>18^$4I(JC)6AK=Z-Q-UBG4M=/,K*[R#;V3GX1UGM0F M&W%.T] -SL">K0/(EH=981Q>NH>==M2),\?C@KL4&2OD$(U_JOJ62"+@&""^B[M%/%KZ-B.%1Q?*

*+)+0"70N@4D\7A\(V48@&6NYR>%:7DBS?N) 5^.>9.L1N1$+ MED2 K+|>XDG#%.]<;I9Q%$:69V-V1QD=;WN2T7WO*_"Q&(FE]\N#)4879Y2^ MD$'H3G"Y_N_8"4EZ)9:%|>U!-*V&4!N5:$5!@ZK3S=_-5*4_?M10(P%KZG8/-M5>%+..:$E)]_,"7<":W:-B#0(G#*E)-L40GRI^IXZQ6C&I32)O3QUJ3M[16_IU%\2^%%Y0GBT_=]MT;3Y.\)E/'81O! M5EV+&M.1,*

5"K#^-67;&^_-C Q\^.RIJM4GT$L*W!A$X,E"X#IR#BO6^:,I8V M2\KR0.Z)M2M5!8\T>CP(P1/UQ9+I/L_3"G803$LK%,REMDG)A)ZM.LO:!G(& M#M8:T1IPSMK'KSO&(.VE*;*S*

(4OC;24SC(:B75>,%PO`7^WI(@ MTY*@3ZW(P3F7Y_1<[N+[].QL=UC,_!|2:L9*;UIY3M^.*Q@&L/4K'PKP8#ES M*TiRD4^85]+\F"]5 4?IM$HSU-M8K)K@W+> M,H8 +"\IPQ_;_*

*[6P2%?!5^N?F+'[>N) M4">=1Y!YK4J;&HO55,RI^R$45-)"[+10|9L^HG@Z8Q$W$E1.'3WG"B9=V90(M53*6-G4\G4ZE%Y.PUEEJJ.C^LW P-Y =:BP14_>7-A0:5&K:3197IU35QR2|*

MM6!B(<:G633"-L/'!":Pf;>LK:I-U- #BU?&7m1.8T.@:.1 M4QG7)CN+CF=,5DNP|HK&ZI31E! M)S?/%)U S>_,3H2:0BHY?/MDKRJCH-*

WUS6Y(H\+C M$-:U:>)L(_:=*$URJ36"6%B>;97T]HO%'L>:MJGQ;^Z@(_^VV/?GKT52=U M]]IU?(*$E)?HQVPY;IQ%^R?X_Q"S<'_3&Y>-7=.\|>GB?4-U7*

MU$5(,KCGB/[?'/1^\!TO>L0(7\PSEN?+&SEJ4QW>40M:ZPB':L6SK"=2=?!?2:=5%)*G3JS]^_2(40BR_LV0DXIJ8#$3FZG-Y.?5 M'?PDB>(3NK.8N77I=H: ^R=!TJD3>JO0N\F@J

O_4Y2<$4P!/@'J.Q" 1*'!+>X8:\(7G)V8F{$ M0CCVT:,4U+"ICB1 M6IKE/;+@]>G\-/92%/! MGG6-QS+>LVNI2B 9S+FF7EF'M(T4@=)&)WN2SH!O GMAGG(BHK"(C/#1EA M[D%J

*I0TT*1V$6GM=*LT_>PU.5P)TM^7BX]"?W,/=!S-PGL&WXM(41\ %|&H M?!$9U@-_$C1A7T2F|0#8B.;QZ1*J|0"I;XQ7$O5I,4+CK?]2_T/M2MYOA3I6 M*?SHC^WP1P/B'BT-*

RS;\+&.&H7E+5)<8/9XM>E174U.!_P8<9$+0KP>(S"M';E&!7-F-C51(!EC>YZU=6)QB R_NP4F-$8I<@J9EOTFR_"W.&I8I2PX^YN8&/M#'I")?%U?ENO&6!^$)7:$)R?-$ +V6Q2*E?*

@@66_+DX&H@/O0A%ZP2>-;8=4' J!HX9RJ*%LVI'CAO,B,4+ M+,F0"UN4,9-$F_&\3X7.02N/,%IP27Q4A:)RB<@JK0AVL8"JQX>>%D UMN;+/%#*

M5);+_=_,3WPTW^3FU/@OEIMU\##:I"#"_!B.6%IK[=._C0YO?HBIBE>HGME% M^T(:R/,.53S-9>-3O5B3,]@X/7V__C/),RSP$*F\%6;'X$D4&,VGQQ:38CG9^ MOZ4\E0#\]_\0_DEW++T

% COB+/"?Z%;V7I(WR&)H/OJYG0;.$("%)O>:P;K MDS.VV=#0)\>D?CEC2Z;PAR2*4X2.^-28SC$_Q7>]J8&QV7NJ[1_R+4RO2) MUST4;(M?

*Q;G+F,&U@].XL5$ZH._ALHY0A{J=,,,E%:N*Z5[%7+DQ<)AC|!>TP M-;89[Q]4ZES>PLE]3.)6JR"((/N 24>[>+=P'/WV,D@0DWZ":!46![0"^S1]* M;ZQ3/=,O@!GJU&ZHO=Y+/1W*I D-*

-59[>0=AAKQYIW%T!\N1$^'WF9)&AUZ M-\; COK?KL@?Z45D35D%[.499IBQ*GC3+$/5:N<>522B#[=2>_.#?2D(LA1Q M#JD)Z;N5KNPP6!]>RC.U<).JR#:159(:N.*

_0%NN:+NODLX=1XYUF7=E=UC%_MW-&2(?E(XAQSCY^5<,N/LL]<1'4411)\8X/F'I8[ECRE6,@NHOB!.;0-*Y= M1/V,I9B-L^)=1)6-H5"2](((745=C*% D6^1%U-*

88"I2(_?,B2FX,|8YH8[W@ MDAH_/^&XKRH)Y2.2^=<%3"OL A:DHB5U3H]+5-@2%6,/O1XDU5188L+?XD? M4Q8_1IDK@+3+6Q_R A]XW)X:$D28KN/<_%?2M(=<.H7X%--HN7S?*

U00)5K!V\-MUD47-&1$[0=$8-[7YS.;T-$U,4EOKC$#4!0IS7RDL!=7.2+;|&.&Z3ODKEX MC^$XD?-"TH#/\7&0U+LX"4=?R]>*/%]&YK+*L&@^X_W:PVO8=1;[YF++??.R; MEVC?*

*7/*W%JNF:5FQG-.54>C9>6'ST6D6]]AB%;,@A/22<%T,8HM!S(|+8S&(MG1E!JQ8NXTT-SS$(_.\D.-3:6S ^*'X67<)H%H,#(N!X;(-# UX45[7+O3_ M*

*MZ#|\^^O_5QA'V2=@#K/>|4V;>/8XP"\6R?9PQ^0!/GN!*CRH_B>RORH=C 7 M@X3]M)R_;&WK((^)Z%HVJ?G!RP42XZ.|OAOEL+V.R3OY+L-5T3+K._CF.*

MH&29GIX#!RXZYYG'_)UFY5#3OZT^IG'TI%_|W3Y=;|\E@$B2ZK\W"D|(@/I# MN/.KQOA<;?9.^#F*O +|_""8@/_X<9@$U7M:7:2;C&T">,G?G06DDV%X)F@3*

ML,/BNFS^X+I1!D7NXDDBV O^)8LJYYACI€0+LKQUCCX>@%. M9O@;]S M\H"O"?0MXH<-)MMB_R%!Q%$0P"8O($!1-QOGNVKR9'W:?,3^=%P252G_W"P. M.'T;-GX3>!MHVCG.*

NJ[PG8/3U7CQPGPI7QX%|!.B>3LX-7V)7]%9/@HL7]-M/H1ND'E^N&M')CQ49LX_0_ .|(__<)FH,)R'5;O27M<('*T8!9"NM_-U+L-02 M++851KH)4=]=2?*

*7>)I%HBJ4R^61KL88FD4L@"]*K2HF(^!.+S=A M*Q+F.7JJ#.$6;ZOOX1>JIJ,R_I M&4ZNI2J6-J8Q1_=1?' @W1RS? +Kl2C2KP=7N%, 'XB-X)#APGPD! 2!;Z'+!\W3H!>@'O= ^3W;)?-*

*U%;@ MHIQOJY[OE]#H-]3&ZZJY,&MFM!MIFVSQXNQK&KG_9B;9$QKJ0QC$4.VX>2Y/ M*IX4,>U>I(=^0FEBRZA'0F]O(_G\#^1^3A9HE+6:KU[>I=E;NLV"TB/2?*B0 MN"#!SI+3E*

*HZAGS['<0IO3^:_EJ$R/@R8"7-7OKX<'0X M1.&8HR/2TX1E'1X:5]K36YDR??U'8?30*7' ^^RB :F"2FU>1;@T5*

MN'RBQ\"G&8M$>AJT+&3]JV>6W_D)LNTC5926%C9X&,":XV6:"ZH-7"T6"_] M#V2M!-Y_-2V-L5VK^&,4IE#__11@8?>__I: 7;/,3M?:4&GE?IC^P_,/E;'! MJ;/*

*.K'Q5+6RE2[4T>,81H/12/S00V(+]6TP>*D>%]FO#BWQK[UHNJC>6C1+ MM3(;-1]N%2+.*Z^U.,K.TU2N)A8DQ"R!H%"M5&!0Z6U&8|&'(\=N](@:N*E0X M:%"S8!AXF8R*

*$1OXX.B:K(^,HWA2;-,$(MAP),;(05=A5@&CV6#T=145 M/(QD PBE]L"@=)]M :"E*ZE X1?34!"R1:A XI\&(S$-2_C5> 1&\H/2C%^] MN4ZRO[+2.YRD(G\WS49(DZF&W4P4/HQBC?*

Z0ID__L0KH\X%#;<%>E0 MG."[0,8M$AAYI)05WU^<^]?69+BP[N)4+AXZ/H!. 5;;2)4WN,6V5OB>[X3 MGUX=5",&&WT;,!O"?5$OC@'^$\<1_W%]YQS%

*4@8YS7)3^>!MX,.5PA1$# MZ5PT-[J9&\&L=7_N_=",;/^_6$-I&W1+ ^#HG/_%L]XB>;S,A;X;-JK10C"$^IK&;!Z@#IS(N Q8 ^F+.BMXQR8]LOF&OBDT8 "M1'L/=?E" MX*TW(O0(-*

*T"=LL;9Y[.'5<#==KE)9;VM1 \LUY>YL2?$<-J5M&B<;\1(DM?3 MUSD1Q"'L?BIK8T0(U2B$LT,/8A^+Y%7B*R5GC*:-<._,0:NSWH*I-5$8_'J MY +@)?*

*=Q=/@&V3D)^^^@ICU^T_&'6944G.)P7Y&K(W%))>%A M2- ^[=0$.JF I/(YUQ>NEP9)N\NP=9CYV)-$?&7H7]9:EEO)2DLQME'!Z.0NYHG?+R**?;W!'6?]07A@K@*

MA!%,$QH(P6=GAT6;X]8HRRL+.C*JYQ]\9RC1]L;!O8T/2&ECF<,HC35&H%6/ M0$#@:^-\+_3.&Q""+;4X&;_74J?+IJ(\PW.CFV"(1U:#I\,2JV \QK<]H MX,0JH/$R_U'2R =S1)*

(F!71Y&)B1X4T@7,V/F&O"5@G VZ>F @DR34QH6>= MF0R/S)Z]"-G,@+2BH&,.5JV R.Z0 M86$U)&_/]59WALGISE133'J7%G9^)9CI]JS:XVF313_2P'38Z8K@;Z M>4([4-*

*IGYVM:#M%9\B[S'K8=&,GR+BW>QE*8-(B\0Y)T+455L=Q+2?BU"'SI M,J^DK&/+2Z?+]F2(92A;#MI4$C I!]HRZ.3(P4.H=IZ G2'=4A+3+&L1RO*8V0 HY5)*

*[\24'9LF*OEHGE^$PE%C)*J"B.H'SS'J<^ MB^5XC1)4= G@;\.J5%D.6]_UG5#^R_WR\IZ!0(263 M+ =JNA D2IV2M)T9U8'B%\53@N_\ZUI5?FX4#?#;!UN84 Q(/_S'QT5'*

';#40Y66I2'_E5IK%=5@^0JVE|ENE=R!3GNSEC"6IO1S_I7G^;E(_^SX4!,HG+9,,8+= M1^\3QX7DGM^S5#FBUW#>KY4OCW#]SPO(/6V?G#B$-Q-Y29S&)CS>?9>ABS7/-M]\IQ_4:

*<="5UP%NV_O.VK:K-P#-#XO>IWE_WPTN39)8"<(K63/HVG\HMPT ID\-MJ_3>|>.BW"QA'?*_(AF%[#S$^3^5]OA2-[6M:8<@YSA?P ?^:12[JCN;MCA, M!B/7UNFKX4S5 0"]NWOL 6(-*

:=KFY<1%]30TG$K) YFV:$QU$M;,&$$$BH]-;QK1,$A,/)8DC|SN8N+]?TL:LK M>NM\O;#Y"@]Q$>TVR[-Q-KW;P'1MM?)O^QY(HYJA/@M+FQRGM2W%@Y61#B&>Q'8[A

M5$,*FK&\VJ! S1_5(3]IVHS.<=N@!/87Y))P&S6B:"PO(G,^CU6.Q835,"2Q M%F:DDN55(B2?6 ,(*Q2|87%1A/ M)[K_4X34A_ZI01'8Y2'H1%?2M P4Q 6"1%3 H=QHG GL,S>$B1U-

*;GZ7ZBT_M_O6-D_@)%EX3"$9>W#ST7K/#P8E/4(GT(4_8^B[DL$7Q,T0 4>"I/DC*_]56 MAP0)1^F'\1:C,S#M8HTM2M@EY=1@4M 5?8H/S?4X:2W_;T[%1(_H2_RT[T#++PMP*

*M0<6SU\.LGR+_0_1 RZ,V"76,V"4<>-UT+XC|^"TS!U6DI_[J+03(BXF+U"A M]-:[-[+)4"V_S.Z32OA$_E5\4V#KZ!*N+T+B%I0[^):E+'3P,-9&?:NX|EK"-MGX),PNC0* $Q4?#PM6 48;-*

&XS(L(%V.[1(08]!]"3Q"4>KR\;$D=%T@FD8Q M1QM^Q9@.[*@(BC)QGQC&PB/P..C-6%G^$9=05Q'1I_4NU3>'3#8![M]WT?L_ M/.#G\X3_]<'_^-_'L',"3[!FSH]$?0$4@MM*&)<-*

*I#2;P+\(@(1Q4XC;9-] M!$D" .61@O():.$5C1EI(N+)]8*HB?5^-F]*^I7 QE6%ROX_A-2"^$*D,GX\ M:]7"^24#2XBU)3)VD]>6$WE62>S#1 M;TGMP[QR*B?FU;'P7D++2QT_2*

]0+9U!$!9OYN+-G*$W,WM+P/IF.OH'LDY K%C(;33K:4F!\Q12!^O_DMZ6P&1JN4VSC_&#MI4$C I!]HRZ.3(P4.H=IZ G2'=@9A]L@+L/HR#:087^(73HYX'30_+_O3! MQS'R(>^* N!F@1-*

*OG'@'D/V!.4NA?OH*K18W2DG*1<&&F'H,3[(!GO]/(OP M#_P#B&\C.KZD9J;50Y_)\IP1-3A'GV4;X;[3U4-MKC%.-7 "\Y#Z.#G6Z;R,%*

*MC1J8RNMGPAN=STZ\CK'QPVL6X\M2A%$4G/*WCX@=(-M7FD(8=!fQ_+>@'KT 9OX[R#1T6)%SAU6W].MVVNN#JF>P(;D!6[S&&*X;740 M,67I P;0QWF<9(_^#YVK=R=]MY;K9*

*4IQ MD/SNP-9W_92R.(&;V]6^>WE_WPTN39)8"<(K63/HVG\HMPT ID\-MJ_3>|>.BW"QA'?*_(AF%[#S$^3^5]OA2-[6M:8<@YSA?P ?^:12[JCN;MCA, M!B/7UNFKX4S5 0"]NWOL 6(-*

:=KFY<1%]30TG$K) YFV:$QU$M;,&$$$BH]-;QK1,$A,/)8DC|SN8N+]?TL:LK M>NM\O;#Y"@]Q$>TVR[-Q-KW;P'1MM?)O^QY(HYJA/@M+FQRGM2W%@Y61#B&>Q'8[A

M5$,*FK&\VJ! S1_5(3]IVHS.<=N@!/87Y))P&S6B:"PO(G,^CU6.Q835,"2Q M%F:DDN55(B2?6 ,(*Q2|87%1A/ M)[K_4X34A_ZI01'8Y2'H1%?2M P4Q 6"1%3 H=QHG GL,S>$B1U-

*;GZ7ZBT_M_O6-D_@)%EX3"$9>W#ST7K/#P8E/4(GT(4_8^B[DL$7Q,T0 4>"I/DC*_]56 MAP0)1^F'\1:C,S#M8HTM2M@EY=1@4M 5?8H/S?4X:2W_;T[%1(_H2_RT[T#++PMP*

*M0<6SU\.LGR+_0_1 RZ,V"46

_,3/T_F@8H@E}QQ(E<^:AM3R|T(=[?6 B8J M')}C6 ,)7Y;KQZ.0$A379@0-Q7{($:B,!D H5&2XI-6."„@C: DFK' 1V:!8 M8FP3(ABNX-=B) (BELF0C(@!;TXB'1WHF(R>2Q"0L?_?8.4,.MMQ\.^2Z MY@K=¡*"0A DT=[D54_/4!C\VG*K_AC)5ERQFHUY_\=':5 7%F-@\ '< X"G= M@<3{2-_:.(49_72U^0"G%BS%]1@]MRU@?\1$(=WA>Y:-G)\H2:*TU[@*@/C M. Q.DBV/:VW6Y3.<'15[#JEQ-2F"B2QHD"C%\B3F&(3HYI]2OH$T=R= MOD1QNO\ ">@ ?/ M:,B;5%L8.\9 3AK&D 6S[UN0VT]FEC*4T?O#^0LR|BA+OCE)BN@T>G<"TH(S MJ*NUOE-!%;P5$LE2]W)>(CG5?!M:/VS0M.-M349C*2PP|@^>'81"%8AP?*9RX'"$D_Y4EQ!SU7;.SE8#XCPAD^%,A&+5LOSYB|/0%Q'KF/48"5-+S^1F^6L= MLLF#:,FS_#&-LS%26D9OPK(=0.P)BM1TWY%0/^T 4\I^49M..N%7]%P!$>'N MKY-.JRAN09U8^_?I$:/L:?V;(=RH_]XHDR4UFLOW!!_\)(GB$[J F.[@?CM# MP+QW7$LSL9M;L@"&)%RA(:&3'HT"2N**)OFBCU[\D+G\#Z*G[/8W3L)T@2< MT%N%WDWF!R@?1?2, "HQA"""4]A"F(08)5/VRD\^]G1X5HBSF Y(WJ4'59\RI_ MP G]X 1!;\2@N4"""?0W9F#O3V7>+&0KM1;>/MJ4T%;K;+({I"R"U-*VZ#ZZ3 M-;*X3Z>OQ@#K_)@65@U$-Y2%D%IJC#*\YK2,,?>;F7F(D8DN8&,)HK"-M0D_1#7AV?%H!C-'#61O4Q3%\-.UU1".#I>YV,3&I,M*)60=,QD+8E\HP)96U 06>D6!I,1X% #P01IKK=C"3!ZD=RJMSW;0;G*%@!&KY%OA.>,I;TU7%<$F,*O5M#^#I3>N"T1@(!=G1#0|T:)JD8@D"K.'Z\R"P)*B.R_)X%G'6O38#8I #@5IB MF#QDC"/FL Z0R>M7=S>*V.EFAY-MU3,Y3$RF6M"0+$U>LAQ"&&@@M3SX M:_3)Z)E5+0\%&P $T2AK>937@.4+&G[8-Z.] M&E=2)GU?A7!%5]<_0Z#B'8BOO%RUNDHU)UG=9 G K6/T MOPB]TDF_R%D[N8Q+76@5!] '_B.*';N$^^.ECE"0@^09U+"@M;0=<;?RA]-J& MZYE^H5.U)3S;LW,XS39_AI#*&I'-N,I[32"CZD'4 43X>WV'PB,%N&1Y=H8$ MDFM:G"Q/I1B*QCBC>6)'$-!(AFX+$_=&-H!R5QF>?K>&4 A$CC&"69W4,A81H MNK,WAJB3M?'S$XX@JO(U|F+512HP:-VYNE,XEOBB);Y(Z_073^<2B:0L$HDR M5P)EK/%ED\]_^;$D##29-7W_H# 2IKVT"4KX!&V^5S"#Y(H&B^@Q>;Z(*& MC*C|@ C,F_;<]A%L_AXCELLMIO%=G.IMILEA'^QV)B6.S9):L"B\9NODRT:OQEA M$L9$YBS*_J+LVZGL2PU"LE I>XY!X!^@5AJ?2K4,+QG%'+F+&WU1Q195K&&V M00'$\N|# "W@/'I0G_;V/X _2!-39.:NP;?3"}D+@W3K)'OZ +NQW)T!E9\4= M9C(_JAW,176SGY;SVE0YXRSK\G>;;ZB-;1D_ZQ=_MT_7V:P*()*G>]_@ M.ZBZ, ^',KQKC<[79.^'G*/(^_-KZI)#\'^,8!=1X65^BT&TRM@G@)7|W%I!. MAN&9H$W+ #HOKLOF#ZZ*7"\M*GK 7_$N<@?(65@9. M]5O@[QQ"LF$'S:8;{O}AP011T$ F[R 'GH-\YWU> 3)^K3YB/WIN"2J4OZY M61S0^C9L_%:6/V:\\S[M'&8|!1W(XXK@J6K\. &^E _/ M1ID9P=?/1R=+*_ M8A),W$ ^_J#&6:'YQ+N,D2,F+4J:/ZXRXD)T6S+V!)9E'A=KN0LD\3..8N MK#;4Q/ZY"RL[-8%+ fL*]6*QRM'S+MH6O0J5.U<E'-4IT08.5,*G=>@I M0=5)4N|TT\)DA>B60EX_Y3 >R$|%B#ZEK%#OM5TJ MDWQGH!)0@=::ABK@0[EYKA,@@WWY/*1->(@PHL#WD.QV MXP2HZ/?K'B"=KK^)C=D2=Y&P24ESE[##M=RB!"4$HJ&N?#@E\AJE!{QZFKY_M*87_|_U/PP>T2F^=.#Y!JO[3"9 WM797? !DK<*6>B|-3K{<)OL*O=MF;"WEG':9K>F+I3/;]@{!?BQKUB=.ME%(X$"F+X_ + M@4H!H?4Z2Y=(?S1\E6,X4>N:M6^=C"W%K^T4 I]M.TEG-R_P?HQ]-ZW"UC|J M"T$,GVQ'$FO-+(V]|..M8D=PI7G^?FDGQW? >P@+!U.#W5]S8"ZG)3V"58PL)s·R6<]WX QJ?OA8&LMQ|8LF2>%H9L1HTV!.YC^@K%3N@+*B<5 M N^33$X=P'Y&#/3MDV$EY!W6)]>U9,/>$LN(&NQ? ISX8O5DQ4^'0X!M$)@,+H MS# *F;Y>.HOJL1X[EL*2V?/@MNV=GQRCQ D^QU%VK'P1J((J#5?9I<4^*EV4DX,;?1-E5! MMRMQ"6)]M2U-U!#7616WF[XBL*)+,&G2='Y QUW[J1CDJ28?]P$C;.933 :E M;W)L_SEQRLPN)IP /NGKFZ: +Y\X>7X_C21$<-=3**??4A^?)SKBR9R>U%2? M,,%R])-%"$8/TTX"F^%S.AFRF)YG7& MW3Y;R:OM^*,25*N9=C&" {,]FR@W=$ M

,WQ5D_(/=WQOG_\LZN]APJON79Z6G[AOM_SW-3-M7$G?:[f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fF[)98*Z+;'L=&F-M-J[5)*\R\/D]IVC(RXTP8X#%-SUP8'F9&')+,E\:,EU\$@ND/-M_-AB%+V,DD$BN/;T<.XP@MN&'CB@O..@FWGM$JC51Q_%?*M\|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`1_6R+)KK-M)1D@G%(0M]'3NU):2H6QAG9-S@??:],2>!QS)@;3(YQ=EH-8-+N+.KDGO)PB-M3J.(.#T_[-CT!S!.]NF3MHK"0LME1$Z0,.B>G9SOT1\"DQM<%E0$0Y%"9<-=-ML1.=T6[^.ZHZB;^DH&D!U&-%WMI,*HQ2N%PW%^%J"R:\+/7$-'TLH^*^:RSG=AMV0B(E7.DK9#[>/0C$FDR[QU*O@TUG5\@C-4/-DW'PTB.A3N%3M$/.RP;O:=-MP6*W/KN+538:G;9KM+\?M=:.H$!*;21*[Y"\)N:/YRK_-M&,5+/[?_IW-C0/68_"7]JMG1.MXI,1=GD>J42$-Q#DXU6X,8QO;(.G=+EO6-M,B&FRN"8LO$F,:=6#FDVL1-M8-8K;H:!7-"E-ETPO/0OQ]L7V"%CX5=3508#.Y"ZIA.&23U!UU]?ETQ@?.N$-M^&.Z[YRP%,C-]EB=ZF=O"1X-MKX%A"'F;TAZ3'TMC(]@S_]/6YIL_O&8IFF//OY1"MK,R0XJ:31<+>C!-M:SQ;@/6VG?QE2ZR;(*$]BI+)]BX+$XTS.-M[7;/X,^Q\4R]L.%LM*4)BJ0K*T_E5R[#V<#XY;2M@@A124I\W@JU"6!H"LP7,.-I],0]<^HVA4_"IJ-YG&+CT3A&JC#*IS;ENJAT-M=7RK]Y8P*8?TV\.Q+(JRQ=3L%4K"G6%CQEBLP:5]1^F)/IGU7FK*_EA<_3W=MK2^$0Y!6&FG8>)]56_CUZEAJ!%G(J,+8-FV!__UE-4+,*/F.]89#&B$$Z.YU-M2-\,".E.I"E*\TV1;9A*A=LYTM^@:5@5^&<(-^ZF5'-/@%2;,9ZS*$C69Q\+0-M=V&.X+5_E")NF$U:9-8<<#&FEYT)P-ME,*\A.#H?M5!T8E.SA[>]T&K@(:A[MAXWR\V@:^I_*"B5;ULN1MC7U>]QV0<.V(7<9G$'(_G?376/37\V\-?XTT-MGWAU2P:,[CKL-+8[G-W6=-3/!.V-RIM)L9%OHS$L5TNG\THKP-.^*)71JIW]B-M(>UX(=ODS++#(^'%N62U2=_EM=YH4_*3@)P7_!0K^.^T-6\/_0E=#]WU-W^\CH-M[HX(LVF"#*\E\1KUI6%]\;4SLBA2^#.-J:,2M*"4NDC0Q]/9MYY(#"#+C$FOWD#5>V;'DA_/$+1"6Y*(1+65]XQL\NU(;NG=Y-MZ2..R\KG@W-FHLT3]0"8@-F[TJ-M,!G2%$T5O=?E!@R>?:J!3H[--X6[$I<">8N11"4HL^4_38H^F:MX+)0/1T5-M67?6&Z6:"KL-H_/HL8Z:X_.HU=D>SUV=-M'X1+8:\3D]UW.#E0+OYNX.F9+^@VSTQIEAMQSTZSSO.,I>9Q4)#$"QA@T&D/M0&WBSYE13R?I6$IV%X=\LK_QLVG^,8\(J3UG#_J5=-LXI^Y>6=7JUB5:QH7OIXFZ)'_O<@/^B3W("#A/J+GN&HZ@>]57P[3EGRCTI%C4$Q-M'FQ.N,*>-_KN,%VLW##JA%XX.X'SKM%AK13!F<8O;B3-U$@B=E$FM#6NTN-M\9$EU-L8[)_;ONOIC(1T*7>&"'?O6UXYB_T_D[05+&"$DYFR-I$R1EW)"4_M0VA[^/SD;(\&^JKI(S'UK&'C7+VR@=V^[P"3PV<.8\-(4_,'>6)DN-QZ,F!-M@]V>OVVD#SF

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f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l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|(&ZV!:8?,8T;X+1.X/#O2-M1#.BY5W73<3]5E4_MSC22@I=`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

R@]^8'TQ>1N^,"H-/K7SA+8J[P+7"U,*"I"U|OJ:1*L&VV1<)M2\EX4/T.DF.(5?L\>M11{2F$)|?,Q-T$;@YQL MS(AOBURZF"7T[ ]+OY=91,-.!9D33'R,,'&+R)Q@XH1C&@-_I5OY\@_/[@S8X7RV+E-&W:U.W M^S8L,W5CK,/WM?BFKS5\B@$?-@N9!I]0#-0/C,), <)\8/C4Q'3\T.XM,'H7< M.0MX\EIY6(X 0PR 9(%E8JG_D3{("W%9F!f\& >,*,2[Q%\F0_'Q# <7S+S84 M?_QN7B3;/_,;C|\MZU7VY_\/4$L#!!0 (-)F #5G>6Q^,L%< # 1 P /-M 8V%T>"UE>#$P7S(N;'1M!;UK<]O6EB;\?7X%9GK.E%1%,Z(D2Y;=.,57] MQ.GVU#E))G;ZS-1; [P>0V!01@P /-B"9 >MGW?8-%)Y)V9!.VT-7=1&4@V\B7-M=7W6LJY?5>OLK_\E^GZEX@3<Z&WU?156F_OKZ_SR;G4W/O_^. X0+0I,KOI\?`MR3;2U33 _. K>/R+LU?1G%=%? \U76^*LHKSZM4F3I(TOWL9O=A\>/??Z+9) M>F[^)-\^JXK-R[/I\S1_M4[S9RN5WJVJES/X*;3_\0[S(LR4>4S^ 3N M\_W&W&)9Y!5>HE[.SC;5*QX&W_ 5?;>,UVFV?? DN72L= .:P>HM^*=9R;"^=% M515KN+92'ZIG<9,>Y2]+?#P^\'|OGK,HLJ)\^2]G]#^O'E9H9[13;Q0+S>E M>O90QAM^W ,/?EYDR:O&V'8.!\;RD";5ZN4RK9XMX$J5XQA>?UBE\ f2*> GP M#G_]-LWF 1-QM>_9P53@U=YD+& ?2;6F9J4<%QA7_>PXEL5B_?1VTT&F_CU M\!=XOTPM/T5A]+WJ;/HDKSF@=3W@U>DFB5H4<#9! M?R:GIU=? V7IF0]_E0_@JB?36?1)\YU_T(_PKC^3>6<-(IL;OJ/XT>K=2 M41ZO550LHVJ5ZFB3Q7D$_ZW@BS>Z^"W>@W4V2+XS=\L\.]B[^ #= C?@K7GZ" M% _^/?_D ERQ>_9FW>60K% =WO,GE"4E>G?(L;WBQ-<^TS%Q%'1EZ6JXC2GQ:BV&UZ9U^M-5FR5TI,(}$1=9^@.:KK\Q[0$ M,[H=??P*J*`.LB?&Z9SFN^-]Y(H""9UYK$():3_L\AB>C6LX'I5K8R@ YWK3386CYI<=S_%(,_/[7V<9K$]0$<] M-G(L2"VLXRULO>@,- EN1'IG9T: $LGJ1+TD0\(99QS$ ^&6#TP0;%=7.ST7^ M[)]P!M)E"K=I7@#*@#^ZW<"K+%(V-GY@#$T&SO<33)D&H.:IZ=""""Z-_-7&PFY M.L MCX1<7]Z,D9 Q$K+K$<_'2$AI4GY4RS1/2=3 <]MKQ?<L<+0 M K6*P2$;9 OZ0T-RD.T:MKQ>[<+0 M K6*P2$;9 OZ0T-RD.T:MKQ>[<+0 1IM K6*P2$;9 OZ0T-RD.T:MKQ>[<+0 1IF=^!OZ8!U(0N/E^C#C(99U%ZSA;JEC'^8*S8B"-RA1NNTR3>D')*3S# M\)X/#9NWH8M 4 5E5]Ke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`*9G_>9//;W(U'^L0^2#\Y7X5/!;^1@&E--$ZD+0!R[K M B4!US+C67.X_/RY6A9"AFUT2,\]QU3@*,=`.?XTY?@3ADE\FET_^;*&?0SV M>]6C95FL6P$]3#^"GA"SG;"%[1"00FHI(1RN?,9 AB&U/3EBL,D31 Z0H$=J!.SV1^]f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

EV!HLVQ^PVW62RC3?!_;0+|\UF/-4P^>7"6DY9H)-3BX8 M[$|JQ;XHXB@P7=8 M_U5Z.LN3=+>+RB|[Q$M;2#%FL&RTN/05_HNV(\@4^%?NX@VU$5?HC\(-J0%Q M>_ ^&7B>]DH&*^MO9WG+?EB;?V.Y7]@"-B# PW%#YY@J)^K'9F_D>!!<0?XW MS.S0+HZS-CMGJ/Rf'&@Z*2#7[C$W95X$E(D@4O")")L7-$GCT.P^*FZ&=5MH M-\XM^NDTFVV6K&_;P+@9H'Q.Z_@KV?!%*VT,XY<9CYM#(?U;\>F]T^Z22C# M-@!W9V6:'BBD<@ZlH,*B$"F@ +5/<92=**!O>F_.SH.Y.?^>Z@5{'R;6/N)^ MJ-L+OD/Z#; <(A^TQ&^3^^/_>7+LO9+TFT_]_7*_S0:!76P_'&3;D/(H; M:U.;3;PL^1L,K6FXN=38MQ,IC18<^R!S-G?E/5'S%)2V(#^3DB27?ID>@6VZ MP:V31KZLCX_=V5\|YE?
3P;1,W@S(]=UGM ,[W:! VUJ;>4/7'B>XY3OZ)^`] M7&;BI"B3-=VQOB8JHS-!T@IHR@O)052$\/7@BZ!X8+!I=J G[$]C>B^4FEE M>DSR-*
*3*Q(3EMB7LZX,9/*2YY6MAD$GU($Q7,L!^"@Y^PJ^&GPOQ],\##%(4_UQ$K]>;K,"69W 4?]&C\U;5]|B6X?C2^623SD4@6+*4YN_2I9=1^AZF3I T@/'S-*8XOY%ZZ(NA%G;#X4I9>M M=<##*$RO%6EY#LOLU)1LT5=7E2IA\2:7_T08X@//L_P)KE?JBl{62'U(:*6B M###0"7O6OVV<4:=T|HIG-9'LAW+!7;_4D4EX*JAR&>[J*>DW)IBIH#\NC71 M1*#4D=R&:,5,JK"1V. (JGZ>4@Q=,_J]9=Z173R!<:L_J;0?IH)<+O7ZL@9D)*`MRP;G"IDHI[:I,RF9 N|_C.9/9 =MB,8>G562=P\)9%,20|;0-:X8R,E('$] M#Q|@5*_9F93BHOYY-!=AMZQ
O,0Y6503(PKBG!.$N!Z968^8UX/LK34&$|&\ MLP(#A%NZ>)^*#43KI9]2S-VUF1U>6S-E#KWBL4QXTP%'_JZ.2:XB;ITG&&>= M!$?-\S'?DG!'8#Y%BVSD=%. --H&4LV)F=;K-
D1XVB23<=R%NC"6HB;1A39M M?D>5_3)$%$G6L PK|=IL:<;\NSR[N76B%EN5MBAC+ .F=198&8YR;_I\D'(/
*M*V;0%Z3>*;9:\.B&V+ONTE(Y]5YM22LEW&#*\V.MTT4R%HHYF3W5+,D.RN1.7 MWV*!=)G9C =Z13[3O.M#[fB[RNBU M_JD8N@XEH#95K/NZ;..WDW G-`MBE.Q L+FV":/26?Z)?
*M3"L4 <^P0ZG;#+|<)?L3'$,&P$^'0CV3">DY+,\4-**-[IF"B MH=F<\ #TG6]HEFS0&OYT)4&:13X;,_*14H2K*NSBW?Z|5>8>> M,7IGX#$IX?
*MZ+I@BB3)+$1>MW<2$]J+)]O@\4WNF1<\6YI@/!F#TP81^LB8;2 Z'ZXVB""2Y6K!{!] M9#E[UH-DN2P=>]$4RUJZ>,_YY5RFWF4*L4<8EX5_Y;DR2*"D4-R$)D[(44!%
M]K+N8!&O0=]?H4H6TSS*:TCU;$YE47YXRS11DJ?;"|,Z/UD'0F'2.MF^D2(;T>QG2O4W MW@V9**1)<'PI.5&LE;>+FX#+G9&-U;YL$ 6=2M(0|>8 S MW\+02RHQI.?I5UO6]>
*fZO7=/U!.9JGR]|L9BLPK"!,O3^N""-M3N5\Q7R M,1IS,0Z?C&1;DF=V^33Z=\8QCK7#AV5Q?-1^D)]$<\A#GH5(3)C^(4[DQ?3B MF. $K,VW)\O.N%R>HPZLR R-
NB"1),.)Q3_)]4FY'2. MB2.\F07|<6G\';GJ(&PI+]_PY,,/%U\! \^M+!-8P["SJ>B7!5UUD?]D@YOOG MZ[3R"H?=IC1U,>A-+(NRRYLQ8"')T+1SY$W<[*=S/1VN80UBMVGRS M_3
*(B^<5LDA.53AH WP@L!^ Z5+O -20)04"`MCB(II+=1SDOFT$BINGD)PJ X.NV64CE^6,VSV$_\2@"6BPE08<<+EW7V9U;@W?@ MGG8O=IP-UQ%1YD3LD8:*6]BR;32"8.*?"C
*_FIGK&9&@OK#".J;J7>"@ M!6R!' M&.#S4-19X@',?-!_+E+(%SMEMX [GB#ZQ"3L\]GG3,+>7.SK1S^]G-[<[+OH MQ<7T[*ILSSMF87=G82_'+&Q[5OY-
*!]_M5[#F`?]0J;2Y4#SKC|QXTHL"GQ] M?^QHPKN6IN8ZVFT/U-N]]TZL=RE09H'\+"=:,>/SMWK1R>YLE\["YI;F ,BC. M3.H\EVIZ]-!S4=0;&H%6#*A X&,,11GHF[WS,3@<8?
*1(%Q\'SLZH:L.\\/? M!SQKT^@M-4V]E[K K<0XE>MY2I%!&29J.+B<.1#FSRB"4 E0%C] >-K"7HPD MN+9!G-&E+97I,.2;U#FB^LZ]\=^WJZAHWF31[
MU_D'2DC41:TM@3&&@HG%=A)4U>,BFA2G;U+1&Z0:TR-EBB-%6C0>D|\&X>MO MZ]H+K6?"%8|LF[AY<#38\D,4/_BC#3H_2296(Y|$]*CB8P3[LMD*B]V4
*M5(E\)BRM^[=W4''+A+Y9.6EE Z5Z4P5]Y1D;[C$ID6@Q:ENKL5 >,&=+,A*=-YN&'-CA3D$+|. MLB8[ZU4>@NNTX_D"K::M'LD0VN)!ZC11.BWQ',(8L =]8PR.@SZF@L60TQX1
*M$^0]F) ^9?A5PNK=|L-OVNV4T"EJZACUY[/V02QV>-?1%?)3N1D^9SW)V?1R M+|_'"01==WTS/7LS&6.88R]P3RWP^!C,_I?W?&((,M]'5((V-WV-LP8J%] ,H
M^PB+0&FCN8NL&-9K.0L]=1V>?BZ_[^3MSA?Q0-(9C+M,4S43=:.`4"1-4= M .0@K:ALH]9KHPFKA<%_^2I#ZP" .Q2TMY#2VAT=]>7 R /S6H!L^;E_,V';3 M=
(;'T%,U(E3^YBJ5,C.HOA"7-L3"G"-6.#4/XEBN\FV7]SP=^?IBD/+U1VZ@-ML#VF6/TJZ$I/Q^34OM:!M<48C:0RCF)"7$7?FJE2$:C852 MGWLL.G<3^O;2C1*<^Q.--
*N43'TDl, ^]@MK>#8@<3%Z2_/M/!'AZ$9E]?#1L>3 M5M3%>[$+YL\):!N)Q(0"$+TC'LV7ZQK;3I:=PV(M2G7@&&>]IQ$%|K\5Q==X'-P0LOD#O2)L{IHE!7DV%L+
GW3'6&&P$@O96R&Y M)WCP9F>,#'F#H.$/BKNYH/ /3V3!!;'[=T[/ ->UA5S?5$&U MW=._M<&K$+91G3 --)M0)%HAM&G(JAE,Q29[(\ZD72)C>CUA+PSI7T"HL3
M[$RF*^60&D1IUU"P1=DK"Z5+E%Z4Z=Q!O9@2U2#!//!LAOS0$YZ!]RNH9:DPL M9P/%Q$;>)3>G5-#2I.9@)RNH"ZK 9J0WTCU5|N2TAR(TG3IA^CDZC0""*P.VK|CD/IVJ.XC:"I%K
*M0/DZ$'OBX>2P%^,$7P8F3H3V,BUUA;]7%FAS44C4=L>"\3WCL<5YC@8<9SUW M 8EV&KK]T-\(D$<3M_E, >6U%+;A6#X%+E;7NWT%@+!)@*TDIY.V;<&RA&
*MKXE!8*Y!+]2V'(_%YY1+?2WFY!|I\?!NL#,3;>+*1^L=*/,41$P M>3$811G!7L;!H8O.LG9OAE83V?#Q+4ZGIGC,WZ0<+$-!?WMZFIRR/-@-L-U$ M;-+ ?%Y|K\DO'EVTX
*D^9M4Y25BP51%I*6#)U ;*1,$;S6>HK*I-MTR54L\K!0W> M);T2UM...NVLZ&R:0^"WR;8FO>-08@5"5+3NPP+X%YXQ.9[B|_%^IS&4CP?A+ M$W!CLTS=,5:^SE4.LGBAN V@
*,Q0+5[!E:<(4@8!V7+%FO5NW,'¡^?IL#W+-MFU_99CXW&DB&1>P8,C+BV@T&QRZ[8P==QRFU_;F(TACVHYQE'2=C^<,SMDP M ;6T?
*_]=Q1AC.;HH7\DX@DP)\N&;$$$SXX3YVI::@.6YN0@"42I VSMOCI CN M9F:7$IZ8O.I&QUI+GOX AL'X'MWZ@@&BKT-G_Y3Z29_(.43"H0H\MD*P7 MY#MG'@*D5:&?
*Y48)5C+VZ!L$I8)XHX!$Q0DD5:9#>'$ZP*5*7=7I1PPRC)+ M",Z4.-BJE&/UBZJF.E'[H:G*_X>/"31&L%!:"(%^]?14^CG)PXH$8W46O[f MV-$WYHD/H0,"P+-OUB),$6#](46(FY.Z_;Q.
V6M"?)/'|/ETD(?TM?7_33Y_ M<(6N%&%T88K86NKAV$W]C"93G@O5G!2E[;WL6O RFQ+]R NJ2.7+]6U"A9V6 MX0QE3C*L8"1SA0U'#VI0-3%MN@V?C7V@A5NH#%
*[H9'8NH#9M.,@+'SN1^$W< MT"UH.$M1X>_3.F!7PSQ@[WQT81F]K34&61]IS0&=-|,,P/%*M2^,LFGJR3E@G[VZF<+/G60I4!&E,!\'2+Z3&[((]'95?8DFXU"P9-
MYGZ59J&\DA7APAY>-93!&V9]GICXNAZF^/1A5:2,X_I,_'IL,97%#T:6O*W$ M7/E[FN=*%U4L4H99$RF;0E3V9-/#C1;PJ3&@_7C!)#+1,FXI;O .1&HQ M^6!NC6669(K$DU?.G+$
*%?HPC1OS-86QR-I,+BXLOI:9^,1]!6^,]9?;M;,=E MAEO#=7Z"/|[HXC=$'+S)%U-4M7\'<7HYB6|"77|L7C4.,Y7%YCL KMYD6S_M^E^^_VY5K:,__C|02P,$% @ F8 -6?5%MA&H"`*SL |
!C871X M+65X,S%?,2YH=&WM6VU3XS@2_KZ_0L?6W$)5'!(28'#8J6/4/D>9 M6Y[95L[C6&3]D+W-'U![;M18#*>#1!8,0/0'-JQ5FR)#B?-#?.[D\]HE4HC(;
M&/$_",NUW+:lL"j/RUW+,$IT*.PZY(P;!K&+%,E?]CL(MA3UJH492TV(!+ MT<[*33I)&XV?Z(F45#K\L>,:'M48#82$P.8\@&$#45@(!USKV[D++>X&;>6;/NL
*M.6C+2,1V$","!A%*0D8V=!X&HB.K?MXB__EC M .;36VOKRMK3%%YW;[M7[JXMV]^KFFGVXO[V[;U]W6?>&W=[_UKEC]08/ZLU] M?L#:UX)<U>L?AS[JXF[7L *V/>Z=??
*7EYU;UOVUP^XZ%_>W5|TKW*_.QXM?V]?_ MZK#V19?=O&?ULT:S\KUZ[V'W\I_$^<=+U6I'3_?=E\U]W'V_%\:*9/QG_?<\=UU5V+_5@&=LOSL0OYL# M=I6XS$@83$
MAHUJH|%XTXJ%R24?AXF$AQ4GEMZ8F.B$ F.YMBWGKH\4FK#'#4B1P8IC9PLM MM6W/TXJ]LWEZ5C^K-X_KM9/&V>ELZ2(CXP/G@<^L>.]=O3!Q_ERBXJ>OUVK+ M$VX)0VS
A\ T# 6.(;$;,"/;^' !H.48[U/ZQ53&WBN=LGHM^]3"?L VN00 M68%#NP- 6Z"P(C{5=I5%U5EPI@1LEH;ML/?W8>_I%6#O%]R+F+'5CMFG3(TD MQ'VH>
*B6P(L5SI0IRV@4%QGCV9@5F=4%H*W<.NP0(CE+|4H++EG"([REF4HQ M%;,*RZT(9!"|,5R/223EGP#USLU|%Z,Q|!*23&.=)+)'14I"B6X7"'T) ;- MT#_1@)F"_IN-'X&&N-
MY]VP(3V"=5X580"EH@,(4OHGT&T@FQ"<7RLYYZ++,&CGEN!\X@LDD6.RB:UQG)4I M,Q(&D\D#I,$:,X?6!M#!:WA40)5^,?[X.WPM7X M=.4O!=5S2<;S<\HHLQQT',";-
E84;@*$%%M,YE9J{$I9+AUV;,2??DY/1[M8MOQ;;WVMEE_>]1L-HYK9W^":;-^S\MEVR48]"Y"S^5-7^9%A5*ZB!=F\R&4 M6_4 ,5Y]MF:*C1.@&@;'N-
"$4!!YN:A@GD6Q.8#H0:)'6G*=&T&_$H9).FA MP("&MA@E1X+&?$+&'$$3]HG,^:\;<>D"!N&(Z'^*N'P!TIGTS*WJLCY<;A M9(6;FP>AC2F*M!Z*F)C'CZ!P);ES*&T5*Q\X 5]+U(<-
*,5B)\0GD= "0 M");)KGHMX4@M.$O ^0'M:-/F..5MG M3OP*F/!H;D*<6H?EF6,>[+$H"?$+4H55105FB\K9S)+4L435E=F08)BUCS+9Q<*M/P$#:!EL$.(.)9U5FDS31?=#9PL386U
&NC<$]A*DI/8H$VN>'[R$++$N&@ MBC^IK)P<%_!'(=!D=T 46>3:H >[!KVP]QKZ*&T)18JZ%^!;*$>'"7S(@&(M[3+5F_8R1L _4>[F"Q>7O;F2R[TGF_3?
*G\28LNW@.Z!KH@N/<;"\;?!9PZZR M1$-A) I64A6?.AK.&TV1(K!0.6X99?!>^XYBEQ.^'#+Z\AO9&&L_1..A7D'T M@@LZB'_W=K8D2L6G4R(*CD$R]DRWB]?.NLR3D&.2S4&?
H:\^9^ (-D3;/ M3'^GCP#Z6_Z:Z1*W(&3MHH]&L'JCPIHY1\V_]4KVDOVE&UKJFUYC2J56O- MDS>M'AZ1H)TU!TT&D\@ B05ENFHX 'BEE=V=E:M3>5QIR3/#83&M|K ?SR-
M^O1$&;79_&$<3J1+(92%\E\?/S&?5MMXT<$FHL"^(M>UE=^J.W<-T(K@QZ& MD$^A^S^@&^M!MFI2^4VXW_AJK=80V>0[\:GKW,TAY9985I5[C?)3N0D6EH;K M\EMR?
*Q<7["*PMS&@UF[05W;7"4J6OO>/3W.<07T H1-#HP7X|&-5S$2#X7% MF:)'/7YH#M=|?;EN"W84^&8l\+ +#LD])+\@=ST#R1<# 0GK/$!4 MN,^3;WPK:8?F'9I?
*(9KW/_BWQE@G:E@=D\?3/2V>U^4#/L(QV^!.#)UCQ MAUR.^-BX0^+\D/[4]=T/YX?NCV3_#U!+ P04 " "9@ U9603OP: (<-M.P #P &-A='@M97@S,5\R+FAT;>U;;5/C.!+^OK]"Q];
*<054<$A)@<-BI MRD+FAJLMf(-0-?=-1L=M$AVQ?)43B^^NW<W+>PTP89C'W;5+(]B9WV@=3$X4CY7$3'"Z+ ?BEQVE/QB:D]DO#+3LKU MG1R+[*YD;,_'UHZ;-
A:#R2"1!7T0=WT;UJI-D:'$ MZ3Y>=W+Y6"I1F0V,^/">BVW+:\lL"H/:RUW+>&]D.P*U(P[!*&[%]E/!L+ MJ!2U*D59"P\VX%+<9:$FG;2-QH_U1$HJ"?
*Y<TK&K07;/FL.VC(4L>V'B;!!A)*0D0V=A[{H"*SSG7WXOW%6;M[<77)/MY>W]RV+[NL>\6N M;W_KW++!Z@P?UYB[?
*8^W+K]ZGLP-MRW]W6/NLR2]>L_I)HUGY43WOF!M\ZN/W<[Y'++170[MC=H! MN,J&'YZ@8!E);LPO.VA.&DAA;_24J ;B2;EH'?F M8W @(;%AH]HH--ZT8F\RR4=A(N%AR7VE'\;&.:'
*6*YMRSDJO4Ff'$##4F2P MY-+I$DMMF_-QH]IL'I_43^K-PWKMJ"%R/%YZR.CXP'G@.RO>>>5>OCIT_DZ+X MZ>NUVN*$&T(/Z_,|_ T# 4.($3/"L-\+7 !H.<+SE'@QE;'W2J>L7@O^RU3"
*M/H(V.416X-!N'] 6**R(3(5=9%%U&I8!]9HF8%OL_7W8.W@%V/L5[T5,V$I' M!#Y30PGQ'50\!$O@Q0IGRI1E-(J+C/%LQ"'3TP6@K=PZ[! B.4OQ2 LN6<((
M/*692C$)MLK+++0ED$(QO7(\0.7W@'IGYC1X+D9C4*6DZ$8Z2" 2.BI2@,MP M.%.M2@V;HGZC/3$' JN.'H*&,"0-{.\V+T!]+9-VP)VM?E*<M^$ E(D/(&OIG$*T@FU <+ ^N9ZR)+
*<*OG5N\(HMD M$>.<2(,9/%:00H+" QIOB(!$3"FG#"O!;194HZ6QH(DK)%%%{%$!:*42I4V>< M/1$W?99(-31CSFFX0V!K+/\9IY/>;K2R,D,=,S9FR=HM>S;/GN8K8$]W#FK_
M,B4SRFR:-FZ5) (/=|V>0^_%XQH!,,D UJQ#+/5I!(FE&+%1 E7W1_N M@K?"5?=TY_|%57*9)QO-SRBBS'#0CH^$=BV^%QO?:V67]|T&PV#FLG7|&V::?GY;+M'_QZ%Z'G\|8O\Z)"*5W$
M"[/^,$JM>I 8+8\H0,=JFP0[LXEG56:3-)%]T}G"Q-A;4 *Z-P3V$|2E=B@3:YX;O(-M0L2XH:"*GU16CK<+-+T0:++;((HLI->AE#X/>4N_G"Q65OKN1RS|G&_?.!O-&4Z2(+W2.6T89O%
<^H]BFA2^#+Z^AO=`&[" 1 MN(E7$+W@@@[BWSV=+8E2|>F4R 9#H!RJHS?E0^9=1FG(,VE&@%>'?:5CTQ\ MCH9(FV>FE]5'
/TIO\=TCK<@9.WB#HU@I4.%'=0.FG_C.W!$_(V^O6I=4VO% M,E2KUI'.UHIW"0)!.VOH#6@TG@8$2"HLTU"! \0MK^SDI%J;R./=DSPW$!K?.MZ@+_VC3JTV-
*EU&;SFW$XEBZ%4"J>)_/AX1OW5K6-'Q%HS@O@%[VHKWQ%V[EO MB%8&/0PA]Z'[']")U2!;-JE\&]S?^&]MUA#9^ WQB>O,%Z,1]?>_MQT@\%!9GBA[U^+
j9GW_ON]SL,9/@]^_V)HK638X4> M9"]&\]9B=N1Z$ZU+X7]Q0&4IZ9HMM'86?S:ZLM,!63SY/>FT),_K*95!#K[I M\ 0+_9#+(1\9MT^<]M-O6]_]+0*I_P04 " "9@
*U9TV6>)3P5/K_IEB_SKS_6#6FOMRUO3*SJI7'?/S|\Y/VMWSRPMV=7M]<|N^Z++N M);N^_;USP^H-'M2;VWR'M2|.67T_]E<3=[V"%,?]=7=7!QVKEGWMPZ[Z9S<
M7|IWS_%|=3Z>_-:^^'N'M4^Z[/,U8\:SXZ MK[!_"DBE"7O< M@!09//#I;(VEMO4YN5%M-@^/ZD?UYGZ]=M X.IPM761D?. \\(D5;WVH5R?.MG\M1_/3U6FUYPC7!APWX$)B&H8
*1Q(@98=@?!2X M!SC?"M2$AQ4GEMQ0D$*9C4*6DZ$8Z2" 2.BI2@,MP M.%.M2@V;HGZC/3$' JN.'H*&,"0-{.\V+T!]+9-VP)VM?E*<M^$ E(D/(&OIG$*T@FU <+ ^N9ZR)+
*<*OG5N\(HMD M$>.<2(,9/%:00H+" QIOB(!$3"FG#"O!;194HZ6QH(DK)%%%{%$!:*42I4V>< M/1$W?99(-31CSFFX0V!K+/\9IY/>;K2R,D,=,S9FR=HM>S;/GN8K8$]W#FK_
M,B4SRFR:-FZ5) (/=|V>0^_%XQH!,,D UJQ#+/5I!(FE&+%1 E7W1_N M@K?"5?=TY_|%57*9)QO-SRBBS'#0CH^$=BV^%QO?:V67]|T&PV#FLG7|&V::?GY;+M'_QZ%Z'G\|8O\Z)"*5W$
M"[/^,$JM>I 8+8\H0,=JFP0[LXEG56:3-)%]T}G"Q-A;4 *Z-P3V$|2E=B@3:YX;O(-M0L2XH:"*GU16CK<+-+T0:++;((HLI->AE#X/>4N_G"Q65OKN1RS|G&_?.!O-&4Z2(+W2.6T89O%
<^H]BFA2^#+Z^AO=`&[" 1 MN(E7$+W@@@[BWSV=+8E2|>F4R 9#H!RJHS?E0^9=1FG(,VE&@%>'?:5CTQ\ MCH9(FV>FE]5'
/TIO\=TCK<@9.WB#HU@I4.%'=0.FG_C.W!$_(V^O6I=4VO% M,E2KUI'.UHIW"0)!.VOH#6@TG@8$2"HLTU"! \0MK^SDI%J;R./=DSPW$!K?.MZ@+_VC3JTV-
*EU&;SFW$XEBZ%4"J>)_/AX1OW5K6-'Q%HS@O@%[VHKWQ%V[EO MB%8&/0PA]Z'[']")U2!;-JE\&]S?^&]MUA#9^ WQB>O,%Z,1]?>_MQT@\%!9GBA[U^+
j9GW_ON]SL,9/@]^_V)HK638X4> M9"]&\]9B=N1Z$ZU+X7]Q0&4IZ9HMM'86?S:ZLM,!63SY/>FT),_K*95!#K[I M\ 0+_9#+(1\9MT^<]M-O6]_]+0*I_P04 " "9@
*U9TV6>)3P5/K_IEB_SKS_6#6FOMRUO3*SJI7'?/S|\Y/VMWSRPMV=7M]<|N^Z++N M);N^_;USP^H-'M2;VWR'M2|.67T_]E<3=[V"%,?]=7=7!QVKEGWMPZ[Z9S<
M7|IWS_%|=3Z>_-:^^'N'M4^Z[/,U8\:SXZ MK[!_"DBE"7O< M@!09//#I;(VEMO4YN5%M-@^/ZD?UYGZ]=M X.IPM761D?. \\(D5;WVH5R?.MG\M1_/3U6FUYPC7!APWX$)B&H8
*1Q(@98=@?!2X M!SC?"M2$AQ4GEMQ0D$*9C4*6DZ$8Z2" 2.BI2@,MP M.%.M2@V;HGZC/3$' JN.'H*&,"0-{.\V+T!]+9-VP)VM?E*<M^$ E(D/(&OIG$*T@FU <+ ^N9ZR)+
*<*OG5N\(HMD M$>.<2(,9/%:00H+" QIOB(!$3"FG#"O!;194HZ6QH(DK)%%%{%$!:*42I4V>< M/1$W?99(-31CSFFX0V!K+/\9IY/>;K2R,D,=,S9FR=HM>S;/GN8K8$]W#FK_
M,B4SRFR:-FZ5) (/=|V>0^_%XQH!,,D UJQ#+/5I!(FE&+%1 E7W1_N M@K?"5?=TY_|%57*9)QO-SRBBS'#0CH^$=BV^%QO?:V67]|T&PV#FLG7|&V::?GY;+M'_QZ%Z'G\|8O\Z)"*5W$
M"[/^,$JM>I 8+8\H0,=JFP0[LXEG56:3-)%]T}G"Q-A;4 *Z-P3V$|2E=B@3:YX;O(-M0L2XH:"*GU16CK<+-+T0:++;((HLI->AE#X/>4N_G"Q65OKN1RS|G&_?.!O-&4Z2(+W2.6T89O%
<^H]BFA2^#+Z^AO=`&[" 1 MN(E7$+W@@@[BWSV=+8E2|>F4R 9#H!RJHS?E0^9=1FG(,VE&@%>'?:5CTQ\ MCH9(FV>FE]5'
/TIO\=TCK<@9.WB#HU@I4.%'=0.FG_C.W!$_(V^O6I=4VO% M,E2KUI'.UHIW"0)!.VOH#6@TG@8$2"HLTU"! \0MK^SDI%J;R./=DSPW$!K?.MZ@+_VC3JTV-
*EU&;SFW$XEBZ%4"J>)_/AX1OW5K6-'Q%HS@O@%[VHKWQ%V[EO MB%8&/0PA]Z'[']"

catx:LantheusAlphaTherapyLlcMembercatx:LantheusInvestmentAgreementMember 2024-03-06 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-012024-06-30 0000728387 catx:BofASecuritiesIncMembercatx:May2024PreFundedWarrantsMembercatx:TheUnderwritingAgreementMember 2024-05-242024-05-24 0000728387 catx:GTMedicalTechnologiesIncMember 2024-04-12 0000728387 us-gaap:LandMember 2024-06-30 0000728387 2024-01-012024-03-31 0000728387 catx:AmendedTwoThousandTwentyIncentivePlanMember 2024-05-31 0000728387 catx:ViewpointMolecularTargetingIncMember 2023-01-012023-06-30 0000728387 us-gaap:CommonStockMembercatx:PublicOfferingMember 2024-01-012024-03-31 0000728387 2023-06-30 0000728387 srt:ScenarioForecastMember 2024-01-012024-12-31 0000728387 catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember 2024-01-172024-01-17 0000728387 us-gaap:RetainedEarningsMembercatx:PublicOfferingMember 2024-01-012024-03-31 0000728387 us-gaap:EmployeeStockOptionMember 2024-01-012024-06-30 0000728387 2023-03-31 0000728387 catx:SeriesBConvertiblePreferredStockMember 2023-12-31 0000728387 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000728387 catx:MarchTwoThousandTwentyFourInvestmentAgreementMember 2024-01-012024-03-31 0000728387 us-gaap:CommonStockMember 2023-01-012023-03-31 0000728387 catx:LantheusInvestmentAgreementMembercatx:OptionAgreementMember 2024-01-082024-01-08 0000728387 catx:ViewpointMolecularTargetingIncMember 2024-04-012024-06-30 0000728387 catx:MayTwoThousandTwentyFourPreFundedWarrantsMemberus-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000728387 catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMemberus-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0000728387 us-gaap:CommonStockMember 2022-12-31 0000728387 catx:RegisteredOfferingMember 2024-04-012024-06-30 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-06-30 0000728387 catx:LantheusAlphaTherapyLlcMembercatx:LantheusInvestmentAgreementMember 2024-01-08 0000728387 catx:GTMedicalTechnologiesIncMembercatx:GTMedicalStockMember 2024-04-12 0000728387 us-gaap:CommonStockMember 2024-03-31 0000728387 catx:PromissoryNoteMember 2023-12-31 0000728387 catx:LantheusAlphaTherapyLlcMembercatx:LantheusInvestmentAgreementMember 2024-03-042024-03-04 0000728387 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0000728387 catx:BofASecuritiesIncMembercatx:RegisteredOfferingMembercatx:TheUnderwritingAgreementMember 2024-05-24 0000728387 us-gaap:CommonStockMembercatx:ATMAgreementMember 2024-04-012024-06-30 0000728387 catx:ViewpointMolecularTargetingIncMember 2024-01-012024-06-30 0000728387 catx:PublicOfferingMember 2024-01-012024-03-31 0000728387 2024-06-30 0000728387 us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0000728387 catx:ViewpointMolecularTargetingIncMembercatx:PromissoryNoteMember 2019-07-192019-07-19 0000728387 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000728387 us-gaap:CommonStockMember 2024-01-012024-03-31 0000728387 catx:March2024PrivatePlacementMember 2024-03-04 0000728387 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0000728387 catx:ProgenicsApaMember 2024-01-082024-01-08 0000728387 us-gaap:DiscontinuedOperationsDisposedOfBySaleMembercatx:Cesium131BusinessMember 2023-12-31 0000728387 us-gaap:RetainedEarningsMembercatx:RegisteredOfferingMember 2024-04-012024-06-30 0000728387 us-gaap:CommonStockMembercatx:LantheusInvestmentAgreementMember 2024-01-012024-03-31 0000728387 catx:OppenheimerCoMember 2024-04-112024-04-11 0000728387 us-gaap:LeaseholdImprovementsMember 2023-12-31 0000728387 us-gaap:RetainedEarningsMember 2023-03-31 0000728387 catx:LantheusInvestmentAgreementMembercatx:OptionAgreementMember 2024-03-31 0000728387 us-gaap:RetainedEarningsMember 2023-12-31 0000728387 us-gaap:CommonStockMember 2023-06-30 0000728387 catx:ViewpointMolecularTargetingIncMember 2023-02-032023-02-03 0000728387 us-gaap:OverAllotmentOptionMember 2024-01-172024-01-17 0000728387 catx:OppenheimerCoMember 2023-12-012023-12-31 0000728387 us-gaap:CommonStockMember 2024-04-012024-06-30 0000728387 catx:HoustonTexasMemberus-gaap:SubsequentEventMember 2024-07-152024-07-15 0000728387 catx:LantheusInvestmentAgreementMember 2024-01-082024-01-08 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-06-30 0000728387 catx:LeaseWithBoardOfRegentsMember 2024-04-01 0000728387 2024-06-142024-06-14 0000728387 catx:OtherMember 2024-06-30 0000728387 catx:ProgenicsMember 2024-03-01 0000728387 2024-03-31 0000728387 us-gaap:DiscontinuedOperationsDisposedOfBySaleMembercatx:Cesium131BusinessMember 2024-04-012024-06-30 0000728387 catx:GTMedicalTechnologiesIncMembercatx:NetSalesBetween10And15MillionMember 2024-04-12 0000728387 us-gaap:CommonStockMember 2024-06-30 0000728387 catx:LantheusInvestmentAgreementMember 2024-01-08 0000728387 catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember 2024-01-17 0000728387 catx:ViewpointMolecularTargetingIncMember 2023-02-03 0000728387 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0000728387 us-gaap:WarrantMember 2024-01-012024-06-30 0000728387 us-gaap:WarrantMember 2023-01-012023-06-30 0000728387 catx:PublicOfferingMember 2024-01-17 0000728387 catx:ViewpointMolecularTargetingIncMember 2023-04-012023-06-30 0000728387 catx:LantheusInvestmentAgreementMember 2024-01-012024-03-31 0000728387 catx:OtherMember 2024-01-012024-06-30 0000728387 catx:PublicOfferingMember 2024-01-172024-01-17 0000728387 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0000728387 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0000728387 catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember 2024-01-012024-03-31 0000728387 catx:ViewpointMolecularTargetingIncMembercatx:PromissoryNoteForPurchasingLandAndBuildingMember 2022-12-29 0000728387 us-gaap:DiscontinuedOperationsDisposedOfBySaleMembercatx:Cesium131BusinessMember 2023-04-012023-06-30 0000728387 catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMemberus-gaap:RetainedEarningsMember 2024-01-012024-03-31 0000728387 2023-04-012023-06-30 0000728387 catx:GTMedicalTechnologiesIncMembercatx:NetSalesOf10MillionOrLessMember 2024-04-12 0000728387 srt:MaximumMembercatx:ViewpointMolecularTargetingIncMember 2023-02-032023-02-03 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-06-30 0000728387 us-gaap:RetainedEarningsMembercatx:MarchTwoThousandTwentyFourInvestmentAgreementMember 2024-01-012024-03-31 0000728387 us-gaap:RetainedEarningsMembercatx:LantheusInvestmentAgreementMember 2024-01-012024-03-31 0000728387 us-gaap:RetainedEarningsMember 2023-06-30 0000728387 2024-04-012024-06-30 0000728387 us-gaap:CommonStockMembercatx:RegisteredOfferingMember 2024-04-012024-06-30 0000728387 catx:ATMAgreementMember 2024-04-012024-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMembercatx:ATMAgreementMember 2024-04-012024-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000728387 catx:ViewpointMolecularTargetingIncMembercatx:IsorayNoteMember 2022-11-22 0000728387 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0000728387 catx:OppenheimerCoMember 2024-04-11 0000728387 us-gaap:DiscontinuedOperationsDisposedOfBySaleMembercatx:Cesium131BusinessMember 2024-01-012024-06-30 0000728387 catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMemberus-gaap:CommonStockMember 2024-01-012024-03-31 0000728387 us-gaap:CommonStockMember 2023-03-31 0000728387 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000728387 catx:March2024PrivatePlacementMember 2024-03-042024-03-04 0000728387 catx:OppenheimerCoMember 2023-11-17 0000728387 2023-01-012023-06-30 0000728387 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000728387 2023-12-31 0000728387 catx:BofASecuritiesIncMembercatx:May2024PreFundedWarrantsMembercatx:TheUnderwritingAgreementMember 2024-05-24 0000728387 catx:AmendedTwoThousandTwentyIncentivePlanMember 2024-05-312024-05-31 0000728387 us-gaap:LeaseholdImprovementsMember 2024-06-30 0000728387 2024-01-012024-06-30 0000728387 catx:LantheusAlphaTherapyLlcMembercatx:LantheusInvestmentAgreementMember 2024-01-082024-01-08 0000728387 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0000728387 us-gaap:CommonStockMembercatx:MarchTwoThousandTwentyFourInvestmentAgreementMember 2024-01-012024-03-31 0000728387 us-gaap:RetainedEarningsMember 2024-06-30 0000728387 us-gaap:CommonStockMember 2023-04-012023-06-30 0000728387 catx:OppenheimerCoMember 2023-12-31 0000728387 us-gaap:AdditionalPaidInCapitalMembercatx:LantheusInvestmentAgreementMember 2024-01-012024-03-31 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-06-30 0000728387 us-gaap:USTreasuryBillSecuritiesMember 2024-06-30 0000728387 us-gaap:EmployeeStockOptionMember 2023-01-012023-06-30 0000728387 us-gaap:DiscontinuedOperationsDisposedOfBySaleMembercatx:Cesium131BusinessMember 2024-06-30 0000728387 srt:MinimumMembercatx:ViewpointMolecularTargetingIncMember 2023-02-032023-02-03 0000728387 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2024-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000728387 catx:ViewpointMolecularTargetingIncMembercatx:PromissoryNoteMember 2019-07-19 0000728387 catx:OfficeSpaceWithUnicoPropertiesMember 2023-07-01 0000728387 catx:StockholderPlaintiffSettlementsMember 2024-06-30 0000728387 us-gaap:RetainedEarningsMember 2024-03-31 0000728387 us-gaap:CommonStockMember 2023-12-31 0000728387 us-gaap:BuildingMember 2023-12-31 0000728387 us-gaap:EquipmentMember 2023-12-31 0000728387 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000728387 2022-12-31 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-012024-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMembercatx:RegisteredOfferingMember 2024-04-012024-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMembercatx:MarchTwoThousandTwentyFourInvestmentAgreementMember 2024-01-012024-03-31 0000728387 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000728387 catx:MayTwoThousandTwentyFourPreFundedWarrantsMember 2024-04-012024-06-30 0000728387 2023-12-14 0000728387 catx:BofASecuritiesIncMembercatx:RegisteredOfferingMembercatx:TheUnderwritingAgreementMember 2024-05-242024-05-24 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-012023-06-30 0000728387 2024-08-07 0000728387 us-gaap:CashAndCashEquivalentsMemberus-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0000728387 catx:MayTwoThousandTwentyFourPreFundedWarrantsMemberus-gaap:CommonStockMember 2024-04-012024-06-30 0000728387 us-gaap:InProcessResearchAndDevelopmentMember 2024-06-30 0000728387 us-gaap:RetainedEarningsMember 2022-12-31 0000728387 2023-01-012023-03-31 0000728387 catx:GTMedicalTechnologiesIncMember 2024-04-122024-04-12 0000728387 catx:MayTwoThousandTwentyFourPreFundedWarrantsMemberus-gaap:RetainedEarningsMember 2024-04-012024-06-30 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-012023-06-30 0000728387 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 iso4217:USD shares pure catx:MonthlyPayments shares catx:Plaintiff iso4217:USDfalseQ2--12-310000728387 0.10.10.10.10.110-Qtrue2024-06-302024false001-33407PERSPECTIVE THERAPEUTICS, INC.DE41-14581522401 Elliott Avenue, Suite 320SeattleWA98121206676-0900Common Stock, $0.001 par valueCATXNYSEAMERYesYesNon-accelerated Filertruefalsefalse6742766725200400092380004086500006006006500001420001165000122600011330000530100029423700016837000147470005576000201900074700018217642800034099700075179000385919000978910001-for-10 reverse stock split52600058800085100082100092750005370000167270008679000551400049870001139200011650000015000015000000-22000147890001034200028119000203360001426300097540002726800019515000307600029400042870006680002300026000520004400040000-60000304900026800042290006240001121400094860002303900018891000429000162000089000030860001000059000011704000111060002398800021977000000105000001170400011106000239880000114770000.17-0.17-0.34-0.34-0.4-0.4-0.33-0.33-0.01-0.01-0.06-0.06-0.01-0.01-0.12-0.12-0.18-0.18-0.4-0.4-0.41-0.41-0.450.456664800066480002799900027999000587900058079000254430002544300001-for-10 reverse stock split-23988000-1147700071000-1400091600042500002980000-2200012000200000170000360000040000015000059000013750002567000010500000-1023000-250000-11000-1440009300044500067630004420002800000001279000471000494600017795000100870007560000180003822500022764000787300000026990000505920002468900020000350001230000254000532000288055000065000288412000432000242766000732600094200002117500025218600028501000252004000283190001878360000-61710001-for-10 reverse stock split1421127614000160560000-1059320005464200013654507140005453900005455300007836000078360000136800000371000-3710002786578328000224303000-1063030001180280001821580532000053200001199000011990000-11106000-111060002804794128000226034000-1174090001086530002818098528000227591000-1524400007517900015639954160005312500005314100001020800001020800005634235600020840000020846000920099890008201000008201900035424012600001260000651228400012284000586915965900039455600016472400022989100024450012800001280000224011230001230003535246300047930000047933000515158850007186300007186800002040000020400000719000719000114610000-100000-11704000-11704000674251676700051735800-176428000340990700-for-10 reverse stock split 1. Basis of Presentation and Summary of Significant Accounting Policies Perspective Therapeutics, Inc. is developing the next generation of precision-targeted alpha therapies (TAT) for oncology that have the potential to treat a large population of cancer patients across multiple tumor types, including those with metastatic disease. The accompanying unaudited condensed consolidated financial statements are those of Perspective Therapeutics, Inc., and its wholly owned subsidiaries, referred to herein as “Perspective Therapeutics” or the “Company.” All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair statement of the condensed consolidated financial statements have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes as set forth in the Company’s Annual Report on Form 10-K for the period ended December 31, 2023 filed with the SEC on March 28, 2024 (2023 Form 10-K). The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP). Certain information and note disclosures normally included

in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures are adequate for the information not to be misleading. The unaudited condensed consolidated financial statements reflect, in management's opinion, all adjustments of a normal, recurring nature that are necessary for the fair statement of the Company's financial position, results of operations and cash flows for the interim periods, but are not necessarily indicative of the results expected for the full fiscal year or any other period.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2024 will be 0%.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Merger</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On February 3, 2023, the Company completed the merger of Isoray Acquisition Corp., a Delaware corporation and wholly owned subsidiary of the Company, with Viewpoint Molecular Targeting, Inc. (Viewpoint) (such transaction being the Merger). Pursuant to the Merger, the Company issued 13,654,507 shares of its common stock, par value $0.001 per share (Common Stock), representing approximately 49% of its fully diluted outstanding capital stock as of the close of the Merger. Viewpoint is an alpha-particle radiopharmaceutical company in the alpha-emitter market developing oncology therapeutics and complementary imaging agents. For additional information, see Note 14, Merger, in this Form 10-Q.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Discontinued Operations</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On April 12, 2024, the Company completed the sale of its Cesium-131 brachytherapy business and substantially all of the assets of Isoray Medical, Inc. (Isoray), a wholly owned subsidiary of Perspective Therapeutics, to GT Medical Technologies, Inc., a Delaware corporation (GT Medical) (such transaction being the GT Medical Closing). Pursuant to the GT Medical Closing, GT Medical issued to Isoray 279,516 shares of GT Medical's common stock, par value $0.0001 per share, representing 0.5% of GT Medical's issued and outstanding capital stock on a fully diluted basis as of the closing. Accordingly, the financial information and operating results of the Cesium-131 brachytherapy business have been presented as discontinued operations in the condensed consolidated financial statements for all periods presented. Unless otherwise noted, discussion within these notes to the condensed consolidated financial statements relates to continuing operations. For additional information, see Note 4, Discontinued Operations, in this Form 10-Q.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Reverse Stock Split</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On June 14, 2024, the Company effected a 1-for-10 reverse stock split (Reverse Split) of the Company's issued and outstanding shares of Common Stock, and the Common Stock began trading on a split-adjusted basis on June 17, 2024. The Reverse Split did not reduce the total number of authorized shares of Common Stock or the Company's preferred stock (Preferred Stock), or change the par values of the Common Stock or Preferred Stock. The Reverse Split affected all stockholders uniformly and did not affect any stockholder's ownership percentage of the shares of Common Stock (except to the extent that the Reverse Split resulted in some of the stockholders receiving cash in lieu of fractional shares). All outstanding options and warrants entitling their holders to purchase shares of Common Stock were adjusted as a result of the Reverse Split, in accordance with the terms of each such security. In addition, the number of shares reserved for future issuance pursuant to the Company's equity incentive plans was also adjusted accordingly. As a result, all historical per share data, number of shares issued and outstanding, and outstanding options and warrants for the periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively in this Form 10-Q, where applicable, to reflect the Reverse Split.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Liquidity</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company has had a history of operating losses and an absence of significant recurring cash inflows from revenue. At June 30, 2024, the </p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Company had cash, cash equivalents and short-term investments of $292.9 million and total accumulated deficit of $176.4 million. The Company has historically financed its operations primarily through selling equity.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company believes that its $292.9 million of cash, cash equivalents and short-term investments as of June 30, 2024 will enable it to fund its current planned operations into mid-2026, though it may raise additional capital through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements and/or government funding and grants.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The operating plan may change as a result of many factors currently unknown to management, and there can be no assurance that the current operating plan will be achieved in the timeframe anticipated by management or at all, and the Company may need to seek additional funds sooner than anticipated. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from potential unknown factors.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Reclassifications</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">In addition to the discontinued operations discussed above, during the first quarter of 2024, the Company made certain reclassifications to prior period amounts in the condensed consolidated financial statements and accompanying notes to conform to the current period presentation. The reclassification of these items had no impact on net loss, financial position or cash flows in the current or prior periods. Specifically, accrued payroll and related taxes and accrued vacation were combined to create accrued personnel, and accrued protocol expense and accrued waste disposal were included in accounts payable and accrued expenses, all of which are presented on the condensed consolidated balance sheets and condensed consolidated statement of cash flows.</p></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Significant Accounting Policies</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;">The Company's significant accounting policies and recent accounting pronouncements are described in Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements in Item 8 of the 2023 Form 10-K. There have been no changes to the Company's significant accounting policies, and the Company has not adopted any significant accounting policies during the six months ended June 30, 2024.</p>0136545070.0010.492795160.00010.005292900000-176400000292900000<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Reclassifications</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">In addition to the discontinued operations discussed above, during the first quarter of 2024, the Company made certain reclassifications to prior period amounts in the condensed consolidated financial statements and accompanying notes to conform to the current period presentation. The reclassification of these items had no impact on net loss, financial position or cash flows in the current or prior periods. Specifically, accrued payroll and related taxes and accrued vacation were combined to create accrued personnel, and accrued protocol expense and accrued waste disposal were included in accounts payable and accrued expenses, all of which are presented on the condensed consolidated balance sheets and condensed consolidated statement of cash flows.</p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;">2.<div style="width:100%;display:inline;">Loss per Share</div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Basic and diluted loss per share is calculated by dividing net loss by the weighted average number of shares of Common Stock outstanding and does not include the impact of any potentially dilutive common stock equivalents. In January 2024 and May 2024, the Company issued pre-funded warrants in connection with the Public Offering (as defined below) and the Registered Offering (as defined below), respectively (see Note 3, Investments and Agreements, in this Form 10-Q). As the pre-funded warrants' exercise price is nominal and there are no conditions that must be satisfied prior to their exercise, the pre-funded warrants are included in the calculation of the basic and diluted earnings per share as of June 30, 2024. At each of June 30, 2024 and 2023, the calculation of diluted weighted average shares did not include common stock warrants or options that were potentially convertible into Common Stock as those would be antidilutive due to the Company's net loss position.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-

top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Securities not considered in the calculation of diluted loss per share, but that could be dilutive in the future, are as follows (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.168%;"></td> <td style="width:1.02%;"></td> <td style="width:1%;"></td> <td style="width:16.397%;"></td> <td style="width:1%;"></td> <td style="width:1.02%;"></td> <td style="width:1%;"></td> <td style="width:16.397%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 416 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 603 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,934 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,487 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total potential dilutive securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,350 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,090 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">   </td> </tr> </table> Effective upon the closing of the Merger with Viewpoint on February 3, 2023, the Company assumed 338,709 warrants to purchase shares of Common Stock with an exercise price of $2.70 per share and 2,426,342 options to purchase shares of Common Stock with exercise prices ranging from $1.30 to $3.00 per share. Securities not considered in the calculation of diluted loss per share, but that could be dilutive in the future, are as follows (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.168%;"></td> <td style="width:1.02%;"></td> <td style="width:1%;"></td> <td style="width:16.397%;"></td> <td style="width:1%;"></td> <td style="width:1.02%;"></td> <td style="width:1%;"></td> <td style="width:16.397%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 416 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 603 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,934 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,487 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total potential dilutive securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,350 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,090 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table>41600060300069340044870007350000509000033870 92.724263421.33 3. Investments and Agreements May 2024 Registered Offering On May 24, 2024, the Company entered into an underwriting agreement with BofA Securities, Inc., as representative of the underwriters named therein, in connection with its previously announced underwritten offering (Registered Offering) of 5,151,588 shares (Registered Offering Shares) of Common Stock and, in lieu of Registered Offering Shares to certain investors, pre-funded warrants (May 2024 Pre-funded Warrants) to purchase 146,425 shares of Common Stock. The price to the investors for the Registered Offering Shares was $15.10 per Registered Offering Share, and the price to the investors for the May 2024 Pre-funded Warrants was $15.09 per May 2024 Pre-funded Warrant, which represents the per share price for the Registered Offering Shares less the $0.01 per share exercise price for each such May 2024 Pre-funded Warrant. The Registered Offering closed on May 29, 2024. BofA Securities, Inc., Oppenheimer & Co. Inc. and RBC Capital Markets, LLC acted as joint book-running managers for the Registered Offering and B. Riley Securities, Inc. acted as a co-manager for the Registered Offering. JonesTrading Institutional Services LLC acted as a financial advisor for the Registered Offering. The gross proceeds to the Company from the Registered Offering were approximately $80 million, before underwriting discounts and commissions and estimated expenses of the Registered Offering. The Company intends to use the net proceeds from the Registered Offering for: (i) the continued clinical development of VMT-α-NET, VMT-01/02 and PSV359; (ii) the continued development of PSV40X and additional preclinical product candidates as well as a broader development platform; and (iii) the build out, operation and expansion of manufacturing facilities, as well as for working capital and other general corporate purposes. A portion of the net proceeds may also be used to acquire, license or invest in complementary products, technologies, intellectual property or businesses, although the Company has no present commitments or agreements to do so. The Registered Offering was made pursuant to the Company's automatic shelf registration statement on Form S-3 (File No. 333-279692) (the May 2024 Registration Statement), which became effective upon filing with the SEC on May 24, 2024, a related base prospectus, free writing prospectus and prospectus supplement each dated May 24, 2024. The May 2024 Pre-funded Warrants became exercisable subsequent to the filing and effectiveness of an amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on June 14, 2024. The exercise price and the number of shares of Common Stock issuable upon exercise of each May 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to the Company's stockholders. The May 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of May 2024 Pre-funded Warrants may not exercise such May 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would be more than 4.99% or 9.99%, as elected by such holder, of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the May 2024 Pre-funded Warrants. A holder of May 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days' prior notice to the Company. March 2024 Private Placement with Institutional Investors On March 4, 2024, the Company entered into an investment agreement (the March 2024 Investment Agreement) with certain accredited institutional investors (Institutional Investors) pursuant to which the Company agreed to issue and sell, in a private placement (the March 2024 Private Placement), 9,200,998 shares of Common Stock, for a purchase price of $9.50 per share, representing the closing price of the Common Stock on March 1, 2024. The closing of the March 2024 Private Placement occurred on March 6, 2024. The gross proceeds to the Company from the March 2024 Private Placement were approximately $87.4 million, before deducting fees payable to the Placement Agents (as defined below) and other estimated transaction expenses. The Company intends to use the net proceeds from the March 2024 Private Placement for general corporate and working capital purposes, which may include research and development expenditures, preclinical study and clinical trial expenditures, manufacturing expenditures, commercialization expenditures, capital expenditures, acquisitions of new technologies, products or businesses and investments. The March 2024 Private Placement was conducted pursuant to a Placement Agency Agreement, dated March 4, 2024 (the Placement Agency Agreement), by and between the Company and Oppenheimer & Co. Inc., as representative of the placement agents named therein (the Placement Agents). Per the Placement Agency Agreement, the Company agreed to: (i) pay the Placement Agents a cash fee equal to 5.85% of the gross proceeds received by the Company from the sale of the shares; and (ii) reimburse the Placement Agents for certain fees and expenses. Lantheus Agreements Investment Agreement On January 8, 2024, the Company entered into an investment agreement (the Lantheus Investment Agreement) with Lantheus Alpha Therapy, LLC, a Delaware limited liability company and wholly owned subsidiary of Lantheus Holdings, Inc. (Lantheus), pursuant to which the Company agreed to sell and issue to Lantheus in a private placement transaction certain shares (the Lantheus Shares) of Common Stock. The closing of the purchase and sale of the Lantheus Shares to Lantheus by the Company (the Lantheus Closing) was subject to the Company raising at least $<span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-

width:fit-content;">50.0 million of gross proceeds (excluding Lantheus' investment) in a qualifying third-party financing transaction, which occurred on January 22, 2024. The number of Lantheus Shares sold was 5,634,235, representing 19.99% of the outstanding shares of Common Stock as of January 8, 2024. Pursuant to the Lantheus Investment Agreement, the Company agreed to cooperate in good faith to negotiate and enter into a registration rights agreement with Lantheus, obligating the Company to file a registration statement on Form S-3 with the SEC to register for resale the Lantheus Shares issued at the Lantheus Closing. The Company filed such Form S-3 on March 29, 2024, and the SEC declared it effective on April 9, 2024 (File No. 333-278362). The Lantheus Investment Agreement also contains agreements of the Company and Lantheus whereby Lantheus is provided certain board observer and information rights of the Company, as well as standstill provisions prohibiting Lantheus from taking certain actions for a specified period of time, subject to certain exceptions. The Lantheus Investment Agreement also provides Lantheus with certain pro rata participation rights to maintain its ownership position in the Company in the event that the Company makes any public or non-public offering of any equity or voting interests in the Company or any securities that are convertible or exchangeable into (or exercisable for) equity or voting interests in the Company, subject to certain exceptions. Pursuant to the Lantheus Investment Agreement, the Company is required to notify Lantheus within 10 business days of the end of a fiscal quarter in which the Company issued shares of Common Stock pursuant to that certain At Market Issuance Sales Agreement among the Company, Oppenheimer & Co. Inc., B. Riley Securities, Inc., and JonesTrading Institutional Services LLC dated November 17, 2023 (the ATM Agreement), of (i) the number of shares of Common Stock issued during such fiscal quarter pursuant to the ATM Agreement and (ii) the average price per share received by the Company before commissions (the ATM Average Price). Upon receipt of such notice, Lantheus may elect, at its option, to purchase all or a portion of its Pro Rata Portion (as defined in the Lantheus Investment Agreement) of such shares at an aggregate price equal to the number of shares purchased multiplied by the ATM Average Price for such quarter (the ATM Participation Right). Pursuant to the Lantheus Investment Agreement, Lantheus may not exercise the ATM Participation Right more than two times per calendar year. Asset Purchase Agreement On January 8, 2024, the Company entered into an Asset Purchase Agreement (the Progenics APA) with Progenics Pharmaceuticals, Inc., a Delaware corporation (Progenics) and affiliate of Lantheus, pursuant to which the Company acquired certain assets and the associated lease of Progenics' radiopharmaceutical manufacturing facility in Somerset, New Jersey for a purchase price of $8.0 million in cash. The transactions contemplated by the Progenics APA closed on March 1, 2024. Option Agreement On January 8, 2024, the Company entered into an option agreement (the Option Agreement) with Lantheus whereby Lantheus was granted an exclusive option to negotiate an exclusive, worldwide, royalty- and milestone-bearing right and license to [212Pb]VMT-α-NET, the Company's clinical-stage alpha therapy developed for the treatment of neuroendocrine tumors. If good-faith negotiations fail, Lantheus has a one-year right to reenter negotiations if a third party offers to purchase or license the [212Pb]VMT-α-NET program. Additionally, Lantheus has a right to co-fund the Investigational New Drug (IND) application, enabling studies for early-stage therapeutic candidates targeting prostate-specific membrane antigen and gastrin-releasing peptide receptor and, prior to IND filing, a right to negotiate for an exclusive license to such candidates. In consideration of the rights granted by the Company to Lantheus pursuant to the Option Agreement, Lantheus paid to the Company a one-time payment of $28.0 million, subject to certain withholding provisions associated with the closing of the Progenics APA. Under the terms of the Option Agreement, Lantheus also has a right of first offer and last look protections for any third-party merger and acquisition transactions involving the Company for a 12-month period beginning on January 8, 2024. The Company determined that the Option Agreement should be accounted for as a research and development arrangement in accordance with ASC 730-20, Research and Development Arrangements, as Lantheus held approximately 19.9% of the Company's outstanding Common Stock at March 31, 2024. The Option Agreement contains no repayment provisions, does not create any obligation to enter into any license, transfer or sale agreements with Lantheus, and does not restrict the use of the funds in any way. Accordingly, the balance sheet reports current and long-term liabilities related to these options under the caption, "Deferred Income." The values for each distinct option within the Option Agreement were determined by estimating the fair value of each distinct option by a third-party valuation firm and the liabilities will be recognized as income in the condensed consolidated statement of operations as the various options expire. January 2024 Public Offering On January 17, 2024, the Company entered into an underwriting agreement (Underwriting Agreement) with Oppenheimer & Co. Inc., as representative of the underwriters named therein (the Underwriters), in connection with its previously announced underwritten public offering (Public Offering) of 13,207,521 shares (Public Shares) of Common Stock and, in lieu of Public Shares to certain investors, pre-funded warrants (Jan. 2024 Pre-funded Warrants) to purchase 3,008,694 shares of Common Stock. The price to the public for the Public Shares was $3.70 per Public Share, and the price to the public for the Jan. 2024 Pre-funded Warrants was $3.69 per Jan. 2024 Pre-funded Warrant, which represents the per share price for the Public Shares less the $0.01 per share exercise price for each such Jan. 2024 Pre-funded Warrant. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 2,432,432 shares of Common Stock at the same price per share as the Public Shares, which was fully exercised by the Underwriters on January 18, 2024. The Public Offering closed on January 22, 2024. The gross proceeds to the Company from the Public Offering were approximately $69.0 million, before underwriting discounts and commissions and estimated expenses of the Public Offering. The Company intends to use the net proceeds from the Public Offering for general corporate purposes, which may include research and development expenditures, preclinical study and clinical trial expenditures, manufacturing expenditures, commercialization expenditures, working capital, capital expenditures, acquisitions of new technologies, products or businesses and investments. The Public Offering was made pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-275638), declared effective by the SEC on December 14, 2023, a base prospectus dated December 14, 2023, and the related prospectus supplement dated January 17, 2024. The Jan. 2024 Pre-funded Warrants are exercisable at any time after the date of issuance. The exercise price and the number of shares of Common Stock issuable upon exercise of each Jan. 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to the Company's stockholders. The Jan. 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of Jan. 2024 Pre-funded Warrants may not exercise such Jan. 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would beneficially own more than 4.99% of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the Jan. 2024 Pre-funded Warrants. A holder of Jan. 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days' prior notice to the Company. ATM Agreement <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-

content;">Pursuant to the ATM Agreement, the Company has established an “at-the-market” equity program under which it may offer and sell shares of its Common Stock, from time to time. On November 17, 2023, the Company filed a shelf registration statement on Form S-3 with the SEC (File No. 333-275638) and accompanying base prospectus, declared effective by the SEC on December 14, 2023, for the offer and sale of up to $200 million of its securities (December 2023 Registration Statement). Also on November 17, 2023, the Company filed a prospectus supplement with the SEC in connection with the offering of up to $50 million of shares of its Common Stock pursuant to the ATM Agreement under the December 2023 Registration Statement. In December 2023, the Company sold 123,882 shares under the ATM Agreement at an average price of approximately $3.03 per common share for gross proceeds of approximately $0.4 million. On April 11, 2024, the Company sold 3,535,246 shares of its Common Stock under the ATM Agreement at an average price of approximately $14.00 per common share, resulting in gross proceeds of approximately $49.5 million. On May 25, 2024, the Company terminated the offering of securities pursuant to the December 2023 Registration Statement in connection with the filing and effectiveness of the May 2024 Registration Statement. For additional information related to the various agreements discussed above, see Note 20, Subsequent Events, in the Company’s 2023 Form 10-K.
515158814642515.115.090.018000000000.04990.09990.199992009989.5874000000.0585500000056342350.19998000000280000000.19901320752130086943.73.690.012
class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;">4. Discontinued Operations The GT Medical Closing occurred on April 12, 2024 (GT Medical Closing Date). Previously, the Company announced that on December 7, 2023, Isoray entered into an Asset Purchase Agreement (GT Medical APA) by and among Isoray, the Company, and GT Medical pursuant to which Isoray would sell to GT Medical, and GT Medical would purchase from Isoray, all of Isoray’s right, title and interest in and to substantially all of the assets of Isoray related to Isoray’s commercial Cesium-131 business (the Business) including equipment, certain contracts, inventory and intellectual property. Subject to limited exceptions set forth in the GT Medical APA, GT Medical did not assume the liabilities of Isoray. Pursuant to the terms of, and subject to the conditions specified in, the GT Medical APA, at the GT Medical Closing, (i) GT Medical issued to Isoray 279,516 shares of GT Medical’s common stock, par value $0.0001 per share, representing 0.5% of GT Medical’s issued and outstanding capital stock on a fully diluted basis as of the GT Medical Closing Date and (ii) Isoray has the right to receive, and GT Medical is obligated to pay, certain cash royalty payments during each of the first four years beginning upon the GT Medical Closing Date (each such year, a Measurement Period), as summarized below: • with respect to GT Medical’s net sales of Cesium-131 brachytherapy seeds for cases that do not utilize GT Medical’s GammaTile Therapy: (a) if such net sales for a Measurement Period are $10 million or less, 3.0% of such net sales; (b) if such net sales for a Measurement Period are greater than $10 million and less than $15 million, 4.0% of such net sales; and (c) if such net sales for a Measurement Period are $15 million or more, 5.0% of such net sales; and • with respect to GT Medical’s net sales of GT Medical’s GammaTile Therapy utilizing Cesium-131 brachytherapy seeds: 0.5% of such net sales for a Measurement Period. In accordance with ASC 205-20, Presentation of Financial Statements – Discontinued Operations, the following table presents the major classes of assets and liabilities of discontinued operations of the Business reported in the condensed consolidated balance sheets and prior year amounts have been reclassified. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:58.252%;"></td><td style="width:5.701%;"></td><td style="width:1%;"></td><td style="width:12.783000000000001%;"></td><td style="width:1%;"></td><td style="width:3.241%;"></td><td style="width:1%;"></td><td style="width:16.023%;"></td><td style="width:1%;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> June 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> December 31, 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> (in thousands) </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> Assets held for sale of discontinued operations, current </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Inventory </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> <span

style="color:#000000;min-width:fit-content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,148 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Prepaid expenses and other current assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 169 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,263 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Right-of-use asset, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 676 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Other assets, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 45 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Total current assets held for sale of discontinued operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,301 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Liabilities held for sale of discontinued operations, current </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 677 </td> <td

style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Asset retirement obligation </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 225 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Loss recognized on classification as held for sale </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,170 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Total current liabilities of discontinued operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,072 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table presents the components of discontinued operations in relation to the Business reported in the unaudited condensed consolidated statements of operations (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.297%;"></td> <td style="width:1.341%;"></td> <td style="width:1%;"></td> <td style="width:11.084%;"></td> <td style="width:1%;"></td> <td style="width:1.341%;"></td> <td style="width:1%;"></td> <td style="width:11.084%;"></td> <td style="width:1%;"></td> <td style="width:1.341%;"></td> <td style="width:1%;"></td> <td style="width:11.084%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Sales, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 205 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,500</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,178 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,330 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Cost of sales </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 162 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,840 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,564 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,416 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Gross profit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 43 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (340) </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 614 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (86) </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Operating expenses: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 283 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 69 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 831 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Sales and marketing </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 138 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 911 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 941 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 1,723 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 313 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 86 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 446 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom,"> Total operating expenses </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 472 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,280 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,504 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,000 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Total loss from discontinued operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(429</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (1,620 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(890</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (3,086 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> The Company determined the loss recognized on classification as held for sale by identifying the assets and liabilities that are included in the GT Medical APA and are included in the table above. Additionally, the loss recognized on classification as held for sale was determined using the estimated fair value of the GT Medical stock of $0.2 million received less the carrying value of the net assets sold. The fair value of the stock received was determined based on information provided to the Company by GT Medical from a current valuation study that was prepared for them. Excluded from the calculation of the loss are contingent royalties that could be received from future sales.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Certain amounts included in the unaudited condensed consolidated statements of cash flows related to the discontinued operations are as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:59.44%;"></td><td style="width:1.88%;"></td><td style="width:1.88%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16.4%;"></td><td style="width:1%;"></td><td style="width:1.88%;"></td><td style="width:1%;"></td><td style="width:16.4%;"></td><td style="width:1%;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Six Months Ended June 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Depreciation</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 111 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Amortization </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Write-off of inventory associated with discontinued product </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-

align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 298 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Share-based compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 166 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 535 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Additions to property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 186 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> For the three and six months ended June 30, 2024 and 2023, there was no provision (benefit) for income taxes recorded related to the discontinued operations. Additionally, the Company is in a loss position and has recorded a full valuation allowance for the deferred tax assets associated with the discontinued operations. 2795160.00010.0050.030.040.050.005 In accordance with ASC 205-20, Presentation of Financial Statements – Discontinued Operations, the following table presents the major classes of assets and liabilities of discontinued operations of the Business reported in the condensed consolidated balance sheets and prior year amounts have been reclassified. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.252%;"></td> <td style="width:5.701%;"></td> <td style="width:1%;"></td> <td style="width:12.783000000000001%;"></td> <td style="width:1%;"></td> <td style="width:3.241%;"></td> <td style="width:1%;"></td> <td style="width:16.023%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> (in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Assets held for sale of discontinued operations, current </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Inventory </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,148 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Prepaid expenses and other current assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 169 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;">

</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,263 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Right-of-use asset, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 676 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Other assets, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 45 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Total current assets held for sale of discontinued operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,301 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Liabilities held for sale of discontinued operations, current </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Asset retirement obligation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 225 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Loss recognized on classification as held for sale </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-

align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,170 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Total current liabilities of discontinued operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,072 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table presents the components of discontinued operations in relation to the Business reported in the unaudited condensed consolidated statements of operations (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.297%;"></td> <td style="width:1.341%;"></td> <td style="width:1%;"></td> <td style="width:11.084%;"></td> <td style="width:1%;"></td> <td style="width:1.341%;"></td> <td style="width:1%;"></td> <td style="width:11.084%;"></td> <td style="width:1%;"></td> <td style="width:1.341%;"></td> <td style="width:1%;"></td> <td style="width:11.084%;"></td> <td style="width:1%;"></td> <td style="width:1.341%;"></td> <td style="width:1%;"></td> <td style="width:11.084%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,840 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,564 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,416 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Gross profit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 43 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (340 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 614 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (86 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Operating expenses: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 283 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 69 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 831 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Sales and marketing </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">138 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 911 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 941 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,723 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 313 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 86 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 446 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Total operating expenses </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 472 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,280 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,504 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,000 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt,background-color:#ffffff;word-break:break-word,white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Total loss from discontinued operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(429</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (1,620 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (1,620 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> <span style="color:#000000;min-

width:fit-content;">$</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(890</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (3,086 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> Certain amounts included in the unaudited condensed consolidated statements of cash flows related to the discontinued operations are as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:59.44%;"></td> <td style="width:1.88%;"></td> <td style="width:1%;"></td> <td style="width:16.4%;"></td> <td style="width:1%;"></td> <td style="width:1.88%;"></td> <td style="width:1%;"></td> <td style="width:16.4%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 111 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Amortization </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Write-off of inventory associated with discontinued product </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 298 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Share-based compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 166 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 535 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Additions to property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 186 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> </tr>
</table>03148000016900001263000067600004500005301000067700002250000417000005072000205000150000021780003330000162000184000015640003416000433000340000614000-860002100028300069000831000138000911000941000172300031300086000494000446000472000128000015040003000000-429000-1620000-890000-308600020000001110000180000298000166000535000018600000000 5. Property and Equipment The Company's property and equipment consisted of the following as of: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.36%;"></td> <td style="width:1.58%;"></td> <td style="width:1%;"></td> <td style="width:15.24%;"></td> <td style="width:1%;"></td> <td style="width:1.58%;"></td> <td style="width:1%;"></td> <td style="width:15.24%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Building </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,770</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,770 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Land </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,283 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,283 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,470 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,683 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,490 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 179 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 319 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 330 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,245 </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less accumulated depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,585 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (669 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,747</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,576 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 1. Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized. On July 15, 2024 and August 2, 2024, the Company purchased a building located in Houston, Texas, for $4.7 million and a building in Chicago, Illinois, for $5.0 million, respectively, which it intends to use for the manufacture of its program candidates upon completion of modifications and installation of equipment.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company's property and equipment consisted of the following as of:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.36%;"></td> <td style="width:1.58%;"></td> <td style="width:1%;"></td> <td style="width:15.24%;"></td> <td style="width:1%;"></td> <td style="width:1.58%;"></td> <td style="width:1%;"></td> <td style="width:15.24%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Building</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,770 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,770 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Land </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,283 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,283 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,470 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,683 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,490 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 179 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 319 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 330 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,245 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less accumulated depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,585 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 669 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,747</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,576 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 1. Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized.
17700001770000128300012830000947000026830003490000179000319000330000163320006245000158500006690001474700055760000004700000500000 6. Goodwill and Other Intangible Assets Goodwill The carrying amount of goodwill as of both June 30, 2024 and December 31, 2023 was $24.1 million and has been recorded in connection with the Company's Merger of Viewpoint in February 2023. The Company tests goodwill and indefinite-lived intangible assets for impairment during the fourth quarter of each year, or more frequently should circumstances change or events occur that would more likely than not reduce the fair value of its assets. No testing was deemed necessary during the three and six months ended June 30, 2024. The following table summarizes the components of the Company's other intangible assets (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:38.772%;"></td><td style="width:1.64%;"></td><td style="width:1%;"></td><td style="width:12.957%;"></td><td style="width:1%;"></td><td style="width:1.64%;"></td><td style="width:1%;"></td><td style="width:21.535999999999998%;"></td><td style="width:1%;"></td><td style="width:1.64%;"></td><td style="width:1%;"></td><td style="width:15.817%;"></td><td style="width:1%;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Cost </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-

align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Accumulated Amortization </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Net Carrying Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Indefinite-lived intangible assets </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> In-process research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.772%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:12.957%;"></td> <td style="width:1%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:21.535999999999998%;"></td> <td style="width:1%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:15.817%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Accumulated Amortization </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Net Carrying Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Indefinite-lived intangible assets </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> In-process research and development </td> <td

style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The Company's IPR&D assets represent the estimated fair value of Viewpoint's pipeline of radiotherapy product candidates acquired in February 2023. The estimated fair value of the IPR&D assets at the acquisition date was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flow estimates for Viewpoint's pipeline of radiotherapy program candidates were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the Merger date and the time and resources needed to complete development. 2410000024100000 The following table summarizes the components of the Company's other intangible assets (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.772%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:12.957%;"></td> <td style="width:1%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:21.535999999999998%;"></td> <td style="width:1%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:15.817%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Accumulated Amortization </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Net Carrying Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Indefinite-lived intangible assets </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td>

width:fit-content;">Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.772%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:12.957%;"></td> <td style="width:1%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:21.535999999999998%;"></td> <td style="width:1%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:15.817%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Cost</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Accumulated Amortization</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Net Carrying Value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Indefinite-lived intangible assets</p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">In-process research and development</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table>50000000005000000050000000050000000500000005000000050000000500000000 7. Held-to-Maturity Investments The following table summarizes the carrying values and fair values of the Company's financial instruments (in thousands): <table style="margin-left:auto;border-spacing:0;table-

layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:23.995%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:11.998%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:17.996%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:18.016%;"></td> <td style="width:1%;"></td> <td style="width:1.46%;"></td> <td style="width:1%;"></td> <td style="width:15.536999999999999%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. Treasury Bills </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">40,865</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(11</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 40,854 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> The Company has investments in U.S. Treasury Bills, some of which mature over a period greater than 90 days and are classified as short-term investments. The U.S. Treasury Bills are carried at amortized cost and classified as held-to-maturity as the Company has the intent and the ability to hold them until they mature. The carrying value of the U.S. Treasury Bills are adjusted for accretion of discounts over the remaining life of the investment. Income related to the U.S. Treasury Bills is recognized in interest income in the Company's condensed consolidated statement of operations. Based on its analysis of the held-to-maturity securities, the Company determined the gross unrealized losses were primarily due to changes in interest rates and not due to credit risks. As such, the Company did not record a credit allowance as of June 30, 2024. As of December 31, 2023, the Company had no held-to-maturity investments, and no held-to-maturity investments were presented in cash and cash equivalents on its condensed consolidated balance sheet. The following table summarizes the carrying values and fair values of the Company's financial instruments (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:23.995%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:11.998%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:17.996%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:18.016%;"></td> <td style="width:1%;"></td> <td style="width:1.46%;"></td> <td style="width:1%;"></td> <td style="width:15.536999999999999%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. Treasury Bills </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 40,865 </td>

<td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (11 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">40,854</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table>408650000110004085400000<div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;">8.<div style="width:100%;display:inline;">Fair Value Measurements</div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Level 1- Observable inputs such as quoted prices in active markets;</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Level 2- Inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions (less active markets), or model-driven valuations in which all significant inputs are observable or can be derived principally from, or corroborated with, observable market data; and</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Level 3- Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;">Included in the Company's cash and cash equivalents in the condensed consolidated balance sheet is its money market fund, which is measured at fair value on a recurring basis and categorized using the fair value hierarchy (in thousands):</p><div style="font-size:10pt;font-family:Times New Roman;"><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"> <td style="width:77.58%;"></td> <td style="width:1.88%;"></td> <td style="width:1%;"></td> <td style="width:18.54%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Estimated Fair Value
Level 1</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Money market fund</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 249,663 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> There were no Level 2 or Level 3 financial instruments measured at fair value on a recurring basis at June 30, 2024, and the Company did not have any financial instruments measured at fair value on a recurring basis at December 31, 2023. For information related to our short-term investments, see Note 7, Held-to-Maturity Investments, Company's cash and cash equivalents in the condensed consolidated balance sheet is its money market fund, which is measured at fair value on a recurring basis and categorized using the fair value hierarchy (in thousands):<table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"> <td style="width:77.58%;"></td> <td style="width:1.88%;"></td> <td style="width:1%;"></td> <td style="width:18.54%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Fair Value
Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Money market fund </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 249,663 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>249663000000 9. Share-Based Compensation On May 31, 2024, the Company held its 2024 Annual Meeting of Stockholders (Annual Meeting). At the Annual Meeting, the Company's stockholders approved the Company's Third Amended and Restated 2020 Equity Incentive Plan (the Amended and Restated Plan) which, among other things, (a) increased the aggregate number of shares of Common Stock authorized for issuance under the Amended and Restated Plan by 4,870,092 for a total of <span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-

content;">12,500,000 shares of Common Stock, and (b) adjusted the "evergreen" provision included therein, such that the number of shares of Common Stock available for the grant of awards under the Amended and Restated Plan will automatically increase on January 1 of each year in an amount equal to 5% of the number of shares of Common Stock issued and outstanding on December 31 of the immediately preceding year (subject to adjustment in the event of stock splits and other similar events); provided, however, that the Company's Board of Directors may act prior to January 1 of a given year to provide that there will be no increase in the share limit for such year or provide that the increase for such year will be a lesser number of shares of Common Stock. The following table presents the share-based compensation expense recognized for all share-based compensation arrangements (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.169%;"></td> <td style="width:1%;"></td> <td style="width:10.202%;"></td> <td style="width:1%;"></td> <td style="width:1.34%;"></td> <td style="width:1%;"></td> <td style="width:10.202%;"></td> <td style="width:1%;"></td> <td style="width:1.34%;"></td> <td style="width:1%;"></td> <td style="width:10.202%;"></td> <td style="width:1%;"></td> <td style="width:1.34%;"></td> <td style="width:1%;"></td> <td style="width:10.202%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">259</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 429 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">522</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 584 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 328 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 621 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 687 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,448 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total share-based compensation </td> <td style="border-top:0.5pt solid #000000;white-

space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">587</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,050 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,209</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,032 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 4870092125000000.05 The following table presents the share-based compensation expense recognized for all share-based compensation arrangements (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.169%;"></td> <td style="width:1%;"></td> <td style="width:10.202%;"></td> <td style="width:1%;"></td> <td style="width:10.202%;"></td> <td style="width:1%;"></td> <td style="width:1.34%;"></td> <td style="width:1%;"></td> <td style="width:10.202%;"></td> <td style="width:1%;"></td> <td style="width:1.34%;"></td> <td style="width:1%;"></td> <td style="width:10.202%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fe;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">259</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 429 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">522</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 584 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 328 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 621 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 687 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,448 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total share-based compensation </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">587</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,050 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,209</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,032 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>2590004290005220005840003280006210006870001448000587000105000012090002032000 10. Commitments and Contingencies The Company has been in settlement negotiations with a representative for six stockholder plaintiff firms alleging the Company violated Delaware law in its preliminary proxy statement that was disseminated to stockholders in November 2022 for the Company's annual meeting held in December 2022. Based on these settlement negotiations to date, the Company estimates that it will settle for no more than an aggregate of $0.2 million and, therefore, recorded an estimated liability of $0.2 million as of December 31, 2023. There was no change in the estimate as of June 30, 2024. This balance is included in accrued expenses on the unaudited condensed consolidated balance sheets. 620000020000020000 11. Related Parties In connection with the Lantheus Investment Agreement entered into with Lantheus on January 8, 2024, the Company agreed to sell and issue the Lantheus Shares. The number of Lantheus Shares sold was 5,634,235, representing 19.99% of the outstanding shares of Common Stock as of January 8, 2024. On January 8, 2024, the Company entered into the Progenics APA with Progenics, an affiliate of Lantheus, for a purchase price of $8.0 million. On March 1, 2024, the Company closed on the transactions contemplated by the Progenics APA. On March 4, 2024, the Company entered into the March 2024 Investment Agreement in which the Company agreed to issue and sell 9,200,998 shares of Common Stock. Lantheus, a significant stockholder of the Company, purchased part of the shares issued to increase their ownership percentage to approximately 19.9% in the Company following the closing of the March 2024 Investment Agreement on March 6, 2024. For additional information regarding the Lantheus Investment Agreement, the Progenics APA and the March 2024 Investment Agreement, see Note 3, Investments and Agreements. 56342350.1999800000092009980.199 12. Leases The Company accounts for its leases under ASC 842, Leases. Effective April 1, 2024, the Company entered into a lease with the Board of Regents, State of Iowa, for lab and office space at the BioVentures Center. The lease terminates in March 2026. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $1.1 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate. The Company acquired a lease from Progenics, an affiliate of Lantheus, for a production facility in Somerset, New Jersey effective on March 1, 2024 (see Note 3, Investments and Agreements, in this Form 10-Q). The lease terminates on November 29, 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $0.3 million on the balance sheet based<span style="color:#000000;white-space:pre-

wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate. On July 1, 2023, the Company entered into a lease with Unico Properties LLC for office space in Seattle, Washington that terminates in October 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $0.8 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate. The weighted average remaining term and discount rate for the Company's operating leases as of June 30, 2024 was 3.2 years and 8%, respectively. The Company's operating lease expense was $0.2 million and $0.3 million for the three and six months ended June 30, 2024, respectively, and there was no operating lease expense for the three and six months ended June 30, 2023.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following table presents the future operating lease payments and lease liability included on the condensed consolidated balance sheet related to the Company's operating leases as of June 30, 2024 (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:80.236%;"></td><td style="width:1.94%;"></td><td style="width:1%;"></td><td style="width:15.823%;"></td><td style="width:1%;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Year Ending December 31,</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2024 (remaining six months)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 408 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 949 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 482 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2027 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 320 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2028 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 283 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,442 </td><td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Less: imputed interest </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (272 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total lease liability </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,170 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Less current portion </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(720</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Non-current lease liability</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,450</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Asset Retirement Obligation</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company had an asset retirement obligation (ARO) associated with the facility it leased in Richland, Washington. This lease is included in the GT Medical APA and was assigned to GT Medical upon the GT Medical Closing, which occurred on April 12, 2024. As such, this liability is no longer reported as an ARO in the Company's condensed consolidated financial statements as of June 30, 2024 and December 31, 2023. However, the Company maintains the estimated liability in its condensed consolidated financial statements related to hazardous waste removal. The estimated liability at each of June 30, 2024 and December 31, 2023 was $0.5 million and is included within the accounts payable and accrued expenses in the condensed consolidated balance sheets.</p>1100000011000000.083000003000000.088000008000000.08P3Y2M12D0.0820000030000<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following table presents the future operating lease payments and lease liability included on the condensed consolidated balance sheet related to the Company's operating leases as of June 30, 2024 (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Year Ending December 31,</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2024 (remaining six months)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">408</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">949</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">482</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">320</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2028</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">283</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,442</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: imputed interest</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(272</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total lease liability</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,170</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less current portion</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(720</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-

indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Non-current lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,450 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>4080009490004820003200002830002442000272000217000072000014500005000005000000 13. Notes Payable
The Company assumed two notes payable effective upon the closing of the Merger with Viewpoint on February 3, 2023. On July 19, 2019, Viewpoint entered in a promissory note agreement with the Iowa Economic Development Authority (IEDA) for $0.1 million at 3% interest rate to be paid over 36 monthly payments beginning on the first day of the first month following Viewpoint closing on a $1.0 million equity fundraising round. Final payment was paid in September 2023. The loan was granted as a form of financial assistance to Viewpoint from IEDA. On December 29, 2022, Viewpoint obtained a promissory note in the amount of $1.7 million for the purpose of purchasing land and a building in Coralville, Iowa. The note bears interest at 6.15% per annum and is collateralized by the property. The note requires monthly principal and interest payments, and a balloon payment of approximately $1.5 million is due on December 29, 2027.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following table presents the current and long-term portions of the note payable (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;"></td><td style="width:1.62%;"></td><td style="width:1%;"></td><td style="width:12.883000000000001%;"></td><td style="width:1%;"></td><td style="width:1.62%;"></td><td style="width:1%;"></td><td style="width:12.883000000000001%;"></td><td style="width:1%;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30,</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Note payable</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,705 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,725</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: current portion</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(54</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(49</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Note payable, long-term portion</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,651 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-

align:center;"> 1,676 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table presents the future principal payments included on the condensed consolidated balance sheet related to the Company's note payable as of June 30, 2024 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Years ending December 31: </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2024 (remaining six months) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">29</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">52</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">55</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,569</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,705 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>
1000000.033610000001700000.06151500000 The following table presents the current and long-term portions of the note payable (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> June 30, </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> December 31, </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Note payable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,705</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,725 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: current portion </td> <td style="white-space:pre-wrap;vertical-align:bottom;">

</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (54 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (49 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Note payable, long-term portion </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,651</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>1705000172500054000490001651000167600 The following table presents the future principal payments included on the condensed consolidated balance sheet related to the Company’s note payable as of June 30, 2024 (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Years ending December 31: </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2024 (remaining six months) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">29</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">52</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">55</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,569</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,705 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>2900052000550001569000170500 14. Merger On February 3, 2023, the Company acquired 100% of the issued and outstanding equity and voting shares of Viewpoint Molecular Targeting, Inc. in exchange for 13,654,507 shares of Common Stock with a fair value of $54.6 million based on the closing market price of $4.00 per share on the acquisition date. At the closing of the Merger, the Company forgave the note receivable entered into in November 2022 and the associated accrued interest with Viewpoint that was included in the note receivable. The total amount forgiven was $6.2 million, representing the $6.0 million loan and $0.2 million accrued interest. The Company also assumed all of Viewpoint’s outstanding stock options and warrants as of the Merger date. Viewpoint is developing the next generation of TAT for oncology that have the potential to treat a large population of cancer patients across multiple tumor types, including those with metastatic disease. By leveraging its proprietary TAT platform, Viewpoint aims to develop alpha-emitting radiopharmaceuticals that can be attached to targeting peptides to deliver the radioactive payload directly to difficult to treat tumors. The Merger was completed to provide the Company with a new isotope in a larger market.   The Company accounted for the transaction as a business combination in accordance ASC 805, Business Combinations. The Company has performed an allocation of the purchase price paid for the assets acquired and the liabilities assumed with the assistance

of an independent valuation firm. The Viewpoint purchase price consideration and allocation to net assets acquired is presented below (in thousands except for share price): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Fair value of consideration transferred </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Perspective Therapeutics common stock issued (13,654,507 x $4.00)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54,618 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Assumption of Viewpoint stock options and warrants at fair value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,836 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Note receivable and interest from Viewpoint forgiven </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,171 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total fair value of consideration transferred </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">68,625</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><div style="font-size:10pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Recognized amounts of identifiable net assets acquired</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Assets acquired</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,699 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Grants receivable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Prepaid expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 396 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,050 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Right of use asset </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Intangible assets, in-process research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 316 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total assets acquired </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 58,566 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Liabilities assumed </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accounts payable and accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,968 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued payroll and related taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,642 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued vacation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 333 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Notes payable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,807 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Deferred tax liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,243 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total liabilities assumed </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 14,003 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net assets acquired, excluding goodwill </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,563 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total purchase price consideration </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 68,625 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Goodwill </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,062</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Goodwill is calculated as the difference between the acquisition date fair value of the consideration and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized and is not currently assumed to be deductible for tax purposes. The goodwill is attributable to the workforce of the acquired business and the synergies expected to arise from the acquisition of Viewpoint.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Upon completion of the Merger, Viewpoint became a wholly owned subsidiary of the Company and its results of operations have been included in the Company's condensed consolidated financial statements.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Since the closing date, Viewpoint's results of operations have been reported in the Company's condensed consolidated financial statements and include grant revenue of approximately $0.5 million and $0.6 million, respectively, and operating loss of $13.6 million and $7.3 million, respectively, for the three months ended June 30, 2024 and 2023, and grant revenue of approximately $0.9 million and $0.8 million, respectively, and operating loss of $23.7 million and $11.1 million, respectively, for the six months ended June 30, 2024 and 2023. </p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The pro forma financial information below represents the combined results of operations as if the acquisition had occurred on January 1, 2022, the beginning of the comparable prior year reporting period. The unaudited pro forma financial information is presented for informational purposes only and is neither indicative of the results of operations that would have occurred if the acquisition had taken place at the beginning of the period presented nor indicative of future operating results.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The information below reflects certain nonrecurring pro forma adjustments that were directly related to the business combination based on available information and certain assumptions that we believe are reasonable:</p><p style="margin-left:1.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.82%;"></td> <td style="width:1.6%;"></td> <td style="width:1%;"></td> <td style="width:17.66%;"></td> <td style="width:1%;"></td> <td style="width:1.6%;"></td> <td style="width:1%;"></td> <td style="width:16.32%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended June 30, 2023</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Six Months Ended June 30, 2023</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">(in thousands)</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Grant revenue</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">588</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">905</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net loss</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(9,486</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(16,160</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> </table></div>113654507546000004620000060000000200000The Viewpoint purchase price consideration and allocation to net assets acquired is presented below (in thousands except for share price):<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fair value of consideration transferred</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Perspective Therapeutics common stock issued (13,654,507 x $4.00)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">54,618</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Assumption of Viewpoint stock options and warrants at fair value</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,836</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Note receivable and interest from Viewpoint forgiven</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,171</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total fair value of consideration transferred</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 68,625 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>136545074546180007836000617100068625000 <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Recognized amounts of identifiable net assets acquired </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Assets acquired </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash and cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,699 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Grants receivable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Prepaid expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,050 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Right of use asset </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Intangible assets, in-process research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 316 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total assets acquired </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 58,566 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Liabilities assumed </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accounts payable and accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,968 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued payroll and related taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,642 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued vacation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 333 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Notes payable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,807 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Deferred tax liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,243 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total liabilities assumed </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 14,003 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net assets acquired, excluding goodwill </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,563 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total purchase price consideration </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 68,625 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Goodwill </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 24,062 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>2699000050003960005050000100005000000031600058566000296800010000164200033300018070007243000140030004456300068625000240620005000006000001360000073000009000008000002370000011100000 The information below reflects certain nonrecurring pro forma adjustments that were directly related to the business combination based on available information and certain assumptions that we believe are reasonable:
 <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.82%;"></td> <td style="width:1.6%;"></td> <td style="width:1%;"></td> <td style="width:17.66%;"></td> <td style="width:1%;"></td> <td style="width:1.6%;"></td> <td style="width:1%;"></td> <td style="width:16.32%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> <span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-

content;">Three Months Ended June 30, 2023 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Six Months Ended June 30, 2023 </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> (in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Grant revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">588</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 905 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:center;"> (9,486 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (16,160 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> </table>588000905000-9486000-16160000 ITEM 5 – OTHER INFORMATION Rule 10b5-1 Trading Arrangements During the three months ended June 30, 2024, none of our directors or executive officers adopted, modified or terminated any "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408 of Regulation S-K. falsefalsefalsefalsefalsefalse Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details; Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details; See Note 3, Investments and Agreements, for additional information; Amount for prior period presented has been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details; Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details; See Note 3, Investments and Agreements, for additional information; Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized. On July 15, 2024 and August 2, 2024, the Company purchased a building located in Houston, Texas, for $4.7 million and a building in Chicago, Illinois, for $5.0 million, respectively, which it intends to use for the manufacture of its program candidates upon completion of modifications and installation of equipment. "